<SEC-DOCUMENT>0000320017-25-000030.txt : 20250508
<SEC-HEADER>0000320017-25-000030.hdr.sgml : 20250508
<ACCEPTANCE-DATETIME>20250508161415
ACCESSION NUMBER:		0000320017-25-000030
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250508
DATE AS OF CHANGE:		20250508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LISATA THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0000320017
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				222343568
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33650
		FILM NUMBER:		25926271

	BUSINESS ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920
		BUSINESS PHONE:		908-229-2590

	MAIL ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CALADRIUS BIOSCIENCES, INC.
		DATE OF NAME CHANGE:	20170808

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Caladrius Biosciences, Inc.
		DATE OF NAME CHANGE:	20150608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NeoStem, Inc.
		DATE OF NAME CHANGE:	20060906
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>lsta-20250331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1dd57249-b3e7-436f-adc4-30cff3fca49a,g:189dfb66-5ef0-4fa0-83c9-286ae40a1a30,d:65296f168ea449b99126b2b55f877ea4-->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:lsta="http://www.caladrius.com/20250331" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lsta-20250331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0000320017</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-26">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-29">false</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-416">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-417">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-422">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-423">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-86" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-502">P1Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-94" decimals="2" name="lsta:SaleOfStockAvailableForSalePercentage" id="f-532">.33</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lsta-20250331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>lsta:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-04</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lsta:BolsterTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lsta:BolsterTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lsta:AscendTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lsta:AscendTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lsta:ChemistryManufacturingAndControlsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lsta:ChemistryManufacturingAndControlsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lsta:ClinicalDepartmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lsta:ClinicalDepartmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lsta:ResearchAndDevelopmentOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lsta:ResearchAndDevelopmentOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lsta:LingmedLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-25</xbrli:startDate><xbrli:endDate>2024-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lsta:LingmedLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-15</xbrli:startDate><xbrli:endDate>2024-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-12</xbrli:startDate><xbrli:endDate>2024-07-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-14</xbrli:startDate><xbrli:endDate>2022-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:KuvaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:KuvaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:KuvaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:KuvaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i65296f168ea449b99126b2b55f877ea4_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:2.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.533%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Quarterly Period Ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March 31, 2025</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"/><td style="width:2.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.972%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Transition Period from __________________&#160;&#160;&#160;to _________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-33650</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">LISATA THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">22-2343568</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">110 Allen Road, 2nd Floor</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Basking Ridge</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">New Jersey</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">07920</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(zip code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">908</ix:nonNumeric>-<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">842-0100</ix:nonNumeric></span></div><div style="text-align:center"><span style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:34.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.817%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.628%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">LSTA</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The <ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric> &#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No &#9744;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric> &#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No &#9744;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-21">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#9744;</span></div><div style="text-indent:20.16pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#9744;&#160;&#160;&#160;&#160;&#160;No&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:3.3pt;padding-right:2.25pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:331.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of May 8, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $0.001 par value per share</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">8,598,204</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">shares</span></td></tr></table></div><div style="padding-right:2.25pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:3.3pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i65296f168ea449b99126b2b55f877ea4_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="margin-bottom:3.3pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report (this &#8220;Quarterly Report&#8221;) contains &#8220;forward-looking&#8221; statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. When used in this Quarterly Report, statements that are not statements of current or historical fact may be deemed to be forward-looking statements, including, without limitation, all statements related to any expectations of revenues, expenses, cash flows, earnings or losses from operations, cash required to maintain current and planned operations, capital or other financial items; any statements of the plans, strategies and objectives of management for future operations; any plans or expectations with respect to product research, development and commercialization, including regulatory approvals; any other statements of expectations, plans, intentions or beliefs; and any statements of assumptions underlying any of the foregoing. Without limiting the foregoing, the words &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;forecast,&#8221; &#8220;outlook,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;likely,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;target&#8221; or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements, although some forward-looking statements are expressed differently. We remind readers that forward-looking statements are merely predictions and therefore inherently subject to uncertainties and other factors and involve known and unknown risks that could cause the actual results, performance, levels of activity or our achievements or industry results, to be materially different from any future results, performance, levels of activity or our achievements or industry results expressed or implied by such forward-looking statements. Factors that could cause our actual results to differ materially from anticipated results expressed or implied by forward-looking statements include, among others:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain sufficient capital or strategic business arrangements to fund our operations and expansion plans, including collecting amounts owed to us under various licensing and other strategic arrangements, meeting our financial obligations under various licensing and other strategic arrangements, the funding of our clinical trials for product candidates, and the commercialization of the relevant technology;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to build and maintain the management and human resources infrastructure necessary to support the operation and/or growth of our business;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether a market is established for our products and our ability to capture a meaningful share of this market;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scientific, regulatory and medical developments beyond our control;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain, as applicable, appropriate governmental licenses, accreditations or certifications or to comply with healthcare laws and regulations or any other adverse effect or limitations caused by government regulation of our business;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether any of our current or future patent applications result in issued patents, the scope of those patents and our ability to obtain and maintain other rights to technology required or desirable for the conduct of our business,&#160;and our ability to commercialize products without infringing upon the claims of third-party patents;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether any potential strategic or financial benefits of various licensing agreements will be realized;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to diversify our pipeline of development product candidates, which could include an acquisition, merger, business combination, in-license or other strategic transaction, and whether any of such efforts will result in us entering into or completing any transaction or that any such transaction, if completed, will add to shareholder value;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our development activities; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to complete our other planned clinical trials (or initiate other trials) in accordance with our estimated timelines due to delays associated with enrolling patients due to the novelty of the treatment, the size of the patient population, competition with other clinical trials for similar subjects, patient and/or investigator site availability and accessibility due to external macroenvironmental factors and the need of patients to meet the inclusion criteria of the trial or otherwise;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which any future public health crisis and their long-term effects may impact, directly or indirectly, our business, including our clinical trials and financial condition; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors discussed in &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on February 27, 2025 (our &#8220;2024 Form 10-K&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The factors discussed herein, including those risks described in &#8220;Item 1A. Risk Factors&#8221; and elsewhere in our 2024 Form 10-K and in our other periodic filings with the SEC, which are available for review at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could cause actual results and developments to be materially different from those expressed or implied by such statements. All forward-looking statements attributable to us are expressly qualified in their entirety by these and other factors. Readers are cautioned not to place undue </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reliance on these forward-looking statements, which speak only as of the date they were made. Except as required by law, we undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></div><div style="margin-bottom:3.3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="margin-bottom:3.3pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:3.3pt;margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.164%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART I- FINANCIAL INFORMATION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page No.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_10">Financial Statements:</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_13">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_16">Consolidated Balance Sheets at March 31 2025 (unaudited) and December 31, 2024</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_16">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_19">Consolidated Statements of Operations for the three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_19"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_19">March 31, 2025</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_19"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_19">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_19"> (unaudited)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_19">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_22">Consolidated Statements of Comprehensive Loss for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_22">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_22">March 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_22">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_22">5</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_22"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_22">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_22"> (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_22">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_25">Consolidated Statements of Equity for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_25">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_25">March 31, 2025</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_25"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_25">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_25"> (unaudited) </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_25">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_31">Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_31">three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_31"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_31">Ma</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_31">rch 31, </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_31">2025</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_31"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_31">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_31"> (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_31">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Unaudited Consolidated Financial Statements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_34">10</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_94">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_106">31</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Controls and Procedures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_109">31</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART II- OTHER INFORMATION</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Legal Proceedings</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_115">33</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1A.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risk Factors</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_118">33</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_121">33</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Defaults Upon Senior Securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_124">33</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Mine Safety Disclosures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_127">33</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 5.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Information</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_130">33</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 6.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_133">33</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Signatures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i65296f168ea449b99126b2b55f877ea4_136">34</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></div></div></div><div id="i65296f168ea449b99126b2b55f877ea4_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_13"></div><div><span><br/></span></div><div><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands, except share data)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.067%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.951%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-30">20,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">16,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-32">5,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-33">15,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableNet" scale="3" id="f-34">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNet" scale="3" id="f-35">900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">2,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">2,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">28,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">34,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-40">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-41">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired license - intangible, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-42">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-43">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-44">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-45">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-46">28,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-47">35,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES, NON-CONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="f-48">602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">1,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">3,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">4,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">3,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">5,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-54">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-55">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-56">3,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-57">5,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commitments and Contingencies (Note 14)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-58"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-59"></ix:nonFraction></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-60"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-61">0.001</ix:nonFraction></ix:nonFraction> par value, authorized <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-62"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-63">500,000,000</ix:nonFraction></ix:nonFraction> shares; issued <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-64">8,620,900</ix:nonFraction></span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-65">8,409,582</ix:nonFraction> shares at March 31, 2025 and December 31, 2024, respectively; and </span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">outstanding, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-66">8,620,162</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-67">8,408,844</ix:nonFraction> shares at March 31, 2025 and December 31, 2024, </span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-68">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-69">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-70">578,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-71">578,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="0" id="f-72"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="0" id="f-73">738</ix:nonFraction></ix:nonFraction> shares at March 31, 2025 and December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:TreasuryStockCommonValue" scale="3" id="f-74">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TreasuryStockCommonValue" scale="3" id="f-75">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-76">552,790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-77">548,066</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-78">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-79">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Lisata Therapeutics, Inc. stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-80">25,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-81">29,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="f-82">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="f-83">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-84">25,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-85">29,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities, non-controlling interests and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-86">28,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-87">35,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands, except per share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"/><td style="width:65.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.202%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-88">2,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-89">3,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-90">3,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-91">3,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-92">5,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-93">6,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-94">5,847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-95">6,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-96">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-97">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-98">105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-99">187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-100">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-101">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net loss before benefit from income taxes and noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-102">5,686</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-103">6,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-104">962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-105">798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-106">4,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-107">5,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less - net income (loss) attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" format="ixt:fixed-zero" scale="3" id="f-108">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" format="ixt:fixed-zero" scale="3" id="f-109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Lisata Therapeutics, Inc. common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-110">4,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-111">5,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic and diluted loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lisata Therapeutics, Inc. common stockholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-112"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-113">0.55</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-114"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-115">0.65</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average common shares outstanding</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted shares</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-116"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-117">8,602</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-118"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-119">8,294</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 </span></div></div></div><div id="i65296f168ea449b99126b2b55f877ea4_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"><tr><td style="width:1.0%"/><td style="width:64.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-120">4,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-121">5,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive gain (loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale securities - net unrealized loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-122">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-123">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative translation adjustment arising during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-124">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-125">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-126">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-127">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss attributable to Lisata Therapeutics, Inc. common</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">stockholders</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-128">4,721</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-129">5,463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 </span></div></div></div><div id="i65296f168ea449b99126b2b55f877ea4_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-right:-2.25pt;text-align:center;text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.316%"><tr><td style="width:1.0%"/><td style="width:27.153%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.933%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.989%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.692%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.347%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.409%"/><td style="width:0.1%"/></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Lisata Therapeutics,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-130">8,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-131">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-132">576,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-133">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-134">528,081</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-135">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-136">48,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-137">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-138">47,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-139">5,401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-140">5,401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-141">5,401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-142">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-143">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-144">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-145">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-146">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-147">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-148">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-149">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-150">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-151">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-152">8,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-153">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-154">577,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-155">104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-156">533,482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-157">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-158">42,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-159">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-160">42,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.341%"><tr><td style="width:1.0%"/><td style="width:27.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.273%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.009%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.273%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.231%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.273%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.075%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.273%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.273%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.273%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.273%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.838%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.273%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.273%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.495%"/><td style="width:0.1%"/></tr><tr style="height:39pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Lisata Therapeutics,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-161">8,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-162">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-163">578,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-164">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-165">548,066</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-166">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-167">29,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-168">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-169">29,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-170">4,724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-171">4,724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-172">4,724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-173">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-174">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-175">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-176">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from issuances of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="f-177">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-178">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-179">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-180">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-181">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from option exercise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-182">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-183">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-184">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-185">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-186">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-187">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-188">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-189">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-190">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-191">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-192">8,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-193">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-194">578,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-195">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-196">552,790</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-197">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-198">25,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-199">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-200">25,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></div></div></div><div id="i65296f168ea449b99126b2b55f877ea4_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.831%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-201">4,724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-202">5,401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 39.25pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="f-203">530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="f-204">454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-205">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-206">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-207">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="f-208">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization/accretion on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-209">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-210">152</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-211">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-212">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-213">405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-214">872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-215">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-216">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="lsta:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-217">1,809</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="lsta:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-218">1,243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-219">5,402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-220">7,027</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-221">5,055</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-222">18,824</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sale of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-223">14,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-224">25,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-225">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in Impilo Therapeutics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-227">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="f-228">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-229">9,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-230">6,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-231">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-232">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax withholding payments on net share settlement equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-233">243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-234">142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-235">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-237">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-238">142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Effect of exchange rate changes on cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-239">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-240">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-241">4,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="f-242">788</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-243">16,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-244">22,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-245">20,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-246">21,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 </span></div></div></div><div id="i65296f168ea449b99126b2b55f877ea4_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_37"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 1&#160;&#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-247" continuedAt="f-247-1" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="f-247-1" continuedAt="f-247-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lisata Therapeutics, Inc. (together with its subsidiaries, the &#8220;Company&#8221;) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The Company's investigational product, certepetide (formerly known as LSTA1 or CEND-1), is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. Certepetide has also been shown to modify the tumor microenvironment (&#8220;TME&#8221;) by reducing T-regulatory cells and augmenting cytotoxic T cells, thereby making tumors more susceptible to immunotherapies while also inhibiting the metastatic cascade (i.e., the spread of cancer to other parts of the body). The Company, its collaborators and other researchers have amassed and continue to amass significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies, and RNA-based therapeutics. To date, certepetide has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. The Company is exploring certepetide as a means to enable a variety of therapeutic modalities to treat a range of solid tumors more effectively. Currently, certepetide is the subject of several Phase 2 clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), cholangiocarcinoma, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. The Company's goal is to develop and commercialize products that address important unmet medical needs. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a history of net operating losses and negative cash flows from operating activities, and has cash, cash equivalents and marketable securities of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="lsta:CashAndCashEquivalentsAndMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="f-248">25.8</ix:nonFraction>&#160;million as of March&#160;31, 2025. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenues from its products currently in development. To manage capital for operating needs in the short-term, initiation of the FORTIFIDE study remains on hold as the Company is investigating a potentially faster and more cost-effective approach to achieving the study objective. The Company has similarly decided to delay commencement of certain phase 3 readiness activities for chemistry, manufacturing and controls (&#8220;CMC&#8221;). The Company believes that, as a result, it currently has sufficient cash to meet its funding requirements over the next year. To meet our long-term liquidity needs, the Company expects that it will need additional financing, which could result in additional potential issuances of debt or equity securities in public or private financings, partnerships and/or collaborations and/or sale of assets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-249" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2025, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2024 and 2023 included in our 2024 Form 10-K. Operating results for the three months ended March&#160;31, 2025 are not necessarily indicative of the results that may be expected for the year ending December 31, 2025.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-250" continuedAt="f-250-1" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><ix:continuation id="f-247-2"><ix:continuation id="f-250-1"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-251" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" id="f-252">one</ix:nonFraction> operating segment, the research and development of its investigational drug product. The Company's Chief Operating Decision Maker (&#8220;CODM&#8221;) is its Chief Executive Officer, who manages the business on a consolidated basis.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-253" continuedAt="f-253-1" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-253-1">The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation</ix:continuation>.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-254" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.</span></div></ix:nonNumeric></ix:continuation><div id="i65296f168ea449b99126b2b55f877ea4_43"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 2 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-255" continuedAt="f-255-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-255-1" continuedAt="f-255-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-256" continuedAt="f-256-1" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-256-1">Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-257" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents, accounts receivable and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government, thereby reducing credit risk exposure. Cash is held at major banks in the United States and may exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return. The Company&#8217;s accounts receivable balance as of March&#160;31, 2025 and December&#160;31, 2024 is derived from its license agreement dated November 30, 2024, more fully described in Note 17. The Company has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-258" continuedAt="f-258-1" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Accounts receivable is stated at historical cost, less allowance for credit losses. The Company records an expense based on a forward-looking current expected credit loss model to maintain its allowance for credit losses, which replaced the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allowance for doubtful accounts. When determining its allowance for trade accounts receivable, the Company considers the probability of recoverability of accounts receivable based on experience, taking into account current collection trends and general economic factors, including bankruptcy rates. The Company also considers future economic trends to estimate expected</span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-258-1">credit losses over the lifetime of the asset. Credit risks are assessed based on historical write-offs, net of recoveries, as well as an analysis of the aged accounts receivable balances with allowances generally increasing as the receivable ages. Accounts receivable may be fully reserved for when specific collection issues are known to exist, such as pending bankruptcies. Account balances are written off against the allowance when it is determined that the receivable will not be recovered.</ix:continuation> As of March 31, 2025 and December 31, 2024, there was <ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt-sec:numwordsen" id="f-259"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt-sec:numwordsen" id="f-260">no</ix:nonFraction></ix:nonFraction> allowance for credit losses.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-261" continuedAt="f-261-1" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><ix:continuation id="f-255-2" continuedAt="f-255-3"><ix:continuation id="f-261-1"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities, that are not the result of credit losses, are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and credit losses recognized through an allowance for credit losses, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-262" continuedAt="f-262-1" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-262-1">The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-263" continuedAt="f-263-1" escape="true">The estimated useful lives of property and equipment are as follows:</ix:nonNumeric></span></div><ix:continuation id="f-263-1" continuedAt="f-263-2"><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:66.334%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.466%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-46" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-264">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-47" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-265">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-48" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-266">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or lease term</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentImpairment" id="f-267" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight-line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-268" continuedAt="f-268-1" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-268-1">The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Share-based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-269" continuedAt="f-269-1" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-269-1">Basic loss per share is based on the weighted effect of all shares of common stock issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock used in the basic loss per share calculation plus the number of shares of common stock that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><ix:continuation id="f-255-3" continuedAt="f-255-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityPolicyTextBlock" id="f-270" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" id="f-271" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (&#8220;R&amp;D&#8221;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive the Company&#8217;s initiatives, the Company will continue targeting key governmental agencies and not-for-profit organizations to contribute funds for the Company&#8217;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="f-272" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#8220;business&#8221; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Asset</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible asset consists of a single asset, a license agreement with Qilu Pharmaceutical, Co., Ltd. (&#8220;Qilu&#8221;) acquired in the Company's acquisition of Cend Therapeutics, Inc (the &#8220;Cend Merger&#8221;), with a value of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-273">0.4</ix:nonFraction>&#160;million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of <ix:nonNumeric contextRef="c-3" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-274">5.00</ix:nonNumeric> years. Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-275">17</ix:nonFraction>&#160;thousand for the three months ended March&#160;31, 2025, and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-276">17</ix:nonFraction>&#160;thousand for the three months ended March&#160;31, 2024, respectively. <ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="f-277" escape="true">The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.</ix:nonNumeric>  The projected amortization expense is $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-278"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-279"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-280">71</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;thousand per year for the next 2.50 years. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-281" continuedAt="f-281-1" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-281-1">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue.</ix:continuation> The Company recognized <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-282"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-283">no</ix:nonFraction></ix:nonFraction> revenue for the three months ended March&#160;31, 2025 and 2024.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="f-284" escape="true"><ix:continuation id="f-255-4"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#8217;s collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#8217;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three months ended March&#160;31, 2025 and March&#160;31, 2024, the Company has <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="f-285"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="f-286">not</ix:nonFraction></ix:nonFraction> recognized revenue related to milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has <ix:nonFraction unitRef="usd" contextRef="c-49" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-287">not</ix:nonFraction> recognized any royalty revenue from any collaborative arrangement.</span></div></ix:continuation></ix:nonNumeric><div id="i65296f168ea449b99126b2b55f877ea4_46"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 3 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="f-288" continuedAt="f-288-1" escape="true">Available-for-Sale Securities</ix:nonNumeric></span></div><ix:continuation id="f-288-1" continuedAt="f-288-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="f-289" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in the Company's Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-290">10,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-291">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-292">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-293">10,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-294">16,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-295">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-296">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-297">16,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-298">12,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-299">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-301">12,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-302">6,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-305">6,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="f-306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-307">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="f-310">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-311">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="f-313">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="f-314">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-316">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-318">1,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-321">1,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="f-322">560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="f-325">560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="f-326">905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-327">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="f-329">905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-330">22,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-331">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-332">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-333">22,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-334">25,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-336">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-337">25,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesTextBlock" id="f-338" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in the Company's Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:360.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-339">17,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-340">10,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-341">5,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-342">15,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-343">22,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-344">25,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="f-345" escape="true"><ix:continuation id="f-288-2"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:361.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-346">22,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-347">22,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="f-348">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" format="ixt:fixed-zero" scale="3" id="f-349">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-350">22,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-351">22,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_49"></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 4 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-352" continuedAt="f-352-1" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="f-352-1"><ix:continuation id="f-263-2"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"><tr><td style="width:1.0pt"/><td style="width:358.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-353">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-354">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-355">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-356">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-357">689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-358">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-359">615</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-360">589</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-361">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-362">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results included depreciation expense of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-363">26</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-364">29</ix:nonFraction>&#160;thousand for the three months ended March&#160;31, 2025 and 2024, respectively.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_52"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 5 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-365" continuedAt="f-365-1" escape="true">Income (Loss) Per Share</ix:nonNumeric></span></div><ix:continuation id="f-365-1"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2025 and 2024, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive in the periods presented. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-366" continuedAt="f-366-1" escape="true">At March&#160;31, 2025 and 2024, the Company excluded the following potentially dilutive securities (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-366-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-63" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-367">1,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-368">1,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-369">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-66" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-370">1,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-67" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-371">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-68" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-372">354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i65296f168ea449b99126b2b55f877ea4_55"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 6 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-373" continuedAt="f-373-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="f-373-1" continuedAt="f-373-2"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 inputs are defined as unobservable inputs for the assets or liabilities. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><ix:continuation id="f-373-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="f-374" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March&#160;31, 2025 and December&#160;31, 2024 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:116.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:12.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-375">17,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-376">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-378">17,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-379">10,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-382">10,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available-for-sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-384">5,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-385">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-386">5,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-388">15,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-389">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-390">15,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-391">17,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-392">5,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-393">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-394">22,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-395">10,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-396">15,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-397">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-398">25,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash, cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value as of March&#160;31, 2025 and December&#160;31, 2024, due to the short maturity nature of these items.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_58"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 7&#160;&#8211;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-399" continuedAt="f-399-1" escape="true">Accrued Liabilities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-400" escape="true"><ix:continuation id="f-399-1"><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of March&#160;31, 2025 and December&#160;31, 2024 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"/><td style="width:313.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-401">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-402">2,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and R&amp;D related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lsta:ClinicalAndRDRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-403">1,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lsta:ClinicalAndRDRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-404">1,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting &amp; tax consulting liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lsta:AccruedGrantFunding" scale="3" id="f-405">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="lsta:AccruedGrantFunding" scale="3" id="f-406">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities &#8212; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-407">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-408">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-409">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-410">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-411">3,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-412">4,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_61"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 8&#160;&#8211;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-413" continuedAt="f-413-1" escape="true">Operating Leases</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-414" escape="true"><ix:continuation id="f-413-1" continuedAt="f-413-2"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an operating lease for one office which expires on September 30, 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as the Company's lease does not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of ASU No. 2016-02, Leases (Topic 842), the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.</span></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><ix:continuation id="f-413-2"><ix:nonNumeric contextRef="c-1" name="lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" id="f-415" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of the Company's balance sheet as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-416"><span style="-sec-ix-hidden:f-417">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-418">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-419">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-420">93</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-421">138</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-422"><span style="-sec-ix-hidden:f-423">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-424">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-425">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="f-426">92</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="f-427">137</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the weighted average remaining lease term for the Company's operating lease was <ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-428">0.50</ix:nonNumeric> years, and the weighted average discount rate for the Company's operating lease was <ix:nonFraction unitRef="number" contextRef="c-3" decimals="5" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-429">9.625</ix:nonFraction>%. As of December&#160;31, 2024, the weighted average remaining lease term for the Company's operating lease was <ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-430">0.75</ix:nonNumeric> years, and the weighted average discount rate for the Company's operating lease was <ix:nonFraction unitRef="number" contextRef="c-4" decimals="5" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-431">9.625</ix:nonFraction>%.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-432" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under the lease agreement as of March&#160;31, 2025 were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:448.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="f-433">95</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="f-434">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-435">3</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="f-436">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_64"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 9 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-437" continuedAt="f-437-1" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="f-437-1" continuedAt="f-437-2"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Issuances</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">At The Market Offering Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC, as sales agent, in connection with an &#8220;at the market offering&#8221; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="lsta:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" format="ixt:num-dot-decimal" scale="6" id="f-438">50.0</ix:nonFraction>&#160;million. As of the date of this filing and so long as the Company&#8217;s public float remains below $75.0 million, the Company is subject to limitations pursuant to General Instruction I.B.6 of Form S-3 (the &#8220;Baby Shelf Limitation&#8221;), which limits the amount the Company can offer to up to one-third of its public float during any trailing 12-month period. Subsequent to the filing of a prospectus supplement to the Company's Registration Statement on Form S-3 (File No. 333-279034) relating to the at the market offering on August 21, 2024, the aggregate market value of its outstanding common stock held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:CommonStockValueOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-439">29.6</ix:nonFraction>&#160;million. Pursuant to the Baby Shelf Limitation, since the aggregate market value of the Company's outstanding common stock held by non-affiliates was below $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="lsta:OutstandingStockThreshold" format="ixt:num-dot-decimal" scale="6" id="f-440">75.0</ix:nonFraction>&#160;million at the time of such prospectus supplement filing, the aggregate amount of securities that the Company is permitted to offer and sell is now $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="0" name="lsta:SaleOfStockAvailableForSale" format="ixt:num-dot-decimal" scale="0" id="f-441">9,855,890</ix:nonFraction>, which is equal to one-third of the aggregate market value of our common stock held by non-affiliates as of August 20, 2024. If the Company&#8217;s public float exceeds $75.0&#160;million on a future measurement date, it will no longer be subject to the Baby Shelf Limitation. During the three months ended March&#160;31, 2025, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-81" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-442">55,578</ix:nonFraction> shares of common stock under the ATM Agreement for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-443">211,369</ix:nonFraction>. Since inception, the Company has issued <ix:nonFraction unitRef="shares" contextRef="c-82" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-444">123,751</ix:nonFraction> shares of common stock under the ATM Agreement for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-445">492,216</ix:nonFraction>.  </span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><ix:continuation id="f-437-2" continuedAt="f-437-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Warrants</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-446" continuedAt="f-446-1" escape="true">The following table summarizes the activity for stock options and warrants for the three months ended March&#160;31, 2025:</ix:nonNumeric></span></div><ix:continuation id="f-446-1"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-447">1,440,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-448">8.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-83" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-449">5.46</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-450">157.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="lsta:CommonStockWarrantsShares" format="ixt:num-dot-decimal" scale="0" id="f-451">1,496,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsOutstanding" scale="0" id="f-452">40.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-83" name="lsta:WeightedAverageRemainingContractualTermWarrantOutstanding" format="ixt-sec:duryear" id="f-453">1.29</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-2" name="lsta:AggregateIntrinsicValueWarrantsOutstanding" scale="3" id="f-454">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-455">111,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-456">3.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="lsta:WarrantsGranted" format="ixt:fixed-zero" scale="0" id="f-457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsGranted" format="ixt:fixed-zero" scale="0" id="f-458">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-459">4,329</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-460">1.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="lsta:WarrantsExercised" format="ixt:fixed-zero" scale="0" id="f-461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsExercised" format="ixt:fixed-zero" scale="0" id="f-462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="f-463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="lsta:WarrantsCanceled" format="ixt:fixed-zero" scale="0" id="f-465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsCanceled" format="ixt:fixed-zero" scale="0" id="f-466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-467">18,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-468">198.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="lsta:WarrantsExpired" format="ixt:fixed-zero" scale="0" id="f-469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsExpired" format="ixt:fixed-zero" scale="0" id="f-470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-471">1,529,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-472">6.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-473">5.62</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-474">79.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="lsta:CommonStockWarrantsShares" format="ixt:num-dot-decimal" scale="0" id="f-475">1,496,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsOutstanding" scale="0" id="f-476">40.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="lsta:WeightedAverageRemainingContractualTermWarrantOutstanding" format="ixt-sec:duryear" id="f-477">1.05</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lsta:AggregateIntrinsicValueWarrantsOutstanding" format="ixt:fixed-zero" scale="3" id="f-478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2025<br/>or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-479">1,517,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-480">6.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-481">5.59</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="f-482">79.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="lsta:Sharesvestedandexpectedtovest" format="ixt:num-dot-decimal" scale="0" id="f-483">1,496,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" scale="0" id="f-484">40.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="lsta:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" format="ixt-sec:duryear" id="f-485">1.05</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lsta:AggregateIntrinsicValueWarrantsVestedAndExpectedToVest" format="ixt:fixed-zero" scale="3" id="f-486">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-487">1,344,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-488">6.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="lsta:OptionsVestedWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="f-489">5.14</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="f-490">78.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="lsta:WarrantsVested" format="ixt:num-dot-decimal" scale="0" id="f-491">1,496,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="lsta:WeightedAverageExercisePriceWarrantsExercisable" scale="0" id="f-492">40.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="lsta:WeightedAverageRemainingContractualTermWarrantsVested" format="ixt-sec:duryear" id="f-493">1.05</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="lsta:AggregateIntrinsicValueWarrantsVested" format="ixt:fixed-zero" scale="3" id="f-494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="f-495" continuedAt="f-495-1" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2025 and 2024, the Company issued restricted stock for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"/><td style="width:322.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:4.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-84" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-496">215,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-85" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-497">203,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-498">819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-499">628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average estimated fair value of restricted stock issued for services in the three months ended March&#160;31, 2025 and 2024 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-84" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-500">3.80</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-85" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-501">3.08</ix:nonFraction> per share, respectively. The fair value of the restricted stock was determined using the Company&#8217;s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally between <span style="-sec-ix-hidden:f-502">one</span> and <ix:nonNumeric contextRef="c-87" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-503">four years</ix:nonNumeric>.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:continuation id="f-495-1"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the changes in non-vested restricted stock for the three months ended March&#160;31, 2025:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"><tr><td style="width:1.0%"/><td style="width:33.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.305%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Stock Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-88" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-504">228,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-88" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-505">3.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the Year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-84" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-506">215,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-84" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-507">3.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-84" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-508">149,367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-84" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-509">4.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-84" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="f-510">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-84" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-511">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-89" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-512">294,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-89" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-513">3.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><ix:continuation id="f-437-3"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="f-514" continuedAt="f-514-1" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2025 and 2024, the Company issued restricted stock units for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"/><td style="width:343.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-515">78,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-516">205,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-517">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-518">632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average estimated fair value of restricted stock units issued for services in the three months ended March&#160;31, 2025 and 2024 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-84" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-519">3.80</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-85" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-520">3.08</ix:nonFraction> per share, respectively. The fair value of the restricted stock units was determined using the Company&#8217;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally <ix:nonNumeric contextRef="c-90" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-521">one year</ix:nonNumeric>, or upon the achievement of performance-based milestones. </span></div><ix:continuation id="f-514-1"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the changes in non-vested restricted stock units for the three months ended March&#160;31, 2025:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"><tr><td style="width:1.0%"/><td style="width:33.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.305%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-92" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-522">103,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-92" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-523">3.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the Year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-524">78,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-90" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-525">3.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-526">97,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-90" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-527">3.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="f-528">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-90" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-529">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-93" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-530">85,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-93" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-531">3.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_70"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 10 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-533" continuedAt="f-533-1" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-533-1" continuedAt="f-533-2"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes share-based compensation in the form of stock options, restricted stock, restricted stock units and warrants.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-534" continuedAt="f-534-1" escape="true">The following table summarizes the components of share-based compensation expense for the three months ended March&#160;31, 2025 and 2024 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-534-1"><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.491%"><tr><td style="width:1.0%"/><td style="width:62.499%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.282%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.620%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-535">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-536">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-537">404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-538">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-539">530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-540">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-541" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March&#160;31, 2025 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"/><td style="width:61.271%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.583%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.755%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.002%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.587%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="f-542">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="f-543">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="f-544">925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-100" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-545">2.21</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-90" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-546">0.75</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-84" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-547">2.32</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><ix:continuation id="f-533-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-548" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March&#160;31, 2025 and 2024 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:530.25pt"><tr><td style="width:1.0pt"/><td style="width:257.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrants</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="f-549">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="f-550">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="f-551">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:fixed-zero" scale="3" id="f-552">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-100" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-553">2.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-554">2.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-555">1.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-556">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#8217;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_73"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 11 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-557" continuedAt="f-557-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-557-1" continuedAt="f-557-2"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="lsta:OperatingLossCarryforwardsBeforeWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-558">57.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="lsta:OperatingLossCarryforwardsBeforeWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-559">43.7</ix:nonFraction>&#160;million, respectively, of Federal NOLs available to offset future taxable income expiring from 2030 through 2036.  The Company performed an analysis and determined that they had an ownership change of greater than 50% on September 15, 2022. As a result of the ownership change, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-560">88.2</ix:nonFraction>&#160;million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-561">34.0</ix:nonFraction>&#160;million of remaining Federal NOLs as of December 31, 2022. The write-off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the consolidated balance sheet or income statement. Losses incurred before the ownership change on September 15, 2022 will be subject to an annual limitation of zero while losses incurred after September 15, 2022 will not be subject to limitations. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, Cend Therapeutics, Inc. (&#8220;Cend&#8221;) had approximately $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-562">3.6</ix:nonFraction>&#160;million of Federal NOLs available to offset future taxable income. The Company performed an analysis and determined that there was an ownership change of greater than 50% on September 15, 2022. As of September 15, 2022 Cend has approximately $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-563">3.1</ix:nonFraction>&#160;million of Federal and $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-564">4.3</ix:nonFraction>&#160;million of state NOLs. The state NOLs will expire from the 2036 through 2042 tax years.  Using a fair market value of $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="lsta:FairValueMarketOfTaxNOLs" format="ixt:num-dot-decimal" scale="6" id="f-565">36.1</ix:nonFraction>&#160;million and applying an applicable federal rate of <ix:nonFraction unitRef="number" contextRef="c-109" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-566">2.54</ix:nonFraction>% Cend will have an annual limitation of approximately $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="lsta:NetCarryforwardOperatingLossCarryforwardAnnualLimitation" format="ixt:num-dot-decimal" scale="3" id="f-567">917</ix:nonFraction>&#160;thousand each year. The Federal NOL of $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="lsta:OperatingLossCarryforwardsPostAcquisition" format="ixt:num-dot-decimal" scale="3" id="f-568">459</ix:nonFraction>&#160;thousand incurred in the post-acquisition period September 15, 2022 to December 31, 2022 is not subject to limitation, and does not expire. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the Company's wholly owned Australian subsidiary had approximately $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-569">2.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-570">2.4</ix:nonFraction>&#160;million, respectively, of NOLs which will be carried forward and do not expire. There is a full valuation allowance against the NOLs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had federal research and development credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-571">0.5</ix:nonFraction>&#160;million expiring from 2027 through 2034 if unutilized, and state research and development credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-572">0.1</ix:nonFraction>&#160;million, which carryforward indefinitely.  Utilization of these credits may be subject to an annual limitation based on changes in ownership.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the Company had State NOLs available in New Jersey of $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-573">24.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-574">19.4</ix:nonFraction>&#160;million, respectively, California of $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-575">9.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-576">9.2</ix:nonFraction>&#160;million, respectively, and New York City of $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-577">1.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-578">1.9</ix:nonFraction>&#160;million, respectively, to offset future taxable income expiring from 2032 through 2044. The usage of the Company&#8217;s NOLs is limited given the change in ownership.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the Financial Accounting Standards Board provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><ix:continuation id="f-557-2"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the Company&#8217;s uncertain tax positions were $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-579">344</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-580">344</ix:nonFraction>&#160;thousand, respectively. The uncertain tax positions are due to the acquisition of Cend related to Federal and state credits and certain state NOLs. The Company will continue to evaluate its uncertain tax positions in future periods. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For years prior to 2021, the federal statute of limitations is closed for assessing tax. The Company&#8217;s state tax returns remain open to examination for a period of three to four years from the date of the tax return filing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, the Company sold a portion of their unused New Jersey net operating losses through the State of New Jersey Economic Development Authority's (&#8220;NJEDA&#8221;) Technology Business Tax Certificate Transfer Program (&#8220;Program&#8221;). Under the Program, the Company sold $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="lsta:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" format="ixt:num-dot-decimal" scale="6" id="f-581">10.7</ix:nonFraction>&#160;million of its New Jersey net operating losses (&#8220;NJ NOLs&#8221;) for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="lsta:ProceedsFromSaleOfNOLS" format="ixt:num-dot-decimal" scale="3" id="f-582">871</ix:nonFraction>&#160;thousand. The sale of NJ NOLs resulted in a $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-583">962</ix:nonFraction>&#160;thousand deferred income tax benefit and a loss on sale of $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="lsta:LossOnSaleOfNOL" format="ixt:num-dot-decimal" scale="3" id="f-584">91</ix:nonFraction>&#160;thousand recorded in other income (expense) in the consolidated financial statements.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_1085"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 12 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-585" continuedAt="f-585-1" escape="true">Segment Information</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-585-1" continuedAt="f-585-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" id="f-586">one</ix:nonFraction> operating segment, the research and development of its investigational drug product. The Company used the management approach to determine its reportable operating segment. The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer, who reviews financial information presented on a consolidated basis. The Company is a clinical-stage pharmaceutical company and has limited revenue associated with a license and collaboration agreement. The CODM uses net loss as a measure of profit and loss, and assesses Company performance through the achievement of its clinical development goals. The CODM is regularly provided with budgeted and forecasted expense information which is used to determine the Company&#8217;s liquidity needs and cash allocation to its development programs. The CODM uses cash and marketable securities as a measure of segment assets in managing the enterprise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt-sec:numwordsen" id="f-587"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt-sec:numwordsen" id="f-588">no</ix:nonFraction></ix:nonFraction> revenue during the three months ended March&#160;31, 2025 and 2024. Depreciation and amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-589">43</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-590">46</ix:nonFraction> thousand for the three months ended March&#160;31, 2025 and 2024, respectively. Equity method investment expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="f-591">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="f-592">100</ix:nonFraction> thousand for the three months ended March&#160;31, 2025 and 2024, respectively. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates our segment information for significant operating expenses and includes a reconciliation to net loss for the three months ended March&#160;31, 2025 and 2024:</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-593" escape="true"><ix:continuation id="f-585-2"><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"><tr><td style="width:1.0%"/><td style="width:67.018%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.405%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.406%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development by significant expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;BOLSTER trial</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="f-594">788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-595">1,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;ASCEND trial</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="f-596">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="f-597">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Chemistry, manufacturing and controls</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="f-598">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="f-599">655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Clinical department</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-600">1,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-601">1,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="f-602">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="f-603">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-604">2,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-605">3,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative by significant expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-606">1,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-607">1,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Investor relations/public relations/communications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:CommunicationsAndInformationTechnology" scale="3" id="f-608">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:CommunicationsAndInformationTechnology" scale="3" id="f-609">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Finance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="lsta:FinanceGeneralAndAdministrativeExpense" scale="3" id="f-610">629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="lsta:FinanceGeneralAndAdministrativeExpense" scale="3" id="f-611">580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Legal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="lsta:LegalGeneralAndAdministrativeExpense" scale="3" id="f-612">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="lsta:LegalGeneralAndAdministrativeExpense" scale="3" id="f-613">671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Business development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:BusinessDevelopment" scale="3" id="f-614">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:BusinessDevelopment" scale="3" id="f-615">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Share based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="lsta:ShareBasedCompensationExpenseGeneralAndAdministrativeExpense" scale="3" id="f-616">404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="lsta:ShareBasedCompensationExpenseGeneralAndAdministrativeExpense" scale="3" id="f-617">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="f-618">386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="f-619">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-620">3,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-621">3,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-622">5,847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-623">6,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-624">161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-625">402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-626">962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-627">798</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-628">4,724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-629">5,401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="lsta:CashCashEquivalentsAndMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-630">25,833</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="lsta:CashCashEquivalentsAndMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-631">43,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Included in Other are the GBM study, FORTIFIDE study and research </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;oncology expenses</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Included in Other are facilities expense, human resource </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;and information technology expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 13 &#8211; <ix:nonNumeric contextRef="c-1" name="lsta:ResearchAndDevelopmentTaxIncentiveTextBlock" id="f-632" continuedAt="f-632-1" escape="true">Australia Research and Development Tax Incentive</ix:nonNumeric></span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-632-1">The Company&#8217;s Australian subsidiary, which conducts core research and development activities, is eligible to receive a refundable tax incentive between <ix:nonFraction unitRef="number" contextRef="c-138" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-633">43.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-139" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-634">48.5</ix:nonFraction>% (depending upon the income tax rate) for qualified research and development activities. As of March&#160;31, 2025 and December&#160;31, 2024, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="lsta:IncomeTaxIncentiveReceivable" format="ixt:num-dot-decimal" scale="6" id="f-635">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="lsta:IncomeTaxIncentiveReceivable" format="ixt:num-dot-decimal" scale="6" id="f-636">0.6</ix:nonFraction>&#160;million, respectively, recorded as an income tax incentive receivable in prepaid and other current assets in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed.</ix:continuation> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_79"></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 14 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-637" continuedAt="f-637-1" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-637-1" continuedAt="f-637-2"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results. The Company has elected to recognize expense for legal fees as incurred when the legal services are provided.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-637-2">In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (&#8220;Lingmed&#8221;) claiming Lingmed was entitled to a success fee based on Cend&#8217;s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend&#8217;s response to the complaint was filed on June 6, 2022 and denied all of Lingmed&#8217;s material allegations. Lingmed filed an answer to Cend&#8217;s response on July 11, 2022, denying all of the Company&#8217;s material allegations. On March 25, 2024 the Company entered into a settlement agreement whereby the Company was required to pay Lingmed $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-638">0.5</ix:nonFraction>&#160;million within <ix:nonNumeric contextRef="c-140" name="lsta:LitigationSettlementPaymentTerm" format="ixt-sec:durday" id="f-639">30</ix:nonNumeric> days of the effective date and the Company effected payment on April 4, 2024. Lingmed is also entitled to <ix:nonFraction unitRef="number" contextRef="c-141" decimals="INF" name="lsta:LitigationSettlementFutureMilestonePaymentsPercent" scale="-2" id="f-640">5.0</ix:nonFraction>% of any future milestone payments received by the Company under the license agreement with Qilu in addition to a sum of $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="lsta:LitigationSettlementMilestonePayment" scale="3" id="f-641">250</ix:nonFraction> thousand with respect to the first future milestone received by the Company. On April 9, 2024, pursuant to the parties&#8217; joint request, the Court entered a dismissal with prejudice of the entire action as to all parties and all claims and the matter was settled.</ix:continuation> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_82"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 15 &#8211; <ix:nonNumeric contextRef="c-1" name="lsta:TechnologyTransferAgreementTextBlock" id="f-642" continuedAt="f-642-1" escape="true">Technology Transfer Agreement</ix:nonNumeric></span></div><ix:continuation id="f-642-1"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impilo Therapeutics </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the Company entered into a technology transfer agreement with Impilo Therapeutics (&#8220;Impilo&#8221;) under which the Company transferred its rights to its tumor penetrating nanocomplex (TPN) platform to Impilo. As consideration for the technology transfer, Impilo issued a total of <ix:nonFraction unitRef="shares" contextRef="c-142" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-643">766,000</ix:nonFraction> shares of its pre-seed preferred stock to the Company. On October 3, 2023, in connection with the Sanford Burnham Prebys license agreement (see Note 16 - License Agreements) Impilo cancelled the original stock certificate for <ix:nonFraction unitRef="shares" contextRef="c-143" decimals="INF" name="lsta:InvestmentOwnedCanceledShares" format="ixt:num-dot-decimal" scale="0" id="f-644">766,000</ix:nonFraction> shares and reissued <ix:nonFraction unitRef="shares" contextRef="c-143" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-645">574,500</ix:nonFraction> shares of its pre-seed preferred stock to the Company. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2024, the Company purchased a Simple Agreement for Future Equity ("SAFE") from Impilo for $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-646">100</ix:nonFraction>&#160;thousand. On July 12, 2024, the Company purchased an additional SAFE from Impilo for $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-647">30</ix:nonFraction>&#160;thousand. As of March&#160;31, 2025 and December&#160;31, 2024, the Company owned <ix:nonFraction unitRef="number" contextRef="c-146" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-648"><ix:nonFraction unitRef="number" contextRef="c-147" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-649">38.6</ix:nonFraction></ix:nonFraction>% of Impilo. These investments were expensed under the equity method of accounting in the prior year in other expense, net in the accompanying statement of operations. The SAFE has a valuation cap of $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="lsta:SAFEValuationCap" format="ixt:num-dot-decimal" scale="6" id="f-650">30.0</ix:nonFraction>&#160;million and an <ix:nonFraction unitRef="number" contextRef="c-146" decimals="2" name="lsta:SAFEDiscountRate" scale="-2" id="f-651">80</ix:nonFraction>% discount rate.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_85"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 16 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-652" continuedAt="f-652-1" escape="true">License Agreements</ix:nonNumeric></span></div><ix:continuation id="f-652-1" continuedAt="f-652-2"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanford Burnham Prebys</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (&#8220;SBP&#8221;) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of certepetide. At the time the license agreement was entered into, Cend&#8217;s founding shareholder was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of <ix:nonFraction unitRef="shares" contextRef="c-148" decimals="INF" name="lsta:SharesIssuedUnderLicenseAgreement" format="ixt:num-dot-decimal" scale="0" id="f-653">382,030</ix:nonFraction> shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" format="ixt:num-dot-decimal" scale="3" id="f-654">10</ix:nonFraction>&#160;thousand increasing to $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" format="ixt:num-dot-decimal" scale="3" id="f-655">20</ix:nonFraction>&#160;thousand on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="lsta:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" format="ixt:num-dot-decimal" scale="6" id="f-656">10.6</ix:nonFraction>&#160;million. The Company has also agreed to pay SBP royalties of <ix:nonFraction unitRef="number" contextRef="c-148" decimals="INF" name="lsta:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" scale="-2" id="f-657">4</ix:nonFraction>% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP <ix:nonFraction unitRef="number" contextRef="c-148" decimals="INF" name="lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="f-658">25</ix:nonFraction>% of any sublicensing income received, which, pursuant to the technology transfer agreement with Impilo, resulted in SBP receiving <ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-659">191,500</ix:nonFraction> shares of the Company&#8217;s pre-seed preferred stock in Impilo on October 3, 2023. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreement may be terminated in its entirety by the Company at any time by giving SBP sixty days&#8217; prior written notice. The agreement may be terminated in its entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreement may be terminated in its entirety by either SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><ix:continuation id="f-652-2" continuedAt="f-652-3"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreement for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SBP did <ix:nonFraction unitRef="shares" contextRef="c-150" decimals="INF" name="lsta:SharesHeldByThirdParty" format="ixt-sec:numwordsen" id="f-660">no</ix:nonFraction>t own shares of the Company&#8217;s common stock as of March&#160;31, 2025. </span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_88"></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 17 &#8211; <ix:continuation id="f-652-3" continuedAt="f-652-4">Research Collaboration and License Agreements</ix:continuation></span></div><ix:continuation id="f-652-4"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement - Qilu Pharmaceuticals</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the &#8220;Qilu Agreement&#8221;) in which Cend granted an exclusive license to Qilu for the development and commercialization of certepetide in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of certepetide in its Territory. In consideration for the license, Qilu made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-661">10.0</ix:nonFraction>&#160;million to Cend, which was recognized as revenue by Cend prior to the Company's acquisition of Cend on September 15, 2022 (the &#8220;Cend Merger&#8221;). In addition, Cend received and recognized as revenue a $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-662">5.0</ix:nonFraction>&#160;million development milestone prior to the Cend Merger. The Company is eligible to receive additional development and commercial milestone payments up to $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-663">96.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-664">125.0</ix:nonFraction>&#160;million, respectively, tiered royalties on net sales ranging from <ix:nonFraction unitRef="number" contextRef="c-153" decimals="INF" name="lsta:RevenuePerformanceObligationPercentageOfNetSale" scale="-2" id="f-665">10</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-154" decimals="INF" name="lsta:RevenuePerformanceObligationPercentageOfNetSale" scale="-2" id="f-666">15</ix:nonFraction>%, and tiered sublicensing revenues ranging from <ix:nonFraction unitRef="number" contextRef="c-153" decimals="INF" name="lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues" scale="-2" id="f-667">12</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-154" decimals="INF" name="lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues" scale="-2" id="f-668">35</ix:nonFraction>%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2024, the Company entered into a settlement agreement with Lingmed whereby Lingmed is entitled to <ix:nonFraction unitRef="number" contextRef="c-141" decimals="INF" name="lsta:LitigationSettlementFutureMilestonePaymentsPercent" scale="-2" id="f-669">5.0</ix:nonFraction>% of any future milestone payments received by the Company under the Qilu Agreement, in addition, Lingmed is also entitled to a sum of $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="lsta:LitigationSettlementMilestonePayment" scale="3" id="f-670">250</ix:nonFraction> thousand with respect to the first future milestone received by the Company. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least <ix:nonNumeric contextRef="c-155" name="lsta:ResearchCollaborationAndLicenseAgreementOptionToTerminate" format="ixt-sec:durwordsen" id="f-671">sixty days</ix:nonNumeric> written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate simultaneously.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement - Kuva Labs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Company entered into an Exclusive License and Collaboration Agreement in which the Company granted an exclusive license to Kuva Labs, Inc. (Kuva) to explore the synergistic potential of the Company's certepetide as a targeting and delivery agent for Kuva&#8217;s NanoMark&#8482; imaging technology in solid tumors. Under the Agreement, Kuva will assume full responsibility for research, development, and commercialization costs, while the Company will be responsible for supplying certepetide for additional consideration pursuant to a Clinical Supply Agreement. In consideration for the license, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-672">1.0</ix:nonFraction>&#160;million as revenue upon delivery of the license in November 2024. The Company is eligible to receive additional development and commercial milestone payments up to $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-673">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-674">17.5</ix:nonFraction>&#160;million, respectively, a <ix:nonFraction unitRef="number" contextRef="c-159" decimals="INF" name="lsta:RevenuePerformanceObligationPercentageOfNetSale" scale="-2" id="f-675">5.0</ix:nonFraction>% percent royalty on net sales, and sublicensing revenues of <ix:nonFraction unitRef="number" contextRef="c-159" decimals="INF" name="lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues" scale="-2" id="f-676">50</ix:nonFraction>%.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24 </span></div></div></div><div id="i65296f168ea449b99126b2b55f877ea4_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that are subject to significant risks and uncertainties. There is no guarantee that our clinical development programs will be successful or result in the necessary regulatory approvals. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; herein and under &#8220;Risk Factors&#8221; in our 2024 Form 10-K. The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report and in our 2024 Form 10-K.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Our investigational product, certepetide (formerly known as LSTA1 or CEND-1), is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. Certepetide has also been shown to modify the tumor microenvironment (&#8220;TME&#8221;) by reducing T-regulatory cells and augmenting cytotoxic T cells, thereby making tumors more susceptible to immunotherapies while also inhibiting the metastatic cascade (i.e., the spread of cancer to other parts of the body). We, our collaborators and other researchers have amassed and continue to amass significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies, and RNA-based therapeutics. To date, certepetide has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. We are exploring certepetide as a means to enable a variety of therapeutic modalities to treat a range of solid tumors more effectively. Currently, certepetide is the subject of several Phase 2 clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), cholangiocarcinoma, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. Our goal is to develop and commercialize products that address important unmet medical needs. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Targeted Solid Tumor Penetration via CendR Active Transport</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many solid tumor cancers, including, for example, pancreatic ductal adenocarcinoma (&#8220;PDAC&#8221;) and cholangiocarcinoma, are surrounded by dense fibrotic tissue, known as the tumor stroma. This stroma often limits the penetration of anti-cancer therapies including chemotherapy into the tumor and thus limits their efficacy. Emerging immunotherapies, including but not limited to checkpoint inhibitors and adoptive cell therapies (e.g., chimeric antigen receptor T cells (CAR-Ts)), also face challenges in effectively treating solid tumors. Many tumors exhibit an immunosuppressive TME, which suppresses a patient's immune system and can thus limit the effectiveness of immunotherapies and/or contribute to metastases. These factors, i.e., the combination of a dense stroma and an immunosuppressive TME, negatively impact the ability of many therapeutic agents to optimally treat these cancers.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To address the tumor stroma&#8217;s role as a key impediment to effective treatment, our approach is to activate the C-end rule (&#8220;CendR&#8221;), or CendR active transport mechanism, a naturally occurring transport system. Our investigational drug, certepetide (a specific, proprietary </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">internalizing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> R-G-D or iRGD peptide), activates this transport system in a tumor-specific manner (Sugahara, Science, 2010). Certepetide enables more selective and efficient uptake of systemically administered anti-cancer drugs resulting in more intratumoral drug accumulation. The overall expected result is enhanced anticancer activity without an increase in systemic adverse side effects. While it is possible to couple/tether or conjugate some anticancer drugs to certepetide, we believe that our initial approach of co-administration of certepetide with anti-cancer therapies is advantageous. Co-administration does not create a new chemical entity (&#8220;NCE&#8221;) with its attendant development and regulatory hurdles, thereby providing an anticipated faster-to-clinic and faster-to-market product opportunity for a range of combination therapies. That said, an attractive life-cycle management strategy for certepetide would be to molecularly bind it to a variety of anti-cancer agents (as an alternative to co-administration), thereby creating new NCEs with the potential for distinct patent protection, compositionally or otherwise.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certepetide has demonstrated favorable safety, tolerability, and activity to date in clinical trials enhancing the selective delivery of standard-of-care chemotherapies for mPDAC. Certepetide&#8217;s cancer targeting characteristics may also enable </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">emerging solid tumor treatment modalities to prove more effective. For example, preliminary results of certepetide in combination with both immunotherapy and chemotherapy are promising. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certepetide as a treatment for solid tumor cancers in combination with other anti-cancer agents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certepetide is an investigational drug that actuates the CendR active transport mechanism. Certepetide has been shown to modify the TME, making it less immunosuppressive and thereby making the tumor more susceptible to attack by the immune system while also inhibiting the metastatic cascade. It targets tumor vasculature, endothelial cells, tumor cells and some intratumoral immunosuppressive cells by its selective affinity for alpha-v beta-3 and alpha-v beta-5 integrins that are upregulated on these cells. Certepetide is a nine amino acid cyclic proprietary internalizing RGD (&#8220;iRGD&#8221;) peptide that, once bound to these integrins, undergoes proteolytic cleavage to release a linear peptide fragment, called a CendR peptide fragment. After dissociation from the integrin receptor, the CendR peptide fragment then binds with high selectivity and affinity to an adjacent receptor, called neuropilin-1, also upregulated in solid tumors, to activate the novel uptake pathway that allows circulating anticancer drugs to more selectively and effectively penetrate solid tumors. The ability of certepetide and iRGD peptides to modify the TME to enhance delivery and efficacy of co-administered drugs has been demonstrated in many preclinical models in a range of solid tumors. Lisata, its collaborators, and research groups around the world have published more than 370 scientific papers related to the benefits of internalizing RGD peptides and the CendR pathway.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinically, certepetide was the subject of a completed Phase 1b/2a trial inclusive of 31 first-line mPDAC patients, of which 29 were evaluable. Results from the trial showed that the safety profile of the certepetide combination regimen was similar to standard of care (&#8220;SoC&#8221;) chemotherapy alone, with certepetide being well-tolerated with no dose limiting toxicities. An Objective Response Rate (&#8220;ORR&#8221;) of 59% was observed, compared to the 23% ORR observed in the &#8220;MPACT&#8221; clinical trial that served as the basis for approval of the chemotherapy combination nab-paclitaxel and gemcitabine for the treatment of first line mPDAC (Von Hoff, et al. 2013). A Disease Control Rate (&#8220;DCR&#8221;) (partial and complete responses plus stable disease) of over 79% was also observed in comparison to a DCR of 48% observed in the MPACT trial. Reduction in the level of circulating tumor biomarker CA19-9 was observed in 96% of patients versus 61% in the MPACT trial. Importantly, median progression-free survival and median overall survival of nearly ten months and over thirteen months were observed versus less than six months and less than nine months, respectively, in the MPACT trial. These results have been published in The Lancet Gastroenterology and Hepatology (Dean, et al. 2022).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certepetide was also examined in another Phase 1b/2a study in first line mPDAC patients. Study CEND1-201 was conducted in China by our development partner, Qilu Pharmaceutical. Two dose levels of certepetide (1.6 and 3.2 mg/kg) were combined with SoC chemotherapy (gemcitabine and nab-paclitaxel). There were 55 patients in the study, 53 of whom were evaluable for efficacy. Twenty-five (25) patients were treated with 1.6 mg/kg certepetide, and 28 patients with 3.2 mg/kg certepetide. In the 1.6 mg/kg certepetide group, partial response occurred in 11/25 (44.0%) patients, and stable disease occurred in 12/25 (48%) patients. In the 3.2 mg/kg certepetide group, partial response occurred in 11/28 (39.3%) patients, and stable disease occurred in 12/28 (42.9%) patients. The ORR was 41.5% for all doses. The ORR was 44.0% and 39.3% in 1.6 mg/kg group and in 3.2 mg/kg group, respectively. The DCR was 86.8% for all doses. The DCR in 1.6 and 3.2 mg/kg groups was 92.0% and 82.1%, respectively. The median PFS was 5.82 months for all doses combined. The median PFS was 7.36 months and 5.75 months in 1.6 mg/kg group and in 3.2 mg/kg group, respectively. The median OS was 11.10 months for all doses combined. The median OS was 10.35 months and 11.10 months in 1.6 mg/kg group and in 3.2 mg/kg group, respectively. The adverse event profile at both dose levels was similar to that for SoC alone. Qilu has completed Phase 2 enrollment (n=96) in first line mPDAC in combination with SoC gemcitabine and nab-paclitaxel.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, certepetide is also the subject of a Phase 2 trial in first-line mPDAC patients, the ASCEND trial. ASCEND is being conducted in collaboration with the Australasian Gastrointestinal Clinical Trials Group (AGITG) and the University of Sydney at 25 sites in Australia and New Zealand. The Phase 2 double-blind, randomized (2:1), placebo-controlled, multi-center ASCEND trial is evaluating certepetide in combination with SoC chemotherapy (gemcitabine and nab-paclitaxel) for the treatment of mPDAC. The original ASCEND protocol included one dosing scheme for certepetide. Following the acquisition of Cend Therapeutics and, by extension, certepetide in September 2022, Lisata collaborated with AGITG to amend the protocol to ensure it respected international regulatory standards. Thus, endpoints typically recognized by regulators as primary in registration studies and more effective in guiding next stages of clinical development (e.g., overall survival), were added. The amended protocol was designed to assess the efficacy of two different dosing regimens of certepetide in two separate cohorts: Cohort A, with 95 patients receiving a single intravenous (IV) dose of certepetide 3.2 mg/kg or placebo in combination with SoC, and Cohort B, with 63 patients receiving two IV doses of certepetide 3.2 mg/kg or placebo administered 4 hours apart in combination with SoC. The preliminary data from Cohort A were reported at the ASCO GI meeting on January 24, 2025, demonstrating a median overall survival (mOS) of 12.68 months for the certepetide treated group, compared to 9.72 months for the placebo treated group. Despite a numerical trend in 6-month PFS favoring the certepetide treatment group, no significant improvement in median PFS was observed (mPFS of 5.5 months in both groups). However, the objective response rate (ORR) benefit are positive with 4/65 (6.2%) complete responses in the certepetide treated group, compared to 0/28 (0%) the placebo </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treated group.  The adverse event profile of Cohort A was similar in subjects treated with certepetide and placebo confirming previous observations of certepetide&#8217;s benign safety profile. Preliminary data from Cohort B will be presented at the ESMO-GI meeting in July 2025 with a final analysis of both cohorts available thereafter.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certepetide is currently the subject of multiple ongoing and planned clinical trials being conducted globally in a variety of solid tumor types and in combination with several chemotherapy and immunotherapy anti-cancer regimens. The following diagram summarizes these studies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><img src="lsta-20250331_g1.jpg" alt="Slide1.jpg" style="height:371px;margin-bottom:5pt;vertical-align:text-bottom;width:660px" id="i-1"/></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Out-licensing Opportunities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intellectual property portfolio comprises notable programs available for out-licensing and/or partnering in order to augment or continue their clinical development. Our current long-term strategy focuses on advancing our therapies through development with the ultimate objective of obtaining market authorizations and entering commercialization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. We believe that we are well-positioned to realize potentially meaningful value increases within our own proprietary pipeline if we are successful in advancing our product candidates to their next significant development milestones.</span></div><div id="i65296f168ea449b99126b2b55f877ea4_97"></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended March&#160;31, 2025 Compared to Three Months Ended March&#160;31, 2024 </span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended March&#160;31, 2025 and March&#160;31, 2024 (in thousands):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.304%"><tr><td style="width:1.0%"/><td style="width:50.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.290%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.290%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.636%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(754)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,847)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,601)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(962)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(798)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,724)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,401)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, net losses were $4.7 million for the three months ended March&#160;31, 2025, compared to $5.4 million for the three months ended March&#160;31, 2024.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2025, operating expenses totaled $5.8 million, compared to $6.6 million for the three months ended March&#160;31, 2024, representing a decrease of $0.8 million or 11.4%.  Operating expenses are comprised of the following:&#160;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Research and development expenses were approximately $2.6 million for the three months ended March&#160;31, 2025, compared to $3.2 million for the three months ended March&#160;31, 2024, representing a decrease of $0.6 million or 19.7%. This was primarily due to a reduction in clinical research organization (&#8220;CRO&#8221;) expenses and site expenses associated with our Phase 2a proof-of-concept Bolster trial and lower spend on chemistry, manufacturing and controls (&#8220;CMC&#8221;).</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were approximately $3.2 million for the three months ended March&#160;31, 2025, compared to $3.4 million for the three months ended March&#160;31, 2024, representing a decrease of $0.1 million or 3.4%. This was primarily due to one off settlement costs in the prior year partially offset by an increase in consulting expenses and severance costs in the current year. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, to minimize our use of cash, we have used a variety of equity instruments to compensate employees, consultants and other service providers. The use of these instruments has resulted in charges to the results of operations, which have been significant in the past.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense) is comprised primarily of investment income from cash, cash equivalents and marketable securities and losses on sales of our New Jersey net operating losses for the three months ended March&#160;31, 2025 and 2024. </span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Benefit</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, we received final approval from the New Jersey Economic Development Authority (&#8220;NJEDA&#8221;) under the Technology Business Tax Certificate Transfer Program (the &#8220;Program&#8221;) to sell a percentage of our NJ NOLs, which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $0.9 million. The $1.0 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million of our NJ NOL tax benefits have been recorded as a benefit from income taxes and the loss on sale of $0.1 million recorded in other income (expense).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In March 2024, we received final approval from the NJEDA under the Program to sell a percentage of our NJ NOLs, which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $0.7&#160;million. The $0.8 million of NJ NOLs related tax benefits have been recorded as a benefit from income taxes and the loss on sale of $0.1 million recorded in other income (expense).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29 </span></div></div></div><div id="i65296f168ea449b99126b2b55f877ea4_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Analysis of Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025, we had cash, cash equivalents and marketable securities of approximately $25.8 million, working capital of approximately $24.8 million, and stockholders&#8217; equity of approximately $25.4 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2025, we met our immediate cash requirements through existing cash balances.  Additionally, we used equity and equity-linked instruments to pay for services and compensation. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in) or provided by, operating, investing and financing activities were as follows (in thousands):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.737%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,402)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,027)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in operating activities during the three months ended March&#160;31, 2025 was $5.4 million, which is comprised of (i) our net loss of $4.7 million, adjusted for non-cash expenses totaling $0.5&#160;million (which includes adjustments for equity-based compensation, depreciation and amortization, and amortization/accretion of marketable securities), and (ii) changes in operating assets and liabilities using approximately $1.2 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in operating activities during the three months ended March&#160;31, 2024 was $7.0 million, which is comprised of (i) our net loss of $5.4 million, adjusted for non-cash expenses totaling $0.4 million (which includes adjustments for equity-based compensation, depreciation and amortization, loss from equity method investment, and amortization/accretion of marketable securities) and (ii) changes in operating assets and liabilities using approximately $2.1 million.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash provided by investing activities during the three months ended March&#160;31, 2025 totaled $9.4 million and was primarily due to net sales of marketable securities (net of purchases of marketable securities). </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash provided by investing activities during the three months ended March&#160;31, 2024 totaled $6.4 million and was primarily due to net sales of marketable securities (net of purchases of marketable securities) partially offset by an investment of $0.1 million in Impilo Therapeutics.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in financing activities during the three months ended March&#160;31, 2025 totaled $23.0 thousand and consisted primarily of tax withholding-related payments on net share settlement equity awards to employees of $0.2 million partially offset by $0.2 million in proceeds from the issuance of shares through our ATM Agreement (as defined below).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in financing activities during the three months ended March&#160;31, 2024 totaled $0.1 million and consisted of tax withholding-related payments on net share settlement equity awards to employees.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Requirements Outlook</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet our short and long-term liquidity needs, we expect to use existing cash balances, marketable securities and a variety of other means. Other sources of liquidity could include additional potential issuances of debt or equity securities in public or private financings, partnerships and/or collaborations and/or sale of assets. Our history of operating losses and liquidity challenges may make it difficult for us to raise capital on acceptable terms or at all. The demand for the equity and debt of pharmaceutical companies like ours is dependent upon many factors, including the general state of the financial markets. During times of extreme market volatility, capital may not be available on favorable terms, if at all. Our inability to obtain such additional capital could materially and adversely affect our business operations. We will also continue to seek, as appropriate, grants for scientific and clinical studies from various governmental agencies and foundations, and other sources of non-dilutive funding. We believe that our cash on hand and marketable securities will enable us to fund current operating expenses for at least the next 12 months following the issuance of our financial statements. Our future capital requirements are difficult to forecast and will depend on many factors including the timing and nature of any other strategic transactions that we undertake; and our ability to establish and maintain collaboration partnerships, in-license/out-license or other similar arrangements and the financial terms of such agreements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, we entered into the ATM Agreement with H.C. Wainwright &amp; Co., LLC as sales agent, in connection with an &#8220;at the market offering&#8221; under which we from time to time may offer and sell shares of our common stock having an aggregate offering price of up to $50.0 million. As of the date of this filing and so long as our public float remains below $75.0 million, we are subject to limitations pursuant to General Instruction I.B.6 of Form S-3 (the &#8220;Baby Shelf Limitation&#8221;), which limits the amount we can offer to up to one-third of our public float during any trailing 12-month period. Subsequent to the filing of a prospectus supplement to our Registration Statement on Form S-3 (File No. 333-279034) relating to the at the market offering on August 21, 2024, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $29.6&#160;million. Pursuant to the Baby Shelf Limitation, since the aggregate market value of our outstanding common stock held by non-affiliates was below $75.0 million at the time of such prospectus supplement filing, the aggregate amount of securities that we are permitted to offer and sell is now $9,855,890, which was equal to one-third of the aggregate market value of our common stock held by non-affiliates as of August 20, 2024. If our public float exceeds $75.0 million on a future measurement date, the Company will no longer be subject to the Baby Shelf Limitation. During the three months ended March&#160;31, 2025, we issued 55,578 shares of common stock under the ATM Agreement for net proceeds of $211,369. Since inception, we have issued 123,751 shares of common stock under the ATM Agreement for net proceeds of $492,216.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and our negotiating position in capital generating efforts may worsen as existing resources are used. Additional equity financing may be dilutive to our stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict our ability to operate as a business; our stock price may not reach levels necessary to induce option or warrant exercises; and asset sales may not be possible on terms we consider acceptable. If we are unable to access capital necessary to meet our long-term liquidity needs, we may have to delay the expansion of our business or raise funds on terms that we currently consider unfavorable. </span></div><div id="i65296f168ea449b99126b2b55f877ea4_103"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our critical accounting policies and estimates during the three months ended March&#160;31, 2025, compared to those reported in our 2024 Form 10-K.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_106"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.<br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_109"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;CONTROLS AND PROCEDURES </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;Disclosure Controls and Procedures </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures are our controls and other procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934), as amended (the &#8220;Exchange Act&#8221;) is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer, who serves as our principal executive officer, and our Senior Vice President, Finance and Treasury and Chief Accounting Officer, who serves as our principal financial officer (together, the &#8220;Evaluating Officers&#8221;), as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well-designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitations of control systems, not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Controls and procedures can only provide reasonable, not absolute, assurance that the above objectives have been met.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we evaluated, with the participation of our management, including our Evaluating Officers, the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on that evaluation, our Evaluating Officers concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms and is accumulated and communicated to management, including the Evaluating Officers, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15, that occurred during our last quarter to which this Quarterly Report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32 </span></div></div></div><div id="i65296f168ea449b99126b2b55f877ea4_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER INFORMATION </span></div><div style="text-align:center"><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_115"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_118"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the risk factors previously reported in our 2024 Form 10-K.  See the risk factors set forth in our 2024 Annual Report on Form 10-K under the caption &#8220;Item 1A - Risk Factors.&#8221;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_121"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_124"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_127"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_130"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2025, <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-677"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-678"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-679"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-680">no director or officer of the Company adopted, modified or terminated a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i65296f168ea449b99126b2b55f877ea4_133"></div><div style="-sec-extract:summary;margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Exhibit Index appearing immediately after the signature page to this Form 10-Q is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33 </span></div></div></div><div id="i65296f168ea449b99126b2b55f877ea4_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:48.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.314%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LISATA THERAPEUTICS, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 8, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> /s/ David J. Mazzo, PhD      </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name: David J. Mazzo, PhD      </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title:   President &amp; Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 8, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">/s/ James Nisco</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name: James Nisco</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title:   SVP, Finance and Treasury and Chief Accounting Officer (Principal Financial Officer and Principal Accounting Officer)</span></div></td></tr></table></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:15.75pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34 </span></div></div></div><div id="i65296f168ea449b99126b2b55f877ea4_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i65296f168ea449b99126b2b55f877ea4_7">Index</a></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:13.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:461.50pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lsta-ex311_20250331.htm">31.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lsta-ex312_20250331.htm">31.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lsta-ex321_20250331.htm">32.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lsta-ex322_20250331.htm">32.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_______________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"/><td style="width:16.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:502.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">             </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35 </span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>lsta-ex311_20250331.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="iacf3203972a641e49d753146d3a9a946_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS UNDER SECTION 302</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David J. Mazzo, PhD, certify that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Lisata Therapeutics, Inc.&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by&#160;this report based on such evaluation&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;The registrant's other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;8, 2025 </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; David J. Mazzo, PhD&#160;&#160;&#160;&#160;       </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; David J. Mazzo, PhD</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; President &#38; Chief Executive Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>lsta-ex312_20250331.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i4433e3fd58d04354b835c8be9b5a8e23_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS UNDER SECTION 302</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Nisco, certify that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Lisata Therapeutics, Inc.&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by&#160;this report based on such evaluation&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;The registrant's other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;8, 2025 </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; James Nisco&#160;&#160;&#160;&#160;       </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; James Nisco</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; Senior Vice President, Finance and Treasury and Chief Accounting Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer and Principal Accounting Officer)</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>lsta-ex321_20250331.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i8d80e313e1034b32aa0ac4dfa0cd0f18_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Lisata Therapeutics, Inc. (the &#8220;Company&#8221;) for the quarter ended March&#160;31, 2025 filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, David J. Mazzo, PhD, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the dates presented and the results of operations of the Company for the periods presented.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;&#160;&#160;May&#160;8, 2025 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:54.834%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; David J. Mazzo, PhD     </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David J. Mazzo, PhD</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President &#38; Chief Executive Officer (Principal Executive Officer)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>lsta-ex322_20250331.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i8ea87c7d73604c8b91a8b89dfcc43f5a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Lisata Therapeutics, Inc. (the &#8220;Company&#8221;) for the quarter ended March&#160;31, 2025 filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, James Nisco, Senior Vice President, Finance and Treasury and Chief Accounting Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the dates presented and the results of operations of the Company for the periods presented.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;&#160;&#160;May&#160;8, 2025 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:54.834%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; James Nisco     </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Nisco</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Finance and Treasury and Chief Accounting Officer (Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>lsta-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1dd57249-b3e7-436f-adc4-30cff3fca49a,g:189dfb66-5ef0-4fa0-83c9-286ae40a1a30-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lsta="http://www.caladrius.com/20250331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.caladrius.com/20250331">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lsta-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lsta-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lsta-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lsta-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.caladrius.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>9952151 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParentheticals" roleURI="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals">
        <link:definition>9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>9952154 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFEQUITY" roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY">
        <link:definition>9952155 - Statement - CONSOLIDATED STATEMENTS OF EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952156 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.caladrius.com/role/DescriptionofBusiness">
        <link:definition>9952157 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952158 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecurities" roleURI="http://www.caladrius.com/role/AvailableforSaleSecurities">
        <link:definition>9952159 - Disclosure - Available-for-Sale-Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.caladrius.com/role/PropertyandEquipment">
        <link:definition>9952160 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShare" roleURI="http://www.caladrius.com/role/IncomeLossPerShare">
        <link:definition>9952161 - Disclosure - Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.caladrius.com/role/FairValueMeasurements">
        <link:definition>9952162 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilities" roleURI="http://www.caladrius.com/role/AccruedLiabilities">
        <link:definition>9952163 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeases" roleURI="http://www.caladrius.com/role/OperatingLeases">
        <link:definition>9952164 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.caladrius.com/role/StockholdersEquity">
        <link:definition>9952165 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.caladrius.com/role/ShareBasedCompensation">
        <link:definition>9952166 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.caladrius.com/role/IncomeTaxes">
        <link:definition>9952167 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.caladrius.com/role/SegmentInformation">
        <link:definition>9952168 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AustraliaResearchandDevelopmentTaxIncentive" roleURI="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive">
        <link:definition>9952169 - Disclosure - Australia Research and Development Tax Incentive</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.caladrius.com/role/Contingencies">
        <link:definition>9952170 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TechnologyTransferAgreement" roleURI="http://www.caladrius.com/role/TechnologyTransferAgreement">
        <link:definition>9952171 - Disclosure - Technology Transfer Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreements" roleURI="http://www.caladrius.com/role/LicenseAgreements">
        <link:definition>9952172 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreement" roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement">
        <link:definition>9952173 - Disclosure - Research Collaboration and License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesTables" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables">
        <link:definition>9955513 - Disclosure - Available-for-Sale-Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.caladrius.com/role/PropertyandEquipmentTables">
        <link:definition>9955514 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShareTables" roleURI="http://www.caladrius.com/role/IncomeLossPerShareTables">
        <link:definition>9955515 - Disclosure - Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.caladrius.com/role/FairValueMeasurementsTables">
        <link:definition>9955516 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.caladrius.com/role/AccruedLiabilitiesTables">
        <link:definition>9955517 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesTables" roleURI="http://www.caladrius.com/role/OperatingLeasesTables">
        <link:definition>9955518 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.caladrius.com/role/StockholdersEquityTables">
        <link:definition>9955519 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.caladrius.com/role/ShareBasedCompensationTables">
        <link:definition>9955520 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.caladrius.com/role/SegmentInformationTables">
        <link:definition>9955521 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://www.caladrius.com/role/DescriptionofBusinessDetails">
        <link:definition>9955522 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails">
        <link:definition>9955523 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9955524 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails">
        <link:definition>9955525 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesScheduleofClassificationofAvailableforSaleSecuritiesDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofClassificationofAvailableforSaleSecuritiesDetails">
        <link:definition>9955526 - Disclosure - Available-for-Sale-Securities - Schedule of Classification of Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails">
        <link:definition>9955527 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.caladrius.com/role/PropertyandEquipmentDetails">
        <link:definition>9955528 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShareDetails" roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails">
        <link:definition>9955529 - Disclosure - Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails">
        <link:definition>9955530 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesDetails" roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails">
        <link:definition>9955531 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesScheduleofBalanceSheetPresentationDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesScheduleofBalanceSheetPresentationDetails">
        <link:definition>9955532 - Disclosure - Operating Leases - Schedule of Balance Sheet Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesNarrativeDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails">
        <link:definition>9955533 - Disclosure - Operating Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails">
        <link:definition>9955534 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.caladrius.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails_1">
        <link:definition>9955534 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityEquityIssuancesDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails">
        <link:definition>9955535 - Disclosure - Stockholders' Equity - Equity Issuances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofStockOptionsandWarrantsDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails">
        <link:definition>9955536 - Disclosure - Stockholders' Equity - Schedule of Stock Options and Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>9955537 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofRestrictedStockUnitsforServicesDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityScheduleofRestrictedStockUnitsforServicesDetails">
        <link:definition>9955538 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Units for Services (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofNonVestedRestrictedStockDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails">
        <link:definition>9955539 - Disclosure - Stockholders' Equity - Schedule of Non Vested Restricted Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails">
        <link:definition>9955540 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofCompensationCostNotYetRecognizedDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationScheduleofCompensationCostNotYetRecognizedDetails">
        <link:definition>9955541 - Disclosure - Share-Based Compensation - Schedule of Compensation Cost Not Yet Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationScheduleofFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails">
        <link:definition>9955542 - Disclosure - Share-Based Compensation - Schedule of Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.caladrius.com/role/IncomeTaxesDetails">
        <link:definition>9955543 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://www.caladrius.com/role/SegmentInformationNarrativeDetails">
        <link:definition>9955544 - Disclosure - Segment Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleofFinancialInformationDetails" roleURI="http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails">
        <link:definition>9955545 - Disclosure - Segment Information - Schedule of Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AustraliaResearchandDevelopmentTaxIncentiveDetails" roleURI="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails">
        <link:definition>9955546 - Disclosure - Australia Research and Development Tax Incentive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.caladrius.com/role/ContingenciesDetails">
        <link:definition>9955547 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TechnologyTransferAgreementDetails" roleURI="http://www.caladrius.com/role/TechnologyTransferAgreementDetails">
        <link:definition>9955548 - Disclosure - Technology Transfer Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsDetails" roleURI="http://www.caladrius.com/role/LicenseAgreementsDetails">
        <link:definition>9955549 - Disclosure - License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementDetails" roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails">
        <link:definition>9955550 - Disclosure - Research Collaboration and License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lsta_EPSAbstract" abstract="true" name="EPSAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" abstract="false" name="IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" abstract="false" name="ResearchAndDevelopmentTaxIncentiveTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lsta_TechnologyTransferAgreementAbstract" abstract="true" name="TechnologyTransferAgreementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lsta_TechnologyTransferAgreementTextBlock" abstract="false" name="TechnologyTransferAgreementTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" abstract="false" name="LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lsta_CashAndCashEquivalentsAndMarketableSecurities" abstract="false" name="CashAndCashEquivalentsAndMarketableSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_ClinicalAndRDRelatedLiabilities" abstract="false" name="ClinicalAndRDRelatedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_AccruedGrantFunding" abstract="false" name="AccruedGrantFunding" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_OperatingLeaseRightOfUseAssetAbstract" abstract="true" name="OperatingLeaseRightOfUseAssetAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lsta_AtTheMarketOfferingAgreementMember" abstract="true" name="AtTheMarketOfferingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" abstract="false" name="SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_OutstandingStockThreshold" abstract="false" name="OutstandingStockThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_SaleOfStockAvailableForSale" abstract="false" name="SaleOfStockAvailableForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_SaleOfStockAvailableForSalePercentage" abstract="false" name="SaleOfStockAvailableForSalePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lsta_OptionsVestedWeightedAverageRemainingContractualTerm" abstract="false" name="OptionsVestedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lsta_CommonStockWarrantsShares" abstract="false" name="CommonStockWarrantsShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_WarrantsGranted" abstract="false" name="WarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_WarrantsExercised" abstract="false" name="WarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_WarrantsCanceled" abstract="false" name="WarrantsCanceled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_WarrantsExpired" abstract="false" name="WarrantsExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_Sharesvestedandexpectedtovest" abstract="false" name="Sharesvestedandexpectedtovest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_WarrantsVested" abstract="false" name="WarrantsVested" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_WarrantsWeightedAverageExercisePriceRollForward" abstract="true" name="WarrantsWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsOutstanding" abstract="false" name="WeightedAverageExercisePriceWarrantsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsGranted" abstract="false" name="WeightedAverageExercisePriceWarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsExercised" abstract="false" name="WeightedAverageExercisePriceWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsCanceled" abstract="false" name="WeightedAverageExercisePriceWarrantsCanceled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsExpired" abstract="false" name="WeightedAverageExercisePriceWarrantsExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" abstract="false" name="WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_WeightedAverageExercisePriceWarrantsExercisable" abstract="false" name="WeightedAverageExercisePriceWarrantsExercisable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="lsta_WarrantsOtherDisclosuresAbstract" abstract="true" name="WarrantsOtherDisclosuresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lsta_WeightedAverageRemainingContractualTermWarrantOutstanding" abstract="false" name="WeightedAverageRemainingContractualTermWarrantOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" abstract="false" name="WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lsta_WeightedAverageRemainingContractualTermWarrantsVested" abstract="false" name="WeightedAverageRemainingContractualTermWarrantsVested" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lsta_AggregateIntrinsicValueWarrantsOutstanding" abstract="false" name="AggregateIntrinsicValueWarrantsOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_AggregateIntrinsicValueWarrantsVestedAndExpectedToVest" abstract="false" name="AggregateIntrinsicValueWarrantsVestedAndExpectedToVest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_AggregateIntrinsicValueWarrantsVested" abstract="false" name="AggregateIntrinsicValueWarrantsVested" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_CENDMember" abstract="true" name="CENDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lsta_OperatingLossCarryforwardsBeforeWriteDown" abstract="false" name="OperatingLossCarryforwardsBeforeWriteDown" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_FairValueMarketOfTaxNOLs" abstract="false" name="FairValueMarketOfTaxNOLs" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" abstract="false" name="NetCarryforwardOperatingLossCarryforwardAnnualLimitation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_OperatingLossCarryforwardsPostAcquisition" abstract="false" name="OperatingLossCarryforwardsPostAcquisition" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" abstract="false" name="ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_ProceedsFromSaleOfNOLS" abstract="false" name="ProceedsFromSaleOfNOLS" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_LossOnSaleOfNOL" abstract="false" name="LossOnSaleOfNOL" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lsta_BolsterTrialMember" abstract="true" name="BolsterTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lsta_AscendTrialMember" abstract="true" name="AscendTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lsta_ChemistryManufacturingAndControlsMember" abstract="true" name="ChemistryManufacturingAndControlsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lsta_ClinicalDepartmentMember" abstract="true" name="ClinicalDepartmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lsta_ResearchAndDevelopmentOtherMember" abstract="true" name="ResearchAndDevelopmentOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lsta_FinanceGeneralAndAdministrativeExpense" abstract="false" name="FinanceGeneralAndAdministrativeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_LegalGeneralAndAdministrativeExpense" abstract="false" name="LegalGeneralAndAdministrativeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense" abstract="false" name="ShareBasedCompensationExpenseGeneralAndAdministrativeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_CashCashEquivalentsAndMarketableSecurities" abstract="false" name="CashCashEquivalentsAndMarketableSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_IncomeTaxIncentiveReceivable" abstract="false" name="IncomeTaxIncentiveReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_LingmedLimitedMember" abstract="true" name="LingmedLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lsta_LitigationSettlementPaymentTerm" abstract="false" name="LitigationSettlementPaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lsta_LitigationSettlementFutureMilestonePaymentsPercent" abstract="false" name="LitigationSettlementFutureMilestonePaymentsPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lsta_LitigationSettlementMilestonePayment" abstract="false" name="LitigationSettlementMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_ImpiloMember" abstract="true" name="ImpiloMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lsta_InvestmentOwnedCanceledShares" abstract="false" name="InvestmentOwnedCanceledShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_SAFEValuationCap" abstract="false" name="SAFEValuationCap" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_SAFEDiscountRate" abstract="false" name="SAFEDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lsta_SanfordBurnhamPrebysMember" abstract="true" name="SanfordBurnhamPrebysMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lsta_SharesIssuedUnderLicenseAgreement" abstract="false" name="SharesIssuedUnderLicenseAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" abstract="false" name="CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" abstract="false" name="CollaborativeArrangementRightsAndObligationsSublicensingFees" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lsta_SharesHeldByThirdParty" abstract="false" name="SharesHeldByThirdParty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lsta_ExclusiveLicenseAndCollaborationAgreementMember" abstract="true" name="ExclusiveLicenseAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lsta_QiluMember" abstract="true" name="QiluMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lsta_KuvaMember" abstract="true" name="KuvaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lsta_RevenuePerformanceObligationPercentageOfNetSale" abstract="false" name="RevenuePerformanceObligationPercentageOfNetSale" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" abstract="false" name="RevenuePerformanceObligationPercentageOfSublicensingRevenues" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" abstract="false" name="ResearchCollaborationAndLicenseAgreementOptionToTerminate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>lsta-20250331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1dd57249-b3e7-436f-adc4-30cff3fca49a,g:189dfb66-5ef0-4fa0-83c9-286ae40a1a30-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="lsta-20250331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0433808d-abbb-43d6-85fe-57693506fb64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_05a9fafd-c3e1-4234-81f6-81aba66a7922" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0433808d-abbb-43d6-85fe-57693506fb64" xlink:to="loc_us-gaap_AssetsCurrent_05a9fafd-c3e1-4234-81f6-81aba66a7922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8782be17-e8dc-4f58-a2b6-695235d8dd71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0433808d-abbb-43d6-85fe-57693506fb64" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8782be17-e8dc-4f58-a2b6-695235d8dd71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_183e00a0-6087-4627-8b95-18608c4c43b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0433808d-abbb-43d6-85fe-57693506fb64" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_183e00a0-6087-4627-8b95-18608c4c43b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ff14a446-59bf-43bd-9b93-a0d1fe476ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0433808d-abbb-43d6-85fe-57693506fb64" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ff14a446-59bf-43bd-9b93-a0d1fe476ccc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e5f6e708-7f59-4f6f-b25d-4b2bb7e39bda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_19cbb657-a335-4b66-bc15-93ca6d79758b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e5f6e708-7f59-4f6f-b25d-4b2bb7e39bda" xlink:to="loc_us-gaap_LiabilitiesCurrent_19cbb657-a335-4b66-bc15-93ca6d79758b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_71480d5e-6c53-4b93-9a48-750fb55cffa6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e5f6e708-7f59-4f6f-b25d-4b2bb7e39bda" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_71480d5e-6c53-4b93-9a48-750fb55cffa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e7d513f9-fe76-4e63-b6fe-33cd78a807da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c3b92309-bb71-4f70-8cf1-ae833a75ba82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e7d513f9-fe76-4e63-b6fe-33cd78a807da" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c3b92309-bb71-4f70-8cf1-ae833a75ba82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_eb063506-ec30-4b54-ab10-ce0426a7addc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e7d513f9-fe76-4e63-b6fe-33cd78a807da" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_eb063506-ec30-4b54-ab10-ce0426a7addc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_81c31d2a-c31d-4c2c-9716-44614e9a4505" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e7d513f9-fe76-4e63-b6fe-33cd78a807da" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_81c31d2a-c31d-4c2c-9716-44614e9a4505" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4d92c22c-a23a-4085-a409-511fa4358cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e7d513f9-fe76-4e63-b6fe-33cd78a807da" xlink:to="loc_us-gaap_CommonStockValue_4d92c22c-a23a-4085-a409-511fa4358cb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_6489a7df-d3f2-4206-b7ec-1bd1b9f6f883" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e7d513f9-fe76-4e63-b6fe-33cd78a807da" xlink:to="loc_us-gaap_TreasuryStockCommonValue_6489a7df-d3f2-4206-b7ec-1bd1b9f6f883" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eb2fa307-4c74-4663-a676-eb105801cc17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8443de7c-8d1e-4c8a-b2e7-7fd7100837cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eb2fa307-4c74-4663-a676-eb105801cc17" xlink:to="loc_us-gaap_StockholdersEquity_8443de7c-8d1e-4c8a-b2e7-7fd7100837cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a5b298e7-3cd1-41c1-aa94-6622a83b7f99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eb2fa307-4c74-4663-a676-eb105801cc17" xlink:to="loc_us-gaap_MinorityInterest_a5b298e7-3cd1-41c1-aa94-6622a83b7f99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9f04fb17-58a9-403c-8ae2-4c0bbb986f59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7e4a2ec8-8ec9-40f4-b513-b4ab9160ab87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9f04fb17-58a9-403c-8ae2-4c0bbb986f59" xlink:to="loc_us-gaap_AccountsPayableCurrent_7e4a2ec8-8ec9-40f4-b513-b4ab9160ab87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_475be02a-d02c-4186-8fa4-49a1404dfa1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9f04fb17-58a9-403c-8ae2-4c0bbb986f59" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_475be02a-d02c-4186-8fa4-49a1404dfa1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_541d2adc-b6fa-4ecd-8c39-f1f7f719c4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_05c023d9-f4c3-4252-aa9c-1ae5513f95f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_541d2adc-b6fa-4ecd-8c39-f1f7f719c4e9" xlink:to="loc_us-gaap_MarketableSecurities_05c023d9-f4c3-4252-aa9c-1ae5513f95f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0b11e0e1-be98-4da4-a08a-12a3003f9493" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_541d2adc-b6fa-4ecd-8c39-f1f7f719c4e9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0b11e0e1-be98-4da4-a08a-12a3003f9493" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_7172a943-9a0c-4b8b-a833-b78972ca4afe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_541d2adc-b6fa-4ecd-8c39-f1f7f719c4e9" xlink:to="loc_us-gaap_AccountsReceivableNet_7172a943-9a0c-4b8b-a833-b78972ca4afe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7f31ae8f-e115-4f3e-941b-5e59c3d9b918" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_541d2adc-b6fa-4ecd-8c39-f1f7f719c4e9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7f31ae8f-e115-4f3e-941b-5e59c3d9b918" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_83188c1c-7906-4380-b3d4-badd38853da2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_349b5521-69c9-4581-bc41-7af74a11767f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_83188c1c-7906-4380-b3d4-badd38853da2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_349b5521-69c9-4581-bc41-7af74a11767f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2a2c495e-1f0a-430e-8f13-09eb6f111958" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_83188c1c-7906-4380-b3d4-badd38853da2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2a2c495e-1f0a-430e-8f13-09eb6f111958" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d53a3f36-440d-4a47-a8f3-8085d4897875" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_83188c1c-7906-4380-b3d4-badd38853da2" xlink:to="loc_us-gaap_Liabilities_d53a3f36-440d-4a47-a8f3-8085d4897875" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lsta-20250331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_362d878c-938d-402f-b987-6b4ea1c45916" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3452da8f-7ef1-4101-bc25-a208d87ce132" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_362d878c-938d-402f-b987-6b4ea1c45916" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3452da8f-7ef1-4101-bc25-a208d87ce132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_bab231ef-e9c8-4957-910a-503581b289b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_362d878c-938d-402f-b987-6b4ea1c45916" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_bab231ef-e9c8-4957-910a-503581b289b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0107c325-b9f2-4154-b44c-612973817bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_62a17937-09f3-460c-bd76-1dba2e33a95f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0107c325-b9f2-4154-b44c-612973817bc6" xlink:to="loc_us-gaap_InvestmentIncomeNet_62a17937-09f3-460c-bd76-1dba2e33a95f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_56a26bb4-950c-477e-8671-b14dab55aeed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0107c325-b9f2-4154-b44c-612973817bc6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_56a26bb4-950c-477e-8671-b14dab55aeed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_57159da2-8513-489b-a86f-7d1cf6311144" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d3dfd4b5-3390-4452-bbee-85877edaa2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_57159da2-8513-489b-a86f-7d1cf6311144" xlink:to="loc_us-gaap_ProfitLoss_d3dfd4b5-3390-4452-bbee-85877edaa2c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_c80d97dc-3ed0-40a4-9f81-bd2f36c38e67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_57159da2-8513-489b-a86f-7d1cf6311144" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_c80d97dc-3ed0-40a4-9f81-bd2f36c38e67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_45ad5c42-b552-4ebd-8920-31e3763f5078" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_20241272-18e6-4169-8e27-dc90033fca3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_45ad5c42-b552-4ebd-8920-31e3763f5078" xlink:to="loc_us-gaap_OperatingIncomeLoss_20241272-18e6-4169-8e27-dc90033fca3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1f319b21-441e-4559-861c-3d456172b57f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_45ad5c42-b552-4ebd-8920-31e3763f5078" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1f319b21-441e-4559-861c-3d456172b57f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e6aa2536-49a6-418b-98fa-ae775dbf19b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_4b01fa19-2e06-43ae-bdcc-daf1c39b1b63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e6aa2536-49a6-418b-98fa-ae775dbf19b8" xlink:to="loc_us-gaap_OperatingExpenses_4b01fa19-2e06-43ae-bdcc-daf1c39b1b63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7d2c9999-dc6c-442e-a6b3-2017f57bc729" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1c9e2f51-2394-4e84-837a-8023b31366c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7d2c9999-dc6c-442e-a6b3-2017f57bc729" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1c9e2f51-2394-4e84-837a-8023b31366c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c08521e3-eb53-41d3-b856-31bc90273a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7d2c9999-dc6c-442e-a6b3-2017f57bc729" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c08521e3-eb53-41d3-b856-31bc90273a9a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="lsta-20250331.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_88b6edc2-7343-406d-9977-b9501d71903e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b7d9f9d6-16dc-42bc-a454-d2ac7aef2593" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_88b6edc2-7343-406d-9977-b9501d71903e" xlink:to="loc_us-gaap_ProfitLoss_b7d9f9d6-16dc-42bc-a454-d2ac7aef2593" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b06dbce5-76a0-46da-a102-c04c124cd4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_88b6edc2-7343-406d-9977-b9501d71903e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b06dbce5-76a0-46da-a102-c04c124cd4a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ce49490e-837c-4492-9338-57c9b5f4463c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_435fb257-37ea-4cde-be8d-4923233c9b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ce49490e-837c-4492-9338-57c9b5f4463c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_435fb257-37ea-4cde-be8d-4923233c9b8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f0e884a6-a903-4acf-9dff-dac732060913" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ce49490e-837c-4492-9338-57c9b5f4463c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f0e884a6-a903-4acf-9dff-dac732060913" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lsta-20250331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74e3e3cb-48e3-48d3-9aba-aeba64cc583c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_22d02623-f1f6-4532-89eb-7aa8a0acb139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74e3e3cb-48e3-48d3-9aba-aeba64cc583c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_22d02623-f1f6-4532-89eb-7aa8a0acb139" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_62b5d216-5d20-49cc-a65a-abd6604bd173" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74e3e3cb-48e3-48d3-9aba-aeba64cc583c" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_62b5d216-5d20-49cc-a65a-abd6604bd173" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_985b1a6c-dc68-4aa5-8ecf-c75a6e37a83d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74e3e3cb-48e3-48d3-9aba-aeba64cc583c" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_985b1a6c-dc68-4aa5-8ecf-c75a6e37a83d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8410ea73-f910-4d01-8b4b-b8fb2c031fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2339988c-ae1c-4e10-96e0-28d8a2134a56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8410ea73-f910-4d01-8b4b-b8fb2c031fb4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2339988c-ae1c-4e10-96e0-28d8a2134a56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_39fbb479-ee45-4715-811d-507c65ef03d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8410ea73-f910-4d01-8b4b-b8fb2c031fb4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_39fbb479-ee45-4715-811d-507c65ef03d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0784f5f5-3716-47e7-8e03-42e5da80563e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8410ea73-f910-4d01-8b4b-b8fb2c031fb4" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0784f5f5-3716-47e7-8e03-42e5da80563e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_10abfa68-f854-4eeb-85d0-17cda1967efc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8410ea73-f910-4d01-8b4b-b8fb2c031fb4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_10abfa68-f854-4eeb-85d0-17cda1967efc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_27d7c7dd-5c57-4031-8e72-4865e5268f40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0188393d-b337-4ce3-ae54-3b12cf1e8936" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_27d7c7dd-5c57-4031-8e72-4865e5268f40" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0188393d-b337-4ce3-ae54-3b12cf1e8936" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_fa98de71-9d7b-467f-8759-4484a5122952" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_27d7c7dd-5c57-4031-8e72-4865e5268f40" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_fa98de71-9d7b-467f-8759-4484a5122952" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_31e9f2d7-2b6b-4a22-8e82-115751861719" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_27d7c7dd-5c57-4031-8e72-4865e5268f40" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_31e9f2d7-2b6b-4a22-8e82-115751861719" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_9ca99f3f-58ec-4227-8958-1fadf881ce91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_27d7c7dd-5c57-4031-8e72-4865e5268f40" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_9ca99f3f-58ec-4227-8958-1fadf881ce91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fbe19c3-59b9-4f7f-ac72-19cb50436789" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_827cfc98-c920-4d57-b009-a8b33f65b8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fbe19c3-59b9-4f7f-ac72-19cb50436789" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_827cfc98-c920-4d57-b009-a8b33f65b8a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f0093ae-b70c-4589-b22a-21f167f79a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fbe19c3-59b9-4f7f-ac72-19cb50436789" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f0093ae-b70c-4589-b22a-21f167f79a0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6d88072e-899e-404a-809d-c16d004400d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fbe19c3-59b9-4f7f-ac72-19cb50436789" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6d88072e-899e-404a-809d-c16d004400d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_052da43d-1e47-41fb-98b6-a51df7b866a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fbe19c3-59b9-4f7f-ac72-19cb50436789" xlink:to="loc_us-gaap_DepreciationAndAmortization_052da43d-1e47-41fb-98b6-a51df7b866a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_bdc1f7dd-5535-4df5-b813-eb5b6cc0e10e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fbe19c3-59b9-4f7f-ac72-19cb50436789" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_bdc1f7dd-5535-4df5-b813-eb5b6cc0e10e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c34197c5-62a8-442e-9da0-cb692e4be20d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fbe19c3-59b9-4f7f-ac72-19cb50436789" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c34197c5-62a8-442e-9da0-cb692e4be20d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_e601a0d0-e1f0-4907-b925-9a0ea12d329a" xlink:href="lsta-20250331.xsd#lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fbe19c3-59b9-4f7f-ac72-19cb50436789" xlink:to="loc_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_e601a0d0-e1f0-4907-b925-9a0ea12d329a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_09e78e92-b998-4ead-b349-85b1c34ba0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fbe19c3-59b9-4f7f-ac72-19cb50436789" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_09e78e92-b998-4ead-b349-85b1c34ba0e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c077eedf-ac23-4f35-85f3-4c1c6e4501c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fbe19c3-59b9-4f7f-ac72-19cb50436789" xlink:to="loc_us-gaap_ProfitLoss_c077eedf-ac23-4f35-85f3-4c1c6e4501c7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6cded802-e7d5-4de0-a543-c8145d559a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d1b38cf2-bb86-4f5f-b367-3e6c9af1e195" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6cded802-e7d5-4de0-a543-c8145d559a2e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d1b38cf2-bb86-4f5f-b367-3e6c9af1e195" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_33b8af2f-1cf2-4af9-b403-e1adb4bbe158" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6cded802-e7d5-4de0-a543-c8145d559a2e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_33b8af2f-1cf2-4af9-b403-e1adb4bbe158" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6e2513ab-7ea8-4fba-b7e7-13aa5b54bbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6cded802-e7d5-4de0-a543-c8145d559a2e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6e2513ab-7ea8-4fba-b7e7-13aa5b54bbdf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofClassificationofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#AvailableforSaleSecuritiesScheduleofClassificationofAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofClassificationofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b4f48e18-db53-423b-97f9-10ae6b47ecef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_83258317-4e28-490a-9cd8-c5fbc0c81403" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b4f48e18-db53-423b-97f9-10ae6b47ecef" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_83258317-4e28-490a-9cd8-c5fbc0c81403" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_047b7c6f-5096-4ee3-8e29-9e380f59df77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b4f48e18-db53-423b-97f9-10ae6b47ecef" xlink:to="loc_us-gaap_MarketableSecurities_047b7c6f-5096-4ee3-8e29-9e380f59df77" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6e88bc20-25b6-40c5-b550-17dde58051df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_575c5db0-b7b8-4feb-a61f-417db0fbe0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6e88bc20-25b6-40c5-b550-17dde58051df" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_575c5db0-b7b8-4feb-a61f-417db0fbe0ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_ab999692-683b-434e-8deb-2419297b5c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6e88bc20-25b6-40c5-b550-17dde58051df" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_ab999692-683b-434e-8deb-2419297b5c5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7ddb7a5c-ee42-4ba7-b5d6-f510653b34a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_8ec4345a-5e05-4b90-8c0b-f1ec7854b755" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7ddb7a5c-ee42-4ba7-b5d6-f510653b34a5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_8ec4345a-5e05-4b90-8c0b-f1ec7854b755" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_86542adb-fd18-4a8a-a591-243a8fdc2bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7ddb7a5c-ee42-4ba7-b5d6-f510653b34a5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_86542adb-fd18-4a8a-a591-243a8fdc2bdd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#PropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c922a66a-07d9-4c3f-9f82-e3103a496c53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c2b74b32-bdb8-43a4-9ac4-0ff22a647b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c922a66a-07d9-4c3f-9f82-e3103a496c53" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c2b74b32-bdb8-43a4-9ac4-0ff22a647b0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_bc6a472a-16b4-4214-b785-57b3cc275e07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c922a66a-07d9-4c3f-9f82-e3103a496c53" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_bc6a472a-16b4-4214-b785-57b3cc275e07" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_bdbce0e2-c6a6-458e-bd8c-6eb72fd37fea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_79429f1d-4da1-4d49-a73e-a6ec11c538cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_bdbce0e2-c6a6-458e-bd8c-6eb72fd37fea" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_79429f1d-4da1-4d49-a73e-a6ec11c538cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_57c72f3b-12e2-4a23-8d99-894c2acf5789" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_bdbce0e2-c6a6-458e-bd8c-6eb72fd37fea" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_57c72f3b-12e2-4a23-8d99-894c2acf5789" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#AccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_823bd0e4-b0b4-45f9-a3f5-972f60e51246" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a2480210-2373-4a49-b8d6-dd8665f606b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_823bd0e4-b0b4-45f9-a3f5-972f60e51246" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a2480210-2373-4a49-b8d6-dd8665f606b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AccruedGrantFunding_d1a8bb81-0f01-41ea-b1dc-d88a1b23c44b" xlink:href="lsta-20250331.xsd#lsta_AccruedGrantFunding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_823bd0e4-b0b4-45f9-a3f5-972f60e51246" xlink:to="loc_lsta_AccruedGrantFunding_d1a8bb81-0f01-41ea-b1dc-d88a1b23c44b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f707ea1c-880c-4371-987f-85c2629531c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_823bd0e4-b0b4-45f9-a3f5-972f60e51246" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f707ea1c-880c-4371-987f-85c2629531c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ClinicalAndRDRelatedLiabilities_44be1e5c-c493-4c44-99d6-6e6d915796dc" xlink:href="lsta-20250331.xsd#lsta_ClinicalAndRDRelatedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_823bd0e4-b0b4-45f9-a3f5-972f60e51246" xlink:to="loc_lsta_ClinicalAndRDRelatedLiabilities_44be1e5c-c493-4c44-99d6-6e6d915796dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bd23a650-4266-4f2f-90f2-0b14c2be83d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_823bd0e4-b0b4-45f9-a3f5-972f60e51246" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bd23a650-4266-4f2f-90f2-0b14c2be83d6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesScheduleofBalanceSheetPresentationDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#OperatingLeasesScheduleofBalanceSheetPresentationDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesScheduleofBalanceSheetPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d49df853-4d61-45d9-aeef-1a4ea3ad70d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9ec81f96-bc9a-423e-8fce-0b0587c0fb97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_d49df853-4d61-45d9-aeef-1a4ea3ad70d9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9ec81f96-bc9a-423e-8fce-0b0587c0fb97" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31a1e840-b893-4696-9672-28e0fce613ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7c1ee8c5-eb40-4952-9adc-82e999165f61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31a1e840-b893-4696-9672-28e0fce613ff" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7c1ee8c5-eb40-4952-9adc-82e999165f61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_41745cdc-4064-4098-934d-e24288d333ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31a1e840-b893-4696-9672-28e0fce613ff" xlink:to="loc_us-gaap_OperatingLeaseLiability_41745cdc-4064-4098-934d-e24288d333ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="lsta-20250331.xsd#OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_410d792a-c7b6-4d35-bd92-0e6bcb36ce0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f8ca7bdb-5d84-49f6-92ca-3b1a4d4c81e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_410d792a-c7b6-4d35-bd92-0e6bcb36ce0a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f8ca7bdb-5d84-49f6-92ca-3b1a4d4c81e9" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>lsta-20250331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1dd57249-b3e7-436f-adc4-30cff3fca49a,g:189dfb66-5ef0-4fa0-83c9-286ae40a1a30-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="simple" xlink:href="lsta-20250331.xsd#CONSOLIDATEDSTATEMENTSOFEQUITY"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0a0b7c34-1508-47da-b718-6d87664d0180" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9dee6fd3-cd5b-4248-a1fe-ea5719d012ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0a0b7c34-1508-47da-b718-6d87664d0180" xlink:to="loc_us-gaap_StatementTable_9dee6fd3-cd5b-4248-a1fe-ea5719d012ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_75816c61-66bb-4757-8185-816a1a5c0381" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9dee6fd3-cd5b-4248-a1fe-ea5719d012ab" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_75816c61-66bb-4757-8185-816a1a5c0381" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_75816c61-66bb-4757-8185-816a1a5c0381_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_75816c61-66bb-4757-8185-816a1a5c0381" xlink:to="loc_us-gaap_EquityComponentDomain_75816c61-66bb-4757-8185-816a1a5c0381_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3feccb0d-ebb8-4fff-9c85-35ab9cceb2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_75816c61-66bb-4757-8185-816a1a5c0381" xlink:to="loc_us-gaap_EquityComponentDomain_3feccb0d-ebb8-4fff-9c85-35ab9cceb2d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_aaadbaad-9e97-4402-b6af-e7b14168c726" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3feccb0d-ebb8-4fff-9c85-35ab9cceb2d0" xlink:to="loc_us-gaap_ParentMember_aaadbaad-9e97-4402-b6af-e7b14168c726" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f9a4a9f3-a6c0-4314-b3fc-977be06b03db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_aaadbaad-9e97-4402-b6af-e7b14168c726" xlink:to="loc_us-gaap_CommonStockMember_f9a4a9f3-a6c0-4314-b3fc-977be06b03db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e021448f-7e86-4b3b-86dc-9e51a7a84952" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_aaadbaad-9e97-4402-b6af-e7b14168c726" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e021448f-7e86-4b3b-86dc-9e51a7a84952" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ec9fc527-6898-4b2d-8230-ea4c2aeed3af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_aaadbaad-9e97-4402-b6af-e7b14168c726" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ec9fc527-6898-4b2d-8230-ea4c2aeed3af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_48230cab-810f-406e-a342-b5a3cac3c420" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_aaadbaad-9e97-4402-b6af-e7b14168c726" xlink:to="loc_us-gaap_RetainedEarningsMember_48230cab-810f-406e-a342-b5a3cac3c420" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_c689d23a-9113-4ea7-aad4-87a995ce0251" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_aaadbaad-9e97-4402-b6af-e7b14168c726" xlink:to="loc_us-gaap_TreasuryStockCommonMember_c689d23a-9113-4ea7-aad4-87a995ce0251" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9e864e64-734b-4a1f-873d-9978e3bfff31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3feccb0d-ebb8-4fff-9c85-35ab9cceb2d0" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9e864e64-734b-4a1f-873d-9978e3bfff31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0a0b7c34-1508-47da-b718-6d87664d0180" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d91034c4-c6df-42fc-9997-dcc62da137c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d91034c4-c6df-42fc-9997-dcc62da137c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e4477ccf-6c07-4734-9563-479304351b42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e4477ccf-6c07-4734-9563-479304351b42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_97bbdb76-ec5b-497f-b6a0-e8d692f3c1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_ProfitLoss_97bbdb76-ec5b-497f-b6a0-e8d692f3c1ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a02b5db3-b5b0-4e4b-bcc7-def94c810de7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a02b5db3-b5b0-4e4b-bcc7-def94c810de7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f200cad3-c6b3-43e8-8c91-d9506103a948" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f200cad3-c6b3-43e8-8c91-d9506103a948" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dc57bff4-61b9-4a1d-934f-b0dcff0101aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dc57bff4-61b9-4a1d-934f-b0dcff0101aa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_25764e1d-8445-4620-8968-95b63d450e47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_25764e1d-8445-4620-8968-95b63d450e47" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5cd8c1f5-cc09-4f0d-80f6-f2c60774a95e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5cd8c1f5-cc09-4f0d-80f6-f2c60774a95e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_119cee07-17d8-4597-87df-65f99b726372" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_119cee07-17d8-4597-87df-65f99b726372" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a3277ce7-d2c7-40db-939d-45efd9be716d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a3277ce7-d2c7-40db-939d-45efd9be716d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_85742c80-3887-42ae-b55f-b21c81a4c994" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_85742c80-3887-42ae-b55f-b21c81a4c994" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ec9ce2eb-7624-405f-9ae2-bfd0b7da19cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3201f76f-40d4-4e9b-bab9-5f6c00e61c03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6bf7f0d4-70ba-4ae3-a38c-1a5f784be173" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_159a11d6-c4d3-4c17-a6ef-92c8b44b2f71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6bf7f0d4-70ba-4ae3-a38c-1a5f784be173" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_159a11d6-c4d3-4c17-a6ef-92c8b44b2f71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9252907-e4cb-427e-b347-2cf919f8ed15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_159a11d6-c4d3-4c17-a6ef-92c8b44b2f71" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9252907-e4cb-427e-b347-2cf919f8ed15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c9252907-e4cb-427e-b347-2cf919f8ed15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9252907-e4cb-427e-b347-2cf919f8ed15" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c9252907-e4cb-427e-b347-2cf919f8ed15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82043226-3bb9-4cec-b065-c374d4364112" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9252907-e4cb-427e-b347-2cf919f8ed15" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82043226-3bb9-4cec-b065-c374d4364112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_a7869b06-79cc-4e42-9b2b-ae2af06ca990" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82043226-3bb9-4cec-b065-c374d4364112" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_a7869b06-79cc-4e42-9b2b-ae2af06ca990" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_af63c9e4-8ce9-4079-9985-227605fd813f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82043226-3bb9-4cec-b065-c374d4364112" xlink:to="loc_us-gaap_ComputerEquipmentMember_af63c9e4-8ce9-4079-9985-227605fd813f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_be6d294f-50eb-4367-8646-383561e10d63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82043226-3bb9-4cec-b065-c374d4364112" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_be6d294f-50eb-4367-8646-383561e10d63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4a977714-4847-4ebe-9910-38ce0bf21148" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6bf7f0d4-70ba-4ae3-a38c-1a5f784be173" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4a977714-4847-4ebe-9910-38ce0bf21148" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d6e6e38f-da1f-41e9-a186-38688de7f5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1ec0ec2e-822f-4642-b3e5-b8a02dead588" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d6e6e38f-da1f-41e9-a186-38688de7f5d9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1ec0ec2e-822f-4642-b3e5-b8a02dead588" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e7a56710-a7d2-4ac1-aef1-d607d88ceae4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1ec0ec2e-822f-4642-b3e5-b8a02dead588" xlink:to="loc_srt_ProductOrServiceAxis_e7a56710-a7d2-4ac1-aef1-d607d88ceae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e7a56710-a7d2-4ac1-aef1-d607d88ceae4_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e7a56710-a7d2-4ac1-aef1-d607d88ceae4" xlink:to="loc_srt_ProductsAndServicesDomain_e7a56710-a7d2-4ac1-aef1-d607d88ceae4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_16d29940-1c59-4f97-84ba-3a279b7aa4ed" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e7a56710-a7d2-4ac1-aef1-d607d88ceae4" xlink:to="loc_srt_ProductsAndServicesDomain_16d29940-1c59-4f97-84ba-3a279b7aa4ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_00bed213-5e3c-41b4-84cf-fcade785370a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_16d29940-1c59-4f97-84ba-3a279b7aa4ed" xlink:to="loc_us-gaap_RoyaltyMember_00bed213-5e3c-41b4-84cf-fcade785370a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_983fbed3-5ca7-41ed-a79a-7728eb658e84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d6e6e38f-da1f-41e9-a186-38688de7f5d9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_983fbed3-5ca7-41ed-a79a-7728eb658e84" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_08d64e95-eb45-479b-b37f-20672cdb3800" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a1f4f6a-d3ee-4b8e-80a8-269c1c86a70e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_08d64e95-eb45-479b-b37f-20672cdb3800" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a1f4f6a-d3ee-4b8e-80a8-269c1c86a70e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_18865e8d-2e1c-4b01-a0a6-4a8f6a7f4355" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a1f4f6a-d3ee-4b8e-80a8-269c1c86a70e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_18865e8d-2e1c-4b01-a0a6-4a8f6a7f4355" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_18865e8d-2e1c-4b01-a0a6-4a8f6a7f4355_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_18865e8d-2e1c-4b01-a0a6-4a8f6a7f4355" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_18865e8d-2e1c-4b01-a0a6-4a8f6a7f4355_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cab9c07a-42c5-48fd-9ef4-7bc36397a080" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_18865e8d-2e1c-4b01-a0a6-4a8f6a7f4355" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cab9c07a-42c5-48fd-9ef4-7bc36397a080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ebc6ea41-4def-417f-bcac-ced86642df22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cab9c07a-42c5-48fd-9ef4-7bc36397a080" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ebc6ea41-4def-417f-bcac-ced86642df22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7c084f9b-4b2b-4188-ad43-92e3bc01b80c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cab9c07a-42c5-48fd-9ef4-7bc36397a080" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7c084f9b-4b2b-4188-ad43-92e3bc01b80c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BondsMember_b4c5c62e-d8b4-45e4-9bfd-a94f62578990" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cab9c07a-42c5-48fd-9ef4-7bc36397a080" xlink:to="loc_us-gaap_BondsMember_b4c5c62e-d8b4-45e4-9bfd-a94f62578990" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_7e9ccaf5-8939-4948-9976-bbbc6031f590" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cab9c07a-42c5-48fd-9ef4-7bc36397a080" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_7e9ccaf5-8939-4948-9976-bbbc6031f590" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_ccaf28f3-9f1b-4ddc-b819-2993c3236c28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cab9c07a-42c5-48fd-9ef4-7bc36397a080" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_ccaf28f3-9f1b-4ddc-b819-2993c3236c28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bd084478-3e95-4cdb-9f93-22cb2240e7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_08d64e95-eb45-479b-b37f-20672cdb3800" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bd084478-3e95-4cdb-9f93-22cb2240e7cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_668f4d93-1c28-4711-b1c3-20af5a6d7678" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_08d64e95-eb45-479b-b37f-20672cdb3800" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_668f4d93-1c28-4711-b1c3-20af5a6d7678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e883bbc9-a5d0-4527-adb5-b7264fac5f75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_08d64e95-eb45-479b-b37f-20672cdb3800" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e883bbc9-a5d0-4527-adb5-b7264fac5f75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ba15a825-69ab-4ec5-a2dc-cf9e8e7a29f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_08d64e95-eb45-479b-b37f-20672cdb3800" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ba15a825-69ab-4ec5-a2dc-cf9e8e7a29f7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#PropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0498588d-a3fc-4d88-b2ac-2d0eae1cf6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_589e837a-2dcc-4556-bbfe-946d4d11dd10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0498588d-a3fc-4d88-b2ac-2d0eae1cf6f7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_589e837a-2dcc-4556-bbfe-946d4d11dd10" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_98a190bf-584f-4ce6-a8ca-b32c0f8c4712" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_589e837a-2dcc-4556-bbfe-946d4d11dd10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_98a190bf-584f-4ce6-a8ca-b32c0f8c4712" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_98a190bf-584f-4ce6-a8ca-b32c0f8c4712_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_98a190bf-584f-4ce6-a8ca-b32c0f8c4712" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_98a190bf-584f-4ce6-a8ca-b32c0f8c4712_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8df601a1-44a0-4982-b098-803445186ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_98a190bf-584f-4ce6-a8ca-b32c0f8c4712" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8df601a1-44a0-4982-b098-803445186ea0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_eb3b4219-2130-4e81-baef-ddf1a777b26c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8df601a1-44a0-4982-b098-803445186ea0" xlink:to="loc_us-gaap_ComputerEquipmentMember_eb3b4219-2130-4e81-baef-ddf1a777b26c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_c349c284-b121-4ee3-a8af-d9d28a46c457" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8df601a1-44a0-4982-b098-803445186ea0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_c349c284-b121-4ee3-a8af-d9d28a46c457" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3f732392-c5af-4957-b2fc-8b72c28e5861" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0498588d-a3fc-4d88-b2ac-2d0eae1cf6f7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_3f732392-c5af-4957-b2fc-8b72c28e5861" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_597311fc-0eef-4275-98f8-0a008817c65b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0498588d-a3fc-4d88-b2ac-2d0eae1cf6f7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_597311fc-0eef-4275-98f8-0a008817c65b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_841009f4-b222-4a1f-8ade-3d72586f1853" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0498588d-a3fc-4d88-b2ac-2d0eae1cf6f7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_841009f4-b222-4a1f-8ade-3d72586f1853" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ad0f4be7-e8ee-4f32-9765-6e21265a5c36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0498588d-a3fc-4d88-b2ac-2d0eae1cf6f7" xlink:to="loc_us-gaap_Depreciation_ad0f4be7-e8ee-4f32-9765-6e21265a5c36" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#IncomeLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bda35d22-9a12-4805-8b92-8c87f6bc0ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6e2d1c67-265b-48d7-acfa-804db1dbfe24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bda35d22-9a12-4805-8b92-8c87f6bc0ac0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6e2d1c67-265b-48d7-acfa-804db1dbfe24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_40d6d9f8-f8eb-49c3-9128-b445e9a4a6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6e2d1c67-265b-48d7-acfa-804db1dbfe24" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_40d6d9f8-f8eb-49c3-9128-b445e9a4a6d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40d6d9f8-f8eb-49c3-9128-b445e9a4a6d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_40d6d9f8-f8eb-49c3-9128-b445e9a4a6d1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40d6d9f8-f8eb-49c3-9128-b445e9a4a6d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5781632d-2af5-4505-8dcc-20fd9deb5d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_40d6d9f8-f8eb-49c3-9128-b445e9a4a6d1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5781632d-2af5-4505-8dcc-20fd9deb5d9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9b3d18fe-298f-4977-a52d-c66f445e8bac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5781632d-2af5-4505-8dcc-20fd9deb5d9d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9b3d18fe-298f-4977-a52d-c66f445e8bac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_a9f7bfca-fde0-4bbd-8c1b-36c0ce8fdf6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5781632d-2af5-4505-8dcc-20fd9deb5d9d" xlink:to="loc_us-gaap_WarrantMember_a9f7bfca-fde0-4bbd-8c1b-36c0ce8fdf6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_352fcd0f-f3f1-4890-80a3-fc1781fab068" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5781632d-2af5-4505-8dcc-20fd9deb5d9d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_352fcd0f-f3f1-4890-80a3-fc1781fab068" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a8b8f1ce-f1b9-4e75-99a7-e7e66b2d2544" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bda35d22-9a12-4805-8b92-8c87f6bc0ac0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a8b8f1ce-f1b9-4e75-99a7-e7e66b2d2544" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2f21d988-0973-4ef0-b6ab-bb94cf3e256c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_789287d9-a769-46eb-a0e8-cccd3db3ed28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2f21d988-0973-4ef0-b6ab-bb94cf3e256c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_789287d9-a769-46eb-a0e8-cccd3db3ed28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92c23db7-3ff1-4f38-a19c-880d91a10c48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_789287d9-a769-46eb-a0e8-cccd3db3ed28" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92c23db7-3ff1-4f38-a19c-880d91a10c48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92c23db7-3ff1-4f38-a19c-880d91a10c48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92c23db7-3ff1-4f38-a19c-880d91a10c48" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92c23db7-3ff1-4f38-a19c-880d91a10c48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9333e0ce-fd16-4b93-9c34-81236ded031f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92c23db7-3ff1-4f38-a19c-880d91a10c48" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9333e0ce-fd16-4b93-9c34-81236ded031f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b68c1ec8-8c8a-434b-95bf-5d031af82ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9333e0ce-fd16-4b93-9c34-81236ded031f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b68c1ec8-8c8a-434b-95bf-5d031af82ed2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_88cadfa1-4380-43cf-8290-6e11f082c50a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9333e0ce-fd16-4b93-9c34-81236ded031f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_88cadfa1-4380-43cf-8290-6e11f082c50a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c37f3be1-5067-428f-8ebd-71d943a9a765" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9333e0ce-fd16-4b93-9c34-81236ded031f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c37f3be1-5067-428f-8ebd-71d943a9a765" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ffff19d6-35f4-4686-b63e-dbf0e794b8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_789287d9-a769-46eb-a0e8-cccd3db3ed28" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ffff19d6-35f4-4686-b63e-dbf0e794b8bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ffff19d6-35f4-4686-b63e-dbf0e794b8bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ffff19d6-35f4-4686-b63e-dbf0e794b8bb" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ffff19d6-35f4-4686-b63e-dbf0e794b8bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_84d581b0-79aa-45a2-af37-cebca29cef5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ffff19d6-35f4-4686-b63e-dbf0e794b8bb" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_84d581b0-79aa-45a2-af37-cebca29cef5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7e0b6537-9cef-495c-9c79-378ae9843ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_84d581b0-79aa-45a2-af37-cebca29cef5b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7e0b6537-9cef-495c-9c79-378ae9843ff7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9b06ba43-520e-41fd-89c6-5d4db66e2d90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2f21d988-0973-4ef0-b6ab-bb94cf3e256c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9b06ba43-520e-41fd-89c6-5d4db66e2d90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4ef51bd0-9c11-43e2-8389-6a093cefdd49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2f21d988-0973-4ef0-b6ab-bb94cf3e256c" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_4ef51bd0-9c11-43e2-8389-6a093cefdd49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ecd482b1-b18e-4fcf-832d-ed2e44e366cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2f21d988-0973-4ef0-b6ab-bb94cf3e256c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ecd482b1-b18e-4fcf-832d-ed2e44e366cf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#StockholdersEquityEquityIssuancesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ec763041-e9df-434d-98a3-126c8aa2f42e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_18dfda42-a172-403a-86a9-362e9fef8d72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_ec763041-e9df-434d-98a3-126c8aa2f42e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_18dfda42-a172-403a-86a9-362e9fef8d72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_78250625-8998-4c4e-b653-4723fef880f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_18dfda42-a172-403a-86a9-362e9fef8d72" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_78250625-8998-4c4e-b653-4723fef880f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_78250625-8998-4c4e-b653-4723fef880f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_78250625-8998-4c4e-b653-4723fef880f6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_78250625-8998-4c4e-b653-4723fef880f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7112fcb0-7489-483c-9384-18a38488ad42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_78250625-8998-4c4e-b653-4723fef880f6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7112fcb0-7489-483c-9384-18a38488ad42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AtTheMarketOfferingAgreementMember_19d1b692-5720-4486-9829-121bdb0b8c83" xlink:href="lsta-20250331.xsd#lsta_AtTheMarketOfferingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7112fcb0-7489-483c-9384-18a38488ad42" xlink:to="loc_lsta_AtTheMarketOfferingAgreementMember_19d1b692-5720-4486-9829-121bdb0b8c83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_5366b7b7-8e56-497b-b84c-e8b4f11dbf57" xlink:href="lsta-20250331.xsd#lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ec763041-e9df-434d-98a3-126c8aa2f42e" xlink:to="loc_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_5366b7b7-8e56-497b-b84c-e8b4f11dbf57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_acd17eda-2a40-4c10-a9aa-50804a7c9ade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ec763041-e9df-434d-98a3-126c8aa2f42e" xlink:to="loc_us-gaap_CommonStockValueOutstanding_acd17eda-2a40-4c10-a9aa-50804a7c9ade" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OutstandingStockThreshold_af422b40-ebd3-447e-89be-7fe8a092b611" xlink:href="lsta-20250331.xsd#lsta_OutstandingStockThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ec763041-e9df-434d-98a3-126c8aa2f42e" xlink:to="loc_lsta_OutstandingStockThreshold_af422b40-ebd3-447e-89be-7fe8a092b611" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAvailableForSale_44e34b97-9be1-45ec-b748-196269dbf726" xlink:href="lsta-20250331.xsd#lsta_SaleOfStockAvailableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ec763041-e9df-434d-98a3-126c8aa2f42e" xlink:to="loc_lsta_SaleOfStockAvailableForSale_44e34b97-9be1-45ec-b748-196269dbf726" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAvailableForSalePercentage_ab055818-aacb-4d55-9b12-f57b1121f1c0" xlink:href="lsta-20250331.xsd#lsta_SaleOfStockAvailableForSalePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ec763041-e9df-434d-98a3-126c8aa2f42e" xlink:to="loc_lsta_SaleOfStockAvailableForSalePercentage_ab055818-aacb-4d55-9b12-f57b1121f1c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7f49153d-d306-4423-88b7-b0c14a007baf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ec763041-e9df-434d-98a3-126c8aa2f42e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7f49153d-d306-4423-88b7-b0c14a007baf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0817ecf4-dac0-46be-9a24-17bab881c0de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ec763041-e9df-434d-98a3-126c8aa2f42e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0817ecf4-dac0-46be-9a24-17bab881c0de" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f139b4a-8828-4c09-844b-0ce21660c84e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fb93054-629d-4e4b-93de-a8b721178576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f139b4a-8828-4c09-844b-0ce21660c84e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fb93054-629d-4e4b-93de-a8b721178576" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_35c126aa-7017-4e79-ae01-887195e3da37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fb93054-629d-4e4b-93de-a8b721178576" xlink:to="loc_us-gaap_AwardTypeAxis_35c126aa-7017-4e79-ae01-887195e3da37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35c126aa-7017-4e79-ae01-887195e3da37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_35c126aa-7017-4e79-ae01-887195e3da37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35c126aa-7017-4e79-ae01-887195e3da37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40cb743c-58f6-4f62-9c14-df75ac7a5764" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_35c126aa-7017-4e79-ae01-887195e3da37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40cb743c-58f6-4f62-9c14-df75ac7a5764" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_68445772-af1c-4cfe-8842-901b1b83560b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40cb743c-58f6-4f62-9c14-df75ac7a5764" xlink:to="loc_us-gaap_RestrictedStockMember_68445772-af1c-4cfe-8842-901b1b83560b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9c57eaf1-9a47-4342-a171-cebba5701da9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fb93054-629d-4e4b-93de-a8b721178576" xlink:to="loc_srt_RangeAxis_9c57eaf1-9a47-4342-a171-cebba5701da9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9c57eaf1-9a47-4342-a171-cebba5701da9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9c57eaf1-9a47-4342-a171-cebba5701da9" xlink:to="loc_srt_RangeMember_9c57eaf1-9a47-4342-a171-cebba5701da9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e107ba00-715c-442e-ab94-9265c41bc12e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9c57eaf1-9a47-4342-a171-cebba5701da9" xlink:to="loc_srt_RangeMember_e107ba00-715c-442e-ab94-9265c41bc12e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_425474cf-188c-4830-b8a6-96b8f5838bfa" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e107ba00-715c-442e-ab94-9265c41bc12e" xlink:to="loc_srt_MinimumMember_425474cf-188c-4830-b8a6-96b8f5838bfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b648cacb-1c0f-449b-b6ea-ffe059801788" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e107ba00-715c-442e-ab94-9265c41bc12e" xlink:to="loc_srt_MaximumMember_b648cacb-1c0f-449b-b6ea-ffe059801788" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d1bab1b1-c0a1-46e7-a3a2-a536d09e8728" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f139b4a-8828-4c09-844b-0ce21660c84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d1bab1b1-c0a1-46e7-a3a2-a536d09e8728" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0bae8e74-d96b-47fc-baaf-40d6b1dad973" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f139b4a-8828-4c09-844b-0ce21660c84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0bae8e74-d96b-47fc-baaf-40d6b1dad973" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityScheduleofRestrictedStockUnitsforServicesDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#StockholdersEquityScheduleofRestrictedStockUnitsforServicesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityScheduleofRestrictedStockUnitsforServicesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d34b9bc-0d1f-4163-9cce-441dae6559d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6b0f89b-40ef-4936-a4e1-90322983a1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d34b9bc-0d1f-4163-9cce-441dae6559d7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6b0f89b-40ef-4936-a4e1-90322983a1fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3e383726-6ee9-43f1-b642-e1850c91dcb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6b0f89b-40ef-4936-a4e1-90322983a1fd" xlink:to="loc_us-gaap_AwardTypeAxis_3e383726-6ee9-43f1-b642-e1850c91dcb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e383726-6ee9-43f1-b642-e1850c91dcb6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3e383726-6ee9-43f1-b642-e1850c91dcb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e383726-6ee9-43f1-b642-e1850c91dcb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb5458ba-b399-4f92-ad79-6d464cf4066f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3e383726-6ee9-43f1-b642-e1850c91dcb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb5458ba-b399-4f92-ad79-6d464cf4066f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_77ced15e-4510-4b23-899e-db14f34a9e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb5458ba-b399-4f92-ad79-6d464cf4066f" xlink:to="loc_us-gaap_RestrictedStockMember_77ced15e-4510-4b23-899e-db14f34a9e6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f50f6460-a784-4ac4-bf73-918fa4492e34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb5458ba-b399-4f92-ad79-6d464cf4066f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f50f6460-a784-4ac4-bf73-918fa4492e34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_1a36ae6a-8582-4bd0-8fc1-3cdb3f0d8e43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d34b9bc-0d1f-4163-9cce-441dae6559d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_1a36ae6a-8582-4bd0-8fc1-3cdb3f0d8e43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_3860f1f6-1aa4-44df-aa62-743134a1c545" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d34b9bc-0d1f-4163-9cce-441dae6559d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_3860f1f6-1aa4-44df-aa62-743134a1c545" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c9f53e30-4bc3-48a4-827c-79c674caec74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d34b9bc-0d1f-4163-9cce-441dae6559d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c9f53e30-4bc3-48a4-827c-79c674caec74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0d8f83a1-32f2-47ea-9044-44d2eadcbff3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d34b9bc-0d1f-4163-9cce-441dae6559d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0d8f83a1-32f2-47ea-9044-44d2eadcbff3" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#StockholdersEquityScheduleofNonVestedRestrictedStockDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da2a7ad9-cf57-4935-a682-9a4cc7a6ca70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ceed9df-5f53-4d5e-a832-0873845cfece" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da2a7ad9-cf57-4935-a682-9a4cc7a6ca70" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ceed9df-5f53-4d5e-a832-0873845cfece" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5d3e83ed-5bfe-40f4-9835-686ce81631d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ceed9df-5f53-4d5e-a832-0873845cfece" xlink:to="loc_us-gaap_AwardTypeAxis_5d3e83ed-5bfe-40f4-9835-686ce81631d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d3e83ed-5bfe-40f4-9835-686ce81631d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5d3e83ed-5bfe-40f4-9835-686ce81631d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d3e83ed-5bfe-40f4-9835-686ce81631d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a1f7002-b3db-4ea1-a1aa-a353ef320afb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5d3e83ed-5bfe-40f4-9835-686ce81631d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a1f7002-b3db-4ea1-a1aa-a353ef320afb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f5c48f8a-80b6-442d-bc42-c3d179447c04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a1f7002-b3db-4ea1-a1aa-a353ef320afb" xlink:to="loc_us-gaap_RestrictedStockMember_f5c48f8a-80b6-442d-bc42-c3d179447c04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c4bc575e-b7e6-4d0c-82ef-d0892f068a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a1f7002-b3db-4ea1-a1aa-a353ef320afb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c4bc575e-b7e6-4d0c-82ef-d0892f068a4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4ec3301d-877f-43ad-b565-2b84925783f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da2a7ad9-cf57-4935-a682-9a4cc7a6ca70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4ec3301d-877f-43ad-b565-2b84925783f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8580c6a9-3772-4277-ac4f-f82dad6aab1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4ec3301d-877f-43ad-b565-2b84925783f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8580c6a9-3772-4277-ac4f-f82dad6aab1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e9985f1f-4e2a-467c-9baf-0c06d4dd3aad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4ec3301d-877f-43ad-b565-2b84925783f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e9985f1f-4e2a-467c-9baf-0c06d4dd3aad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_065a098d-2118-4ada-b1dd-bc6f39336968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4ec3301d-877f-43ad-b565-2b84925783f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_065a098d-2118-4ada-b1dd-bc6f39336968" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37dbcd12-65a3-4f1e-b337-9bdbf54c846c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4ec3301d-877f-43ad-b565-2b84925783f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37dbcd12-65a3-4f1e-b337-9bdbf54c846c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_99e88d7a-4b7e-413d-87c5-264d4cdd14f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1732c56c-26a2-4957-b97d-9ee984d12bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da2a7ad9-cf57-4935-a682-9a4cc7a6ca70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1732c56c-26a2-4957-b97d-9ee984d12bdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cadf608c-0a86-4413-9928-135d9c47d97d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1732c56c-26a2-4957-b97d-9ee984d12bdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cadf608c-0a86-4413-9928-135d9c47d97d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4a95e315-4a89-41c2-bf65-bd7cf38748da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1732c56c-26a2-4957-b97d-9ee984d12bdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4a95e315-4a89-41c2-bf65-bd7cf38748da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cff5c807-61e8-4bc8-bffc-12813cfe2964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1732c56c-26a2-4957-b97d-9ee984d12bdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cff5c807-61e8-4bc8-bffc-12813cfe2964" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c34bd74b-89e0-439e-92b0-a170060a4410" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1732c56c-26a2-4957-b97d-9ee984d12bdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c34bd74b-89e0-439e-92b0-a170060a4410" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c375f5ff-b6be-4a5a-9544-81215a382f37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb6876a2-1bdc-4714-8caf-1b1affc6db5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd6eb450-3ae1-454e-a30e-e7acf357dd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb6876a2-1bdc-4714-8caf-1b1affc6db5b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd6eb450-3ae1-454e-a30e-e7acf357dd5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ef6141bf-2830-434f-a32e-023f2979ab9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd6eb450-3ae1-454e-a30e-e7acf357dd5f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ef6141bf-2830-434f-a32e-023f2979ab9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ef6141bf-2830-434f-a32e-023f2979ab9f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ef6141bf-2830-434f-a32e-023f2979ab9f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ef6141bf-2830-434f-a32e-023f2979ab9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_db339341-dbaa-42b5-a66c-82ea206a3378" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ef6141bf-2830-434f-a32e-023f2979ab9f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_db339341-dbaa-42b5-a66c-82ea206a3378" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1cca062d-5a02-4207-b1a2-a7c72d5f8fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_db339341-dbaa-42b5-a66c-82ea206a3378" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1cca062d-5a02-4207-b1a2-a7c72d5f8fd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_092907d2-1ae4-4d45-8c08-7be0d55cb3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_db339341-dbaa-42b5-a66c-82ea206a3378" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_092907d2-1ae4-4d45-8c08-7be0d55cb3d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_78adaa3d-7641-4190-967b-d8d4113817b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb6876a2-1bdc-4714-8caf-1b1affc6db5b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_78adaa3d-7641-4190-967b-d8d4113817b9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationScheduleofCompensationCostNotYetRecognizedDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#ShareBasedCompensationScheduleofCompensationCostNotYetRecognizedDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationScheduleofCompensationCostNotYetRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_08b6a94a-d0b9-4ed9-9a70-6a061758f611" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2ee9e1d-d7b4-4b9f-b9b2-1ba76fac1f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_08b6a94a-d0b9-4ed9-9a70-6a061758f611" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2ee9e1d-d7b4-4b9f-b9b2-1ba76fac1f8a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a064a7c0-2c94-4103-b0b1-91dda0f79e50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2ee9e1d-d7b4-4b9f-b9b2-1ba76fac1f8a" xlink:to="loc_us-gaap_AwardTypeAxis_a064a7c0-2c94-4103-b0b1-91dda0f79e50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a064a7c0-2c94-4103-b0b1-91dda0f79e50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a064a7c0-2c94-4103-b0b1-91dda0f79e50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a064a7c0-2c94-4103-b0b1-91dda0f79e50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02c6d5fb-f110-481c-8337-5074a36b17e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a064a7c0-2c94-4103-b0b1-91dda0f79e50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02c6d5fb-f110-481c-8337-5074a36b17e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_46f070ab-c87f-4127-aa9d-1329dc6fe5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02c6d5fb-f110-481c-8337-5074a36b17e8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_46f070ab-c87f-4127-aa9d-1329dc6fe5c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cbc9a030-8499-40b6-8ac5-f86742636bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02c6d5fb-f110-481c-8337-5074a36b17e8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cbc9a030-8499-40b6-8ac5-f86742636bd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_a218f0ae-2bd6-43f8-aa07-21ff6be80c75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02c6d5fb-f110-481c-8337-5074a36b17e8" xlink:to="loc_us-gaap_WarrantMember_a218f0ae-2bd6-43f8-aa07-21ff6be80c75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0590946b-264b-404f-8b84-731efa974665" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02c6d5fb-f110-481c-8337-5074a36b17e8" xlink:to="loc_us-gaap_RestrictedStockMember_0590946b-264b-404f-8b84-731efa974665" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f07ba5e5-7a12-4a39-9f92-472c2fd6afda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_08b6a94a-d0b9-4ed9-9a70-6a061758f611" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f07ba5e5-7a12-4a39-9f92-472c2fd6afda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5530aea7-1e26-4ece-ba23-87e2a57f207a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_08b6a94a-d0b9-4ed9-9a70-6a061758f611" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5530aea7-1e26-4ece-ba23-87e2a57f207a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationScheduleofFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#ShareBasedCompensationScheduleofFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationScheduleofFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f5f9a4d-e6ed-4781-bdef-1ffa50bb4e74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ad4c1eb-5830-4139-ad6b-e4c2514ee383" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f5f9a4d-e6ed-4781-bdef-1ffa50bb4e74" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ad4c1eb-5830-4139-ad6b-e4c2514ee383" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_43daf1ae-ed36-4a32-a667-cb9dc4747de5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ad4c1eb-5830-4139-ad6b-e4c2514ee383" xlink:to="loc_us-gaap_AwardTypeAxis_43daf1ae-ed36-4a32-a667-cb9dc4747de5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43daf1ae-ed36-4a32-a667-cb9dc4747de5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_43daf1ae-ed36-4a32-a667-cb9dc4747de5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43daf1ae-ed36-4a32-a667-cb9dc4747de5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77aea21b-10a0-42c0-92e0-dd0de4fd9a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_43daf1ae-ed36-4a32-a667-cb9dc4747de5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77aea21b-10a0-42c0-92e0-dd0de4fd9a9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5f99b116-5df7-4eff-810e-602795349862" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77aea21b-10a0-42c0-92e0-dd0de4fd9a9c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5f99b116-5df7-4eff-810e-602795349862" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_9f18b615-5c22-4257-abb2-64e2b29fe6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77aea21b-10a0-42c0-92e0-dd0de4fd9a9c" xlink:to="loc_us-gaap_WarrantMember_9f18b615-5c22-4257-abb2-64e2b29fe6ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_479e6d45-826d-4cb6-aed4-87678a774d03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f5f9a4d-e6ed-4781-bdef-1ffa50bb4e74" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_479e6d45-826d-4cb6-aed4-87678a774d03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_41e87329-76a4-44de-896b-f525fac0eb39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f5f9a4d-e6ed-4781-bdef-1ffa50bb4e74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_41e87329-76a4-44de-896b-f525fac0eb39" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_69eca5b7-83dd-4dac-b4fe-26d4c73f14c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_69eca5b7-83dd-4dac-b4fe-26d4c73f14c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e442ac5c-2911-4298-bda7-7bc41f8c3af5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_69eca5b7-83dd-4dac-b4fe-26d4c73f14c5" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e442ac5c-2911-4298-bda7-7bc41f8c3af5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e442ac5c-2911-4298-bda7-7bc41f8c3af5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e442ac5c-2911-4298-bda7-7bc41f8c3af5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e442ac5c-2911-4298-bda7-7bc41f8c3af5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_c41d564e-aef1-4920-bac7-c39001fc7b77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e442ac5c-2911-4298-bda7-7bc41f8c3af5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_c41d564e-aef1-4920-bac7-c39001fc7b77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_9f373bb4-9ef9-42c6-8cc9-52f5629dc341" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c41d564e-aef1-4920-bac7-c39001fc7b77" xlink:to="loc_us-gaap_DomesticCountryMember_9f373bb4-9ef9-42c6-8cc9-52f5629dc341" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_010cdb9e-360e-4df2-a04b-f606fc814f20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c41d564e-aef1-4920-bac7-c39001fc7b77" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_010cdb9e-360e-4df2-a04b-f606fc814f20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_ddf77a61-dc19-4e42-94eb-ca6ed7b7efef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c41d564e-aef1-4920-bac7-c39001fc7b77" xlink:to="loc_us-gaap_ForeignCountryMember_ddf77a61-dc19-4e42-94eb-ca6ed7b7efef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_78e25972-cfa7-4d88-96c6-9e53c6bb9aac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_69eca5b7-83dd-4dac-b4fe-26d4c73f14c5" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_78e25972-cfa7-4d88-96c6-9e53c6bb9aac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_78e25972-cfa7-4d88-96c6-9e53c6bb9aac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_78e25972-cfa7-4d88-96c6-9e53c6bb9aac" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_78e25972-cfa7-4d88-96c6-9e53c6bb9aac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_2baaba00-d81e-4cb4-a673-01fe93c54bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_78e25972-cfa7-4d88-96c6-9e53c6bb9aac" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_2baaba00-d81e-4cb4-a673-01fe93c54bc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_b4d4b255-3220-4bfe-bd97-6b613d1f62b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_2baaba00-d81e-4cb4-a673-01fe93c54bc9" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_b4d4b255-3220-4bfe-bd97-6b613d1f62b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_b5b9597a-d1c9-4db5-bba2-df077974f75a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_2baaba00-d81e-4cb4-a673-01fe93c54bc9" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_b5b9597a-d1c9-4db5-bba2-df077974f75a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_02b83c1b-679e-448e-947c-a49dc37ef60a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_2baaba00-d81e-4cb4-a673-01fe93c54bc9" xlink:to="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_02b83c1b-679e-448e-947c-a49dc37ef60a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a22ed3cb-e680-4da8-81b2-98676c01b542" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_69eca5b7-83dd-4dac-b4fe-26d4c73f14c5" xlink:to="loc_dei_LegalEntityAxis_a22ed3cb-e680-4da8-81b2-98676c01b542" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a22ed3cb-e680-4da8-81b2-98676c01b542_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a22ed3cb-e680-4da8-81b2-98676c01b542" xlink:to="loc_dei_EntityDomain_a22ed3cb-e680-4da8-81b2-98676c01b542_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_074e451d-fc4e-46d3-a7ea-8b0e700d0711" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a22ed3cb-e680-4da8-81b2-98676c01b542" xlink:to="loc_dei_EntityDomain_074e451d-fc4e-46d3-a7ea-8b0e700d0711" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CENDMember_ee3ebc25-771f-4a89-b672-006ca7426891" xlink:href="lsta-20250331.xsd#lsta_CENDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_074e451d-fc4e-46d3-a7ea-8b0e700d0711" xlink:to="loc_lsta_CENDMember_ee3ebc25-771f-4a89-b672-006ca7426891" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_d32283e6-e349-4631-b07f-41ba544984f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_69eca5b7-83dd-4dac-b4fe-26d4c73f14c5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_d32283e6-e349-4631-b07f-41ba544984f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_d32283e6-e349-4631-b07f-41ba544984f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_d32283e6-e349-4631-b07f-41ba544984f4" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_d32283e6-e349-4631-b07f-41ba544984f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_ad158d5b-726d-49d2-85e0-7e8b74f9a442" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_d32283e6-e349-4631-b07f-41ba544984f4" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_ad158d5b-726d-49d2-85e0-7e8b74f9a442" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_30306d3c-1035-4a67-9a8b-dae24b11b018" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_ad158d5b-726d-49d2-85e0-7e8b74f9a442" xlink:to="loc_us-gaap_ResearchMember_30306d3c-1035-4a67-9a8b-dae24b11b018" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLossCarryforwardsBeforeWriteDown_ce4c5f67-cca2-4fc4-9668-341b35721b7a" xlink:href="lsta-20250331.xsd#lsta_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_lsta_OperatingLossCarryforwardsBeforeWriteDown_ce4c5f67-cca2-4fc4-9668-341b35721b7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_f4940e8e-3fea-452d-b596-c8be42fdd419" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_f4940e8e-3fea-452d-b596-c8be42fdd419" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_3086bfab-576f-46d8-8127-4d4cae50b5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_us-gaap_OperatingLossCarryforwards_3086bfab-576f-46d8-8127-4d4cae50b5f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_FairValueMarketOfTaxNOLs_d6bc1d10-f318-4c78-a137-024cd7212905" xlink:href="lsta-20250331.xsd#lsta_FairValueMarketOfTaxNOLs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_lsta_FairValueMarketOfTaxNOLs_d6bc1d10-f318-4c78-a137-024cd7212905" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_40819c75-f339-4fbc-a95a-ce879a2b3122" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_40819c75-f339-4fbc-a95a-ce879a2b3122" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_9c48c22b-9b16-4c5f-8c81-6689bdc9353a" xlink:href="lsta-20250331.xsd#lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_9c48c22b-9b16-4c5f-8c81-6689bdc9353a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLossCarryforwardsPostAcquisition_a321b140-12d1-4007-99af-09fbc4ccd00a" xlink:href="lsta-20250331.xsd#lsta_OperatingLossCarryforwardsPostAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_lsta_OperatingLossCarryforwardsPostAcquisition_a321b140-12d1-4007-99af-09fbc4ccd00a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_0250719f-0031-4be4-a2a2-81c0d796f62f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_0250719f-0031-4be4-a2a2-81c0d796f62f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_b5604aa0-a961-404f-9a51-b5a42370add3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_b5604aa0-a961-404f-9a51-b5a42370add3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_552646a3-2c4d-4ede-939e-87a0ecf21d05" xlink:href="lsta-20250331.xsd#lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_552646a3-2c4d-4ede-939e-87a0ecf21d05" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ProceedsFromSaleOfNOLS_300da3fd-5e42-4288-8e74-c8bb6ab54bd2" xlink:href="lsta-20250331.xsd#lsta_ProceedsFromSaleOfNOLS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_lsta_ProceedsFromSaleOfNOLS_300da3fd-5e42-4288-8e74-c8bb6ab54bd2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_14c56605-3daf-4311-bd37-f8845fb6aa5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_14c56605-3daf-4311-bd37-f8845fb6aa5d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LossOnSaleOfNOL_4e893c4e-2eb2-4383-aacf-a0e59c676d56" xlink:href="lsta-20250331.xsd#lsta_LossOnSaleOfNOL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_lsta_LossOnSaleOfNOL_4e893c4e-2eb2-4383-aacf-a0e59c676d56" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#SegmentInformationScheduleofFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e4cc137f-3430-4cb3-98c6-c44f09f3006f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2f1e5157-b789-4a4d-875a-924bd20d85dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e4cc137f-3430-4cb3-98c6-c44f09f3006f" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2f1e5157-b789-4a4d-875a-924bd20d85dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f750b750-4483-4dcf-9330-364ea55d744d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2f1e5157-b789-4a4d-875a-924bd20d85dc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f750b750-4483-4dcf-9330-364ea55d744d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f750b750-4483-4dcf-9330-364ea55d744d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f750b750-4483-4dcf-9330-364ea55d744d" xlink:to="loc_us-gaap_SegmentDomain_f750b750-4483-4dcf-9330-364ea55d744d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_072300d8-caa3-4828-9d94-883b792f7e88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f750b750-4483-4dcf-9330-364ea55d744d" xlink:to="loc_us-gaap_SegmentDomain_072300d8-caa3-4828-9d94-883b792f7e88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ReportableSegmentMember_790447b2-60ef-4c45-a723-b06bc5ea65df" xlink:href="lsta-20250331.xsd#lsta_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_072300d8-caa3-4828-9d94-883b792f7e88" xlink:to="loc_lsta_ReportableSegmentMember_790447b2-60ef-4c45-a723-b06bc5ea65df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ca73ad08-d303-4e55-bbf7-2f51a7738b8e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2f1e5157-b789-4a4d-875a-924bd20d85dc" xlink:to="loc_srt_ProductOrServiceAxis_ca73ad08-d303-4e55-bbf7-2f51a7738b8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ca73ad08-d303-4e55-bbf7-2f51a7738b8e_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ca73ad08-d303-4e55-bbf7-2f51a7738b8e" xlink:to="loc_srt_ProductsAndServicesDomain_ca73ad08-d303-4e55-bbf7-2f51a7738b8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_edf3fca4-f744-47e5-8bf6-c286d8dfe2ad" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ca73ad08-d303-4e55-bbf7-2f51a7738b8e" xlink:to="loc_srt_ProductsAndServicesDomain_edf3fca4-f744-47e5-8bf6-c286d8dfe2ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_BolsterTrialMember_33c13de0-dbd5-44dc-b5f3-6e4d943f6c19" xlink:href="lsta-20250331.xsd#lsta_BolsterTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_edf3fca4-f744-47e5-8bf6-c286d8dfe2ad" xlink:to="loc_lsta_BolsterTrialMember_33c13de0-dbd5-44dc-b5f3-6e4d943f6c19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AscendTrialMember_a856db5d-8265-46ea-9ec9-a73f7ee342db" xlink:href="lsta-20250331.xsd#lsta_AscendTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_edf3fca4-f744-47e5-8bf6-c286d8dfe2ad" xlink:to="loc_lsta_AscendTrialMember_a856db5d-8265-46ea-9ec9-a73f7ee342db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ChemistryManufacturingAndControlsMember_120e2d14-db0a-4961-891d-be9450dfe17a" xlink:href="lsta-20250331.xsd#lsta_ChemistryManufacturingAndControlsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_edf3fca4-f744-47e5-8bf6-c286d8dfe2ad" xlink:to="loc_lsta_ChemistryManufacturingAndControlsMember_120e2d14-db0a-4961-891d-be9450dfe17a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ClinicalDepartmentMember_5f953d39-8eb3-4d12-a90a-d4ee38ea63ab" xlink:href="lsta-20250331.xsd#lsta_ClinicalDepartmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_edf3fca4-f744-47e5-8bf6-c286d8dfe2ad" xlink:to="loc_lsta_ClinicalDepartmentMember_5f953d39-8eb3-4d12-a90a-d4ee38ea63ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ResearchAndDevelopmentOtherMember_bb803e36-8d99-4595-a418-fe7b4dfd2d15" xlink:href="lsta-20250331.xsd#lsta_ResearchAndDevelopmentOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_edf3fca4-f744-47e5-8bf6-c286d8dfe2ad" xlink:to="loc_lsta_ResearchAndDevelopmentOtherMember_bb803e36-8d99-4595-a418-fe7b4dfd2d15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_17c7deca-63d3-4a16-9381-83667ffd8e59" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2f1e5157-b789-4a4d-875a-924bd20d85dc" xlink:to="loc_srt_ConsolidationItemsAxis_17c7deca-63d3-4a16-9381-83667ffd8e59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_17c7deca-63d3-4a16-9381-83667ffd8e59_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_17c7deca-63d3-4a16-9381-83667ffd8e59" xlink:to="loc_srt_ConsolidationItemsDomain_17c7deca-63d3-4a16-9381-83667ffd8e59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a35aee48-be78-4cd3-baa5-61c280effa62" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_17c7deca-63d3-4a16-9381-83667ffd8e59" xlink:to="loc_srt_ConsolidationItemsDomain_a35aee48-be78-4cd3-baa5-61c280effa62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_b1b4bb4d-1c8f-4f2a-b184-179884ac625c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_a35aee48-be78-4cd3-baa5-61c280effa62" xlink:to="loc_us-gaap_CorporateNonSegmentMember_b1b4bb4d-1c8f-4f2a-b184-179884ac625c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e4cc137f-3430-4cb3-98c6-c44f09f3006f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_751cf9a8-249a-4314-981a-79478ba043a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_751cf9a8-249a-4314-981a-79478ba043a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5d7da108-5c4c-4993-8cc4-007c8f97f0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5d7da108-5c4c-4993-8cc4-007c8f97f0d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommunicationsAndInformationTechnology_3a982b01-36d1-41db-a44e-3d63fd55fa62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommunicationsAndInformationTechnology"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_us-gaap_CommunicationsAndInformationTechnology_3a982b01-36d1-41db-a44e-3d63fd55fa62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_FinanceGeneralAndAdministrativeExpense_5c1d8264-2020-4aef-9ce7-bfe29ab86c56" xlink:href="lsta-20250331.xsd#lsta_FinanceGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_lsta_FinanceGeneralAndAdministrativeExpense_5c1d8264-2020-4aef-9ce7-bfe29ab86c56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LegalGeneralAndAdministrativeExpense_db42057c-a2a4-4f13-a72a-372b3b273c9d" xlink:href="lsta-20250331.xsd#lsta_LegalGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_lsta_LegalGeneralAndAdministrativeExpense_db42057c-a2a4-4f13-a72a-372b3b273c9d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDevelopment_f3edd3b5-e700-4bfa-95ef-a283f77073d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_us-gaap_BusinessDevelopment_f3edd3b5-e700-4bfa-95ef-a283f77073d5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense_855d5c31-3fd2-4887-a716-443f336125d2" xlink:href="lsta-20250331.xsd#lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense_855d5c31-3fd2-4887-a716-443f336125d2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_ba58004e-6c4b-4b2e-914e-56a7a900a0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_ba58004e-6c4b-4b2e-914e-56a7a900a0f1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_beedaed0-2732-4c68-bb0e-8da874911372" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_us-gaap_OperatingIncomeLoss_beedaed0-2732-4c68-bb0e-8da874911372" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2e122452-0857-4f2e-a26a-d6bf9a14144f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2e122452-0857-4f2e-a26a-d6bf9a14144f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e1867642-01ab-42da-a31d-b691c03fde92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e1867642-01ab-42da-a31d-b691c03fde92" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c6f653af-20d4-4294-80a9-675a5beb8425" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_us-gaap_ProfitLoss_c6f653af-20d4-4294-80a9-675a5beb8425" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CashCashEquivalentsAndMarketableSecurities_21c11c0c-8e85-4caf-ba91-eb30c121e405" xlink:href="lsta-20250331.xsd#lsta_CashCashEquivalentsAndMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_lsta_CashCashEquivalentsAndMarketableSecurities_21c11c0c-8e85-4caf-ba91-eb30c121e405" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#AustraliaResearchandDevelopmentTaxIncentiveDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayLineItems_2665eff8-9175-467a-ba00-270299e4152f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayTable_e7495fe9-9fbf-4e27-b06e-fd2899565388" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_2665eff8-9175-467a-ba00-270299e4152f" xlink:to="loc_us-gaap_IncomeTaxHolidayTable_e7495fe9-9fbf-4e27-b06e-fd2899565388" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_367e319d-fb41-4e8c-a1f0-778130a27200" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxHolidayTable_e7495fe9-9fbf-4e27-b06e-fd2899565388" xlink:to="loc_srt_RangeAxis_367e319d-fb41-4e8c-a1f0-778130a27200" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_367e319d-fb41-4e8c-a1f0-778130a27200_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_367e319d-fb41-4e8c-a1f0-778130a27200" xlink:to="loc_srt_RangeMember_367e319d-fb41-4e8c-a1f0-778130a27200_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9bea058c-b818-4ca5-9dca-9e7974f57696" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_367e319d-fb41-4e8c-a1f0-778130a27200" xlink:to="loc_srt_RangeMember_9bea058c-b818-4ca5-9dca-9e7974f57696" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cdbcd02b-61f3-44f1-8468-660ef4295787" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9bea058c-b818-4ca5-9dca-9e7974f57696" xlink:to="loc_srt_MinimumMember_cdbcd02b-61f3-44f1-8468-660ef4295787" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5c076c86-17a5-4a7d-a0ee-7326b2895224" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9bea058c-b818-4ca5-9dca-9e7974f57696" xlink:to="loc_srt_MaximumMember_5c076c86-17a5-4a7d-a0ee-7326b2895224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_e6e9be67-7817-49e0-ae2c-3d36954f7d07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_2665eff8-9175-467a-ba00-270299e4152f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_e6e9be67-7817-49e0-ae2c-3d36954f7d07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_IncomeTaxIncentiveReceivable_d6f125ec-e738-4de7-923b-4a061e65556a" xlink:href="lsta-20250331.xsd#lsta_IncomeTaxIncentiveReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_2665eff8-9175-467a-ba00-270299e4152f" xlink:to="loc_lsta_IncomeTaxIncentiveReceivable_d6f125ec-e738-4de7-923b-4a061e65556a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#ContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_c08fbdff-5203-4922-b471-95b6b2ccdeeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_91f6c0f6-1011-40de-866f-a99664dcd3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_c08fbdff-5203-4922-b471-95b6b2ccdeeb" xlink:to="loc_us-gaap_LossContingenciesTable_91f6c0f6-1011-40de-866f-a99664dcd3ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_19fa1bc6-6e00-4215-905f-8d643d9b48e0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_91f6c0f6-1011-40de-866f-a99664dcd3ce" xlink:to="loc_srt_LitigationCaseAxis_19fa1bc6-6e00-4215-905f-8d643d9b48e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_19fa1bc6-6e00-4215-905f-8d643d9b48e0_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_19fa1bc6-6e00-4215-905f-8d643d9b48e0" xlink:to="loc_srt_LitigationCaseTypeDomain_19fa1bc6-6e00-4215-905f-8d643d9b48e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_8b399682-8f58-4b55-a462-8ffde29454ae" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_19fa1bc6-6e00-4215-905f-8d643d9b48e0" xlink:to="loc_srt_LitigationCaseTypeDomain_8b399682-8f58-4b55-a462-8ffde29454ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LingmedLimitedMember_5e392d02-ae2e-4602-ae65-d857827db4a3" xlink:href="lsta-20250331.xsd#lsta_LingmedLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_8b399682-8f58-4b55-a462-8ffde29454ae" xlink:to="loc_lsta_LingmedLimitedMember_5e392d02-ae2e-4602-ae65-d857827db4a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_207d0fab-553b-4a4d-8af4-2523517834ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c08fbdff-5203-4922-b471-95b6b2ccdeeb" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_207d0fab-553b-4a4d-8af4-2523517834ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementPaymentTerm_7c1f6228-3c59-4a63-abdc-05a2d0006328" xlink:href="lsta-20250331.xsd#lsta_LitigationSettlementPaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c08fbdff-5203-4922-b471-95b6b2ccdeeb" xlink:to="loc_lsta_LitigationSettlementPaymentTerm_7c1f6228-3c59-4a63-abdc-05a2d0006328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementFutureMilestonePaymentsPercent_87be91b4-4a0c-4085-a5b3-f58caf806b60" xlink:href="lsta-20250331.xsd#lsta_LitigationSettlementFutureMilestonePaymentsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c08fbdff-5203-4922-b471-95b6b2ccdeeb" xlink:to="loc_lsta_LitigationSettlementFutureMilestonePaymentsPercent_87be91b4-4a0c-4085-a5b3-f58caf806b60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementMilestonePayment_4c03b2a5-985d-4540-9fa1-ea6533e2dfbe" xlink:href="lsta-20250331.xsd#lsta_LitigationSettlementMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c08fbdff-5203-4922-b471-95b6b2ccdeeb" xlink:to="loc_lsta_LitigationSettlementMilestonePayment_4c03b2a5-985d-4540-9fa1-ea6533e2dfbe" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TechnologyTransferAgreementDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#TechnologyTransferAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/TechnologyTransferAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_8f4fb6fb-a105-4146-98f6-f5bae57a287e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_15728ea2-69d4-4e15-b2b6-b4d6b82adceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_8f4fb6fb-a105-4146-98f6-f5bae57a287e" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_15728ea2-69d4-4e15-b2b6-b4d6b82adceb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ca72dad2-d89a-408e-af3f-98d77c740780" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_15728ea2-69d4-4e15-b2b6-b4d6b82adceb" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ca72dad2-d89a-408e-af3f-98d77c740780" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ca72dad2-d89a-408e-af3f-98d77c740780_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ca72dad2-d89a-408e-af3f-98d77c740780" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ca72dad2-d89a-408e-af3f-98d77c740780_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e824a706-aa03-4e3a-90fa-1bfde7c3c03d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ca72dad2-d89a-408e-af3f-98d77c740780" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e824a706-aa03-4e3a-90fa-1bfde7c3c03d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ImpiloMember_9e7791c3-63dc-4372-9ceb-11b387b118f3" xlink:href="lsta-20250331.xsd#lsta_ImpiloMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e824a706-aa03-4e3a-90fa-1bfde7c3c03d" xlink:to="loc_lsta_ImpiloMember_9e7791c3-63dc-4372-9ceb-11b387b118f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_2db5dbcf-67bd-4487-a106-29e8b56abffd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_8f4fb6fb-a105-4146-98f6-f5bae57a287e" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_2db5dbcf-67bd-4487-a106-29e8b56abffd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_InvestmentOwnedCanceledShares_746ff23b-7539-47ac-b389-bc845e63e0fa" xlink:href="lsta-20250331.xsd#lsta_InvestmentOwnedCanceledShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_8f4fb6fb-a105-4146-98f6-f5bae57a287e" xlink:to="loc_lsta_InvestmentOwnedCanceledShares_746ff23b-7539-47ac-b389-bc845e63e0fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_68d2a3bf-c3c1-4705-91db-04b81f32463f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_8f4fb6fb-a105-4146-98f6-f5bae57a287e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_68d2a3bf-c3c1-4705-91db-04b81f32463f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_2d93eb62-d3dd-4c7b-85b4-8ae32c4cc38a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_8f4fb6fb-a105-4146-98f6-f5bae57a287e" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_2d93eb62-d3dd-4c7b-85b4-8ae32c4cc38a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9bd94d91-82a7-4e80-9e8f-633c0ea22d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_8f4fb6fb-a105-4146-98f6-f5bae57a287e" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9bd94d91-82a7-4e80-9e8f-633c0ea22d5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SAFEValuationCap_2d460e9a-3773-4b9c-bb92-f0937db81dc9" xlink:href="lsta-20250331.xsd#lsta_SAFEValuationCap"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_8f4fb6fb-a105-4146-98f6-f5bae57a287e" xlink:to="loc_lsta_SAFEValuationCap_2d460e9a-3773-4b9c-bb92-f0937db81dc9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SAFEDiscountRate_acbb6530-4831-4f92-b4d5-e5b4a3e23a8e" xlink:href="lsta-20250331.xsd#lsta_SAFEDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_8f4fb6fb-a105-4146-98f6-f5bae57a287e" xlink:to="loc_lsta_SAFEDiscountRate_acbb6530-4831-4f92-b4d5-e5b4a3e23a8e" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#LicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/LicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c8d1c2-db2d-42ea-a24f-4e7a0c1246a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae51398-afb8-4209-840f-711032b70f01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c8d1c2-db2d-42ea-a24f-4e7a0c1246a2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae51398-afb8-4209-840f-711032b70f01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_37416ffb-a839-4fff-90c4-3e1e1322abd9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae51398-afb8-4209-840f-711032b70f01" xlink:to="loc_srt_CounterpartyNameAxis_37416ffb-a839-4fff-90c4-3e1e1322abd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37416ffb-a839-4fff-90c4-3e1e1322abd9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_37416ffb-a839-4fff-90c4-3e1e1322abd9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37416ffb-a839-4fff-90c4-3e1e1322abd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_30f31751-04f8-4538-8f74-bbcbc986a162" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_37416ffb-a839-4fff-90c4-3e1e1322abd9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_30f31751-04f8-4538-8f74-bbcbc986a162" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SanfordBurnhamPrebysMember_cb2748cc-1488-4069-8fc2-c8a440bfc0e8" xlink:href="lsta-20250331.xsd#lsta_SanfordBurnhamPrebysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_30f31751-04f8-4538-8f74-bbcbc986a162" xlink:to="loc_lsta_SanfordBurnhamPrebysMember_cb2748cc-1488-4069-8fc2-c8a440bfc0e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7ac2bcf5-cb25-4615-a25d-18b079f03ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae51398-afb8-4209-840f-711032b70f01" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7ac2bcf5-cb25-4615-a25d-18b079f03ecb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7ac2bcf5-cb25-4615-a25d-18b079f03ecb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7ac2bcf5-cb25-4615-a25d-18b079f03ecb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7ac2bcf5-cb25-4615-a25d-18b079f03ecb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b0b6cd52-08c3-4612-b952-c9bf2f20f750" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7ac2bcf5-cb25-4615-a25d-18b079f03ecb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b0b6cd52-08c3-4612-b952-c9bf2f20f750" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_eba1d8dd-2fcc-4df0-a6a3-19a0c5b344c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b0b6cd52-08c3-4612-b952-c9bf2f20f750" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_eba1d8dd-2fcc-4df0-a6a3-19a0c5b344c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bd137df2-b8c7-42c4-b479-e1577bfbc1a6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae51398-afb8-4209-840f-711032b70f01" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bd137df2-b8c7-42c4-b479-e1577bfbc1a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_bd137df2-b8c7-42c4-b479-e1577bfbc1a6_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bd137df2-b8c7-42c4-b479-e1577bfbc1a6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_bd137df2-b8c7-42c4-b479-e1577bfbc1a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ecce0135-3ba5-4047-9ec4-f88bc7a496cc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bd137df2-b8c7-42c4-b479-e1577bfbc1a6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ecce0135-3ba5-4047-9ec4-f88bc7a496cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ImpiloMember_a509a8cc-6eec-4bb4-8761-ac2bdc117721" xlink:href="lsta-20250331.xsd#lsta_ImpiloMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ecce0135-3ba5-4047-9ec4-f88bc7a496cc" xlink:to="loc_lsta_ImpiloMember_a509a8cc-6eec-4bb4-8761-ac2bdc117721" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SharesIssuedUnderLicenseAgreement_0c55d1e9-3bd4-4411-81b7-06facc69de88" xlink:href="lsta-20250331.xsd#lsta_SharesIssuedUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c8d1c2-db2d-42ea-a24f-4e7a0c1246a2" xlink:to="loc_lsta_SharesIssuedUnderLicenseAgreement_0c55d1e9-3bd4-4411-81b7-06facc69de88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_d70d7d85-3973-403c-bb42-a2721702ea4f" xlink:href="lsta-20250331.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c8d1c2-db2d-42ea-a24f-4e7a0c1246a2" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_d70d7d85-3973-403c-bb42-a2721702ea4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_171d8007-1a8d-41fa-9c61-ea6eb3975029" xlink:href="lsta-20250331.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c8d1c2-db2d-42ea-a24f-4e7a0c1246a2" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_171d8007-1a8d-41fa-9c61-ea6eb3975029" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_991173ee-733e-4bc7-9345-eab5bcb8d38f" xlink:href="lsta-20250331.xsd#lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c8d1c2-db2d-42ea-a24f-4e7a0c1246a2" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_991173ee-733e-4bc7-9345-eab5bcb8d38f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_82daf716-5480-49c4-9412-680a1dba9b1a" xlink:href="lsta-20250331.xsd#lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c8d1c2-db2d-42ea-a24f-4e7a0c1246a2" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_82daf716-5480-49c4-9412-680a1dba9b1a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_83822e36-c6ce-48a1-b6ab-fb3703e34937" xlink:href="lsta-20250331.xsd#lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c8d1c2-db2d-42ea-a24f-4e7a0c1246a2" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_83822e36-c6ce-48a1-b6ab-fb3703e34937" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_66a710f7-e4df-4c8d-9bd5-fea737f3136c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c8d1c2-db2d-42ea-a24f-4e7a0c1246a2" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_66a710f7-e4df-4c8d-9bd5-fea737f3136c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SharesHeldByThirdParty_8276bc02-3e28-49c1-870d-2de3ecb2d324" xlink:href="lsta-20250331.xsd#lsta_SharesHeldByThirdParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c8d1c2-db2d-42ea-a24f-4e7a0c1246a2" xlink:to="loc_lsta_SharesHeldByThirdParty_8276bc02-3e28-49c1-870d-2de3ecb2d324" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#ResearchCollaborationandLicenseAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f63264e2-9410-46e4-951d-a63980517b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7dbc55a-2745-437f-8f87-e0da2d4db766" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f63264e2-9410-46e4-951d-a63980517b4e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7dbc55a-2745-437f-8f87-e0da2d4db766" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_be47dc59-d615-4e89-9c16-316d1486466c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7dbc55a-2745-437f-8f87-e0da2d4db766" xlink:to="loc_us-gaap_TypeOfArrangementAxis_be47dc59-d615-4e89-9c16-316d1486466c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_be47dc59-d615-4e89-9c16-316d1486466c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_be47dc59-d615-4e89-9c16-316d1486466c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_be47dc59-d615-4e89-9c16-316d1486466c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ef890c3a-bea2-4aaf-92e5-43566b3656b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_be47dc59-d615-4e89-9c16-316d1486466c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ef890c3a-bea2-4aaf-92e5-43566b3656b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ExclusiveLicenseAndCollaborationAgreementMember_ebd43310-9cef-478c-86ab-13ac35c539b4" xlink:href="lsta-20250331.xsd#lsta_ExclusiveLicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ef890c3a-bea2-4aaf-92e5-43566b3656b2" xlink:to="loc_lsta_ExclusiveLicenseAndCollaborationAgreementMember_ebd43310-9cef-478c-86ab-13ac35c539b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0c28d588-1147-424b-8d12-0546e971abda" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7dbc55a-2745-437f-8f87-e0da2d4db766" xlink:to="loc_srt_CounterpartyNameAxis_0c28d588-1147-424b-8d12-0546e971abda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c28d588-1147-424b-8d12-0546e971abda_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0c28d588-1147-424b-8d12-0546e971abda" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c28d588-1147-424b-8d12-0546e971abda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7deb10af-0e4e-4442-8110-900b7818b539" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0c28d588-1147-424b-8d12-0546e971abda" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7deb10af-0e4e-4442-8110-900b7818b539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_QiluMember_d7600670-6b6e-4be4-9ca2-3c89e07bc3ee" xlink:href="lsta-20250331.xsd#lsta_QiluMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7deb10af-0e4e-4442-8110-900b7818b539" xlink:to="loc_lsta_QiluMember_d7600670-6b6e-4be4-9ca2-3c89e07bc3ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_KuvaMember_162a6a2c-ff6a-497f-a758-8b7a6b629f95" xlink:href="lsta-20250331.xsd#lsta_KuvaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7deb10af-0e4e-4442-8110-900b7818b539" xlink:to="loc_lsta_KuvaMember_162a6a2c-ff6a-497f-a758-8b7a6b629f95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_479b30e4-b14c-4df8-aa54-23c15ae0849b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7dbc55a-2745-437f-8f87-e0da2d4db766" xlink:to="loc_srt_ProductOrServiceAxis_479b30e4-b14c-4df8-aa54-23c15ae0849b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_479b30e4-b14c-4df8-aa54-23c15ae0849b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_479b30e4-b14c-4df8-aa54-23c15ae0849b" xlink:to="loc_srt_ProductsAndServicesDomain_479b30e4-b14c-4df8-aa54-23c15ae0849b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_74a9397f-cd28-4115-9822-c419ab9ca62e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_479b30e4-b14c-4df8-aa54-23c15ae0849b" xlink:to="loc_srt_ProductsAndServicesDomain_74a9397f-cd28-4115-9822-c419ab9ca62e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_32f6c2f7-af13-4919-bfef-30f8c6611639" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_74a9397f-cd28-4115-9822-c419ab9ca62e" xlink:to="loc_us-gaap_LicenseMember_32f6c2f7-af13-4919-bfef-30f8c6611639" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c3d47e7d-9826-4a34-9923-396706485517" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7dbc55a-2745-437f-8f87-e0da2d4db766" xlink:to="loc_srt_RangeAxis_c3d47e7d-9826-4a34-9923-396706485517" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c3d47e7d-9826-4a34-9923-396706485517_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c3d47e7d-9826-4a34-9923-396706485517" xlink:to="loc_srt_RangeMember_c3d47e7d-9826-4a34-9923-396706485517_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_79a1c480-8455-4807-ba3c-aef9f595df64" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c3d47e7d-9826-4a34-9923-396706485517" xlink:to="loc_srt_RangeMember_79a1c480-8455-4807-ba3c-aef9f595df64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cd6f447f-2dc0-472f-a904-d11408651f31" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_79a1c480-8455-4807-ba3c-aef9f595df64" xlink:to="loc_srt_MinimumMember_cd6f447f-2dc0-472f-a904-d11408651f31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1809d657-035f-4670-a21f-ed31564d1602" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_79a1c480-8455-4807-ba3c-aef9f595df64" xlink:to="loc_srt_MaximumMember_1809d657-035f-4670-a21f-ed31564d1602" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_5725c0ac-3168-4a42-9d0e-0656ddf0369a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7dbc55a-2745-437f-8f87-e0da2d4db766" xlink:to="loc_srt_LitigationCaseAxis_5725c0ac-3168-4a42-9d0e-0656ddf0369a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_5725c0ac-3168-4a42-9d0e-0656ddf0369a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_5725c0ac-3168-4a42-9d0e-0656ddf0369a" xlink:to="loc_srt_LitigationCaseTypeDomain_5725c0ac-3168-4a42-9d0e-0656ddf0369a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_09346bb0-9093-4d21-97c5-85333ef89cb1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_5725c0ac-3168-4a42-9d0e-0656ddf0369a" xlink:to="loc_srt_LitigationCaseTypeDomain_09346bb0-9093-4d21-97c5-85333ef89cb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LingmedLimitedMember_1fb1cb6b-e9cd-4039-a6da-bf803cddc681" xlink:href="lsta-20250331.xsd#lsta_LingmedLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_09346bb0-9093-4d21-97c5-85333ef89cb1" xlink:to="loc_lsta_LingmedLimitedMember_1fb1cb6b-e9cd-4039-a6da-bf803cddc681" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c8e12c90-88af-427e-a2b8-5263441c6672" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f63264e2-9410-46e4-951d-a63980517b4e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c8e12c90-88af-427e-a2b8-5263441c6672" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_6b7b3eb3-d1e1-4170-8ce4-a05e2ed67e71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f63264e2-9410-46e4-951d-a63980517b4e" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_6b7b3eb3-d1e1-4170-8ce4-a05e2ed67e71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_9aa0e3b0-1d47-4756-8e0e-8bcef7b07d82" xlink:href="lsta-20250331.xsd#lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f63264e2-9410-46e4-951d-a63980517b4e" xlink:to="loc_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_9aa0e3b0-1d47-4756-8e0e-8bcef7b07d82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenuePerformanceObligationPercentageOfNetSale_1067e6bc-adc0-42e5-a90c-e3af99952fb1" xlink:href="lsta-20250331.xsd#lsta_RevenuePerformanceObligationPercentageOfNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f63264e2-9410-46e4-951d-a63980517b4e" xlink:to="loc_lsta_RevenuePerformanceObligationPercentageOfNetSale_1067e6bc-adc0-42e5-a90c-e3af99952fb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_ad950723-b2da-425d-8e6a-241390327408" xlink:href="lsta-20250331.xsd#lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f63264e2-9410-46e4-951d-a63980517b4e" xlink:to="loc_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_ad950723-b2da-425d-8e6a-241390327408" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementFutureMilestonePaymentsPercent_d921bcfb-d115-4872-9642-9b7dcef22ba2" xlink:href="lsta-20250331.xsd#lsta_LitigationSettlementFutureMilestonePaymentsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f63264e2-9410-46e4-951d-a63980517b4e" xlink:to="loc_lsta_LitigationSettlementFutureMilestonePaymentsPercent_d921bcfb-d115-4872-9642-9b7dcef22ba2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementMilestonePayment_6a7c87e1-34d0-4d8a-8023-8e3e66c18fe6" xlink:href="lsta-20250331.xsd#lsta_LitigationSettlementMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f63264e2-9410-46e4-951d-a63980517b4e" xlink:to="loc_lsta_LitigationSettlementMilestonePayment_6a7c87e1-34d0-4d8a-8023-8e3e66c18fe6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_298e0994-4712-4d29-99cc-fa4105ad9343" xlink:href="lsta-20250331.xsd#lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f63264e2-9410-46e4-951d-a63980517b4e" xlink:to="loc_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_298e0994-4712-4d29-99cc-fa4105ad9343" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="101"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="41"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>lsta-20250331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1dd57249-b3e7-436f-adc4-30cff3fca49a,g:189dfb66-5ef0-4fa0-83c9-286ae40a1a30-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_5f787d7e-0f3e-4210-bf2a-ec42c8b3e077_terseLabel_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California</link:label>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_label_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SaleOfStockAvailableForSalePercentage_776b36f2-3f1d-4795-90de-56848707aa45_terseLabel_en-US" xlink:label="lab_lsta_SaleOfStockAvailableForSalePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage held by non-affiliates</link:label>
    <link:label id="lab_lsta_SaleOfStockAvailableForSalePercentage_label_en-US" xlink:label="lab_lsta_SaleOfStockAvailableForSalePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock Available for Sale, Percentage</link:label>
    <link:label id="lab_lsta_SaleOfStockAvailableForSalePercentage_documentation_en-US" xlink:label="lab_lsta_SaleOfStockAvailableForSalePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock Available for Sale, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAvailableForSalePercentage" xlink:href="lsta-20250331.xsd#lsta_SaleOfStockAvailableForSalePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SaleOfStockAvailableForSalePercentage" xlink:to="lab_lsta_SaleOfStockAvailableForSalePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1789f90e-b2e4-4677-8188-099466743332_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_93bd124d-a48e-4d18-a0f7-5154ca84309a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_1b77811a-a105-4f17-84a0-d3cfb8abd67a_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8bf8e304-1122-458d-9037-dd6d10aa23a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_e5956eaa-7781-4580-8386-5e841884b18d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_BolsterTrialMember_736275ee-5a6d-49e7-b83a-96fcd97f2d6b_terseLabel_en-US" xlink:label="lab_lsta_BolsterTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BOLSTER trial</link:label>
    <link:label id="lab_lsta_BolsterTrialMember_label_en-US" xlink:label="lab_lsta_BolsterTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bolster Trial [Member]</link:label>
    <link:label id="lab_lsta_BolsterTrialMember_documentation_en-US" xlink:label="lab_lsta_BolsterTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bolster Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_BolsterTrialMember" xlink:href="lsta-20250331.xsd#lsta_BolsterTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_BolsterTrialMember" xlink:to="lab_lsta_BolsterTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_45fc6791-b635-44d2-8672-cd852437ac35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_59d5e086-381c-4ceb-a825-42dfd719c8aa_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_Sharesvestedandexpectedtovest_b7a51d89-edfb-46a6-9da2-7b680964977e_terseLabel_en-US" xlink:label="lab_lsta_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_lsta_Sharesvestedandexpectedtovest_label_en-US" xlink:label="lab_lsta_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">shares, vested and expected to vest</link:label>
    <link:label id="lab_lsta_Sharesvestedandexpectedtovest_documentation_en-US" xlink:label="lab_lsta_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">shares, vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_Sharesvestedandexpectedtovest" xlink:href="lsta-20250331.xsd#lsta_Sharesvestedandexpectedtovest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_Sharesvestedandexpectedtovest" xlink:to="lab_lsta_Sharesvestedandexpectedtovest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4b6fbafd-15bc-426b-9ac4-0d75d782f8e5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Lease Payments Under Lease Agreements</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_5747c80a-7f5c-410e-9afb-e9a468521fbc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c0a8f86e-a0c9-43d8-88a7-196c96801b23_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_e904fd98-d4a4-42c7-bd8c-e5781560c79a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7dd6e2cc-dc8a-4882-81ac-786146b7c560_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_47091bf3-63c5-45aa-9816-ee7ff9f328d4_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense_e83bd8b5-e5ed-4235-8174-da8f9a799df5_terseLabel_en-US" xlink:label="lab_lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation expense</link:label>
    <link:label id="lab_lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Expense, General And Administrative Expense</link:label>
    <link:label id="lab_lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense_documentation_en-US" xlink:label="lab_lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Expense, General And Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense" xlink:href="lsta-20250331.xsd#lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense" xlink:to="lab_lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_cc267141-574c-4664-a1dd-47ddf730b06f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentImpairment_6767be53-8b68-4eaf-8fbb-4a9666d18929_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-lived Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentImpairment_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Impairment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_b44b4d6c-63a9-4c1a-bf1e-26109459c235_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_fa7892b2-df02-48ba-8ef7-89e009949382_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_6837d91a-a6e9-42aa-8fa3-c81fb9bcd65e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_1756a1ca-3f1b-447d-80e5-2efe3ca597a1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_d704e584-5fb2-4389-baaf-133dbccf1959_terseLabel_en-US" xlink:label="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option to terminate</link:label>
    <link:label id="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_label_en-US" xlink:label="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Collaboration and License Agreement, Option to Terminate</link:label>
    <link:label id="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_documentation_en-US" xlink:label="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Collaboration and License Agreement, Option to Terminate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:href="lsta-20250331.xsd#lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:to="lab_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1c637ad9-56cf-460a-90d6-3f4a5e4f01a4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available for sale securities - net unrealized loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_7fc02064-5ab3-48bb-bb16-ad0e0902d235_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_59d78fbf-24ee-4eff-bf11-488a3750c0eb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_dc687920-8371-4119-9d7a-5d1383bc0c52_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable_cb6a8370-885a-4883-9b58-5b61b31c9981_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Vested, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercisable</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsExercisable" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageExercisePriceWarrantsExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsExercisable" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_45cb8678-9056-42ef-9e88-b3f83bcb33c6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b11b9caa-6b92-4281-ac3f-bf6dbbc4937b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ef7d657b-b004-4174-b448-a469ee640d95_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Common stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e5813fca-a2b2-4d6a-b2fb-5065fae6c8fb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Common stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_32fef769-b402-4b10-a4c5-5d66e044e507_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6c4acb45-a150-4bfd-8088-6f2934751cb8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_db4b0653-7951-4982-a52a-dc24d8aa92a8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_c3f17ef9-5d84-461a-8ad8-6b1c8650cacf_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_fd3713c2-23d9-400c-ac25-b4bd2bde5244_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_d315cc33-7fff-46fb-8a20-61e08f62a95b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_80ed71b4-4525-4ef4-a1eb-a61cbbd8e0cf_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_0a337ecc-53e3-4107-a05e-3eb9f589b8e2_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_73c20e5d-c23f-447c-91f3-f29f7b48eada_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_8fe28e25-1a55-47be-9ad5-7664b6674ce8_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e8d9d48-258f-4cf4-acdf-5b5dad3a1fd0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bd0fd1ee-b42d-40e7-a04a-b105fbf397e7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_1898f50e-1733-4656-acb0-459a121b1c46_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_1406f5ab-a209-41aa-b0f8-d5580c7d9ab3_terseLabel_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublicensing fee</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_label_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sublicensing Fees</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_documentation_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sublicensing Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:href="lsta-20250331.xsd#lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:to="lab_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_InvestmentOwnedCanceledShares_01554450-b5e0-4230-8f95-cf27a3acced9_terseLabel_en-US" xlink:label="lab_lsta_InvestmentOwnedCanceledShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares canceled (in shares)</link:label>
    <link:label id="lab_lsta_InvestmentOwnedCanceledShares_label_en-US" xlink:label="lab_lsta_InvestmentOwnedCanceledShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Owned, Canceled, Shares</link:label>
    <link:label id="lab_lsta_InvestmentOwnedCanceledShares_documentation_en-US" xlink:label="lab_lsta_InvestmentOwnedCanceledShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment Owned, Canceled, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_InvestmentOwnedCanceledShares" xlink:href="lsta-20250331.xsd#lsta_InvestmentOwnedCanceledShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_InvestmentOwnedCanceledShares" xlink:to="lab_lsta_InvestmentOwnedCanceledShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_b88817ef-48a9-4f5d-91c9-812444f91760_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SAFEDiscountRate_7b743cc3-c284-4251-91a6-cc6f0f655eff_terseLabel_en-US" xlink:label="lab_lsta_SAFEDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SAFE, discount rate</link:label>
    <link:label id="lab_lsta_SAFEDiscountRate_label_en-US" xlink:label="lab_lsta_SAFEDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SAFE, Discount Rate</link:label>
    <link:label id="lab_lsta_SAFEDiscountRate_documentation_en-US" xlink:label="lab_lsta_SAFEDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SAFE, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SAFEDiscountRate" xlink:href="lsta-20250331.xsd#lsta_SAFEDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SAFEDiscountRate" xlink:to="lab_lsta_SAFEDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_78bbd492-8c62-4c10-9c04-1d92707cf31f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options, Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8329bc7d-a179-4efe-9b5b-613e034f1e95_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_874e6757-15da-478a-98e1-aaf7b1361f5e_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_d0bedcc0-d611-42da-8ae2-141d36943b0e_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_ddf25dad-90fe-443f-b7b4-238caf39ecd5_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Weighted Average Exercise Price, Vested or expected to vest in the future (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6494672f-82ee-4996-9bb5-01a08f9d9e16_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_a4ff3818-b835-411d-b4cd-943a9c881183_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_cfd18942-b163-4fcc-bfae-12c09bfc9f9d_terseLabel_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Municipal debt securities</link:label>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_label_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US States and Political Subdivisions Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_977b9687-7213-4022-9f8b-ecc02503abba_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_a4e47577-5a30-4198-a74c-8c12c7d1e271_terseLabel_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual license maintenance fee</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_label_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_documentation_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:href="lsta-20250331.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:to="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_71de1096-3280-4d4e-90a5-97eb41bf151a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a71634d4-9aba-4ee9-ab1d-0bc42d4073fe_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_2f73cbf4-331a-4ade-94d3-cd5e917e3e32_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_b25d5a38-a1b0-4334-bc3f-4c69c73bdfe0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4447ae50-8d4d-46ca-98a0-0539e10af215_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f6394fe9-a912-4d67-9a8e-9e83fce12634_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_19d8bfba-8a66-4fc9-aa93-0d012e06a3dc_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_cfb02443-e394-436e-80b2-45b5147e6dd1_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_adbd5c19-271d-4b4e-9e2b-ccf9b0ba05da_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CashAndCashEquivalentsAndMarketableSecurities_eb066829-8d85-4b3a-841b-9ae7b20f0b06_terseLabel_en-US" xlink:label="lab_lsta_CashAndCashEquivalentsAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and marketable securities</link:label>
    <link:label id="lab_lsta_CashAndCashEquivalentsAndMarketableSecurities_label_en-US" xlink:label="lab_lsta_CashAndCashEquivalentsAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents And Marketable Securities</link:label>
    <link:label id="lab_lsta_CashAndCashEquivalentsAndMarketableSecurities_documentation_en-US" xlink:label="lab_lsta_CashAndCashEquivalentsAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents And Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CashAndCashEquivalentsAndMarketableSecurities" xlink:href="lsta-20250331.xsd#lsta_CashAndCashEquivalentsAndMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CashAndCashEquivalentsAndMarketableSecurities" xlink:to="lab_lsta_CashAndCashEquivalentsAndMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_KuvaMember_5d25cd99-80e5-4895-9f43-212537452dcf_terseLabel_en-US" xlink:label="lab_lsta_KuvaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kuva</link:label>
    <link:label id="lab_lsta_KuvaMember_label_en-US" xlink:label="lab_lsta_KuvaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kuva [Member]</link:label>
    <link:label id="lab_lsta_KuvaMember_documentation_en-US" xlink:label="lab_lsta_KuvaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kuva</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_KuvaMember" xlink:href="lsta-20250331.xsd#lsta_KuvaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_KuvaMember" xlink:to="lab_lsta_KuvaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_461f366f-75b1-4e7f-b59e-823444b190b3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f27580fd-07f4-46bc-9479-9aa51446516c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ResearchAndDevelopmentOtherMember_895be99b-16c1-4d0d-9c61-7d7bb3fc3a25_terseLabel_en-US" xlink:label="lab_lsta_ResearchAndDevelopmentOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lsta_ResearchAndDevelopmentOtherMember_label_en-US" xlink:label="lab_lsta_ResearchAndDevelopmentOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development, Other [Member]</link:label>
    <link:label id="lab_lsta_ResearchAndDevelopmentOtherMember_documentation_en-US" xlink:label="lab_lsta_ResearchAndDevelopmentOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ResearchAndDevelopmentOtherMember" xlink:href="lsta-20250331.xsd#lsta_ResearchAndDevelopmentOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ResearchAndDevelopmentOtherMember" xlink:to="lab_lsta_ResearchAndDevelopmentOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_74af25f6-ed8a-47e7-8913-aea0ad1314a2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization/accretion on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_cdd9bab2-545e-4634-a0ed-6f72b3b6b953_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_e4ac9737-3ee9-4d78-86af-d4f807a4f925_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_aca6f19a-0ec0-4f33-8690-3264324fd331_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9dfdf253-9e3e-4364-bfec-a49fc18ed7b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax withholding payments on net share settlement equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b9e0fbc4-41e0-4561-b90c-553fa5ac1d84_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive gain (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_f72cb10e-5899-46ac-91be-ad2956e04f4b_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_589927e9-437e-4fba-b3cf-2781b4ec4b61_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2c6a2f7d-3373-475d-be49-bdb31e884b2f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_03de7de3-b0e1-46e7-b8ed-684c5e5af1da_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5542209e-d925-4e8e-96a5-9b4fbbe22d26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_51df9454-8293-4816-8fbf-ca24f6807d81_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_cd0914cb-91d9-4c3e-af8f-9414fd1b6966_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_186072c8-4ecb-4db3-8a70-84aca390db42_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_170cbef1-175a-4d46-affa-99db76a4ba58_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_24733633-b6a8-43fb-ae7a-3cd20985bfac_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_TechnologyTransferAgreementAbstract_label_en-US" xlink:label="lab_lsta_TechnologyTransferAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology Transfer Agreement [Abstract]</link:label>
    <link:label id="lab_lsta_TechnologyTransferAgreementAbstract_documentation_en-US" xlink:label="lab_lsta_TechnologyTransferAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Technology Transfer Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_TechnologyTransferAgreementAbstract" xlink:href="lsta-20250331.xsd#lsta_TechnologyTransferAgreementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_TechnologyTransferAgreementAbstract" xlink:to="lab_lsta_TechnologyTransferAgreementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_fbb9e190-18e4-4abd-aec5-188b2f1fd2a3_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_6907bea0-6759-420f-8b0c-df3c8ade87a1_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f43e717b-b32d-42d9-9933-3544876aa58c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_6496e225-376d-4902-b84d-3c61b928fef5_terseLabel_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_label_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_documentation_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:href="lsta-20250331.xsd#lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:to="lab_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_4ec58977-4487-4892-8731-b5c652834177_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments Classified by Contractual Maturity Date</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_fc75323e-5054-4406-823e-a2adf903a9dd_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_1d026e09-84fa-4d2e-a1fd-9c387c7956a7_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxHolidayTable_a2221ad4-267d-42c1-9381-4fec0af78be9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Holiday [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxHolidayTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Holiday [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxHolidayTable" xlink:to="lab_us-gaap_IncomeTaxHolidayTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_551bd0dc-ed89-4645-a1e4-b834287a8b0a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3667584b-0b6c-4e5d-9097-21b270b149a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f7d43064-9faa-4f78-a400-232a7252c00d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1c438306-4c40-49e0-a8a0-bdd82af86fb5_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_3cd4a18d-2055-408d-90b2-62ab28a03f08_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_16269b78-a49d-4090-b67a-66de225bef6d_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_dbfc9998-94dc-47a7-9e56-e1cd9ac646f5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fc94983-fd76-4751-bf55-4b48204ccad7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_90b027d8-f173-4891-9aae-9ec86da4da6c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Remeasurement</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ec606556-8e8b-4604-a555-0db68e6f0a4c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_682228a1-c76a-449e-a579-510d4d021186_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_b89e0ca2-6260-41c1-b878-185761aea91d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment owned (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SharesHeldByThirdParty_f3e1bcd5-6bc9-46c7-b9d0-4cac1a94b97a_terseLabel_en-US" xlink:label="lab_lsta_SharesHeldByThirdParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares held by third party (in shares)</link:label>
    <link:label id="lab_lsta_SharesHeldByThirdParty_label_en-US" xlink:label="lab_lsta_SharesHeldByThirdParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Held by Third Party</link:label>
    <link:label id="lab_lsta_SharesHeldByThirdParty_documentation_en-US" xlink:label="lab_lsta_SharesHeldByThirdParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Held by Third Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SharesHeldByThirdParty" xlink:href="lsta-20250331.xsd#lsta_SharesHeldByThirdParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SharesHeldByThirdParty" xlink:to="lab_lsta_SharesHeldByThirdParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2ecba651-9add-4739-b542-395f106c9bf1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities &#8212; current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_05343782-7c52-4796-afac-60917ef7edef_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0e204f6b-1ed7-4077-95ec-bc4ee98f60da_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_IncomeTaxIncentiveReceivable_ccf4a31b-4acd-4dbc-981a-d6a28ae412b8_terseLabel_en-US" xlink:label="lab_lsta_IncomeTaxIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax incentive receivable</link:label>
    <link:label id="lab_lsta_IncomeTaxIncentiveReceivable_label_en-US" xlink:label="lab_lsta_IncomeTaxIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Incentive Receivable</link:label>
    <link:label id="lab_lsta_IncomeTaxIncentiveReceivable_documentation_en-US" xlink:label="lab_lsta_IncomeTaxIncentiveReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Incentive Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_IncomeTaxIncentiveReceivable" xlink:href="lsta-20250331.xsd#lsta_IncomeTaxIncentiveReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_IncomeTaxIncentiveReceivable" xlink:to="lab_lsta_IncomeTaxIncentiveReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_f573451b-d0c4-49cf-959c-87cd8e873c17_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_9467a2a2-40e9-4b42-b337-19faea82aebd_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_0dbb875e-c495-425e-9780-2d97c3481ffe_verboseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_3aacf96d-2f64-4de5-903e-a32946c01331_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7329b1d1-cc82-4c37-ad81-49c4e2a1b291_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_e8bf3364-c69e-4dc6-80bd-a6015564f876_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AscendTrialMember_d8fdd6aa-a49f-4132-8e27-5067b4c18576_terseLabel_en-US" xlink:label="lab_lsta_AscendTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASCEND trial</link:label>
    <link:label id="lab_lsta_AscendTrialMember_label_en-US" xlink:label="lab_lsta_AscendTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ascend Trial [Member]</link:label>
    <link:label id="lab_lsta_AscendTrialMember_documentation_en-US" xlink:label="lab_lsta_AscendTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ascend Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AscendTrialMember" xlink:href="lsta-20250331.xsd#lsta_AscendTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AscendTrialMember" xlink:to="lab_lsta_AscendTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_39657591-7b14-4ea4-b5f9-0f4fd0a8b1a5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from option exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c13ca366-8b0b-488b-9da0-e2d8c03df3b6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Options, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_188e7541-2d9a-4eb4-9e94-13ffc2e13523_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsGranted_7d7d650f-f25e-45fb-9c12-8facb93adb99_terseLabel_en-US" xlink:label="lab_lsta_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Granted (in shares)</link:label>
    <link:label id="lab_lsta_WarrantsGranted_label_en-US" xlink:label="lab_lsta_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Granted</link:label>
    <link:label id="lab_lsta_WarrantsGranted_documentation_en-US" xlink:label="lab_lsta_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsGranted" xlink:href="lsta-20250331.xsd#lsta_WarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsGranted" xlink:to="lab_lsta_WarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2756f6ae-4c50-4790-893a-d5aff0110c50_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_554e5c9b-5155-47b7-92fb-c10f05e5901e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_f909bc22-ec3e-40b4-a2f8-7df06047ce51_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7f7f0cc6-7fce-4699-a4a3-d9c078e9f4ec_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6d88ce3e-fa79-4fc7-83a6-aff9508d96db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f907edeb-2020-4772-9ddb-ab687bdcd3c9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding_24e0ac44-d470-4fc0-94fb-b05f68f5dea5_periodStartLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Warrants Outstanding, Beginning of Period (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding_f1f84e19-72fd-4cbc-9d3e-023610e64e9b_periodEndLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Warrants Outstanding, End of Period (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5e3f69bb-3d27-4784-9b41-6ebfb24d2651_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected amortization, remainder of fiscal year</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_575d4136-50dd-4663-b6fe-5c29dc70ccdb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_365acaf0-88a3-4ff8-bf32-d9cb77139ab4_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Lisata Therapeutics, Inc. stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_1b420ffa-36d5-4fa2-88b8-99143318fe8f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_70da9199-ddee-4e43-9e89-a187a691c4bd_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_b9069a15-7aaa-4867-99e4-6f81b1e7c538_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research Collaboration and License Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_5760bd5a-f8f3-41a9-95d1-5ef48fd9e15a_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_671a0be2-5e05-48c9-abeb-b2febdcc9aa2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_d790d04c-76cc-427e-9e55-3f0f8113bcb4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_837fa258-2040-4768-9d4c-ff8cfeda56b1_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_eca552bf-095d-43a5-8973-a29c56fb8baf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_241031f9-05ce-4dd1-a786-7aca49475e77_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in and Advances to Affiliates [Line Items]</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in and Advances to Affiliates [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:to="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_7b9d8285-eeac-46e0-ab31-8eff419ce4eb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_OperatingLeaseRightOfUseAssetAbstract_cec55086-4862-4a67-8b17-7eed7b0e2954_terseLabel_en-US" xlink:label="lab_lsta_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-Use Assets:</link:label>
    <link:label id="lab_lsta_OperatingLeaseRightOfUseAssetAbstract_label_en-US" xlink:label="lab_lsta_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-Of-Use Asset [Abstract]</link:label>
    <link:label id="lab_lsta_OperatingLeaseRightOfUseAssetAbstract_documentation_en-US" xlink:label="lab_lsta_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLeaseRightOfUseAssetAbstract" xlink:href="lsta-20250331.xsd#lsta_OperatingLeaseRightOfUseAssetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_OperatingLeaseRightOfUseAssetAbstract" xlink:to="lab_lsta_OperatingLeaseRightOfUseAssetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6d2c2111-3e4c-4846-8255-aa4d4d718633_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_8866753a-dd25-4506-9eb8-ec0366d0f233_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5bf762f3-3e04-49a5-bbda-65d6649b8b6a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected amortization, year two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_79158dc3-70c2-455b-82cd-1f7e22b2fef6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_3402780b-8a99-4119-8b1d-579b35bbada8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_73a36524-e044-4de9-9ca7-9f7c72f2d828_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_label_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</link:label>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_documentation_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:to="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d4593cd7-6174-43b6-ab0e-6d0560bdf62b_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_72b2dff9-e536-461f-bcd4-f493937092a5_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ClinicalDepartmentMember_26002562-9546-488a-acc9-c22bb636e00a_terseLabel_en-US" xlink:label="lab_lsta_ClinicalDepartmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical department</link:label>
    <link:label id="lab_lsta_ClinicalDepartmentMember_label_en-US" xlink:label="lab_lsta_ClinicalDepartmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Department [Member]</link:label>
    <link:label id="lab_lsta_ClinicalDepartmentMember_documentation_en-US" xlink:label="lab_lsta_ClinicalDepartmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Department</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ClinicalDepartmentMember" xlink:href="lsta-20250331.xsd#lsta_ClinicalDepartmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ClinicalDepartmentMember" xlink:to="lab_lsta_ClinicalDepartmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_0353bfff-5f06-4b99-8392-5d3a8ebe12c4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_75126eae-edcc-4d41-8e07-1585037ddb40_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_f27304dc-f342-4f0c-8092-a4514a5878a0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_b9c8b946-5bac-4f19-aa2b-66c46325526d_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_c921d988-5518-41ae-a099-d33413435b8b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember_0a206c9e-dd40-4e0e-86a7-e1e15bf6d378_terseLabel_en-US" xlink:label="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exclusive License and Collaboration Agreement</link:label>
    <link:label id="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember_label_en-US" xlink:label="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exclusive License and Collaboration Agreement [Member]</link:label>
    <link:label id="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exclusive License and Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ExclusiveLicenseAndCollaborationAgreementMember" xlink:href="lsta-20250331.xsd#lsta_ExclusiveLicenseAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ExclusiveLicenseAndCollaborationAgreementMember" xlink:to="lab_lsta_ExclusiveLicenseAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e89fa1da-5822-441d-9342-c621c4200a62_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc12b459-51bb-482c-8ba0-6e2aadbbce55_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_06a966d8-bc4f-4521-8ba0-4758b913e130_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Lisata Therapeutics, Inc. Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_OperatingLossCarryforwardsPostAcquisition_e8cd1e6f-19fa-48d1-a6d2-600567843151_terseLabel_en-US" xlink:label="lab_lsta_OperatingLossCarryforwardsPostAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards, post acquisition</link:label>
    <link:label id="lab_lsta_OperatingLossCarryforwardsPostAcquisition_label_en-US" xlink:label="lab_lsta_OperatingLossCarryforwardsPostAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Post Acquisition</link:label>
    <link:label id="lab_lsta_OperatingLossCarryforwardsPostAcquisition_documentation_en-US" xlink:label="lab_lsta_OperatingLossCarryforwardsPostAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Post Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLossCarryforwardsPostAcquisition" xlink:href="lsta-20250331.xsd#lsta_OperatingLossCarryforwardsPostAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_OperatingLossCarryforwardsPostAcquisition" xlink:to="lab_lsta_OperatingLossCarryforwardsPostAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a788694a-257b-4963-8b3e-fc6bafa5d3b9_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_817869d8-ec8a-49e5-a35b-75e5abfd18d7_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_c27c4bba-db23-405d-9afe-0af82b34a771_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_548629b5-608f-48de-af7d-f78fd0b491db_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_eaaa6092-e9de-4947-976c-05245ce21558_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_9173daab-b0b7-4b94-9d08-25f85b04eedc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired license - intangible, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c3b69f51-eba8-41fe-ba50-29b068265e9a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_62b46268-48fd-4ba6-9324-a1cc77e99557_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_3f455d98-8384-44bc-b82e-8f4fd8abb578_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_f5489392-ba6b-4576-8e46-2fd7c2a10bac_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding_3c33a5cd-129f-447e-85db-6cd953903628_terseLabel_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding_label_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Warrants Outstanding</link:label>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding_documentation_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AggregateIntrinsicValueWarrantsOutstanding" xlink:href="lsta-20250331.xsd#lsta_AggregateIntrinsicValueWarrantsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AggregateIntrinsicValueWarrantsOutstanding" xlink:to="lab_lsta_AggregateIntrinsicValueWarrantsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7c9f40ca-9822-4269-a501-d10b00219b7d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_e80552ec-463d-4758-97c5-9ddba2ee9022_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_dc012636-4e3a-4f33-9e7d-06b892962bc4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_13a21add-a5b7-47ac-889e-9cd2546961c6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Share-based Compensation Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_b2ae4195-228e-4c40-88cb-b4ca17b06cf6_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_65677f32-94de-418d-9697-ba3533000fbb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Amounts representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_bcbdcb33-6d32-4d9f-bb66-787249af0a91_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_82afc2f5-d8ee-4a1f-b229-d0ec217211b5_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b68d0274-38f4-426a-b17b-ba5a4a17a7c5_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss before benefit from income taxes and noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_864291d8-0967-41dd-809f-6c1b2df50bf9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_5cd54fa0-7900-4e86-a78e-6b7099e62a67_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a5b8aa9a-ea60-4c94-869b-e20aa9aa9b1a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5281b125-9537-4cfb-9f65-30f7d7a01b30_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AtTheMarketOfferingAgreementMember_a2ed6959-ecc5-4483-b400-3e5157b45179_terseLabel_en-US" xlink:label="lab_lsta_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATM Agreement</link:label>
    <link:label id="lab_lsta_AtTheMarketOfferingAgreementMember_label_en-US" xlink:label="lab_lsta_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering Agreement [Member]</link:label>
    <link:label id="lab_lsta_AtTheMarketOfferingAgreementMember_documentation_en-US" xlink:label="lab_lsta_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At The Market Offering Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AtTheMarketOfferingAgreementMember" xlink:href="lsta-20250331.xsd#lsta_AtTheMarketOfferingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AtTheMarketOfferingAgreementMember" xlink:to="lab_lsta_AtTheMarketOfferingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8064c7c4-ca0e-4727-901e-b502379a198c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_326c4699-5f86-4f37-9f26-313debf08c5f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities - available-for-sale</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6e73d3f7-bf44-4208-854f-6f67f2000f9d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVested_28ab7f08-677a-453e-81e8-99ef165f3570_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Vested, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVested_label_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">weighted Average Remaining Contractual Term, Warrants Vested</link:label>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVested_documentation_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">weighted Average Remaining Contractual Term, Warrants Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageRemainingContractualTermWarrantsVested" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageRemainingContractualTermWarrantsVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageRemainingContractualTermWarrantsVested" xlink:to="lab_lsta_WeightedAverageRemainingContractualTermWarrantsVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_bd8abb80-4ef1-4c1f-82c4-aca07d73790c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_81c2abaa-2ba7-4b23-935d-bdf2ccbc7599_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CommonStockWarrantsShares_7d47fab6-f720-4d1c-af19-d7ff33ebc3c3_periodStartLabel_en-US" xlink:label="lab_lsta_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Warrants, Outstanding, Beginning of Period (in shares)</link:label>
    <link:label id="lab_lsta_CommonStockWarrantsShares_726bbdc7-b979-4d31-9577-482ad063ae9f_periodEndLabel_en-US" xlink:label="lab_lsta_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Warrants, Outstanding, End of Period (in shares)</link:label>
    <link:label id="lab_lsta_CommonStockWarrantsShares_label_en-US" xlink:label="lab_lsta_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Warrants, Shares</link:label>
    <link:label id="lab_lsta_CommonStockWarrantsShares_documentation_en-US" xlink:label="lab_lsta_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Warrants, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CommonStockWarrantsShares" xlink:href="lsta-20250331.xsd#lsta_CommonStockWarrantsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CommonStockWarrantsShares" xlink:to="lab_lsta_CommonStockWarrantsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_dd7555d3-e938-4a87-9cae-06e2f8b5ae1b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7e36eebd-34c3-4dca-9e00-f9673efa2670_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_4cdb60b8-771d-4081-a706-336f280a6458_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_031df7ad-094c-4893-9211-1bce1e483b4c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_45f6ce7e-b7db-4245-8cc1-fe80b502c888_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e6110064-b042-4036-ab32-5b29f4524a6b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_LitigationSettlementMilestonePayment_845b8509-98fc-4756-9406-e51f1f5c0f73_terseLabel_en-US" xlink:label="lab_lsta_LitigationSettlementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, first milestone payment</link:label>
    <link:label id="lab_lsta_LitigationSettlementMilestonePayment_label_en-US" xlink:label="lab_lsta_LitigationSettlementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Milestone Payment</link:label>
    <link:label id="lab_lsta_LitigationSettlementMilestonePayment_documentation_en-US" xlink:label="lab_lsta_LitigationSettlementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementMilestonePayment" xlink:href="lsta-20250331.xsd#lsta_LitigationSettlementMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_LitigationSettlementMilestonePayment" xlink:to="lab_lsta_LitigationSettlementMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_846f37d8-d93c-4e81-a04f-8aa06e064158_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_d45d6c58-ffda-4c9b-ba37-2a182f5099ea_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_fe54323a-acc1-478f-9997-3e04cb1af43b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_cfa1a1de-5096-4c59-b04e-f89451c9935c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_47e26863-ea02-4713-a5ea-6a22f30b8bc5_terseLabel_en-US" xlink:label="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NOL annual limitation</link:label>
    <link:label id="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_label_en-US" xlink:label="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Carryforward Operating Loss Carryforward Annual Limitation</link:label>
    <link:label id="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_documentation_en-US" xlink:label="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Carryforward Operating Loss Carryforward Annual Limitation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" xlink:href="lsta-20250331.xsd#lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" xlink:to="lab_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsVested_12ad0c6c-33f6-4177-b699-e77406c7a29b_terseLabel_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Vested, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsVested_label_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Warrants Vested</link:label>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsVested_documentation_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Warrants Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AggregateIntrinsicValueWarrantsVested" xlink:href="lsta-20250331.xsd#lsta_AggregateIntrinsicValueWarrantsVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AggregateIntrinsicValueWarrantsVested" xlink:to="lab_lsta_AggregateIntrinsicValueWarrantsVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_51b2123c-ef8a-4974-8817-b9f289bb14f3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_68a39617-c773-4ea7-bde4-6de9b734c146_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_3e8cce2c-dc09-401d-9376-519564fc085d_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury bills</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_059981b7-246c-4927-81da-0ea39c022394_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_bf4831d5-2db5-4f05-8bbd-c28e95bd6655_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_EPSAbstract_f91535e0-c39a-45ca-9611-742ccd8fe67f_terseLabel_en-US" xlink:label="lab_lsta_EPSAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted loss per share</link:label>
    <link:label id="lab_lsta_EPSAbstract_label_en-US" xlink:label="lab_lsta_EPSAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EPS [Abstract]</link:label>
    <link:label id="lab_lsta_EPSAbstract_documentation_en-US" xlink:label="lab_lsta_EPSAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">EPS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_EPSAbstract" xlink:href="lsta-20250331.xsd#lsta_EPSAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_EPSAbstract" xlink:to="lab_lsta_EPSAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_202e20c8-0f8a-4271-9da5-ba08911adead_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_80ac4166-47ab-461c-af9f-851c948f1519_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_541c02ef-7f3b-444a-84ad-02ed0ee079b0_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item, Corporate Nonsegment</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsOtherDisclosuresAbstract_09d03585-57bb-425c-afe4-676837bd2edd_terseLabel_en-US" xlink:label="lab_lsta_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Weighted Average Contractual Term and Intrinsic Value</link:label>
    <link:label id="lab_lsta_WarrantsOtherDisclosuresAbstract_label_en-US" xlink:label="lab_lsta_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Other Disclosures [Abstract]</link:label>
    <link:label id="lab_lsta_WarrantsOtherDisclosuresAbstract_documentation_en-US" xlink:label="lab_lsta_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Other Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsOtherDisclosuresAbstract" xlink:href="lsta-20250331.xsd#lsta_WarrantsOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract" xlink:to="lab_lsta_WarrantsOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2922ced0-4e7f-4d7b-a1c9-9145ca824ba0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected weighted-average period in years of compensation cost to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5edb7016-327d-45a8-b97b-4a2b755be9aa_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue excluding taxes</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_4e3c3348-915c-4167-90d3-ed2cb1a82257_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Investment in Impilo Therapeutics</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_4e4285c2-74ac-459d-86c6-346205ce298b_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6fdc5a31-d92c-44c5-b5f9-672c5b72c381_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_78441aef-b3d3-4789-a87e-2a91b31bb60c_terseLabel_en-US" xlink:label="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New York</link:label>
    <link:label id="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_label_en-US" xlink:label="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New York State Division of Taxation and Finance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:to="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_99aeb414-30d4-4a52-9ab2-8f4800367724_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_d05f711e-0ca9-4460-a854-e269a8cc81b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_403ad5fb-e9a9-413b-a98d-5545a193dc42_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ac2ed78-f6b3-45da-bd1c-917ca85cfb61_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_de43fe17-0d10-4cca-bcd8-c83bcadd1171_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_d9a793cc-9f35-45d6-8a20-c70dc62a2dd9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1caf6711-8f40-401c-98db-9b9e8940c065_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0cb6ae52-0bfc-43fd-8a8a-071728db9938_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities, non-controlling interests and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_01f56d06-b5cd-4add-9a02-2fcdb437037c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Salaries, employee benefits and related taxes</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_abaeaf25-667c-42be-9d1a-16d65e062787_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_743d9fe4-7f22-4ec0-a720-493b743d836e_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b832910e-7cb7-4564-a7a9-c2661176089e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_27b2e481-5aa9-4b1e-b1d1-34140e0c8af6_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73c2d006-d76b-422b-bf23-66d3d8f62b9e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_133225ec-8971-4ea8-a942-19dbce1b8ab4_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c6caab0f-3b6a-40d8-aca7-5fdb0582b0a5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_05198feb-be2e-4485-9eff-a9cb9418c8c6_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_TechnologyTransferAgreementTextBlock_ef045415-22bc-4855-8b1e-30a7cfd0c08e_terseLabel_en-US" xlink:label="lab_lsta_TechnologyTransferAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technology Transfer Agreement</link:label>
    <link:label id="lab_lsta_TechnologyTransferAgreementTextBlock_label_en-US" xlink:label="lab_lsta_TechnologyTransferAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology Transfer Agreement [Text Block]</link:label>
    <link:label id="lab_lsta_TechnologyTransferAgreementTextBlock_documentation_en-US" xlink:label="lab_lsta_TechnologyTransferAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Technology Transfer Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_TechnologyTransferAgreementTextBlock" xlink:href="lsta-20250331.xsd#lsta_TechnologyTransferAgreementTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_TechnologyTransferAgreementTextBlock" xlink:to="lab_lsta_TechnologyTransferAgreementTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CashCashEquivalentsAndMarketableSecurities_323e7cec-b330-4d24-b73e-6d7fbaf6cd85_terseLabel_en-US" xlink:label="lab_lsta_CashCashEquivalentsAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and marketable securities</link:label>
    <link:label id="lab_lsta_CashCashEquivalentsAndMarketableSecurities_label_en-US" xlink:label="lab_lsta_CashCashEquivalentsAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities</link:label>
    <link:label id="lab_lsta_CashCashEquivalentsAndMarketableSecurities_documentation_en-US" xlink:label="lab_lsta_CashCashEquivalentsAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CashCashEquivalentsAndMarketableSecurities" xlink:href="lsta-20250331.xsd#lsta_CashCashEquivalentsAndMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CashCashEquivalentsAndMarketableSecurities" xlink:to="lab_lsta_CashCashEquivalentsAndMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_ba17290c-bfd5-4f98-a354-361b74d82328_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_4dc97746-ff98-4cc3-a5d6-a7ca031f5b90_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, value, outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9da12f41-3d9d-43ed-980c-7f2d7cf54070_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_562b2ce4-f495-4e80-9e6f-3e488be1252b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_FinanceGeneralAndAdministrativeExpense_8dfefa26-d165-4dab-b508-c65d2a2c1956_terseLabel_en-US" xlink:label="lab_lsta_FinanceGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance</link:label>
    <link:label id="lab_lsta_FinanceGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_lsta_FinanceGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance, General And Administrative Expense</link:label>
    <link:label id="lab_lsta_FinanceGeneralAndAdministrativeExpense_documentation_en-US" xlink:label="lab_lsta_FinanceGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance, General And Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_FinanceGeneralAndAdministrativeExpense" xlink:href="lsta-20250331.xsd#lsta_FinanceGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_FinanceGeneralAndAdministrativeExpense" xlink:to="lab_lsta_FinanceGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_02a8120d-b8d8-4158-835a-0f4fd91eb0ac_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_96eaf1fd-1f07-4d3b-9aff-961eab4d5b62_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_d5ec1248-f67e-4b1b-9bce-5e2cc874c46f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_007f82be-9084-40bc-a3d1-f903472097d3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_LitigationSettlementFutureMilestonePaymentsPercent_d5945dee-d02f-496b-a620-30c6d9ccdf63_terseLabel_en-US" xlink:label="lab_lsta_LitigationSettlementFutureMilestonePaymentsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, future milestone payments</link:label>
    <link:label id="lab_lsta_LitigationSettlementFutureMilestonePaymentsPercent_label_en-US" xlink:label="lab_lsta_LitigationSettlementFutureMilestonePaymentsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Future Milestone Payments, Percent</link:label>
    <link:label id="lab_lsta_LitigationSettlementFutureMilestonePaymentsPercent_documentation_en-US" xlink:label="lab_lsta_LitigationSettlementFutureMilestonePaymentsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Future Milestone Payments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementFutureMilestonePaymentsPercent" xlink:href="lsta-20250331.xsd#lsta_LitigationSettlementFutureMilestonePaymentsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_LitigationSettlementFutureMilestonePaymentsPercent" xlink:to="lab_lsta_LitigationSettlementFutureMilestonePaymentsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_61e014aa-b29f-4c0f-8d5a-176ad8501744_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_4ecb11ae-aab8-4bd3-aa8a-86e2fdfbd4a6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ecb3c406-6269-4be7-85ef-88aacfcceaf0_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SharesIssuedUnderLicenseAgreement_dc6b23c2-7591-4008-883d-7df7966aaae4_terseLabel_en-US" xlink:label="lab_lsta_SharesIssuedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under license agreement (in shares)</link:label>
    <link:label id="lab_lsta_SharesIssuedUnderLicenseAgreement_label_en-US" xlink:label="lab_lsta_SharesIssuedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued Under License Agreement</link:label>
    <link:label id="lab_lsta_SharesIssuedUnderLicenseAgreement_documentation_en-US" xlink:label="lab_lsta_SharesIssuedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Issued Under License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SharesIssuedUnderLicenseAgreement" xlink:href="lsta-20250331.xsd#lsta_SharesIssuedUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SharesIssuedUnderLicenseAgreement" xlink:to="lab_lsta_SharesIssuedUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SaleOfStockAvailableForSale_3565194a-db02-4b55-af99-b203e9619bfc_terseLabel_en-US" xlink:label="lab_lsta_SaleOfStockAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock available for sale</link:label>
    <link:label id="lab_lsta_SaleOfStockAvailableForSale_label_en-US" xlink:label="lab_lsta_SaleOfStockAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock Available for Sale</link:label>
    <link:label id="lab_lsta_SaleOfStockAvailableForSale_documentation_en-US" xlink:label="lab_lsta_SaleOfStockAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock Available for Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAvailableForSale" xlink:href="lsta-20250331.xsd#lsta_SaleOfStockAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SaleOfStockAvailableForSale" xlink:to="lab_lsta_SaleOfStockAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2b903384-9a65-449d-80ae-f5d42fd98623_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0b15dc5e-bc77-454d-86bc-41669c03d90d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3792f5a9-8809-4b4a-b7f0-93d1eb9a9170_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES, NON-CONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommunicationsAndInformationTechnology_434f7d40-cd23-4497-95af-06dbec636bc0_terseLabel_en-US" xlink:label="lab_us-gaap_CommunicationsAndInformationTechnology" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investor relations/public relations/communications</link:label>
    <link:label id="lab_us-gaap_CommunicationsAndInformationTechnology_label_en-US" xlink:label="lab_us-gaap_CommunicationsAndInformationTechnology" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Communications and Information Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommunicationsAndInformationTechnology" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommunicationsAndInformationTechnology"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommunicationsAndInformationTechnology" xlink:to="lab_us-gaap_CommunicationsAndInformationTechnology" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_b1a733fe-5a0c-4828-9a57-86b40c96e181_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e08d78a4-c4e4-46c9-b58d-e522c5fc6694_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_00287f81-a601-4f2e-b0d9-fc7027f77a7d_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_34d339e1-2681-4bf2-aa77-d9a262ce5d06_terseLabel_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual license maintenance fee, year seven</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_label_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_documentation_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:href="lsta-20250331.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:to="lab_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_0627315d-9f43-44a5-95e9-d7c9a4b07612_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SAFEValuationCap_ba6da274-cab5-4d63-b5b2-caf2544df0fa_terseLabel_en-US" xlink:label="lab_lsta_SAFEValuationCap" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SAFE, valuation cap</link:label>
    <link:label id="lab_lsta_SAFEValuationCap_label_en-US" xlink:label="lab_lsta_SAFEValuationCap" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SAFE, Valuation Cap</link:label>
    <link:label id="lab_lsta_SAFEValuationCap_documentation_en-US" xlink:label="lab_lsta_SAFEValuationCap" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SAFE, Valuation Cap</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SAFEValuationCap" xlink:href="lsta-20250331.xsd#lsta_SAFEValuationCap"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SAFEValuationCap" xlink:to="lab_lsta_SAFEValuationCap" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_LossOnSaleOfNOL_c6d97ffc-a466-4e55-be00-4bcc5eb20483_terseLabel_en-US" xlink:label="lab_lsta_LossOnSaleOfNOL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on sale of NOL</link:label>
    <link:label id="lab_lsta_LossOnSaleOfNOL_label_en-US" xlink:label="lab_lsta_LossOnSaleOfNOL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss On Sale of NOL</link:label>
    <link:label id="lab_lsta_LossOnSaleOfNOL_documentation_en-US" xlink:label="lab_lsta_LossOnSaleOfNOL" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss On Sale of NOL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LossOnSaleOfNOL" xlink:href="lsta-20250331.xsd#lsta_LossOnSaleOfNOL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_LossOnSaleOfNOL" xlink:to="lab_lsta_LossOnSaleOfNOL" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_62a6a010-4750-4800-840f-bd98700b662a_terseLabel_en-US" xlink:label="lab_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of NOLs, gross</link:label>
    <link:label id="lab_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_label_en-US" xlink:label="lab_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross</link:label>
    <link:label id="lab_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_documentation_en-US" xlink:label="lab_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:href="lsta-20250331.xsd#lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:to="lab_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7bda9db9-a70e-4e20-b5e1-23896e41037f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e59fcbbe-0d2f-4314-b7bc-da1f8f8338da_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options, Outstanding. Beginning of Period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9761e8e3-8abd-419a-adf8-f43f0a9c838d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options, Outstanding, End of Period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_f9720640-bb0d-40f5-8895-8f40083cdf0a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a92e1f34-077d-4b74-bbab-dd1748bc7f78_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options, Outstanding, Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8699d68f-9f92-41c1-b415-0c004b94f3da_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options, Outstanding, End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_1c762608-8cd1-466a-bd3a-7e5832c6a33c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExercised_697f0f51-171b-414e-a885-c90a9df7cd56_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Exercised (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExercised_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercised</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExercised_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsExercised" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageExercisePriceWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsExercised" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_759b8127-06db-4d13-ab4a-7026dfb126d8_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Total Compensation Cost Related to Nonvested Awards</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_1c74479d-3593-42fb-afa4-4eec0a50d7fb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_b41ed126-0a06-4daa-a2f2-43b80db58af3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_492a127a-aa3e-449a-a050-8df71e98310d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_01dac4d4-f8ae-458f-b4c8-7a3f93b2e1a2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from option exercises</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_434b2d32-9f30-439c-9965-71594d929bcc_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research tax credit rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsExpired_8cb4914e-1a66-4472-8d30-3162aef8ca93_negatedTerseLabel_en-US" xlink:label="lab_lsta_WarrantsExpired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Expired (in shares)</link:label>
    <link:label id="lab_lsta_WarrantsExpired_label_en-US" xlink:label="lab_lsta_WarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expired</link:label>
    <link:label id="lab_lsta_WarrantsExpired_documentation_en-US" xlink:label="lab_lsta_WarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsExpired" xlink:href="lsta-20250331.xsd#lsta_WarrantsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsExpired" xlink:to="lab_lsta_WarrantsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b841ffab-616e-49f4-a800-6f4fe3c5c19a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_17c2ed0d-88bc-4429-b90a-21623eff6bcc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average estimated fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3624f134-3d0a-4b26-a7c5-38cff558f7eb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsExercised_9e754461-40c4-44ef-9c2d-498b1769b0c3_negatedTerseLabel_en-US" xlink:label="lab_lsta_WarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Exercised (in shares)</link:label>
    <link:label id="lab_lsta_WarrantsExercised_label_en-US" xlink:label="lab_lsta_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Exercised</link:label>
    <link:label id="lab_lsta_WarrantsExercised_documentation_en-US" xlink:label="lab_lsta_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsExercised" xlink:href="lsta-20250331.xsd#lsta_WarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsExercised" xlink:to="lab_lsta_WarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_dca2b8ea-83a4-4b90-9ed2-0407ef6b96f6_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_c3530f3f-a0aa-4b90-83d7-49a656af292f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ChemistryManufacturingAndControlsMember_22645de4-f8d0-48c4-adc5-2d327fa9b96d_terseLabel_en-US" xlink:label="lab_lsta_ChemistryManufacturingAndControlsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chemistry, manufacturing and controls</link:label>
    <link:label id="lab_lsta_ChemistryManufacturingAndControlsMember_label_en-US" xlink:label="lab_lsta_ChemistryManufacturingAndControlsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chemistry Manufacturing And Controls [Member]</link:label>
    <link:label id="lab_lsta_ChemistryManufacturingAndControlsMember_documentation_en-US" xlink:label="lab_lsta_ChemistryManufacturingAndControlsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chemistry Manufacturing And Controls</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ChemistryManufacturingAndControlsMember" xlink:href="lsta-20250331.xsd#lsta_ChemistryManufacturingAndControlsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ChemistryManufacturingAndControlsMember" xlink:to="lab_lsta_ChemistryManufacturingAndControlsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ImpiloMember_a0e3ed78-45b0-46db-be62-7e3461fb55da_terseLabel_en-US" xlink:label="lab_lsta_ImpiloMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impilo</link:label>
    <link:label id="lab_lsta_ImpiloMember_label_en-US" xlink:label="lab_lsta_ImpiloMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impilo [Member]</link:label>
    <link:label id="lab_lsta_ImpiloMember_documentation_en-US" xlink:label="lab_lsta_ImpiloMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Impilo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ImpiloMember" xlink:href="lsta-20250331.xsd#lsta_ImpiloMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ImpiloMember" xlink:to="lab_lsta_ImpiloMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_f542670c-b0ab-46b3-8a30-46245de0efbc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_d1bfa36d-65c5-4e8d-a24b-839ea301a632_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_7acfd6ff-6682-470e-b1b9-4c2a61382e43_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_42f2b972-29d0-400c-93da-3939e0f89bfa_terseLabel_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties, net of sales</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_label_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales</link:label>
    <link:label id="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_documentation_en-US" xlink:label="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:href="lsta-20250331.xsd#lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:to="lab_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6ccd5299-d64f-4e33-9a76-3a2503308a48_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_b0284cc2-f147-454a-877f-75e8de5188c6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1c1f8c0f-f2d8-4915-9701-7cecf692de95_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsVested_933309cf-8699-4ef2-ad4d-4cada5db6a9f_terseLabel_en-US" xlink:label="lab_lsta_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Vested (in shares)</link:label>
    <link:label id="lab_lsta_WarrantsVested_label_en-US" xlink:label="lab_lsta_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants, Vested</link:label>
    <link:label id="lab_lsta_WarrantsVested_documentation_en-US" xlink:label="lab_lsta_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsVested" xlink:href="lsta-20250331.xsd#lsta_WarrantsVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsVested" xlink:to="lab_lsta_WarrantsVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_da75ff08-0720-427e-aef4-2028d28862b3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_e6fedca9-b847-4837-9fcc-45ab4b8f08b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss from equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_2b7ce5e3-7289-4171-8db9-939bf8fb308b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity method investment expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_0b01acf7-aa7c-4ff1-abcb-dedaeaeb647d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost; 738 shares at March 31, 2025 and December 31, 2024</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_0e4e1107-0e55-4bcf-ad08-b4f4a349ecdb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_LingmedLimitedMember_ece484e5-f218-4b1e-9260-8f7e812d1faa_terseLabel_en-US" xlink:label="lab_lsta_LingmedLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lingmed Limited</link:label>
    <link:label id="lab_lsta_LingmedLimitedMember_label_en-US" xlink:label="lab_lsta_LingmedLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lingmed Limited [Member]</link:label>
    <link:label id="lab_lsta_LingmedLimitedMember_documentation_en-US" xlink:label="lab_lsta_LingmedLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lingmed Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LingmedLimitedMember" xlink:href="lsta-20250331.xsd#lsta_LingmedLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_LingmedLimitedMember" xlink:to="lab_lsta_LingmedLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_OptionsVestedWeightedAverageRemainingContractualTerm_7519393e-509b-4bee-9cd6-4c673b805904_terseLabel_en-US" xlink:label="lab_lsta_OptionsVestedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Vested, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_lsta_OptionsVestedWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_lsta_OptionsVestedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options, Vested, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_lsta_OptionsVestedWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_lsta_OptionsVestedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options, Vested, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OptionsVestedWeightedAverageRemainingContractualTerm" xlink:href="lsta-20250331.xsd#lsta_OptionsVestedWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_OptionsVestedWeightedAverageRemainingContractualTerm" xlink:to="lab_lsta_OptionsVestedWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0955226a-baf0-4d56-804f-a1de0ca74263_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_cee4ee1f-9f5f-4ded-8ea8-8b01054ac1b6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Greater than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_bc4b7699-e213-4bcc-bd19-9a5456e647d0_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-Sale-Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ae644618-e52b-48bf-917f-bf28dd32e5d3_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_5f52bd43-a9be-4207-a9b0-1bcad197afaa_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ef8eb49d-a045-4b75-be9e-b840eec893b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options, Weighted Average Contractual Term and Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_14fea7a6-714c-4497-830d-b55f4ea2a0e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7da2f6bb-d72b-48da-92dc-fc2b7b7643e7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_LitigationSettlementPaymentTerm_11dc759c-4074-46a2-a621-83b8dda3c848_terseLabel_en-US" xlink:label="lab_lsta_LitigationSettlementPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, payment term</link:label>
    <link:label id="lab_lsta_LitigationSettlementPaymentTerm_label_en-US" xlink:label="lab_lsta_LitigationSettlementPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Payment Term</link:label>
    <link:label id="lab_lsta_LitigationSettlementPaymentTerm_documentation_en-US" xlink:label="lab_lsta_LitigationSettlementPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementPaymentTerm" xlink:href="lsta-20250331.xsd#lsta_LitigationSettlementPaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_LitigationSettlementPaymentTerm" xlink:to="lab_lsta_LitigationSettlementPaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_67f0ec82-aa63-45f5-8765-90bf21958b74_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_600d326f-c52a-434c-a0bd-d8edc58084da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_bfca7d7c-878b-45cd-a2f9-6a3cc050eef1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9a055fce-d239-496a-9f1a-4e60ba9534ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e0b55990-9e6d-4534-9dfb-64490fc0e6b3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c1ad2e26-2113-4876-94a8-3256419f1ac3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_78604ffb-d57e-4cd8-80fd-e0b0a7c548ec_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_c640acbd-ccac-44fe-9c48-63466b25d754_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e457af43-eb40-4477-ac30-0155d87d5d40_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuances of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_71ab4ef8-9f70-4244-a570-fc527c55e919_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_e5b8731c-7e3f-42e7-9e28-ac8d47d8f87b_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_CENDMember_5a49eef0-6a11-428b-86a7-b27b66a8cb9c_terseLabel_en-US" xlink:label="lab_lsta_CENDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CEND</link:label>
    <link:label id="lab_lsta_CENDMember_label_en-US" xlink:label="lab_lsta_CENDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CEND [Member]</link:label>
    <link:label id="lab_lsta_CENDMember_documentation_en-US" xlink:label="lab_lsta_CENDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CEND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CENDMember" xlink:href="lsta-20250331.xsd#lsta_CENDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_CENDMember" xlink:to="lab_lsta_CENDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_bdafb943-dbb7-409a-a355-0224aeb8ec0f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8fb882ea-0289-46ef-bffa-1297ba512bed_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_1698e31b-3536-49a8-a1e8-2a2e441817e6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, balance sheet line item</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_6919b9b2-affe-42b0-b545-2116736d8a74_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c91c5a6f-4cc5-4bed-a58e-e57ee77fd7d6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ReportableSegmentMember_cb7abd23-09a0-4f89-871f-4414925a6389_terseLabel_en-US" xlink:label="lab_lsta_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_lsta_ReportableSegmentMember_label_en-US" xlink:label="lab_lsta_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_lsta_ReportableSegmentMember_documentation_en-US" xlink:label="lab_lsta_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ReportableSegmentMember" xlink:href="lsta-20250331.xsd#lsta_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ReportableSegmentMember" xlink:to="lab_lsta_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_09a7aebb-ea49-40ab-a6cd-f89f362573ea_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_053012ad-36c6-4f21-8f2c-75c385b2e195_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExpired_d98a4cf6-6cbf-44ea-9926-15c3a5488222_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Expired (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExpired_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Expired</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsExpired_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsExpired" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageExercisePriceWarrantsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsExpired" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c4d524bb-598a-4f75-b31a-f6c4b6a12db4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_0ff66b65-ec0b-4732-9f19-89531305e792_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_8bb60d16-4cd9-4fec-8015-c2c63c937a13_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_52e90734-5891-499e-bdb4-27e23e09fd9a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsVestedAndExpectedToVest_64f5c1b0-dda7-486a-bd1f-194670df83a9_terseLabel_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsVestedAndExpectedToVest_label_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Warrants Vested And Expected To Vest</link:label>
    <link:label id="lab_lsta_AggregateIntrinsicValueWarrantsVestedAndExpectedToVest_documentation_en-US" xlink:label="lab_lsta_AggregateIntrinsicValueWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Warrants Vested And Expected To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AggregateIntrinsicValueWarrantsVestedAndExpectedToVest" xlink:href="lsta-20250331.xsd#lsta_AggregateIntrinsicValueWarrantsVestedAndExpectedToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AggregateIntrinsicValueWarrantsVestedAndExpectedToVest" xlink:to="lab_lsta_AggregateIntrinsicValueWarrantsVestedAndExpectedToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsCanceled_30f3031a-9e36-4d9b-85c7-51e77505b7d5_negatedLabel_en-US" xlink:label="lab_lsta_WarrantsCanceled" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Warrants, Forfeited (in shares)</link:label>
    <link:label id="lab_lsta_WarrantsCanceled_label_en-US" xlink:label="lab_lsta_WarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Canceled</link:label>
    <link:label id="lab_lsta_WarrantsCanceled_documentation_en-US" xlink:label="lab_lsta_WarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsCanceled" xlink:href="lsta-20250331.xsd#lsta_WarrantsCanceled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsCanceled" xlink:to="lab_lsta_WarrantsCanceled" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_123d0283-93f7-4bef-b224-5f60df76e50b_terseLabel_en-US" xlink:label="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of sublicensing revenues</link:label>
    <link:label id="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_label_en-US" xlink:label="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Percentage of Sublicensing Revenues</link:label>
    <link:label id="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_documentation_en-US" xlink:label="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Percentage of Sublicensing Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:href="lsta-20250331.xsd#lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:to="lab_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0d6dbac8-5c54-491a-b9ab-d4cba95609be_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_aff67522-5e14-442f-8fb8-d5ea5d550528_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_199631d1-665b-444e-b731-96ca950100fa_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_27a110f0-156d-477a-b0d8-1a0912675d1a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale_efa3576b-35f0-49d3-9c4b-5c96415858b9_terseLabel_en-US" xlink:label="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of net sale</link:label>
    <link:label id="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale_label_en-US" xlink:label="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Percentage of Net Sale</link:label>
    <link:label id="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale_documentation_en-US" xlink:label="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation, Percentage of Net Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenuePerformanceObligationPercentageOfNetSale" xlink:href="lsta-20250331.xsd#lsta_RevenuePerformanceObligationPercentageOfNetSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_RevenuePerformanceObligationPercentageOfNetSale" xlink:to="lab_lsta_RevenuePerformanceObligationPercentageOfNetSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_dd029205-239a-4fa5-b9da-6cc738fdaeb1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_6a1e9ea0-944e-4932-a270-74aca322638f_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_0a5dd03d-9f10-454a-a37e-b20ead1a7eda_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1c053e1d-1f80-4dde-8770-50c011b0f637_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_0b901d0a-c2b0-40b8-8455-4f08a6d22be4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_940468a6-76f1-44e3-9574-8e1ec6146cf5_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bf7cae34-84c0-4c7f-b0df-0e241f30743c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BondsMember_afedcc07-f17b-4dd6-9f46-041311606d1e_terseLabel_en-US" xlink:label="lab_us-gaap_BondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agency bonds</link:label>
    <link:label id="lab_us-gaap_BondsMember_label_en-US" xlink:label="lab_us-gaap_BondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BondsMember" xlink:to="lab_us-gaap_BondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_3c215f6a-e4b1-4138-92fd-a770a945a445_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_01e83409-1876-4f8c-9134-e3706e4dffa3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative translation adjustment arising during the period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_89c8901c-cd7d-4749-82d0-e21cb1674820_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_7264a50d-6c9c-4861-90c5-0005ba70a1fb_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_8c09c1a7-68b8-4614-b672-8111271dd1b3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_600f24d2-8146-4ffd-9b62-fc2b0a80bdf1_terseLabel_en-US" xlink:label="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable consideration amounts, milestones</link:label>
    <link:label id="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:label id="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="lsta-20250331.xsd#lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_a9b010e1-9eb2-4cc2-9021-7045320baeb0_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_af20b746-4745-4620-8dc5-5515ec2a4727_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_FairValueMarketOfTaxNOLs_d2d49421-a8ff-4921-9916-9e593dfc5ffa_terseLabel_en-US" xlink:label="lab_lsta_FairValueMarketOfTaxNOLs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value market of tax NOLs</link:label>
    <link:label id="lab_lsta_FairValueMarketOfTaxNOLs_label_en-US" xlink:label="lab_lsta_FairValueMarketOfTaxNOLs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Market of Tax NOLs</link:label>
    <link:label id="lab_lsta_FairValueMarketOfTaxNOLs_documentation_en-US" xlink:label="lab_lsta_FairValueMarketOfTaxNOLs" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Market of Tax NOLs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_FairValueMarketOfTaxNOLs" xlink:href="lsta-20250331.xsd#lsta_FairValueMarketOfTaxNOLs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_FairValueMarketOfTaxNOLs" xlink:to="lab_lsta_FairValueMarketOfTaxNOLs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ef6fcba4-d107-4712-a519-5443025c4e3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average estimated fair value of shares granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6d83d371-f416-4695-9234-a0f07d1327e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant-Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4da26353-d4dc-4241-85c3-22850c8d375c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_79a1286d-ef81-4bc8-8447-5f3bf82f4f9b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_aadff250-7043-464d-9c1a-b2e9db3860c9_terseLabel_en-US" xlink:label="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate offering amount authorized per agreement</link:label>
    <link:label id="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_label_en-US" xlink:label="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</link:label>
    <link:label id="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_documentation_en-US" xlink:label="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:href="lsta-20250331.xsd#lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:to="lab_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_45f7e9cc-72b1-40ab-ab52-a8e21acbf6d1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_333490a9-70c5-43d3-b65b-452a8a8de0f5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less - net income (loss) attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_f98f879d-1547-4d2c-ac38-c3aa2bd5b8a3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2e2e9b7c-ecf1-4d45-8ac4-9c643351aa07_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_fe0c587a-bb70-4812-aa0e-9163e8371110_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_a2b38972-fa65-4e47-b87d-7f0646f5f113_terseLabel_en-US" xlink:label="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable, accrued liabilities and other liabilities</link:label>
    <link:label id="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_label_en-US" xlink:label="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</link:label>
    <link:label id="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_documentation_en-US" xlink:label="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:href="lsta-20250331.xsd#lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:to="lab_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_3fa232d6-36e3-4706-9900-765d5d5903b8_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_86dc5101-59d7-4843-b326-bb4eec579695_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, amount awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_OutstandingStockThreshold_d4cd5368-5a69-4268-b675-57aa2cb9108c_terseLabel_en-US" xlink:label="lab_lsta_OutstandingStockThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding stock threshold</link:label>
    <link:label id="lab_lsta_OutstandingStockThreshold_label_en-US" xlink:label="lab_lsta_OutstandingStockThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Stock Threshold</link:label>
    <link:label id="lab_lsta_OutstandingStockThreshold_documentation_en-US" xlink:label="lab_lsta_OutstandingStockThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Outstanding Stock Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OutstandingStockThreshold" xlink:href="lsta-20250331.xsd#lsta_OutstandingStockThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_OutstandingStockThreshold" xlink:to="lab_lsta_OutstandingStockThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown_fbf51eed-f5b5-4a68-8939-ff36692714d4_terseLabel_en-US" xlink:label="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards, prior to write down</link:label>
    <link:label id="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown_label_en-US" xlink:label="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Before Write Down</link:label>
    <link:label id="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown_documentation_en-US" xlink:label="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Before Write Down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLossCarryforwardsBeforeWriteDown" xlink:href="lsta-20250331.xsd#lsta_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_OperatingLossCarryforwardsBeforeWriteDown" xlink:to="lab_lsta_OperatingLossCarryforwardsBeforeWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c1dc598c-d620-4b40-8a3d-a186f5767725_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_75940afc-5fca-436c-af4d-6a0b563b8ffc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate for operating leases (percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_05e234a1-0a97-491e-95cd-15247a9b4c8c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ff41f7dc-6894-4704-84c0-cf9083dbba65_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_96a176f4-04a8-4826-91ca-4e61dc3d0bd7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward_9be02144-99f4-48d8-bb19-ea66aeb57dc4_terseLabel_en-US" xlink:label="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Weighted Average Exercise Price</link:label>
    <link:label id="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward" xlink:href="lsta-20250331.xsd#lsta_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward" xlink:to="lab_lsta_WarrantsWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_b857e6c3-cda3-4c52-b6d4-15f95048d6a5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_80bc6035-d997-4359-884d-4ad385a351c5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f9fa8c3c-d5e3-4434-909c-6c9a128cc1d9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c3879420-7ea1-4157-8fa0-6ee44a3a4d22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_a12d29e8-6d33-438c-b0a2-1d18cd6750e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d5b23aab-11bf-4083-ae7c-719f0fe2aad0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDevelopment_17d7fc73-e44d-4943-981e-2dba7be6293a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business development</link:label>
    <link:label id="lab_us-gaap_BusinessDevelopment_label_en-US" xlink:label="lab_us-gaap_BusinessDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDevelopment" xlink:to="lab_us-gaap_BusinessDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_40704abb-6151-45a3-9242-2f53b6f6fb3f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuances of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_669b19b8-663c-4b9d-9693-3a8e87fee058_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestones, Royalties</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_AccruedGrantFunding_ca4e622c-4bf8-4e60-9d3a-87fb6ecd455c_terseLabel_en-US" xlink:label="lab_lsta_AccruedGrantFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting &amp; tax consulting liabilities</link:label>
    <link:label id="lab_lsta_AccruedGrantFunding_label_en-US" xlink:label="lab_lsta_AccruedGrantFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Grant Funding</link:label>
    <link:label id="lab_lsta_AccruedGrantFunding_documentation_en-US" xlink:label="lab_lsta_AccruedGrantFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Grant Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AccruedGrantFunding" xlink:href="lsta-20250331.xsd#lsta_AccruedGrantFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_AccruedGrantFunding" xlink:to="lab_lsta_AccruedGrantFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_356ca469-7e7e-4e7b-963e-1badbd7644e3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_4ad436a6-5672-40bb-ae6c-687fd1c0dd14_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e6fb1c1e-997d-4cea-be5c-fa6186553d64_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Share-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_59e9afdc-7771-4f67-940e-0b33e31a3cf2_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c721d789-f705-4ee9-94d7-ca6735508bbd_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d66212d6-d5f8-48e0-b06c-2c52106edc44_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_4d948555-421d-46e5-a624-0fae781c5de1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,620,900 and 8,409,582 shares at March 31, 2025 and December 31, 2024, respectively; and outstanding, 8,620,162 and 8,408,844 shares at March 31, 2025 and December 31, 2024, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b311583a-b924-4d33-a7e8-ad5d96c6d661_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_8ca0454f-a841-4cec-b1b4-ded6877ed685_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_eb3f9160-4a96-4c22-a206-00789afc387f_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Greater than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2187b4b7-e6d8-4d3d-81a4-8db5717fb88b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_81253345-ac47-4aea-8edd-0c3bd324e200_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled_30edd488-3637-4bb4-b1cd-3450fa5c937f_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Canceled</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsCanceled" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageExercisePriceWarrantsCanceled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsCanceled" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsCanceled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1f088f1e-cd50-4c63-b9ee-dc354fbe3ac9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Vested, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsGranted_28786da7-4082-42f1-9335-6794b5b96b27_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Granted (in dollars per share)</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsGranted_label_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Granted</link:label>
    <link:label id="lab_lsta_WeightedAverageExercisePriceWarrantsGranted_documentation_en-US" xlink:label="lab_lsta_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsGranted" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageExercisePriceWarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageExercisePriceWarrantsGranted" xlink:to="lab_lsta_WeightedAverageExercisePriceWarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_SanfordBurnhamPrebysMember_73185b1e-77c2-41a4-8c8b-3c761f3d924c_terseLabel_en-US" xlink:label="lab_lsta_SanfordBurnhamPrebysMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanford Burnham Prebys</link:label>
    <link:label id="lab_lsta_SanfordBurnhamPrebysMember_label_en-US" xlink:label="lab_lsta_SanfordBurnhamPrebysMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanford Burnham Prebys [Member]</link:label>
    <link:label id="lab_lsta_SanfordBurnhamPrebysMember_documentation_en-US" xlink:label="lab_lsta_SanfordBurnhamPrebysMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sanford Burnham Prebys</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SanfordBurnhamPrebysMember" xlink:href="lsta-20250331.xsd#lsta_SanfordBurnhamPrebysMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_SanfordBurnhamPrebysMember" xlink:to="lab_lsta_SanfordBurnhamPrebysMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e936f9eb-e07f-4ab7-aedd-daeaae5d3476_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermWarrantOutstanding_f8e8ff92-7c01-43ff-9786-38fddcb5000e_terseLabel_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermWarrantOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermWarrantOutstanding_label_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermWarrantOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term Warrant Outstanding</link:label>
    <link:label id="lab_lsta_WeightedAverageRemainingContractualTermWarrantOutstanding_documentation_en-US" xlink:label="lab_lsta_WeightedAverageRemainingContractualTermWarrantOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term Warrant Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageRemainingContractualTermWarrantOutstanding" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageRemainingContractualTermWarrantOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_WeightedAverageRemainingContractualTermWarrantOutstanding" xlink:to="lab_lsta_WeightedAverageRemainingContractualTermWarrantOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3e0e0e01-9095-4bea-8381-941bf24a0e0a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_362878df-8562-407a-91e1-ec1f4305a429_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current, balance sheet line item</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_c06f6fe0-542c-43ac-b993-d858ba3998d2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_21396346-ed75-4abc-973e-9f673eef46ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_f54b0425-773e-4db6-81f1-dcac111983e6_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ClinicalAndRDRelatedLiabilities_a2bfbcb2-9795-401a-b186-6056321150e5_terseLabel_en-US" xlink:label="lab_lsta_ClinicalAndRDRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical and R&amp;D related liabilities</link:label>
    <link:label id="lab_lsta_ClinicalAndRDRelatedLiabilities_label_en-US" xlink:label="lab_lsta_ClinicalAndRDRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical and R&amp;D Related Liabilities</link:label>
    <link:label id="lab_lsta_ClinicalAndRDRelatedLiabilities_documentation_en-US" xlink:label="lab_lsta_ClinicalAndRDRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical and R&amp;D Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ClinicalAndRDRelatedLiabilities" xlink:href="lsta-20250331.xsd#lsta_ClinicalAndRDRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ClinicalAndRDRelatedLiabilities" xlink:to="lab_lsta_ClinicalAndRDRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_000a3d05-6641-4fac-a9bf-ab263bfe9b93_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lisata Therapeutics, Inc. common stockholders- basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_c160d31d-8fb8-4eef-8795-ae451cdf156e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxHolidayLineItems_9d6e549f-7351-4ab0-87dc-4ec2a2892845_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Holiday [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxHolidayLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Holiday [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems" xlink:to="lab_us-gaap_IncomeTaxHolidayLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1b5bec20-a339-43fe-bb03-74e926cba08b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_6b72613c-c818-48ef-9d1c-f74536a85e11_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_a885c9ee-39ca-4f2d-b948-c380caa74075_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_82eb3325-4bb0-43f0-bd40-172277dcfd23_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a0521dee-71ad-4a77-8ca6-16c3678807c0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_3caefb8f-198c-4fe9-91b2-bf16d7f32d6f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_220319c8-ee4e-4ffe-9da2-0ebec86d7a48_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected amortization, year one</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ad70921d-9295-4cac-9829-03ed98590b97_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_ea3b536b-de98-4c00-8cca-26d342ce1252_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3687b1b9-13e3-46af-9a17-f1cb78fd64a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_be70a987-c76e-48d4-bd45-8d676599fb88_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_1fc89146-1323-4443-84ea-96dc5ba60999_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_82ded7db-d990-4a49-8a3c-1db51256c096_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies (Note 14)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_414cb737-394a-44b8-b74e-53490705a489_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_LegalGeneralAndAdministrativeExpense_ed1a98d3-712a-43e3-ac26-9c07802922cc_terseLabel_en-US" xlink:label="lab_lsta_LegalGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal</link:label>
    <link:label id="lab_lsta_LegalGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_lsta_LegalGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal, General And Administrative Expense</link:label>
    <link:label id="lab_lsta_LegalGeneralAndAdministrativeExpense_documentation_en-US" xlink:label="lab_lsta_LegalGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Legal, General And Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LegalGeneralAndAdministrativeExpense" xlink:href="lsta-20250331.xsd#lsta_LegalGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_LegalGeneralAndAdministrativeExpense" xlink:to="lab_lsta_LegalGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1d12e4f9-e0ed-434e-aa60-d841658821b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fb65e654-84ce-4c4a-baea-3c31680046ae_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_db8645ca-450f-4626-9017-1755db2280a7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_ef0f0aae-e684-4281-ac49-94544315a33d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8a854ad4-3781-471c-a885-f26693081959_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option and Warrants Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_af14c516-fa62-447b-b24d-eb0c6c0ccee2_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_c560484e-dc15-43b0-a332-006a408ed629_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue from collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_ecba315c-d67b-48d8-b52c-663be59c0808_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from contract</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_30e6feb7-5091-4329-8524-d2d73c2c4c81_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to Lisata Therapeutics, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e08ed819-3a44-43a7-8e92-19850a488cab_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7c611e2d-bcae-4ef2-9f15-24a52306e3d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_67ab47bb-60d2-4a56-93fb-8609fd285344_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a3b3ea09-7162-4b1e-a592-63c3116048ae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_b3de0ecb-3559-406c-a204-55ce5a06dcd7_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8aba9a87-83b6-4636-8f50-116add0d5a5c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_966e3286-d8b2-4495-b9eb-ad8fbb6e1edc_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ProceedsFromSaleOfNOLS_b8b4439e-d448-4882-babb-1d2ae4dff35a_terseLabel_en-US" xlink:label="lab_lsta_ProceedsFromSaleOfNOLS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of NOLs</link:label>
    <link:label id="lab_lsta_ProceedsFromSaleOfNOLS_label_en-US" xlink:label="lab_lsta_ProceedsFromSaleOfNOLS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Sale of NOLS</link:label>
    <link:label id="lab_lsta_ProceedsFromSaleOfNOLS_documentation_en-US" xlink:label="lab_lsta_ProceedsFromSaleOfNOLS" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Sale of NOLS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ProceedsFromSaleOfNOLS" xlink:href="lsta-20250331.xsd#lsta_ProceedsFromSaleOfNOLS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ProceedsFromSaleOfNOLS" xlink:to="lab_lsta_ProceedsFromSaleOfNOLS" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock_9a943103-a2f2-4fdc-abac-e9d34436e3f6_terseLabel_en-US" xlink:label="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Australia Research and Development Tax Incentive</link:label>
    <link:label id="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock_label_en-US" xlink:label="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Tax Incentive [Text Block]</link:label>
    <link:label id="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock_documentation_en-US" xlink:label="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Tax Incentive</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:href="lsta-20250331.xsd#lsta_ResearchAndDevelopmentTaxIncentiveTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:to="lab_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_64508536-8be6-408f-b13a-aa7c112c5814_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_ee7e48cf-261a-4a9e-bb14-b74ab9b99a52_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non- Controlling Interest in Subsidiary</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_860a29fc-2980-4035-82fe-6c7e270aa465_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_deb3d82b-a8ea-43e6-ab70-e5aef9b40545_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_da239f04-4de9-458e-81fb-1ae294a8e580_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_6619a472-fc84-4bf5-9617-c9af0625a62b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_00f3f910-71fe-497f-9ea9-706b1dbbb206_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Assets, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_130f45c8-7f3a-44c6-af25-740e0aecab3c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3d7aeb68-9a7e-4200-ba58-732751a2d654_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term for operating leases (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_58b02227-7520-4cee-974b-4588f190b4b1_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_1cc3d0af-d574-4b69-8668-d98410000fac_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f013ed61-816e-4b3e-8c51-6e8c2561dd00_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_991190da-db82-4c2f-b1e0-0b8a5ff30a8c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4db690de-f675-46b8-b59e-da959245c0e3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_95397639-6bdf-4f23-a109-fd0ef2fe3a44_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Options, Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_dc8f561b-b57b-438d-a0de-d85a8ebe6eb2_terseLabel_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Jersey</link:label>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_label_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Jersey Division of Taxation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:to="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_a756f28b-d318-4c16-bbb2-1e963311e59a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_66b3a291-7282-4c9f-8930-5715fabec05b_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1e9b97cf-2d30-4c5b-9ca9-fed60d087097_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d2392d3c-5179-479b-9402-b07c40a3246e_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_a54d3f61-6b10-4dda-8726-ff89ca81d713_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_e950cc69-101e-4e2b-8c5b-c3bcb52ac8a4_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_f6891f84-2965-4361-8db8-41e69663c5c6_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire Impilo SAFE</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_5938c1fe-794d-4b97-8a05-d8a3474b1b05_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6fa11cdd-011e-4f6b-98a9-c860d880d72a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_99da7aee-6cc2-4779-b02d-7c6a22494a6b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_3d93bf6b-5d6a-43b5-b95a-b2069addf4fc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_QiluMember_f8d281c4-ca4f-419a-9f1a-c6fc77205b07_terseLabel_en-US" xlink:label="lab_lsta_QiluMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Qilu</link:label>
    <link:label id="lab_lsta_QiluMember_label_en-US" xlink:label="lab_lsta_QiluMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Qilu [Member]</link:label>
    <link:label id="lab_lsta_QiluMember_documentation_en-US" xlink:label="lab_lsta_QiluMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Qilu</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_QiluMember" xlink:href="lsta-20250331.xsd#lsta_QiluMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_QiluMember" xlink:to="lab_lsta_QiluMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_384415d1-054e-417a-9dd1-fc8eb333fc17_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b6375b63-9b7c-4390-8cf0-6a642949e8e3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_0cd38bf9-59fe-4867-8e8e-0b73237b9fea_terseLabel_en-US" xlink:label="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet</link:label>
    <link:label id="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_label_en-US" xlink:label="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</link:label>
    <link:label id="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_documentation_en-US" xlink:label="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:href="lsta-20250331.xsd#lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:to="lab_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d3f203f0-48c3-4d22-8c14-585f3c23d1ec_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_722b70f1-119d-401b-a37f-74bf613163bf_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_556dc56c-d15e-42d1-923c-97f0919a3371_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d9302d5c-5fd5-4cc5-a5b0-73015f22d41c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_9455d7d2-2a1d-4ce8-b4c1-69cb4ed174ef_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c361af0d-cbee-432c-9111-a2105bb67ed3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b259a4cc-268b-48e6-87f4-64548a788f7b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_3756f746-65a1-4556-be04-30a757bebf2b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_92b21495-e468-409b-84ee-ec9f17b7c81f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_c1100cea-65fb-446d-b04f-046627b36627_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_22862ed1-320f-4acb-941f-f87b63dfbf4a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_75e102b9-c32f-45f1-9a82-56e3678b12d9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>lsta-20250331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1dd57249-b3e7-436f-adc4-30cff3fca49a,g:189dfb66-5ef0-4fa0-83c9-286ae40a1a30-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.caladrius.com/role/Cover" xlink:type="simple" xlink:href="lsta-20250331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9a6273d7-e2fd-4153-b3f2-6624768380ae" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_DocumentType_9a6273d7-e2fd-4153-b3f2-6624768380ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_7ed3e845-ee1b-4f36-b488-ade6fbd5aacc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_DocumentQuarterlyReport_7ed3e845-ee1b-4f36-b488-ade6fbd5aacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0861a4de-81db-4fa0-a7a3-c8c679203fab" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_DocumentPeriodEndDate_0861a4de-81db-4fa0-a7a3-c8c679203fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4412f25d-b533-407f-92fd-27fb7a31384d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_DocumentTransitionReport_4412f25d-b533-407f-92fd-27fb7a31384d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e8c83d6b-79ed-48f8-b63f-1645e7ef06a7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_EntityFileNumber_e8c83d6b-79ed-48f8-b63f-1645e7ef06a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e50b4195-21ae-44b6-be9e-d82a86cccab4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_EntityRegistrantName_e50b4195-21ae-44b6-be9e-d82a86cccab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_54672408-8688-4ada-b4cc-fddd5c93fefa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_EntityIncorporationStateCountryCode_54672408-8688-4ada-b4cc-fddd5c93fefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d1eb15d4-df48-45d1-9f54-78c22412df3c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_EntityTaxIdentificationNumber_d1eb15d4-df48-45d1-9f54-78c22412df3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c0b43edd-e110-4f81-838f-11b156ed66af" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_EntityAddressAddressLine1_c0b43edd-e110-4f81-838f-11b156ed66af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c4ee46c9-a579-4378-a91a-b52f6cf1c01d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_EntityAddressCityOrTown_c4ee46c9-a579-4378-a91a-b52f6cf1c01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9c3676da-29fb-4a2b-90bd-6f2e5037308c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_EntityAddressStateOrProvince_9c3676da-29fb-4a2b-90bd-6f2e5037308c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_dbd771a6-962c-4b1f-a651-c764c3cc629f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_EntityAddressPostalZipCode_dbd771a6-962c-4b1f-a651-c764c3cc629f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_813e7069-89ab-49cf-bc77-f103c2ba3e56" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_CityAreaCode_813e7069-89ab-49cf-bc77-f103c2ba3e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_dbf76f1c-d5d3-46cb-beaf-130f674b5df1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_LocalPhoneNumber_dbf76f1c-d5d3-46cb-beaf-130f674b5df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_310b5c75-1e04-40b6-9bed-844ed8e83160" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_Security12bTitle_310b5c75-1e04-40b6-9bed-844ed8e83160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3b125518-55d9-4528-ad73-3f967addd157" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_TradingSymbol_3b125518-55d9-4528-ad73-3f967addd157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0235893e-ab10-4c76-80de-a62b6dfc6e2f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_SecurityExchangeName_0235893e-ab10-4c76-80de-a62b6dfc6e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9b6e430e-9fe6-4d4e-b8fc-b04d895af2dc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_EntityCurrentReportingStatus_9b6e430e-9fe6-4d4e-b8fc-b04d895af2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_3aba45c0-b8c4-447d-b64a-0c2281ab809d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_EntityInteractiveDataCurrent_3aba45c0-b8c4-447d-b64a-0c2281ab809d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c1ce8d1c-13d1-4b24-94d2-aa95773008fa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_EntityFilerCategory_c1ce8d1c-13d1-4b24-94d2-aa95773008fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_4897a8f1-1c53-41b3-80c8-34f2cc4c5642" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_EntitySmallBusiness_4897a8f1-1c53-41b3-80c8-34f2cc4c5642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_581caaf4-675b-44d4-9762-c753c3d6ef40" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_EntityEmergingGrowthCompany_581caaf4-675b-44d4-9762-c753c3d6ef40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_2efff845-7b83-46f6-bc57-17ae2d21d324" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_EntityShellCompany_2efff845-7b83-46f6-bc57-17ae2d21d324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fcc74f88-06a5-4aca-98a7-97dc16911f76" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fcc74f88-06a5-4aca-98a7-97dc16911f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ba64c511-75c5-4ec2-b10e-e082a8c882ce" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_EntityCentralIndexKey_ba64c511-75c5-4ec2-b10e-e082a8c882ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c32c72a8-cdc5-46c6-86a1-bf5da48ca7c6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_CurrentFiscalYearEndDate_c32c72a8-cdc5-46c6-86a1-bf5da48ca7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_1664df07-fbd8-4bea-8f98-6b41cf543f79" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_DocumentFiscalYearFocus_1664df07-fbd8-4bea-8f98-6b41cf543f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_23a3e12f-a8d0-4688-914f-f96de71a1d39" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_DocumentFiscalPeriodFocus_23a3e12f-a8d0-4688-914f-f96de71a1d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a85a8398-8617-4432-b727-52c933296804" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_142a6faa-6fd9-4571-b995-b048134f4c43" xlink:to="loc_dei_AmendmentFlag_a85a8398-8617-4432-b727-52c933296804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="lsta-20250331.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0038e1c9-e839-40e2-9df3-c3b5fe907858" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5b3ee61d-aed4-4cb7-9e54-067ccf0a8f03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0038e1c9-e839-40e2-9df3-c3b5fe907858" xlink:to="loc_us-gaap_AssetsAbstract_5b3ee61d-aed4-4cb7-9e54-067ccf0a8f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c16fbef3-cf03-4baf-98a7-acf3a8e634bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5b3ee61d-aed4-4cb7-9e54-067ccf0a8f03" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c16fbef3-cf03-4baf-98a7-acf3a8e634bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_54aa5595-4316-41d5-88f5-22cbe0ed3ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5b3ee61d-aed4-4cb7-9e54-067ccf0a8f03" xlink:to="loc_us-gaap_MarketableSecurities_54aa5595-4316-41d5-88f5-22cbe0ed3ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_9edbdb2d-7299-4334-b020-c8bc33b86f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5b3ee61d-aed4-4cb7-9e54-067ccf0a8f03" xlink:to="loc_us-gaap_AccountsReceivableNet_9edbdb2d-7299-4334-b020-c8bc33b86f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ff563fc-d8c2-476e-90ad-64e2f5542ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5b3ee61d-aed4-4cb7-9e54-067ccf0a8f03" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ff563fc-d8c2-476e-90ad-64e2f5542ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_11ea9e78-3723-4df2-93d2-09b24a2a45bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5b3ee61d-aed4-4cb7-9e54-067ccf0a8f03" xlink:to="loc_us-gaap_AssetsCurrent_11ea9e78-3723-4df2-93d2-09b24a2a45bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fb958052-761c-4225-9783-8b09bedd4f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5b3ee61d-aed4-4cb7-9e54-067ccf0a8f03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fb958052-761c-4225-9783-8b09bedd4f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f869d250-0d6f-4e23-8ec4-37b2bc9d2a27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5b3ee61d-aed4-4cb7-9e54-067ccf0a8f03" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f869d250-0d6f-4e23-8ec4-37b2bc9d2a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fd4e269f-3c7d-4461-a264-97dd895725ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5b3ee61d-aed4-4cb7-9e54-067ccf0a8f03" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fd4e269f-3c7d-4461-a264-97dd895725ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_47b316ad-b467-42c0-b8a2-3f8b4e6b29e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5b3ee61d-aed4-4cb7-9e54-067ccf0a8f03" xlink:to="loc_us-gaap_Assets_47b316ad-b467-42c0-b8a2-3f8b4e6b29e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7c5488c4-b146-41d0-9173-acf36cf75271" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0038e1c9-e839-40e2-9df3-c3b5fe907858" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7c5488c4-b146-41d0-9173-acf36cf75271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_7aefcd52-a796-42ab-8b70-5da72ecc9f06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7c5488c4-b146-41d0-9173-acf36cf75271" xlink:to="loc_us-gaap_LiabilitiesAbstract_7aefcd52-a796-42ab-8b70-5da72ecc9f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_bbef3e5a-6da7-45b6-9186-a761a9a43965" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_7aefcd52-a796-42ab-8b70-5da72ecc9f06" xlink:to="loc_us-gaap_AccountsPayableCurrent_bbef3e5a-6da7-45b6-9186-a761a9a43965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1f66f117-6305-4cb7-9a9d-05bba780fcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_7aefcd52-a796-42ab-8b70-5da72ecc9f06" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1f66f117-6305-4cb7-9a9d-05bba780fcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ffb02025-39a6-4fbf-9d01-cd048f0b0f81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_7aefcd52-a796-42ab-8b70-5da72ecc9f06" xlink:to="loc_us-gaap_LiabilitiesCurrent_ffb02025-39a6-4fbf-9d01-cd048f0b0f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a26faf05-e441-484f-8ec3-e0c2e43a7205" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_7aefcd52-a796-42ab-8b70-5da72ecc9f06" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a26faf05-e441-484f-8ec3-e0c2e43a7205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a271acde-e674-4c1e-955c-3d96b895d093" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_7aefcd52-a796-42ab-8b70-5da72ecc9f06" xlink:to="loc_us-gaap_Liabilities_a271acde-e674-4c1e-955c-3d96b895d093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d90ab998-6f0c-4a15-99b2-6f38c438a6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7c5488c4-b146-41d0-9173-acf36cf75271" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d90ab998-6f0c-4a15-99b2-6f38c438a6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_f18b1d37-87e7-4c94-a776-a598cdbe6e86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7c5488c4-b146-41d0-9173-acf36cf75271" xlink:to="loc_us-gaap_StockholdersEquityAbstract_f18b1d37-87e7-4c94-a776-a598cdbe6e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b53159f1-d161-4778-8733-e9c31f2eba9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f18b1d37-87e7-4c94-a776-a598cdbe6e86" xlink:to="loc_us-gaap_CommonStockValue_b53159f1-d161-4778-8733-e9c31f2eba9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_cdf2537f-894d-4de9-9a55-691242990cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f18b1d37-87e7-4c94-a776-a598cdbe6e86" xlink:to="loc_us-gaap_AdditionalPaidInCapital_cdf2537f-894d-4de9-9a55-691242990cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_423a5d3c-a833-4d4b-bba4-24c3df0a97ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f18b1d37-87e7-4c94-a776-a598cdbe6e86" xlink:to="loc_us-gaap_TreasuryStockCommonValue_423a5d3c-a833-4d4b-bba4-24c3df0a97ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_79892da0-b660-45d2-baf3-ddec87f0a463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f18b1d37-87e7-4c94-a776-a598cdbe6e86" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_79892da0-b660-45d2-baf3-ddec87f0a463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3ff64988-a7cc-44e1-99d0-b89432c66545" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f18b1d37-87e7-4c94-a776-a598cdbe6e86" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3ff64988-a7cc-44e1-99d0-b89432c66545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a825063f-8525-41ab-9eac-72741d0af40a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f18b1d37-87e7-4c94-a776-a598cdbe6e86" xlink:to="loc_us-gaap_StockholdersEquity_a825063f-8525-41ab-9eac-72741d0af40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_126ea683-a5c4-4768-814d-c9512b301103" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f18b1d37-87e7-4c94-a776-a598cdbe6e86" xlink:to="loc_us-gaap_MinorityInterest_126ea683-a5c4-4768-814d-c9512b301103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e2d43b59-f882-4909-b572-6d331bb5c3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f18b1d37-87e7-4c94-a776-a598cdbe6e86" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e2d43b59-f882-4909-b572-6d331bb5c3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_95671f73-a4e0-4ea0-8eb6-7810646bb979" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7c5488c4-b146-41d0-9173-acf36cf75271" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_95671f73-a4e0-4ea0-8eb6-7810646bb979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" xlink:type="simple" xlink:href="lsta-20250331.xsd#CONSOLIDATEDBALANCESHEETSParentheticals"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0bbc3aa9-efae-45fe-b0e4-11431c9c6399" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_18729874-f88b-457a-90a7-d3f15622a229" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0bbc3aa9-efae-45fe-b0e4-11431c9c6399" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_18729874-f88b-457a-90a7-d3f15622a229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_58652f04-5d5d-4561-b145-b8edc6fcbaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0bbc3aa9-efae-45fe-b0e4-11431c9c6399" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_58652f04-5d5d-4561-b145-b8edc6fcbaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_534308c3-d5d4-4292-9fd9-dd873f8a0b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0bbc3aa9-efae-45fe-b0e4-11431c9c6399" xlink:to="loc_us-gaap_CommonStockSharesIssued_534308c3-d5d4-4292-9fd9-dd873f8a0b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_11bbea8f-95b0-4238-b8d4-b1526f1a1e47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0bbc3aa9-efae-45fe-b0e4-11431c9c6399" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_11bbea8f-95b0-4238-b8d4-b1526f1a1e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_0b04b77a-2701-471b-bced-46713afe4707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0bbc3aa9-efae-45fe-b0e4-11431c9c6399" xlink:to="loc_us-gaap_TreasuryStockCommonShares_0b04b77a-2701-471b-bced-46713afe4707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lsta-20250331.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4e4c2aa4-9c5d-4c3c-85a4-a58802dde98c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d17a9bbd-1f8c-491b-9630-7184559ba27a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e4c2aa4-9c5d-4c3c-85a4-a58802dde98c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d17a9bbd-1f8c-491b-9630-7184559ba27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_547271ca-cf3a-45c5-946c-392ac70db51a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d17a9bbd-1f8c-491b-9630-7184559ba27a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_547271ca-cf3a-45c5-946c-392ac70db51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4bf32b92-ca9b-45f5-9d01-3705c5147440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d17a9bbd-1f8c-491b-9630-7184559ba27a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4bf32b92-ca9b-45f5-9d01-3705c5147440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_35547aae-759f-4b93-ad4b-ec0532cf0a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d17a9bbd-1f8c-491b-9630-7184559ba27a" xlink:to="loc_us-gaap_OperatingExpenses_35547aae-759f-4b93-ad4b-ec0532cf0a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9533daa4-7ea7-456f-a9f4-85bf22645297" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e4c2aa4-9c5d-4c3c-85a4-a58802dde98c" xlink:to="loc_us-gaap_OperatingIncomeLoss_9533daa4-7ea7-456f-a9f4-85bf22645297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_22c639b5-12b8-44b2-860f-be30d9f83b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e4c2aa4-9c5d-4c3c-85a4-a58802dde98c" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_22c639b5-12b8-44b2-860f-be30d9f83b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_e7b3f124-abcf-4962-afa3-6caac0936f86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_22c639b5-12b8-44b2-860f-be30d9f83b8f" xlink:to="loc_us-gaap_InvestmentIncomeNet_e7b3f124-abcf-4962-afa3-6caac0936f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fd6799b3-7ff2-4ded-943c-0392951afa77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_22c639b5-12b8-44b2-860f-be30d9f83b8f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fd6799b3-7ff2-4ded-943c-0392951afa77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_dc45e76f-c675-4b32-b840-a9b71d42c8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_22c639b5-12b8-44b2-860f-be30d9f83b8f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_dc45e76f-c675-4b32-b840-a9b71d42c8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_140723cd-2712-4a54-b39a-1d258242b220" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e4c2aa4-9c5d-4c3c-85a4-a58802dde98c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_140723cd-2712-4a54-b39a-1d258242b220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1f45db1a-991b-4b2f-9e4b-7588e45aef76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e4c2aa4-9c5d-4c3c-85a4-a58802dde98c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1f45db1a-991b-4b2f-9e4b-7588e45aef76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8e7723c7-3387-40ee-af05-0dfaf95ee98c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e4c2aa4-9c5d-4c3c-85a4-a58802dde98c" xlink:to="loc_us-gaap_ProfitLoss_8e7723c7-3387-40ee-af05-0dfaf95ee98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_1cceacb4-dac7-4571-8917-1d6b21d3bd8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e4c2aa4-9c5d-4c3c-85a4-a58802dde98c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_1cceacb4-dac7-4571-8917-1d6b21d3bd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_de33faf6-281c-47e4-ad89-7d8e506b5095" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e4c2aa4-9c5d-4c3c-85a4-a58802dde98c" xlink:to="loc_us-gaap_NetIncomeLoss_de33faf6-281c-47e4-ad89-7d8e506b5095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_EPSAbstract_18993697-71fb-4ada-a799-54cb1be624f4" xlink:href="lsta-20250331.xsd#lsta_EPSAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e4c2aa4-9c5d-4c3c-85a4-a58802dde98c" xlink:to="loc_lsta_EPSAbstract_18993697-71fb-4ada-a799-54cb1be624f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_045dd52f-0062-4377-8d72-8534ec1b89ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_EPSAbstract_18993697-71fb-4ada-a799-54cb1be624f4" xlink:to="loc_us-gaap_EarningsPerShareBasic_045dd52f-0062-4377-8d72-8534ec1b89ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_15136a73-448b-4db1-ad62-9117ab181626" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_EPSAbstract_18993697-71fb-4ada-a799-54cb1be624f4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_15136a73-448b-4db1-ad62-9117ab181626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_39800025-02cb-4eb1-9f84-5967bfa43c77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e4c2aa4-9c5d-4c3c-85a4-a58802dde98c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_39800025-02cb-4eb1-9f84-5967bfa43c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e0cd077e-167b-46ab-8ecd-238289a23795" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_39800025-02cb-4eb1-9f84-5967bfa43c77" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e0cd077e-167b-46ab-8ecd-238289a23795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c536c7f3-5f4a-4ed3-ac8c-2789cb135ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_39800025-02cb-4eb1-9f84-5967bfa43c77" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c536c7f3-5f4a-4ed3-ac8c-2789cb135ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="lsta-20250331.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a1c12db8-5b75-4fce-83bf-a383fb72e8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8b9d6b60-ad48-48a5-be4f-fd31cd61c865" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a1c12db8-5b75-4fce-83bf-a383fb72e8eb" xlink:to="loc_us-gaap_ProfitLoss_8b9d6b60-ad48-48a5-be4f-fd31cd61c865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ce47cddc-c15a-460f-8c55-df93bc67d5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a1c12db8-5b75-4fce-83bf-a383fb72e8eb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ce47cddc-c15a-460f-8c55-df93bc67d5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b213b26f-dfb0-4188-8188-7854f976b32b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ce47cddc-c15a-460f-8c55-df93bc67d5e3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b213b26f-dfb0-4188-8188-7854f976b32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2b061078-5d28-47df-b8ed-09b49c327adc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ce47cddc-c15a-460f-8c55-df93bc67d5e3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2b061078-5d28-47df-b8ed-09b49c327adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4aa0d628-a011-4970-a6ed-8d92d691d8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ce47cddc-c15a-460f-8c55-df93bc67d5e3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4aa0d628-a011-4970-a6ed-8d92d691d8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_bcbaab04-8cc3-4558-bf49-d07cb3b77da9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a1c12db8-5b75-4fce-83bf-a383fb72e8eb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_bcbaab04-8cc3-4558-bf49-d07cb3b77da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="simple" xlink:href="lsta-20250331.xsd#CONSOLIDATEDSTATEMENTSOFEQUITY"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_79e6d5c9-ed1c-4a57-9b05-636bf9cd863a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9dee6fd3-cd5b-4248-a1fe-ea5719d012ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_79e6d5c9-ed1c-4a57-9b05-636bf9cd863a" xlink:to="loc_us-gaap_StatementTable_9dee6fd3-cd5b-4248-a1fe-ea5719d012ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_75816c61-66bb-4757-8185-816a1a5c0381" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9dee6fd3-cd5b-4248-a1fe-ea5719d012ab" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_75816c61-66bb-4757-8185-816a1a5c0381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3feccb0d-ebb8-4fff-9c85-35ab9cceb2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_75816c61-66bb-4757-8185-816a1a5c0381" xlink:to="loc_us-gaap_EquityComponentDomain_3feccb0d-ebb8-4fff-9c85-35ab9cceb2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_aaadbaad-9e97-4402-b6af-e7b14168c726" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3feccb0d-ebb8-4fff-9c85-35ab9cceb2d0" xlink:to="loc_us-gaap_ParentMember_aaadbaad-9e97-4402-b6af-e7b14168c726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f9a4a9f3-a6c0-4314-b3fc-977be06b03db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_aaadbaad-9e97-4402-b6af-e7b14168c726" xlink:to="loc_us-gaap_CommonStockMember_f9a4a9f3-a6c0-4314-b3fc-977be06b03db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e021448f-7e86-4b3b-86dc-9e51a7a84952" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_aaadbaad-9e97-4402-b6af-e7b14168c726" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e021448f-7e86-4b3b-86dc-9e51a7a84952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ec9fc527-6898-4b2d-8230-ea4c2aeed3af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_aaadbaad-9e97-4402-b6af-e7b14168c726" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ec9fc527-6898-4b2d-8230-ea4c2aeed3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_48230cab-810f-406e-a342-b5a3cac3c420" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_aaadbaad-9e97-4402-b6af-e7b14168c726" xlink:to="loc_us-gaap_RetainedEarningsMember_48230cab-810f-406e-a342-b5a3cac3c420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_c689d23a-9113-4ea7-aad4-87a995ce0251" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_aaadbaad-9e97-4402-b6af-e7b14168c726" xlink:to="loc_us-gaap_TreasuryStockCommonMember_c689d23a-9113-4ea7-aad4-87a995ce0251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9e864e64-734b-4a1f-873d-9978e3bfff31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3feccb0d-ebb8-4fff-9c85-35ab9cceb2d0" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9e864e64-734b-4a1f-873d-9978e3bfff31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0a0b7c34-1508-47da-b718-6d87664d0180" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9dee6fd3-cd5b-4248-a1fe-ea5719d012ab" xlink:to="loc_us-gaap_StatementLineItems_0a0b7c34-1508-47da-b718-6d87664d0180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0a0b7c34-1508-47da-b718-6d87664d0180" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d91034c4-c6df-42fc-9997-dcc62da137c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d91034c4-c6df-42fc-9997-dcc62da137c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e4477ccf-6c07-4734-9563-479304351b42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e4477ccf-6c07-4734-9563-479304351b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_97bbdb76-ec5b-497f-b6a0-e8d692f3c1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_ProfitLoss_97bbdb76-ec5b-497f-b6a0-e8d692f3c1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a02b5db3-b5b0-4e4b-bcc7-def94c810de7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a02b5db3-b5b0-4e4b-bcc7-def94c810de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f200cad3-c6b3-43e8-8c91-d9506103a948" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f200cad3-c6b3-43e8-8c91-d9506103a948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dc57bff4-61b9-4a1d-934f-b0dcff0101aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dc57bff4-61b9-4a1d-934f-b0dcff0101aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_25764e1d-8445-4620-8968-95b63d450e47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_25764e1d-8445-4620-8968-95b63d450e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5cd8c1f5-cc09-4f0d-80f6-f2c60774a95e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5cd8c1f5-cc09-4f0d-80f6-f2c60774a95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_119cee07-17d8-4597-87df-65f99b726372" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_119cee07-17d8-4597-87df-65f99b726372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a3277ce7-d2c7-40db-939d-45efd9be716d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a3277ce7-d2c7-40db-939d-45efd9be716d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_85742c80-3887-42ae-b55f-b21c81a4c994" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_85742c80-3887-42ae-b55f-b21c81a4c994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ec9ce2eb-7624-405f-9ae2-bfd0b7da19cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ec9ce2eb-7624-405f-9ae2-bfd0b7da19cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3201f76f-40d4-4e9b-bab9-5f6c00e61c03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d38264d3-dbf7-403a-b78a-10df6e3a035c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3201f76f-40d4-4e9b-bab9-5f6c00e61c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lsta-20250331.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f290716e-8f4f-449b-a652-0a851ae9bdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_476fe97d-dd17-4473-bd86-574900c8ecc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f290716e-8f4f-449b-a652-0a851ae9bdc5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_476fe97d-dd17-4473-bd86-574900c8ecc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6b9562b3-a63b-4fe3-a359-8c91ec5dfa7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_476fe97d-dd17-4473-bd86-574900c8ecc7" xlink:to="loc_us-gaap_ProfitLoss_6b9562b3-a63b-4fe3-a359-8c91ec5dfa7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78204660-dfb2-443c-a9cb-c209f4828448" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_476fe97d-dd17-4473-bd86-574900c8ecc7" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78204660-dfb2-443c-a9cb-c209f4828448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_d5ea5b13-6f8a-4232-90d2-b65f9abe68d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78204660-dfb2-443c-a9cb-c209f4828448" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_d5ea5b13-6f8a-4232-90d2-b65f9abe68d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_ed7265e3-069f-4859-8298-08d92ab5606c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78204660-dfb2-443c-a9cb-c209f4828448" xlink:to="loc_us-gaap_DepreciationAndAmortization_ed7265e3-069f-4859-8298-08d92ab5606c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6d0a743a-e7fe-4aef-bebe-15f392a3f50e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78204660-dfb2-443c-a9cb-c209f4828448" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6d0a743a-e7fe-4aef-bebe-15f392a3f50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d71a37ba-9c8a-433f-8d0d-39f701b73b36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78204660-dfb2-443c-a9cb-c209f4828448" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d71a37ba-9c8a-433f-8d0d-39f701b73b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_86a55475-e331-4ee7-98ab-0c410751f640" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_78204660-dfb2-443c-a9cb-c209f4828448" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_86a55475-e331-4ee7-98ab-0c410751f640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_50841d71-85d3-4449-8420-6f5d2fdef14e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_86a55475-e331-4ee7-98ab-0c410751f640" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_50841d71-85d3-4449-8420-6f5d2fdef14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7f2bbd4e-67e9-465d-ae14-a43987a3e750" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_86a55475-e331-4ee7-98ab-0c410751f640" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7f2bbd4e-67e9-465d-ae14-a43987a3e750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_30147604-99cf-4d0c-8b18-7652f20b9d40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_86a55475-e331-4ee7-98ab-0c410751f640" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_30147604-99cf-4d0c-8b18-7652f20b9d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_b54a0f4e-136e-4a89-aeb7-492800900128" xlink:href="lsta-20250331.xsd#lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_86a55475-e331-4ee7-98ab-0c410751f640" xlink:to="loc_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_b54a0f4e-136e-4a89-aeb7-492800900128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f45d6c04-ec39-410b-8871-01c336a190bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_476fe97d-dd17-4473-bd86-574900c8ecc7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f45d6c04-ec39-410b-8871-01c336a190bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ae796a21-4978-4487-ae11-530dd4aa560a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f290716e-8f4f-449b-a652-0a851ae9bdc5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ae796a21-4978-4487-ae11-530dd4aa560a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_7e533ba6-71d1-4021-aae5-759a49318561" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ae796a21-4978-4487-ae11-530dd4aa560a" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_7e533ba6-71d1-4021-aae5-759a49318561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_895729d7-e6a8-49c8-be90-0330ecf15d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ae796a21-4978-4487-ae11-530dd4aa560a" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_895729d7-e6a8-49c8-be90-0330ecf15d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_850ed98b-f38f-481c-8de6-880526667b50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ae796a21-4978-4487-ae11-530dd4aa560a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_850ed98b-f38f-481c-8de6-880526667b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7664fa3b-44f0-41d1-8db2-b3da069cb950" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ae796a21-4978-4487-ae11-530dd4aa560a" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7664fa3b-44f0-41d1-8db2-b3da069cb950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_278be18b-35ca-44aa-a97a-702ca308f33d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ae796a21-4978-4487-ae11-530dd4aa560a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_278be18b-35ca-44aa-a97a-702ca308f33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_83fbb2ef-b09f-4fad-b36d-b7a7cf374bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f290716e-8f4f-449b-a652-0a851ae9bdc5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_83fbb2ef-b09f-4fad-b36d-b7a7cf374bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_854673f9-4301-483b-bd2e-fdf7a4fc8e53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_83fbb2ef-b09f-4fad-b36d-b7a7cf374bb1" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_854673f9-4301-483b-bd2e-fdf7a4fc8e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b724a327-a587-476d-81da-e04f3c2513b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_83fbb2ef-b09f-4fad-b36d-b7a7cf374bb1" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b724a327-a587-476d-81da-e04f3c2513b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_05763e3d-6d5a-47e9-83cb-d7def803a0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_83fbb2ef-b09f-4fad-b36d-b7a7cf374bb1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_05763e3d-6d5a-47e9-83cb-d7def803a0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3fd355ff-da94-4860-a282-269a202d7a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_83fbb2ef-b09f-4fad-b36d-b7a7cf374bb1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3fd355ff-da94-4860-a282-269a202d7a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52d523fe-8ac7-412c-b8a2-e9d5894b2a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f290716e-8f4f-449b-a652-0a851ae9bdc5" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52d523fe-8ac7-412c-b8a2-e9d5894b2a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8763170a-162b-46ac-880b-192eff6877d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f290716e-8f4f-449b-a652-0a851ae9bdc5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8763170a-162b-46ac-880b-192eff6877d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_462989b1-281b-44dd-b848-3eb3b825012e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f290716e-8f4f-449b-a652-0a851ae9bdc5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_462989b1-281b-44dd-b848-3eb3b825012e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c9c120a5-8af7-438c-b831-a6350fad36fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f290716e-8f4f-449b-a652-0a851ae9bdc5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c9c120a5-8af7-438c-b831-a6350fad36fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="lsta-20250331.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a8b6199c-4da7-40d9-bc4d-379b55b4d100" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6aa5695e-bd49-4263-a9c9-913cbd84221c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a8b6199c-4da7-40d9-bc4d-379b55b4d100" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6aa5695e-bd49-4263-a9c9-913cbd84221c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lsta-20250331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_708d3a61-6485-4a99-8474-a538e7fc56bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_97252bdf-c336-4bb3-a9a3-40d7a7ce357d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_708d3a61-6485-4a99-8474-a538e7fc56bb" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_97252bdf-c336-4bb3-a9a3-40d7a7ce357d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecurities" xlink:type="simple" xlink:href="lsta-20250331.xsd#AvailableforSaleSecurities"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_da6ae23f-a0f4-4a98-a26f-8feedbfecdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_67b719ef-302d-4c50-96fa-7df053f6885f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_da6ae23f-a0f4-4a98-a26f-8feedbfecdcd" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_67b719ef-302d-4c50-96fa-7df053f6885f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="lsta-20250331.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_91f06008-1ea8-4b44-8336-4ba76fb4f019" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_d3559b32-bf95-4b53-8a49-94181defe386" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_91f06008-1ea8-4b44-8336-4ba76fb4f019" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_d3559b32-bf95-4b53-8a49-94181defe386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShare" xlink:type="simple" xlink:href="lsta-20250331.xsd#IncomeLossPerShare"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fd798f5f-47bf-4785-9a46-1eda5e3d62eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_9753e410-2d02-4534-8f4b-b03524df29eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fd798f5f-47bf-4785-9a46-1eda5e3d62eb" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_9753e410-2d02-4534-8f4b-b03524df29eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lsta-20250331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_71ecd4c4-8c85-4586-bf16-8769ceb44a05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_c4cd96d4-8e71-4291-a43f-2965388d403d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_71ecd4c4-8c85-4586-bf16-8769ceb44a05" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_c4cd96d4-8e71-4291-a43f-2965388d403d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="lsta-20250331.xsd#AccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_c2e60d2f-5fe4-4d95-a88c-34f63751929d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_56695f12-bc4a-448b-8651-d11e8bd8f561" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_c2e60d2f-5fe4-4d95-a88c-34f63751929d" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_56695f12-bc4a-448b-8651-d11e8bd8f561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeases" xlink:type="simple" xlink:href="lsta-20250331.xsd#OperatingLeases"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2c1dce68-8811-45ad-8180-a50ecf2bdbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_b5a3c0fe-0cf0-4c3c-9ba1-af1b3237229c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2c1dce68-8811-45ad-8180-a50ecf2bdbc9" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_b5a3c0fe-0cf0-4c3c-9ba1-af1b3237229c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquity" xlink:type="simple" xlink:href="lsta-20250331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4af749eb-5047-4d5f-b005-c484d7545988" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8b37b9eb-177e-4ca2-9c8e-f07222c4f06a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4af749eb-5047-4d5f-b005-c484d7545988" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8b37b9eb-177e-4ca2-9c8e-f07222c4f06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="lsta-20250331.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c0e1abb5-07d6-4a3d-b16c-96d2a208d7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8a8d0a30-af10-444f-98fd-04618a210dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c0e1abb5-07d6-4a3d-b16c-96d2a208d7cb" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8a8d0a30-af10-444f-98fd-04618a210dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lsta-20250331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e0e38059-ad8d-45ae-86a7-1e2f83cab240" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a52721c3-d734-4aec-bbbf-48e30188370c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0e38059-ad8d-45ae-86a7-1e2f83cab240" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a52721c3-d734-4aec-bbbf-48e30188370c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SegmentInformation" xlink:type="simple" xlink:href="lsta-20250331.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7e62ef40-997f-4942-8465-69f1642b3368" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_7b7c6141-b605-4c8d-9010-556f45dca22c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7e62ef40-997f-4942-8465-69f1642b3368" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_7b7c6141-b605-4c8d-9010-556f45dca22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive" xlink:type="simple" xlink:href="lsta-20250331.xsd#AustraliaResearchandDevelopmentTaxIncentive"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8d9c2366-e8af-4fb2-9799-ee355dab9c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock_e714c14c-65b7-452d-b883-45f21be71486" xlink:href="lsta-20250331.xsd#lsta_ResearchAndDevelopmentTaxIncentiveTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8d9c2366-e8af-4fb2-9799-ee355dab9c0f" xlink:to="loc_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock_e714c14c-65b7-452d-b883-45f21be71486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/Contingencies" xlink:type="simple" xlink:href="lsta-20250331.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5932890d-2322-42a9-96f1-85e57c1b8830" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_cf1c1598-a935-4ee3-822c-f3f9cc337445" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5932890d-2322-42a9-96f1-85e57c1b8830" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_cf1c1598-a935-4ee3-822c-f3f9cc337445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TechnologyTransferAgreement" xlink:type="simple" xlink:href="lsta-20250331.xsd#TechnologyTransferAgreement"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/TechnologyTransferAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lsta_TechnologyTransferAgreementAbstract_819017ad-410d-4bff-ad78-ad71217a7e4a" xlink:href="lsta-20250331.xsd#lsta_TechnologyTransferAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_TechnologyTransferAgreementTextBlock_c93d3690-351c-4792-adad-c714cfa7d97e" xlink:href="lsta-20250331.xsd#lsta_TechnologyTransferAgreementTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_TechnologyTransferAgreementAbstract_819017ad-410d-4bff-ad78-ad71217a7e4a" xlink:to="loc_lsta_TechnologyTransferAgreementTextBlock_c93d3690-351c-4792-adad-c714cfa7d97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/LicenseAgreements" xlink:type="simple" xlink:href="lsta-20250331.xsd#LicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/LicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b5f64054-ff2e-4bad-b8fd-8fbea1b3e60b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_69229422-c96f-4ee0-9e4d-1d31073edf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b5f64054-ff2e-4bad-b8fd-8fbea1b3e60b" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_69229422-c96f-4ee0-9e4d-1d31073edf9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement" xlink:type="simple" xlink:href="lsta-20250331.xsd#ResearchCollaborationandLicenseAgreement"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0723fa1-3caf-4996-b9fe-0bb80df7ffaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5e5389d1-1637-4939-b233-eedaeb08bd41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0723fa1-3caf-4996-b9fe-0bb80df7ffaf" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5e5389d1-1637-4939-b233-eedaeb08bd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lsta-20250331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7eea8ce8-c3b3-4844-a289-eb6dc141240e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7eea8ce8-c3b3-4844-a289-eb6dc141240e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_55fb3d34-1f77-467c-8249-e1111c10ac6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:to="loc_us-gaap_UseOfEstimates_55fb3d34-1f77-467c-8249-e1111c10ac6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_016d2acf-1e38-4000-8fd6-b0743216eca4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_016d2acf-1e38-4000-8fd6-b0743216eca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_63b36782-9d47-430c-9ca3-c68fb2e427f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_63b36782-9d47-430c-9ca3-c68fb2e427f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_d9d08976-1b69-4c3b-8a84-b4e81190eec8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_d9d08976-1b69-4c3b-8a84-b4e81190eec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e08e2ec2-a95c-4e58-8e97-723df07006f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e08e2ec2-a95c-4e58-8e97-723df07006f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_ff0c15ac-5dd0-42f0-be71-2aa42ad157cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_ff0c15ac-5dd0-42f0-be71-2aa42ad157cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1faecfe7-9ac1-4363-b18d-5e3477aa0457" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1faecfe7-9ac1-4363-b18d-5e3477aa0457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_0d5c5801-ed01-4fab-be5b-f7426de12a28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_0d5c5801-ed01-4fab-be5b-f7426de12a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0400adc4-2e1a-4707-8312-dac6b4a31991" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0400adc4-2e1a-4707-8312-dac6b4a31991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment_0673acbf-3282-4f34-9dc7-c00806919aae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentImpairment_0673acbf-3282-4f34-9dc7-c00806919aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3ee651f9-87af-4257-91e9-d7231b5d9886" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3ee651f9-87af-4257-91e9-d7231b5d9886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_a47e90cc-3de8-459b-a4f2-647078008b24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_a47e90cc-3de8-459b-a4f2-647078008b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_c5816682-e6db-4836-8f02-d2d51cf44983" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_c5816682-e6db-4836-8f02-d2d51cf44983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_f0aac36e-a469-4e0a-9954-15534e5509c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_f0aac36e-a469-4e0a-9954-15534e5509c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_a2e9ee60-b5d3-4318-aad1-3198112b0282" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_a2e9ee60-b5d3-4318-aad1-3198112b0282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_cab68f20-3185-44d9-b73a-b7c61243f5be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_cab68f20-3185-44d9-b73a-b7c61243f5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_7a711cac-1ad3-419e-b2d5-d69bc18b6c06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_7a711cac-1ad3-419e-b2d5-d69bc18b6c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_ff94315e-d031-46e8-bd2c-c8a0b5778cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_ff94315e-d031-46e8-bd2c-c8a0b5778cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_c3189856-64f8-4cd6-9541-5299fc02d4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c204819-ac74-4fe3-a995-63bdfe5bbe81" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_c3189856-64f8-4cd6-9541-5299fc02d4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lsta-20250331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_97777d49-3dd6-4369-b2a1-0f2a15d45a13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_c3e2a89c-1412-4754-9a84-79053e8e57be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97777d49-3dd6-4369-b2a1-0f2a15d45a13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_c3e2a89c-1412-4754-9a84-79053e8e57be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" xlink:type="simple" xlink:href="lsta-20250331.xsd#AvailableforSaleSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e7b9b209-d019-41d3-812a-83ec09e13f68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_53ad4ffe-7ad7-4f56-941d-b4864198aaab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e7b9b209-d019-41d3-812a-83ec09e13f68" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_53ad4ffe-7ad7-4f56-941d-b4864198aaab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_40280b9f-647a-44ba-8e12-b47ee7d6e9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e7b9b209-d019-41d3-812a-83ec09e13f68" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_40280b9f-647a-44ba-8e12-b47ee7d6e9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_eb84d6b6-d32a-4ae4-ad74-624e29b47843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e7b9b209-d019-41d3-812a-83ec09e13f68" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_eb84d6b6-d32a-4ae4-ad74-624e29b47843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="lsta-20250331.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d3ec8af7-ced1-4243-a603-716294cf3dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_85f1ef3e-0e62-40e7-a128-aa06a02846d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d3ec8af7-ced1-4243-a603-716294cf3dd0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_85f1ef3e-0e62-40e7-a128-aa06a02846d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareTables" xlink:type="simple" xlink:href="lsta-20250331.xsd#IncomeLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8dbb113b-fb3b-4457-b429-60a85eebc57a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7c52bd90-fa30-4530-a665-476abc805d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8dbb113b-fb3b-4457-b429-60a85eebc57a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7c52bd90-fa30-4530-a665-476abc805d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lsta-20250331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c4b1a3e3-5667-48dc-bc0c-b4d2d13ba974" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9512536f-0e87-4d5a-bab8-909aad46edfe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c4b1a3e3-5667-48dc-bc0c-b4d2d13ba974" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9512536f-0e87-4d5a-bab8-909aad46edfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="lsta-20250331.xsd#AccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_12ef36b9-b1fa-4059-9c0f-494c8a83f44b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_79ab121b-bf4d-4bae-bbe9-d8daf591b829" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_12ef36b9-b1fa-4059-9c0f-494c8a83f44b" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_79ab121b-bf4d-4bae-bbe9-d8daf591b829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesTables" xlink:type="simple" xlink:href="lsta-20250331.xsd#OperatingLeasesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_925942df-cbad-461e-96df-5efae75ac9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_78045530-ccec-4da2-a0ae-be5779dc53a1" xlink:href="lsta-20250331.xsd#lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_925942df-cbad-461e-96df-5efae75ac9ed" xlink:to="loc_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_78045530-ccec-4da2-a0ae-be5779dc53a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_187ff416-1cea-4693-a12a-e63028027af4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_925942df-cbad-461e-96df-5efae75ac9ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_187ff416-1cea-4693-a12a-e63028027af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="lsta-20250331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_026ee118-7634-4f79-b50b-2764a151d6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ae57e172-3a55-488a-ace1-f40e8ea50550" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_026ee118-7634-4f79-b50b-2764a151d6ce" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ae57e172-3a55-488a-ace1-f40e8ea50550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_a2f978ab-5fa6-435f-92b0-32fb3a4aef81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_026ee118-7634-4f79-b50b-2764a151d6ce" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_a2f978ab-5fa6-435f-92b0-32fb3a4aef81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_6a9e761c-0ee1-4b3c-938b-4ece8d5de6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_026ee118-7634-4f79-b50b-2764a151d6ce" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_6a9e761c-0ee1-4b3c-938b-4ece8d5de6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="lsta-20250331.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2d77b6ef-4f18-4ac8-90bd-0f32d881adf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_70f6a751-2c99-4cf7-afb8-0f7d6d646ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2d77b6ef-4f18-4ac8-90bd-0f32d881adf8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_70f6a751-2c99-4cf7-afb8-0f7d6d646ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_c731fab9-d1b0-469b-aa4f-6a647b8e42e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2d77b6ef-4f18-4ac8-90bd-0f32d881adf8" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_c731fab9-d1b0-469b-aa4f-6a647b8e42e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_49d5db8d-f87c-48ed-9a2f-245fc168520a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2d77b6ef-4f18-4ac8-90bd-0f32d881adf8" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_49d5db8d-f87c-48ed-9a2f-245fc168520a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="lsta-20250331.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_cbdbcee1-aef2-4434-8bc2-9e45b034ebbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_29f2e9e2-abe5-497a-a149-62949538bb76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbdbcee1-aef2-4434-8bc2-9e45b034ebbe" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_29f2e9e2-abe5-497a-a149-62949538bb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a2770863-5205-40dd-aba0-ce6ff2d0abf2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CashAndCashEquivalentsAndMarketableSecurities_d3ec8d3b-3a5e-4620-83e4-52c73e9f0b51" xlink:href="lsta-20250331.xsd#lsta_CashAndCashEquivalentsAndMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a2770863-5205-40dd-aba0-ce6ff2d0abf2" xlink:to="loc_lsta_CashAndCashEquivalentsAndMarketableSecurities_d3ec8d3b-3a5e-4620-83e4-52c73e9f0b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_f6611509-8395-4eb0-a9e2-2a808e800136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a2770863-5205-40dd-aba0-ce6ff2d0abf2" xlink:to="loc_us-gaap_NumberOfOperatingSegments_f6611509-8395-4eb0-a9e2-2a808e800136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_014c4f52-a3f3-41a1-a706-e6b1a9229d06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_159a11d6-c4d3-4c17-a6ef-92c8b44b2f71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_014c4f52-a3f3-41a1-a706-e6b1a9229d06" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_159a11d6-c4d3-4c17-a6ef-92c8b44b2f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9252907-e4cb-427e-b347-2cf919f8ed15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_159a11d6-c4d3-4c17-a6ef-92c8b44b2f71" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9252907-e4cb-427e-b347-2cf919f8ed15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82043226-3bb9-4cec-b065-c374d4364112" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c9252907-e4cb-427e-b347-2cf919f8ed15" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82043226-3bb9-4cec-b065-c374d4364112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_a7869b06-79cc-4e42-9b2b-ae2af06ca990" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82043226-3bb9-4cec-b065-c374d4364112" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_a7869b06-79cc-4e42-9b2b-ae2af06ca990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_af63c9e4-8ce9-4079-9985-227605fd813f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82043226-3bb9-4cec-b065-c374d4364112" xlink:to="loc_us-gaap_ComputerEquipmentMember_af63c9e4-8ce9-4079-9985-227605fd813f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_be6d294f-50eb-4367-8646-383561e10d63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82043226-3bb9-4cec-b065-c374d4364112" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_be6d294f-50eb-4367-8646-383561e10d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6bf7f0d4-70ba-4ae3-a38c-1a5f784be173" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_159a11d6-c4d3-4c17-a6ef-92c8b44b2f71" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6bf7f0d4-70ba-4ae3-a38c-1a5f784be173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4a977714-4847-4ebe-9910-38ce0bf21148" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6bf7f0d4-70ba-4ae3-a38c-1a5f784be173" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4a977714-4847-4ebe-9910-38ce0bf21148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7028f21f-ddab-4f1f-aaec-018f51ec81a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_2a9315e8-c331-48a4-ae37-90ddcd1b9f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7028f21f-ddab-4f1f-aaec-018f51ec81a0" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_2a9315e8-c331-48a4-ae37-90ddcd1b9f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b5bf2965-edcf-48e8-b85f-be8789c74b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7028f21f-ddab-4f1f-aaec-018f51ec81a0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b5bf2965-edcf-48e8-b85f-be8789c74b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1d52af0f-40b8-48d6-8868-a724b6e55977" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7028f21f-ddab-4f1f-aaec-018f51ec81a0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1d52af0f-40b8-48d6-8868-a724b6e55977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4cc8748d-ab35-4f15-bd1a-1047857dbdb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7028f21f-ddab-4f1f-aaec-018f51ec81a0" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4cc8748d-ab35-4f15-bd1a-1047857dbdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7d46e55c-bd22-4932-a03e-eef07e139fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7028f21f-ddab-4f1f-aaec-018f51ec81a0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7d46e55c-bd22-4932-a03e-eef07e139fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e1811f3c-8732-4aba-8da5-d8ee74f26673" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7028f21f-ddab-4f1f-aaec-018f51ec81a0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e1811f3c-8732-4aba-8da5-d8ee74f26673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_54d58d47-a378-42d7-829c-d35aef212b32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7028f21f-ddab-4f1f-aaec-018f51ec81a0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_54d58d47-a378-42d7-829c-d35aef212b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_100569ce-ab27-4f01-b1d4-16eb828d3ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7028f21f-ddab-4f1f-aaec-018f51ec81a0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_100569ce-ab27-4f01-b1d4-16eb828d3ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_a7e4b593-b7a5-4bfd-bf41-8174381af9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7028f21f-ddab-4f1f-aaec-018f51ec81a0" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_a7e4b593-b7a5-4bfd-bf41-8174381af9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1ec0ec2e-822f-4642-b3e5-b8a02dead588" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7028f21f-ddab-4f1f-aaec-018f51ec81a0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1ec0ec2e-822f-4642-b3e5-b8a02dead588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e7a56710-a7d2-4ac1-aef1-d607d88ceae4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1ec0ec2e-822f-4642-b3e5-b8a02dead588" xlink:to="loc_srt_ProductOrServiceAxis_e7a56710-a7d2-4ac1-aef1-d607d88ceae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_16d29940-1c59-4f97-84ba-3a279b7aa4ed" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e7a56710-a7d2-4ac1-aef1-d607d88ceae4" xlink:to="loc_srt_ProductsAndServicesDomain_16d29940-1c59-4f97-84ba-3a279b7aa4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_00bed213-5e3c-41b4-84cf-fcade785370a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_16d29940-1c59-4f97-84ba-3a279b7aa4ed" xlink:to="loc_us-gaap_RoyaltyMember_00bed213-5e3c-41b4-84cf-fcade785370a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d6e6e38f-da1f-41e9-a186-38688de7f5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1ec0ec2e-822f-4642-b3e5-b8a02dead588" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_d6e6e38f-da1f-41e9-a186-38688de7f5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_983fbed3-5ca7-41ed-a79a-7728eb658e84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d6e6e38f-da1f-41e9-a186-38688de7f5d9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_983fbed3-5ca7-41ed-a79a-7728eb658e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_dc77568f-bca8-4409-99f2-fd919fb1ea30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a1f4f6a-d3ee-4b8e-80a8-269c1c86a70e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_dc77568f-bca8-4409-99f2-fd919fb1ea30" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a1f4f6a-d3ee-4b8e-80a8-269c1c86a70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_18865e8d-2e1c-4b01-a0a6-4a8f6a7f4355" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a1f4f6a-d3ee-4b8e-80a8-269c1c86a70e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_18865e8d-2e1c-4b01-a0a6-4a8f6a7f4355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cab9c07a-42c5-48fd-9ef4-7bc36397a080" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_18865e8d-2e1c-4b01-a0a6-4a8f6a7f4355" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cab9c07a-42c5-48fd-9ef4-7bc36397a080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ebc6ea41-4def-417f-bcac-ced86642df22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cab9c07a-42c5-48fd-9ef4-7bc36397a080" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ebc6ea41-4def-417f-bcac-ced86642df22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7c084f9b-4b2b-4188-ad43-92e3bc01b80c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cab9c07a-42c5-48fd-9ef4-7bc36397a080" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7c084f9b-4b2b-4188-ad43-92e3bc01b80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BondsMember_b4c5c62e-d8b4-45e4-9bfd-a94f62578990" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cab9c07a-42c5-48fd-9ef4-7bc36397a080" xlink:to="loc_us-gaap_BondsMember_b4c5c62e-d8b4-45e4-9bfd-a94f62578990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_7e9ccaf5-8939-4948-9976-bbbc6031f590" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cab9c07a-42c5-48fd-9ef4-7bc36397a080" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_7e9ccaf5-8939-4948-9976-bbbc6031f590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_ccaf28f3-9f1b-4ddc-b819-2993c3236c28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cab9c07a-42c5-48fd-9ef4-7bc36397a080" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_ccaf28f3-9f1b-4ddc-b819-2993c3236c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_08d64e95-eb45-479b-b37f-20672cdb3800" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a1f4f6a-d3ee-4b8e-80a8-269c1c86a70e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_08d64e95-eb45-479b-b37f-20672cdb3800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bd084478-3e95-4cdb-9f93-22cb2240e7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_08d64e95-eb45-479b-b37f-20672cdb3800" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bd084478-3e95-4cdb-9f93-22cb2240e7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_668f4d93-1c28-4711-b1c3-20af5a6d7678" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_08d64e95-eb45-479b-b37f-20672cdb3800" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_668f4d93-1c28-4711-b1c3-20af5a6d7678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e883bbc9-a5d0-4527-adb5-b7264fac5f75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_08d64e95-eb45-479b-b37f-20672cdb3800" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e883bbc9-a5d0-4527-adb5-b7264fac5f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ba15a825-69ab-4ec5-a2dc-cf9e8e7a29f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_08d64e95-eb45-479b-b37f-20672cdb3800" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ba15a825-69ab-4ec5-a2dc-cf9e8e7a29f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofClassificationofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#AvailableforSaleSecuritiesScheduleofClassificationofAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofClassificationofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_db88d8a3-287f-4ddb-82c1-c1ef1aa319b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_7ba3f064-1921-4bce-a34a-a745fc1831bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_db88d8a3-287f-4ddb-82c1-c1ef1aa319b7" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_7ba3f064-1921-4bce-a34a-a745fc1831bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_5b1f5b16-58da-4a19-b25a-9edba538319c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_db88d8a3-287f-4ddb-82c1-c1ef1aa319b7" xlink:to="loc_us-gaap_MarketableSecurities_5b1f5b16-58da-4a19-b25a-9edba538319c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_490cd4f1-ccd6-461d-8e8c-219c0305cd41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_db88d8a3-287f-4ddb-82c1-c1ef1aa319b7" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_490cd4f1-ccd6-461d-8e8c-219c0305cd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_36e69858-25d2-4c8b-8e41-d027baaf8c54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_2fd2e08e-5c04-45bf-bf86-43892df9b65d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_36e69858-25d2-4c8b-8e41-d027baaf8c54" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_2fd2e08e-5c04-45bf-bf86-43892df9b65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_3a4d24a4-124a-4ca0-98c4-cbb843751281" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_2fd2e08e-5c04-45bf-bf86-43892df9b65d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_3a4d24a4-124a-4ca0-98c4-cbb843751281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_fb8837c5-23bd-4959-8d84-d5e176ea7c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_2fd2e08e-5c04-45bf-bf86-43892df9b65d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_fb8837c5-23bd-4959-8d84-d5e176ea7c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ab92527b-0dee-47b7-9bb8-2455500d798f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_2fd2e08e-5c04-45bf-bf86-43892df9b65d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ab92527b-0dee-47b7-9bb8-2455500d798f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8557784b-53af-4a40-972b-1995638eb595" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_36e69858-25d2-4c8b-8e41-d027baaf8c54" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8557784b-53af-4a40-972b-1995638eb595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_4c6a278a-e125-4cbc-bc52-eb59b21dc1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8557784b-53af-4a40-972b-1995638eb595" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_4c6a278a-e125-4cbc-bc52-eb59b21dc1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_56542823-f5ff-4481-b8d3-a63992cac1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8557784b-53af-4a40-972b-1995638eb595" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_56542823-f5ff-4481-b8d3-a63992cac1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_267176f3-69ef-4151-b56f-92d03cc4c233" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8557784b-53af-4a40-972b-1995638eb595" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_267176f3-69ef-4151-b56f-92d03cc4c233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_36fa143b-6224-4a46-959f-29779e0b7c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_589e837a-2dcc-4556-bbfe-946d4d11dd10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_36fa143b-6224-4a46-959f-29779e0b7c8f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_589e837a-2dcc-4556-bbfe-946d4d11dd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_98a190bf-584f-4ce6-a8ca-b32c0f8c4712" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_589e837a-2dcc-4556-bbfe-946d4d11dd10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_98a190bf-584f-4ce6-a8ca-b32c0f8c4712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8df601a1-44a0-4982-b098-803445186ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_98a190bf-584f-4ce6-a8ca-b32c0f8c4712" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8df601a1-44a0-4982-b098-803445186ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_eb3b4219-2130-4e81-baef-ddf1a777b26c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8df601a1-44a0-4982-b098-803445186ea0" xlink:to="loc_us-gaap_ComputerEquipmentMember_eb3b4219-2130-4e81-baef-ddf1a777b26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_c349c284-b121-4ee3-a8af-d9d28a46c457" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8df601a1-44a0-4982-b098-803445186ea0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_c349c284-b121-4ee3-a8af-d9d28a46c457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0498588d-a3fc-4d88-b2ac-2d0eae1cf6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_589e837a-2dcc-4556-bbfe-946d4d11dd10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0498588d-a3fc-4d88-b2ac-2d0eae1cf6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3f732392-c5af-4957-b2fc-8b72c28e5861" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0498588d-a3fc-4d88-b2ac-2d0eae1cf6f7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_3f732392-c5af-4957-b2fc-8b72c28e5861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_597311fc-0eef-4275-98f8-0a008817c65b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0498588d-a3fc-4d88-b2ac-2d0eae1cf6f7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_597311fc-0eef-4275-98f8-0a008817c65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_841009f4-b222-4a1f-8ade-3d72586f1853" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0498588d-a3fc-4d88-b2ac-2d0eae1cf6f7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_841009f4-b222-4a1f-8ade-3d72586f1853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ad0f4be7-e8ee-4f32-9765-6e21265a5c36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0498588d-a3fc-4d88-b2ac-2d0eae1cf6f7" xlink:to="loc_us-gaap_Depreciation_ad0f4be7-e8ee-4f32-9765-6e21265a5c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#IncomeLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7095620a-0010-431c-b5cc-f2f3a0739b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6e2d1c67-265b-48d7-acfa-804db1dbfe24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7095620a-0010-431c-b5cc-f2f3a0739b7d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6e2d1c67-265b-48d7-acfa-804db1dbfe24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_40d6d9f8-f8eb-49c3-9128-b445e9a4a6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6e2d1c67-265b-48d7-acfa-804db1dbfe24" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_40d6d9f8-f8eb-49c3-9128-b445e9a4a6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5781632d-2af5-4505-8dcc-20fd9deb5d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_40d6d9f8-f8eb-49c3-9128-b445e9a4a6d1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5781632d-2af5-4505-8dcc-20fd9deb5d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9b3d18fe-298f-4977-a52d-c66f445e8bac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5781632d-2af5-4505-8dcc-20fd9deb5d9d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9b3d18fe-298f-4977-a52d-c66f445e8bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_a9f7bfca-fde0-4bbd-8c1b-36c0ce8fdf6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5781632d-2af5-4505-8dcc-20fd9deb5d9d" xlink:to="loc_us-gaap_WarrantMember_a9f7bfca-fde0-4bbd-8c1b-36c0ce8fdf6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_352fcd0f-f3f1-4890-80a3-fc1781fab068" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5781632d-2af5-4505-8dcc-20fd9deb5d9d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_352fcd0f-f3f1-4890-80a3-fc1781fab068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bda35d22-9a12-4805-8b92-8c87f6bc0ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6e2d1c67-265b-48d7-acfa-804db1dbfe24" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bda35d22-9a12-4805-8b92-8c87f6bc0ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a8b8f1ce-f1b9-4e75-99a7-e7e66b2d2544" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bda35d22-9a12-4805-8b92-8c87f6bc0ac0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a8b8f1ce-f1b9-4e75-99a7-e7e66b2d2544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_aac6eeca-9d40-443f-8da6-396e86f00bda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_789287d9-a769-46eb-a0e8-cccd3db3ed28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_aac6eeca-9d40-443f-8da6-396e86f00bda" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_789287d9-a769-46eb-a0e8-cccd3db3ed28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92c23db7-3ff1-4f38-a19c-880d91a10c48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_789287d9-a769-46eb-a0e8-cccd3db3ed28" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92c23db7-3ff1-4f38-a19c-880d91a10c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9333e0ce-fd16-4b93-9c34-81236ded031f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92c23db7-3ff1-4f38-a19c-880d91a10c48" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9333e0ce-fd16-4b93-9c34-81236ded031f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b68c1ec8-8c8a-434b-95bf-5d031af82ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9333e0ce-fd16-4b93-9c34-81236ded031f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b68c1ec8-8c8a-434b-95bf-5d031af82ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_88cadfa1-4380-43cf-8290-6e11f082c50a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9333e0ce-fd16-4b93-9c34-81236ded031f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_88cadfa1-4380-43cf-8290-6e11f082c50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c37f3be1-5067-428f-8ebd-71d943a9a765" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9333e0ce-fd16-4b93-9c34-81236ded031f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c37f3be1-5067-428f-8ebd-71d943a9a765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ffff19d6-35f4-4686-b63e-dbf0e794b8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_789287d9-a769-46eb-a0e8-cccd3db3ed28" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ffff19d6-35f4-4686-b63e-dbf0e794b8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_84d581b0-79aa-45a2-af37-cebca29cef5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ffff19d6-35f4-4686-b63e-dbf0e794b8bb" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_84d581b0-79aa-45a2-af37-cebca29cef5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7e0b6537-9cef-495c-9c79-378ae9843ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_84d581b0-79aa-45a2-af37-cebca29cef5b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7e0b6537-9cef-495c-9c79-378ae9843ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2f21d988-0973-4ef0-b6ab-bb94cf3e256c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_789287d9-a769-46eb-a0e8-cccd3db3ed28" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2f21d988-0973-4ef0-b6ab-bb94cf3e256c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9b06ba43-520e-41fd-89c6-5d4db66e2d90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2f21d988-0973-4ef0-b6ab-bb94cf3e256c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9b06ba43-520e-41fd-89c6-5d4db66e2d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4ef51bd0-9c11-43e2-8389-6a093cefdd49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2f21d988-0973-4ef0-b6ab-bb94cf3e256c" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_4ef51bd0-9c11-43e2-8389-6a093cefdd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ecd482b1-b18e-4fcf-832d-ed2e44e366cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2f21d988-0973-4ef0-b6ab-bb94cf3e256c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ecd482b1-b18e-4fcf-832d-ed2e44e366cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#AccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_69a0dbec-5f23-407c-b281-c6a7bde376e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6eeb1802-baec-4d5c-8c98-343f91d42a94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_69a0dbec-5f23-407c-b281-c6a7bde376e2" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6eeb1802-baec-4d5c-8c98-343f91d42a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ClinicalAndRDRelatedLiabilities_3f7ebe20-7fbb-4227-84c4-2350a3e8dedc" xlink:href="lsta-20250331.xsd#lsta_ClinicalAndRDRelatedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_69a0dbec-5f23-407c-b281-c6a7bde376e2" xlink:to="loc_lsta_ClinicalAndRDRelatedLiabilities_3f7ebe20-7fbb-4227-84c4-2350a3e8dedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AccruedGrantFunding_17fd4302-24cb-41b3-8743-8715863989bb" xlink:href="lsta-20250331.xsd#lsta_AccruedGrantFunding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_69a0dbec-5f23-407c-b281-c6a7bde376e2" xlink:to="loc_lsta_AccruedGrantFunding_17fd4302-24cb-41b3-8743-8715863989bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7aabd38f-eca0-439d-af54-dac4bc53390e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_69a0dbec-5f23-407c-b281-c6a7bde376e2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7aabd38f-eca0-439d-af54-dac4bc53390e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_56000300-c6e3-4438-a0ec-51007ead5da3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_69a0dbec-5f23-407c-b281-c6a7bde376e2" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_56000300-c6e3-4438-a0ec-51007ead5da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4da28985-4d48-4fc9-87cd-067c494e6950" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_69a0dbec-5f23-407c-b281-c6a7bde376e2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4da28985-4d48-4fc9-87cd-067c494e6950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesScheduleofBalanceSheetPresentationDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#OperatingLeasesScheduleofBalanceSheetPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesScheduleofBalanceSheetPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1402ef7f-89fd-4621-93a0-cf6d36f8debd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLeaseRightOfUseAssetAbstract_de331982-6911-483a-81d0-e6aa4bdb93e2" xlink:href="lsta-20250331.xsd#lsta_OperatingLeaseRightOfUseAssetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1402ef7f-89fd-4621-93a0-cf6d36f8debd" xlink:to="loc_lsta_OperatingLeaseRightOfUseAssetAbstract_de331982-6911-483a-81d0-e6aa4bdb93e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b4403573-27a5-44c9-b4e6-bba4c246c9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_OperatingLeaseRightOfUseAssetAbstract_de331982-6911-483a-81d0-e6aa4bdb93e2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b4403573-27a5-44c9-b4e6-bba4c246c9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_16e7ef60-d959-4952-abeb-0548674be6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_b4403573-27a5-44c9-b4e6-bba4c246c9fe" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_16e7ef60-d959-4952-abeb-0548674be6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_20d3e83d-70c5-4424-9c73-442474a92c41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1402ef7f-89fd-4621-93a0-cf6d36f8debd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_20d3e83d-70c5-4424-9c73-442474a92c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9c496eaf-f39f-44d4-ad86-8564b39c6e21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_20d3e83d-70c5-4424-9c73-442474a92c41" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9c496eaf-f39f-44d4-ad86-8564b39c6e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_64d2bc2c-e831-44e2-90e4-2a7dba790845" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_9c496eaf-f39f-44d4-ad86-8564b39c6e21" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_64d2bc2c-e831-44e2-90e4-2a7dba790845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_00000e65-e8d2-4f69-92fd-9d3fe297f63b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_20d3e83d-70c5-4424-9c73-442474a92c41" xlink:to="loc_us-gaap_OperatingLeaseLiability_00000e65-e8d2-4f69-92fd-9d3fe297f63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#OperatingLeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_33de375f-4c07-4668-816e-e8b077021ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_295b4d64-5797-43af-9596-a04af9aa3011" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_33de375f-4c07-4668-816e-e8b077021ec9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_295b4d64-5797-43af-9596-a04af9aa3011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f14c83d1-4938-455b-8bc9-2257f8cd408b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_33de375f-4c07-4668-816e-e8b077021ec9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f14c83d1-4938-455b-8bc9-2257f8cd408b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ceadbcc1-bd85-495b-9335-120274e16504" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_fd149ece-bb4f-415b-bb5b-04ef56092c43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ceadbcc1-bd85-495b-9335-120274e16504" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_fd149ece-bb4f-415b-bb5b-04ef56092c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fe1e9718-4615-4b7a-9225-64eb9a864ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_fd149ece-bb4f-415b-bb5b-04ef56092c43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fe1e9718-4615-4b7a-9225-64eb9a864ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_998a7f47-a404-48d5-8709-1ff6d1419123" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_fd149ece-bb4f-415b-bb5b-04ef56092c43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_998a7f47-a404-48d5-8709-1ff6d1419123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8e4ff789-b68a-4053-9625-ce40ac7b09be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_fd149ece-bb4f-415b-bb5b-04ef56092c43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8e4ff789-b68a-4053-9625-ce40ac7b09be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_779b0368-1398-4833-aa0c-65a5872ab387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_fd149ece-bb4f-415b-bb5b-04ef56092c43" xlink:to="loc_us-gaap_OperatingLeaseLiability_779b0368-1398-4833-aa0c-65a5872ab387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#StockholdersEquityEquityIssuancesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_259909c5-d8d0-4c22-ba49-ab3f6295b924" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_18dfda42-a172-403a-86a9-362e9fef8d72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_259909c5-d8d0-4c22-ba49-ab3f6295b924" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_18dfda42-a172-403a-86a9-362e9fef8d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_78250625-8998-4c4e-b653-4723fef880f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_18dfda42-a172-403a-86a9-362e9fef8d72" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_78250625-8998-4c4e-b653-4723fef880f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7112fcb0-7489-483c-9384-18a38488ad42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_78250625-8998-4c4e-b653-4723fef880f6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7112fcb0-7489-483c-9384-18a38488ad42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AtTheMarketOfferingAgreementMember_19d1b692-5720-4486-9829-121bdb0b8c83" xlink:href="lsta-20250331.xsd#lsta_AtTheMarketOfferingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7112fcb0-7489-483c-9384-18a38488ad42" xlink:to="loc_lsta_AtTheMarketOfferingAgreementMember_19d1b692-5720-4486-9829-121bdb0b8c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ec763041-e9df-434d-98a3-126c8aa2f42e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_18dfda42-a172-403a-86a9-362e9fef8d72" xlink:to="loc_us-gaap_ClassOfStockLineItems_ec763041-e9df-434d-98a3-126c8aa2f42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_5366b7b7-8e56-497b-b84c-e8b4f11dbf57" xlink:href="lsta-20250331.xsd#lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ec763041-e9df-434d-98a3-126c8aa2f42e" xlink:to="loc_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_5366b7b7-8e56-497b-b84c-e8b4f11dbf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_acd17eda-2a40-4c10-a9aa-50804a7c9ade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ec763041-e9df-434d-98a3-126c8aa2f42e" xlink:to="loc_us-gaap_CommonStockValueOutstanding_acd17eda-2a40-4c10-a9aa-50804a7c9ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OutstandingStockThreshold_af422b40-ebd3-447e-89be-7fe8a092b611" xlink:href="lsta-20250331.xsd#lsta_OutstandingStockThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ec763041-e9df-434d-98a3-126c8aa2f42e" xlink:to="loc_lsta_OutstandingStockThreshold_af422b40-ebd3-447e-89be-7fe8a092b611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAvailableForSale_44e34b97-9be1-45ec-b748-196269dbf726" xlink:href="lsta-20250331.xsd#lsta_SaleOfStockAvailableForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ec763041-e9df-434d-98a3-126c8aa2f42e" xlink:to="loc_lsta_SaleOfStockAvailableForSale_44e34b97-9be1-45ec-b748-196269dbf726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SaleOfStockAvailableForSalePercentage_ab055818-aacb-4d55-9b12-f57b1121f1c0" xlink:href="lsta-20250331.xsd#lsta_SaleOfStockAvailableForSalePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ec763041-e9df-434d-98a3-126c8aa2f42e" xlink:to="loc_lsta_SaleOfStockAvailableForSalePercentage_ab055818-aacb-4d55-9b12-f57b1121f1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7f49153d-d306-4423-88b7-b0c14a007baf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ec763041-e9df-434d-98a3-126c8aa2f42e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7f49153d-d306-4423-88b7-b0c14a007baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0817ecf4-dac0-46be-9a24-17bab881c0de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ec763041-e9df-434d-98a3-126c8aa2f42e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0817ecf4-dac0-46be-9a24-17bab881c0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#StockholdersEquityScheduleofStockOptionsandWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_58de56ba-acc7-4dba-9d26-80e1a1cc95af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_f67e7a28-985d-4000-a38b-ab65e95600e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_58de56ba-acc7-4dba-9d26-80e1a1cc95af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_f67e7a28-985d-4000-a38b-ab65e95600e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70cd1055-1b40-4f39-b5d5-fa9e63df7723" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_f67e7a28-985d-4000-a38b-ab65e95600e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70cd1055-1b40-4f39-b5d5-fa9e63df7723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4dafc547-abc8-434e-b221-2baa3b05718e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70cd1055-1b40-4f39-b5d5-fa9e63df7723" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4dafc547-abc8-434e-b221-2baa3b05718e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1e6342f6-d51b-4bb3-a1d6-ee88a80c4622" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70cd1055-1b40-4f39-b5d5-fa9e63df7723" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1e6342f6-d51b-4bb3-a1d6-ee88a80c4622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6a62a7e9-3e6f-45f3-b832-2286fe3dc2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70cd1055-1b40-4f39-b5d5-fa9e63df7723" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6a62a7e9-3e6f-45f3-b832-2286fe3dc2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_431336a8-3d11-40fa-b334-5c09da5da838" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70cd1055-1b40-4f39-b5d5-fa9e63df7723" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_431336a8-3d11-40fa-b334-5c09da5da838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2de1daa7-34f6-4770-8769-048929bb6972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70cd1055-1b40-4f39-b5d5-fa9e63df7723" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2de1daa7-34f6-4770-8769-048929bb6972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a2423c09-2ce1-41dd-a4cb-d6713f35fe32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70cd1055-1b40-4f39-b5d5-fa9e63df7723" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a2423c09-2ce1-41dd-a4cb-d6713f35fe32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8a0b84ef-6b24-4e35-8a85-df4f27191bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_f67e7a28-985d-4000-a38b-ab65e95600e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8a0b84ef-6b24-4e35-8a85-df4f27191bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_4bc37ddd-3761-4499-b23e-35e33b5aa887" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_f67e7a28-985d-4000-a38b-ab65e95600e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_4bc37ddd-3761-4499-b23e-35e33b5aa887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac4d3e5c-f91b-4a91-b27b-9114de6483e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_f67e7a28-985d-4000-a38b-ab65e95600e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac4d3e5c-f91b-4a91-b27b-9114de6483e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_65d6c7b0-c8e0-4d62-a3fe-662c0b2ee6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac4d3e5c-f91b-4a91-b27b-9114de6483e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_65d6c7b0-c8e0-4d62-a3fe-662c0b2ee6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_53be9671-bc42-46a6-8cbb-a2add6521057" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac4d3e5c-f91b-4a91-b27b-9114de6483e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_53be9671-bc42-46a6-8cbb-a2add6521057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8b6642b9-91e3-4dcf-91f1-5f4d28807a51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac4d3e5c-f91b-4a91-b27b-9114de6483e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8b6642b9-91e3-4dcf-91f1-5f4d28807a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8ca8158f-9e2e-449d-a4eb-e05e98468621" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac4d3e5c-f91b-4a91-b27b-9114de6483e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8ca8158f-9e2e-449d-a4eb-e05e98468621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_b76a70e8-fb1f-4ee4-b6d3-61ea164aee91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac4d3e5c-f91b-4a91-b27b-9114de6483e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_b76a70e8-fb1f-4ee4-b6d3-61ea164aee91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_27ac1e1d-0d4a-46fa-9f5f-54e99271c0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac4d3e5c-f91b-4a91-b27b-9114de6483e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_27ac1e1d-0d4a-46fa-9f5f-54e99271c0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_481ac0ef-ad70-4e8b-b8d4-462bed98970e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_f67e7a28-985d-4000-a38b-ab65e95600e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_481ac0ef-ad70-4e8b-b8d4-462bed98970e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_cc775d4f-93b2-41e5-8b00-731ecfe2c633" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_f67e7a28-985d-4000-a38b-ab65e95600e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_cc775d4f-93b2-41e5-8b00-731ecfe2c633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9498db42-9e3d-4678-8f87-e6f09eebe33c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_f67e7a28-985d-4000-a38b-ab65e95600e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9498db42-9e3d-4678-8f87-e6f09eebe33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6c82573b-bc39-431a-875a-e18ca5874a63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9498db42-9e3d-4678-8f87-e6f09eebe33c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6c82573b-bc39-431a-875a-e18ca5874a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2a9ed446-7fcc-41cb-8f88-08e498140d44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9498db42-9e3d-4678-8f87-e6f09eebe33c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2a9ed446-7fcc-41cb-8f88-08e498140d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OptionsVestedWeightedAverageRemainingContractualTerm_4e3b8ffe-bb51-4f87-952f-5d51f925c2f3" xlink:href="lsta-20250331.xsd#lsta_OptionsVestedWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9498db42-9e3d-4678-8f87-e6f09eebe33c" xlink:to="loc_lsta_OptionsVestedWeightedAverageRemainingContractualTerm_4e3b8ffe-bb51-4f87-952f-5d51f925c2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ca7765fe-a76d-4136-a9dc-f216a44ff10d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9498db42-9e3d-4678-8f87-e6f09eebe33c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ca7765fe-a76d-4136-a9dc-f216a44ff10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_d014f3ea-367c-454d-8b83-121b12bcf581" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9498db42-9e3d-4678-8f87-e6f09eebe33c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_d014f3ea-367c-454d-8b83-121b12bcf581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_e61f0342-7038-4492-a9d5-92cf6f47c86c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9498db42-9e3d-4678-8f87-e6f09eebe33c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_e61f0342-7038-4492-a9d5-92cf6f47c86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6026b33f-a7e7-4868-88af-f927b5808537" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_58de56ba-acc7-4dba-9d26-80e1a1cc95af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6026b33f-a7e7-4868-88af-f927b5808537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a6c2c1f4-1b51-44b3-982e-1bcfebf5f6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6026b33f-a7e7-4868-88af-f927b5808537" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a6c2c1f4-1b51-44b3-982e-1bcfebf5f6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CommonStockWarrantsShares_e7f6e005-5529-45e4-84f1-504ee23e78b5" xlink:href="lsta-20250331.xsd#lsta_CommonStockWarrantsShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a6c2c1f4-1b51-44b3-982e-1bcfebf5f6ea" xlink:to="loc_lsta_CommonStockWarrantsShares_e7f6e005-5529-45e4-84f1-504ee23e78b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsGranted_a1db8e3a-1e2c-417f-9b7f-a8e83780777c" xlink:href="lsta-20250331.xsd#lsta_WarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a6c2c1f4-1b51-44b3-982e-1bcfebf5f6ea" xlink:to="loc_lsta_WarrantsGranted_a1db8e3a-1e2c-417f-9b7f-a8e83780777c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsExercised_53863ff2-f5bb-4dfb-a968-f9eb75f3458e" xlink:href="lsta-20250331.xsd#lsta_WarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a6c2c1f4-1b51-44b3-982e-1bcfebf5f6ea" xlink:to="loc_lsta_WarrantsExercised_53863ff2-f5bb-4dfb-a968-f9eb75f3458e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsCanceled_078e8297-1a39-476c-b377-04d997bc2ef7" xlink:href="lsta-20250331.xsd#lsta_WarrantsCanceled"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a6c2c1f4-1b51-44b3-982e-1bcfebf5f6ea" xlink:to="loc_lsta_WarrantsCanceled_078e8297-1a39-476c-b377-04d997bc2ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsExpired_9a111627-f89c-4233-8d26-417a3856d527" xlink:href="lsta-20250331.xsd#lsta_WarrantsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a6c2c1f4-1b51-44b3-982e-1bcfebf5f6ea" xlink:to="loc_lsta_WarrantsExpired_9a111627-f89c-4233-8d26-417a3856d527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CommonStockWarrantsShares_3e2b20c6-817f-4967-b942-08d3fd5c909f" xlink:href="lsta-20250331.xsd#lsta_CommonStockWarrantsShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a6c2c1f4-1b51-44b3-982e-1bcfebf5f6ea" xlink:to="loc_lsta_CommonStockWarrantsShares_3e2b20c6-817f-4967-b942-08d3fd5c909f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_Sharesvestedandexpectedtovest_6b2a248f-22cc-4a86-8225-d021e2022563" xlink:href="lsta-20250331.xsd#lsta_Sharesvestedandexpectedtovest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6026b33f-a7e7-4868-88af-f927b5808537" xlink:to="loc_lsta_Sharesvestedandexpectedtovest_6b2a248f-22cc-4a86-8225-d021e2022563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsVested_7a331111-4847-4653-92c6-92d06b60e4d6" xlink:href="lsta-20250331.xsd#lsta_WarrantsVested"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6026b33f-a7e7-4868-88af-f927b5808537" xlink:to="loc_lsta_WarrantsVested_7a331111-4847-4653-92c6-92d06b60e4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_4f5aeaea-de51-4b47-9b87-70a53d0d77e4" xlink:href="lsta-20250331.xsd#lsta_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6026b33f-a7e7-4868-88af-f927b5808537" xlink:to="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_4f5aeaea-de51-4b47-9b87-70a53d0d77e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsOutstanding_44f458f8-b7cc-4e7a-8e1d-c92fe562ce24" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_4f5aeaea-de51-4b47-9b87-70a53d0d77e4" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsOutstanding_44f458f8-b7cc-4e7a-8e1d-c92fe562ce24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsGranted_a21d4389-9652-4c2e-909b-fd9d3aca7f38" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageExercisePriceWarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_4f5aeaea-de51-4b47-9b87-70a53d0d77e4" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsGranted_a21d4389-9652-4c2e-909b-fd9d3aca7f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsExercised_eab927c4-d045-4af0-aa2f-6822f7e67b12" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageExercisePriceWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_4f5aeaea-de51-4b47-9b87-70a53d0d77e4" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsExercised_eab927c4-d045-4af0-aa2f-6822f7e67b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsCanceled_b23aadd4-1f30-4d98-9bae-aff24c882cfe" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageExercisePriceWarrantsCanceled"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_4f5aeaea-de51-4b47-9b87-70a53d0d77e4" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsCanceled_b23aadd4-1f30-4d98-9bae-aff24c882cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsExpired_87fec86a-fd73-47ed-800a-56d2b045cffa" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageExercisePriceWarrantsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_4f5aeaea-de51-4b47-9b87-70a53d0d77e4" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsExpired_87fec86a-fd73-47ed-800a-56d2b045cffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsOutstanding_97aab7bd-31a0-4c4d-adad-59dccf7805ce" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsWeightedAverageExercisePriceRollForward_4f5aeaea-de51-4b47-9b87-70a53d0d77e4" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsOutstanding_97aab7bd-31a0-4c4d-adad-59dccf7805ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_e121fb2b-8252-45a5-8e2d-5ead4a382c09" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6026b33f-a7e7-4868-88af-f927b5808537" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_e121fb2b-8252-45a5-8e2d-5ead4a382c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageExercisePriceWarrantsExercisable_931207a7-5d4c-49fa-a24f-8a81a72bc2a6" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageExercisePriceWarrantsExercisable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6026b33f-a7e7-4868-88af-f927b5808537" xlink:to="loc_lsta_WeightedAverageExercisePriceWarrantsExercisable_931207a7-5d4c-49fa-a24f-8a81a72bc2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WarrantsOtherDisclosuresAbstract_71bae87b-052c-464b-8dd3-c5385fa31eda" xlink:href="lsta-20250331.xsd#lsta_WarrantsOtherDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6026b33f-a7e7-4868-88af-f927b5808537" xlink:to="loc_lsta_WarrantsOtherDisclosuresAbstract_71bae87b-052c-464b-8dd3-c5385fa31eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageRemainingContractualTermWarrantOutstanding_47482b47-47b3-4b45-9056-0517ef9787ca" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageRemainingContractualTermWarrantOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract_71bae87b-052c-464b-8dd3-c5385fa31eda" xlink:to="loc_lsta_WeightedAverageRemainingContractualTermWarrantOutstanding_47482b47-47b3-4b45-9056-0517ef9787ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_18ce018d-25b1-445c-821a-41529970d416" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract_71bae87b-052c-464b-8dd3-c5385fa31eda" xlink:to="loc_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_18ce018d-25b1-445c-821a-41529970d416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_WeightedAverageRemainingContractualTermWarrantsVested_5cc97eb2-ffe1-4af5-b669-818154cd0a0e" xlink:href="lsta-20250331.xsd#lsta_WeightedAverageRemainingContractualTermWarrantsVested"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract_71bae87b-052c-464b-8dd3-c5385fa31eda" xlink:to="loc_lsta_WeightedAverageRemainingContractualTermWarrantsVested_5cc97eb2-ffe1-4af5-b669-818154cd0a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AggregateIntrinsicValueWarrantsOutstanding_f2569b8f-c805-417b-a1c9-0ac9fd0443e0" xlink:href="lsta-20250331.xsd#lsta_AggregateIntrinsicValueWarrantsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract_71bae87b-052c-464b-8dd3-c5385fa31eda" xlink:to="loc_lsta_AggregateIntrinsicValueWarrantsOutstanding_f2569b8f-c805-417b-a1c9-0ac9fd0443e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AggregateIntrinsicValueWarrantsVestedAndExpectedToVest_8c6be252-bdcf-4213-b623-438dc5b25e2b" xlink:href="lsta-20250331.xsd#lsta_AggregateIntrinsicValueWarrantsVestedAndExpectedToVest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract_71bae87b-052c-464b-8dd3-c5385fa31eda" xlink:to="loc_lsta_AggregateIntrinsicValueWarrantsVestedAndExpectedToVest_8c6be252-bdcf-4213-b623-438dc5b25e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AggregateIntrinsicValueWarrantsVested_bad37eef-6718-4f18-afe9-57273dae86cb" xlink:href="lsta-20250331.xsd#lsta_AggregateIntrinsicValueWarrantsVested"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_WarrantsOtherDisclosuresAbstract_71bae87b-052c-464b-8dd3-c5385fa31eda" xlink:to="loc_lsta_AggregateIntrinsicValueWarrantsVested_bad37eef-6718-4f18-afe9-57273dae86cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6943f9a1-1d1b-4f9e-af0c-62de63085941" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fb93054-629d-4e4b-93de-a8b721178576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6943f9a1-1d1b-4f9e-af0c-62de63085941" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fb93054-629d-4e4b-93de-a8b721178576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_35c126aa-7017-4e79-ae01-887195e3da37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fb93054-629d-4e4b-93de-a8b721178576" xlink:to="loc_us-gaap_AwardTypeAxis_35c126aa-7017-4e79-ae01-887195e3da37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40cb743c-58f6-4f62-9c14-df75ac7a5764" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_35c126aa-7017-4e79-ae01-887195e3da37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40cb743c-58f6-4f62-9c14-df75ac7a5764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_68445772-af1c-4cfe-8842-901b1b83560b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_40cb743c-58f6-4f62-9c14-df75ac7a5764" xlink:to="loc_us-gaap_RestrictedStockMember_68445772-af1c-4cfe-8842-901b1b83560b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9c57eaf1-9a47-4342-a171-cebba5701da9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fb93054-629d-4e4b-93de-a8b721178576" xlink:to="loc_srt_RangeAxis_9c57eaf1-9a47-4342-a171-cebba5701da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e107ba00-715c-442e-ab94-9265c41bc12e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9c57eaf1-9a47-4342-a171-cebba5701da9" xlink:to="loc_srt_RangeMember_e107ba00-715c-442e-ab94-9265c41bc12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_425474cf-188c-4830-b8a6-96b8f5838bfa" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e107ba00-715c-442e-ab94-9265c41bc12e" xlink:to="loc_srt_MinimumMember_425474cf-188c-4830-b8a6-96b8f5838bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b648cacb-1c0f-449b-b6ea-ffe059801788" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e107ba00-715c-442e-ab94-9265c41bc12e" xlink:to="loc_srt_MaximumMember_b648cacb-1c0f-449b-b6ea-ffe059801788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f139b4a-8828-4c09-844b-0ce21660c84e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fb93054-629d-4e4b-93de-a8b721178576" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f139b4a-8828-4c09-844b-0ce21660c84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d1bab1b1-c0a1-46e7-a3a2-a536d09e8728" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f139b4a-8828-4c09-844b-0ce21660c84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d1bab1b1-c0a1-46e7-a3a2-a536d09e8728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0bae8e74-d96b-47fc-baaf-40d6b1dad973" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f139b4a-8828-4c09-844b-0ce21660c84e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0bae8e74-d96b-47fc-baaf-40d6b1dad973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityScheduleofRestrictedStockUnitsforServicesDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#StockholdersEquityScheduleofRestrictedStockUnitsforServicesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityScheduleofRestrictedStockUnitsforServicesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_980aad6e-a858-416d-8420-8c599b8a39f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6b0f89b-40ef-4936-a4e1-90322983a1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_980aad6e-a858-416d-8420-8c599b8a39f2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6b0f89b-40ef-4936-a4e1-90322983a1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3e383726-6ee9-43f1-b642-e1850c91dcb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6b0f89b-40ef-4936-a4e1-90322983a1fd" xlink:to="loc_us-gaap_AwardTypeAxis_3e383726-6ee9-43f1-b642-e1850c91dcb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb5458ba-b399-4f92-ad79-6d464cf4066f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3e383726-6ee9-43f1-b642-e1850c91dcb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb5458ba-b399-4f92-ad79-6d464cf4066f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_77ced15e-4510-4b23-899e-db14f34a9e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb5458ba-b399-4f92-ad79-6d464cf4066f" xlink:to="loc_us-gaap_RestrictedStockMember_77ced15e-4510-4b23-899e-db14f34a9e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f50f6460-a784-4ac4-bf73-918fa4492e34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb5458ba-b399-4f92-ad79-6d464cf4066f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f50f6460-a784-4ac4-bf73-918fa4492e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d34b9bc-0d1f-4163-9cce-441dae6559d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b6b0f89b-40ef-4936-a4e1-90322983a1fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d34b9bc-0d1f-4163-9cce-441dae6559d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_1a36ae6a-8582-4bd0-8fc1-3cdb3f0d8e43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d34b9bc-0d1f-4163-9cce-441dae6559d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_1a36ae6a-8582-4bd0-8fc1-3cdb3f0d8e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_3860f1f6-1aa4-44df-aa62-743134a1c545" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d34b9bc-0d1f-4163-9cce-441dae6559d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_3860f1f6-1aa4-44df-aa62-743134a1c545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c9f53e30-4bc3-48a4-827c-79c674caec74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d34b9bc-0d1f-4163-9cce-441dae6559d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c9f53e30-4bc3-48a4-827c-79c674caec74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0d8f83a1-32f2-47ea-9044-44d2eadcbff3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d34b9bc-0d1f-4163-9cce-441dae6559d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0d8f83a1-32f2-47ea-9044-44d2eadcbff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#StockholdersEquityScheduleofNonVestedRestrictedStockDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_33a216d6-a2cc-4ec3-b70c-68c2e84e3d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ceed9df-5f53-4d5e-a832-0873845cfece" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_33a216d6-a2cc-4ec3-b70c-68c2e84e3d9f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ceed9df-5f53-4d5e-a832-0873845cfece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5d3e83ed-5bfe-40f4-9835-686ce81631d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ceed9df-5f53-4d5e-a832-0873845cfece" xlink:to="loc_us-gaap_AwardTypeAxis_5d3e83ed-5bfe-40f4-9835-686ce81631d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a1f7002-b3db-4ea1-a1aa-a353ef320afb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5d3e83ed-5bfe-40f4-9835-686ce81631d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a1f7002-b3db-4ea1-a1aa-a353ef320afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f5c48f8a-80b6-442d-bc42-c3d179447c04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a1f7002-b3db-4ea1-a1aa-a353ef320afb" xlink:to="loc_us-gaap_RestrictedStockMember_f5c48f8a-80b6-442d-bc42-c3d179447c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c4bc575e-b7e6-4d0c-82ef-d0892f068a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a1f7002-b3db-4ea1-a1aa-a353ef320afb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c4bc575e-b7e6-4d0c-82ef-d0892f068a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da2a7ad9-cf57-4935-a682-9a4cc7a6ca70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ceed9df-5f53-4d5e-a832-0873845cfece" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da2a7ad9-cf57-4935-a682-9a4cc7a6ca70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4ec3301d-877f-43ad-b565-2b84925783f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da2a7ad9-cf57-4935-a682-9a4cc7a6ca70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4ec3301d-877f-43ad-b565-2b84925783f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8580c6a9-3772-4277-ac4f-f82dad6aab1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4ec3301d-877f-43ad-b565-2b84925783f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8580c6a9-3772-4277-ac4f-f82dad6aab1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e9985f1f-4e2a-467c-9baf-0c06d4dd3aad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4ec3301d-877f-43ad-b565-2b84925783f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e9985f1f-4e2a-467c-9baf-0c06d4dd3aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_065a098d-2118-4ada-b1dd-bc6f39336968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4ec3301d-877f-43ad-b565-2b84925783f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_065a098d-2118-4ada-b1dd-bc6f39336968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37dbcd12-65a3-4f1e-b337-9bdbf54c846c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4ec3301d-877f-43ad-b565-2b84925783f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_37dbcd12-65a3-4f1e-b337-9bdbf54c846c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_99e88d7a-4b7e-413d-87c5-264d4cdd14f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4ec3301d-877f-43ad-b565-2b84925783f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_99e88d7a-4b7e-413d-87c5-264d4cdd14f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1732c56c-26a2-4957-b97d-9ee984d12bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da2a7ad9-cf57-4935-a682-9a4cc7a6ca70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1732c56c-26a2-4957-b97d-9ee984d12bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cadf608c-0a86-4413-9928-135d9c47d97d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1732c56c-26a2-4957-b97d-9ee984d12bdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cadf608c-0a86-4413-9928-135d9c47d97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4a95e315-4a89-41c2-bf65-bd7cf38748da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1732c56c-26a2-4957-b97d-9ee984d12bdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4a95e315-4a89-41c2-bf65-bd7cf38748da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cff5c807-61e8-4bc8-bffc-12813cfe2964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1732c56c-26a2-4957-b97d-9ee984d12bdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cff5c807-61e8-4bc8-bffc-12813cfe2964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c34bd74b-89e0-439e-92b0-a170060a4410" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1732c56c-26a2-4957-b97d-9ee984d12bdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c34bd74b-89e0-439e-92b0-a170060a4410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c375f5ff-b6be-4a5a-9544-81215a382f37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1732c56c-26a2-4957-b97d-9ee984d12bdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c375f5ff-b6be-4a5a-9544-81215a382f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a20918b5-8cf7-43b9-bdc5-66abb1d42117" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd6eb450-3ae1-454e-a30e-e7acf357dd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a20918b5-8cf7-43b9-bdc5-66abb1d42117" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd6eb450-3ae1-454e-a30e-e7acf357dd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ef6141bf-2830-434f-a32e-023f2979ab9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd6eb450-3ae1-454e-a30e-e7acf357dd5f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ef6141bf-2830-434f-a32e-023f2979ab9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_db339341-dbaa-42b5-a66c-82ea206a3378" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ef6141bf-2830-434f-a32e-023f2979ab9f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_db339341-dbaa-42b5-a66c-82ea206a3378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1cca062d-5a02-4207-b1a2-a7c72d5f8fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_db339341-dbaa-42b5-a66c-82ea206a3378" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1cca062d-5a02-4207-b1a2-a7c72d5f8fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_092907d2-1ae4-4d45-8c08-7be0d55cb3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_db339341-dbaa-42b5-a66c-82ea206a3378" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_092907d2-1ae4-4d45-8c08-7be0d55cb3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb6876a2-1bdc-4714-8caf-1b1affc6db5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd6eb450-3ae1-454e-a30e-e7acf357dd5f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb6876a2-1bdc-4714-8caf-1b1affc6db5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_78adaa3d-7641-4190-967b-d8d4113817b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eb6876a2-1bdc-4714-8caf-1b1affc6db5b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_78adaa3d-7641-4190-967b-d8d4113817b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationScheduleofCompensationCostNotYetRecognizedDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#ShareBasedCompensationScheduleofCompensationCostNotYetRecognizedDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationScheduleofCompensationCostNotYetRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89c00fe2-350b-434c-a687-0c1e2dbcc912" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2ee9e1d-d7b4-4b9f-b9b2-1ba76fac1f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89c00fe2-350b-434c-a687-0c1e2dbcc912" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2ee9e1d-d7b4-4b9f-b9b2-1ba76fac1f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a064a7c0-2c94-4103-b0b1-91dda0f79e50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2ee9e1d-d7b4-4b9f-b9b2-1ba76fac1f8a" xlink:to="loc_us-gaap_AwardTypeAxis_a064a7c0-2c94-4103-b0b1-91dda0f79e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02c6d5fb-f110-481c-8337-5074a36b17e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a064a7c0-2c94-4103-b0b1-91dda0f79e50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02c6d5fb-f110-481c-8337-5074a36b17e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_46f070ab-c87f-4127-aa9d-1329dc6fe5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02c6d5fb-f110-481c-8337-5074a36b17e8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_46f070ab-c87f-4127-aa9d-1329dc6fe5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cbc9a030-8499-40b6-8ac5-f86742636bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02c6d5fb-f110-481c-8337-5074a36b17e8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cbc9a030-8499-40b6-8ac5-f86742636bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_a218f0ae-2bd6-43f8-aa07-21ff6be80c75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02c6d5fb-f110-481c-8337-5074a36b17e8" xlink:to="loc_us-gaap_WarrantMember_a218f0ae-2bd6-43f8-aa07-21ff6be80c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0590946b-264b-404f-8b84-731efa974665" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02c6d5fb-f110-481c-8337-5074a36b17e8" xlink:to="loc_us-gaap_RestrictedStockMember_0590946b-264b-404f-8b84-731efa974665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_08b6a94a-d0b9-4ed9-9a70-6a061758f611" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2ee9e1d-d7b4-4b9f-b9b2-1ba76fac1f8a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_08b6a94a-d0b9-4ed9-9a70-6a061758f611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f07ba5e5-7a12-4a39-9f92-472c2fd6afda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_08b6a94a-d0b9-4ed9-9a70-6a061758f611" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f07ba5e5-7a12-4a39-9f92-472c2fd6afda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5530aea7-1e26-4ece-ba23-87e2a57f207a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_08b6a94a-d0b9-4ed9-9a70-6a061758f611" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5530aea7-1e26-4ece-ba23-87e2a57f207a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationScheduleofFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#ShareBasedCompensationScheduleofFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationScheduleofFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_db2ca312-625f-4ca0-91dc-a895376689a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ad4c1eb-5830-4139-ad6b-e4c2514ee383" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_db2ca312-625f-4ca0-91dc-a895376689a2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ad4c1eb-5830-4139-ad6b-e4c2514ee383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_43daf1ae-ed36-4a32-a667-cb9dc4747de5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ad4c1eb-5830-4139-ad6b-e4c2514ee383" xlink:to="loc_us-gaap_AwardTypeAxis_43daf1ae-ed36-4a32-a667-cb9dc4747de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77aea21b-10a0-42c0-92e0-dd0de4fd9a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_43daf1ae-ed36-4a32-a667-cb9dc4747de5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77aea21b-10a0-42c0-92e0-dd0de4fd9a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5f99b116-5df7-4eff-810e-602795349862" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77aea21b-10a0-42c0-92e0-dd0de4fd9a9c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5f99b116-5df7-4eff-810e-602795349862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_9f18b615-5c22-4257-abb2-64e2b29fe6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77aea21b-10a0-42c0-92e0-dd0de4fd9a9c" xlink:to="loc_us-gaap_WarrantMember_9f18b615-5c22-4257-abb2-64e2b29fe6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f5f9a4d-e6ed-4781-bdef-1ffa50bb4e74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ad4c1eb-5830-4139-ad6b-e4c2514ee383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f5f9a4d-e6ed-4781-bdef-1ffa50bb4e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_479e6d45-826d-4cb6-aed4-87678a774d03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f5f9a4d-e6ed-4781-bdef-1ffa50bb4e74" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_479e6d45-826d-4cb6-aed4-87678a774d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_41e87329-76a4-44de-896b-f525fac0eb39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f5f9a4d-e6ed-4781-bdef-1ffa50bb4e74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_41e87329-76a4-44de-896b-f525fac0eb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_73fb2b3f-ad48-48f1-ae49-f241aa6b4770" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_69eca5b7-83dd-4dac-b4fe-26d4c73f14c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73fb2b3f-ad48-48f1-ae49-f241aa6b4770" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_69eca5b7-83dd-4dac-b4fe-26d4c73f14c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e442ac5c-2911-4298-bda7-7bc41f8c3af5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_69eca5b7-83dd-4dac-b4fe-26d4c73f14c5" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e442ac5c-2911-4298-bda7-7bc41f8c3af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_c41d564e-aef1-4920-bac7-c39001fc7b77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e442ac5c-2911-4298-bda7-7bc41f8c3af5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_c41d564e-aef1-4920-bac7-c39001fc7b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_9f373bb4-9ef9-42c6-8cc9-52f5629dc341" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c41d564e-aef1-4920-bac7-c39001fc7b77" xlink:to="loc_us-gaap_DomesticCountryMember_9f373bb4-9ef9-42c6-8cc9-52f5629dc341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_010cdb9e-360e-4df2-a04b-f606fc814f20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c41d564e-aef1-4920-bac7-c39001fc7b77" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_010cdb9e-360e-4df2-a04b-f606fc814f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_ddf77a61-dc19-4e42-94eb-ca6ed7b7efef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c41d564e-aef1-4920-bac7-c39001fc7b77" xlink:to="loc_us-gaap_ForeignCountryMember_ddf77a61-dc19-4e42-94eb-ca6ed7b7efef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_78e25972-cfa7-4d88-96c6-9e53c6bb9aac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_69eca5b7-83dd-4dac-b4fe-26d4c73f14c5" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_78e25972-cfa7-4d88-96c6-9e53c6bb9aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_2baaba00-d81e-4cb4-a673-01fe93c54bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_78e25972-cfa7-4d88-96c6-9e53c6bb9aac" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_2baaba00-d81e-4cb4-a673-01fe93c54bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_b4d4b255-3220-4bfe-bd97-6b613d1f62b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_2baaba00-d81e-4cb4-a673-01fe93c54bc9" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_b4d4b255-3220-4bfe-bd97-6b613d1f62b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_b5b9597a-d1c9-4db5-bba2-df077974f75a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_2baaba00-d81e-4cb4-a673-01fe93c54bc9" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_b5b9597a-d1c9-4db5-bba2-df077974f75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_02b83c1b-679e-448e-947c-a49dc37ef60a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_2baaba00-d81e-4cb4-a673-01fe93c54bc9" xlink:to="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_02b83c1b-679e-448e-947c-a49dc37ef60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a22ed3cb-e680-4da8-81b2-98676c01b542" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_69eca5b7-83dd-4dac-b4fe-26d4c73f14c5" xlink:to="loc_dei_LegalEntityAxis_a22ed3cb-e680-4da8-81b2-98676c01b542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_074e451d-fc4e-46d3-a7ea-8b0e700d0711" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a22ed3cb-e680-4da8-81b2-98676c01b542" xlink:to="loc_dei_EntityDomain_074e451d-fc4e-46d3-a7ea-8b0e700d0711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CENDMember_ee3ebc25-771f-4a89-b672-006ca7426891" xlink:href="lsta-20250331.xsd#lsta_CENDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_074e451d-fc4e-46d3-a7ea-8b0e700d0711" xlink:to="loc_lsta_CENDMember_ee3ebc25-771f-4a89-b672-006ca7426891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_d32283e6-e349-4631-b07f-41ba544984f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_69eca5b7-83dd-4dac-b4fe-26d4c73f14c5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_d32283e6-e349-4631-b07f-41ba544984f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_ad158d5b-726d-49d2-85e0-7e8b74f9a442" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_d32283e6-e349-4631-b07f-41ba544984f4" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_ad158d5b-726d-49d2-85e0-7e8b74f9a442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_30306d3c-1035-4a67-9a8b-dae24b11b018" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_ad158d5b-726d-49d2-85e0-7e8b74f9a442" xlink:to="loc_us-gaap_ResearchMember_30306d3c-1035-4a67-9a8b-dae24b11b018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_69eca5b7-83dd-4dac-b4fe-26d4c73f14c5" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLossCarryforwardsBeforeWriteDown_ce4c5f67-cca2-4fc4-9668-341b35721b7a" xlink:href="lsta-20250331.xsd#lsta_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_lsta_OperatingLossCarryforwardsBeforeWriteDown_ce4c5f67-cca2-4fc4-9668-341b35721b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_f4940e8e-3fea-452d-b596-c8be42fdd419" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_f4940e8e-3fea-452d-b596-c8be42fdd419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_3086bfab-576f-46d8-8127-4d4cae50b5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_us-gaap_OperatingLossCarryforwards_3086bfab-576f-46d8-8127-4d4cae50b5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_FairValueMarketOfTaxNOLs_d6bc1d10-f318-4c78-a137-024cd7212905" xlink:href="lsta-20250331.xsd#lsta_FairValueMarketOfTaxNOLs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_lsta_FairValueMarketOfTaxNOLs_d6bc1d10-f318-4c78-a137-024cd7212905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_40819c75-f339-4fbc-a95a-ce879a2b3122" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_40819c75-f339-4fbc-a95a-ce879a2b3122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_9c48c22b-9b16-4c5f-8c81-6689bdc9353a" xlink:href="lsta-20250331.xsd#lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation_9c48c22b-9b16-4c5f-8c81-6689bdc9353a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_OperatingLossCarryforwardsPostAcquisition_a321b140-12d1-4007-99af-09fbc4ccd00a" xlink:href="lsta-20250331.xsd#lsta_OperatingLossCarryforwardsPostAcquisition"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_lsta_OperatingLossCarryforwardsPostAcquisition_a321b140-12d1-4007-99af-09fbc4ccd00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_0250719f-0031-4be4-a2a2-81c0d796f62f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_0250719f-0031-4be4-a2a2-81c0d796f62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_b5604aa0-a961-404f-9a51-b5a42370add3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_b5604aa0-a961-404f-9a51-b5a42370add3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_552646a3-2c4d-4ede-939e-87a0ecf21d05" xlink:href="lsta-20250331.xsd#lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_552646a3-2c4d-4ede-939e-87a0ecf21d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ProceedsFromSaleOfNOLS_300da3fd-5e42-4288-8e74-c8bb6ab54bd2" xlink:href="lsta-20250331.xsd#lsta_ProceedsFromSaleOfNOLS"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_lsta_ProceedsFromSaleOfNOLS_300da3fd-5e42-4288-8e74-c8bb6ab54bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_14c56605-3daf-4311-bd37-f8845fb6aa5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_14c56605-3daf-4311-bd37-f8845fb6aa5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LossOnSaleOfNOL_4e893c4e-2eb2-4383-aacf-a0e59c676d56" xlink:href="lsta-20250331.xsd#lsta_LossOnSaleOfNOL"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6a90e416-1f37-4ef4-b71a-99e6f30413f7" xlink:to="loc_lsta_LossOnSaleOfNOL_4e893c4e-2eb2-4383-aacf-a0e59c676d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e3719842-8936-442f-a01c-d12101c3790a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_760d1dff-81bc-45b1-8d8c-3c2c4b6ed479" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e3719842-8936-442f-a01c-d12101c3790a" xlink:to="loc_us-gaap_NumberOfOperatingSegments_760d1dff-81bc-45b1-8d8c-3c2c4b6ed479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5e110a21-9a48-4f69-bb65-6a6c22207170" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e3719842-8936-442f-a01c-d12101c3790a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5e110a21-9a48-4f69-bb65-6a6c22207170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_81459122-d752-4f32-bf49-4ac4caf9ad63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e3719842-8936-442f-a01c-d12101c3790a" xlink:to="loc_us-gaap_DepreciationAndAmortization_81459122-d752-4f32-bf49-4ac4caf9ad63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4735e34e-4911-4d68-8907-7c06ce2fc8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e3719842-8936-442f-a01c-d12101c3790a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4735e34e-4911-4d68-8907-7c06ce2fc8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#SegmentInformationScheduleofFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a633ac51-288f-414e-acb9-064c10d34f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2f1e5157-b789-4a4d-875a-924bd20d85dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a633ac51-288f-414e-acb9-064c10d34f5c" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2f1e5157-b789-4a4d-875a-924bd20d85dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f750b750-4483-4dcf-9330-364ea55d744d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2f1e5157-b789-4a4d-875a-924bd20d85dc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f750b750-4483-4dcf-9330-364ea55d744d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_072300d8-caa3-4828-9d94-883b792f7e88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f750b750-4483-4dcf-9330-364ea55d744d" xlink:to="loc_us-gaap_SegmentDomain_072300d8-caa3-4828-9d94-883b792f7e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ReportableSegmentMember_790447b2-60ef-4c45-a723-b06bc5ea65df" xlink:href="lsta-20250331.xsd#lsta_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_072300d8-caa3-4828-9d94-883b792f7e88" xlink:to="loc_lsta_ReportableSegmentMember_790447b2-60ef-4c45-a723-b06bc5ea65df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ca73ad08-d303-4e55-bbf7-2f51a7738b8e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2f1e5157-b789-4a4d-875a-924bd20d85dc" xlink:to="loc_srt_ProductOrServiceAxis_ca73ad08-d303-4e55-bbf7-2f51a7738b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_edf3fca4-f744-47e5-8bf6-c286d8dfe2ad" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ca73ad08-d303-4e55-bbf7-2f51a7738b8e" xlink:to="loc_srt_ProductsAndServicesDomain_edf3fca4-f744-47e5-8bf6-c286d8dfe2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_BolsterTrialMember_33c13de0-dbd5-44dc-b5f3-6e4d943f6c19" xlink:href="lsta-20250331.xsd#lsta_BolsterTrialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_edf3fca4-f744-47e5-8bf6-c286d8dfe2ad" xlink:to="loc_lsta_BolsterTrialMember_33c13de0-dbd5-44dc-b5f3-6e4d943f6c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_AscendTrialMember_a856db5d-8265-46ea-9ec9-a73f7ee342db" xlink:href="lsta-20250331.xsd#lsta_AscendTrialMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_edf3fca4-f744-47e5-8bf6-c286d8dfe2ad" xlink:to="loc_lsta_AscendTrialMember_a856db5d-8265-46ea-9ec9-a73f7ee342db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ChemistryManufacturingAndControlsMember_120e2d14-db0a-4961-891d-be9450dfe17a" xlink:href="lsta-20250331.xsd#lsta_ChemistryManufacturingAndControlsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_edf3fca4-f744-47e5-8bf6-c286d8dfe2ad" xlink:to="loc_lsta_ChemistryManufacturingAndControlsMember_120e2d14-db0a-4961-891d-be9450dfe17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ClinicalDepartmentMember_5f953d39-8eb3-4d12-a90a-d4ee38ea63ab" xlink:href="lsta-20250331.xsd#lsta_ClinicalDepartmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_edf3fca4-f744-47e5-8bf6-c286d8dfe2ad" xlink:to="loc_lsta_ClinicalDepartmentMember_5f953d39-8eb3-4d12-a90a-d4ee38ea63ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ResearchAndDevelopmentOtherMember_bb803e36-8d99-4595-a418-fe7b4dfd2d15" xlink:href="lsta-20250331.xsd#lsta_ResearchAndDevelopmentOtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_edf3fca4-f744-47e5-8bf6-c286d8dfe2ad" xlink:to="loc_lsta_ResearchAndDevelopmentOtherMember_bb803e36-8d99-4595-a418-fe7b4dfd2d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_17c7deca-63d3-4a16-9381-83667ffd8e59" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2f1e5157-b789-4a4d-875a-924bd20d85dc" xlink:to="loc_srt_ConsolidationItemsAxis_17c7deca-63d3-4a16-9381-83667ffd8e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a35aee48-be78-4cd3-baa5-61c280effa62" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_17c7deca-63d3-4a16-9381-83667ffd8e59" xlink:to="loc_srt_ConsolidationItemsDomain_a35aee48-be78-4cd3-baa5-61c280effa62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_b1b4bb4d-1c8f-4f2a-b184-179884ac625c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_a35aee48-be78-4cd3-baa5-61c280effa62" xlink:to="loc_us-gaap_CorporateNonSegmentMember_b1b4bb4d-1c8f-4f2a-b184-179884ac625c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e4cc137f-3430-4cb3-98c6-c44f09f3006f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_2f1e5157-b789-4a4d-875a-924bd20d85dc" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e4cc137f-3430-4cb3-98c6-c44f09f3006f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e4cc137f-3430-4cb3-98c6-c44f09f3006f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_751cf9a8-249a-4314-981a-79478ba043a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_751cf9a8-249a-4314-981a-79478ba043a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5d7da108-5c4c-4993-8cc4-007c8f97f0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5d7da108-5c4c-4993-8cc4-007c8f97f0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommunicationsAndInformationTechnology_3a982b01-36d1-41db-a44e-3d63fd55fa62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommunicationsAndInformationTechnology"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_us-gaap_CommunicationsAndInformationTechnology_3a982b01-36d1-41db-a44e-3d63fd55fa62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_FinanceGeneralAndAdministrativeExpense_5c1d8264-2020-4aef-9ce7-bfe29ab86c56" xlink:href="lsta-20250331.xsd#lsta_FinanceGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_lsta_FinanceGeneralAndAdministrativeExpense_5c1d8264-2020-4aef-9ce7-bfe29ab86c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LegalGeneralAndAdministrativeExpense_db42057c-a2a4-4f13-a72a-372b3b273c9d" xlink:href="lsta-20250331.xsd#lsta_LegalGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_lsta_LegalGeneralAndAdministrativeExpense_db42057c-a2a4-4f13-a72a-372b3b273c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDevelopment_f3edd3b5-e700-4bfa-95ef-a283f77073d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_us-gaap_BusinessDevelopment_f3edd3b5-e700-4bfa-95ef-a283f77073d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense_855d5c31-3fd2-4887-a716-443f336125d2" xlink:href="lsta-20250331.xsd#lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense_855d5c31-3fd2-4887-a716-443f336125d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_ba58004e-6c4b-4b2e-914e-56a7a900a0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_ba58004e-6c4b-4b2e-914e-56a7a900a0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_beedaed0-2732-4c68-bb0e-8da874911372" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_us-gaap_OperatingIncomeLoss_beedaed0-2732-4c68-bb0e-8da874911372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2e122452-0857-4f2e-a26a-d6bf9a14144f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2e122452-0857-4f2e-a26a-d6bf9a14144f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e1867642-01ab-42da-a31d-b691c03fde92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e1867642-01ab-42da-a31d-b691c03fde92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c6f653af-20d4-4294-80a9-675a5beb8425" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_us-gaap_ProfitLoss_c6f653af-20d4-4294-80a9-675a5beb8425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CashCashEquivalentsAndMarketableSecurities_21c11c0c-8e85-4caf-ba91-eb30c121e405" xlink:href="lsta-20250331.xsd#lsta_CashCashEquivalentsAndMarketableSecurities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dbc9031-99ac-474b-b042-bb1a3dfcfa55" xlink:to="loc_lsta_CashCashEquivalentsAndMarketableSecurities_21c11c0c-8e85-4caf-ba91-eb30c121e405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#AustraliaResearchandDevelopmentTaxIncentiveDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_435e2088-2816-4122-aeb9-20dcff2984b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayTable_e7495fe9-9fbf-4e27-b06e-fd2899565388" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_435e2088-2816-4122-aeb9-20dcff2984b9" xlink:to="loc_us-gaap_IncomeTaxHolidayTable_e7495fe9-9fbf-4e27-b06e-fd2899565388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_367e319d-fb41-4e8c-a1f0-778130a27200" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayTable_e7495fe9-9fbf-4e27-b06e-fd2899565388" xlink:to="loc_srt_RangeAxis_367e319d-fb41-4e8c-a1f0-778130a27200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9bea058c-b818-4ca5-9dca-9e7974f57696" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_367e319d-fb41-4e8c-a1f0-778130a27200" xlink:to="loc_srt_RangeMember_9bea058c-b818-4ca5-9dca-9e7974f57696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cdbcd02b-61f3-44f1-8468-660ef4295787" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9bea058c-b818-4ca5-9dca-9e7974f57696" xlink:to="loc_srt_MinimumMember_cdbcd02b-61f3-44f1-8468-660ef4295787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5c076c86-17a5-4a7d-a0ee-7326b2895224" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9bea058c-b818-4ca5-9dca-9e7974f57696" xlink:to="loc_srt_MaximumMember_5c076c86-17a5-4a7d-a0ee-7326b2895224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayLineItems_2665eff8-9175-467a-ba00-270299e4152f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayTable_e7495fe9-9fbf-4e27-b06e-fd2899565388" xlink:to="loc_us-gaap_IncomeTaxHolidayLineItems_2665eff8-9175-467a-ba00-270299e4152f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_e6e9be67-7817-49e0-ae2c-3d36954f7d07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_2665eff8-9175-467a-ba00-270299e4152f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_e6e9be67-7817-49e0-ae2c-3d36954f7d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_IncomeTaxIncentiveReceivable_d6f125ec-e738-4de7-923b-4a061e65556a" xlink:href="lsta-20250331.xsd#lsta_IncomeTaxIncentiveReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_2665eff8-9175-467a-ba00-270299e4152f" xlink:to="loc_lsta_IncomeTaxIncentiveReceivable_d6f125ec-e738-4de7-923b-4a061e65556a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#ContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fc7dad87-fa35-444d-b7a2-221bd3cff9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_91f6c0f6-1011-40de-866f-a99664dcd3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fc7dad87-fa35-444d-b7a2-221bd3cff9f2" xlink:to="loc_us-gaap_LossContingenciesTable_91f6c0f6-1011-40de-866f-a99664dcd3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_19fa1bc6-6e00-4215-905f-8d643d9b48e0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_91f6c0f6-1011-40de-866f-a99664dcd3ce" xlink:to="loc_srt_LitigationCaseAxis_19fa1bc6-6e00-4215-905f-8d643d9b48e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_8b399682-8f58-4b55-a462-8ffde29454ae" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_19fa1bc6-6e00-4215-905f-8d643d9b48e0" xlink:to="loc_srt_LitigationCaseTypeDomain_8b399682-8f58-4b55-a462-8ffde29454ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LingmedLimitedMember_5e392d02-ae2e-4602-ae65-d857827db4a3" xlink:href="lsta-20250331.xsd#lsta_LingmedLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_8b399682-8f58-4b55-a462-8ffde29454ae" xlink:to="loc_lsta_LingmedLimitedMember_5e392d02-ae2e-4602-ae65-d857827db4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_c08fbdff-5203-4922-b471-95b6b2ccdeeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_91f6c0f6-1011-40de-866f-a99664dcd3ce" xlink:to="loc_us-gaap_LossContingenciesLineItems_c08fbdff-5203-4922-b471-95b6b2ccdeeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_207d0fab-553b-4a4d-8af4-2523517834ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c08fbdff-5203-4922-b471-95b6b2ccdeeb" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_207d0fab-553b-4a4d-8af4-2523517834ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementPaymentTerm_7c1f6228-3c59-4a63-abdc-05a2d0006328" xlink:href="lsta-20250331.xsd#lsta_LitigationSettlementPaymentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c08fbdff-5203-4922-b471-95b6b2ccdeeb" xlink:to="loc_lsta_LitigationSettlementPaymentTerm_7c1f6228-3c59-4a63-abdc-05a2d0006328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementFutureMilestonePaymentsPercent_87be91b4-4a0c-4085-a5b3-f58caf806b60" xlink:href="lsta-20250331.xsd#lsta_LitigationSettlementFutureMilestonePaymentsPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c08fbdff-5203-4922-b471-95b6b2ccdeeb" xlink:to="loc_lsta_LitigationSettlementFutureMilestonePaymentsPercent_87be91b4-4a0c-4085-a5b3-f58caf806b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementMilestonePayment_4c03b2a5-985d-4540-9fa1-ea6533e2dfbe" xlink:href="lsta-20250331.xsd#lsta_LitigationSettlementMilestonePayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c08fbdff-5203-4922-b471-95b6b2ccdeeb" xlink:to="loc_lsta_LitigationSettlementMilestonePayment_4c03b2a5-985d-4540-9fa1-ea6533e2dfbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TechnologyTransferAgreementDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#TechnologyTransferAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/TechnologyTransferAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lsta_TechnologyTransferAgreementAbstract_788ee237-2eff-42f9-a6ad-510a8c1d979e" xlink:href="lsta-20250331.xsd#lsta_TechnologyTransferAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_15728ea2-69d4-4e15-b2b6-b4d6b82adceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lsta_TechnologyTransferAgreementAbstract_788ee237-2eff-42f9-a6ad-510a8c1d979e" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_15728ea2-69d4-4e15-b2b6-b4d6b82adceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ca72dad2-d89a-408e-af3f-98d77c740780" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_15728ea2-69d4-4e15-b2b6-b4d6b82adceb" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ca72dad2-d89a-408e-af3f-98d77c740780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e824a706-aa03-4e3a-90fa-1bfde7c3c03d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ca72dad2-d89a-408e-af3f-98d77c740780" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e824a706-aa03-4e3a-90fa-1bfde7c3c03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ImpiloMember_9e7791c3-63dc-4372-9ceb-11b387b118f3" xlink:href="lsta-20250331.xsd#lsta_ImpiloMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e824a706-aa03-4e3a-90fa-1bfde7c3c03d" xlink:to="loc_lsta_ImpiloMember_9e7791c3-63dc-4372-9ceb-11b387b118f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_8f4fb6fb-a105-4146-98f6-f5bae57a287e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_15728ea2-69d4-4e15-b2b6-b4d6b82adceb" xlink:to="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_8f4fb6fb-a105-4146-98f6-f5bae57a287e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_2db5dbcf-67bd-4487-a106-29e8b56abffd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_8f4fb6fb-a105-4146-98f6-f5bae57a287e" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_2db5dbcf-67bd-4487-a106-29e8b56abffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_InvestmentOwnedCanceledShares_746ff23b-7539-47ac-b389-bc845e63e0fa" xlink:href="lsta-20250331.xsd#lsta_InvestmentOwnedCanceledShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_8f4fb6fb-a105-4146-98f6-f5bae57a287e" xlink:to="loc_lsta_InvestmentOwnedCanceledShares_746ff23b-7539-47ac-b389-bc845e63e0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_68d2a3bf-c3c1-4705-91db-04b81f32463f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_8f4fb6fb-a105-4146-98f6-f5bae57a287e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_68d2a3bf-c3c1-4705-91db-04b81f32463f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_2d93eb62-d3dd-4c7b-85b4-8ae32c4cc38a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_8f4fb6fb-a105-4146-98f6-f5bae57a287e" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_2d93eb62-d3dd-4c7b-85b4-8ae32c4cc38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9bd94d91-82a7-4e80-9e8f-633c0ea22d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_8f4fb6fb-a105-4146-98f6-f5bae57a287e" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9bd94d91-82a7-4e80-9e8f-633c0ea22d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SAFEValuationCap_2d460e9a-3773-4b9c-bb92-f0937db81dc9" xlink:href="lsta-20250331.xsd#lsta_SAFEValuationCap"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_8f4fb6fb-a105-4146-98f6-f5bae57a287e" xlink:to="loc_lsta_SAFEValuationCap_2d460e9a-3773-4b9c-bb92-f0937db81dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SAFEDiscountRate_acbb6530-4831-4f92-b4d5-e5b4a3e23a8e" xlink:href="lsta-20250331.xsd#lsta_SAFEDiscountRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems_8f4fb6fb-a105-4146-98f6-f5bae57a287e" xlink:to="loc_lsta_SAFEDiscountRate_acbb6530-4831-4f92-b4d5-e5b4a3e23a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#LicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/LicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_257e8039-e562-4526-ab0d-aca10cda5367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae51398-afb8-4209-840f-711032b70f01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_257e8039-e562-4526-ab0d-aca10cda5367" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae51398-afb8-4209-840f-711032b70f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_37416ffb-a839-4fff-90c4-3e1e1322abd9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae51398-afb8-4209-840f-711032b70f01" xlink:to="loc_srt_CounterpartyNameAxis_37416ffb-a839-4fff-90c4-3e1e1322abd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_30f31751-04f8-4538-8f74-bbcbc986a162" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_37416ffb-a839-4fff-90c4-3e1e1322abd9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_30f31751-04f8-4538-8f74-bbcbc986a162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SanfordBurnhamPrebysMember_cb2748cc-1488-4069-8fc2-c8a440bfc0e8" xlink:href="lsta-20250331.xsd#lsta_SanfordBurnhamPrebysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_30f31751-04f8-4538-8f74-bbcbc986a162" xlink:to="loc_lsta_SanfordBurnhamPrebysMember_cb2748cc-1488-4069-8fc2-c8a440bfc0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7ac2bcf5-cb25-4615-a25d-18b079f03ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae51398-afb8-4209-840f-711032b70f01" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7ac2bcf5-cb25-4615-a25d-18b079f03ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b0b6cd52-08c3-4612-b952-c9bf2f20f750" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7ac2bcf5-cb25-4615-a25d-18b079f03ecb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b0b6cd52-08c3-4612-b952-c9bf2f20f750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_eba1d8dd-2fcc-4df0-a6a3-19a0c5b344c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b0b6cd52-08c3-4612-b952-c9bf2f20f750" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_eba1d8dd-2fcc-4df0-a6a3-19a0c5b344c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bd137df2-b8c7-42c4-b479-e1577bfbc1a6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae51398-afb8-4209-840f-711032b70f01" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bd137df2-b8c7-42c4-b479-e1577bfbc1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ecce0135-3ba5-4047-9ec4-f88bc7a496cc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bd137df2-b8c7-42c4-b479-e1577bfbc1a6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ecce0135-3ba5-4047-9ec4-f88bc7a496cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ImpiloMember_a509a8cc-6eec-4bb4-8761-ac2bdc117721" xlink:href="lsta-20250331.xsd#lsta_ImpiloMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ecce0135-3ba5-4047-9ec4-f88bc7a496cc" xlink:to="loc_lsta_ImpiloMember_a509a8cc-6eec-4bb4-8761-ac2bdc117721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c8d1c2-db2d-42ea-a24f-4e7a0c1246a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bae51398-afb8-4209-840f-711032b70f01" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c8d1c2-db2d-42ea-a24f-4e7a0c1246a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SharesIssuedUnderLicenseAgreement_0c55d1e9-3bd4-4411-81b7-06facc69de88" xlink:href="lsta-20250331.xsd#lsta_SharesIssuedUnderLicenseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c8d1c2-db2d-42ea-a24f-4e7a0c1246a2" xlink:to="loc_lsta_SharesIssuedUnderLicenseAgreement_0c55d1e9-3bd4-4411-81b7-06facc69de88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_d70d7d85-3973-403c-bb42-a2721702ea4f" xlink:href="lsta-20250331.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c8d1c2-db2d-42ea-a24f-4e7a0c1246a2" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_d70d7d85-3973-403c-bb42-a2721702ea4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_171d8007-1a8d-41fa-9c61-ea6eb3975029" xlink:href="lsta-20250331.xsd#lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c8d1c2-db2d-42ea-a24f-4e7a0c1246a2" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_171d8007-1a8d-41fa-9c61-ea6eb3975029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_991173ee-733e-4bc7-9345-eab5bcb8d38f" xlink:href="lsta-20250331.xsd#lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c8d1c2-db2d-42ea-a24f-4e7a0c1246a2" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_991173ee-733e-4bc7-9345-eab5bcb8d38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_82daf716-5480-49c4-9412-680a1dba9b1a" xlink:href="lsta-20250331.xsd#lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c8d1c2-db2d-42ea-a24f-4e7a0c1246a2" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_82daf716-5480-49c4-9412-680a1dba9b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_83822e36-c6ce-48a1-b6ab-fb3703e34937" xlink:href="lsta-20250331.xsd#lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c8d1c2-db2d-42ea-a24f-4e7a0c1246a2" xlink:to="loc_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees_83822e36-c6ce-48a1-b6ab-fb3703e34937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_66a710f7-e4df-4c8d-9bd5-fea737f3136c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c8d1c2-db2d-42ea-a24f-4e7a0c1246a2" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_66a710f7-e4df-4c8d-9bd5-fea737f3136c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_SharesHeldByThirdParty_8276bc02-3e28-49c1-870d-2de3ecb2d324" xlink:href="lsta-20250331.xsd#lsta_SharesHeldByThirdParty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c8d1c2-db2d-42ea-a24f-4e7a0c1246a2" xlink:to="loc_lsta_SharesHeldByThirdParty_8276bc02-3e28-49c1-870d-2de3ecb2d324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" xlink:type="simple" xlink:href="lsta-20250331.xsd#ResearchCollaborationandLicenseAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_155512a8-f9c5-465b-94f7-81c10ecb1218" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7dbc55a-2745-437f-8f87-e0da2d4db766" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_155512a8-f9c5-465b-94f7-81c10ecb1218" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7dbc55a-2745-437f-8f87-e0da2d4db766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_be47dc59-d615-4e89-9c16-316d1486466c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7dbc55a-2745-437f-8f87-e0da2d4db766" xlink:to="loc_us-gaap_TypeOfArrangementAxis_be47dc59-d615-4e89-9c16-316d1486466c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ef890c3a-bea2-4aaf-92e5-43566b3656b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_be47dc59-d615-4e89-9c16-316d1486466c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ef890c3a-bea2-4aaf-92e5-43566b3656b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ExclusiveLicenseAndCollaborationAgreementMember_ebd43310-9cef-478c-86ab-13ac35c539b4" xlink:href="lsta-20250331.xsd#lsta_ExclusiveLicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ef890c3a-bea2-4aaf-92e5-43566b3656b2" xlink:to="loc_lsta_ExclusiveLicenseAndCollaborationAgreementMember_ebd43310-9cef-478c-86ab-13ac35c539b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0c28d588-1147-424b-8d12-0546e971abda" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7dbc55a-2745-437f-8f87-e0da2d4db766" xlink:to="loc_srt_CounterpartyNameAxis_0c28d588-1147-424b-8d12-0546e971abda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7deb10af-0e4e-4442-8110-900b7818b539" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0c28d588-1147-424b-8d12-0546e971abda" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7deb10af-0e4e-4442-8110-900b7818b539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_QiluMember_d7600670-6b6e-4be4-9ca2-3c89e07bc3ee" xlink:href="lsta-20250331.xsd#lsta_QiluMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7deb10af-0e4e-4442-8110-900b7818b539" xlink:to="loc_lsta_QiluMember_d7600670-6b6e-4be4-9ca2-3c89e07bc3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_KuvaMember_162a6a2c-ff6a-497f-a758-8b7a6b629f95" xlink:href="lsta-20250331.xsd#lsta_KuvaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7deb10af-0e4e-4442-8110-900b7818b539" xlink:to="loc_lsta_KuvaMember_162a6a2c-ff6a-497f-a758-8b7a6b629f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_479b30e4-b14c-4df8-aa54-23c15ae0849b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7dbc55a-2745-437f-8f87-e0da2d4db766" xlink:to="loc_srt_ProductOrServiceAxis_479b30e4-b14c-4df8-aa54-23c15ae0849b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_74a9397f-cd28-4115-9822-c419ab9ca62e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_479b30e4-b14c-4df8-aa54-23c15ae0849b" xlink:to="loc_srt_ProductsAndServicesDomain_74a9397f-cd28-4115-9822-c419ab9ca62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_32f6c2f7-af13-4919-bfef-30f8c6611639" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_74a9397f-cd28-4115-9822-c419ab9ca62e" xlink:to="loc_us-gaap_LicenseMember_32f6c2f7-af13-4919-bfef-30f8c6611639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c3d47e7d-9826-4a34-9923-396706485517" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7dbc55a-2745-437f-8f87-e0da2d4db766" xlink:to="loc_srt_RangeAxis_c3d47e7d-9826-4a34-9923-396706485517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_79a1c480-8455-4807-ba3c-aef9f595df64" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c3d47e7d-9826-4a34-9923-396706485517" xlink:to="loc_srt_RangeMember_79a1c480-8455-4807-ba3c-aef9f595df64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cd6f447f-2dc0-472f-a904-d11408651f31" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_79a1c480-8455-4807-ba3c-aef9f595df64" xlink:to="loc_srt_MinimumMember_cd6f447f-2dc0-472f-a904-d11408651f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1809d657-035f-4670-a21f-ed31564d1602" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_79a1c480-8455-4807-ba3c-aef9f595df64" xlink:to="loc_srt_MaximumMember_1809d657-035f-4670-a21f-ed31564d1602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_5725c0ac-3168-4a42-9d0e-0656ddf0369a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7dbc55a-2745-437f-8f87-e0da2d4db766" xlink:to="loc_srt_LitigationCaseAxis_5725c0ac-3168-4a42-9d0e-0656ddf0369a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_09346bb0-9093-4d21-97c5-85333ef89cb1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_5725c0ac-3168-4a42-9d0e-0656ddf0369a" xlink:to="loc_srt_LitigationCaseTypeDomain_09346bb0-9093-4d21-97c5-85333ef89cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LingmedLimitedMember_1fb1cb6b-e9cd-4039-a6da-bf803cddc681" xlink:href="lsta-20250331.xsd#lsta_LingmedLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_09346bb0-9093-4d21-97c5-85333ef89cb1" xlink:to="loc_lsta_LingmedLimitedMember_1fb1cb6b-e9cd-4039-a6da-bf803cddc681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f63264e2-9410-46e4-951d-a63980517b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7dbc55a-2745-437f-8f87-e0da2d4db766" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f63264e2-9410-46e4-951d-a63980517b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c8e12c90-88af-427e-a2b8-5263441c6672" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f63264e2-9410-46e4-951d-a63980517b4e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c8e12c90-88af-427e-a2b8-5263441c6672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_6b7b3eb3-d1e1-4170-8ce4-a05e2ed67e71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f63264e2-9410-46e4-951d-a63980517b4e" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_6b7b3eb3-d1e1-4170-8ce4-a05e2ed67e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_9aa0e3b0-1d47-4756-8e0e-8bcef7b07d82" xlink:href="lsta-20250331.xsd#lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f63264e2-9410-46e4-951d-a63980517b4e" xlink:to="loc_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount_9aa0e3b0-1d47-4756-8e0e-8bcef7b07d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenuePerformanceObligationPercentageOfNetSale_1067e6bc-adc0-42e5-a90c-e3af99952fb1" xlink:href="lsta-20250331.xsd#lsta_RevenuePerformanceObligationPercentageOfNetSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f63264e2-9410-46e4-951d-a63980517b4e" xlink:to="loc_lsta_RevenuePerformanceObligationPercentageOfNetSale_1067e6bc-adc0-42e5-a90c-e3af99952fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_ad950723-b2da-425d-8e6a-241390327408" xlink:href="lsta-20250331.xsd#lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f63264e2-9410-46e4-951d-a63980517b4e" xlink:to="loc_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues_ad950723-b2da-425d-8e6a-241390327408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementFutureMilestonePaymentsPercent_d921bcfb-d115-4872-9642-9b7dcef22ba2" xlink:href="lsta-20250331.xsd#lsta_LitigationSettlementFutureMilestonePaymentsPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f63264e2-9410-46e4-951d-a63980517b4e" xlink:to="loc_lsta_LitigationSettlementFutureMilestonePaymentsPercent_d921bcfb-d115-4872-9642-9b7dcef22ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_LitigationSettlementMilestonePayment_6a7c87e1-34d0-4d8a-8023-8e3e66c18fe6" xlink:href="lsta-20250331.xsd#lsta_LitigationSettlementMilestonePayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f63264e2-9410-46e4-951d-a63980517b4e" xlink:to="loc_lsta_LitigationSettlementMilestonePayment_6a7c87e1-34d0-4d8a-8023-8e3e66c18fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_298e0994-4712-4d29-99cc-fa4105ad9343" xlink:href="lsta-20250331.xsd#lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f63264e2-9410-46e4-951d-a63980517b4e" xlink:to="loc_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate_298e0994-4712-4d29-99cc-fa4105ad9343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>lsta-20250331_g1.jpg
<TEXT>
begin 644 lsta-20250331_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKZO
M_P""9TKP?M+/)&[1R)X?U)E=3@J1%P0:]+_8K@UC]LSPU\0_A_\ %?6K_P 2
M:%:V]K=Z?XAU>8W5[I-X\P15AN)26'F@$;"Q!V$ <L#YE?&^PE.\?=CRMN^N
MK:T5NENYSSJ\C=UHK?B? M%?I-H?P_\ V7_^%\>(?AEXPTWP?:64%^NCZ#;:
M6_B"/5UN]XB*WD[HL#[F.0P<H#@#<.:T/AO^P-\._A_X:U2#XG:;'J/BG3VU
MC7X1/?7*))I5F5AA$J6Q)V.SK,2B&3'R@=5/-+-J,%[\))Z65M[]M>G4AXF*
MW3/S)HK]/?V2+?X/>)/%D=QX8U+PQ:?$HZ+JUKJ5IX0M=6BTR:R>-?+FQ?1)
ML=& 4A3R'SS_  \Y'^SY\+)_VF=0_9Q'@*UCL+?PYYR^-/M%S_:IOA:K-]J+
MF7RO+^;'E^7MW>W%/^U8*<H2@URJ_P NKU^5NX?6$FTT]#\Y:*_3V/\ 9I^!
M$_[37A/X.GX6CR=3\*IK=QKD&N:AYRS\M@*9B@C(C93QG,@P5QSS?CKX0_ G
MPYX?^/\ JMM\(+8_\*TU&TL+&)M?U,K?&?;&3/\ Z1D!9&+?(5)&!GJ21S:E
M)I*$M4GTZNRZ]P6(B]+/\/3N?G-17Z=_&W]D;X/?L_>#M>\>VEEH$']HWUC9
MZ98^,Y=4O-,TH/ ))5VV:R3R.^&P9,A>.1P&X'QOX _9OTWX!>._BEX)\+:?
MXXDM+O3K2&UFO-8MK'3[N546XB4,\$LD0Y=2W/S@9 &T.&:TZJ4H0DTVE>W5
MVTWMU_,:Q$96:3/@*BOU.^('@7P5\"OV>OCU8^'O ND2:,;'P[J3:?>WNH2+
M<_:)MVR9Q<J^(VSL\MD.,;R_.>6_X)SQ^&=<_9E^(/A7Q7F+2?%WB-?#ZLJA
MA'-/: 1'D\'<H"GG#;?J(>:IT95XP=DTO6Z3\]K[?B+ZPN5S2V/S:HK]<_@Q
M\)+?X#_LR^(/AGJ;-%XTN)+/7-<-G=%)(%GU!((%22,AD/EVY8$,"#D@@GC3
M^*'P \/?%74?A_\ #_5KJ_;PXOCS5IYQ=:A/<W5S'%:O*8C<2NTK%B,%BQ8+
MG!&!C'^VJ:FX\ONIO6_1*]_\B?K4;VMH?CS17WMX>@_98UR+Q%9^+1X!T_Q%
M;7$\?AVWTAO$MK9LNQUCBU&22%#E7V%I$()YZ=#ZI\'?AWI?PX\'?$76K/X7
M^$K+2M0^'.J7"Z_X?\3WVK:;K9C"B6&,/,'@CSC<I)DR3ME&"!TU,S5-:TY)
M^=E?TN]?DBW72^RS\M:*_09?A1\+O"'Q-^!_PZN?AAI&M6_Q'TJ'5-7U?[3?
M>=;-=%S''9-]H/EI#@??WLR@;F)RQZOQQ^RE\'+C]I'5/@KHG@.#1XT\%3:O
M'XD?5K^2\CO0<1OM:<P^6!C<IC.23C XH>:TD[.+V;Z;)VON'UB*Z,_,ZBOT
M0^(WPI_9P^#7Q,N/AGXTG\-Z5X=M-'CCN-6\O6Y?$OVYX0ZW2O' UH4)8'RP
M2H[CJE<?\1/@G\+O&G@_QI>?!7POX8\7Z5INDQWUI>Z=XJO[?Q%8K&H-Q<75
ME= Q2IG/R1HAQC!R0!<,RA*SY))/9M66OFW8:KIVT9\/T445ZYTG3?$__DI?
MBW_L+W?_ *.>N9K]C->_X)+_  A\0ZYJ.JW/B/QLEQ?7,EU(L5]9A SL6(4&
MU)QD\9)JC_PZ ^#?_0R^.?\ P/L__D2OFH9]@E%)M_<<"Q=)(_(&BOU^_P"'
M0'P;_P"AE\<_^!]G_P#(E'_#H#X-_P#0R^.?_ ^S_P#D2J_M_!=W]P_KE(_(
M&BOU^_X= ?!O_H9?'/\ X'V?_P B4?\ #H#X-_\ 0R^.?_ ^S_\ D2C^W\%W
M?W!]<I'Y T5^OW_#H#X-_P#0R^.?_ ^S_P#D2C_AT!\&_P#H9?'/_@?9_P#R
M)1_;^"[O[@^N4C\@:*_7[_AT!\&_^AE\<_\ @?9__(E'_#H#X-_]#+XY_P#
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M;_Z&7QS_ .!]G_\ (E']OX+N_N#ZY2/R!HK]?O\ AT!\&_\ H9?'/_@?9_\
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MP?7*1^0-%?K]_P .@/@W_P!#+XY_\#[/_P"1*/\ AT!\&_\ H9?'/_@?9_\
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M\1BYT+5IX)Y]-CLH(X8_( 6%(@J Q(@4 (A /)()))_2;_AT!\&_^AE\<_\
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M_P#D2DLURI.ZA_Y*'UC#]OP/R!HK]?O^'0'P;_Z&7QS_ .!]G_\ (E'_  Z
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M7],T9XDU#4;2Q>4A8UN9UC+D] ,D9JZCK(H92&4C((.013LP'4444@"BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBC]N.QUKXF_$+QWJ%M;SW;VL%S)']INKR10"[ LP6.)"P4* >C !0HS]6_\
M!6K1KO4_V7;.ZMS)Y&G>(K2YN0HROEF*>(%O0;Y4]LD>U=)_P3 U_3M7_8_\
M,V5G(C76E7E]:WJJ>5E:YDF7/_;.:.O-P]26#RUXBA\<I6;[+^OS,(2=*ASP
MW;/$?V0O#GQ:_96_:EU'X17\&N>*_AE<[E35H;"XDL+5C%YT,ZG#+ 6)$<BY
MQN;DG:#7E/P)_P"4N.I?]C1XC_\ 2:]K]$F_:Q^'8^/ ^#Z:A=S^-2P3R(+1
MY(0_D^<5,BY *QY)SP,$$Y&*_.WX$_\ *7'4O^QH\1_^DU[79AZM2LJ]2K#E
M;I??H_>^9K"3FIRDK/E^_P SU;_@LO\ \BS\+?\ K\U#_P! @KG_ (:?L4>,
M_P!L_P"%N@>./B!X^N?#]D=.BL_#.AVMMY\-I:0H(DD=6=0"^S<=O+;@2W.T
M=!_P67_Y%GX6_P#7YJ'_ *!!7UU^QOJUEK/[+'PMGL)8YH8_#]I;.8R"!+%&
M(Y%..X=6!]Q6/UFIA<KHU*6CNU>VVK_,CGE3P\7'?4_/;]@[XH>+OV:_VJ;S
MX)^*;R:71;Z^FTF2R,C/!;WJY,5Q"#T63 7C&X2*Q^Z,?5'[<'P^^/WQE\3^
M&O!OP[$NB?#NX,0UK6K74(H)2[R%7\Q/,65X8TPVQ1\Q)R#A2/D+Q<\?CG_@
MK+;G1)/,6'QA8AVA&>;2.+[0/P,$H/T->F_MV?M)?$7QA^TK8? 3P'KD_A6T
MDNK#3;BZM)6@ENKF[$;+OE7YEB59D!5<9(;.> .RM2G5QE*M345)PYI76B\[
M=S647*K&44KM79UOB3_@D-\-[#P=-]D\>>(+/Q"(=L5[J,EM]B:?'&8A$K!2
M>WF$CU-8/_!(WXW>)O$=UXK^'FLZG<:II.FV4>HZ8+N5I&M '$;Q(23B,[D(
M7H"#CJ:]"L?^"7/P?\+>&+W6/'GB'Q#XCO;:W:ZU#5KF^%O&JHA+LJ@$A< G
MYF8\=:^>/^"/'_)</&G_ &+I_P#2F&LG56)P.(YJCJ<MFFXVL_+7_+\2>;VE
M*=Y<UO(\4_:4_9:M?@I^TEH/PX@\0S:M!K7V.5M0DM1$T7VB=HR @8@[=N>H
MS[5^E'P:^!NA_P#!.[X.?$;Q%=>([GQ1IXB74I0]HMN^Z)&5(EP[9+LZJ"<8
M)KY*_P""A3"']O\ ^'TDAV((-&8LW P+V3)K[<_X*"Z3=ZS^QW\28+)G66.T
M@N6V#K'%=0R2 ^VQ&I8RO5Q%/"TJDO=J6YMM=4%2<IQIQD]'N?$7[.WP$\1_
M\%'_ !%XH^(WQ6\8:M!H%E>?8K2STQE7;(5#M%"'5DBCC1H_X6+%\DYR3G_&
MKX;>*?\ @F/\7O"OBCP#XHU#5?!^M._F6%\X!G$17S;>X50$?*N"L@52#G !
M7)ROV&?V'? O[5/PXUS6M;\3:SI6M:9JILWL]-:':(3%&\<A#HQ!9C*.N/D^
MM>P?$/\ X)L?L_?"5-.;QE\7-8\-)J+O':MJ-Q:Q"4H 6P3%V!&3[CU%=M3$
M4:6*E0G4;AMR*&EK=_QO8UE.,:C@WIVL>M_M_?M42>!_V7] U+P7?SV>H?$"
M*+^SK^+Y)8;)XEEDD4Y^5RCQH".1YA(((!KYK_9@_P""84'QI^#NG^./%7BV
M_P!"O=;1KG3;6Q@23RHMQ"2S%^6+X+!5(^4J=V20+W_!3CX>6G@GX(_L_P!C
MH.J3:YX9T:UNM.M=1=UD6XC:*V:!]Z *=R1-@C@@<=Z^]OV0M:L=>_9;^%5S
MI\J301^'+&U9HSD"6&%891]1)&X/N#7F.M+ 9=">%=G*3N^NC=E]R.?F=&BG
M3ZL_*KX<:/XK\._\%%?"NC>-M0.K>)=+\1VFGW.H,<FZ2&-(H923R=T21MD_
M,<Y/.:_;.OR$\3:[8^(O^"M5O>:=.ES;+XJLK8R1D$>9#!%%(,CT>-A^%?KW
M7-G<G/V$FK-P1&*=^1OL<-\=_P#DA_Q#_P"Q=U'_ -)I*_/G_@DGXNT;P%X&
M^-?B'Q!J,&E:+IW]F3W5Y<-A(T"W7XDDX  Y)( !)%?H-\=_^2'_ !#_ .Q=
MU'_TFDK\5OV1O@+XU_:8\17?@71[^YTOP0;FWU#Q'>)_J8Q'YBQ9'\<I#RA%
M/<LQX4D:Y92A6P->%27+&\;OR3O_ ,,50BI4IJ3LM#Z%O=;\6_\ !4WX_P#]
MC6=Q/X;^$7AEQ<21[AYBQ,2HE9<D-<2@,%ZK&H/7#;_JS]KWXM:=^Q)^S)8:
M-X LH='U&Y(T?0HHT#+:\%I;A@?O,!DY;)+NI.>:^,M(CG_X)R?MVI9R33CP
M!JNV(S3MGS-+N&^5V/=H)%Y.,GRFZ;J]A_X+):9<W?A#X7:O#(SZ;!>7UO)L
MY1GECA:,Y_W8I,?C7;4I0JXO#45_ :O%=]+N_=WW]?4U<5*I"/V.AB_L_?\
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MQR,'1CEF,H]/D^M1@9KZK6QE2?+-RMS6NUMTTW%2?[N55NSON:_QN^%WB?\
MX)E_%OPIXM^'_BC4=3\'ZQ*PDL;UP#,(BIEMKD* D@9'RKA00<X *@GZ*_X*
M;>*[#QW^Q7X9\2Z6SOIFL:IINH6ID&&,4MO,Z9'8X89%<!\1/^";/[/WPD33
MG\9_%S6?#2:B[QVK:C<6L0E9 "V"8NP(R?<>HKI/^"@7A+2O ?[ 7@GP_H6K
MMKVB:?J.G0V&IO(DGVFW$$WEN&3Y6!4C!7@C%;*K2KU\--2<IIV<N6UU_P
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MS26(G)-=S!\?>&=*\9^!_$&@ZYL&C:G83VEXSD +$\95VR>F 2<]L9K\V_\
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ML8;R+2-B&=(BWS.S,,M(P!(X 'S;L#]OK]A;5_VG-4T3Q7X0U2RLO%&FVO\
M9\UKJ;M'!<VP=Y$*NJL5=6=^",$-U7;S]GT5*S#$+$?6N;WOZTMV!5IJ?M+Z
MGRY^Q'\-/CM\.K?Q+#\9?$K:[;21VL6D12ZB;R2'9YGFDL1GG=&,DDG;V[^:
M?L/?L4_$']GCX]^)_&/BF;1I-(U+2;JR@73[MY91))=02KN4QJ -L39.>N*^
M[J*<LPJOVMDE[2U[+MV!UI>]YGP_^W5^P'J?Q_\ %-KX_P# 6HVFF^+XH$@O
M+2]=HH[P1_ZN1)%!*RJ,+R,$!>5V\\1X<_8A^/GQ7TJ>#XW?$ ZQI6EV<[:/
MH#:BUPMQ?>4RP27#!0-JLP.X[V.". 3G]%Z*UIYIB:=*-)6]W9M:KT92Q$U%
M1['R'_P3T_96\:?LOZ-XVM?&,NERRZQ<6LMM_9EPTP C64-NW(N/OC'7O7,_
MM6_\$]]6^(7Q+_X6E\)/$L?A+QP\RW%U#/-);Q22JN//AEB4M'(<#(((8DDE
M><_<5%9_VCB%B)8E/WGOV?R)]O/G<^K/S/UG]C#]JS]H![/0?BO\2;&#PI!.
M)I +A9B2. RPQ1HLC#)QYC#&3^/WW\'/A'X=^!GP[TGP9X7MV@TK3T(#RMNE
MGD8[GED;NS,23V'     [6BHQ..JXF*IRLHKHE97[BG5E45GHO(*^,OVY/V
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M5D*=651)/8****X#$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6TK5IOB,_P //AAIEJ]QJ\VF7LEIJ+RX;;M=4(*\H N>3GY6)7"OY!IV/?\
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MO8_V6?'WBO1/C]\2/A+K/B/4?&6FZ,KW5AJ>KSF:XBVNBE'D.2<B5>,X!C.
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M5/$&I36ER]K=#Q+=I=W<,@56V>>L:>8F&!#%<\D'I7N=,045SNN?\)9]N/\
M8W]C?8MHQ]N\[S-W?[O&*S_^+@_]2S_Y,4 =E17&_P#%P?\ J6?_ "8H_P"+
M@_\ 4L_^3% '945QO_%P?^I9_P#)BC_BX/\ U+/_ ),4 =E17&_\7!_ZEG_R
M8H_XN#_U+/\ Y,4 =E17&_\ %P?^I9_\F*/^+@_]2S_Y,4 =E17&_P#%P?\
MJ6?_ "8H_P"+@_\ 4L_^3% '945QO_%P?^I9_P#)BC_BX/\ U+/_ ),4 =E1
M7&_\7!_ZEG_R8H_XN#_U+/\ Y,4 =E17&_\ %P?^I9_\F*/^+@_]2S_Y,4 =
ME17&_P#%P?\ J6?_ "8H_P"+@_\ 4L_^3% '945QO_%P?^I9_P#)BC_BX/\
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M=/,G&24*;\D#&[?N_P!JOH?3["WTJPMK*TB6"TMHEAAB3HB* %4>P  KE_\
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M7&_\7!_ZEG_R8IT/_"?>:GF_\(YY6X;]GVC=COCWIB.PHHHH **** "BBB@
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MW/U6>X4445) 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^I_M$Q>,-0\!?#3X?_$#QM9Q:_XB-OK<GB28)K.EQ;T46T<X7< <O\QD=P4
M+8)!^F/ _P"R-I/PPO[^X\'>/O&_AN&[N9;DZ?:7UK)91&0\JEO+;/'QA0&*
MEP% W5!=_L2?#J_TN]6Z?6)_$=WJ8UB3Q:UVJZJ+H,2'614"*!N.$$>WH<9
M(0SP+]IC2O%WP@^,WP^TS1/B1XJU/PKX@U>VCD\*Q^)[@ZF3O1)%69YE<1R
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M17YW_$[X5:IX%^#OA[48O#NK:7)?>"I_^$DNI;>9#)=&YA9%NF8??!+;5?D
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M.[S.O!4#_:KI_AU^QUK7PYT]?#B>%_A9XGTM-4>=/$OB327N]2^QMSY30>6
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MWP5_X W?_P E4?\ #V'XN?\ 0N^"O_ &[_\ DJOBRBCV-/\ E#ZS6_F/M/\
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M ( W?_R51_P]A^+G_0N^"O\ P!N__DJOBRBCV-/^4/K-;^8^T_\ A[#\7/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBKW_ "+^IT/Y?Q9\2_#O_@G'?_"_3[J/1?B+I[7]TW[Z_N_#+R2;1T10+T
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M!_ZJU_Y;?_W77Z,T4?6*O?\ (/J=#^7\6?G-_P .@?\ JK7_ );?_P!UT?\
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M5A1113("BBB@ HHHH **** "BBB@ HHHH **** "BBB@!\/^M3_>%:=9D/\
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M .!\O_Q5'_"+P?\ /[J?_@?+_P#%5L446 Q_^$7@_P"?W4__  /E_P#BJ/\
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M\'_/[J?_ ('R_P#Q5;%%%@,?_A%X/^?W4_\ P/E_^*H_X1>#_G]U/_P/E_\
MBJV**+ 8_P#PB\'_ #^ZG_X'R_\ Q5'_  B\'_/[J?\ X'R__%5L446 Q_\
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M_/\ ZK_X,)?_ (JC_A$H/^?_ %7_ ,&$O_Q5;E% &'_PB4'_ #_ZK_X,)?\
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M?"^DW/@V2276YKF-88 TC&(R;G4%7;:N-PSNXI/$/Q6\5?LDZC\/+3XG>&_
M?CK1[:U:WT'7M$A":G:0(%4,I=<*-K+_ *M0#S\Y- 6/M^R\?>&-2\2W7AVS
M\1Z3=^(;12]QI,%]$]W"HQDO$&WJ!N7J.X]:SO GQ8\,?$F^UVRT"^GN;S0Y
MUM=1M[FPN+22VE()"LLT:$_=/3-?G'X07Q7\'O$7PX^/FN:%JUI%K^KSS>(-
M7NIH)+6:UO6!B,:),TJ@1F1OGC09" 9XKZU_99D2;XV_M#R1L'1_$-NRLIR"
M#&^#3 ^EJ***!!1110 4444 %%%% !636M636D#6GU"BBBM#8**** "BBB@
MHHHH **** "BBB@ HHK*\4^*]'\$:#=ZUKVHV^E:7:(9)KFY?:J@#/U)/8#)
M)X )H U:*XRQ^,?@_4D\'O;:OYB^+E=M$/V:8?:PJ>8W5/DPO/S[?SKI-?U[
M3O"VBWNKZM>16&F6433W%S,V$C11DDT"/CC]HV+0-+^..LZ5X^TP1^&_%5K;
M26'B."'=<:9-'&(]RG^*,-DO&.H<'TKQ7QY\1M&\&^'+OP!\.97.DS876O$)
M79/K,B\%5[I;@YPF><G/4Y^MOB3\9/@A\1M$33/'1N[*TFMS?:=-JVD7EG+<
M1[@OF6;-&&=B2ORIDL"/E(S7G/@_X1?L]:;J>MWVHW7B..;P_9C5K[2/%5O-
M:F*VZB40^0CR)GC +<X!'(!_/\?DN,J5IO#.-I-^\]))/5KT_&VFQ^7YGP]C
MZN(F\(X\LV_>>DDI:N/I=O5:VTVT/3OV&M O]$^!,$M\CHNHZA/>6RR#!$)"
M(,#T)1F'KNSTQ7T%7-?#CQIX:\?^#--UKPA=PWGAV5#':200M"@5"4*B-E4K
M@J1@@=*XR?\ :E^'-OHMYK+:CJ[:+9RO#<:I'X;U-[2-T?8P,PMRG#<?>ZU]
MG@\.L)AX4$[\JL?H. PJP.%IX9._*DKGK%%>8R?M*_#RVCU5KW6;O2WTRQ&I
MW,&J:/>V<XM2VP3)%+"KR+N.,H&Q7I-I=Q7]I#<P-O@F19(VP1E2,@X//0UV
MG>2T444#"BBB@ HHHH **** +%E_K3_NU>JC9?ZT_P"[5ZL9;G//<****D@*
M*** "BBB@ HHHH **Y3XJ?$;3?A+\/=<\6ZL<V>EVS3>4&VM,_1(U/JS%5'U
MKSOX??M6>'?$?PTTCQ/XHM+CPAJ>H7\^FCP_Y<]]>_:(V.42*.'S9#LVL<1_
M+NY]: /;ZXWXP>$+[QU\-M<T;2[Q[#59H1)9W*.4*3QL)(SD<@;E7D5Y19?M
MR?#J_P#B#>:)#?>9H%MHW]JR:[%%<.8W$I1X9+=82\6P89FD*XR!CO70Z'^U
MAX!U*&^O+CQ#I8TQ;B9+*;3FNKJ6>&'B6>2+[,IC13QO!>,]I.U9U(1JP=.6
MS5C.K2C6IRIRV::^\^,_%_[0>IZ!'>B7P=#X<^+4T9L-8\1O%LF,0'#QQ8Q'
M,X/S2 <@ CJ-M+]D3X6:Q\2/C)H^LF"=M)T:[74;S49 Q4RH0Z)NZ%R^TXSG
M&3]?LOQ#\;?@!XP\.P>)=>U3PUK&DC47T>&]U+3_ #A]I4!F1=\9.T!@=X&S
M# [N172:1\=OA;I'AVXDT_6K/3=/T^:"T>Q2SE@FCDGYA06WEB0F3DKA#NP2
M,X-?'QX?J3Q,:M>MS1B[I6M?U\WU>[/@H<+U9XN%;$U^:$'=*UF^NO2[ZO=D
M7[2/@CQ=\3_AGK/@[PS::*R:S:M;SWVK:E-;&V.Y2I6..WE\S.#G+)CCKVXV
MU^&?Q2L_BOX=\<KHWA"272_#C>'WTX^([I0^9%<3"7^SS_=QMV?\"K;T;]JO
MP[J7@_XE>+[BSGM/"W@V^:P%X=XFOI%1"RB&1$,;>9(L85CR<$D"IO@G\?\
M4OB_J4:+H&B1Z9)9BZ>\T/Q7;:J]DY^[#=0JJ-&Y&?N>8 002.M?:'Z$-^)?
MPV\8>)]>^'WC_2K71K?QKX6EN!-HTE_(]E=V\Z;)8EN3 '# !2K&(#)(([UQ
M^N?";XP^(_B7I/Q/N[SP^FK:!=NFD>$1<$VPL)8?+N%DO!;A_.<X8':R+CW.
M.V@_:_\ A-<ZK_9T7B>:2\-Q+:1HND7Q6::,@21Q-Y.V1@67A"3@@]*OG]J;
MX4^5:2CQMI[PW,23"5!(R0H[;%,S!<09;C]Z5H XJP^ /B7XG_%/6O&'Q6:V
M@T\6 TW0=%\.:W=Q/90N3]H\Z:(0%R^%R,LI#$$?**BD_9V\72?LE:S\))-3
MTNXU-3)::5?2SR^4;07(DA$Q\O<KA/E(56 VC!-=)J/[8WPHL=(U+44\227$
M%C<R6#2)IEYY3W2J6\A9/)VESC@ G/49%<-\/OV]O#/BC6(+/Q!HMUX4@/A]
M=<N+F5+JX$):3&S:+9=T8C*R>?PAW8&<9H Z#XH_"CQ]\9/"WAOP[K>A^$=/
MT_2]8L-0N-NM7%\MU#"W[V(QO8QCYE)X)(/0X'-;7BG]G>P3QQ\-M4\%Z-X?
M\,:5X>U>?4=1M;*U6T,X>W,2E%BCVL^<?>(X'7M74^'?CSX+\8:L=/T"^O\
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M-Y<Q74FU5+K<!595Y+;,$]J8'WG17QE\8/V@/%?Q6T_XL>$_"UGHVEZ!H'A
M7VJSZM%+/<W#7%N)#%"4D14Q&[#>P?YE'&#QBV/Q4\%G_@GHWAK_ (2_0?\
MA(_^$7DA_LC^TX/M>_+';Y.[?NQSC&: /N>BOS<\._&Z[^$L>F:AH_ACP]/K
M6D_"W3[Z'5KR&X:XDS) GE.5F53'AB<!0<@<UZ!K7[=GC7X5O9_\)SHV@:G_
M &KX1@\0V$>APSVS13S.%CAE,DL@91G)88]LT@/N.BOF[X0?'GXD>)?B)H&B
M^(_"S7N@ZQI@N7UO3?#&JZ9#IET$+F&5[L%94( "R*5!)''(%<5\-IO$/[2W
MQ5^-0UGQKX@\/V'AN[;1=&L/#^K36$=J0TJ_:'$3+YC9B!^?(^9AC  #$?8U
M%?"GP8U?QY\7OC_J7P]\:?$RXU32?!VC[_M7@[4I; :I*QC DEFA96=E$N",
M@90<9+%LGXT>.O&G@30=!^$)^,UE)K&I:U/*OBO^UC!=:=IL2G9%=W&Y,2%P
M1DMEMI4]J!GZ UDUXG^PW\7[CXO? ;39M3O9K_7]&F?2]0N+B4R22NF&21F)
M);=&R98]2&KVRM(&L.H4445H:A1110 4444 %%%% !1110 4444 %<%\;KC3
M8OA_J<-_I-YK$T\$T=E#9://J3I<&)PC!88W,?/ <@ 9Z\U)\;_'5_\ #7X7
MZUXDTR&VGOK+R?+CNU9HCOGCC.0K*>CGN.<5\I?\-S^//^@3X<_\!I__ (_7
MO8#),9F5)UL.E9.VKMKH_P!3[')^%,SSW#RQ.#2<4^75VU23_)HO^%9[_3=/
M_9P:Y\+^+8_^$02XBUM?^$6U(M:,]J47@09<%N,IN%>S_M$:9>?&_P#9U\36
M?A2QU&:]9HI8[#4=.N+":Y\F:.5XQ'<1HYW*I .W!/&>M>$_\-S^//\ H$^'
M/_ :?_X_1_PW/X\_Z!/AS_P&G_\ C]>E_JEF>UE]Y[G_ !#G/OY8_P#@2.D^
M.WCF3XGWGPPNO#/P\\2ZRGAC5(->U8R:'- ]C#&55[91+&IDD).=D9.?*!P1
MR)?CAKES^T1XLT?P3X1\!ZBEAJ@ABU'X@ZGH-S%%;6R/Y\EI^\CC<HQC3(\Q
M 2=O4Y'+?\-S^//^@3X<_P# :?\ ^/T?\-S^//\ H$^'/_ :?_X_2_U2S/LO
MO#_B'.??RQ_\"1[3^SEX0\0?"7QQX\\$:A9(WAV2:+7-(O\ 3=,DM-.4S BX
MMX@SR"/8ZJ1'YC'!)& <#Q6;X/\ C:;]D/QK;+=>+8+Z;4;UXO",>F6Y6X4W
MV0P1K4W)##Y\K)VR..*7_AN?QY_T"?#G_@-/_P#'Z/\ AN?QY_T"?#G_ (#3
M_P#Q^G_JEF79?>'_ !#G/?Y8_P#@1Z'\</V?)YOA+XM\0_VAXE\;^,Y/#:Z5
M96]W'"S01F1'>.&"V@C!8D<DAFPO6OI#PO#);^&=(BE1HI4LX5='&&4A "".
MQKXL_P"&Y_'G_0)\.?\ @-/_ /'Z/^&Y_'G_ $"?#G_@-/\ _'Z/]4\R[+[P
M_P"(<Y[_ "Q_\"1]S45\,_\ #<_CS_H$^'/_  &G_P#C]'_#<_CS_H$^'/\
MP&G_ /C]/_5/,^R^\?\ Q#K/OY8_^!(^YJ*^&?\ AN?QY_T"?#G_ (#3_P#Q
M^C_AN?QY_P! GPY_X#3_ /Q^C_5/,^R^\/\ B'6??RQ_\"1]S45\,_\ #<_C
MS_H$^'/_  &G_P#C]'_#<_CS_H$^'/\ P&G_ /C]'^J>9]E]X?\ $.L^_EC_
M .!(^YJ*^&?^&Y_'G_0)\.?^ T__ ,?H_P"&Y_'G_0)\.?\ @-/_ /'Z/]4\
MS[+[P_XAUGW\L?\ P)'W=9?ZT_[M7J^!HOV[/'L+$C2/#A.,<VUQ_P#'ZE_X
M;T^('_0'\-?^ MQ_\?K-\)9FWM'[S*7AOG[?PQ_\"1]Z45^;WQ,_X*1?$SP9
MH,%[9:'X4EEDN5A(N+2Y*X*N>UP.?E%>9_\ #V_XO_\ 0M^"/_ &\_\ DJO#
MQ>4XK!5?954K^I^>9U@*V08MX+&V4TD]-59[:GZVT5^27_#V_P"+_P#T+?@C
M_P  ;S_Y*H_X>W_%_P#Z%OP1_P" -Y_\E5Q_4ZIX/UND?K;17Y)?\/;_ (O_
M /0M^"/_  !O/_DJC_A[?\7_ /H6_!'_ ( WG_R51]3JA];I'ZVT5^27_#V_
MXO\ _0M^"/\ P!O/_DJC_A[?\7_^A;\$?^ -Y_\ )5'U.J'UND?I%\:/@K;_
M !N_X1K3M8U.2#POIU^;_4-*@1TDU!U0B%?/216B568L< DX&"N,UYG;_L=7
MGAGXH-XV\)^.I=-NX+R>ZL;36;*75HX1<6ZQ7 =Y;D22,S(KA]X(.0=P/'Q3
M_P /;_B__P!"WX(_\ ;S_P"2J/\ A[?\7_\ H6_!'_@#>?\ R51]3JC^MTC[
MB_X9/U:^T;XH#6?B#)K7B/QS8VNGRZY/HT43VL,2;718HW52K9/ VXXSN(R>
M,\*?\$^+'P9;:8+/Q)H^J746G/I]X_B'PI!J43DW#S+-!')+B"10Y3DR*1R5
M-?*'_#V_XO\ _0M^"/\ P!O/_DJC_A[?\7_^A;\$?^ -Y_\ )5'U.J'URF?6
M6M_\$Y?"FKZUXKOX]=-FFI+ ^E6D.EPB#2YT\LR2^2"(I!(8QE D8"LRCC&.
MK;]D$Q)I&HZ=K7AS0O$VEZU#J]O<:/X/M[.QQ'&Z+$]O'*))/]8S;GF)!^Z%
MR:^(O^'M_P 7_P#H6_!'_@#>?_)5'_#V_P"+_P#T+?@C_P  ;S_Y*H^IU0^M
MTC[QTW]D^UF^!'B?X=>(O$L^LW/B+4)]5O=<M[1;9VN9)5E#B+<XP&1<KG!
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MCZG5.3ZW2/UMHK\DO^'M_P 7_P#H6_!'_@#>?_)5'_#V_P"+_P#T+?@C_P
M;S_Y*H^IU0^MTC]9[K_4-^'\ZSZ_*:3_ (*U_%^1"I\.>"<'TL;S_P"2JA_X
M>P_%S_H7?!7_ ( W?_R56D<+42-8XVBEJ?J_17Y0?\/8?BY_T+O@K_P!N_\
MY*H_X>P_%S_H7?!7_@#=_P#R55?5:A?UZB?J_17Y0?\ #V'XN?\ 0N^"O_ &
M[_\ DJC_ (>P_%S_ *%WP5_X W?_ ,E4?5:@?7J)^K]%?E!_P]A^+G_0N^"O
M_ &[_P#DJC_A[#\7/^A=\%?^ -W_ /)5'U6H'UZB?J_17Y0?\/8?BY_T+O@K
M_P  ;O\ ^2J/^'L/Q<_Z%WP5_P" -W_\E4?5:@?7J)^D/QVM-%O_ (5Z[;^(
M?#6J>,-+>--^B:/%-)<W;!U**HA(8?,%).0 !D]*^$-;\'>)OBUIGC37]=^'
M?CK3_%5OH:V'A_2$T&6/3;&T26-%A21CYL\NQFXV#JYYP-O&_P##V'XN?]"[
MX*_\ ;O_ .2J/^'L/Q<_Z%WP5_X W?\ \E5VT/:T%9+\?Z^9[F XBIX"#C&+
M;O>]WIM=6\[:O=K38^S?V9/B!J-U\//#GPXOO /CGPUJ=EHQMI-8U?16MK!9
M$3'RRLV<DG@%1G%?._@3X?ZWX/\ AMK/PE\4_ G7_&FLSZ^;FWU*WWVFG',8
M1)S?*.-O) /RD.0Q!R*\Z_X>P_%S_H7?!7_@#=__ "56[H/_  4>^-OCV*2P
ML-&\*6-S<(5BN+.PG,L7_30>;<.@Q_M*1[5T4*=>I4<:4-9-/=[_ "UZGH8+
M.X5:M5TH*,7[\FY.*CRW;DY75HJ^OX:G6?#?P'K'@CX>ZC\*/%WP"UWQUJDG
MB(7<5Y TEGIKKY8193?H/EV_-CMASDJ<BN>^*_P"^*_Q2\2>._B79>'+BQ33
M-32#3M.N8;M=3EA@"I&UK$8_WB;=K;C@DH<<Y!S_ /A,_C:T_P!O/Q7U07I;
MS/)$C>1N]-OW<>VS'M4^O_\ !1CXW?#^"*PU#1_"NH7-N@$EU>V$XEF'_/0^
M5.B'/^RH'M7LXG 9A@OWTH+7?5_/R5[&^!XSR_,:E6MD^(IUZD%><4YWM=<S
MC&:5XZ*[A>W7H>X?M50>+?'?AGX%^)[?P7XBO[VSNTU+5=-L-+FEN;5@(&='
MC"Y4Y5@ V,XK"^($OC?X_?M,^ =<\)^&/&_PV2PLY;1M?\0^%R4M'Q*VXHQ,
M9!#;/F8<M]*\-_X>P_%S_H7?!7_@#=__ "51_P /8?BY_P!"[X*_\ ;O_P"2
MJ\&$JD(I*"TO;7N>=1XFHT:<81IJ\5)+K92WT>CMYGM7A_\ 90U'X)?M,_"R
MXTU-7\5022W%YK'B!-.9+:*1@X53MW+$,8X9B26/., ?>M?E!_P]A^+G_0N^
M"O\ P!N__DJC_A[#\7/^A=\%?^ -W_\ )585XU\0TY[I'!CL^68.$JSUBK7[
MZM_KT/U?HK\H/^'L/Q<_Z%WP5_X W?\ \E4?\/8?BY_T+O@K_P  ;O\ ^2JY
MOJM0\SZ]1/U?HK\H/^'L/Q<_Z%WP5_X W?\ \E4?\/8?BY_T+O@K_P  ;O\
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M"O\ P!N__DJCZK4#Z]1/U?HK\H/^'L/Q<_Z%WP5_X W?_P E4?\ #V'XN?\
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M[4P'_01#_P "C_F'^L.3?]!E+_P9#_,\CHKUS_AD[XJ_]"M_Y4;3_P".T?\
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M^'<W[0__ $3W_P K6G?_ "17SOMJ?\R^\_+?95/Y7]Q\VT5])?\ #N;]H?\
MZ)[_ .5K3O\ Y(H_X=S?M#_]$]_\K6G?_)%'MJ?\R^\/95/Y7]Q\VT5])?\
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ME]Y_1?LJG\K^X^;:*^DO^'<W[0__ $3W_P K6G?_ "11_P .YOVA_P#HGO\
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M%'M8?S+[P]A5_E?W,^<Z*^C/^'>/[07_ $('_E9T_P#^2*/^'>/[07_0@?\
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MUIW_ ,D4?\.YOVA_^B>_^5K3O_DBCVU/^9?>'LJG\K^X^;:*^DO^'<W[0_\
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M_P"!2?XT?\)7HG_08T__ ,"D_P :O?8+;_GWB_[X%'V"V_Y]XO\ O@4 4?\
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M-'_"5Z)_T&-/_P# I/\ &KWV"V_Y]XO^^!1]@MO^?>+_ +X% %'_ (2O1/\
MH,:?_P"!2?XT?\)7HG_08T__ ,"D_P :O?8+;_GWB_[X%'V"V_Y]XO\ O@4
M4?\ A*]$_P"@QI__ (%)_C1_PE>B?]!C3_\ P*3_ !J]]@MO^?>+_O@4?8+;
M_GWB_P"^!0!1_P"$KT3_ *#&G_\ @4G^-'_"5Z)_T&-/_P# I/\ &KWV"V_Y
M]XO^^!1]@MO^?>+_ +X% %'_ (2O1/\ H,:?_P"!2?XUF?\ "3Z/_P!!:Q_\
M"4_QKH?L%M_S[Q?]\"LK[%;_ //"+_O@5I UAU*?_"3Z/_T%K'_P)3_&C_A)
M]'_Z"UC_ .!*?XU<^Q6__/"+_O@4?8K?_GA%_P!\"KU-2G_PD^C_ /06L?\
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M_P \(O\ O@4:@4_^$GT?_H+6/_@2G^-'_"3Z/_T%K'_P)3_&KGV*W_YX1?\
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M_P \(O\ O@4:@4_^$GT?_H+6/_@2G^-'_"3Z/_T%K'_P)3_&KGV*W_YX1?\
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MX1?]\"C[%;_\\(O^^!1J!3_X2?1_^@M8_P#@2G^-'_"3Z/\ ]!:Q_P# E/\
M&KGV*W_YX1?]\"C[%;_\\(O^^!1J!3_X2?1_^@M8_P#@2G^-'_"3Z/\ ]!:Q
M_P# E/\ &KGV*W_YX1?]\"C[%;_\\(O^^!1J!3_X2?1_^@M8_P#@2G^-'_"3
MZ/\ ]!:Q_P# E/\ &KGV*W_YX1?]\"C[%;_\\(O^^!1J!3_X2?1_^@M8_P#@
M2G^--?Q)HLB,CZI8,C#!5KA""/3K5[[%;_\ /"+_ +X%'V*W_P">$7_? HU
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MD^C_ /06L?\ P)3_ !JY]BM_^>$7_? H^Q6__/"+_O@4:@4_^$GT?_H+6/\
MX$I_C1_PD^C_ /06L?\ P)3_ !JY]BM_^>$7_? H^Q6__/"+_O@4:@4_^$GT
M?_H+6/\ X$I_C1_PD^C_ /06L?\ P)3_ !JY]BM_^>$7_? H^Q6__/"+_O@4
M:@4_^$GT?_H+6/\ X$I_C1_PD^C_ /06L?\ P)3_ !JY]BM_^>$7_? H^Q6_
M_/"+_O@4:@4_^$GT?_H+6/\ X$I_C1_PD^C_ /06L?\ P)3_ !JY]BM_^>$7
M_? H^Q6__/"+_O@4:@4_^$GT?_H+6/\ X$I_C1_PD^C_ /06L?\ P)3_ !JY
M]BM_^>$7_? H^Q6__/"+_O@4:@4_^$GT?_H+6/\ X$I_C1_PD^C_ /06L?\
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M;_GWB_[X%'V"V_Y]XO\ O@4 4?\ A*]$_P"@QI__ (%)_C1_PE>B?]!C3_\
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M[[MZ6Z7>GX7E\)4LP@L'&4JSDK\RU@K^]?N][MZ6Z7>GZ%4445^RG[^%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 6
M++_6G_=J]5&R_P!:?]VKU8RW.>>X4445) 4444 %%%% !1110 4444 (S;5)
M]!GBORT_:B\2^./&WQ&6Y\0VMW!IE[B70;)'\R V[8"&/:2I=N-V/FW'!Q@
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M\1_A'X)\#:OI/CVZ\17OB_P[)J%V;NTM76QF58I!- JP@*F9&CVON&/< U]
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M9P^[!R/EXP=WQ-^SKJ]]XR\6:OX;\?WWA2R\626<FL6]I:EKH-  N;6Y65#
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MLTCKM=X]JC8S#@D8)'!KD_B?X$\ :'X%U*]O? _AJ]2W:2Y@@NM(MY(_M4I
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M]N_XQZZ_CNU\#^%/'3>"9M$T:XUW4+F'4VL7NI=O[FT5@Z;W8#(09SO!P<4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ?\ :)(YP1N;/I/PA^">A_!:V\10:)=:A=IKFJ2ZO<G4)$<I+(!N5-B+A>.
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M,=O%=/$,;RWE&2-GYW^4Z;L]J]9_X26?_H :K_WS%_\ '*/^$EG_ .@!JO\
MWS%_\<H \N\+_LH:!X(C6P\.^+?&>A^&5O\ ^T1X=L-8\JU\PKM*^:$^T^6>
MI3SL$\FK7@S]EWP[X!^'?B#P?HGB#Q186NLZB^J2:E::G]FOK>9@@/E2PHF%
M^0?*P8')SD5Z/_PDL_\ T -5_P"^8O\ XY1_PDL__0 U7_OF+_XY0(XOP)^S
M[HG@KX@W_CFXUC6O%'BV\LDT]M4UJ:$NENNW"*D,42?P+EBI8\\\G/J%8?\
MPDL__0 U7_OF+_XY1_PDL_\ T -5_P"^8O\ XY0!N45A_P#"2S_] #5?^^8O
M_CE'_"2S_P#0 U7_ +YB_P#CE &Y7QCXW_X)E?"_Q[XTU_Q-J&O>+H;_ %K4
M+C4KB.VO+58DDFD:1@@:V)"@L< DG'<U]9?\)+/_ - #5?\ OF+_ ..5F_\
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M_@=:?_(M'_#I[X1_]#%XU_\  ZT_^1:^N_\ A(9_^@'J?_?,7_QRC_A(9_\
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MF#ZM1_E/D3_AT]\(_P#H8O&O_@=:?_(M'_#I[X1_]#%XU_\  ZT_^1:^N_\
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MT?\ X)3_  KT'4[;4+'Q5XXM[NW</'(M]9\'_P !.1V([UL>)_V*]6CU!O\
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MR9]LL/22LHH^0/\ ATA\(/\ H9/&_P#X'6?_ ,BT?\.D/A!_T,GC?_P.L_\
MY%KZ_P#^$EG_ .@!JO\ WS%_\<H_X26?_H :K_WS%_\ '*/K%7^8?U>E_*?(
M'_#I#X0?]#)XW_\  ZS_ /D6C_ATA\(/^AD\;_\ @=9__(M?7_\ PDL__0 U
M7_OF+_XY1_PDL_\ T -5_P"^8O\ XY1]8J_S!]7I?RGR!_PZ0^$'_0R>-_\
MP.L__D6C_ATA\(/^AD\;_P#@=9__ "+7U_\ \)+/_P! #5?^^8O_ (Y1_P )
M+/\ ] #5?^^8O_CE'UBK_,'U>E_*?('_  Z0^$'_ $,GC?\ \#K/_P"1:/\
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M^8O_ (Y1_P )#/\ ] /4_P#OF+_XY1[>I_,'U:C_ "GR)_PZ>^$?_0Q>-?\
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M^8O_ (Y1_P )#/\ ] /4_P#OF+_XY1[>I_,'U:C_ "GR)_PZ>^$?_0Q>-?\
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M?_\ "2S_ /0 U7_OF+_XY1_PDL__ $ -5_[YB_\ CE1]8J_S$?5Z7\I\@?\
M#I#X0?\ 0R>-_P#P.L__ )%H_P"'2'P@_P"AD\;_ /@=9_\ R+7U_P#\)+/_
M - #5?\ OF+_ ..4?\)+/_T -5_[YB_^.4?6*O\ ,'U>E_*?('_#I#X0?]#)
MXW_\#K/_ .1:/^'2'P@_Z&3QO_X'6?\ \BU]?_\ "2S_ /0 U7_OF+_XY1_P
MDL__ $ -5_[YB_\ CE'UBK_,'U>E_*?('_#I#X0?]#)XW_\  ZS_ /D6C_AT
MA\(/^AD\;_\ @=9__(M?7_\ PDL__0 U7_OF+_XY1_PDL_\ T -5_P"^8O\
MXY1]8J_S!]7I?RGR!_PZ0^$'_0R>-_\ P.L__D6C_ATA\(/^AD\;_P#@=9__
M "+7U_\ \)+/_P! #5?^^8O_ (Y1_P )+/\ ] #5?^^8O_CE'UBK_,'U>E_*
M?('_  Z0^$'_ $,GC?\ \#K/_P"1:/\ ATA\(/\ H9/&_P#X'6?_ ,BU]?\
M_"2S_P#0 U7_ +YB_P#CE'_"2S_] #5?^^8O_CE'UBK_ #!]7I?RGR!_PZ0^
M$'_0R>-__ ZS_P#D6C_ATA\(/^AD\;_^!UG_ /(M?7__  DL_P#T -5_[YB_
M^.4?\)+/_P! #5?^^8O_ (Y1]8J_S!]7I?RGR!_PZ0^$'_0R>-__  .L_P#Y
M%H_X=(?"#_H9/&__ ('6?_R+7U__ ,)+/_T -5_[YB_^.4?\)+/_ - #5?\
MOF+_ ..4?6*O\P?5Z7\I\@?\.D/A!_T,GC?_ ,#K/_Y%H_X=(?"#_H9/&_\
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M@HHHJS0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** 'P_ZU/\ >%:=
M9D/^M3_>%:=9S,:FX4445F9!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7S_J_P =O%7B_P#:%U/X5^ 8-&LFT*P%[K&MZ[;S72*S!-L,
M4,4D1)_>1Y9G ^]QP,_0%?.WBGX,>+/A[\==?^+_ ( @T[7WU;26MM5\-:C<
MR6KSR1JIC>WE6-QO/E(-K@#.?F&[*@'D^N_MIZO/HLND:UJ-UX-\<Z'XE;0K
M]/#-A;W]G>O\XC/^E-NBB9HW!*[G&W/? [']EC]K67Q?X;\">'_&<VHZQXU\
M16U_?+J,-I;Q6WE033#:X0IAML1 VH<\9/6O(?#_ .R5XF^+_A.+Q*DATCQS
MJ?BD>(?$-KXBTN\TJ.W'SD6]N'A;S=ID<[P=OS 9!'/;_#K]C;XC?#"?X;:S
MIVH^%]0UKPU9:C8W=I=75S';.MP\S(\<BP%B0)N5*K]W /.0AGN'PR_:W^'O
MQ1_X1V&RN;_2]2\0SW,&FZ=J5FPEG,'^L.Z(O&H';<X)]*ROBW\9?&/A_P#:
M%\ ?#;PTVAV=OXELKFXEU#5=/FO'A:)9& 5([B$$$1XY/?/M67^S5\&OBG\"
M/#/AKPM-<^#[O0%O+RZUJ2.2ZDNOWG,0MB41>N-V\?2M3XM_LY3_ !3_ &A?
M 'C'4+;0]4\(Z'97-MJ.E:JAF>X9UDV;8FC:-@&93\S#&,CD"@#YV\6_MQ?$
M33/C)I/@QX;>X;2?%1TS4I_"UDCQ:S 755A1+AG,4O## E'+$9&W)^F/#?[5
MFB^,+:Z30_!OC+5=9M-6ET:[T:VTV)IK2:/[S32^=]GC3L&:89P<9P:S/BI^
MS.-=\5_"F[\$Z?X?\,Z+X4UTZK?6,$/V19%)C)\I(HRI<[#][;VYKR.7]A[Q
MQ+XZUO79]<T#4=&O/%4^N'PM>37)L=0A=LH+G:@PZ=AM=?F/.,A@#U&P_;E\
M#ZMJMKH5EH7B:X\6W&J3:0/#8M;=+M)HA\Y9FG$.WMD2DY[5T<O[4NB?:?#V
MEP>$O&%QXKUJ*:XB\+/IB6VHV\,6[=+,L\D<:IE2%8.0QX7-> >&_P!AKQ7I
M$VO0ZQX<^&7BC1-2UE[]-,EDO[&6VA96&RWN8D)MP/D&S9("%^]P*=X)_8/\
M6^#/$ND>*-2NO"GQ"N8DGM;CPSXH:>:PM[9LF)+>>2*5LHQ)RT0X)Z$DD ^I
M/AY\:=(^+'PZF\6>%-/U'4_):2!]'D2.WO4N$QN@<2.J*XR.K[>>M>.^!OVE
M/&_C34_CII.JZ3IGAN[\%:>9;%+)FN)8I3%*W[V1CLD*E%^Z@'4?,.3ZQ\./
M!WB#X=?#>6VM?#G@>U\2RS&X?3?#<$FCZ4SG:IRXCE<L%7_6>7\V%&U1S7BO
MA[]G_P"*V@^+/C#K7V#P;/\ \+"A,/D?\)!=K_9^4D7.[[ ?-_UF>B=/>F!/
M^S7^V#_PD?@[X=Z?X^M-<37_ !/+<VEKXCN+*WBT^^N(Y2-B>4^5."B#,:@L
M#SU-=S-\3O%7BWX\Z_I7A/S+SPOX(TMCJEE L"MJ^J2J3#:+-*,1A%&2RLN&
M(#<5\W?$#X,>/_@Y\)?AQ_PDU[X:DL? %^USI,.CS7$]YJ^I32AK6#RWB0*H
MD)W$,25!.T=*^L?@M\+-0^#WP:CTFR%I?>,;B.74;^ZO9&2.\U.4;G>5U4MM
MW87< 3M4<4@/,?%'[07Q2^$)\ ZG\0]&\-0V?BC5_P"RYO#^E+*U_IX<GRW\
M_P YXYRHQN"HHR0 >>.TUW]J_1/"MSI3Z[X-\9Z'HVJ:J-(M-9U+3(X(7F.=
MI,+2BX5#@D,T(SVK@- ^ 7Q1OOB$/'7Q!L?"GC;Q1;DKI;_\)'=6UCI"GHUM
M:_V>XWC@[G=CE0>",UP6H_L(^.9-,TJW_M#PEK&L67B)=8N/%6HO=#5-0A!S
MY4CE)-N,#Y02#P<@@E@#V?QC\1O%$'[8_A;P1;>()]-\)R^''U>ZL;>VMV\^
M5)91AG>)G"D*H(1E/'!!YKEO!_[17Q9^,7@_Q=XY\ Z!X>;P[I%^UKINBZA;
MW$NHZJD>TR$2I*J1L58;5\MN<@DXR5\=ZA86'_!0OP2FH7<%I'=>#I;6/SY1
M'YLCS3A8UR1EFZ #D]J3P;^SM\6?@WX0\7>!_ &O^'5\.ZM?M=:;K6HW%Q%J
M&E))M$@$21,DK!5&UMZ\Y) S@ &'\._VZY_$'P)\>^)?$MYX3\/>.M(FNX]*
M\.SW!ADG$<*-&K0R3>9(Q=F4[-N2N  0:P_AI^W_ .(=4^*?A#0_&&EZ-8^&
M];LK4S:C8V\Z-;75PF8\LTK*(RPVX(R <YPIKN_A-^RIXO\  7[-/Q+^'>IZ
MQI6H:[XEGO9+6_2:8Q'SH(XU:9FCW!MR$M@-UZFN:^'_ .PGJUMH?BG1O&-]
MH]S9:MX9L])MY=.FE>2WO(#N68;HT^4, 1SDC((P30&A#XK_ &F?B!K?P";Q
MQ8:K!X<U:Q\:-H#0Z99Q/!<VWF*O[P7"RL&QGE&7KTZ5]JU^>GQ)^%&I_L]_
MLC:5X,\5ZQI-WX@O?&<%_"MC=,_GH63<5\Q49BN,MA3C(YYK]"Z8!636M636
MD#2GU.)^-/Q)_P"%0?##7O%_]G?VM_9<2R?8O/\ )\W+JF-^UMOWL_=/2N G
M_:@C\%^+KC1/B)H]EX9A30QKRZCI6I2:I$L!E$161!;QR(VYEQA&!R>>*[+]
MH/X=ZC\6/@[XE\)Z3-:V^HZG"D<,MZ[+"I$B,=Q56(X4] :Y;XE_LWZ1J_P5
M\2^$_!6@>&_#6MZQ9PV\EU;V:6D<I21&_>/%&6(X;'!Y-4[]#1W)H_VO/AG<
M_:FM=1U>[ALH$N[Z:+P_?A+*!P"DTQ:$;8RK!@W0C)Z5AV?[8&AR>+=5TR]@
ML-.TNQU=].34GO9YC>1K;>?YT*0VS@_+_"SJ,<AB>*P_%?[+VOGQ=XLU+1?[
M,U*Q\46EM#=VM]K^J:9';O'"(6#169"W4;+SM<H1DC.":XF\_8@\6Q:E<?V=
MJ/A^+3AJDMU;QF>Y!6 V'V9%PR2,"&P<%W^7^)C2O(-3VZW_ &P_A+=)"8O$
MEVYG@-U!'_8>H;YX1OW21KY&9$7RWRR@@;3DC%)=?M9?#[3-7N$OO$6G1Z-]
MFL[BVOK;[5/)+]HSLW(MOL0':<$2,>NX)BN;\,?LY>(M&U3P'=7%YI,BZ!X(
MG\-W&R60EKIPH#QYC&8^#DG#<_=KS'P]^Q+XYTG4/#D\VJ^'F33O[$\T)<3D
MM]CE9Y=N8><AAMSC)ZXHNPU/H^3]HWX>JL"QZY+=7DUW)8IIMIIMW/?B:-=S
MHUJD1F7:I!)* <CGD5SWB3]J[X,_V-:QZOXBBO-.U:UEF6W?2+NX62%&9)?,
MC$+;-I5@RN 1CD8KS_6/V<?BE!\8O%?B?1_$EC_PBVMZD+V3P_#K=[I,EQBW
M\M&DN;>$R+M;!V(<,!RPK&^&'[,6N_":_G\0^.C8:YI']C:GI]]8Z"M[J5S,
MUW<A]L:>29)!M)4L26YR21EJ'=Z-":YE9K0]+T/X+_ >]\>3Z;IGAW3[W7[:
MSBU26V5KB:W2"0_NV(+&'YL9"]2.<8YK&T']J[4F\+^%?$=YX'L-/\*:UKH\
M.P&SUPRWD,GFO$K?9FMD5EW1]$D) .<<5H_L8_"*Z^&'POEN=8BO8?$.MRB>
M:#4W+7-M:H#':0/G[NR-?N]BQ'; UOV??V<-(^%OABR;7= \-WWC&WO+JY&M
MVMDDDX$DSLF)WC63(1@OMT'%84</2H?P8*-][)(YJ&$H8:_L*:A?>R2_(Y+4
M?VM/$UG\)]3^(J> =)D\.V.HOIQC?Q+(ETS+<>1N*_8BBKN(.3)P*]@\ >,O
M%'B6\FCUSPK9Z98-;I<6FL:/K<>I6=QNZIDI%(&&<Y\LH1G#] ?)_!/[+3>#
M_AS=Q-X:\ :UX]_M2YOH=1UK2OM<3QO.SHC2[%E5@I W ,%(X#"MOX3_  .U
M?P?\7M2\8-I?AOP3I%SI*V#>'/"EQ++;W4_F!OM,NZ&%%90-H"QD_,<MZ]&I
MU:DOQ3_:U\(?#V5K#3V;Q'K4>KP:/-:P1SQP13.P#H;H0M%YB*2QCW;N".*Z
M+6?VE/AYH&H7=G=ZS=%[2]_LV:>VTB]N+=;O&?LXGCA:-I>VP,6SQC/%>/>(
MOV8O'YTG6O"VCW7ABY\-ZCXR7Q4NH7]Q/%>Q*95D>#RDA9"P*X#[QD9&T9X9
M\0OV;OBOXXU.\2\\1:=JUI)XDCU2"\OM?U")8+&.17CMDT^.+[.'7:?WC%B?
M8\A7879W?P__ &P/"7B[3VDU2SU71-1DU*YL+33HM*O[R6[$+$%XQ';98X&7
M0 F/(#8)&?6O!'CG0_B-X=M]=\.WZZEI<[,J3*CQD,K%65D<!E8$$$, 17S9
M8?L]?%WPW>IINF:SI$GA&+6=3U26TM?$-]I,^H?:6W0B62WMR\?EG)*I(0W3
MC&:]7_9E^%>N_"#X;2:'XCN+"YU2;4KJ^=].GFGBQ*^X#?, [$=RV3ZDGFFF
M^H*YZS1115%!1110 4444 %%%% !1110 4444 %%%% %BR_UI_W:O51LO]:?
M]VKU8RW.>>X4445) 4444 %%%% !1110 4444 %%%% !1110 4444 %>4V/Q
M\_M[Q)XGT;P_X"\4^(9/#M^=.OKFS?38HA,%#87S[R-F&&'.VO5J^?/AI\ K
ME/B#\4M9\31ZYID.K>(C>Z8VE^)+NSCN+?RD&]H[6X4$[@1^\7=@>E '?>'_
M (^^"=8TR.YO]?TGPY<NT@^P:GK6GM,H1]C$F"XE3&[CAB0>#@\5K^(/BIX#
MT*\ATO7/&'AW3KN[C5XK+4-3@BDFC?A2J.P+*W8@8-?)GP7_ &8O&_A_QU<W
M_B/PI"+'^Q]=MH9)[FUGQ/<W):$ !V(+1LW.. Q!(SBN+TOX"?'BR^#&N^#[
MWP8R7%[I=M86T6A2:)''<A&;/]HW$Y:=VC4($$) P  PI#L?0?A/X0_ SXG>
M-/&<5IX$^S7_ (7U$6-\TKM#:O(5WYCCCEV%,?WE7Z5W7ASX[_#:+QMI'P\\
M*ZAIM\[V,]RC:%/;2V5C'!C<DICDS&W/ V]CTKRCX<? ?QI!X#^./A[4X8]%
MU+Q;%LTR::[CD$F;,1%F\MF95W\'(SSG!KF=-^#WQ%N/$GA:[M/A7I^ARZ#X
M#NO#\LFK7=E<65_=F+;&C1Q2LS0D@\N!GS"& QD\]/#T:+;I046][)+\CEI8
M3#X=N5&FHM[V25_N/H#Q;^U'\+O"?A75=='C;0M:CTZ/S'LM(U:UGN93SA(T
M\T;G.#@9&<&M+3?VA?AGJ5AIER/'WAJV.HQ)-;V]QK-LDK;CC;M\SE@P*D#/
MS CM7R5KOP!^,'CRZ1;WP[?VWE>"+O1C+J5QHUM;K=2*I%O;Q6."L 9<(9"V
M,C)3G-GQO\-?C5XP\)^,M(C^'5[I,>IZ78:=:6VG2:!&+PQ1*LLE_<2223/M
M9?W8C*\ <H:Z#J/NX'(R.12UC^#K*YTSPAH=G>J4O+>Q@BG4L&(D6-0PR"0>
M0>0:V*8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ANO]0WX?SK/K0NO
M]0WX?SK/K6&QO#8****LT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!\/^M3_>%:=9D/^M3_ 'A6G6<S&IN%%%%9F04444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5Y#X@_:2TS2/C#/\,]/\*^(O$?BB&R74&C
MTT6:0F$@'(>>YBY&1D?EFO7J^0M5^&?BC6_V_-0UJW3Q#H&@MX<6(>(-.LU\
MEG"I^Z\Z6&2/)/8?-\OUH ]93]HZTTKQT^B^,+/2/A]IXM//67Q+XJTZ*_+D
M_*IM(Y9 $(SA_,[?=%=0/CY\,6GCA'Q&\)&:1MB1C7+7<S9Q@#S.3GC'K7Y]
M_MX?!7Q[XD^.L$^B^&/%/B^RCTBT@;5K?2I+@2NI?.YX8@F[D9  ^E=]\3/@
MJ_PT\5>+3\-O#/B2SFNK*SB;P[>^"(M:T+6]FP*B3+O$&"HD<RA6W G/(PAG
MU5X$_:@^'WQ$^(FO>#-)UJW.K:5+'#&\MU (M29E9F^R%9"TVP(=^%&/>N.U
M3]K.:U\5?$S0X/#>E12>#+FSM_M>L^)(M.M[L3YY,DD6V(KCA<MNSVKRW]G;
M0OB7X.^+?Q#&JZ /!&M^*SIEW;W#^&[K5='7;#*98%DMY8TA*LZ@;Y<#:5Y)
M!KRWXP_"3XCZBW[0HN/#.JZW?ZGJ6CO;76DZ%<Q07X1FWM;QEI254$9P[X[D
M4 ?>>A?'3X=^([RRL-/\>^%KW5+LJD5C9ZW;3RO(?X$57)8_0<UIZY\4?!GA
MC6XM&UGQ=H6DZO-M\O3[[4H8;A]QPN(V8,<G@8'-?G+X(^"/C'3?V;O"41\!
MZ];>(X_B-!>SQ-I$ZW<=LL"@2LI3<L8/\7W<Y[UZ'>?"#4K;Q-\9M(^(.E_$
M/48O$VM)=VO_  B.AVM]%JMLTI\D?:9;:00-#D'#2Q!1TYZ@'V[XL^(?A7P"
M+4^)_$VC^'!=;A =6OXK7SMN-VSS&&[&Y<XZ9'K6;9_&GX>ZC<Z?;VGCSPS=
M7&HMLLHH=8MW:Y;=MQ& ^7.[C"YYXKY[^.WPLU+4?'G[,EE9Z!K6MZ-H5Z$O
MYKNV^U/;1J+4*UV\0,:M\ARV=I*MCBO!=4^"7BM?@EXZ2W\!ZT-;G^)2W=LD
M>D3?:'LU#[94 3<8AO;##Y?F//-,#["NOVJ]*_X2+QYI&F>"O%FO2>"3_P 3
MF?3X['9&NUFW(LETCR A'X52>.G(SB>$?VX?!OQ'\4'0/!7AWQ/XOU!; :BP
MT^&TB"QX7>I\^YC.]2P4J!R?N[AS7!?#'X)^)/%'QN_:#34M1\6>"M!UNZ@B
MCN;"U@A34XF697V37%O(3M!^]$RD;^3TQS?@#X8VW[-'[7NLW>E>#?% \"6W
MAI;2UO=-T2\U$7-P5A9AOBC8%V97R3A0>/E&!2 ^AK7]K'P%=_!S6OB.LU]'
MI>C2&WU#3)X%BU"VN=RK]G:)F \PE@!\V/?@XKZ+^U_\/-7^"4_Q2DN;W3?#
MT-P]FUM=PK]L-P#@1"-'8%F!!&&Q@Y) !Q\=Z/\  3XF^/?BG+;77A[4?"VA
M>-_$K^*+Q-2TR2:ULK>!II+=+G8RJ'D:5U,/F*W"$XR#53XJ_LY?%3P]XI\9
M>$M)T*X\4:-/JD'C2UN--TV:"PDF7S!-;Q!FD5'Q*?W9D9BL*XR6 (!]P>$_
MVE-#\0^-](\):KX>\1>#=;UFS^W:7#XAM88UOHP"S!&BED =0,E'VL..,\5Z
MY7@^E?$_6_B7\4/"5OI?PNOK?1;:U:ZU37?%FD36$NG.R_+#;>:@+ON #%,K
MR.<<U[Q3$%%%% !1110 4444 %?&/C?_ (*:_"_P%XTU_P ,ZAH/BZ:_T74+
MC3;B2VL[5HGDAD:-BA:Y!*DJ<$@''85]G5_/[^TE_P G%?%/_L:M5_\ 2N6N
M["TXU&U(Y<16G1BG _1G_A[#\(_^A=\:_P#@#:?_ "51_P /8?A'_P!"[XU_
M\ ;3_P"2J_*"BO2^JTSA^O5C]7_^'L/PC_Z%WQK_ . -I_\ )5'_  ]A^$?_
M $+OC7_P!M/_ )*K\H**/JM,/KU8_5__ (>P_"/_ *%WQK_X VG_ ,E4?\/8
M?A'_ -"[XU_\ ;3_ .2J_*"BCZK3#Z]6/UAC_P""KWPDED5%\.^--S$ 9LK,
M#/U-U6WJW_!2;P/H0+:A\/\ XC6:#_EI+H]N$/T;[3@_@:_(.OKK]E/XA:OX
MET.ZT/4()KFVTM%%OJ)Y4*>!"Q[D=1[<'&!GJP^!HUI\DFTSZ;(*4,WQ7U.M
M4<)2^%I75UJTUZ=;GV'+^U[IN@WVH_$2]TC7)?"]QIL!33(88FOHT^4JS(90
MF07<D;^ QZXI;+_@I)X'U&UDNK?X?_$5[2-#(]R=)MEB50,DES<A0,<]:\VK
MYD_:U^(6KVMQ;^%(()K+3)XQ/-<G@7?/W%(_A4]1U)QVQGU,9EN'C%5'?1):
M=3]'XFR3"X##+'2J-*$8QY5'XI+1-OI?KIT[Z'V+_P /8?A'_P!"[XU_\ ;3
M_P"2J/\ A[#\(_\ H7?&O_@#:?\ R57Y045X/U6F?B7UZL?J_P#\/8?A'_T+
MOC7_ , ;3_Y*H_X>P_"/_H7?&O\ X VG_P E5^4%%'U6F'UZL?J__P /8?A'
M_P!"[XU_\ ;3_P"2J/\ A[#\(_\ H7?&O_@#:?\ R57Y044?5:8?7JQ^K_\
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M_P# &S_^2J/^'M_P@_Z%OQO_ . -G_\ )5?DE11]3I!];JGZV_\ #V_X0?\
M0M^-_P#P!L__ )*H_P"'M_P@_P"A;\;_ /@#9_\ R57Y)44?4Z0?6ZI^MO\
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M^2*_;:BE]=J=E_7S)^I4^[_KY'XD_P##N;]H?_HGO_E:T[_Y(H_X=S?M#_\
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M,A_UJ?[PK3K.9C4W"BBBLS(**** "BBB@ HHHH **** "BBB@ HHHH ****
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M*V**+ 8_E>(/^?K3/_ :3_XY1Y7B#_GZTS_P&D_^.5L446 Q_*\0?\_6F?\
M@-)_\<H\KQ!_S]:9_P" TG_QRMBBBP&/Y7B#_GZTS_P&D_\ CE'E>(/^?K3/
M_ :3_P".5L446 Q_*\0?\_6F?^ TG_QRCRO$'_/UIG_@-)_\<K8HHL!C^5X@
M_P"?K3/_  &D_P#CE'E>(/\ GZTS_P !I/\ XY6Q118#'\KQ!_S]:9_X#2?_
M !RCRO$'_/UIG_@-)_\ '*V**+ 8_E>(/^?K3/\ P&D_^.4>5X@_Y^M,_P#
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M5_X"R?\ QRMRB@##\GQ)_P _>E?^ LG_ ,<H\GQ)_P _>E?^ LG_ ,<K<HH
MP_)\2?\ /WI7_@+)_P#'*/)\2?\ /WI7_@+)_P#'*W** ,/R?$G_ #]Z5_X"
MR?\ QRCR?$G_ #]Z5_X"R?\ QRMRB@##\GQ)_P _>E?^ LG_ ,<H\GQ)_P _
M>E?^ LG_ ,<K<HH P_)\2?\ /WI7_@+)_P#'*/)\2?\ /WI7_@+)_P#'*W**
M ,/R?$G_ #]Z5_X"R?\ QRCR?$G_ #]Z5_X"R?\ QRMRB@##\GQ)_P _>E?^
M LG_ ,<H\GQ)_P _>E?^ LG_ ,<K<HH P_)\2?\ /WI7_@+)_P#'*/)\2?\
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M*W68>7:M/N\QMV#F4@<\&F!]/^3XD_Y^]*_\!9/_ (Y1Y/B3_G[TK_P%D_\
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M.TQVTTSQ+C)QA..V* ///V6W$GQN_:(93E6\16Y!_P"V;U]+5XS\"/A-XD\
M^./BAXB\1-I2?\)9JD5_;6VF74MQY*JKJ5=GBCY^8= >]>S4Q!1110 4444
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M^ ?'O@OP]XU?XA:!XKU.QFM@FK:\NLZ-K4\2;I'5V>5H9, NJJ(.."#T./\
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M 6]AT[[-"-DQ$)+>8$\P_?;@MCGI7TC7@^I_LYZ]!^T/JOQ9\.^,=.T^_O\
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MI;_P_;W5R+K=F:6!@R11^9DC:T+A1C'(S0!XY\=OVP-9^*GP/\>ZI\--+O\
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M*Q])='_7S/VMHK\6?^'AW[07_0__ /E&T_\ ^1Z/^'AW[07_ $/_ /Y1M/\
M_D>J^J3[HK^T*79_A_F?M-17XL_\/#OV@O\ H?\ _P HVG__ "/1_P /#OV@
MO^A__P#*-I__ ,CT?5)]T']H4NS_  _S/VFHK\6?^'AW[07_ $/_ /Y1M/\
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M+_H?_P#RC:?_ /(]'U2?=!_:%+L_P_S/VFHK\6?^'AW[07_0_P#_ )1M/_\
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MG=?U\@^NT^S_ *^9^VU%?B3_ ,/&?VA_^BA?^473O_D>C_AXS^T/_P!%"_\
M*+IW_P CT?4JG=?U\@^NT^S_ *^9^VU%?B3_ ,/&?VA_^BA?^473O_D>C_AX
MS^T/_P!%"_\ *+IW_P CT?4JG=?U\@^NT^S_ *^9^VU%?B3_ ,/&?VA_^BA?
M^473O_D>C_AXS^T/_P!%"_\ *+IW_P CT?4JG=?U\@^NT^S_ *^9^VU%?B3_
M ,/&?VA_^BA?^473O_D>C_AXS^T/_P!%"_\ *+IW_P CT?4JG=?U\@^NT^S_
M *^9^VU%?B3_ ,/&?VA_^BA?^473O_D>C_AXS^T/_P!%"_\ *+IW_P CT?4J
MG=?U\@^NT^S_ *^9^VU%?B3_ ,/&?VA_^BA?^473O_D>C_AXS^T/_P!%"_\
M*+IW_P CT?4JG=?U\@^NT^S_ *^9^VU%?B3_ ,/&?VA_^BA?^473O_D>C_AX
MS^T/_P!%"_\ *+IW_P CT?4JG=?U\@^NT^S_ *^9^VU%?B3_ ,/&?VA_^BA?
M^473O_D>C_AXS^T/_P!%"_\ *+IW_P CT?4JG=?U\@^NT^S_ *^9^VU%?B3_
M ,/&?VA_^BA?^473O_D>C_AXS^T/_P!%"_\ *+IW_P CT?4JG=?U\@^NT^S_
M *^9^VU%?B3_ ,/&?VA_^BA?^473O_D>C_AXS^T/_P!%"_\ *+IW_P CT?4J
MG=?U\@^NT^S_ *^9^VU%?B3_ ,/&?VA_^BA?^473O_D>C_AXS^T/_P!%"_\
M*+IW_P CT?4JG=?U\@^NT^S_ *^9^VU%?B3_ ,/&?VA_^BA?^473O_D>C_AX
MS^T/_P!%"_\ *+IW_P CT?4JG=?U\@^NT^S_ *^9^VU%?B3_ ,/&?VA_^BA?
M^473O_D>C_AXS^T/_P!%"_\ *+IW_P CT?4JG=?U\@^NT^S_ *^9^VU%?B3_
M ,/&?VA_^BA?^473O_D>C_AXS^T/_P!%"_\ *+IW_P CT?4JG=?U\@^NT^S_
M *^9^VU%?B3_ ,/&?VA_^BA?^473O_D>C_AXS^T/_P!%"_\ *+IW_P CT?4J
MG=?U\@^NT^S_ *^9^VU%?B3_ ,/&?VA_^BA?^473O_D>C_AXS^T/_P!%"_\
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M  \._:"_Z'__ ,HVG_\ R/1]4GW0?VA2[/\ #_,_::BOQ9_X>'?M!?\ 0_\
M_E&T_P#^1Z/^'AW[07_0_P#_ )1M/_\ D>CZI/N@_M"EV?X?YG[345^+/_#P
M[]H+_H?_ /RC:?\ _(]'_#P[]H+_ *'_ /\ *-I__P CT?5)]T']H4NS_#_,
M_::BOQ9_X>'?M!?]#_\ ^4;3_P#Y'H_X>'?M!?\ 0_\ _E&T_P#^1Z/JD^Z#
M^T*79_A_F?M-17XL_P##P[]H+_H?_P#RC:?_ /(]'_#P[]H+_H?_ /RC:?\
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MCZI/N@_M"EV?X?YG[345^+/_  \._:"_Z'__ ,HVG_\ R/1_P\._:"_Z'_\
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M_:%+L_P_S/VFHK\6?^'AW[07_0__ /E&T_\ ^1Z/^'AW[07_ $/_ /Y1M/\
M_D>CZI/N@_M"EV?X?YG[35@Z9X%T/1_%VL^)[.Q\G7-8BAAOKKS7;SDB!$8V
M%BJX!/W0,]\U^.__  \._:"_Z'__ ,HVG_\ R/1_P\._:"_Z'_\ \HVG_P#R
M/1]4GW0?VA2[/\/\S]A[+X>^'K?Q?JWB---0ZQK%O%97\\DCNL\,>0B&,DH
M QZ 9SSFN.UG]E;P:=$%OX=@FT34+,R3:-)=7MY?66DW+ @7$%E)<"%73<2N
MT+M.".F*_*H?\%$/V@U((^('(Y_Y NG_ /R/4O\ P\9_:'_Z*%_Y1=._^1ZB
M6"J/JOZ^1G+'4WLG_7S/V"T;X1>&]+^%D'P_GL5U+PZME]BGAN_F:Y!'SNY'
M.]F)8L,'<<C!KSSQ'\+_ (5_"@Z?<Z_9W6LMK\D'A*W;7]1GU#RX9CQ GG.P
MCC^7)VX/'6OS;\._M^_M :VQ4?$H1W,9W>3)H6GE9%^H@!^M=O\ M&?M5ZE\
M?M+\$H]B=%O-'A>:]6W<^5)>,P'F1'.X*%12 >5+L,M@,?E<SS&EEZG#FO45
MM+/]59JW8_7N#^!,PXEK4*\X6PD^:]12B[63T:3;3YK*S2[['Z0^%_@#X'\(
M:]IFLV&F7<^I:7 ]MI\VIZM>7_V&-AAE@6XE=8L@8^0#CCI5;Q[^S=\._B9J
MFHZAX@T"2XNM2BC@OVM-1NK-;U(R#&)U@E19=N!@N"1@8Z"OG72_^"CL.K6V
MB:3HW@/4M?\ %%W'!;O"URD"2W3 !A'M#DKO)QD#(QG';[%\/2ZI/H=E)K4%
MO:ZJ\0:Y@M'+Q1.>2BL>6 Z9P,XS@=*ZL-C:&+O[%WMOHSY;.N&<UX>4'F=/
MV?.WRKFBV[;NR;:7FTCRZ3]D3X42& ?\(U<);P7JZE%91:Q?):I=  "80+.(
MP^%&6VY/?-2W'[*'PQGUZ368]$O[+46GN+D2Z?KNH6@CDG_UYC2*=5C\S@,$
M ! P:]=HKN/ECEOAO\,?#7PC\,IX?\)Z;_96D)*\XMS<2S_.YRQW2,S<_6NI
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y76/BMX)\/:VVC:KXQT#3-8
M79G3[S4X(K@;\;/W;,&^;(QQSD8ZUU5?"WQ9_9]UCXJ?M6?%">3PM/=6DW@R
M2/1=3U"Q8V)U PQ1IME=?++C<^.<J1NX*Y !]?Z7\5O!.N:S<:1IOC'0-0U:
MW#M-86NJ02SQ!/OEHU8L-O?(X[TOASXJ^"O&$MU%H/C#0-;EM(S-<)IVIP7#
M0QCJ[A&.U?<\5\)Z%\";#Q7\,/!?A?Q1X9^,$NNZ';7:R:?HNB:=96]@V2)=
MMW-!$)DESN"B:4MSGGKS7B7X5_%;5_"<?A#P-H6J^(-(;0O(:]\3>#$T35=)
MMUD+FP2[;!G+[2"$9U(D([DA#/T3\-_%'P9XR:\70/%VA:XUG'YMR--U*&X,
M"?WGV,=HX/)KS_XB_M@?"GX=>&+C66\7Z5XD,,B1_P!F^'=2M;N\<LP7*Q^:
M.!G).> #7RA\1/@;?_$SP/$_A/2?B>?&FF^&8;0#5]&L](L([<$>;IY(M[>2
M=@H8*$\Q>5RV":V/VA/#Z?%3X#:/HG@_X*^*%\3:'IVG>9J=YX9%I+;01@J]
MK&\NV:5@3DI"KJ<DYZT ?84OQ[^&=O9VEU/\0_"MO;W:&2"276[95E4$J2I+
MX;# @XZ$$5PY_:T\+:?\<-9\!ZW=:/H.EV6EPZE;^([_ %J**"\,@C98T5PJ
M_=<D$.<A<X]/ ?BM/XY\?ZW\29;'P7X@T?0-4\/_ &;39=)\%QB^UJ41*IBO
MI;B$S($8,% "9"@H2=N[S?X3^!=>\&ZKK=YXE^%_BW48+OX??V-:HGARZFQ>
M-&!Y9'EY4G:R[B,#/) /(!]N6G[0MI>?M 3?#>/386L4\/C7U\0+?@Q/&2H
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MVI_S!]6K?RGQ917VG_PZ>^+G_0Q>"O\ P.N__D6C_AT]\7/^AB\%?^!UW_\
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M .1:/^'3WQ<_Z&+P5_X'7?\ \BT>VI_S!]6K?RGQ917VG_PZ>^+G_0Q>"O\
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M6C_ATA\7_P#H9/!'_@=>?_(M'UBE_,'L*O\ *?$E%?;?_#I#XO\ _0R>"/\
MP.O/_D6C_ATA\7_^AD\$?^!UY_\ (M'UBE_,'L*O\I\245]M_P##I#XO_P#0
MR>"/_ Z\_P#D6C_ATA\7_P#H9/!'_@=>?_(M'UBE_,'L*O\ *?$E%?;?_#I#
MXO\ _0R>"/\ P.O/_D6C_ATA\7_^AD\$?^!UY_\ (M'UBE_,'L*O\I\245]M
M_P##I#XO_P#0R>"/_ Z\_P#D6C_ATA\7_P#H9/!'_@=>?_(M'UBE_,'L*O\
M*?$E%?;?_#I#XO\ _0R>"/\ P.O/_D6C_ATA\7_^AD\$?^!UY_\ (M'UBE_,
M'L*O\I\245]M_P##I#XO_P#0R>"/_ Z\_P#D6C_ATA\7_P#H9/!'_@=>?_(M
M'UBE_,'L*O\ *?$E%?;?_#I#XO\ _0R>"/\ P.O/_D6C_ATA\7_^AD\$?^!U
MY_\ (M'UBE_,'L*O\I\245]M_P##I#XO_P#0R>"/_ Z\_P#D6C_ATA\7_P#H
M9/!'_@=>?_(M'UBE_,'L*O\ *?$E%?;?_#I#XO\ _0R>"/\ P.O/_D6C_ATA
M\7_^AD\$?^!UY_\ (M'UBE_,'L*O\I\245]M_P##I#XO_P#0R>"/_ Z\_P#D
M6C_ATA\7_P#H9/!'_@=>?_(M'UBE_,'L*O\ *?$E%?;?_#I#XO\ _0R>"/\
MP.O/_D6C_ATA\7_^AD\$?^!UY_\ (M'UBE_,'L*O\I\245]M_P##I#XO_P#0
MR>"/_ Z\_P#D6C_ATA\7_P#H9/!'_@=>?_(M'UBE_,'L*O\ *?$E%?;?_#I#
MXO\ _0R>"/\ P.O/_D6C_ATA\7_^AD\$?^!UY_\ (M'UBE_,'L*O\I\245]M
M_P##I#XO_P#0R>"/_ Z\_P#D6C_ATA\7_P#H9/!'_@=>?_(M'UBE_,'L*O\
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M&+P5_P"!UW_\BT>VI_S!]6K?RGQ917VG_P .GOBY_P!#%X*_\#KO_P"1:/\
MAT]\7/\ H8O!7_@==_\ R+1[:G_,'U:M_*?%E%?:?_#I[XN?]#%X*_\  Z[_
M /D6C_AT]\7/^AB\%?\ @==__(M'MJ?\P?5JW\I\645]I_\ #I[XN?\ 0Q>"
MO_ Z[_\ D6C_ (=/?%S_ *&+P5_X'7?_ ,BT>VI_S!]6K?RGQ917VHO_  2<
M^+C, /$7@K)./^/Z[_\ D6I_^'2'Q?\ ^AD\$?\ @=>?_(M+V])?:$\/56\3
MX]\*:9<ZAJT3P.T2PD.\H_A'I^->HU[Y;?\ !*;XUVD/DP^+/!D$1.2(K^\4
MG\K7FO2?C3^PA:_#+P+\-].\*RW&K:U>:JNEZOJ<^2;F>XV[)=N3Y<:%&4 =
M 1DDY)_..)<%6QC>)4DU'112UM?5M_H?U3X3<695D:ADTJ<U.LW*=232@FHN
MRC%7TLK7T;>^EDO+OV-OBAX:^%7QFLM0\3V,+VEU&;.+4Y>NG.Y \T#I@C*L
M>H5B0<9!_6A'65%=&#HPRK*<@CU%<#)\ ?AW=:!8:3?>#=$U""RMH[2*6YL(
MFE"(H4?/MW X'4&NPT#0K'PQHUGI.F0FVT^TC$4$)=G\M!T4%B3@= ,\# '
MKIRO!5L!3=*<DUNK;WZ^I\)QUQ+EW%>+AF&&I3IU$N62DTXN*^%KJGW5K/?>
M]]"BBBO;/S$**** "BBB@ HHHH **** "BBB@ HHHH **** "BLS4-!BU&X\
MY[J^A; &VWNY(U_('%5O^$2@_P"?_5?_  82_P#Q5 &Y16'_ ,(E!_S_ .J_
M^#"7_P"*H_X1*#_G_P!5_P#!A+_\50!N45A_\(E!_P _^J_^#"7_ .*H_P"$
M2@_Y_P#5?_!A+_\ %4 ;E%8?_")0?\_^J_\ @PE_^*H_X1*#_G_U7_P82_\
MQ5 &Y16'_P (E!_S_P"J_P#@PE_^*H_X1*#_ )_]5_\ !A+_ /%4 ;E%8?\
MPB4'_/\ ZK_X,)?_ (JC_A$H/^?_ %7_ ,&$O_Q5 &Y16'_PB4'_ #_ZK_X,
M)?\ XJC_ (1*#_G_ -5_\&$O_P 50!N45A_\(E!_S_ZK_P"#"7_XJC_A$H/^
M?_5?_!A+_P#%4 ;E%8?_  B4'_/_ *K_ .#"7_XJC_A$H/\ G_U7_P &$O\
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M_P _NI_^!\O_ ,50!L45C_\ "+P?\_NI_P#@?+_\51_PB\'_ #^ZG_X'R_\
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MX1*#_G_U7_P82_\ Q5 &Y16'_P (E!_S_P"J_P#@PE_^*H_X1*#_ )_]5_\
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M_P"J_P#@PE_^*H W**P_^$2@_P"?_5?_  82_P#Q5'_")0?\_P#JO_@PE_\
MBJ -RBL/_A$H/^?_ %7_ ,&$O_Q5'_")0?\ /_JO_@PE_P#BJ -RBL/_ (1*
M#_G_ -5_\&$O_P 51_PB4'_/_JO_ (,)?_BJ -:Z_P!0WX?SK/JI<^$X%A8_
M;]4/3KJ$OK_O52_X1>#_ )_=3_\  ^7_ .*K6.QO#8V**Q_^$7@_Y_=3_P#
M^7_XJC_A%X/^?W4__ ^7_P"*JBS8HK'_ .$7@_Y_=3_\#Y?_ (JC_A%X/^?W
M4_\ P/E_^*H V**Q_P#A%X/^?W4__ ^7_P"*H_X1>#_G]U/_ ,#Y?_BJ -BB
ML?\ X1>#_G]U/_P/E_\ BJ/^$7@_Y_=3_P# ^7_XJ@#8HK'_ .$7@_Y_=3_\
M#Y?_ (JC_A%X/^?W4_\ P/E_^*H V**Q_P#A%X/^?W4__ ^7_P"*H_X1>#_G
M]U/_ ,#Y?_BJ -BBL?\ X1>#_G]U/_P/E_\ BJ/^$7@_Y_=3_P# ^7_XJ@#8
MHK'_ .$7@_Y_=3_\#Y?_ (JC_A%X/^?W4_\ P/E_^*H V**Q_P#A%X/^?W4_
M_ ^7_P"*H_X1>#_G]U/_ ,#Y?_BJ -BBL?\ X1>#_G]U/_P/E_\ BJ/^$7@_
MY_=3_P# ^7_XJ@#8HK'_ .$7@_Y_=3_\#Y?_ (JC_A%X/^?W4_\ P/E_^*H
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MM)D#9)(&VHV648)!^8>M '445P5K\?\ X7WLZPV_Q(\(SS-G;'%KMJS' R<
M2>E;#?$WP>OARU\0'Q7H@T&[E\BWU3^T8?LLTFXKL27=M9LJPP#G(([4 =+6
M36-X$^+'ACXDWVNV6@7T]S>:'.MKJ-O<V%Q:26TI!(5EFC0G[IZ9K9K2!K3Z
MA1116AL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGSZ%>Z6\*VT>ARVJI;O&/NQK"ZA6 P/E [=*]'AACMX4BB18HHU"HB#"J!P
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M/_1<E>#5^5\1?[^_1'\8>*?_ "4D_P#!#\@HHHKYD_(0HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ5_X&Q__ !5'_"=>&_\ H8=*_P# V/\ ^*H W**P_P#A.O#?_0PZ5_X&Q_\
MQ5'_  G7AO\ Z&'2O_ V/_XJ@#<HK#_X3KPW_P!##I7_ (&Q_P#Q5'_"=>&_
M^AATK_P-C_\ BJ -RBL/_A.O#?\ T,.E?^!L?_Q5'_"=>&_^AATK_P #8_\
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M ,:+H#9HK&_X33P]_P!!W3/_  ,C_P :/^$T\/?]!W3/_ R/_&BZ V:*QO\
MA-/#W_0=TS_P,C_QH_X33P]_T'=,_P# R/\ QHN@-FBL;_A-/#W_ $'=,_\
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MGC?_ ,#K/_Y%H_X=(?"#_H9/&_\ X'6?_P BU]?_ /"=>&_^AATK_P #8_\
MXJC_ (3KPW_T,.E?^!L?_P 57-]8J_S'E_5Z?\I\@?\ #I#X0?\ 0R>-_P#P
M.L__ )%H_P"'2'P@_P"AD\;_ /@=9_\ R+7U_P#\)UX;_P"AATK_ ,#8_P#X
MJC_A.O#?_0PZ5_X&Q_\ Q5'UBK_,'U>G_*?('_#I#X0?]#)XW_\  ZS_ /D6
MC_ATA\(/^AD\;_\ @=9__(M?7_\ PG7AO_H8=*_\#8__ (JC_A.O#?\ T,.E
M?^!L?_Q5'UBK_,'U>G_*?('_  Z0^$'_ $,GC?\ \#K/_P"1:/\ ATA\(/\
MH9/&_P#X'6?_ ,BU]?\ _"=>&_\ H8=*_P# V/\ ^*H_X3KPW_T,.E?^!L?_
M ,51]8J_S!]7I_RGR!_PZ0^$'_0R>-__  .L_P#Y%H_X=(?"#_H9/&__ ('6
M?_R+7U__ ,)UX;_Z&'2O_ V/_P"*H_X3KPW_ -##I7_@;'_\51]8J_S!]7I_
MRGR!_P .D/A!_P!#)XW_ / ZS_\ D6C_ (=(?"#_ *&3QO\ ^!UG_P#(M?7_
M /PG7AO_ *&'2O\ P-C_ /BJ/^$Z\-_]##I7_@;'_P#%4?6*O\P?5Z?\I\@?
M\.D/A!_T,GC?_P #K/\ ^1:/^'2'P@_Z&3QO_P"!UG_\BU]?_P#"=>&_^AAT
MK_P-C_\ BJ/^$Z\-_P#0PZ5_X&Q__%4?6*O\P?5Z?\I\@?\ #I#X0?\ 0R>-
M_P#P.L__ )%H_P"'2'P@_P"AD\;_ /@=9_\ R+7U_P#\)UX;_P"AATK_ ,#8
M_P#XJC_A.O#?_0PZ5_X&Q_\ Q5'UBK_,'U>G_*?)M_\ \$V/#_ACPL]IX)\4
MZR]\C[XXO$4L4T!'.5!BA1DR><_-WXYS7DEQ^QG\6H;UH$\.0SQ!MHN8]1MA
M&1ZX:0-C_@.?:OT-_P"$Z\-_]##I7_@;'_\ %4?\)UX;_P"AATK_ ,#8_P#X
MJOLLMXSS7+:*H1<9Q6W,F[>C37XW/H\)F^*P=-4H6<5M?I^*/D7PG_P3LM]?
M\/7,'CSQ'?6,URH46_AN6-6C7N&EEB<'(XPJC']XU%_PZ0^$'_0R>-__  .L
M_P#Y%KZ__P"$Z\-_]##I7_@;'_\ %4?\)UX;_P"AATK_ ,#8_P#XJO S#.L=
MFE;V^)J7?3HDNR1Y6,K3Q]3VN(U?Y>A\@?\ #I#X0?\ 0R>-_P#P.L__ )%H
M_P"'2'P@_P"AD\;_ /@=9_\ R+7U_P#\)UX;_P"AATK_ ,#8_P#XJC_A.O#?
M_0PZ5_X&Q_\ Q5>9]8J_S'#]7I_RGR!_PZ0^$'_0R>-__ ZS_P#D6C_ATA\(
M/^AD\;_^!UG_ /(M?7__  G7AO\ Z&'2O_ V/_XJC_A.O#?_ $,.E?\ @;'_
M /%4?6*O\P?5Z?\ *?('_#I#X0?]#)XW_P# ZS_^1:/^'2'P@_Z&3QO_ .!U
MG_\ (M?7_P#PG7AO_H8=*_\  V/_ .*H_P"$Z\-_]##I7_@;'_\ %4?6*O\
M,'U>G_*?('_#I#X0?]#)XW_\#K/_ .1:/^'2'P@_Z&3QO_X'6?\ \BU]?_\
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M?6*O\P?5Z?\ *?('_#I#X0?]#)XW_P# ZS_^1:/^'2'P@_Z&3QO_ .!UG_\
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M_P#@=:?_ "+1_P .GOA'_P!#%XU_\#K3_P"1:^NO^$T\/?\ 0=TS_P #(_\
M&C_A-/#W_0=TS_P,C_QJO;U/YB_JU'^5'R+_ ,.GOA'_ -#%XU_\#K3_ .1:
M/^'3WPC_ .AB\:_^!UI_\BU]=?\ ":>'O^@[IG_@9'_C1_PFGA[_ *#NF?\
M@9'_ (T>WJ?S!]6H_P J/D7_ (=/?"/_ *&+QK_X'6G_ ,BT?\.GOA'_ -#%
MXU_\#K3_ .1:^NO^$T\/?]!W3/\ P,C_ ,:/^$T\/?\ 0=TS_P #(_\ &CV]
M3^8/JU'^5'R+_P .GOA'_P!#%XU_\#K3_P"1:/\ AT]\(_\ H8O&O_@=:?\
MR+7UU_PFGA[_ *#NF?\ @9'_ (T?\)IX>_Z#NF?^!D?^-'MZG\P?5J/\J/D7
M_AT]\(_^AB\:_P#@=:?_ "+1_P .GOA'_P!#%XU_\#K3_P"1:^NO^$T\/?\
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M_H8O&O\ X'6G_P BT?\ #I[X1_\ 0Q>-?_ ZT_\ D6OKK_A-/#W_ $'=,_\
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M+1_PZ>^$?_0Q>-?_  .M/_D6OKK_ (33P]_T'=,_\#(_\:/^$T\/?]!W3/\
MP,C_ ,:/;U/Y@^K4?Y4?(O\ PZ>^$?\ T,7C7_P.M/\ Y%H_X=/?"/\ Z&+Q
MK_X'6G_R+7UU_P )IX>_Z#NF?^!D?^-'_":>'O\ H.Z9_P"!D?\ C1[>I_,'
MU:C_ "H^1?\ AT]\(_\ H8O&O_@=:?\ R+1_PZ>^$?\ T,7C7_P.M/\ Y%KZ
MZ_X33P]_T'=,_P# R/\ QH_X33P]_P!!W3/_  ,C_P :/;U/Y@^K4?Y4?(O_
M  Z>^$?_ $,7C7_P.M/_ )%H_P"'3WPC_P"AB\:_^!UI_P#(M?77_":>'O\
MH.Z9_P"!D?\ C1_PFGA[_H.Z9_X&1_XT>WJ?S!]6H_RH^1T_X).?"-G4'Q%X
MUP3C_C^M/_D6KG_#I#X0?]#)XW_\#K/_ .1:^KXO&OAX2H3KVF 9'_+Y'_\
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MI/X8I)\R?9[Z=6WOI:]TOT\HI3U]?J,4E?II^PA1110,**** "BBB@ HHHH
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MOA[4O#_B+PA?^)+,WNBGQ!;0QI?H!N*H8II-KA>=L@4X([D \]\#M/TKX#?
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M]!_8A5/%.BW^A:O=?$"&[DM=1M)+60AW0[@C@':3G!]J_2:F 4444""BBB@
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MU)M L["^OSX70>7J5V]M$$VID[DBD)/3C'?KQ@@'T#\+?&7PA3Q!=>&OAR=
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M&P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1]4AW8?VA5[+\?\ ,_:;_AX=^S[_ -#_ /\ E&U#_P"1Z/\ AX=^S[_T/_\
MY1M0_P#D>OQ9HH^J0[L/[0J]E^/^9^TW_#P[]GW_ *'_ /\ *-J'_P CT?\
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M4+_RBZC_ /(]'_#QG]GC_HH7_E%U'_Y'K\2:*/J5/N_Z^0?7:G9?U\S]MO\
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M_0^WX1X@I<-XZ>+JTW-2@XV5ENXN^OH?D]17ZJ_\*:^'_P#T(WAK_P %%O\
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M/6G_ ,;J/K<>QM_9TOYC\$Z*_>S_ (9M^$?_ $2SP5_X3UI_\;H_X9M^$?\
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M ,;H^MQ[!_9TOYC\$Z*_>S_AFWX1_P#1+/!7_A/6G_QNC_AFWX1_]$L\%?\
MA/6G_P ;H^MQ[!_9TOYC\$Z*_>S_ (9M^$?_ $2SP5_X3UI_\;H_X9M^$?\
MT2SP5_X3UI_\;H^MQ[!_9TOYC\$Z*_>S_AFWX1_]$L\%?^$]:?\ QNC_ (9M
M^$?_ $2SP5_X3UI_\;H^MQ[!_9TOYC\$Z]\^ _BKP'\+-)EUO6=3^T^(KQ2B
M6MM \C6\.>F<;0S8R>>F!ZU^N'_#-OPC_P"B6>"O_">M/_C='_#-OPC_ .B6
M>"O_  GK3_XW6M+,%2ESJ.IZV6.ME6(6*I*,IK;F3:3[V36O8^&H_BAHDOP[
M/C0-,-'$)FP5'F\-LVXSC=NXQGK7SO\ ';Q;X"^*VBQ:QI&I_9?$=DNTVUU
M\;7$.>4W8VEER2/F]1W%?J\?V<O W_"0J!X0\/CPO]C,;:&-,@^QF?S-PD,&
MW9G'?'4 ]:O_ /#-OPC_ .B6>"O_  GK3_XW7H8C-U4BH*-TUKZGW&=\0U\Q
MPT<+RQE&4%S73NI]7&S5K:6W\S\$Z*_>Z+]FSX1F5 ?A9X*(R/\ F7K3_P"-
MUH_\,S_"#_HE/@C_ ,)VS_\ C=>0\;%=#\OE@)1^T?@!17[_ /\ PS/\(/\
MHE/@C_PG;/\ ^-T?\,S_  @_Z)3X(_\ "=L__C=3]>C_ "D?4I=S\ **_?\
M_P"&9_A!_P!$I\$?^$[9_P#QNC_AF?X0?]$I\$?^$[9__&Z/KT?Y0^I2[GX
M45^__P#PS/\ "#_HE/@C_P )VS_^-T?\,S_"#_HE/@C_ ,)VS_\ C='UZ/\
M*'U*7<_ "BOW_P#^&9_A!_T2GP1_X3MG_P#&Z/\ AF?X0?\ 1*?!'_A.V?\
M\;H^O1_E#ZE+N?@!17[_ /\ PS/\(/\ HE/@C_PG;/\ ^-T?\,S_  @_Z)3X
M(_\ "=L__C='UZ/\H?4I=S\ **_?_P#X9G^$'_1*?!'_ (3MG_\ &Z/^&9_A
M!_T2GP1_X3MG_P#&Z/KT?Y0^I2[GX 45^_\ _P ,S_"#_HE/@C_PG;/_ .-T
M?\,S_"#_ *)3X(_\)VS_ /C='UZ/\H?4I=S\ **_?_\ X9G^$'_1*?!'_A.V
M?_QNC_AF?X0?]$I\$?\ A.V?_P ;H^O1_E#ZE+N?@!17[_\ _#,_P@_Z)3X(
M_P#"=L__ (W1_P ,S_"#_HE/@C_PG;/_ .-T?7H_RA]2EW/P HK]_P#_ (9G
M^$'_ $2GP1_X3MG_ /&Z/^&9_A!_T2GP1_X3MG_\;H^O1_E#ZE+N=MJ&K75G
M<>7#HM]?)@'SK=X OT^>53^E5O\ A(;_ /Z%G5?^_MI_\?K<HKQSUS#_ .$A
MO_\ H6=5_P"_MI_\?H_X2&__ .A9U7_O[:?_ !^MRB@##_X2&_\ ^A9U7_O[
M:?\ Q^C_ (2&_P#^A9U7_O[:?_'ZW** ,/\ X2&__P"A9U7_ +^VG_Q^C_A(
M;_\ Z%G5?^_MI_\ 'ZW** ,/_A(;_P#Z%G5?^_MI_P#'Z/\ A(;_ /Z%G5?^
M_MI_\?K<HH P_P#A(;__ *%G5?\ O[:?_'Z/^$AO_P#H6=5_[^VG_P ?K<HH
M P_^$AO_ /H6=5_[^VG_ ,?H_P"$AO\ _H6=5_[^VG_Q^MRB@##_ .$AO_\
MH6=5_P"_MI_\?H_X2&__ .A9U7_O[:?_ !^MRB@##_X2&_\ ^A9U7_O[:?\
MQ^C_ (2&_P#^A9U7_O[:?_'ZW** ,/\ X2&__P"A9U7_ +^VG_Q^C_A(;_\
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MLI;F$]S#_P"$AO\ _H6=5_[^VG_Q^C_A(;__ *%G5?\ O[:?_'ZW**D@P_\
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MB@##_P"$AO\ _H6=5_[^VG_Q^C_A(;__ *%G5?\ O[:?_'ZW** ,/_A(;_\
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MY:__ !ZNINO]0WX?SK/K6.QO#8QO[=OO^A<U/_OY:_\ QZC^W;[_ *%S4_\
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M/_OY:_\ QZMFB@#&_MV^_P"A<U/_ +^6O_QZC^W;[_H7-3_[^6O_ ,>K9HH
MQO[=OO\ H7-3_P"_EK_\>H_MV^_Z%S4_^_EK_P#'JV:* ,;^W;[_ *%S4_\
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MB@##_P"$AO\ _H6=5_[^VG_Q^C_A(;__ *%G5?\ O[:?_'ZW** ,/_A(;_\
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M%% !1110 4444 %9-:U9-:0-:?4****T-@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +%E_K3_NU>JC
M9?ZT_P"[5ZL9;G//<****D@**** "BBB@ HHHH **** "BBB@ HHHH ****
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M*7Q%JVG6\,J(8W!CM=HNXF4YVR>61DC.#FM]?V1/$VG?"GQ7X2TW4-%@DO\
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M'AW[07_0_P#_ )1M/_\ D>G]4GW0_P"T*79_A_F?M-17XL_\/#OV@O\ H?\
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MQ1K?[?FH:U;IXAT#06\.+$/$&G6:^2SA4_=>=+#)'DGL/F^7ZU]>T4 ?E_\
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MHHH **** "BBB@"Q9?ZT_P"[5ZJ-E_K3_NU>K&6YSSW"BBBI("BBB@ HHHH
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M*O\ *_N9\YT5]&?\.\?V@O\ H0/_ "LZ?_\ )%'_  [Q_:"_Z$#_ ,K.G_\
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M]H+_ *$#_P K.G__ "11[6'\R^\/85?Y7]S/G.BOHS_AWC^T%_T('_E9T_\
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M@?\ E9T__P"2*/:P_F7WA["K_*_N9\YT5]&C_@G?^T&Q 'P_Y/'_ "&M/_\
MDBI?^'<W[0__ $3W_P K6G?_ "11[6G_ #+[P]C47V7]Q\VT5])?\.YOVA_^
MB>_^5K3O_DBC_AW-^T/_ -$]_P#*UIW_ ,D4O;4_YE]XO95/Y7]Q\VT5])?\
M.YOVA_\ HGO_ )6M._\ DBC_ (=S?M#_ /1/?_*UIW_R11[:G_,OO#V53^5_
M<?-M%?27_#N;]H?_ *)[_P"5K3O_ )(KZ7_8S_X)N:EH/B4>+?C'I4$+Z?*#
MI_AMIXKE)9!R)IVC9D*@](\G)'S<##3/$4XJ][EQH5).UK'T)_P3ZO/BC>_
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M[%'ZM^=',@YT5(?]:G^\*TZ@6S16!!;(.:GJ).YG)I[!1114$!1110 4444
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M,G"]N=)6];7O;Y7\C[SHK&\'^*[#QOX;L-;TR3S+.[CWKG[R'HRM[@@@^XK
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MS3):KE"#M*,MUY[+OY^NEB\3@,-/#O%8*3:CNGNCZWHKS/X[_&<?!30-'O\
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MRQVOB?SK>ZM9SP72589PRD=E2-AC[QI@7['X^^'+?2=>D\2B?PMJ_ANPBO\
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MU>^T)(X/%9UV6WBU:^OY1;_9_*"":XC\R608&2[ 'U' 'V+3$%%%% !1110
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M/$223L>21,G..N?I:BO"/D3YO7]FSQ-X)\)?$^UT;Q6?%*^*]'EBEM-6LO\
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MU;9X.;8]8^NI05HQ5D>+^"?V4?"7@/6VU33]1UJ:X-A?:=MN9X63R[N<S2G
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MD]UT/M?$'CS#Y]5KY7&A&I1@U[.HFU-.RN[ZIINZM975NMFN5^*7PYTWXM^
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M#-Y)DX()5>E:US^PKX*FLX--B\2>*[/0+:ZNKVTT2WN[9;2UFGC,;N@-N6R
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ME8J$N'@*B6-!'([%@S!<XVD@@-P:Z+3OV3?"FF^,7\3KJ^O3ZLU[J>H^9+/
M5$]]"L,K "$8VH@V#H.<[JR-;_8A^'VO^'_"FCW5WKBVOAC3I+#3&@NXXI(G
M>19#<[EC'[[<H.>%ZY4T <WJ_P"W/X?UW4?#FG>"F@GOY];@MM5@U%5F\FP,
M,DTLT3P3&,L%C(^^VTY#+TIGPZ_;S\.>(_!6M>)-2T?Q%+HND74<5[K<6BQ6
MEK;K*X6)2OVV9G8;EW;"3R#L -=[K_[*NC^+KNSO=?\ &7C#6[^UAOH8[F\O
MX?E%U;_9W*QK"(T*H25*(OS'+;JIZ/\ L:^!M'^$UG\.1>:U=^&X=836ITN9
MX6DO'4@^3*1$ 8CM7(4*W'WJ0&#>_P#!0CX0VGVADOM0O(5$OV>2U@1S=&/&
M0J>9OCSR0TRQJ0"<XKU+X=_&[1_B3X;UC6]/M6@LM,!,K-JFF7(;";R-]M=R
MHA _YZ,G7/3FN8T7]EO3_#N@0:)I?Q \>Z=I-D&73+6SUI8%T\&3S,)LB!E
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MJ'A<  ?+0!%X9_;A\#:['I]YJ&C>)?"^AWYO$MM;UFT@6SE>V0O,@>*:0D@
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F-V,X[5U%-CC2&-8XU5$4855& !Z 4ZO/FXRFW%671=C%V;T/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LISATA THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-2343568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">110 Allen Road, 2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Basking Ridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">842-0100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LSTA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,598,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000320017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 20,217<span></span>
</td>
<td class="nump">$ 16,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">5,616<span></span>
</td>
<td class="nump">15,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">2,034<span></span>
</td>
<td class="nump">2,433<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">28,617<span></span>
</td>
<td class="nump">34,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Acquired license - intangible, net</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">28,981<span></span>
</td>
<td class="nump">35,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">1,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">3,205<span></span>
</td>
<td class="nump">4,329<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,807<span></span>
</td>
<td class="nump">5,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,879<span></span>
</td>
<td class="nump">5,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,620,900 and 8,409,582 shares at March 31, 2025 and December 31, 2024, respectively; and outstanding, 8,620,162 and 8,408,844 shares at March 31, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">578,923<span></span>
</td>
<td class="nump">578,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost; 738 shares at March 31, 2025 and December 31, 2024</a></td>
<td class="num">(708)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(552,790)<span></span>
</td>
<td class="num">(548,066)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(78)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Lisata Therapeutics, Inc. stockholders' equity</a></td>
<td class="nump">25,356<span></span>
</td>
<td class="nump">29,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests</a></td>
<td class="num">(254)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">25,102<span></span>
</td>
<td class="nump">29,317<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, non-controlling interests and stockholders' equity</a></td>
<td class="nump">$ 28,981<span></span>
</td>
<td class="nump">$ 35,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">8,620,900<span></span>
</td>
<td class="nump">8,409,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">8,620,162<span></span>
</td>
<td class="nump">8,408,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 2,602<span></span>
</td>
<td class="nump">$ 3,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,245<span></span>
</td>
<td class="nump">3,360<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">5,847<span></span>
</td>
<td class="nump">6,601<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(5,847)<span></span>
</td>
<td class="num">(6,601)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income, net</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(105)<span></span>
</td>
<td class="num">(187)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before benefit from income taxes and noncontrolling interests</a></td>
<td class="num">(5,686)<span></span>
</td>
<td class="num">(6,199)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="num">(962)<span></span>
</td>
<td class="num">(798)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(4,724)<span></span>
</td>
<td class="num">(5,401)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less - net income (loss) attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Lisata Therapeutics, Inc. common stockholders</a></td>
<td class="num">$ (4,724)<span></span>
</td>
<td class="num">$ (5,401)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_EPSAbstract', window );"><strong>Basic and diluted loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Lisata Therapeutics, Inc. common stockholders- basic (in usd per share)</a></td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share)</a></td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic shares (in shares)</a></td>
<td class="nump">8,602<span></span>
</td>
<td class="nump">8,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares (in shares)</a></td>
<td class="nump">8,602<span></span>
</td>
<td class="nump">8,294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_EPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_EPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (4,724)<span></span>
</td>
<td class="num">$ (5,401)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive gain (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Available for sale securities - net unrealized loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment arising during the period</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive gain (loss)</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders</a></td>
<td class="num">$ (4,721)<span></span>
</td>
<td class="num">$ (5,463)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total Lisata Therapeutics, Inc. Stockholders' Equity</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Non- Controlling Interest in Subsidiary</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 47,894<span></span>
</td>
<td class="nump">$ 48,148<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 576,971<span></span>
</td>
<td class="num">$ (42)<span></span>
</td>
<td class="num">$ (528,081)<span></span>
</td>
<td class="num">$ (708)<span></span>
</td>
<td class="num">$ (254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(5,401)<span></span>
</td>
<td class="num">(5,401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">312<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 42,743<span></span>
</td>
<td class="nump">42,997<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">577,283<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="num">(533,482)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">8,408,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 29,317<span></span>
</td>
<td class="nump">29,571<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">578,418<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(548,066)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(4,724)<span></span>
</td>
<td class="num">(4,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuances of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuances of common stock</a></td>
<td class="nump">$ 212<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from option exercises (in shares)</a></td>
<td class="nump">4,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from option exercises</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="nump">8,620,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,621,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">$ 25,102<span></span>
</td>
<td class="nump">$ 25,356<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 578,923<span></span>
</td>
<td class="num">$ (78)<span></span>
</td>
<td class="num">$ (552,790)<span></span>
</td>
<td class="num">$ (708)<span></span>
</td>
<td class="num">$ (254)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (4,724)<span></span>
</td>
<td class="num">$ (5,401)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share-based compensation</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization/accretion on marketable securities</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(152)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="nump">405<span></span>
</td>
<td class="num">(872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities', window );">Accounts payable, accrued liabilities and other liabilities</a></td>
<td class="num">(1,809)<span></span>
</td>
<td class="num">(1,243)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,402)<span></span>
</td>
<td class="num">(7,027)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(5,055)<span></span>
</td>
<td class="num">(18,824)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sale of marketable securities</a></td>
<td class="nump">14,514<span></span>
</td>
<td class="nump">25,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(28)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Investment in Impilo Therapeutics</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">9,431<span></span>
</td>
<td class="nump">6,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding payments on net share settlement equity awards</a></td>
<td class="num">(243)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">4,008<span></span>
</td>
<td class="num">(788)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">16,209<span></span>
</td>
<td class="nump">22,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 20,217<span></span>
</td>
<td class="nump">$ 21,805<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lisata Therapeutics, Inc. (together with its subsidiaries, the &#8220;Company&#8221;) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The Company's investigational product, certepetide (formerly known as LSTA1 or CEND-1), is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. Certepetide has also been shown to modify the tumor microenvironment (&#8220;TME&#8221;) by reducing T-regulatory cells and augmenting cytotoxic T cells, thereby making tumors more susceptible to immunotherapies while also inhibiting the metastatic cascade (i.e., the spread of cancer to other parts of the body). The Company, its collaborators and other researchers have amassed and continue to amass significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies, and RNA-based therapeutics. To date, certepetide has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. The Company is exploring certepetide as a means to enable a variety of therapeutic modalities to treat a range of solid tumors more effectively. Currently, certepetide is the subject of several Phase 2 clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), cholangiocarcinoma, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. The Company's goal is to develop and commercialize products that address important unmet medical needs. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a history of net operating losses and negative cash flows from operating activities, and has cash, cash equivalents and marketable securities of approximately $25.8&#160;million as of March&#160;31, 2025. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenues from its products currently in development. To manage capital for operating needs in the short-term, initiation of the FORTIFIDE study remains on hold as the Company is investigating a potentially faster and more cost-effective approach to achieving the study objective. The Company has similarly decided to delay commencement of certain phase 3 readiness activities for chemistry, manufacturing and controls (&#8220;CMC&#8221;). The Company believes that, as a result, it currently has sufficient cash to meet its funding requirements over the next year. To meet our long-term liquidity needs, the Company expects that it will need additional financing, which could result in additional potential issuances of debt or equity securities in public or private financings, partnerships and/or collaborations and/or sale of assets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2025, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2024 and 2023 included in our 2024 Form 10-K. Operating results for the three months ended March&#160;31, 2025 are not necessarily indicative of the results that may be expected for the year ending December 31, 2025.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one operating segment, the research and development of its investigational drug product. The Company's Chief Operating Decision Maker (&#8220;CODM&#8221;) is its Chief Executive Officer, who manages the business on a consolidated basis.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents, accounts receivable and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government, thereby reducing credit risk exposure. Cash is held at major banks in the United States and may exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return. The Company&#8217;s accounts receivable balance as of March&#160;31, 2025 and December&#160;31, 2024 is derived from its license agreement dated November 30, 2024, more fully described in Note 17. The Company has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Accounts receivable is stated at historical cost, less allowance for credit losses. The Company records an expense based on a forward-looking current expected credit loss model to maintain its allowance for credit losses, which replaced the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allowance for doubtful accounts. When determining its allowance for trade accounts receivable, the Company considers the probability of recoverability of accounts receivable based on experience, taking into account current collection trends and general economic factors, including bankruptcy rates. The Company also considers future economic trends to estimate expected</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">credit losses over the lifetime of the asset. Credit risks are assessed based on historical write-offs, net of recoveries, as well as an analysis of the aged accounts receivable balances with allowances generally increasing as the receivable ages. Accounts receivable may be fully reserved for when specific collection issues are known to exist, such as pending bankruptcies. Account balances are written off against the allowance when it is determined that the receivable will not be recovered. As of March 31, 2025 and December 31, 2024, there was no allowance for credit losses.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities, that are not the result of credit losses, are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and credit losses recognized through an allowance for credit losses, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:66.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.466%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or lease term</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight-line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Share-based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is based on the weighted effect of all shares of common stock issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock used in the basic loss per share calculation plus the number of shares of common stock that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (&#8220;R&amp;D&#8221;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive the Company&#8217;s initiatives, the Company will continue targeting key governmental agencies and not-for-profit organizations to contribute funds for the Company&#8217;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#8220;business&#8221; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Asset</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible asset consists of a single asset, a license agreement with Qilu Pharmaceutical, Co., Ltd. (&#8220;Qilu&#8221;) acquired in the Company's acquisition of Cend Therapeutics, Inc (the &#8220;Cend Merger&#8221;), with a value of $0.4&#160;million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5.00 years. Amortization expense was $17&#160;thousand for the three months ended March&#160;31, 2025, and $17&#160;thousand for the three months ended March&#160;31, 2024, respectively. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.  The projected amortization expense is $71&#160;thousand per year for the next 2.50 years. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company recognized no revenue for the three months ended March&#160;31, 2025 and 2024.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#8217;s collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#8217;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three months ended March&#160;31, 2025 and March&#160;31, 2024, the Company has not recognized revenue related to milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale-Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Available-for-Sale-Securities</a></td>
<td class="text">Available-for-Sale Securities<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in the Company's Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,984&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,653&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,649&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in the Company's Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:360.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,613&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,649&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:361.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,990&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"><tr><td style="width:1.0pt"></td><td style="width:358.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(589)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results included depreciation expense of approximately $26&#160;thousand and $29&#160;thousand for the three months ended March&#160;31, 2025 and 2024, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Income (Loss) Per Share</a></td>
<td class="text">Income (Loss) Per Share<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2025 and 2024, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive in the periods presented. At March&#160;31, 2025 and 2024, the Company excluded the following potentially dilutive securities (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 inputs are defined as unobservable inputs for the assets or liabilities. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March&#160;31, 2025 and December&#160;31, 2024 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:116.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available-for-sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,368&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,616&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,984&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,613&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,036&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,649&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash, cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value as of March&#160;31, 2025 and December&#160;31, 2024, due to the short maturity nature of these items.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">Accrued Liabilities<div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of March&#160;31, 2025 and December&#160;31, 2024 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:313.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and R&amp;D related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting &amp; tax consulting liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities &#8212; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,205&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,329&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text">Operating Leases<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an operating lease for one office which expires on September 30, 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as the Company's lease does not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of ASU No. 2016-02, Leases (Topic 842), the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of the Company's balance sheet as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-416"><span style="-sec-ix-hidden:f-417">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-422"><span style="-sec-ix-hidden:f-423">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the weighted average remaining lease term for the Company's operating lease was 0.50 years, and the weighted average discount rate for the Company's operating lease was 9.625%. As of December&#160;31, 2024, the weighted average remaining lease term for the Company's operating lease was 0.75 years, and the weighted average discount rate for the Company's operating lease was 9.625%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under the lease agreement as of March&#160;31, 2025 were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Issuances</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">At The Market Offering Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC, as sales agent, in connection with an &#8220;at the market offering&#8221; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0&#160;million. As of the date of this filing and so long as the Company&#8217;s public float remains below $75.0 million, the Company is subject to limitations pursuant to General Instruction I.B.6 of Form S-3 (the &#8220;Baby Shelf Limitation&#8221;), which limits the amount the Company can offer to up to one-third of its public float during any trailing 12-month period. Subsequent to the filing of a prospectus supplement to the Company's Registration Statement on Form S-3 (File No. 333-279034) relating to the at the market offering on August 21, 2024, the aggregate market value of its outstanding common stock held by non-affiliates was approximately $29.6&#160;million. Pursuant to the Baby Shelf Limitation, since the aggregate market value of the Company's outstanding common stock held by non-affiliates was below $75.0&#160;million at the time of such prospectus supplement filing, the aggregate amount of securities that the Company is permitted to offer and sell is now $9,855,890, which is equal to one-third of the aggregate market value of our common stock held by non-affiliates as of August 20, 2024. If the Company&#8217;s public float exceeds $75.0&#160;million on a future measurement date, it will no longer be subject to the Baby Shelf Limitation. During the three months ended March&#160;31, 2025, the Company issued 55,578 shares of common stock under the ATM Agreement for net proceeds of $211,369. Since inception, the Company has issued 123,751 shares of common stock under the ATM Agreement for net proceeds of $492,216.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Warrants</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following table summarizes the activity for stock options and warrants for the three months ended March&#160;31, 2025:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,440,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.46</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,496,744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.29</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,529,391&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.22&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.62</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,496,744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.52&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.05</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2025<br/>or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,517,488&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.24&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.0&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,496,744&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.52&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,344,298&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.60&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,496,744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.52&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.05</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2025 and 2024, the Company issued restricted stock for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"></td><td style="width:322.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average estimated fair value of restricted stock issued for services in the three months ended March&#160;31, 2025 and 2024 was $3.80 and $3.08 per share, respectively. The fair value of the restricted stock was determined using the Company&#8217;s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally between <span style="-sec-ix-hidden:f-502">one</span> and four years.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the changes in non-vested restricted stock for the three months ended March&#160;31, 2025:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"><tr><td style="width:1.0%"></td><td style="width:33.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Stock Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the Year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294,611&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.47&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2025 and 2024, the Company issued restricted stock units for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"></td><td style="width:343.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average estimated fair value of restricted stock units issued for services in the three months ended March&#160;31, 2025 and 2024 was $3.80 and $3.08 per share, respectively. The fair value of the restricted stock units was determined using the Company&#8217;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the changes in non-vested restricted stock units for the three months ended March&#160;31, 2025:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"><tr><td style="width:1.0%"></td><td style="width:33.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the Year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85,345&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes share-based compensation in the form of stock options, restricted stock, restricted stock units and warrants.&#160;The following table summarizes the components of share-based compensation expense for the three months ended March&#160;31, 2025 and 2024 (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.491%"><tr><td style="width:1.0%"></td><td style="width:62.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.282%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.620%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March&#160;31, 2025 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:61.271%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.002%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.587%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.32</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March&#160;31, 2025 and 2024 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:530.25pt"><tr><td style="width:1.0pt"></td><td style="width:257.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrants</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#8217;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the Company had approximately $57.9&#160;million and $43.7&#160;million, respectively, of Federal NOLs available to offset future taxable income expiring from 2030 through 2036.  The Company performed an analysis and determined that they had an ownership change of greater than 50% on September 15, 2022. As a result of the ownership change, $88.2&#160;million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $34.0&#160;million of remaining Federal NOLs as of December 31, 2022. The write-off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the consolidated balance sheet or income statement. Losses incurred before the ownership change on September 15, 2022 will be subject to an annual limitation of zero while losses incurred after September 15, 2022 will not be subject to limitations. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, Cend Therapeutics, Inc. (&#8220;Cend&#8221;) had approximately $3.6&#160;million of Federal NOLs available to offset future taxable income. The Company performed an analysis and determined that there was an ownership change of greater than 50% on September 15, 2022. As of September 15, 2022 Cend has approximately $3.1&#160;million of Federal and $4.3&#160;million of state NOLs. The state NOLs will expire from the 2036 through 2042 tax years.  Using a fair market value of $36.1&#160;million and applying an applicable federal rate of 2.54% Cend will have an annual limitation of approximately $917&#160;thousand each year. The Federal NOL of $459&#160;thousand incurred in the post-acquisition period September 15, 2022 to December 31, 2022 is not subject to limitation, and does not expire. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the Company's wholly owned Australian subsidiary had approximately $2.3&#160;million and $2.4&#160;million, respectively, of NOLs which will be carried forward and do not expire. There is a full valuation allowance against the NOLs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had federal research and development credit carryforwards of $0.5&#160;million expiring from 2027 through 2034 if unutilized, and state research and development credit carryforwards of $0.1&#160;million, which carryforward indefinitely.  Utilization of these credits may be subject to an annual limitation based on changes in ownership.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the Company had State NOLs available in New Jersey of $24.6&#160;million and $19.4&#160;million, respectively, California of $9.2&#160;million and $9.2&#160;million, respectively, and New York City of $1.9&#160;million and $1.9&#160;million, respectively, to offset future taxable income expiring from 2032 through 2044. The usage of the Company&#8217;s NOLs is limited given the change in ownership.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the Financial Accounting Standards Board provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the Company&#8217;s uncertain tax positions were $344&#160;thousand and $344&#160;thousand, respectively. The uncertain tax positions are due to the acquisition of Cend related to Federal and state credits and certain state NOLs. The Company will continue to evaluate its uncertain tax positions in future periods. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For years prior to 2021, the federal statute of limitations is closed for assessing tax. The Company&#8217;s state tax returns remain open to examination for a period of three to four years from the date of the tax return filing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, the Company sold a portion of their unused New Jersey net operating losses through the State of New Jersey Economic Development Authority's (&#8220;NJEDA&#8221;) Technology Business Tax Certificate Transfer Program (&#8220;Program&#8221;). Under the Program, the Company sold $10.7&#160;million of its New Jersey net operating losses (&#8220;NJ NOLs&#8221;) for net proceeds of $871&#160;thousand. The sale of NJ NOLs resulted in a $962&#160;thousand deferred income tax benefit and a loss on sale of $91&#160;thousand recorded in other income (expense) in the consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one operating segment, the research and development of its investigational drug product. The Company used the management approach to determine its reportable operating segment. The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer, who reviews financial information presented on a consolidated basis. The Company is a clinical-stage pharmaceutical company and has limited revenue associated with a license and collaboration agreement. The CODM uses net loss as a measure of profit and loss, and assesses Company performance through the achievement of its clinical development goals. The CODM is regularly provided with budgeted and forecasted expense information which is used to determine the Company&#8217;s liquidity needs and cash allocation to its development programs. The CODM uses cash and marketable securities as a measure of segment assets in managing the enterprise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no revenue during the three months ended March&#160;31, 2025 and 2024. Depreciation and amortization expense was $43 thousand and $46 thousand for the three months ended March&#160;31, 2025 and 2024, respectively. Equity method investment expense was $0 and $100 thousand for the three months ended March&#160;31, 2025 and 2024, respectively. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates our segment information for significant operating expenses and includes a reconciliation to net loss for the three months ended March&#160;31, 2025 and 2024:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"><tr><td style="width:1.0%"></td><td style="width:67.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development by significant expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;BOLSTER trial</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;ASCEND trial</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Chemistry, manufacturing and controls</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Clinical department</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,602&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative by significant expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Investor relations/public relations/communications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Finance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Legal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Business development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Share based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,245&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,360&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,847)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,601)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(798)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(4,724)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5,401)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25,833</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43,349</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Included in Other are the GBM study, FORTIFIDE study and research </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;oncology expenses</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Included in Other are facilities expense, human resource </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;and information technology expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Australia Research and Development Tax Incentive<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock', window );">Australia Research and Development Tax Incentive</a></td>
<td class="text">Australia Research and Development Tax IncentiveThe Company&#8217;s Australian subsidiary, which conducts core research and development activities, is eligible to receive a refundable tax incentive between 43.5% to 48.5% (depending upon the income tax rate) for qualified research and development activities. As of March&#160;31, 2025 and December&#160;31, 2024, the Company had $0.6&#160;million and $0.6&#160;million, respectively, recorded as an income tax incentive receivable in prepaid and other current assets in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_ResearchAndDevelopmentTaxIncentiveTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Tax Incentive</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_ResearchAndDevelopmentTaxIncentiveTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results. The Company has elected to recognize expense for legal fees as incurred when the legal services are provided.</span></div>In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (&#8220;Lingmed&#8221;) claiming Lingmed was entitled to a success fee based on Cend&#8217;s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend&#8217;s response to the complaint was filed on June 6, 2022 and denied all of Lingmed&#8217;s material allegations. Lingmed filed an answer to Cend&#8217;s response on July 11, 2022, denying all of the Company&#8217;s material allegations. On March 25, 2024 the Company entered into a settlement agreement whereby the Company was required to pay Lingmed $0.5&#160;million within 30 days of the effective date and the Company effected payment on April 4, 2024. Lingmed is also entitled to 5.0% of any future milestone payments received by the Company under the license agreement with Qilu in addition to a sum of $250 thousand with respect to the first future milestone received by the Company. On April 9, 2024, pursuant to the parties&#8217; joint request, the Court entered a dismissal with prejudice of the entire action as to all parties and all claims and the matter was settled.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Technology Transfer Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_TechnologyTransferAgreementAbstract', window );"><strong>Technology Transfer Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_TechnologyTransferAgreementTextBlock', window );">Technology Transfer Agreement</a></td>
<td class="text">Technology Transfer Agreement<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impilo Therapeutics </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the Company entered into a technology transfer agreement with Impilo Therapeutics (&#8220;Impilo&#8221;) under which the Company transferred its rights to its tumor penetrating nanocomplex (TPN) platform to Impilo. As consideration for the technology transfer, Impilo issued a total of 766,000 shares of its pre-seed preferred stock to the Company. On October 3, 2023, in connection with the Sanford Burnham Prebys license agreement (see Note 16 - License Agreements) Impilo cancelled the original stock certificate for 766,000 shares and reissued 574,500 shares of its pre-seed preferred stock to the Company. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2024, the Company purchased a Simple Agreement for Future Equity ("SAFE") from Impilo for $100&#160;thousand. On July 12, 2024, the Company purchased an additional SAFE from Impilo for $30&#160;thousand. As of March&#160;31, 2025 and December&#160;31, 2024, the Company owned 38.6% of Impilo. These investments were expensed under the equity method of accounting in the prior year in other expense, net in the accompanying statement of operations. The SAFE has a valuation cap of $30.0&#160;million and an 80% discount rate.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_TechnologyTransferAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Technology Transfer Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_TechnologyTransferAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_TechnologyTransferAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Technology Transfer Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_TechnologyTransferAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text">License Agreements<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanford Burnham Prebys</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (&#8220;SBP&#8221;) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of certepetide. At the time the license agreement was entered into, Cend&#8217;s founding shareholder was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10&#160;thousand increasing to $20&#160;thousand on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6&#160;million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income received, which, pursuant to the technology transfer agreement with Impilo, resulted in SBP receiving 191,500 shares of the Company&#8217;s pre-seed preferred stock in Impilo on October 3, 2023. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreement may be terminated in its entirety by the Company at any time by giving SBP sixty days&#8217; prior written notice. The agreement may be terminated in its entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreement may be terminated in its entirety by either SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreement for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SBP did not own shares of the Company&#8217;s common stock as of March&#160;31, 2025. </span></div>Research Collaboration and License Agreements<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement - Qilu Pharmaceuticals</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the &#8220;Qilu Agreement&#8221;) in which Cend granted an exclusive license to Qilu for the development and commercialization of certepetide in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of certepetide in its Territory. In consideration for the license, Qilu made an upfront payment of $10.0&#160;million to Cend, which was recognized as revenue by Cend prior to the Company's acquisition of Cend on September 15, 2022 (the &#8220;Cend Merger&#8221;). In addition, Cend received and recognized as revenue a $5.0&#160;million development milestone prior to the Cend Merger. The Company is eligible to receive additional development and commercial milestone payments up to $96.0&#160;million and $125.0&#160;million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2024, the Company entered into a settlement agreement with Lingmed whereby Lingmed is entitled to 5.0% of any future milestone payments received by the Company under the Qilu Agreement, in addition, Lingmed is also entitled to a sum of $250 thousand with respect to the first future milestone received by the Company. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate simultaneously.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement - Kuva Labs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Company entered into an Exclusive License and Collaboration Agreement in which the Company granted an exclusive license to Kuva Labs, Inc. (Kuva) to explore the synergistic potential of the Company's certepetide as a targeting and delivery agent for Kuva&#8217;s NanoMark&#8482; imaging technology in solid tumors. Under the Agreement, Kuva will assume full responsibility for research, development, and commercialization costs, while the Company will be responsible for supplying certepetide for additional consideration pursuant to a Clinical Supply Agreement. In consideration for the license, the Company recognized $1.0&#160;million as revenue upon delivery of the license in November 2024. The Company is eligible to receive additional development and commercial milestone payments up to $1.5&#160;million and $17.5&#160;million, respectively, a 5.0% percent royalty on net sales, and sublicensing revenues of 50%.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Research Collaboration and License Agreement</a></td>
<td class="text">License Agreements<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanford Burnham Prebys</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (&#8220;SBP&#8221;) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of certepetide. At the time the license agreement was entered into, Cend&#8217;s founding shareholder was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10&#160;thousand increasing to $20&#160;thousand on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6&#160;million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income received, which, pursuant to the technology transfer agreement with Impilo, resulted in SBP receiving 191,500 shares of the Company&#8217;s pre-seed preferred stock in Impilo on October 3, 2023. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreement may be terminated in its entirety by the Company at any time by giving SBP sixty days&#8217; prior written notice. The agreement may be terminated in its entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreement may be terminated in its entirety by either SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreement for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SBP did not own shares of the Company&#8217;s common stock as of March&#160;31, 2025. </span></div>Research Collaboration and License Agreements<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement - Qilu Pharmaceuticals</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the &#8220;Qilu Agreement&#8221;) in which Cend granted an exclusive license to Qilu for the development and commercialization of certepetide in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of certepetide in its Territory. In consideration for the license, Qilu made an upfront payment of $10.0&#160;million to Cend, which was recognized as revenue by Cend prior to the Company's acquisition of Cend on September 15, 2022 (the &#8220;Cend Merger&#8221;). In addition, Cend received and recognized as revenue a $5.0&#160;million development milestone prior to the Cend Merger. The Company is eligible to receive additional development and commercial milestone payments up to $96.0&#160;million and $125.0&#160;million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2024, the Company entered into a settlement agreement with Lingmed whereby Lingmed is entitled to 5.0% of any future milestone payments received by the Company under the Qilu Agreement, in addition, Lingmed is also entitled to a sum of $250 thousand with respect to the first future milestone received by the Company. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate simultaneously.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement - Kuva Labs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Company entered into an Exclusive License and Collaboration Agreement in which the Company granted an exclusive license to Kuva Labs, Inc. (Kuva) to explore the synergistic potential of the Company's certepetide as a targeting and delivery agent for Kuva&#8217;s NanoMark&#8482; imaging technology in solid tumors. Under the Agreement, Kuva will assume full responsibility for research, development, and commercialization costs, while the Company will be responsible for supplying certepetide for additional consideration pursuant to a Clinical Supply Agreement. In consideration for the license, the Company recognized $1.0&#160;million as revenue upon delivery of the license in November 2024. The Company is eligible to receive additional development and commercial milestone payments up to $1.5&#160;million and $17.5&#160;million, respectively, a 5.0% percent royalty on net sales, and sublicensing revenues of 50%.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">$ (4,724)<span></span>
</td>
<td class="num">$ (5,401)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2025, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2024 and 2023 included in our 2024 Form 10-K. Operating results for the three months ended March&#160;31, 2025 are not necessarily indicative of the results that may be expected for the year ending December 31, 2025.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one operating segment, the research and development of its investigational drug product. The Company's Chief Operating Decision Maker (&#8220;CODM&#8221;) is its Chief Executive Officer, who manages the business on a consolidated basis.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div>The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Remeasurement</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div>Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risks</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents, accounts receivable and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government, thereby reducing credit risk exposure. Cash is held at major banks in the United States and may exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return. The Company&#8217;s accounts receivable balance as of March&#160;31, 2025 and December&#160;31, 2024 is derived from its license agreement dated November 30, 2024, more fully described in Note 17. The Company has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Accounts receivable is stated at historical cost, less allowance for credit losses. The Company records an expense based on a forward-looking current expected credit loss model to maintain its allowance for credit losses, which replaced the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allowance for doubtful accounts. When determining its allowance for trade accounts receivable, the Company considers the probability of recoverability of accounts receivable based on experience, taking into account current collection trends and general economic factors, including bankruptcy rates. The Company also considers future economic trends to estimate expected</span></div>credit losses over the lifetime of the asset. Credit risks are assessed based on historical write-offs, net of recoveries, as well as an analysis of the aged accounts receivable balances with allowances generally increasing as the receivable ages. Accounts receivable may be fully reserved for when specific collection issues are known to exist, such as pending bankruptcies. Account balances are written off against the allowance when it is determined that the receivable will not be recovered.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities, that are not the result of credit losses, are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and credit losses recognized through an allowance for credit losses, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div>The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Long-lived Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight-line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div>The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Share-based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div>Basic loss per share is based on the weighted effect of all shares of common stock issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock used in the basic loss per share calculation plus the number of shares of common stock that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Treasury Stock</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (&#8220;R&amp;D&#8221;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive the Company&#8217;s initiatives, the Company will continue targeting key governmental agencies and not-for-profit organizations to contribute funds for the Company&#8217;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In-process Research and Development Expense</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#8220;business&#8221; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text">The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div>If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Milestones, Royalties</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#8217;s collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#8217;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three months ended March&#160;31, 2025 and March&#160;31, 2024, the Company has not recognized revenue related to milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an operating lease for one office which expires on September 30, 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as the Company's lease does not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of ASU No. 2016-02, Leases (Topic 842), the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-40/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/730/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text">The estimated useful lives of property and equipment are as follows:<div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:66.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.466%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or lease term</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"><tr><td style="width:1.0pt"></td><td style="width:358.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(589)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale-Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-sale Securities Reconciliation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in the Company's Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,984&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,653&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,649&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in the Company's Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:360.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,613&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,649&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Investments Classified by Contractual Maturity Date</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:361.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,990&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text">The estimated useful lives of property and equipment are as follows:<div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:66.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.466%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or lease term</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"><tr><td style="width:1.0pt"></td><td style="width:358.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(589)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">At March&#160;31, 2025 and 2024, the Company excluded the following potentially dilutive securities (in thousands):<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March&#160;31, 2025 and December&#160;31, 2024 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:116.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available-for-sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,368&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,616&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,984&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,613&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,036&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,649&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of March&#160;31, 2025 and December&#160;31, 2024 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:313.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and R&amp;D related liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting &amp; tax consulting liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities &#8212; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,205&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,329&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock', window );">Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of the Company's balance sheet as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-416"><span style="-sec-ix-hidden:f-417">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-422"><span style="-sec-ix-hidden:f-423">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments Under Lease Agreements</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under the lease agreement as of March&#160;31, 2025 were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option and Warrants Activity</a></td>
<td class="text">The following table summarizes the activity for stock options and warrants for the three months ended March&#160;31, 2025:<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,440,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.46</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,496,744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.29</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,529,391&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.22&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.62</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,496,744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.52&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.05</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2025<br/>or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,517,488&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.24&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.0&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,496,744&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.52&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,344,298&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.60&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,496,744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.52&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.05</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2025 and 2024, the Company issued restricted stock for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"></td><td style="width:322.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the changes in non-vested restricted stock for the three months ended March&#160;31, 2025:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"><tr><td style="width:1.0%"></td><td style="width:33.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Stock Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the Year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294,611&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.47&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2025 and 2024, the Company issued restricted stock units for services as follows (in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"></td><td style="width:343.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the changes in non-vested restricted stock units for the three months ended March&#160;31, 2025:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"><tr><td style="width:1.0%"></td><td style="width:33.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the Year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85,345&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule Share-based Compensation Expense</a></td>
<td class="text">The following table summarizes the components of share-based compensation expense for the three months ended March&#160;31, 2025 and 2024 (in thousands):<div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.491%"><tr><td style="width:1.0%"></td><td style="width:62.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.282%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.620%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Total Compensation Cost Related to Nonvested Awards</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March&#160;31, 2025 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:61.271%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.002%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.587%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.32</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Share-based Compensation Awards</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March&#160;31, 2025 and 2024 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:530.25pt"><tr><td style="width:1.0pt"></td><td style="width:257.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrants</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"><tr><td style="width:1.0%"></td><td style="width:67.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development by significant expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;BOLSTER trial</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;ASCEND trial</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Chemistry, manufacturing and controls</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Clinical department</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,602&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative by significant expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Investor relations/public relations/communications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Finance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Legal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Business development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Share based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,245&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,360&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,847)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,601)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(798)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(4,724)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5,401)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25,833</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43,349</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Included in Other are the GBM study, FORTIFIDE study and research </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;oncology expenses</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Included in Other are facilities expense, human resource </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;and information technology expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CashAndCashEquivalentsAndMarketableSecurities', window );">Cash, cash equivalents and marketable securities | $</a></td>
<td class="nump">$ 25.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CashAndCashEquivalentsAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents And Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CashAndCashEquivalentsAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts receivable, allowance for credit loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected amortization, remainder of fiscal year</a></td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected amortization, year one</a></td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected amortization, year two</a></td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue excluding taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative arrangement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue excluding taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue excluding taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue excluding taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 22,990<span></span>
</td>
<td class="nump">$ 25,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">22,984<span></span>
</td>
<td class="nump">25,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">10,301<span></span>
</td>
<td class="nump">16,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">10,295<span></span>
</td>
<td class="nump">16,021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">12,129<span></span>
</td>
<td class="nump">6,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">12,129<span></span>
</td>
<td class="nump">6,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_BondsMember', window );">Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">560<span></span>
</td>
<td class="nump">905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 560<span></span>
</td>
<td class="nump">$ 905<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_BondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_BondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Schedule of Classification of Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 17,368<span></span>
</td>
<td class="nump">$ 10,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">5,616<span></span>
</td>
<td class="nump">15,036<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total</a></td>
<td class="nump">$ 22,984<span></span>
</td>
<td class="nump">$ 25,649<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Schedule of Available-for-Sale Securities by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis', window );">Less than one year</a></td>
<td class="nump">$ 22,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis', window );">Greater than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">22,990<span></span>
</td>
<td class="nump">$ 25,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue', window );">Less than one year</a></td>
<td class="nump">22,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Greater than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 22,984<span></span>
</td>
<td class="nump">$ 25,649<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(615)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(589)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">1,529<span></span>
</td>
<td class="nump">1,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">1,497<span></span>
</td>
<td class="nump">1,422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 17,368<span></span>
</td>
<td class="nump">$ 10,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available-for-sale</a></td>
<td class="nump">5,616<span></span>
</td>
<td class="nump">15,036<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">22,984<span></span>
</td>
<td class="nump">25,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">17,368<span></span>
</td>
<td class="nump">10,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">17,368<span></span>
</td>
<td class="nump">10,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available-for-sale</a></td>
<td class="nump">5,616<span></span>
</td>
<td class="nump">15,036<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">5,616<span></span>
</td>
<td class="nump">15,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Salaries, employee benefits and related taxes</a></td>
<td class="nump">$ 1,532<span></span>
</td>
<td class="nump">$ 2,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_ClinicalAndRDRelatedLiabilities', window );">Clinical and R&amp;D related liabilities</a></td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">1,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_AccruedGrantFunding', window );">Accounting &amp; tax consulting liabilities</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities &#8212; current</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 3,205<span></span>
</td>
<td class="nump">$ 4,329<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_AccruedGrantFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Grant Funding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_AccruedGrantFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_ClinicalAndRDRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical and R&amp;D Related Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_ClinicalAndRDRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Schedule of Balance Sheet Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_OperatingLeaseRightOfUseAssetAbstract', window );"><strong>Right-of-Use Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Right-of-use assets, balance sheet line item</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease liabilities, current, balance sheet line item</a></td>
<td class="text">Accrued liabilities<span></span>
</td>
<td class="text">Accrued liabilities<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total Operating Lease Liabilities</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_OperatingLeaseRightOfUseAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_OperatingLeaseRightOfUseAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Narrative (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating leases (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate for operating leases (percent)</a></td>
<td class="nump">9.625%<span></span>
</td>
<td class="nump">9.625%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Schedule of Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2025</a></td>
<td class="nump">$ 95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amounts representing interest</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Equity Issuances (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">46 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Aug. 21, 2024</div></th>
<th class="th"><div>Mar. 21, 2024</div></th>
<th class="th"><div>Jun. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_OutstandingStockThreshold', window );">Outstanding stock threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_SaleOfStockAvailableForSalePercentage', window );">Percentage held by non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 212,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lsta_AtTheMarketOfferingAgreementMember', window );">ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement', window );">Aggregate offering amount authorized per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, value, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_SaleOfStockAvailableForSale', window );">Sale of stock available for sale</a></td>
<td class="nump">$ 9,855,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,855,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (in shares)</a></td>
<td class="nump">55,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 211,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 492,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_OutstandingStockThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding Stock Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_OutstandingStockThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_SaleOfStockAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock Available for Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_SaleOfStockAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_SaleOfStockAvailableForSalePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock Available for Sale, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_SaleOfStockAvailableForSalePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lsta_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lsta_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Stock Options and Warrants (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding, Beginning of Period (in shares)</a></td>
<td class="nump">1,440,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options, Granted (in shares)</a></td>
<td class="nump">111,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised (in shares)</a></td>
<td class="num">(4,329)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, Expired (in shares)</a></td>
<td class="num">(18,215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding, End of Period (in shares)</a></td>
<td class="nump">1,529,391<span></span>
</td>
<td class="nump">1,440,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, Vested and expected to vest (in shares)</a></td>
<td class="nump">1,517,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options, Vested (in shares)</a></td>
<td class="nump">1,344,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Stock Options, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options, Outstanding. Beginning of Period (in dollars per share)</a></td>
<td class="nump">$ 8.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options, Granted (in dollars per share)</a></td>
<td class="nump">3.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options, Exercised (in dollars per share)</a></td>
<td class="nump">1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options, Forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options, Expired (in dollars per share)</a></td>
<td class="nump">198.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options, Outstanding, End of Period (in dollars per share)</a></td>
<td class="nump">6.22<span></span>
</td>
<td class="nump">$ 8.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options, Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">6.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options, Vested (in dollars per share)</a></td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Weighted Average Contractual Term and Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 years 7 months 13 days<span></span>
</td>
<td class="text">5 years 5 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options, Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_OptionsVestedWeightedAverageRemainingContractualTerm', window );">Options, Vested, Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 years 1 month 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options, Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 79,000.0<span></span>
</td>
<td class="nump">$ 157,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options, Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">79,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options, Vested, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 78,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Warrants, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CommonStockWarrantsShares', window );">Warrants, Outstanding, Beginning of Period (in shares)</a></td>
<td class="nump">1,496,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsGranted', window );">Warrants, Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsExercised', window );">Warrants, Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsCanceled', window );">Warrants, Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsExpired', window );">Warrants, Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CommonStockWarrantsShares', window );">Warrants, Outstanding, End of Period (in shares)</a></td>
<td class="nump">1,496,744<span></span>
</td>
<td class="nump">1,496,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_Sharesvestedandexpectedtovest', window );">Warrants, Vested and expected to vest (in shares)</a></td>
<td class="nump">1,496,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsVested', window );">Warrants, Vested (in shares)</a></td>
<td class="nump">1,496,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsWeightedAverageExercisePriceRollForward', window );"><strong>Warrants, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsOutstanding', window );">Warrants Outstanding, Beginning of Period (in dollars per share)</a></td>
<td class="nump">$ 40.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsGranted', window );">Warrants, Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsExercised', window );">Warrants, Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsCanceled', window );">Warrants, Forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsExpired', window );">Warrants, Expired (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsOutstanding', window );">Warrants Outstanding, End of Period (in dollars per share)</a></td>
<td class="nump">40.52<span></span>
</td>
<td class="nump">$ 40.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest', window );">Warrants, Weighted Average Exercise Price, Vested or expected to vest in the future (in dollars per share)</a></td>
<td class="nump">40.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageExercisePriceWarrantsExercisable', window );">Warrants, Vested, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 40.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WarrantsOtherDisclosuresAbstract', window );"><strong>Warrants, Weighted Average Contractual Term and Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageRemainingContractualTermWarrantOutstanding', window );">Warrants, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">1 year 18 days<span></span>
</td>
<td class="text">1 year 3 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest', window );">Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">1 year 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_WeightedAverageRemainingContractualTermWarrantsVested', window );">Warrants, Vested, Weighted Average Remaining Contractual Term</a></td>
<td class="text">1 year 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_AggregateIntrinsicValueWarrantsOutstanding', window );">Warrants Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_AggregateIntrinsicValueWarrantsVestedAndExpectedToVest', window );">Warrants, Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_AggregateIntrinsicValueWarrantsVested', window );">Warrants, Vested, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_AggregateIntrinsicValueWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_AggregateIntrinsicValueWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_AggregateIntrinsicValueWarrantsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants Vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_AggregateIntrinsicValueWarrantsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_AggregateIntrinsicValueWarrantsVestedAndExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants Vested And Expected To Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_AggregateIntrinsicValueWarrantsVestedAndExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CommonStockWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrants, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CommonStockWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_OptionsVestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options, Vested, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_OptionsVestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_Sharesvestedandexpectedtovest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>shares, vested and expected to vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_Sharesvestedandexpectedtovest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Canceled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Other Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WarrantsWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Weighted Average Exercise Price [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WarrantsWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Canceled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Exercisable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Vested And Expected To Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageRemainingContractualTermWarrantOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term Warrant Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageRemainingContractualTermWarrantOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageRemainingContractualTermWarrantsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>weighted Average Remaining Contractual Term, Warrants Vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageRemainingContractualTermWarrantsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - Restricted Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value (in dollars per share)</a></td>
<td class="nump">$ 3.80<span></span>
</td>
<td class="nump">$ 3.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Restricted Stock Units for Services (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of shares issued (in shares)</a></td>
<td class="nump">215,550<span></span>
</td>
<td class="nump">203,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of shares issued</a></td>
<td class="nump">$ 819<span></span>
</td>
<td class="nump">$ 628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value (in dollars per share)</a></td>
<td class="nump">$ 3.80<span></span>
</td>
<td class="nump">$ 3.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of shares issued (in shares)</a></td>
<td class="nump">78,945<span></span>
</td>
<td class="nump">205,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of shares issued</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value (in dollars per share)</a></td>
<td class="nump">$ 3.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Non Vested Restricted Stock (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">228,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">215,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(149,367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">294,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant-Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 3.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">3.80<span></span>
</td>
<td class="nump">$ 3.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">4.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 3.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">103,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">78,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(97,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">85,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant-Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">3.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">3.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 3.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 530<span></span>
</td>
<td class="nump">$ 454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 404<span></span>
</td>
<td class="nump">$ 368<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Compensation Cost Not Yet Recognized (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">2 years 2 months 15 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">2 years 3 months 25 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of shares vested</a></td>
<td class="nump">$ 263<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value of shares granted</a></td>
<td class="nump">$ 2.60<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of shares vested</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value of shares granted</a></td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards subject to expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross', window );">Proceeds from sale of NOLs, gross</a></td>
<td class="nump">$ 10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_ProceedsFromSaleOfNOLS', window );">Proceeds from sale of NOLs</a></td>
<td class="nump">871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="nump">962<span></span>
</td>
<td class="num">$ (962)<span></span>
</td>
<td class="num">$ (798)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_LossOnSaleOfNOL', window );">Loss on sale of NOL</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=lsta_CENDMember', window );">CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_FairValueMarketOfTaxNOLs', window );">Fair value market of tax NOLs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate reconciliation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.54%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation', window );">NOL annual limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_OperatingLossCarryforwardsBeforeWriteDown', window );">Net operating loss carryforwards, prior to write down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,700<span></span>
</td>
<td class="nump">57,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_OperatingLossCarryforwardsPostAcquisition', window );">Operating loss carryforwards, post acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400<span></span>
</td>
<td class="nump">24,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority | CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_FairValueMarketOfTaxNOLs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Market of Tax NOLs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_FairValueMarketOfTaxNOLs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_LossOnSaleOfNOL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss On Sale of NOL</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_LossOnSaleOfNOL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Carryforward Operating Loss Carryforward Annual Limitation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_OperatingLossCarryforwardsBeforeWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Before Write Down</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_OperatingLossCarryforwardsBeforeWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_OperatingLossCarryforwardsPostAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Post Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_OperatingLossCarryforwardsPostAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_ProceedsFromSaleOfNOLS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale of NOLS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_ProceedsFromSaleOfNOLS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lsta_CENDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lsta_CENDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue excluding taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">43,000<span></span>
</td>
<td class="nump">46,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity method investment expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Financial Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,602<span></span>
</td>
<td class="nump">$ 3,241<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,847)<span></span>
</td>
<td class="num">(6,601)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="num">(187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="nump">$ 962<span></span>
</td>
<td class="num">(962)<span></span>
</td>
<td class="num">(798)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,724)<span></span>
</td>
<td class="num">(5,401)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=lsta_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,602<span></span>
</td>
<td class="nump">3,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,245<span></span>
</td>
<td class="nump">3,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommunicationsAndInformationTechnology', window );">Investor relations/public relations/communications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_FinanceGeneralAndAdministrativeExpense', window );">Finance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_LegalGeneralAndAdministrativeExpense', window );">Legal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="nump">671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDevelopment', window );">Business development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,847)<span></span>
</td>
<td class="num">(6,601)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(962)<span></span>
</td>
<td class="num">(798)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,724)<span></span>
</td>
<td class="num">(5,401)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CashCashEquivalentsAndMarketableSecurities', window );">Cash and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,833<span></span>
</td>
<td class="nump">43,349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=lsta_ReportableSegmentMember', window );">Reportable Segment | Segment Reporting, Reconciling Item, Corporate Nonsegment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=lsta_ReportableSegmentMember', window );">Reportable Segment | BOLSTER trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">788<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=lsta_ReportableSegmentMember', window );">Reportable Segment | ASCEND trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=lsta_ReportableSegmentMember', window );">Reportable Segment | Chemistry, manufacturing and controls</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=lsta_ReportableSegmentMember', window );">Reportable Segment | Clinical department</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,156<span></span>
</td>
<td class="nump">1,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=lsta_ReportableSegmentMember', window );">Reportable Segment | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 417<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CashCashEquivalentsAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CashCashEquivalentsAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_FinanceGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance, General And Administrative Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_FinanceGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_LegalGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal, General And Administrative Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_LegalGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Expense, General And Administrative Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommunicationsAndInformationTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense in the period for communications and data processing expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommunicationsAndInformationTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=lsta_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=lsta_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lsta_BolsterTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lsta_BolsterTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lsta_AscendTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lsta_AscendTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lsta_ChemistryManufacturingAndControlsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lsta_ChemistryManufacturingAndControlsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lsta_ClinicalDepartmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lsta_ClinicalDepartmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lsta_ResearchAndDevelopmentOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lsta_ResearchAndDevelopmentOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Australia Research and Development Tax Incentive (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayLineItems', window );"><strong>Income Tax Holiday [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_IncomeTaxIncentiveReceivable', window );">Income tax incentive receivable</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayLineItems', window );"><strong>Income Tax Holiday [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research tax credit rate</a></td>
<td class="nump">43.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayLineItems', window );"><strong>Income Tax Holiday [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research tax credit rate</a></td>
<td class="nump">48.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_IncomeTaxIncentiveReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Incentive Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_IncomeTaxIncentiveReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies (Details) - Lingmed Limited<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 25, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_LitigationSettlementPaymentTerm', window );">Litigation settlement, payment term</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_LitigationSettlementFutureMilestonePaymentsPercent', window );">Litigation settlement, future milestone payments</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_LitigationSettlementMilestonePayment', window );">Litigation settlement, first milestone payment</a></td>
<td class="nump">$ 250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_LitigationSettlementFutureMilestonePaymentsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Future Milestone Payments, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_LitigationSettlementFutureMilestonePaymentsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_LitigationSettlementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_LitigationSettlementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_LitigationSettlementPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Payment Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_LitigationSettlementPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lsta_LingmedLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lsta_LingmedLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Technology Transfer Agreement (Details) - Impilo - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 12, 2024</div></th>
<th class="th"><div>Mar. 15, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems', window );"><strong>Investments in and Advances to Affiliates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_InvestmentOwnedCanceledShares', window );">Shares canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">574,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Payments to acquire Impilo SAFE</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_SAFEValuationCap', window );">SAFE, valuation cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_SAFEDiscountRate', window );">SAFE, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_InvestmentOwnedCanceledShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment Owned, Canceled, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_InvestmentOwnedCanceledShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_SAFEDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>SAFE, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_SAFEDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_SAFEValuationCap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>SAFE, Valuation Cap</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_SAFEValuationCap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lsta_ImpiloMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lsta_ImpiloMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lsta_ImpiloMember', window );">Impilo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lsta_SanfordBurnhamPrebysMember', window );">Sanford Burnham Prebys</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_SharesHeldByThirdParty', window );">Shares held by third party (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lsta_SanfordBurnhamPrebysMember', window );">Sanford Burnham Prebys | Impilo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lsta_SanfordBurnhamPrebysMember', window );">Sanford Burnham Prebys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_SharesIssuedUnderLicenseAgreement', window );">Shares issued under license agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee', window );">Annual license maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven', window );">Annual license maintenance fee, year seven</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales', window );">Royalties, net of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sublicensing Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_SharesHeldByThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Held by Third Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_SharesHeldByThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_SharesIssuedUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued Under License Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_SharesIssuedUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lsta_ImpiloMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lsta_ImpiloMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lsta_SanfordBurnhamPrebysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lsta_SanfordBurnhamPrebysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 14, 2022</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=lsta_LingmedLimitedMember', window );">Lingmed Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_LitigationSettlementFutureMilestonePaymentsPercent', window );">Litigation settlement, future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_LitigationSettlementMilestonePayment', window );">Litigation settlement, first milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lsta_ExclusiveLicenseAndCollaborationAgreementMember', window );">Exclusive License and Collaboration Agreement | Qilu | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from contract</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate', window );">Option to terminate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lsta_ExclusiveLicenseAndCollaborationAgreementMember', window );">Exclusive License and Collaboration Agreement | Qilu | License | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Variable consideration amounts, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenuePerformanceObligationPercentageOfNetSale', window );">Percentage of net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues', window );">Percentage of sublicensing revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lsta_ExclusiveLicenseAndCollaborationAgreementMember', window );">Exclusive License and Collaboration Agreement | Qilu | License | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Variable consideration amounts, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenuePerformanceObligationPercentageOfNetSale', window );">Percentage of net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues', window );">Percentage of sublicensing revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lsta_ExclusiveLicenseAndCollaborationAgreementMember', window );">Exclusive License and Collaboration Agreement | Kuva | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenuePerformanceObligationPercentageOfNetSale', window );">Percentage of net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues', window );">Percentage of sublicensing revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lsta_ExclusiveLicenseAndCollaborationAgreementMember', window );">Exclusive License and Collaboration Agreement | Kuva | License | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Variable consideration amounts, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lsta_ExclusiveLicenseAndCollaborationAgreementMember', window );">Exclusive License and Collaboration Agreement | Kuva | License | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Variable consideration amounts, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_LitigationSettlementFutureMilestonePaymentsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Future Milestone Payments, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_LitigationSettlementFutureMilestonePaymentsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_LitigationSettlementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_LitigationSettlementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research Collaboration and License Agreement, Option to Terminate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_RevenuePerformanceObligationPercentageOfNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Percentage of Net Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_RevenuePerformanceObligationPercentageOfNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Percentage of Sublicensing Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lsta_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lsta_LingmedLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lsta_LingmedLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lsta_ExclusiveLicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lsta_ExclusiveLicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lsta_QiluMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lsta_QiluMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lsta_KuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lsta_KuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,:!J%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( ,:!J%IMP#PU\0   "L"   1
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M(Z,']]P$C%K5!+:M<E:UCD$>Q9Z0\)HR_<:>D8F"ODF$)*Y(8R6W\.L;Z^&
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M +\_"!!4U4MQ 5M?N,_^!U!+ P04    " #&@:A:-2U\#<T"  #^!P  &
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MP:0=-F>N7Y/OGR0_+?,R8_;R!SH^0MN^K0?)/W1;NA/'%-=<K"$A1=10IJ%
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M*3OR0-!X('!IGWU3O2=EPIH;U<IQN5(WF-UL&$RTWW>'Z"U28>#!1NH(5MC
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M659>)@3'A&L!]?V:,?E\HU_0_+(R^Q]02P,$%     @ QH&H6LUSF[0$#0
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M30>;6I! DSL963/AX"'M',,ADZ.4VY-;7L;>W?$MQXC#16#W-G<&WKR<(!*
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M"LB$FDA(/AXR^!R)<,_'O/BLUVLZ5R -):22[F^Y;CQ%H2W:(5!&8R"2XQ>
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M6=\#W6Q0S<&JLMY:,F5I!ZK))2V=J)T W<^5LMN#,]"NL9._ 5!+ P04
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M<_J1@)85Z#PS=-TW&W;0_>R8_PM02P,$%     @ QH&H6L-<?=.Y @  . 8
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MNRI3SY>^O4KX.5L8J^FK^+6OX)8OV\_G.F5D&I;C)*!6,*@?,9B>',6#Z.*
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MV-&TT$B'? \MJ-B;N6D^;, ,1N<6Q ZKYBK.<9(K7M28[ 2-EWP80YX$PYI
MA"%OSI)&W4F\@<W<UVKT$PR0ZVTW=\90%4(_H:/DK!3&B4!1QEQI80Z9QL+W
MQDZP#4A-X%(Q#DVFTC)DJRK]C[:1+E4/Y(M8$9%CLIYM6B775?_-=F$U=7%
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MAF +_IDKB1#3 GQ?6!O:!U+0_<?#U7\!4$L#!!0    ( ,:!J%JV>SS0$P8
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MG-*<E#MOZ521GI_?H\RU*<QZ"_=6:+=""XNU1:3 ^VGLR00+QK*%NVC@TA_
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MS&/T>!<PUL@C=31*+]85=RNBXDCM@3[D!PM,0B/D'#5ERP;U$%0!4LA0E7
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M73];(1T9*MPAO- PWPA8 ZPRDA1B?U@I8,0ML*]BAU!")%)5*D#U2%P$7A*
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M2/S&D))*IM/AV[(BGZ@^:*(282>O.YPL@30#2A\'(Y@"'ZLT +9\)&[=ATE
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ME>/@8P %+E@CZ%ZM;[#3,W1\N1+&?V'=^@Z' >2-(55U8)M!Q66[LN>N#EN
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M:N=@[Q=*T<9P ?IAG?T&4$L#!!0    ( ,:!J%H3K8?K1 (  (H&   9
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MP])\+$#: /,^%T(?)W:#X?.3_@%02P,$%     @ QH&H6F=SXH4Q%@  GD8
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M1H*4_$$'( /3,9^0J&1EL@K- 9)=#&95VY;IAC1DFD\DBPUO ,%5KJ?D;RN
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MA78T:L*VH-F.Q@?0^5)KMS5\@O;?8OH;4$L#!!0    ( ,:!J%I<_>'T, ,
M !((   9    >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;(U6;6_3,!#^*Z>
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MLPRLE5U[:WM#\N\[]@(E*J$OQO;.G#DSQV,SVDKUJDM$ ^]U)?38*XUIKH-
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MYV.5$2\F[V(C66:&UT<FU2ALEK'Z6P&N'=3S#6/RL-$'5/\_P5]02P,$%
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M82!5'V1UP\BR.@NFTN#)4MWF>/:#L@7X?"ZE>6G8XZ7Y-Y'^ E!+ P04
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M65#%!NL7T/S*&-QW?%%H_P/2OU!+ P04    " #&@:A:'&]QZ8T"  !Y!P
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M;PLSX-P2H8R_#:?7+FF!A^T]^Y7SCEY65,-,\C\L,_G4^^J1#-:TXN96[GY
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MJU:[JAU!-VJQY9D*03.U&1,<$59>(,^O*!5O.V6 9LUQ^C]02P,$%     @
MQH&H6IQ;0G@)!P  ?S(  !D   !X;"]W;W)K<VAE971S+W-H965T-3(N>&UL
MM9MK<YLX%(;_BL:[L]O.M#:Z8.-NXIG<=K<?.LTTV_8S-;+-%"-7R+G\^Q47
M(RZRD(GYDAB"SM%[)*0G+^;BB?&?R892 9ZW49Q<CC9"[#Y,)LER0[=^,F8[
M&LN_K!C?^D(>\O4DV7'J!UFC;31!CC.=;/TP'BTNLG/W?''!]B(*8WK/0;+?
M;GW^<DTC]G0Y@J/#B2_A>B/2$Y/%Q<Y?TP<JON[NN3R:E%&"<$OC)&0QX'1U
M.;J"'VY<E#;(KO@6TJ>D\AFD4GXP]C,]^!A<CIRT1S2B2Y&&\.6O1WI#HRB-
M)/OQJP@Z*G.F#:N?#]'_SL1+,3_\A-ZPZ'L8B,WER!N!@*[\?22^L*=_:2'(
M3>,M691D/\%3<:TS LM](MBV:"Q[L WC_+?_7!2BT@"Y1QJ@H@&R;8"+!C@3
MFO<LDW7K"W]QP=D3X.G5,EKZ(:M-UEJJ">-T&!\$EW\-93NQ>!!L^7/#HH#R
MY$]P]VL?BA?P'CS(Z1+L(PK8"F27@,^[M.P)\., ?/<Y]V.1@#>W5/AAE+R5
M3;X^W((WO[^]F C9K33X9%ETX3KO CK2!0P^L5AL$G 7!S30M+\QMX?($& B
MZU$6!1V*<HV,$3_Y? PP? >0@UQ=A\S-;^FR;$X,W<'E&.$L'C:-T6$ WH&'
MC<]IHJMS'H;HPZ0+PH=DYR_IY4C>\0GECW2T^.,W.'7^TFD\4[":8E(J)J;H
MBU+KY[U(A)QR8;Q^!Z[I.HQC^3&=E?>4ARP ;\(8)%E!M#,O3^-F:=(5[7$!
M"7%<+$?UL2K6V)V>8MU2K&LG]I_TIJ*=FMRV)@B)XS0D&9/VE#0M)4WM)-T]
M4[X,DVY1TY:H]P2C>4.3,6M/3;-2T\Q.D]P^5C2T&*A92U-SC(P9>^KQ2CV>
M[1CM0MZMQFN/$/00;-Y)QJ0])<U+2?,>RX;<%>P7C'G[YG+1',]A0Z;FNL;"
M4E, ';4?.W8:OM$DG6/I?DN?=Y)ZY(%@X%&>[A)1I*BK@#/B>0T5YK[T'"U8
M80]XDM8N6; M"Q."YBU9QK1]92$E"YVR7W_/4%+*NWJD7*)QN2B">QXNJ58I
M.N=.?JYH]7(H>H%&5-#>E>.CFWG HLCG"=A1GL\%_53(4WJ5J>"-/=2<!T,P
M#%00 RTIIKJQ6^K+(T-4$8C'K7D^!+9 Q2W0$ESJN[RE0K>M$([;*]00& ,5
MQT!+D*EO^I82VU#3! !S^K[R%-) 2Z:I,H"EN)EF_.;>&.&FQ"$@!RK*@9:8
MT\$$EJJ]MNKI&+46'L^\/-6U*+R!EGS3Q0:68N9:,:0IQMBIG@.(%!"ATX#(
M7E\1V*O)FS;4F;/W5:<0",%7L<(-BP7WEV+O1^ _RK?9F'^4Y\(X"9?@FQ_M
MM02!SH1 19&& "JD@ H9">7(/=RJU1>:^I8I4C2KIJV0.:<+7F@ZQ69@FYM+
M$(/ ?]'Y+C>6H=PRE*L)5:^-HBMD25>&->'UM3+WH54K=+Q40R 94DB&+)$L
MK];K"V-.=R@,S L#D'.\,$.P'%(LARQ9KG:+7:W7G*Y]0:V6G#S#M++<SN9.
MRY?27 ;=6?6ZN@3%:LB2U8QWPFF2V@2GE30$Q2%%<<B2X@Z3^C2-L_:P>1J-
M0V <4AB'/.,^>7CD8+*_T9F\IT+P$$X64JR'S*RG!+_6 T<ZKVH^G9$FZ)E[
MU%,Q5J"'S:"G%%L:X;AM<S5GK3EE7TF*[K#9X%*2K(UPW#:Y6J*&H#&L: R;
M<4:)LG;"BXA&44.85+CRB,V,,-61LK+#BWA&24.P#E:L@\WP<60%.<D.Q[H'
M:+JUP^+"N@Q%)MA,)DK&*QQQK'EHIM<QA-^$%<-@,\.TQ';I:@/*$5U#( I6
MB()GEMMW#S<<GPD]BDH, 3)8@0PV^U'E=R>LMG4[HP.W[2;BC-VF*V7N65_E
MBFBP+=&<[H?C-L.T5MLAZ(4H>B&V]-+'#2?=*&/.WU>?0AEBBS)]K'#2337F
M_'WU*:HAME1SNA=.NO'&G+VO.H4WQ YOSN."%\EJQK%NP2'MIW3UR^IJ*M\.
MLB6;CMVDW$89;R.#E"LV%*SV8L_I*>HUS^:TZH=P=(CB)G(:-W46ZY02N%8;
MCKF'?2N@8(I,^T)'7UN=G FCBOH, 65$01DQ^T9'_D%XI27:D11FEBB WE$G
MU"X +LUTTF6F$P5GQ [.AG73.SIA4:$A0(XHD".V('<F%[TCGT5!AF _5[&?
M:\=^KS#/BPQ3 T)H+IFYQVQS5X&=:PMVY_/-W6[<,_>J[Y IW'-M<:^7:5Y$
M-P[768EO4OF*_Y;R=?;F0P*6;!^+_-O^Y=GR[8JK[)V"B;H\?S7CD\_E/YL)
MB.A*-G7&,SE,/'_;(3\0;)>],/"#"<&VV<<-]0/*TPODWU>,B<-!FJ!\YV3Q
M/U!+ P04    " #&@:A:A\<$0AT#  #:"P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970U,RYX;6S%5N]OVC 0_5>L;-I6:26!\+.#2)1U6J5U0JW6?ICVP20'
ML9K8J>U ^>]W=B"%*F3KAM0O$%_\WMV[G*TW7 EYKV( 31[3A*N1$VN=G;FN
M"F-(J6J(##B^F0N94HU+N7!5)H%&%I0F;LOSNFY*&7>"H8U-93 4N4X8AZDD
M*D]3*M?GD(C5R&DZV\ U6\3:!-Q@F-$%W(#^D4TEKMR2)6(I<,4$)Q+F(V?<
M/)LT/0.P.VX9K-3.,S%29D+<F\5E-'(\4Q$D$&I#0?%O"1-($L.$=3QL2)TR
MIP'N/F_9OUCQ*&9&%4Q$<L<B'8^<OD,BF-,\T==B]14V@CJ&+Q2)LK]D5>SM
M#1P2YDJ+= /&"E+&BW_ZN&G$#@!YJ@&M#:#U'- ^ / W -\*+2JSLCY338.A
M%"LBS6YD,P^V-Q:-:A@WG_%&2WS+$*>#&RW"^U@D$4CUGEP\Y$ROR2GY3J6D
MIL'DPV?0E"7J!*/7H+1DH8:(6!R&WA*7J)A*4$-78SV&U0TWN<^+W*T#N7UR
M);B.%;G@$43[>!=UE&):6S'GK5K"*RH;Q&]^)"VOU:FH9_+W\'9-.7[96]_R
M^8=Z:_IR:H8L(A.1XLE3U,[N&)O+%X"G09/9FNSNF]*U#8]75$;DYS>D))<:
M4O6KJK]%_G9U?G,#G*F,AC!R\(@KD$MP@G=OFEWO4U5SCD2VUZIVV:IV'7MP
M9X\;ZJ=+D'A]$)PTAH<4(W/*)%G2),=99)Q$(DFH5"0#60S>255CBFQ]F\W<
M9,O ;_2'[G)7;]4>[VG3GHY.J:-3J^.*<9;F:55)M<"7?JLCD>UI[)8:NZ\\
MUMUCMNI(9'NMZI6MZM6.PZT98[X@&F3E3-2CFV0-5%9IJL7]HZ9^J:E?/^+T
M\="(UP)?^MV.1+:G<5!J'+SRB ^.V:HCD>VUJND].0COOX;\#_"VG?(J^S"I
M1[Y4F+OCDE*0"VL>%0E%SG7A,<IH85#/C4$U+NM9'(WKV-HU]XFF<+WH(!:,
M*Y+ '"F]1@_O:5D8R6*A16:]V$QH=';V,4;S#=)LP/=S(?1V81*4=C[X#5!+
M P04    " #&@:A:_^+P7K$#  #+#0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970U-"YX;6S%5VUOVS80_BL'K=@2H(W>+,?.; .)TV$%UB*(F_3#L ^T=+:$
M2*)+4G;][W>D9%EV9*$=O.V+35)W#Y_GQ#L=1QLN7F2,J.!;EN9R;,5*K6YL
M6X8Q9DQ>\17F]&3!1<843<72EBN!+#).66I[CM.W,Y;DUF1DUA[$9,0+E28Y
M/@B0198QL;W#E&_&EFOM%AZ39:ST@CT9K=@29ZB>5@^"9G:-$B49YC+A.0A<
MC*U;]V;J^MK!6#PGN)&-,6@I<\Y?].1#-+8<S0A3#)6&8/2WQBFFJ48B'E\K
M4*O>4SLVQSOTWXQX$C-G$J<\_9)$*AY; PLB7+ B58]\\SM6@@*-%_)4FE_8
M5+:.!6$A%<\J9V*0)7GYS[Y5@6@X$$Z[@U<Y>,<.O1,.?N5@(F>7S(RL>Z;8
M9"3X!H2V)C0],+$QWJ0FR?5KG"E!3Q/R4Y.9XN%+S-,(A?P%WG\M$K6%=S"C
MXQ(5*0)?P"-*)9)0803&&I[R1$F@(P0S%.LD1 D7]ZA8DLI+\GV:W</%FTMX
M S;(F EZG.2ETUM:I/'GF!>2Y9$<V8HT:"9V6/&]*_EZ)_CZ\)'G*I;P/H\P
M.O2W27L= &\7@#NO$_ C$U?@NV_!<[R@A<_T^]U['73\^GWX!J]W N\XV&T1
MZD30>7\C5RS$L46)+>D-H37Y^2>W[_S:)N],8 =B>[78GD'W3QT^?3K>Z2R,
M8,HS*DV2F>2^%8+E2Z1RH6"^A:;= ]N:Y=L-$Q'\^0=!P@>%F?RK+52]<X;J
M3& 'H0KJ4 6=Y^)3D<U1Z'3<I924!87C@M*I7+ELTU^"!@945_3UQ'.#('!&
M]KJIK,7,\0?.WNR <[_FW._D_,S2 E]1;J-9XO0;^P_<X1''US9];]!.\+HF
M>-U)\(LI\A1%MD9!'RV@Y$OHTT K"Y8(6!L!.L013U,F)*SH'1@UK=$N=QLT
M*/I7@R,9;3;."1V#6L?@>XN&-!6ZT,6VC6$GSH_FPYG #B0/:\G#_[ET#,\9
MJC.!'83*=?;?>.??*!X5:K,L7 ^&O>#H1+>8>4[@GZH>;J,U<<]4/RJ@9G%H
M[E_Q?&W4][T3)+T]2>\_K2'5=MU%I)O3/SU/^Q[%[6Y2GK7&? D*1=:JH=O=
MA2TRT98FW8X_JLMNM,49BJ6Y+4@(>9&KLD&L5\L;R9V^D>BV^FB=;BJWIC^W
M]S#E-8?:OV622TAQ09#.U35E@2AO#N5$\95ION=<42MOAC'=ME!H WJ^X%SM
M)GJ#^OXV^1M02P,$%     @ QH&H6AOYGF>,!   <AH  !D   !X;"]W;W)K
M<VAE971S+W-H965T-34N>&ULM9E=<Z,V%(;_BH9VVMV9QB !-G9MS\3>W;87
MZ622V>RU8F2;"2"O)-N[_[Y"$+ZC8(IOS(<YK\XKH:-GT/Q,V0O?$R+ CRB,
M^<+8"W&8F2;?[$F$^8@>2"S_V5(682$OV<[D!T:PKX*BT$26-38C',3&<J[N
MW;/EG!Y%&,3DG@%^C"+,?JY(2,\+ QJO-QZ"W5XD-\SE_(!WY)&(KX=[)J_,
M7,4/(A+S@,: D>W"N(6S-?*2 /7$4T#.O'0.$BO/E+XD%__X"\-*,B(AV8A$
M LO#B:Q)&"9*,H_OF:B1MYD$EL]?U;\H\]+,,^9D3<-O@2_V"\,S@$^V^!B*
M!WK^FV2&W$1O0T.N?L$Y>]8RP.;(!8VR8)E!%,3I$?_(.J(4('7: U 6@.H!
MSAL!=A9@*Z-I9LK6)RSP<L[H&;#D::F6G*B^4='231 GP_@HF/PWD'%B^2CH
MYF5/0Y\P_COX_/T8B)_@!CS*U\4_A@30+?A7]O83X8+XX$$>6+!)3E4@^/")
M"!R$_*.,^168@.\Q(WQN"IE:TH"YR=)8I6F@-]*PP1V-Q9Z#S[%/_&J\*2WE
MOM"KKQ72"MYA-@(V_ ,@"[DM^:R[ASN:=.R\FVVEY[RA5^^XMA[2*B33><8/
M>$,6AIROG+ 3,9:__0+'UI]M]@82JYAU<K..4K<[F@5?XT"TOA3.D)8'$JM8
M=G/+KG9\5V07Q'$0[V1-"7&\(>!#$&>SX6.;\U3.57))J3TM$?(<Y,W-4]F3
MMM6>GL:YI['6TU\,Q\D8ON-DW'0"7=>U:DZT;?5T,LF=3+1.LNKUCI%)P\@-
M=*;V>%)SHFVKIQ,O=^)IG<BE:TN"#F:\AIGZ@&@;ZFECFMN8:FW(*G_!7)DV
MW["I,X:P9DC;9$]#T"K644M;]+XI8) #<WLB3 (04-/G1B[*!'S! 0-/.#R2
MUI71&K(*#J56[8823L >A="G88@9!P?"TH%N'>=,VBL-M#UJ3#]] GT-HL(@
MZEP5.]I*!2&J^*I7^NRIJGFK>*J:;L$=4 \>I=+7,5N[F:TS0N-ZNM< #%@0
M!M2NYK4ZV-&9\VY-U+?:UU4!$5!/$2UEL:,UM^7E<1HSYQHT 0N<@'J>*&$A
M5UAX? L+]4(75\1KH <LV -.!J)A.!!99+:OP2FP !6H)Y6+B1@VD05:MF<U
MYN@UP 46Y +UZ-*1BF$36B;>U''K9JX!+:B %J2E@8Y@G(E4R'@Z<1HCHV^L
MKYD"/9 >/3JS<::C6PCT3?6U4D &TD/&97R<B97]>*[=>-?T;?;U5) (LJ\$
MR&C0+R-#J56[H2 7I">7_P/(F71UF6]\,] GT-=@ 3%(#S&7 W(F^ X@ZYOM
M:ZN@%Z2GEXM!.M.KN;(:MJY!)ZB@$Z3_--('I%'S2TFC?EX#/E !'T@/'[U!
M.M.MSK!I8\P&11"S]/4^(FRG-C4XV-!C+-(/WOG==.-D!6=KM;]0NW\+9[=J
M&\$L9-+=F#O,9-7A("1;*6F-)G+L6+K!D5X(>E![!,]4"!JITSW!/F') _+_
M+:7B]2)I(-]F6OX'4$L#!!0    ( ,:!J%IR??\'&@,  +\+   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;,5686^;,!#]*Q:KIDY:"P%"TRY!:M)N
MJ[1*4=-N'Z9]<. 24 $SVTG:?[^S(112BE8I5;\DMKE[?O=\F#?<,'XO(@!)
M'M(D$R,CDC(_,TT11)!2<<QRR/#)@O&42ISRI2ER#C3426EBVI;EF2F-,\,?
MZK4I]X=L)9,X@RDG8I6FE#^.(6&;D=$SM@LW\3*2:L'TASE=P@SD73[E.#,K
ME#!.(1,QRPB'Q<@X[YU->I9*T!$_8]B(VIBH4N:,W:O)53@R+,4($@BD@J#X
MMX8))(E"0AY_2U"CVE,EUL=;]*^Z>"QF3@5,6/(K#F4T,@8&"6%!5XF\89OO
M4!;45W@!2X3^)9LRUC)(L!*2I64R,DCCK/BG#Z40M03$:4^PRP1[-\%](<$I
M$QQ=:,%,EW5!)?6'G&T(5]&(I@9:&YV-U<29.L:9Y/@TQCSISR+*X6B,0H1D
MPE+L#D&UOD=DABT3KA(@;$%>#+M\4&,@AQ<@:9R(3YAX-[L@AP>?R &),W(;
ML96@62B&ID2^:E<S*+F-"V[V"]P<<LTR&0ERF840-O--K+,JUMX6.[8[ :\I
M/R9.[S.Q+;O?PF?R_^EN!QVGTM[1>$ZG]O/GHIYS3K,EX-LBR?R1U..F]%$O
MGV\H#\GO'PA)KB2DXD^;OL7^;OO^ZH8X$SD-8&3@%2" K\'P/W[H>=:7-G'V
M!-:0RJVD<KO0_5LF:4)$38B@+A@47=@F08'K:5QUIZW]OF,-S76]LN<Q;M^M
M8AJ$^Q7A?B?A&Y2 \B BV/IXK:SQOLS5P;51[$1Z[2GM":Q1M%<5[;US0WO[
ME&I/8 VI3BJI3MZHH0O<?JU9>[:WT]#/8P9>>S\/*KZ#3K[?( ..C%4[TQ _
M1+&0G*I/<!O'3JS7'M.>P!IEGU9EG[YS1Y_N4ZH]@36DZEE/5L)ZHYXN@1LW
ML.7N-'5+D.,-=MK:K%FA%/A2.T2!1%:9+(Q"M5JXT+%RH<I*[:RC.SW7GLQ\
M@BFL+=J 99P)DL "(:WC$WS/>.$6BXEDN39<<R;1ONEAA X;N K YPO&Y':B
M-J@\N_\/4$L#!!0    ( ,:!J%HN8$4000,  %4,   9    >&PO=V]R:W-H
M965T<R]S:&5E=#4W+GAM;,57:V_:,!3]*U=9-772VCQX%#I  MIIE=8)P;II
MFO;!)!=B-;$SVT#9KY_MA$!5R+:J7;\0O^[Q.?:Q?>FLN+B5,:*"NS1ALNO$
M2F7GKBO#&%,B3WF&3/?,N$B)TE4Q=V4FD$0V*$W<P/.:;DHH<WH=VS82O0Y?
MJ(0R' F0BS0E8CW A*^ZCN]L&L9T'BO3X/8Z&9GC!-5--A*ZYI8H$4V12<H9
M")QUG;Y_/O#K)L".^$)Q)7?*8*1,.;\UE:NHZWB&$288*@-!]&>)0TP2@Z1Y
M_"Q G7).$[A;WJ"_M^*UF"F1..3)5QJIN.NT'(AP1A:)&O/5!RP$-0Q>R!-I
M?V%5C/4<"!=2\;0(U@Q2RO(ON2L68B<@:!P("(J P/+.)[(L+X@BO8[@*Q!F
MM$8S!2O51FMRE)E=F2BA>ZF.4[U)3 2>#+2N"(8\U9LMB5VN$YAH!T2+!('/
M[G<-N53PB2OXIETSQI#/&?VEXX\O4!&:R#=P!)3!YY@O)&&1[+A*,S7SN6'!
M:I"S"@ZPJL$U9RJ6<,DBC.['NUIA*3/8R!P$E8#71)Q"S7\+@1<TX&9R <='
M;RIP:^7RU2QN_=#R*1[> L_,NNS561ENCMRYS$B(74>?*8EBB4[O]2N_Z;VK
M(%<OR=4M>JUR;Z</][8O!&%SU(=+P70-N^-&9&V;^RLB(OC^44/"E<)4_MBG
MKOX,ZAJEND;ETM\PL;5>N"LOU/[<QS;':UH\<ULM>[5VK>,N]Y!HEB2:E20N
M[S)]O6@"*WO\,3HA2Q3Z.H,,!>61.0=K)$*:0_2 )"@.4X2MCGVLJPD$!7P
M:7YB_ 9$9"TK%OBLU'96"3U&J02UZJ2U^8)1M=?DE3B/M$&K9-EZ89.WGD%=
MNU37?F*3MQ^8/&CX^TWN>]M'PGMIF_^!0;OP=\6:^CMOGO^WSK87^%X^E1"/
MW'8_V%(,7MC6!8$G%KA]./WJE_/?G5T [EJ['30.6'O[1OJ5C]1_L78U@\T5
M7MM<X<'A*]S=R?12%'.;STI-9<%4GO25K67.W,\SQ>WP/.'6*=&<,@D)SG2H
M=WJFGT>1Y[!Y1?',YHU3KG06:HNQSOM1F &Z?\:YVE3,!.4_B=YO4$L#!!0
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M+@Y8O7M7-P0MJLVC1RH$S:K#!' ,3'60OV\I%2\-M1_5;J$N_@=02P,$%
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M2\5H_8X[ZU922_;K8AD/DURV-1,0&S#J-&/>,Q4C,J&"3Q4'5D(S+E8VW(/
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MHLB- .9V$ 08 D\CCF .P .&!$'U'MQY'_GK]Y3?_@]S_!M02P,$%     @
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M$\4W93F12W)3:"Z8U@[<%P#N"RY<7.0Y5;L2+.8KP>UI5!@R2!)9",,=R*\
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M!Y0N?_-<3$@@'K) 8$S?Q82<XB$[!<SKR86+"?G%0_9+<V9/+A8ENO[DSGQ
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MU<LBRX:V;":FDJ:'CT\/'\Y>_P102P,$%     @ QH&H6A[?F5X< @  /2<
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M<' N>&UL4$L! A0#%     @ QH&H6FW /#7Q    *P(  !$
M ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ QH&H6IE<G",0
M!@  G"<  !,              ( !XP$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " #&@:A:$<3S$]H%  #3'@  &               @($D"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ QH&H6KJEAA'=
M!0  ?!<  !@              ("!- X  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( ,:!J%HU+7P-S0(  /X'   8              "
M@4<4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #&@:A:
MQNQ*<NH$  !6$P  &               @(%*%P  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ QH&H6@/Z I1P P  P@D  !@
M     ("!:AP  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M ,:!J%J?3K#EW <  #,_   8              " @1 @  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " #&@:A:0?KUL2<&  !E&0  &
M            @($B*   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ QH&H6LUSF[0$#0  >"   !@              ("!?RX  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ,:!J%HO=,BV914  * ^
M   8              " @;D[  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " #&@:A:RB/_^P@$  #2"@  &0              @(%440
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,:!J%H(!&TP
MUP(  &\&   9              " @9-5  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ QH&H6F2JUKGI @  @P8  !D
M ("!H5@  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #&
M@:A:%8>WK_<$  ""#   &0              @('!6P  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,:!J%K#7'W3N0(  #@&   9
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M970Q."YX;6Q02P$"% ,4    " #&@:A:MGL\T!,&    #@  &0
M    @('5?@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M ,:!J%H^O]@;6P,  *0'   9              " @1^%  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ QH&H6@6%I=0" P  F@8  !D
M             ("!L8@  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " #&@:A:Z<NV[PP$  !3"0  &0              @('JBP  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ,:!J%KM/XS/BPH
M  (<   9              " @2V0  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ QH&H6J.AT.62"@  -AP  !D              ("!
M[YH  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #&@:A:
MMB -CED"  "X!0  &0              @(&XI0  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,:!J%H3K8?K1 (  (H&   9
M      " @4BH  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ QH&H6F=SXH4Q%@  GD8  !D              ("!PZH  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #&@:A:9&W:H/X"  "V!@
M&0              @($KP0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( ,:!J%K<CN<D7@0  $P,   9              " @6#$  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ QH&H6D5Q%@_G
M @  K 8  !D              ("!]<@  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " #&@:A:$LL&K9X"  ##!0  &0
M@($3S   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ,:!
MJ%I/ ?=*!0,   4'   9              " @>C.  !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ QH&H6D?(K3O) @  .08  !D
M         ("!)-(  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
M    " #&@:A:7/WA]# #   2"   &0              @($DU0  >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ,:!J%K41_GMV@0   8/
M   9              " @8O8  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL
M4$L! A0#%     @ QH&H6CP &N?D P  QPH  !D              ("!G-T
M 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #&@:A:CEEZ
M^/H#  !V"   &0              @(&WX0  >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;%!+ 0(4 Q0    ( ,:!J%K.VBUJBP(  (X%   9
M  " @>CE  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
MQH&H6A:R+]2& @  O@@  !D              ("!JN@  'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    " #&@:A:TN' NEH$  #=%P  &0
M            @(%GZP  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( ,:!J%H$?:)V]P0  )P=   9              " @?CO  !X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ QH&H6KQN2.&( @
MC 8  !D              ("!)O4  'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    " #&@:A:.TA[FM0"  #2"0  &0              @('E
M]P  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( ,:!J%H4
M)W0B?@,  *D0   9              " @?#Z  !X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ QH&H6G,<+6$I P  "PT  !D
M     ("!I?X  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,:!J%H<;W'IC0(  'D'   9              "
M@9H. 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ QH&H
M6LVP]&.D!   ?QP  !D              ("!7A$! 'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    " #&@:A:G%M"> D'  !_,@  &0
M        @($Y%@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( ,:!J%J'QP1"'0,  -H+   9              " @7D= 0!X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ QH&H6O_B\%ZQ P  RPT
M !D              ("!S2 ! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q0
M2P$"% ,4    " #&@:A:&_F>9XP$  !R&@  &0              @(&U) $
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( ,:!J%IR??\'
M&@,  +\+   9              " @7@I 0!X;"]W;W)K<VAE971S+W-H965T
M-38N>&UL4$L! A0#%     @ QH&H6BY@11!! P  50P  !D
M ("!R2P! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " #&
M@:A:OF[;<48#  "+"P  &0              @(%!, $ >&PO=V]R:W-H965T
M<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( ,:!J%H;#WB^!0D  ')I   9
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M970V,RYX;6Q02P$"% ,4    " #&@:A:/S.MBM@#  !.%0  &0
M    @('C3 $ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (
M ,:!J%IZG?[VE00  /(>   9              " @?)0 0!X;"]W;W)K<VAE
M971S+W-H965T-C4N>&UL4$L! A0#%     @ QH&H6NF"&@TR!P  N$P  !D
M             ("!OE4! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"
M% ,4    " #&@:A:^O 2ND(#  #0%   #0              @ $G70$ >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,:!J%J7BKL<P    !,"   +
M      "  91@ 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,:!J%H&Z\L;+P4
M +PK   /              "  7UA 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " #&@:A:'M^97AP"   ])P  &@              @ '99@$ >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #&@:A:I7\.<>X!  "0
M)@  $P              @ $M:0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    2@!* #T4  !,:P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>159</ContextCount>
  <ElementCount>310</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>56</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONSOLIDATED STATEMENTS OF EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Available-for-Sale-Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecurities</Role>
      <ShortName>Available-for-Sale-Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShare</Role>
      <ShortName>Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Australia Research and Development Tax Incentive</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive</Role>
      <ShortName>Australia Research and Development Tax Incentive</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Technology Transfer Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/TechnologyTransferAgreement</Role>
      <ShortName>Technology Transfer Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Research Collaboration and License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement</Role>
      <ShortName>Research Collaboration and License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Available-for-Sale-Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesTables</Role>
      <ShortName>Available-for-Sale-Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AvailableforSaleSecurities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/PropertyandEquipment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShareTables</Role>
      <ShortName>Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeLossPerShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/FairValueMeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AccruedLiabilities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/OperatingLeases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/StockholdersEquity</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/ShareBasedCompensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/SegmentInformation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/DescriptionofBusiness</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails</Role>
      <ShortName>Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Available-for-Sale-Securities - Schedule of Classification of Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofClassificationofAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Available-for-Sale-Securities - Schedule of Classification of Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>Available-for-Sale-Securities - Schedule of Available-for-Sale Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShareDetails</Role>
      <ShortName>Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeLossPerShareTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Operating Leases - Schedule of Balance Sheet Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesScheduleofBalanceSheetPresentationDetails</Role>
      <ShortName>Operating Leases - Schedule of Balance Sheet Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Operating Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesNarrativeDetails</Role>
      <ShortName>Operating Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Operating Leases - Schedule of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Stockholders' Equity - Equity Issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails</Role>
      <ShortName>Stockholders' Equity - Equity Issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Stockholders' Equity - Schedule of Stock Options and Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Stock Options and Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Units for Services (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityScheduleofRestrictedStockUnitsforServicesDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Restricted Stock Units for Services (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Stockholders' Equity - Schedule of Non Vested Restricted Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Non Vested Restricted Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Share-Based Compensation - Schedule of Compensation Cost Not Yet Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationScheduleofCompensationCostNotYetRecognizedDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Compensation Cost Not Yet Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Share-Based Compensation - Schedule of Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationScheduleofFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeTaxes</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Segment Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Segment Information - Schedule of Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails</Role>
      <ShortName>Segment Information - Schedule of Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Australia Research and Development Tax Incentive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails</Role>
      <ShortName>Australia Research and Development Tax Incentive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/Contingencies</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Technology Transfer Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/TechnologyTransferAgreementDetails</Role>
      <ShortName>Technology Transfer Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/TechnologyTransferAgreement</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/LicenseAgreementsDetails</Role>
      <ShortName>License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/LicenseAgreements</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="lsta-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Research Collaboration and License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails</Role>
      <ShortName>Research Collaboration and License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement</ParentRole>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="lsta-20250331.htm">lsta-20250331.htm</File>
    <File>lsta-20250331.xsd</File>
    <File>lsta-20250331_cal.xml</File>
    <File>lsta-20250331_def.xml</File>
    <File>lsta-20250331_lab.xml</File>
    <File>lsta-20250331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>lsta-20250331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="564">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lsta-20250331.htm": {
   "nsprefix": "lsta",
   "nsuri": "http://www.caladrius.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "lsta-20250331.htm"
     ]
    },
    "schema": {
     "local": [
      "lsta-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "lsta-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lsta-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "lsta-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lsta-20250331_pre.xml"
     ]
    }
   },
   "keyStandard": 249,
   "keyCustom": 61,
   "axisStandard": 21,
   "axisCustom": 0,
   "memberStandard": 39,
   "memberCustom": 14,
   "hidden": {
    "total": 11,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://fasb.org/us-gaap/2024": 5,
    "http://www.caladrius.com/20250331": 1
   },
   "contextCount": 159,
   "entityCount": 1,
   "segmentCount": 56,
   "elementCount": 584,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 564,
    "http://xbrl.sec.gov/dei/2024": 29,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.caladrius.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "9952151 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals",
     "longName": "9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "longName": "9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "longName": "9952154 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
     "longName": "9952155 - Statement - CONSOLIDATED STATEMENTS OF EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952156 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.caladrius.com/role/DescriptionofBusiness",
     "longName": "9952157 - Disclosure - Description of Business",
     "shortName": "Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952158 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.caladrius.com/role/AvailableforSaleSecurities",
     "longName": "9952159 - Disclosure - Available-for-Sale-Securities",
     "shortName": "Available-for-Sale-Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.caladrius.com/role/PropertyandEquipment",
     "longName": "9952160 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.caladrius.com/role/IncomeLossPerShare",
     "longName": "9952161 - Disclosure - Income (Loss) Per Share",
     "shortName": "Income (Loss) Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.caladrius.com/role/FairValueMeasurements",
     "longName": "9952162 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.caladrius.com/role/AccruedLiabilities",
     "longName": "9952163 - Disclosure - Accrued Liabilities",
     "shortName": "Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.caladrius.com/role/OperatingLeases",
     "longName": "9952164 - Disclosure - Operating Leases",
     "shortName": "Operating Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.caladrius.com/role/StockholdersEquity",
     "longName": "9952165 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.caladrius.com/role/ShareBasedCompensation",
     "longName": "9952166 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.caladrius.com/role/IncomeTaxes",
     "longName": "9952167 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.caladrius.com/role/SegmentInformation",
     "longName": "9952168 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive",
     "longName": "9952169 - Disclosure - Australia Research and Development Tax Incentive",
     "shortName": "Australia Research and Development Tax Incentive",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lsta:ResearchAndDevelopmentTaxIncentiveTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lsta:ResearchAndDevelopmentTaxIncentiveTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.caladrius.com/role/Contingencies",
     "longName": "9952170 - Disclosure - Contingencies",
     "shortName": "Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.caladrius.com/role/TechnologyTransferAgreement",
     "longName": "9952171 - Disclosure - Technology Transfer Agreement",
     "shortName": "Technology Transfer Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lsta:TechnologyTransferAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lsta:TechnologyTransferAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.caladrius.com/role/LicenseAgreements",
     "longName": "9952172 - Disclosure - License Agreements",
     "shortName": "License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement",
     "longName": "9952173 - Disclosure - Research Collaboration and License Agreement",
     "shortName": "Research Collaboration and License Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables",
     "longName": "9955513 - Disclosure - Available-for-Sale-Securities (Tables)",
     "shortName": "Available-for-Sale-Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.caladrius.com/role/PropertyandEquipmentTables",
     "longName": "9955514 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://www.caladrius.com/role/IncomeLossPerShareTables",
     "longName": "9955515 - Disclosure - Income (Loss) Per Share (Tables)",
     "shortName": "Income (Loss) Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.caladrius.com/role/FairValueMeasurementsTables",
     "longName": "9955516 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.caladrius.com/role/AccruedLiabilitiesTables",
     "longName": "9955517 - Disclosure - Accrued Liabilities (Tables)",
     "shortName": "Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.caladrius.com/role/OperatingLeasesTables",
     "longName": "9955518 - Disclosure - Operating Leases (Tables)",
     "shortName": "Operating Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.caladrius.com/role/StockholdersEquityTables",
     "longName": "9955519 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.caladrius.com/role/ShareBasedCompensationTables",
     "longName": "9955520 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.caladrius.com/role/SegmentInformationTables",
     "longName": "9955521 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.caladrius.com/role/DescriptionofBusinessDetails",
     "longName": "9955522 - Disclosure - Description of Business (Details)",
     "shortName": "Description of Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "lsta:CashAndCashEquivalentsAndMarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "lsta:CashAndCashEquivalentsAndMarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails",
     "longName": "9955523 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-46",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-46",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9955524 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails",
     "longName": "9955525 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)",
     "shortName": "Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofClassificationofAvailableforSaleSecuritiesDetails",
     "longName": "9955526 - Disclosure - Available-for-Sale-Securities - Schedule of Classification of Available-for-Sale Securities (Details)",
     "shortName": "Available-for-Sale-Securities - Schedule of Classification of Available-for-Sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails",
     "longName": "9955527 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities by Contractual Maturity (Details)",
     "shortName": "Available-for-Sale-Securities - Schedule of Available-for-Sale Securities by Contractual Maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.caladrius.com/role/PropertyandEquipmentDetails",
     "longName": "9955528 - Disclosure - Property and Equipment (Details)",
     "shortName": "Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.caladrius.com/role/IncomeLossPerShareDetails",
     "longName": "9955529 - Disclosure - Income (Loss) Per Share (Details)",
     "shortName": "Income (Loss) Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-63",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-63",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.caladrius.com/role/FairValueMeasurementsDetails",
     "longName": "9955530 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-72",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-72",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
     "longName": "9955531 - Disclosure - Accrued Liabilities (Details)",
     "shortName": "Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.caladrius.com/role/OperatingLeasesScheduleofBalanceSheetPresentationDetails",
     "longName": "9955532 - Disclosure - Operating Leases - Schedule of Balance Sheet Presentation (Details)",
     "shortName": "Operating Leases - Schedule of Balance Sheet Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails",
     "longName": "9955533 - Disclosure - Operating Leases - Narrative (Details)",
     "shortName": "Operating Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.caladrius.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails",
     "longName": "9955534 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments (Details)",
     "shortName": "Operating Leases - Schedule of Future Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails",
     "longName": "9955535 - Disclosure - Stockholders' Equity - Equity Issuances (Details)",
     "shortName": "Stockholders' Equity - Equity Issuances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-79",
      "name": "lsta:OutstandingStockThreshold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-79",
      "name": "lsta:OutstandingStockThreshold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails",
     "longName": "9955536 - Disclosure - Stockholders' Equity - Schedule of Stock Options and Warrants (Details)",
     "shortName": "Stockholders' Equity - Schedule of Stock Options and Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.caladrius.com/role/StockholdersEquityNarrativeDetails",
     "longName": "9955537 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-84",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-87",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.caladrius.com/role/StockholdersEquityScheduleofRestrictedStockUnitsforServicesDetails",
     "longName": "9955538 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Units for Services (Details)",
     "shortName": "Stockholders' Equity - Schedule of Restricted Stock Units for Services (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-84",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-84",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails",
     "longName": "9955539 - Disclosure - Stockholders' Equity - Schedule of Non Vested Restricted Stock (Details)",
     "shortName": "Stockholders' Equity - Schedule of Non Vested Restricted Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-88",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-88",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.caladrius.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails",
     "longName": "9955540 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details)",
     "shortName": "Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.caladrius.com/role/ShareBasedCompensationScheduleofCompensationCostNotYetRecognizedDetails",
     "longName": "9955541 - Disclosure - Share-Based Compensation - Schedule of Compensation Cost Not Yet Recognized (Details)",
     "shortName": "Share-Based Compensation - Schedule of Compensation Cost Not Yet Recognized (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-99",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-99",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.caladrius.com/role/ShareBasedCompensationScheduleofFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
     "longName": "9955542 - Disclosure - Share-Based Compensation - Schedule of Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)",
     "shortName": "Share-Based Compensation - Schedule of Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-100",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-100",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.caladrius.com/role/IncomeTaxesDetails",
     "longName": "9955543 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.caladrius.com/role/SegmentInformationNarrativeDetails",
     "longName": "9955544 - Disclosure - Segment Information - Narrative (Details)",
     "shortName": "Segment Information - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R61": {
     "role": "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails",
     "longName": "9955545 - Disclosure - Segment Information - Schedule of Financial Information (Details)",
     "shortName": "Segment Information - Schedule of Financial Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-132",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails",
     "longName": "9955546 - Disclosure - Australia Research and Development Tax Incentive (Details)",
     "shortName": "Australia Research and Development Tax Incentive (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "lsta:IncomeTaxIncentiveReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "lsta:IncomeTaxIncentiveReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.caladrius.com/role/ContingenciesDetails",
     "longName": "9955547 - Disclosure - Contingencies (Details)",
     "shortName": "Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-140",
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-140",
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.caladrius.com/role/TechnologyTransferAgreementDetails",
     "longName": "9955548 - Disclosure - Technology Transfer Agreement (Details)",
     "shortName": "Technology Transfer Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-142",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-143",
      "name": "lsta:InvestmentOwnedCanceledShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.caladrius.com/role/LicenseAgreementsDetails",
     "longName": "9955549 - Disclosure - License Agreements (Details)",
     "shortName": "License Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-142",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-150",
      "name": "lsta:SharesHeldByThirdParty",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
     "longName": "9955550 - Disclosure - Research Collaboration and License Agreement (Details)",
     "shortName": "Research Collaboration and License Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "us-gaap:CollaborativeArrangementAccountingPolicy",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-151",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lsta-20250331.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Liabilities",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r55",
      "r58",
      "r991"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r816"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r648",
      "r753",
      "r828",
      "r1025",
      "r1026"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization/accretion on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "lsta_AccruedGrantFunding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "AccruedGrantFunding",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting &amp; tax consulting liabilities",
        "label": "Accrued Grant Funding",
        "documentation": "Accrued Grant Funding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Liabilities [Abstract]",
        "label": "Accrued Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/PropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r140",
      "r574"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r68",
      "r146",
      "r569",
      "r612",
      "r613"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9",
      "r19",
      "r462",
      "r465",
      "r517",
      "r608",
      "r609",
      "r936",
      "r937",
      "r938",
      "r942",
      "r943",
      "r944",
      "r945"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r816",
      "r1059"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r626",
      "r942",
      "r943",
      "r944",
      "r945",
      "r1004",
      "r1061"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r381"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_AggregateIntrinsicValueWarrantsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "AggregateIntrinsicValueWarrantsOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Outstanding, Aggregate Intrinsic Value",
        "label": "Aggregate Intrinsic Value, Warrants Outstanding",
        "documentation": "Aggregate Intrinsic Value, Warrants Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_AggregateIntrinsicValueWarrantsVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "AggregateIntrinsicValueWarrantsVested",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested, Aggregate Intrinsic Value",
        "label": "Aggregate Intrinsic Value, Warrants Vested",
        "documentation": "Aggregate Intrinsic Value, Warrants Vested"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_AggregateIntrinsicValueWarrantsVestedAndExpectedToVest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "AggregateIntrinsicValueWarrantsVestedAndExpectedToVest",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested and expected to vest, Aggregate Intrinsic Value",
        "label": "Aggregate Intrinsic Value, Warrants Vested And Expected To Vest",
        "documentation": "Aggregate Intrinsic Value, Warrants Vested And Expected To Vest"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r854",
      "r864",
      "r896"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r857",
      "r867",
      "r899"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r858",
      "r868",
      "r892",
      "r900",
      "r904",
      "r912"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r422"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, allowance for credit loss",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r247",
      "r286",
      "r289",
      "r290",
      "r1026"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r308",
      "r309",
      "r784"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "lsta_AscendTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "AscendTrialMember",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASCEND trial",
        "label": "Ascend Trial [Member]",
        "documentation": "Ascend Trial"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r112",
      "r142",
      "r170",
      "r202",
      "r209",
      "r234",
      "r238",
      "r283",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r337",
      "r455",
      "r459",
      "r495",
      "r566",
      "r653",
      "r775",
      "r776",
      "r816",
      "r835",
      "r984",
      "r985",
      "r1015"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r148",
      "r170",
      "r283",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r337",
      "r455",
      "r459",
      "r495",
      "r816",
      "r984",
      "r985",
      "r1015"
     ]
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/FairValueMeasurementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Assets, fair value disclosure",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r474",
      "r805"
     ]
    },
    "lsta_AtTheMarketOfferingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "AtTheMarketOfferingAgreementMember",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Agreement",
        "label": "At The Market Offering Agreement [Member]",
        "documentation": "At The Market Offering Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails",
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r294",
      "r565"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]",
        "label": "Debt Securities, Available-for-Sale [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Less than one year",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than one year",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Greater than one year",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Greater than one year",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value",
        "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails",
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Estimated Fair Value",
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r294",
      "r473",
      "r558",
      "r805",
      "r808",
      "r957",
      "r1008",
      "r1009",
      "r1010"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/StockholdersEquityNarrativeDetails",
      "http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails",
      "http://www.caladrius.com/role/StockholdersEquityScheduleofRestrictedStockUnitsforServicesDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r385",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_BolsterTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "BolsterTrialMember",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BOLSTER trial",
        "label": "Bolster Trial [Member]",
        "documentation": "Bolster Trial"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BondsMember",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agency bonds",
        "label": "Bonds [Member]",
        "documentation": "Debt security, in which the authorized issuer owes the holder a debt and is obliged to repay the principal and interest (the coupon)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business development",
        "label": "Business Development",
        "documentation": "Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "lsta_CENDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "CENDMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CEND",
        "label": "CEND [Member]",
        "documentation": "CEND"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "California Franchise Tax Board [Member]",
        "documentation": "Designated tax department of the government of the state of California."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_CashAndCashEquivalentsAndMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "CashAndCashEquivalentsAndMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and marketable securities",
        "label": "Cash and Cash Equivalents And Marketable Securities",
        "documentation": "Cash and Cash Equivalents And Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r138",
      "r761"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/FairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1007"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "lsta_CashCashEquivalentsAndMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "CashCashEquivalentsAndMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and marketable securities",
        "label": "Cash, Cash Equivalents, and Marketable Securities",
        "documentation": "Cash, Cash Equivalents, and Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-Sale-Securities",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofClassificationofAvailableforSaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofClassificationofAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r81",
      "r167"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r81"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofClassificationofAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofClassificationofAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r1024"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "lsta_ChemistryManufacturingAndControlsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "ChemistryManufacturingAndControlsMember",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chemistry, manufacturing and controls",
        "label": "Chemistry Manufacturing And Controls [Member]",
        "documentation": "Chemistry Manufacturing And Controls"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r204",
      "r342",
      "r343",
      "r344",
      "r346",
      "r349",
      "r354",
      "r356",
      "r618",
      "r619",
      "r620",
      "r621",
      "r788",
      "r922",
      "r939"
     ]
    },
    "lsta_ClinicalAndRDRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "ClinicalAndRDRelatedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical and R&amp;D related liabilities",
        "label": "Clinical and R&amp;D Related Liabilities",
        "documentation": "Clinical and R&amp;D Related Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_ClinicalDepartmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "ClinicalDepartmentMember",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical department",
        "label": "Clinical Department [Member]",
        "documentation": "Clinical Department"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestones, Royalties",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreements",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreements",
        "verboseLabel": "Research Collaboration and License Agreement",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r120",
      "r131"
     ]
    },
    "lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual license maintenance fee",
        "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual license maintenance fee, year seven",
        "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone payments",
        "label": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties, net of sales",
        "label": "Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_CollaborativeArrangementRightsAndObligationsSublicensingFees": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "CollaborativeArrangementRightsAndObligationsSublicensingFees",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublicensing fee",
        "label": "Collaborative Arrangement, Rights and Obligations, Sublicensing Fees",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sublicensing Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies (Note 14)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r102",
      "r567",
      "r639"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/Contingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r319",
      "r320",
      "r754",
      "r977",
      "r979"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r826",
      "r827",
      "r829",
      "r830",
      "r831",
      "r832",
      "r942",
      "r943",
      "r945",
      "r1004",
      "r1058",
      "r1061"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r640"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals",
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock outstanding (in shares)",
        "periodStartLabel": "Common stock, beginning balance (in shares)",
        "periodEndLabel": "Common stock, ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r62",
      "r640",
      "r659",
      "r1061",
      "r1062"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,620,900 and 8,409,582 shares at March 31, 2025 and December 31, 2024, respectively; and outstanding, 8,620,162 and 8,408,844 shares at March 31, 2025 and December 31, 2024, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r568",
      "r816"
     ]
    },
    "us-gaap_CommonStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValueOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, value, outstanding",
        "label": "Common Stock, Value, Outstanding",
        "documentation": "Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r640"
     ]
    },
    "lsta_CommonStockWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "CommonStockWarrantsShares",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants, Outstanding, Beginning of Period (in shares)",
        "periodEndLabel": "Warrants, Outstanding, End of Period (in shares)",
        "label": "Common Stock Warrants, Shares",
        "documentation": "Common Stock Warrants, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommunicationsAndInformationTechnology": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommunicationsAndInformationTechnology",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor relations/public relations/communications",
        "label": "Communications and Information Technology",
        "documentation": "The amount of expense in the period for communications and data processing expense."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r154",
      "r156",
      "r161",
      "r560",
      "r582",
      "r583"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Computer equipment",
        "terseLabel": "Computer equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Computer Software, Intangible Asset [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r760",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r974",
      "r975"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Risks",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r123"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Axis]",
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r110",
      "r174",
      "r202",
      "r211",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r775",
      "r776",
      "r984",
      "r985"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Domain]",
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r110",
      "r174",
      "r202",
      "r211",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r775",
      "r776",
      "r984",
      "r985"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r765"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, liability",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r370"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r798",
      "r805",
      "r817",
      "r823",
      "r1055"
     ]
    },
    "us-gaap_CorporateNonSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateNonSegmentMember",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Reconciling Item, Corporate Nonsegment",
        "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]",
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r949"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r338",
      "r344",
      "r518",
      "r535",
      "r564",
      "r762",
      "r764"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-sale Securities [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards subject to expiration",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r31"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.caladrius.com/role/SegmentInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r31"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r383",
      "r414",
      "r415",
      "r417",
      "r800"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Total Compensation Cost Related to Nonvested Awards",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r42"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "lsta_EPSAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "EPSAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and diluted loss per share",
        "label": "EPS [Abstract]",
        "documentation": "EPS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lisata Therapeutics, Inc. common stockholders- basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r190",
      "r192",
      "r194",
      "r195",
      "r196",
      "r201",
      "r449",
      "r452",
      "r470",
      "r471",
      "r561",
      "r584",
      "r767"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r192",
      "r194",
      "r195",
      "r196",
      "r201",
      "r449",
      "r452",
      "r470",
      "r471",
      "r561",
      "r584",
      "r767"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r198"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income (Loss) Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r197",
      "r199",
      "r200"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective income tax rate reconciliation",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r802"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research tax credit rate",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r941",
      "r994",
      "r995"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salaries, employee benefits and related taxes",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofCompensationCostNotYetRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofCompensationCostNotYetRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected weighted-average period in years of compensation cost to be recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Major Customer [Line Items]",
        "label": "Revenue, Major Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r132",
      "r157",
      "r158",
      "r159",
      "r175",
      "r176",
      "r177",
      "r179",
      "r184",
      "r186",
      "r188",
      "r203",
      "r284",
      "r285",
      "r312",
      "r357",
      "r438",
      "r439",
      "r446",
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r469",
      "r498",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r508",
      "r517",
      "r580",
      "r608",
      "r609",
      "r610",
      "r626",
      "r679"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r445",
      "r923",
      "r924",
      "r925",
      "r999",
      "r1000",
      "r1001",
      "r1002"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r854",
      "r864",
      "r896"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r851",
      "r861",
      "r893"
     ]
    },
    "lsta_ExclusiveLicenseAndCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "ExclusiveLicenseAndCollaborationAgreementMember",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exclusive License and Collaboration Agreement",
        "label": "Exclusive License and Collaboration Agreement [Member]",
        "documentation": "Exclusive License and Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r474",
      "r487",
      "r805"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets Measured at Fair Value on Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1007"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r486",
      "r487",
      "r489",
      "r522",
      "r523",
      "r524",
      "r786",
      "r787",
      "r796",
      "r797",
      "r798",
      "r805",
      "r808"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r474",
      "r475",
      "r477",
      "r805",
      "r1009",
      "r1012"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r484",
      "r485",
      "r486",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r557",
      "r805",
      "r809"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r372",
      "r377",
      "r474",
      "r487",
      "r522",
      "r796",
      "r797",
      "r798",
      "r805"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r372",
      "r377",
      "r474",
      "r475",
      "r487",
      "r523",
      "r786",
      "r787",
      "r796",
      "r797",
      "r798",
      "r805"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r474",
      "r475",
      "r476",
      "r477",
      "r487",
      "r524",
      "r786",
      "r787",
      "r796",
      "r797",
      "r798",
      "r805",
      "r808"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r488"
     ]
    },
    "lsta_FairValueMarketOfTaxNOLs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "FairValueMarketOfTaxNOLs",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value market of tax NOLs",
        "label": "Fair Value Market of Tax NOLs",
        "documentation": "Fair Value Market of Tax NOLs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r474",
      "r475",
      "r477",
      "r805",
      "r1009",
      "r1012"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r486",
      "r487",
      "r489",
      "r522",
      "r523",
      "r524",
      "r786",
      "r787",
      "r796",
      "r797",
      "r798",
      "r805",
      "r808"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1012"
     ]
    },
    "lsta_FinanceGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "FinanceGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance",
        "label": "Finance, General And Administrative Expense",
        "documentation": "Finance, General And Administrative Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r340",
      "r354",
      "r467",
      "r494",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r581",
      "r782",
      "r805",
      "r806",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r817",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r961",
      "r962",
      "r963",
      "r964",
      "r1005",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset, useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected amortization, year one",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r757",
      "r784"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected amortization, remainder of fiscal year",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected amortization, year two",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r757",
      "r784"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired license - intangible, net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r972"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Authority",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Remeasurement",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r858",
      "r868",
      "r900"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r858",
      "r868",
      "r900"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r858",
      "r868",
      "r900"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r858",
      "r868",
      "r900"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r858",
      "r868",
      "r900"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r663"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "lsta_ImpiloMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "ImpiloMember",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impilo",
        "label": "Impilo [Member]",
        "documentation": "Impilo"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process Research and Development Expense",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less - net income (loss) attributable to noncontrolling interests",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r100",
      "r184"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before benefit from income taxes and noncontrolling interests",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r107",
      "r111",
      "r562",
      "r577",
      "r769",
      "r775",
      "r946",
      "r948",
      "r950",
      "r951",
      "r952"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.caladrius.com/role/SegmentInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss from equity method investment",
        "negatedLabel": "Equity method investment expense",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r70",
      "r106",
      "r202",
      "r216",
      "r238",
      "r279",
      "r576"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r315",
      "r316",
      "r479",
      "r483",
      "r488",
      "r605",
      "r607",
      "r664",
      "r757",
      "r807",
      "r1028"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation expense",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r479",
      "r483",
      "r488",
      "r605",
      "r607",
      "r664",
      "r757",
      "r807",
      "r1028"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r427",
      "r428",
      "r432",
      "r436",
      "r802",
      "r996"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r427",
      "r428",
      "r432",
      "r436",
      "r802",
      "r996"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name [Axis]",
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r996"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name [Domain]",
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r996"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r424",
      "r427",
      "r429",
      "r430",
      "r431",
      "r434",
      "r435",
      "r440",
      "r442",
      "r443",
      "r444",
      "r623",
      "r802"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.caladrius.com/role/IncomeTaxesDetails",
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefit from income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r129",
      "r187",
      "r188",
      "r202",
      "r217",
      "r238",
      "r426",
      "r427",
      "r441",
      "r585",
      "r802"
     ]
    },
    "us-gaap_IncomeTaxHolidayLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxHolidayLineItems",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Holiday [Line Items]",
        "label": "Income Tax Holiday [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxHolidayTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxHolidayTable",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Holiday [Table]",
        "label": "Income Tax, Holiday [Table]",
        "documentation": "Disclosure of information about income tax exemption and reduction granted by tax authority for specified period. Includes, but is not limited to, description of factual circumstance for income tax exemption and reduction, date when special tax status terminates, and aggregate dollar and per share effect of tax benefit from income tax exemption and reduction."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "lsta_IncomeTaxIncentiveReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "IncomeTaxIncentiveReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax incentive receivable",
        "label": "Income Tax Incentive Receivable",
        "documentation": "Income Tax Incentive Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable, accrued liabilities and other liabilities",
        "label": "Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities",
        "documentation": "Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r858",
      "r868",
      "r892",
      "r900",
      "r904",
      "r912"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r916"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r916"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r916"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r553",
      "r554",
      "r556",
      "r766",
      "r966"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r972",
      "r973"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment income, net",
        "label": "Investment Income, Net",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r77"
     ]
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment owned (in shares)",
        "label": "Investment Owned, Balance, Shares",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r629",
      "r692",
      "r718",
      "r743",
      "r827"
     ]
    },
    "lsta_InvestmentOwnedCanceledShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "InvestmentOwnedCanceledShares",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares canceled (in shares)",
        "label": "Investment Owned, Canceled, Shares",
        "documentation": "Investment Owned, Canceled, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments Classified by Contractual Maturity Date",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/FairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities - available-for-sale",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1007",
      "r1011"
     ]
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInAndAdvancesToAffiliatesLineItems",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in and Advances to Affiliates [Line Items]",
        "label": "Investments in and Advances to Affiliates [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "lsta_KuvaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "KuvaMember",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kuva",
        "label": "Kuva [Member]",
        "documentation": "Kuva"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r516"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_LegalGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "LegalGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal",
        "label": "Legal, General And Administrative Expense",
        "documentation": "Legal, General And Administrative Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "lsta_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet",
        "label": "Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]",
        "documentation": "Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Lease Payments Under Lease Agreements",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.caladrius.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Amounts representing interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r170",
      "r283",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r337",
      "r456",
      "r459",
      "r460",
      "r495",
      "r638",
      "r768",
      "r835",
      "r984",
      "r1015",
      "r1016"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, non-controlling interests and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r104",
      "r572",
      "r816",
      "r940",
      "r965",
      "r1013"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES, NON-CONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r137",
      "r170",
      "r283",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r337",
      "r456",
      "r459",
      "r460",
      "r495",
      "r816",
      "r984",
      "r1015",
      "r1016"
     ]
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "lsta_LingmedLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "LingmedLimitedMember",
     "presentation": [
      "http://www.caladrius.com/role/ContingenciesDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lingmed Limited",
        "label": "Lingmed Limited [Member]",
        "documentation": "Lingmed Limited"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.caladrius.com/role/ContingenciesDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.caladrius.com/role/ContingenciesDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation settlement, amount awarded to other party",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_LitigationSettlementFutureMilestonePaymentsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "LitigationSettlementFutureMilestonePaymentsPercent",
     "presentation": [
      "http://www.caladrius.com/role/ContingenciesDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation settlement, future milestone payments",
        "label": "Litigation Settlement, Future Milestone Payments, Percent",
        "documentation": "Litigation Settlement, Future Milestone Payments, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_LitigationSettlementMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "LitigationSettlementMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/ContingenciesDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation settlement, first milestone payment",
        "label": "Litigation Settlement, Milestone Payment",
        "documentation": "Litigation Settlement, Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_LitigationSettlementPaymentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "LitigationSettlementPaymentTerm",
     "presentation": [
      "http://www.caladrius.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation settlement, payment term",
        "label": "Litigation Settlement, Payment Term",
        "documentation": "Litigation Settlement, Payment Term"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.caladrius.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r326",
      "r423",
      "r785",
      "r980",
      "r981"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.caladrius.com/role/ContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r326",
      "r423",
      "r785",
      "r980",
      "r981"
     ]
    },
    "lsta_LossOnSaleOfNOL": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "LossOnSaleOfNOL",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on sale of NOL",
        "label": "Loss On Sale of NOL",
        "documentation": "Loss On Sale of NOL"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofClassificationofAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofClassificationofAvailableforSaleSecuritiesDetails",
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "verboseLabel": "Marketable securities",
        "label": "Marketable Securities",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r934"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Marketable Securities",
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r325",
      "r378",
      "r423",
      "r477",
      "r551",
      "r604",
      "r606",
      "r614",
      "r630",
      "r631",
      "r688",
      "r707",
      "r711",
      "r712",
      "r740",
      "r755",
      "r756",
      "r781",
      "r788",
      "r799",
      "r808",
      "r809",
      "r813",
      "r814",
      "r819",
      "r986",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r325",
      "r378",
      "r423",
      "r477",
      "r551",
      "r604",
      "r606",
      "r614",
      "r630",
      "r631",
      "r688",
      "r707",
      "r711",
      "r712",
      "r740",
      "r755",
      "r756",
      "r781",
      "r788",
      "r799",
      "r808",
      "r809",
      "r813",
      "r819",
      "r986",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r103",
      "r170",
      "r283",
      "r327",
      "r330",
      "r331",
      "r332",
      "r336",
      "r337",
      "r495",
      "r571",
      "r642"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "lsta_NetCarryforwardOperatingLossCarryforwardAnnualLimitation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "NetCarryforwardOperatingLossCarryforwardAnnualLimitation",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOL annual limitation",
        "label": "Net Carryforward Operating Loss Carryforward Annual Limitation",
        "documentation": "Net Carryforward Operating Loss Carryforward Annual Limitation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r83"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to Lisata Therapeutics, Inc. common stockholders",
        "terseLabel": "Net Income (Loss) Attributable to Parent",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r83",
      "r108",
      "r135",
      "r152",
      "r155",
      "r159",
      "r170",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r187",
      "r188",
      "r193",
      "r283",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r337",
      "r449",
      "r452",
      "r471",
      "r495",
      "r579",
      "r661",
      "r677",
      "r678",
      "r833",
      "r984"
     ]
    },
    "us-gaap_NewJerseyDivisionOfTaxationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewJerseyDivisionOfTaxationMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Jersey",
        "label": "New Jersey Division of Taxation [Member]",
        "documentation": "Designated tax department of the government of the state of New Jersey."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewYorkStateDivisionOfTaxationAndFinanceMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New York",
        "label": "New York State Division of Taxation and Finance [Member]",
        "documentation": "Designated tax department of the government of the state of New York."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r858",
      "r868",
      "r892",
      "r900"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non- Controlling Interest in Subsidiary",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r357",
      "r942",
      "r943",
      "r944",
      "r945",
      "r1061"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Activity",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.caladrius.com/role/DescriptionofBusinessDetails",
      "http://www.caladrius.com/role/SegmentInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r776",
      "r947"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r769",
      "r946",
      "r948",
      "r950",
      "r951",
      "r952"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.caladrius.com/role/OperatingLeasesScheduleofBalanceSheetPresentationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesScheduleofBalanceSheetPresentationDetails",
      "http://www.caladrius.com/role/OperatingLeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Operating Lease Liabilities",
        "verboseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesScheduleofBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease Liabilities:",
        "label": "Operating Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.caladrius.com/role/OperatingLeasesScheduleofBalanceSheetPresentationDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
      "http://www.caladrius.com/role/OperatingLeasesScheduleofBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities \u2014 current",
        "verboseLabel": "Accrued liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesScheduleofBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current, balance sheet line item",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesScheduleofBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "lsta_OperatingLeaseRightOfUseAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "OperatingLeaseRightOfUseAssetAbstract",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesScheduleofBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-Use Assets:",
        "label": "Operating Lease, Right-Of-Use Asset [Abstract]",
        "documentation": "Operating Lease, Right-Of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesScheduleofBalanceSheetPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets, balance sheet line item",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate for operating leases (percent)",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r815"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term for operating leases (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r815"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "lsta_OperatingLossCarryforwardsBeforeWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "OperatingLossCarryforwardsBeforeWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards, prior to write down",
        "label": "Operating Loss Carryforwards, Before Write Down",
        "documentation": "Operating Loss Carryforwards, Before Write Down"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "lsta_OperatingLossCarryforwardsPostAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "OperatingLossCarryforwardsPostAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, post acquisition",
        "label": "Operating Loss Carryforwards, Post Acquisition",
        "documentation": "Operating Loss Carryforwards, Post Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "lsta_OptionsVestedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "OptionsVestedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested, Weighted Average Remaining Contractual Term",
        "label": "Options, Vested, Weighted Average Remaining Contractual Term",
        "documentation": "Options, Vested, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/DescriptionofBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r99",
      "r615",
      "r616"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized loss on marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r580"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative translation adjustment arising during the period",
        "verboseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r580"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive gain (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r16",
      "r153",
      "r156",
      "r160",
      "r184",
      "r498",
      "r499",
      "r504",
      "r559",
      "r580",
      "r936",
      "r937"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive gain (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available for sale securities - net unrealized loss",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r151",
      "r278"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other General and Administrative Expense",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r1060"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense, net",
        "verboseLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r856",
      "r866",
      "r898"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r859",
      "r869",
      "r901"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r859",
      "r869",
      "r901"
     ]
    },
    "lsta_OutstandingStockThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "OutstandingStockThreshold",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding stock threshold",
        "label": "Outstanding Stock Threshold",
        "documentation": "Outstanding Stock Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ParentMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Lisata Therapeutics, Inc. Stockholders' Equity",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax withholding payments on net share settlement equity awards",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Investment in Impilo Therapeutics",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireOtherInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to acquire Impilo SAFE",
        "label": "Payments to Acquire Other Investments",
        "documentation": "Amount of cash outflow to acquire investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r342"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of marketable securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_ProceedsFromSaleOfNOLS": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "ProceedsFromSaleOfNOLS",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of NOLs",
        "label": "Proceeds From Sale of NOLS",
        "documentation": "Proceeds From Sale of NOLS"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of NOLs, gross",
        "label": "Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross",
        "documentation": "Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r242",
      "r555",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r759",
      "r789",
      "r818",
      "r819",
      "r820",
      "r822",
      "r824",
      "r982",
      "r983",
      "r987",
      "r1027",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1056",
      "r1057"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r242",
      "r555",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r759",
      "r789",
      "r818",
      "r819",
      "r820",
      "r822",
      "r824",
      "r982",
      "r983",
      "r987",
      "r1027",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1056",
      "r1057"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r152",
      "r155",
      "r164",
      "r170",
      "r178",
      "r184",
      "r187",
      "r188",
      "r283",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r337",
      "r449",
      "r452",
      "r454",
      "r457",
      "r458",
      "r471",
      "r495",
      "r562",
      "r578",
      "r625",
      "r661",
      "r677",
      "r678",
      "r803",
      "r804",
      "r834",
      "r938",
      "r984"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r516"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r124",
      "r127",
      "r128"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/PropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r139",
      "r575"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentImpairment": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentImpairment",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-lived Assets",
        "label": "Property, Plant and Equipment, Impairment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.caladrius.com/role/PropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.caladrius.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r516",
      "r563",
      "r575",
      "r816"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r124",
      "r127",
      "r573"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentTables",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r516"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "lsta_QiluMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "QiluMember",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Qilu",
        "label": "Qilu [Member]",
        "documentation": "Qilu"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r325",
      "r371",
      "r378",
      "r409",
      "r410",
      "r411",
      "r423",
      "r477",
      "r525",
      "r534",
      "r551",
      "r604",
      "r606",
      "r614",
      "r630",
      "r631",
      "r688",
      "r707",
      "r711",
      "r712",
      "r740",
      "r755",
      "r756",
      "r781",
      "r788",
      "r799",
      "r808",
      "r809",
      "r813",
      "r814",
      "r819",
      "r827",
      "r978",
      "r986",
      "r1009",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentiveDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r325",
      "r371",
      "r378",
      "r409",
      "r410",
      "r411",
      "r423",
      "r477",
      "r525",
      "r534",
      "r551",
      "r604",
      "r606",
      "r614",
      "r630",
      "r631",
      "r688",
      "r707",
      "r711",
      "r712",
      "r740",
      "r755",
      "r756",
      "r781",
      "r788",
      "r799",
      "r808",
      "r809",
      "r813",
      "r814",
      "r819",
      "r827",
      "r978",
      "r986",
      "r1009",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r851",
      "r861",
      "r893"
     ]
    },
    "lsta_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r338",
      "r344",
      "r518",
      "r535",
      "r564",
      "r763",
      "r764"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_ResearchAndDevelopmentOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "ResearchAndDevelopmentOtherMember",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Research And Development, Other [Member]",
        "documentation": "Research And Development, Other"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_ResearchAndDevelopmentTaxIncentiveTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "ResearchAndDevelopmentTaxIncentiveTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Australia Research and Development Tax Incentive",
        "label": "Research and Development Tax Incentive [Text Block]",
        "documentation": "Research and Development Tax Incentive"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_ResearchCollaborationAndLicenseAgreementOptionToTerminate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "ResearchCollaborationAndLicenseAgreementOptionToTerminate",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option to terminate",
        "label": "Research Collaboration and License Agreement, Option to Terminate",
        "documentation": "Research Collaboration and License Agreement, Option to Terminate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination."
       }
      }
     },
     "auth_ref": [
      "r976",
      "r992",
      "r1063"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Tax Credit Carryforward",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r842",
      "r852",
      "r862",
      "r894"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r853",
      "r863",
      "r895"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r860",
      "r870",
      "r902"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/StockholdersEquityNarrativeDetails",
      "http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails",
      "http://www.caladrius.com/role/StockholdersEquityScheduleofRestrictedStockUnitsforServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails",
      "http://www.caladrius.com/role/StockholdersEquityScheduleofRestrictedStockUnitsforServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r94",
      "r570",
      "r611",
      "r613",
      "r622",
      "r641",
      "r816"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r175",
      "r176",
      "r177",
      "r179",
      "r184",
      "r186",
      "r188",
      "r284",
      "r285",
      "r312",
      "r438",
      "r439",
      "r446",
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r461",
      "r463",
      "r464",
      "r466",
      "r469",
      "r505",
      "r508",
      "r608",
      "r610",
      "r626",
      "r1061"
     ]
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue from collaborative arrangement",
        "terseLabel": "Revenue from contract",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r1003"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationNarrativeDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue excluding taxes",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r202",
      "r210",
      "r211",
      "r232",
      "r238",
      "r242",
      "r244",
      "r245",
      "r368",
      "r369",
      "r555"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r758"
     ]
    },
    "lsta_RevenuePerformanceObligationPercentageOfNetSale": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "RevenuePerformanceObligationPercentageOfNetSale",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of net sale",
        "label": "Revenue, Performance Obligation, Percentage of Net Sale",
        "documentation": "Revenue, Performance Obligation, Percentage of Net Sale"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_RevenuePerformanceObligationPercentageOfSublicensingRevenues": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "RevenuePerformanceObligationPercentageOfSublicensingRevenues",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of sublicensing revenues",
        "label": "Revenue, Performance Obligation, Percentage of Sublicensing Revenues",
        "documentation": "Revenue, Performance Obligation, Percentage of Sublicensing Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable consideration amounts, milestones",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "lsta_SAFEDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "SAFEDiscountRate",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SAFE, discount rate",
        "label": "SAFE, Discount Rate",
        "documentation": "SAFE, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_SAFEValuationCap": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "SAFEValuationCap",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SAFE, valuation cap",
        "label": "SAFE, Valuation Cap",
        "documentation": "SAFE, Valuation Cap"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate offering amount authorized per agreement",
        "label": "Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement",
        "documentation": "Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_SaleOfStockAvailableForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "SaleOfStockAvailableForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock available for sale",
        "label": "Sale of Stock Available for Sale",
        "documentation": "Sale of Stock Available for Sale"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_SaleOfStockAvailableForSalePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "SaleOfStockAvailableForSalePercentage",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage held by non-affiliates",
        "label": "Sale of Stock Available for Sale, Percentage",
        "documentation": "Sale of Stock Available for Sale, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock, Name of Transaction [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "lsta_SanfordBurnhamPrebysMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "SanfordBurnhamPrebysMember",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanford Burnham Prebys",
        "label": "Sanford Burnham Prebys [Member]",
        "documentation": "Sanford Burnham Prebys"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-sale Securities Reconciliation",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Share-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "documentation": "Disclosure of information about the extent of the entity's reliance on its major customers."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r445",
      "r923",
      "r924",
      "r925",
      "r999",
      "r1000",
      "r1001",
      "r1002"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInvestmentsTable",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments [Table]",
        "label": "Schedule of Investments [Table]",
        "documentation": "Disclosure of information about investments owned by investment company."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Units Activity",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r516"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails",
      "http://www.caladrius.com/role/StockholdersEquityNarrativeDetails",
      "http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails",
      "http://www.caladrius.com/role/StockholdersEquityScheduleofRestrictedStockUnitsforServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r382",
      "r384",
      "r385",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option and Warrants Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r95"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Share-based Compensation Awards",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r90",
      "r92",
      "r93",
      "r94",
      "r143",
      "r144",
      "r145",
      "r204",
      "r342",
      "r343",
      "r344",
      "r346",
      "r349",
      "r354",
      "r356",
      "r618",
      "r619",
      "r620",
      "r621",
      "r788",
      "r922",
      "r939"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r112",
      "r202",
      "r206",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r245",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r311",
      "r317",
      "r318",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r772",
      "r775",
      "r776",
      "r783",
      "r821",
      "r1027",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1056",
      "r1057"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r202",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r221",
      "r223",
      "r224",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r245",
      "r770",
      "r773",
      "r774",
      "r775",
      "r777",
      "r779",
      "r780"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r241",
      "r244",
      "r771",
      "r772",
      "r778"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityNarrativeDetails",
      "http://www.caladrius.com/role/StockholdersEquityScheduleofRestrictedStockUnitsforServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityNarrativeDetails",
      "http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails",
      "http://www.caladrius.com/role/StockholdersEquityScheduleofRestrictedStockUnitsforServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average estimated fair value (in dollars per share)",
        "verboseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant-Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofShareBasedCompensationExpenseDetails",
      "http://www.caladrius.com/role/StockholdersEquityNarrativeDetails",
      "http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails",
      "http://www.caladrius.com/role/StockholdersEquityScheduleofRestrictedStockUnitsforServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r382",
      "r384",
      "r385",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted Stock Units",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Weighted Average Contractual Term and Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Options, Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options, Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average estimated fair value of shares granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Outstanding, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options, Outstanding, Beginning of Period (in shares)",
        "periodEndLabel": "Options, Outstanding, End of Period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options, Outstanding. Beginning of Period (in dollars per share)",
        "periodEndLabel": "Options, Outstanding, End of Period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options, Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested and expected to vest, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested and expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/StockholdersEquityNarrativeDetails",
      "http://www.caladrius.com/role/StockholdersEquityScheduleofNonVestedRestrictedStockDetails",
      "http://www.caladrius.com/role/StockholdersEquityScheduleofRestrictedStockUnitsforServicesDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r385",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "lsta_ShareBasedCompensationExpenseGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "ShareBasedCompensationExpenseGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation expense",
        "label": "Share Based Compensation Expense, General And Administrative Expense",
        "documentation": "Share Based Compensation Expense, General And Administrative Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r387",
      "r406",
      "r407",
      "r408",
      "r409",
      "r412",
      "r418",
      "r419",
      "r420",
      "r421"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Outstanding, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Vested and expected to vest, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of shares vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "lsta_SharesHeldByThirdParty": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "SharesHeldByThirdParty",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares held by third party (in shares)",
        "label": "Shares Held by Third Party",
        "documentation": "Shares Held by Third Party"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_SharesIssuedUnderLicenseAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "SharesIssuedUnderLicenseAgreement",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued under license agreement (in shares)",
        "label": "Shares Issued Under License Agreement",
        "documentation": "Shares Issued Under License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_Sharesvestedandexpectedtovest": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "Sharesvestedandexpectedtovest",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested and expected to vest (in shares)",
        "label": "shares, vested and expected to vest",
        "documentation": "shares, vested and expected to vest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r168"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.caladrius.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r112",
      "r134",
      "r202",
      "r206",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r245",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r311",
      "r314",
      "r317",
      "r318",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r772",
      "r775",
      "r776",
      "r783",
      "r821",
      "r1027",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1056",
      "r1057"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement, Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r62",
      "r65",
      "r66",
      "r132",
      "r157",
      "r158",
      "r159",
      "r175",
      "r176",
      "r177",
      "r179",
      "r184",
      "r186",
      "r188",
      "r203",
      "r284",
      "r285",
      "r312",
      "r357",
      "r438",
      "r439",
      "r446",
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r469",
      "r498",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r508",
      "r517",
      "r580",
      "r608",
      "r609",
      "r610",
      "r626",
      "r679"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r203",
      "r508",
      "r555",
      "r617",
      "r627",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r640",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r649",
      "r650",
      "r651",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r660",
      "r662",
      "r663",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r679",
      "r828"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r203",
      "r246",
      "r508",
      "r555",
      "r617",
      "r627",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r640",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r649",
      "r650",
      "r651",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r660",
      "r662",
      "r663",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r679",
      "r828"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r855",
      "r865",
      "r897"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net proceeds from issuances of common stock (in shares)",
        "terseLabel": "Stock issued (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r61",
      "r62",
      "r94",
      "r618",
      "r679",
      "r750"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofRestrictedStockUnitsforServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r94"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r61",
      "r62",
      "r94"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from option exercises (in shares)",
        "negatedTerseLabel": "Options, Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r61",
      "r62",
      "r94",
      "r393"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issuances of common stock",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r61",
      "r62",
      "r94",
      "r626",
      "r679",
      "r750",
      "r834"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofRestrictedStockUnitsforServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of shares issued",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r61",
      "r62",
      "r94"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from option exercises",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r62",
      "r65",
      "r66",
      "r94"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Lisata Therapeutics, Inc. stockholders' equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r65",
      "r66",
      "r86",
      "r642",
      "r659",
      "r680",
      "r681",
      "r816",
      "r835",
      "r940",
      "r965",
      "r1013",
      "r1061"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r49",
      "r132",
      "r133",
      "r158",
      "r175",
      "r176",
      "r177",
      "r179",
      "r184",
      "r186",
      "r284",
      "r285",
      "r312",
      "r357",
      "r438",
      "r439",
      "r446",
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r469",
      "r498",
      "r500",
      "r504",
      "r506",
      "r517",
      "r609",
      "r610",
      "r624",
      "r642",
      "r659",
      "r680",
      "r681",
      "r751",
      "r834",
      "r940",
      "r965",
      "r1013",
      "r1061"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r169",
      "r341",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r357",
      "r468",
      "r682",
      "r684",
      "r752"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r683"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "lsta_TechnologyTransferAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "TechnologyTransferAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Technology Transfer Agreement [Abstract]",
        "documentation": "Technology Transfer Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_TechnologyTransferAgreementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "TechnologyTransferAgreementTextBlock",
     "presentation": [
      "http://www.caladrius.com/role/TechnologyTransferAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technology Transfer Agreement",
        "label": "Technology Transfer Agreement [Text Block]",
        "documentation": "Technology Transfer Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r953",
      "r954",
      "r955"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r340",
      "r354",
      "r467",
      "r494",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r581",
      "r805",
      "r806",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r817",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r961",
      "r962",
      "r963",
      "r964",
      "r1005",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Treasury stock, at cost; 738 shares at March 31, 2025 and December 31, 2024",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r65"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Municipal debt securities",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r817",
      "r823",
      "r1055"
     ]
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasuryBillSecuritiesMember",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury bills",
        "label": "US Treasury Bill Securities [Member]",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r433",
      "r801"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r119",
      "r121",
      "r125",
      "r126"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationScheduleofFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "verboseLabel": "Warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r826",
      "r829",
      "r830",
      "r831",
      "r832"
     ]
    },
    "lsta_WarrantsCanceled": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "WarrantsCanceled",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrants, Forfeited (in shares)",
        "label": "Warrants Canceled",
        "documentation": "Warrants Canceled"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "WarrantsExercised",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Warrants, Exercised (in shares)",
        "label": "Warrants Exercised",
        "documentation": "Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WarrantsExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "WarrantsExpired",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Warrants, Expired (in shares)",
        "label": "Warrants Expired",
        "documentation": "Warrants Expired"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WarrantsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "WarrantsGranted",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Granted (in shares)",
        "label": "Warrants Granted",
        "documentation": "Warrants Granted"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WarrantsOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "WarrantsOtherDisclosuresAbstract",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Weighted Average Contractual Term and Intrinsic Value",
        "label": "Warrants Other Disclosures [Abstract]",
        "documentation": "Warrants Other Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WarrantsVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "WarrantsVested",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested (in shares)",
        "label": "Warrants, Vested",
        "documentation": "Warrants, Vested"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WarrantsWeightedAverageExercisePriceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "WarrantsWeightedAverageExercisePriceRollForward",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Weighted Average Exercise Price",
        "label": "Warrants Weighted Average Exercise Price [Roll Forward]",
        "documentation": "Warrants Weighted Average Exercise Price [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageExercisePriceWarrantsCanceled": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "WeightedAverageExercisePriceWarrantsCanceled",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Forfeited (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Canceled",
        "documentation": "Weighted Average Exercise Price, Warrants Canceled"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageExercisePriceWarrantsExercisable": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "WeightedAverageExercisePriceWarrantsExercisable",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested, Weighted Average Exercise Price (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Exercisable",
        "documentation": "Weighted Average Exercise Price, Warrants Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageExercisePriceWarrantsExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "WeightedAverageExercisePriceWarrantsExercised",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Exercised (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Exercised",
        "documentation": "Weighted Average Exercise Price, Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageExercisePriceWarrantsExpired": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "WeightedAverageExercisePriceWarrantsExpired",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Expired (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Expired",
        "documentation": "Weighted Average Exercise Price, Warrants Expired"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageExercisePriceWarrantsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "WeightedAverageExercisePriceWarrantsGranted",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Granted (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Granted",
        "documentation": "Weighted Average Exercise Price, Warrants Granted"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageExercisePriceWarrantsOutstanding": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "WeightedAverageExercisePriceWarrantsOutstanding",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants Outstanding, Beginning of Period (in dollars per share)",
        "periodEndLabel": "Warrants Outstanding, End of Period (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Outstanding",
        "documentation": "Weighted Average Exercise Price, Warrants Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Weighted Average Exercise Price, Vested or expected to vest in the future (in dollars per share)",
        "label": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest",
        "documentation": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted shares (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r196"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.caladrius.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic shares (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r196"
     ]
    },
    "lsta_WeightedAverageRemainingContractualTermWarrantOutstanding": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "WeightedAverageRemainingContractualTermWarrantOutstanding",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Outstanding, Weighted Average Remaining Contractual Term",
        "label": "Weighted Average Remaining Contractual Term Warrant Outstanding",
        "documentation": "Weighted Average Remaining Contractual Term Warrant Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageRemainingContractualTermWarrantsVested": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "WeightedAverageRemainingContractualTermWarrantsVested",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested, Weighted Average Remaining Contractual Term",
        "label": "weighted Average Remaining Contractual Term, Warrants Vested",
        "documentation": "weighted Average Remaining Contractual Term, Warrants Vested"
       }
      }
     },
     "auth_ref": []
    },
    "lsta_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.caladrius.com/20250331",
     "localname": "WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityScheduleofStockOptionsandWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term",
        "label": "Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest",
        "documentation": "Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479428/808-10-45-3"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-40/tableOfContent"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/730/tableOfContent"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0000320017-25-000030-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000320017-25-000030-xbrl.zip
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ME:_P]8!X-&INOOG)K4T;FE)$Y)7O$MM#/!$?,(^S+Q5*6D'58IT4 !@+'47
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MUNS"!8 R10(WQ#)!']DF^>X26Q^9'G[PS0']E!TI(%S,2)+ L:6 <,&E3)$
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M>%(80Q<C_*Q@D&EA2HE;H';$#>5<ZP>6DE#*:E[!W(UEIE"DV;'+-!^>LJG
MUJDC\"*T1EH*K%G7I )+L(HP1])$YW6]!AL2RYNIL$JHPBKGKL+Z3^W[7I<I
M*JG#!))RD0Z;4VZDQ(:N,U;^=^4_OJ[X3]]):!;^)U7.+M.\<<9CT\,(FO+=
M!(4"L@#C:MO+H0Z+>>&W_--(S%0Q5JD6RN5:M;3139,H>F>:N^+BB3YC/5%B
M^QC.C?!1R[7NNKUVOXTB[JG]V/G9[][T\DKW_J:XM1LM"D@^==Z([K.5*\Y0
M<6<K5HBG>!.J8SS<4$Q;,7U/T4?,6/Z\\[(^&*O<\-GI3;EZJ;YK+*):+I9*
MU51LN4JE6&^^W]7';3F."*'LD%WY%Z](X86!0"JS6B7A59@WCK'HHL&,=,P,
M\.G$=5ZPG[EO5L^U;JE%7HE+T[7SS@#"??+6#7?-= ;E1=75R+4TK:"5*^5J
MK?$N\,Z*3C\Q6E/ .G.P&*3RK]CU/RAES3A=LF;N,['-?[._/Y\=47WJ%I^*
MO:+2&4\L9PKP6"09Y=XI?DZ)&(1SG98LH_/P!Q,6=2"4B64Q?4A$M@W#I9X7
M_G,'_:F1>&SF6JI:4MJ616V8&C'RBF8;RG?+<=QE:9G?V9,(1[R!7Q_<OO,Z
M4VAJ*=?Z1KQ?@!#ER32>5]3:A\=B<N_!?00="C)N>Q6KJKD6HH??8OJ^$7TV
M8O&#,'YT (C6_V=.N!$3 E #)['>U-8[B.>G9$-XH$*=N$!NYH18"GVC>H#'
MF>$Q*!CJG:$Z_;<Y@548-$%IROC9+M.<^_?_]9>&IM:_>(I/+3H9.395;&;)
MYM%8LP(D#P4< ,( ?[V#?$3QVX8/%[BUG&LU2RL&<6'[7MFMDH\XST6#6ZWD
M6HT*YMN7-L>*MD7'@.B_GEWPG(Q"B)DA_ <0/0Z>.#L:5 \-YFN8"'6Q56XQ
M/G *$E)V#VP<.4C1*#;*I5V#%.5*4:NF$Z30FL6&FD[R15DKUC9L@R6JN&8F
MK>P>:#+7]$WHD8?EJ$L-91*X7H#Q.=]1H 5SH%3MT^ SZD'<#&CK_O4Y:/UZ
M\E:4Z5LL4DF)/E)TBWA>AA7\FC6ZA.F;WG0\<*Q/F39ADE=X'X:;&1+IFS["
M#&,%*/EU9,*3.;F? R'O:_V'<F"J:@-&_3-=7^6;3@"VGN_HO_+*A+C*"[$"
MJOQGJ5@JJ<H$\^!'1PI<^LY$>%B&K,4Y:P9(W-'I]=N'W\7G(!++$N8B!Q3'
M[A39"3F7[XXM^_K(UTMN?AU9WS/(GROI33=D8H);J_P@[B_J)WC\R>[-TDY0
M:!B5BV58=8B; B+BNL;3\*-G+EN[!D;."?:- .3 G3O;9&#)-4O)KY:LG^AE
MB.)PC8D$'"XVG+XV\15VT8(2D5Q$X"4D[]D0V7 S]R&*."?_*_!\<SCECTP;
M@]?7:KG(P7J*=7=M V/G5!E,%7U$]5\*+/47*$_*MAO0"HQMY'Y2/RLCXBE#
MTP+[D5@6O,3\)C0K_PQ,-"K!EAS0L 'T.;,KR[@YP3-Z0NLR9I1&W(\6)[[&
MC![%8'=NLJ83E^J4&3*JIK#L1T_Y!/V!G%"\ -2\-W)P-UGAQW3@&^(OS_V5
M+,X2I\@_#M?P.:\0VU ^:7R- Y V\'[P+U@!MF=-X2.<1=@/NY^ 38)-DGB^
MTBPI!IEZQ9W#GC>!ZT)W/%\,]8I/_,";B;M&KO5/ZJW(NEG>\TYNZ_YY<:'#
M>D)O^=Y19AESDFG?8UHD9J#CL>G[0/G4 GIV'79%I355**B8J=)%>P%K.KY0
MY9;XA*<=+?'TO(^XX_@40,M*J8IL^T2? XMOQ/4*?>43"M7Z%T4#9SMLX8],
MEOHQP=2/0W,XGS!CZHD#O!EQ,/4^[\Z?,1 AA$)VG?%G4_*GY,^/\2=P!%$L
M@ 55B*X#?^+M4P8C5!=54N)3!:BLD/C"&P-CPRANI$F ML< A&D>-3!T!VH+
MX?ZL/+O.JS^*7A=!(5/%H$/3-J/L HQE:[#"-9-CK]4O4;.5!N'[?-1@[=2B
MCI!5P[9K9AFU-&TN><"3+6B111$W(ZY%3?7ZH,FN58N-#2;[]D?8&I64HJCU
MHE:JI#.I=-?7%/A80JKN]ETR;YY=FLBB*MF\JIF7F?W%MR\0N6?$H1])VW=O
M -O/CCM-B(6Q1HP.]+#1/"RFE=#R2K ,SOQ8T9*=?5GRH;?.K#HS)._*2 PN
MT762&P^1J]N=(M]2,&U)7NDVRP(2.\EV_863:@25OS*@W'"8;#PUJFG;'1M]
M?\,C[C:7:Z=SFH?O.*>8.Y7H4YO#I' 7"W*!ZK,=%J,*/,I:P4(I.Y+OST\Y
MAO$DC#/A6-84!W\U86@85K%A;0Y*UA?38ZK4)K9N$@L-;CS_@8VQ4)1!7,-3
M,!O5--9E5I0_D<])GFIQ]2AE]//]^$D<<1JX-G/<;7]&*C%VTLA2Y,0;4<N*
MZ$3Y!-AG,0Q^TNS]&,'GX@X@.A%$_DF]!6I83RSX\]X)-[)V594(Q*W%3GFS
MJMPEUK<AKO=1FCXU"2.U\<Q/I#V6.^$I3N S>8&"(\I:"2G3]+R NK]Y/!6)
MLFQDG2=E>#PI@WA16PL&\'P0.!B1UEG\"BN#K*?GQ:#7:@;&T<-@514/+_+X
M6W(8;&;Q+(:<RBK_+CD@M..+1N/(G25OJZO:._OJ8MH]R=E8-^]FT=6$3[!*
M7M5#C&DY#_X@4Z41E==9]0Z6T?M>VH28Z$TV:V\6Q%&4&39+%8OEB*VA "UQ
MV24E8?%,*PBU^E"I?G?Y[7=*8)M<I7+9GEM2L[!6@^HF.*'>[[GN_?>$/7\&
M3I9QUV-=Q AM40N#'BD8#DM=QPX!B@ 3Z*LTT\F8K9^O-AMYK52)M'(TTS5'
M!Y,)D.&BM"TFSL(GY?C;P65:;[FLFM#;%1Y8OPFJ%E$[+!E+X<-5L?FQ22Q5
MF)TXW#FZ=JG%+G1<J3D[-Q/8M$OS3\C <ZS 7_UD4YG:7<OEUF?E<D?N'"_/
MM#!P*?E5($, QS6Q7LG40RK]2$W=!#H<#C]"AXU]SZ804::BC%R4;G_9"C]@
M"M.WKU<D$=^[\$"EN)H'P)\=/^MUQ43@)7O:/[%R5?OIG\K]0[^C/'7^VGZZ
M[=[_5?G^\/0/^+5P]_#P-_R;52_^T;GO;U7!>(-_OI-P:6R1-G$ZU[^/J4%_
MSDHH\F"V\HEE#(4Y ?,"BSQ-+DP&^,P4+S'M64-0G:_$-0J6X^#1Y"AI@!T9
MYDE[&.$Q;>9+C2FQ0W<,_WQTS1=TWV+IB7?PSS//:P+=#FIYGJ?8K#*W[!5C
M$/ O3-9W7-1KBFES!0Y?%95_C*B-82@6E&!+6EY+/CX[EMT$.HD%L&+/T2/D
MB4<8E8H--L3*.V,P2@>8P@&M9XF8BY"(=18[CIAGX #75+',L>FS.>=9>F=L
M;*8+>+\8:*%O$ZKSIAXO]_-"[8!"M_C&]O WG7@C96@YK_B4N AE#R=N.<R_
M997%G GE0B9J'\_@&@-2$;&S5;-<+HO8&-Y9_)+G?,_J9,PC=28LP/O"YKP(
M299V!GUY"'K<*GM&7.,(#DOZ!+W'V@%E$UZTGD4)AX$? &;FH_.^64\X_@)@
M6" 1;(M)F$0ZX47W\1'%(IUYP-8+M9S).%H=>OS4Q9F'13SBQT9=GF#GN%.%
M3##:"+8E'YZO>G&!\9GDHZ4"0'$'T>&3'5#+I$./9]ZL@@B<N6 \X:VY#F#A
M438@!R! A#X[\!!H/$Y#45[?['V>_?GJ8)PTY%*<T7(.$2P*8;_\&+L!ZEAY
M#N,A92\_9HLTEI\"?RP_>C4M:_D9!]M*<A, #<^%^W3YC67^HM9*SPRR+RN-
M=2>P5B:VOF\*(GJ<\!P%G@GLMOS<QVR02"XB@CU AD485>()]PCOG%Q>B&N2
M&2VP$*K+@D @F,!( L'_/&5BB,.3\V1XM<4T3*=\1[X0"PGB>:1XSO@]2<2&
M""<(8QCF<$B1VZTI$!4&?&$N!OR#URJ$LG%#9\!!@!),*@U+Y7"^QD6C_,8%
MC<(AXBG>@:V#5X(R9R8)N# !Z>JX_(EIOSC6"U5^V<ZKS9X$-O_=-;U?X?08
MED$H11L/\'U ,%G>"RR$#,@.IAQ@O+QBH03@[(9"!_Q"AJ' A;]'2$,A.[JX
M!P(ZVYW..^)"'BD$,(GYO#/@<>F*G!H*K+0'CV$,WXXGELE3_C?015'Y'H)S
M!51\V#BH<(%\2?%%ADN+F,;8.*5WR(4+5X $ 5?\F2/<VY@\&+.H%@Q5W#_;
M9&,53FAD,<FP<SYRFB?P%WW;"L_298@?F!:2'V#<&3"E[P58=\-$8H[I]TA7
MZ\H@W-H'EI_=*\,H9A@@ZT*?<R7-.!7(@["+:>;*,-*L&-]&G8_:;8P[>T#S
MKUS@!:'N8^+2@;\L=D\-5X3&3/-&LXI/)@^2B+).<39SF\096*%!N4_?3+\&
ML[T$'$('>#.#T$=6X6=3(IM#Q\ 2[A)X^4@:KEH;D5X'^4E?V XFU4=<$VR;
MR"V9XB!,,0A,RV"(FUG%S'N96Z?X;A3  V5V(Q%Z(2[832X0 "H!F\)#C[A3
M?CYBPGPL[&;&*=C+%5!-N/\>TE7$:I(&CDL#T<8W8?O@E&UY@TT(1IKIC2A/
M6T#\A#P>&BV+A .RD^&>1)[N,+!XF'YV(H=W+I%[7.1Z3+=A\<+\@F>'+(Z&
M*XCQF'>()Q*G3HA>M/]=QY(8$\%.B<MD%@T"W]SBN_)Y[J=/T,^BRK/S0ET;
MD0FHY9J>*6-=1T?%C[EBN#D2%;5D3Y"/67H2#RF,*#I7.O*P15XYV[NSTW<>
M/^D3106(\8+%\!0*=K3.(D?S,(_'36]F)<^G%^M+:@!!- "/N3#FGX< 0]\.
MO2 T #C=<;QRGXB5V\;$$B-L%-J-G@X:G\M_QXLZ2%0?"40>TA6+PS.#>VXD
MSL-W,#N#>B8/*$1GI$%N,5MTB:CR?(,R27G%#%0Z5W-1O!+-&P 96L#!Q.$6
MD6X1<QQ&^$QP^M@EFM$*)?F>CGPG#@L]$BOFT3AQMVA ;3HT>>@QP2&*[@%%
M]%O8&F-"2!>&Q.I)]2# &Q0,Q@29+6I.*':#6(Q'MY/\4%ZDB<> PD@,/_$*
M0H1O**,+[3[CT=:9NP\R80 T$P7'"Z$FG<<UY^3%$GUY$@1W>I?$*8M5@5YD
M-2P85<W%)A ?VU%$V@.YYT0Q4HM[]-A#K'NFI-FVC1V&P!;&-H?1M]3(\Y$
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MX*%?+(ENS)$^+HDV,T^BI]=VHK:26[VSS=QEK7MG>L0G2G\$7#6A <S7RRO
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M'X=KE)\)]EG(;!6M6*\"0TX<C]W5=NU2S*9ZH5]>3<,?1<P8^S"DO]+\$S(
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M:/:;8<TDY9,15DWZC X \P;P* O[A<YQ>5EQ]A1E_EX<] BSQQN0ENM;Z5:
M$(WS*N??77-Z*FJN5<F72GOOHLH ?H9E_[%I=)4,M5RKWMCGY)98\7^1I?_-
M.A&O$%\9T&?3MC$ A&<;&69EY'\=>U4.*/EW%N1XXKR6UQ)*8,I=@\Q3FEH6
MB=3P^+F6KS9%N>;Z DSV=X4VQ2K&Z\1U:LFIB5PE&IS^\W#+/QMA(I0LP9WN
M4EY35TLK?LP!$:+HYSO>B61'R8Z+[*C51.+'&F:>Y!NIW19TC'JGT20B%&C
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MR-811$X&YT8T\BD>& &$#\&[PN%=RLI]AV6:7KBI"$A]\Y4IF+,<__B1$[A
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ME4H^9IC:S0OG[402:^"7 M&1WPTY;&H<HAHA"_S:2J'*0:+FUOKNV!C?";@
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MD>)[!HV/#.9; 8^8HD- S,6:&=AG;D:+*R#P%1?O2]&I0=6:AG:!_#>NZ'=
MZ<$R\%/#GL$CP 10Q,U:)7'N?KI@,]]D=_-K6#]8/LKE__23"XG/CKWDR4^T
MY[MY 63M9R!K/XVLUUZ)JV!B/QO)N2N@.W@3S30+813KUI5*WMV'$/HYA(#\
M4GN%)-[1J#74NK_DY_#^DI7 VN^W^L-1YE?M5B?S\[RE.KV6UN^76BK_<ZVK
M5K6I0:>[=:D=Z96GY/[/UNS#0YUX0[$R2;%G=&OGV*6K:!*X;&V6!%JIQ/"S
MR+&^)PW*7J'LE?DF1=Q*I"RZJ4RM76'.PQ2^ZR6 W"MM"P\:XTY3RS6':Y53
M(#-77A1?=P517P5?AXBO/>V4FEJ==;[+/W7'T64Z]RY:VN'.?!U:&A$MC0ZN
MT9$Y,#7%NGX-L6[0)JQ3:Y9B7OO:SK.V,7XPUW.,*;I<N<,6,?L@8^,"J'M'
MQ69%U)TFX$YCW%73.9/[*6 G9A-< %H-7PFM5$"KRO3Z%VL:E KGODY<;0-*
M92.^VGE%?/M[1GS#!IQ1YQ\W'4@;=-.!M$$W'4B+QA\H7YF.BXG"USV"77S]
MC+=N[?E3\U@PPN>)X&//E;EAZ=;4T$U%=UWF\8BN:>@3P^0Q0V^A>Q1YG3 ,
M,2XY2'EJB<-P5!#^ =_/&*R%_^;CA-C/Z4*W'IFR F@SOLRS[9LS6 @>G#)@
M9#/%LQ67F?!RB[]?L1UEI1OTA0<6KCMGCJ*'&\(@-/Z6W ?FFO]$,-@)\YX9
MLY0E#2F&59#'&"NTDL,XL6-8^)$9_ CVA)\O(SQ19CI@\AOVT_#XSM^VE(=X
M$!PSA_[C&P[?_)3/F5HK\PBJL=7HS=A?.M5':0JO>;0=@'#1'DKUQJHO[(F9
M2@?."T+(W42(__@VH@D!U%7>^)8^P_VSV5NZ4$K;$7?B4@J0@>=!$1&@)7R6
MPDJ$*$=!A"@^  BR$/@7( Q<D@[2R77S+KMU1O!7<^ O/K4Q58,W/4_>2)@$
M]VQX"[B1X#9#XK<GL*\GBNL'&5J9%]-4F$$OF0&%3#T@4;Q,*_CKG&#=S8&U
M;\6 )7ZR%68MY2R@\GF7)$$X3<.Y?,I$=['!'.?,P!7!%E5,@BPP2X(;1S_@
MN"X<%QZ: B\GP8"<-)/?)GAUF.J)^W%=(GC!AZ,%ISS'4X@+W]2=X-W;WA/(
M %?YMS][I$_PM$M]K>CS.: Z/8N/A;E-&XOA2W/ Q%.JX)<K4Y_RUPFRW%AC
M83 '4P36'&YNF;3'BYP/JLGYH+782J7S07/T=K51<GIH:(5<$UT*VV%V9_U
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M69+S?D')ZLA9JSA?4I*S)&=)SB5CP]61<[^J$(PD9TG.DISW"\]78C=7WGI
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MF>*2@)$V; "^@W^O=,?;62BTI7SL&(5#2>NXIU)R_?N5[1K$H"G7QWABHIQ
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M#%9YUP&L*+;04G<>#2L US!)WV+IJE&VTPYPEE9\9WCPNFD"BP>;6*PB%O\
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MK&[Z5D1 A*[G$$MUT#'!*#%SM<)<.L;3FN$#W])%C34U/F3Q5+HFQEO65&Y
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M@ 5V'&(W8Q@Y'F<D!S 'C:\%UDZ#&DF<8^ /YT>F\2>&24@\*%=4EMZ4NT_
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MI1SLV.!P)!WP]5,Y>8KF/('L,),<T(0Y\.HHNRA-@?W2TFY$CH7]7E5"AWX
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M>SI $^DOB+B3?<M-<F4^LNC0N=>72']!FA#_)E\G570\CJ0ILXPD LFG5"S
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M>&@3G^0FVHVB3>#^NW](4;C**S.>NJ8Q 4T;YT2 :K5L-WPA>FB+2E3(]:(
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M-96,73 .DL5PM$RA+K ?,[A!AY/=C=EX6DF\H+#0A(1BK]O(VV5T(\O@,Z[
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MT';F4X^P!>C4V(PD)V%__4JR#3:R+8N7QJV9#U."=1_=J^?J[5Y9?/CM>>:
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MC2(<L/C(E"ZMY>%DG0>! R00B"-5B <^21(?V1T,1]@QG!Y442T#I\JT$("
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MW#MC;_P.$9EE._1&8'L:OB.A(LL-;\9]0_(5'7<-DL79"XULB5VS&DY&$KV
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M>9OH+1!_8!!27K1%K2GOYQ]?_1]02P,$%     @ QH&H6J?L-/%Y&   !>8
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MVYJ#ILS31 FP7$HB:=DWQU4YOP8\XTGPZQO8;Q;CUP*S#MG,W\-!/HG^>NK
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MU=PITD&]VQJ<8]GSP%EJ?AW-=L@.%<L]+'DV,;F=$ONX2N^F0_,ZWK/"[BW
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M'&5AV:%J'HF\%](CY%_/KFW_"NTC3'XSZBZ$OQFT=(857@SP$.C=4;E "$:
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MI)Q GH;7%J*W&3RB=XK8&O/@763#BN !;8T'C@8= 04?E+.[O3A&*>1BF$O
M@JM9"B[!>^& 2YU]4C:30![A:_B WKUC(/\1OL@[,?=!O;V[5JFK4"=><TUN
M4KWJE2<!L9 9&K--13JK7-YJ@N11O,*/MSGBNWJ/^^3P XZ9;;&KE:*38Q8,
M1U?[3AP)HB3@PG&9"@H__!4!0RW^Q\M\G"]SGQQ^B,&[U1P76TA!*MJ]5 3G
MD8&2'L&+R.JH:L8,"V2Q'$U[1-.5_WB-C_,U[HV]#S-FN(T,K"ZZ%(CU!DL5
M= "OE0+'!==!.E&:7V=V#.ONI=OOQG5=M,#=_//G?]2_[G5!9XOG-NG_:RZ
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M.SO)+#[,EF%R5PQU1 =O#!HUV, %D'0\^'J'F[(BB9)-*,U[QGI;S!&RM]\
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MN44J1PTQ!@&Y,&N]5<7JUMU#=X)Z1 QIJX!^]I#_FLW_T?E+UUE,'M2+\92
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M0QB)SEF9G$=F8Y*XW5BJB\\\UL;EG20^VU]<K0L*_[_5E["&P8T()H@$I9@
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M"46!!&DBK]&_[HEA \3<44NE$RX8]_EOG;@RR3.C=_EV$[&5^%+3*D%ECN)
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MZ2I'/(6HCCR\9ZCI.*H>0[/WMJG%5(\CI2R9<6O'O[AOC9F_2%+PWEMGKX>
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M.(*0639/\=]Z9RA"@CF6!(.]VIOJ#HUF26,4"_53B^87'9:ZOJ+RCI-8'4T
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M\(.6RW=K;$Q+WWX?2[^!5Y1HG/1Y]>*4A:-\/-ZT@5#C#T0;)R<NW\0Y8M;
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M$ F+YNDH42CZO#7MNQUB8S<P,EW&IR/IIH=4:W,66^%;V^<YA,\'DDP;5L@
M/%>;+!E0:&ON@Q/:).0"XZ&[EEED@#ZJ8A1%D=[B-F@H,<&!FQ* U95CSQ-D
M50@5,V^@*0VI,(F7&F,4:[V&C&?!*0V&K._'P=^X.H<"/.A!@9NCU\%>9J@
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MV50 *<V C)$!=7OQ>*U0X*0: U1P@KW1L'19Z[)/K9U.@537\XN=-\Q8,EP
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MSG@=,N)V<HJZX>!) SWU&:QV&L,=!OFG)@V<OM],@TU(VV<LI"!/KWJ_#\X
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M$7%O>)"!@Y*=*/P[2I)]>(/7<=7PC5ZJ_L[/EO'1$V*#C)347<]]-^/SZ$N
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MH[%SL'GN6%LK5T[;H]MC=7?0EZ%)<4#_8.(2,)%IAEQ2I#$8@SG0:"L"_GE
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M_$EH?@R#64VRP$=\<M7NXU=T,7+U_?5T1&=??Q'8 CN-)UK3%:#2&0PX(W2
MD(1JNKPF6HMG^T"D#*&H^W#Y]?"UM3F?I\"PUPKP1:DMBFPHS1B>-V]=5A)1
M:J_(6^-O*CO_.(R)*5>7<6K.JBPHD7]A;UZZ]-K$(08C?FAQ J/T*>_4"M?3
MHB><H#LH!4!UUB^Y4AR6,FZ6W0\'6$IS$PU#77!<)7@-7#XFNJU6;SS=,1^G
MI)N\>R+PG<WJ'6-KT,WG+T';TSMT;#)PIE&D!9)E#LJ+!8?1Z&%PR#&HZSF
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MCS^RC2\[RNH?'5JD##^SA]4+:%?<.@<89^Y<'RE>L=1UR8X2$./\]_[L"GP
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M,4#%\' 9VOM@P^5$ R172MVQNPEA#B@'0PWJ@&=ZN.<9/BZ[F2[!;EB5\2:
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M5!]:K%:X=.PO<SHY6^/Q"VP<T#7Q9]?)^1/T;D#Z1F%3'TH33'Z8AQ"3Q#F
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M#RZXFYC=/4O?I.GDH*@"75V;X\!T)*&VS )4GU655YDH2?N[4[\WS)D:2 M
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M]=3B8<$:O2(==NQ+HB/<[N3*7NM7.X1+<21/7HN@&S6E]K79UG?(BQ3BD68
M777&4>*W,!*TF%IG=@$3+X9N+R7D'.#P&&M6D:T(7V#9HD2M1I;:E W)ZWG[
MLD;[K+&B-5_6H?5W9RZK#["5J]X1#A^W[4[:G!NHT-[ 2KO6@$O-EU4_)35D
M6J>/[(TY0*M*H$H8AA9'X5U8J+.G*UHA\':G;L,+]<_3TK>VS!66U\F1LQTW
M?.':%S6%IP_OL\2V#!YL3-=MNY:)4TD9<.YP16Y\O$X6 ^\9LD0D>#N0#OH
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MW(_/>7F]55<MW9X&/BHKS/O0SG8HR>/8\+'E0$.UV/U>AGFZ*N>](2W%20I
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M;L!\%!K(+*!:"F"?B0RB[N8;%3A"TGY]"P7]9WN,=-#;0TZ"3!H1W:V^*YM
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M(O) 6RFMQ7EZ#R[ZA6AR-SG'8F";7J9R8&WFSE%)P\=>N)N6L(09+N9FKX_
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MW/$_,"3=)H :%07K6/7]0)SAY OE?=8#J*VPY4NV3",VZK2?"UX_>GMT1%5
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M@L%\!O/X\&Q7FXI(I6)2XUA=7A;[5IY=5:Y)C<"/%HG1H)CALV3EAEL15O%
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MP >E\"_# E=/C+\W<&K^3+Q!-=6O8\V0\_$2MH'IA(\PT3ZK1JBP8X_J3\(
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M;=C:V],T4Y)ST9IV^1:WRZRF;M4_N':V'L9;YVW^YW6K_^AZU0J9GQ E=9'
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MDG #;5R ,B['4'D#9>>=AH,G(X9A4A4ZZU6S:E\5Y1AH.(1?0),(6?-& *>
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MU.%D/NVOL4):>*JZ%&0I_>WSS6]^#+G5SERE;.YN>0CVA#<U/SPK#7TP":
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M<WY0(&T$Q,IPDR&Q[R%I9(=&+?FB./V2X%)8X G#8)ELY"+BYM[*)X^!+<M
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M<-P=.Y:1PM;C<:NBG(PB\2Z(7Q ?>GULX*8YLT2BZA'M9DU86^X4!-=/X,/
M[L#Q^H>3OEQ.4=#HEPKV:Q\R X="3'N2?9L"+SO9A$>;ZP5R6_N ]0CN">SW
MZT]ZYRBE"C0_TR/$=ZIL00M>J_\(C/HC?=_]D:CFF^=T$&#SMT&2:[/-LW2
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M*RK.FT;&3XUTQ<:V^1A9+67BJ,>)S@M1690+U/<:9U$90]>E0I0]3LCR\51
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MQ=CZT4?6M.Q\1$@]'8#WK&EJ>N=^I W> ;UR$[VN5RH!(#]GW6;Z,*<M=J@
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M$!:\6^LT(AVO/-!C">EUO]&G]+$T8.^\Q/-;,1?Q]BE*R$-5S.4L-BG5L-D
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M<75,<=[SY(V@DY,& $@DF/S8^H8FB)X>->W"Y)?*:DWZU?LYG_["DSM;D/%
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M@3;[L=$##"U^UL>^ %4'OJ4T\,7&VN".\#FNQ&*%YT=UK[6PL1V^T>\X!GF
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M">T4#?6?J5)T@ Y(XU!T0+R3#G#MW\G18@P^JS NLF4UT"RP ^5BQ@C4N5;
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M76;X%8\:)^@ C!H++MU$-+6K"Z^/1SOS?(*':9CB1P]=,]90S7--JLZ/>F6
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MJW$4]TLEF5FD\B5RR<I2&SA>I HP?'AX2M.%Z]IQ,8XCPT-6=[@L=PN^=7'
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MNL"04$@ G!D))*8UYOT(M"08?ZW^WJ'_K\=^UII@.]=7(%@.X%^._?";<1
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MTM9W 1';DMNUZ EY6?N4\:,[0W(<MG /NXX>3^7,0ZN,3&R\0:A2W:?W"D+
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M#K/W<=%!SZQOS&EJJ X*E]4I3X]+!FYW6 7:?$VXKE[]1H4L@M:KPF@.P40
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M:]\3/E/V?\CKV-?,V0:[-RUN-_<%>-D^^\I7.99?E+,A]<<XE"I9[ZJZ6Q$
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MKZSN4R"M_8+;B>6J%[&L#!^._,F#C[S!?#*E[5QX\=:W[\0CGP2*GX/53Z%
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MWB(6])@FE%/;9YR1C!V>&CWH)5G*%W^.P4;*0.NFF:+C$12Z34ZL1,Y^OT(
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MTIQMBR1U763=\ [3C*JG5-\@J)?##!EUX\;=.>1'$JF>^4@]W.^]*HSD1'#
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MR.8T^.9LO@5^)RL2;7DO2-/RG ((M^YI'FCK<$L*-C6;<0*?'I.V!SJ U#D
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MK$3PZUGSR:?1ZWBQ/IYN<$%'-@&YL^MIXUDZ^VBWXB"PW/-*[IVX6'45K;-
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M:-BC.>%$+?QWS(PP1BD/F[#8$T8TSVFS=R^TCQ6([8)%8BON\*6WF6BB8QX
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M9HEC5"ZW>:;Q1/!GQK*]"*:[P89)#PS"V  4O?N_=8-/ 946C8N]1,'LA5.
M]48&]UE\(GUQ*1C T%HN^T4/,0JE"9K9V5PH-Y9"S"O288!C_A+0\YU*=\<I
MJ=J5*'"U(4I]_=R(,.*F;[')T(41@^ W?>HV&E-6NQPO(!5X KK?3]@BH3,;
M3N- YBP//P5 1LJ>_%1*YPI(5+*^,?+D03RHLH?MFW[KX 3<D3<H@W=\]#$*
M)QT[AT0BT31Y\PKJM*TJ5V+XV@V8FSJ70]M>T-'""+GD;@A3$_=B)IN=@FTH
M2!YS"626;;:>G*S0-?<3,KTB!Q, J-Y(DHDZ%/%Z>IONMNQDWAJ\LI1X"L!F
MSD"#E[0S=7 201[-E_E?[TG'#CF]MK*G^_6$21.93)E0;4WWD6("IDTJ 5%A
M&[O?X-V?33CE-+Y+1$I#)=*W^>TB0_6_(1,%7F:EEZP'4:Y&&DZ&@^TAP61:
MU+"HIRX#9?/$UA)JU*GT=9ES7F.P&@TGGRHG@W$&*V<T/1<75/W#*< *S'H)
M)E((11D.>PXXP51D\S$B$_;A9[>%04TX6U@HRPVF7[+#OWFTGV$16[XXK;;#
MHX09Z,2@UM3.5C7!>/N )D(X5;G6GKK:L0!]QZPQ^>ECRY;5^5RJR@U>)#CD
M%0[\WB.3?K:W%.[L&+\F%XQ^59[Y^#,_'>R;4*C2&_6^!R3'F<TE!*7_MWFE
MD19!>PN1\=UJ@6AZYG0O,RC2<?-8%35-S IT#"7V6K.QB[?RZK7ROAR]^B]T
MCOVK>RQNE<@D3+;F)83"MY$P'TAIRPVL;0C1_!"^/4>C/=$RU-A+'JZ.A@.]
MY)SFZ:20[M%U/(DQ_\F)C9 <&Y"^NGB;"HV"=MV"65DI:HS4& *ZW_[KLSE7
M2]XES8[49^/(A.0-?P,]2!'JGZ=-_L=C(8T0Y$;+4\#J]Y9]/XE_/X*R)[/<
MB)A(LB*WZL/759O]?'"UZ$RBN$10PRG@/:H:50E&OC1NF?WE0S84,!H<Z&_<
M6=JE0U9E0<^WDYF;?)L9.]ZJQ7C@/J7XTK!E>3U0OF7"Q' G:VGJK2')'Y[^
MZO: I LC]5ZQH.TO?YDN^3G0*4 2NO'$5?OL"Q_6;E0 +[;. W%Y&NX"MX9;
M:HJFDGM6CPG;&5>LOIO7+32B'OM.TA:2>R8K[92X1ZMW6=9K1M<YKBC<<F#$
M>W#6I2@ELQQ=?:X">ABOTQ/_L'=0877= =BN]/"X&?YJB!$JW YAW/9P8<YD
M0H3O^[Q,&C6L/ 7HUC6Q"%%:>J\6T6X'>G>_):%[R\#JI##D @M1X4<.SB4:
ML=6D8H]N=&*8/RODFR*H/X2)EFLM]Y+CE71OQFY<CB8Y;EV^>7Z9E]Z_DY7,
MCN/'1^CBOB;8%*N7F6UZ)4U8L+*<.#6J,L6Q!56:GZ\N>1^[X7;'3<<A.1CU
M(JP:2');6>W*X![/-&LA>/X\(E,A&^MJA=2\S8SJD@Q";SOEO^W]<94"4;:6
M19\&LR1P=V!V*?"$]EU,CKT+!L6 "+TRO-Z::L )?L/ZG:).%]7*3F@RW(DC
M*&S4P*M:BK%)A*ZDY+>P!E_[&HZ/'(HJ,DW6"9^?_;R=6,^%2+J[/N ;Q43Q
M.ZIVR^_0A<*QY6R_?:CU/LP/$P.IG&6P/WTL=!,)Z2TNBDV(YKBH.3KY$X6S
MQ!JA2/KRLCYUL2?<\(?D1S.@['PC93@$.\71S/!96O)GA\#3['ZF<+WA;H-W
MBX&*X>L=AB?-4$/DL:G7OO?=BBF7,DL'-,(9VB>W[3$^U/\6N+80ME#)@[0M
MTO9>W)5X.KKBUF\E6LQ4;DWZ\?U!971GK'^SHW ;;Z5P!#)=FRHT28)^O<^=
M_U).ABU/Z+50HN;2CWW$PHW,Y?B<;5*E%I*T2Z1R/V;)I[:-[?(SVAAQ/FRP
MV$7(=;@8;?C2;WDS?X=?RK?O\'GJX"[3LI,JJT9WKS:$Y-B(G\4.D5EYV^?@
M;0LSD&G>F0I1B-/>V18%TB'24Y.]YWKFN1T+L.3W-F@_AG[-44N60UE7ZNQ(
MK_/U!\*%]WJ%JH'8D@Z&BD\-GT*+162'-HBIYT6K)+Z\3RM#,Z7^WMS;@J%Q
MK(=6N.0N,17ENDFB-[JXV(ECPM?125:76E,F53JL:C">W67.XMGY6ST!OAS+
M,&$"]88_W0\GCV8P1A"96\%V"L!X6Z)W*QR&+[A]KYA3=OL02">I,!#]TU)]
M4MHHPU>X#WSM%/ *S&;/6]73"3Z/MS5XW^7J:+0PH^#W(<G1$1K?Z\,T0E7O
M&R,R=JO^%& 8<H]@,.![*-Z",]]/V:E:.AIOTG1UMQ3[-N;Q(4&[/GA"]EF@
MX\-$4*N6LT!OH/H<HJ @2[W/XC(I]  2\MMTP9Y'J9PC5[NPV&>>BV^HK_D9
M71BEM^;REDABQU*L+&[0Y3UJ,:-&B;K"$2AQ;2VY?$ZLOJEN L1K7V N$)>P
M(E.23+=)'?N"V>/CN3N2&4JH['>9(M#\0[H:G&Z;"PU1,:%;U]$IV\'[;6A3
MB-83&T;VR]V, ^T7YN5[OUE$9-P#=L'/(6.X8=='8,RE^*^]91Z;L\#0 R#W
M#;11^/1P(H=0'?QSS=7G=[FP32\(W$S46 D:<A\*&[6625=]"L _4OK3B#DD
M5!RY($4 N\P05SX>&__6^>Z#\A5+\V!?6K#+#KB,*# I^V+I[M!# ]*^IO3N
M'>]$B9[>7;7<YT)E&9'V==63*JNZM!M'O/1$XR'/\RP?JEFOT>7Y+NU1OITL
MA, LL:3F""T7T5HCMF.GSL?Y2K\B_1].Y$> *+Y":QET2B_,1(I]OTL;H\;=
MY7:5>"G,YJ*YS;SH7J$S,^I>S['1HO'KU,B[9C.+=S3:2R_5+(G(0!=Z^Q2.
M1K2T9LUX7?19$U\]1^*BNNT=$K?(OTX!:FX6%*,[,-VE N=I-_ZT^<'%-]1.
M';]?&_V023Z+*;13T)?]6Q-7CQUTS*>6?YY4[)HFG@A3O?F%=Z>X91SVV[!0
MW!Z))(@?[H[70.5K[EEM%BJ;2AJJ1^"%#_6PR0$'->/2)'73E,4IB/VLLVU0
M0G]CVH!(:RAW6]AE]P"%0)\R$Y0E+Z5*$5[?8+1)%5/*:X@=KV:9,)KP-IRW
MOR9U1VJW]H7NH#+@@F6;/D1C& *%YB<9DX?>/N98")))W66 IIJ/PQ3AG@5M
MGL4.-(K:@IW^9L6![Y[>1GG=_>! [ZP#W08?\F-E4W.ANSH1!C@:Y25@O^^V
M<L8*[3!(JGJ-CS0($/W%W18M^0TT^>/C$ZK/N@0E_*LMF*99V(%(-FY/+27W
ME:<>FP8L[E?B$Z/E7SMB0[7,'7);VFBM8C\',94N"^ X76&V"OK0-S7BOM,6
M)EXNBN_2ZZ)<MH!?7,N5=]PA*GKW>6XLZ4[+=<Q+XN-8H_4[YP5_P)19/DGG
M)C]*&;O549%SEV&V_HK!E#/EM5GFE0QITOM] IQ2%YU)U7O8.29Z?51X#*19
M$#!QK</-5O-+."=D_MOC^,(+2VRM.XZ;13?/MR$14ZOM;W?B+D8H-6.DL;_T
M9M4:A#-=Q!I\  !+^Q<^3D=._=0"D0R:;$)%IX .%KP%-^^S$3&8"6;63U@_
M'J/5K&16;-;H;9_IRQR.F5>-"G[#<QL17:(KL\_-1)&(AM :X^4Z3"W>?RT)
MRU^O&9XQ*ZEDYU(+9W;KB7^CD#+^AP>><(C%,N^&^7.OFQY\U 8?,G<@VZ_W
M&@M>9B>'?_M\*'!8QGKXC%0$DU]$7#3#@[M&E3YS)]17CK$(Q<NJNRUSW12E
M?O6:RXHJS2JSVC90\9-UL-V$<>[3&,X"&QM^RJMOWT.D8<JD#R!AC)^:XP+]
M1JT2BT^JNYDHW\J<)FCK05_?O=H77@#7L\R'O<4DM!]<\3NB^QIL^.-;EU^$
MEA@U/QYZUN#"X).,.QLB<S*C)Y,Y(C _4GD3#YERO!I\R4*IOFC#:\C.5L/B
MKE/<I*.D[7EW)V$*9?8-M=L^8+SP4<"ND0&.*O)55':%[,)TTO>.<Z_$*S74
M*X_MI#;FNQO@E^!M8)ABWL8E<"A(RP=AEF.[53/1/@"9CCYZ#6]X1I@</1$/
MLT0/"$T^'MGF*Q_=?J).VW29^9KZ"_"@X_,.V3XW8N57HP1YW1GP6[=1G9F\
M]4I-B)<%/^N'#K1-4)OY;^>%?10_9T\&+XX.9677PHF[ W7>N]09SQFEH+CI
M6' *"!>Q>EE:?=+#)X=R.!XR)065(8=8-GB$,KLY),<D5N)-]O.Q12WAN:TW
M-!F^_5Q\C)+RB=Y-DN_A(MFJ^MO!>O>4XDX!E.3J*FSPER\+T/%=(HEO4B=P
MT?Y1-ON+!M_096M[<^L'$/M0['VP'.BU.?F;4<KCI!:^41FGBPN=IFK9*:6)
M&>\79Q4YY1^^:?!+ZZSJWF,5][=W?G-IZ<6 G[(J +9 $" /S<2T]\>P.#9L
MIS4X#>9X"W#H)(/.U)^>X/R>85JD=>LAC]&KJ7@EP/,JKO%TUL-'"1W^+%CS
MKY^7J) XJB!/Q^VG0P;D[X;ANDBIX[A>BMC5RV@5*FZI+:60[  E/2SKEJ3K
MXBX-[-G(+LB/A/!>ZK>\,HF::N>M4CIFSYT2OK%G#3I7UV4'>T@*VN=EF5J?
MF&'YD@^]=WU88,097E5]M[4Q<8;!^;E 6!)I\+:;CO\1%^F>*@ Z@20H]A9#
M,[O?=EJ(U(]:XUB#;V QJ8I^\3-L1_XDZX5!;[^?]$>-,;<J28$"[W5QVL70
M?JUJ<Y?[[Y4OY4*M37K8PNUR"0_#Q8T'^'ULW24IDP;? !!E!5GTGUJ _EV[
M.'Y,DY)<3.?,,UV6V)0GHYZ9=+2/%FY%9GA-U-TW=OZ950@(\$'<Q=<2&/#!
M$A1$Q6&87,&&Q?5)D*3]O;RD/+M8XQX7J3F!7E=@\X_XVP'EYP02HW\2\YF/
M!)GH5OO#"(P#>>I,/+RX1%3(TK,:R#90C+%W?,FN]?<CBS:0*K']+%W(%>AT
MWE!GUID\Y$:-)#R555(H=XSH+5O1VARBC:F9EA[Y?-YL3MGU2I^1*WKN1UIL
M1)K1^/X3UCM-P.Q^-(K6_NVSD\3Y*IG$:J_= DC-^H[)L_,"(8U<UIEOSS""
MDAFSP+$/YH2I-)K3/QPUI;U\CL.Q<$6CZWMZ\*6?!OYI&;Z7#U. ^?3FZ*);
M<9I(Y"E :KC5RB9YTCA4^9&6X]S?)P OG@)8\%2&6-LPJQ^(I_(NN<8SX*H*
MFP3X><IW"_P;M&^'WI'982IX;8SQ :<BFZ>C$&GN)TLR,,QJZ 5!!SW&Y7DH
MU/R^"T7W!2<1 Q)#E#^W=[KQB0?QKD&"L'Q,=*Q%P!G3^O)N*@OL-)]%2$3F
M=P(,SC*&",[3?'!G)6)56]'B<&V\!C7 ;DJ.<,&< JXX*&@/IW":ZPQJF3RR
MM'D8=SG-^BK;Q1WZ>\5=GO13_>WS?-B6&#3B&CZGRT(0.Q]E-Y'BG.CKZ<3$
MDM^_-Z)WZ N-C.=;==2 L(.X4HY.@,M#@_1I*Z00&+^?]!%'2'B36:&Y3-#7
M5!?0D6SX:W1-G,#[OF<U!A<>6^U>I!*+U1PP'09;T=.NS;3$O)V7Q'E]X?F,
MD NSJFS(^*XL1K@M(?I.S"#U;K?<E7.ND9,_GOW5#OQ\.O[=DAD\9)X!-2DN
M)G[ Z)S94%$>E)>QHM+>'9X5KTD$](+.0Y)1K&1>F .^H@C_'B,1#N(N-IE1
M9M2]WABQM6GC$! ;QO5!=IP=="5#\U<"I"313'_4"1DEN].^)Y@QLB$<:)>:
MDW.N)'_C$O/2"CM\<B3RZX@YJ_\6B??#W0Z27EKQDPXU3Z$1]P3O)R.X<,,J
M/_.Y_5$5G"UZMUV7%6:8_"2B_2W7R5@*3$NFK_5;'E,\U;QEO,:9-'KF$WG"
M#9@.+GTBO.4"/@9-LM7$7?S,(NK)_6C0>(0\!YVQMD3F*B^ [_SN-91!$'B)
M%U(7(1] JB[^]6-(6@OX?%S@87FC.L7);?KKAQ^-6HQ2/RZ[MW?+_$Q)F/-0
MFNSD 76LCCLNNW[A^/ABLJH@55^G;^?D:VH#,G&\8;K,")/<D2Z'60A PJDW
M&>=F[1O2'+E&IAIR^\X7T^8E!BRK/W&DQ\2TEE)A)C*S3#:.WD95FP)[!>LK
MDZ1M)<X_\-Y1&^K[A8MVG0W?=P!NQ+0.4> RMXP6(=QV_E='#KC5+31@8GE1
M0-UXFH+$OHMJ)@+?5<W;(CTYWR[KLF4JDV)!4CG0=1#$'0-AW#3%CF,F<NO&
MG,5"DZ 8Z,?;T7, [<IK2-?A-_?9$-[9 2 IC-%6&-HE+"4D[%7])%$KQQ@?
M;^8;!=$:<?ZB9=;[@BU:S>2&EV$K^TPK=U9<+*WRXM#44GL+S011$<X:VJ1=
M:(;W']SIT!Z5*!-K&:"4H^@LHGS#'^^=4%?Q^EV\J\7!&;8WYL/;E$#TN78*
MT2&VF%WVMNP-UMOFYL81C7>J0)2?5"21$DCW]IT>G46.DR CAP %BG#3F^<[
M3P&.].^JB,YX#[']\DQLK+U;:O'5+2;M;AX^W?-OUN!-Q?$7'7_/=OO+XL-R
M\1:SZ*$P<4\@M]3CSY^E^W-O3F_E+HD'_"KHY97CKCC9U*QV;UU%-,,F;.)[
MN/7&\_7:M4UFGTVF-"BIR*+75@S,WQJ8RVN:&HYK^A0COA/QI"CXJRAW4]S7
M]"67J^N_[5-8DDX!=M5:'T4$?R[M7,V/C3BJ];YQ?^@N8;:S@185#E,LLIMT
M$?!JB"JIB6\2H'H6=[GBJ3)@,<V:-\\N -"Z^'0R)]EFOW)&J2\594BH&N]S
M:Y#7X9UZZMU2VE)RC)&8,D.7,/:#; VTPF"RL#NCERQ_OI0,C1HZ*?'+Z>>4
M\_MINUS@.32EW_KVX+WI0 D^!>"2-<9BYOB-X6$*IZ4+N^$>M+W Q;Q#OH=Y
MWXEY@V?XUV_R4/M>'UJ\A0^_LT'V+=B)(C:4V%(P%41LM>A./[9F,'E,Y=HF
M?_W::L@A ,M'^V06&M,ER^!0%N_ 8-)KQ3K#+<3('\32:'EKT:KW4FN/>^;7
MM2QZQK-"Q_H,VNP7&#T60N525D-E%MA,?B+;Q@Y$%L7NWO8!,I:\R?Y@T$MQ
M+BTMWE%1G135)(EVTG\V#I+#(%CPMOKC_B,-03N)OI1N<P(CQWELG^CFHF*C
M4ZV?:,Q#$7YGF[*X)[.J)6JI>(@6PGL5&J,Z[D$CLD_0?M1^(%AO]RI2_7K<
M#G^R>R+OYEU8O+>1X&+F5&,'+ZU'[UDA=AF/ZO;GJ6[42- S!S\-%D+M_:RL
MJ@OQ< J^:<K(#IQ,2]AG9J+XO3RYI;7HB+J ]^Z@+\)_,+8S3$E,KPY<H9<9
MV4^0=+-LXP>+ *Q:-N:QX*WF+T3Y^NJ(#K(([E5JEAF$5A.FZ%0H8"BF]".W
MYMO$TT@CUXCO>[W"OWJ8MZJ?4 6H$ACQYWK,)SP'%%9-1I!S*B;:7K0Z@U!#
M/P6TR:Q3O>2UY=I/;?'W%]]O:Y7X]RC0(<6+W>6B86XR8J^ZM16-QN@*F>(W
M6'8(3;4F-ZQ5+1Z$)MVFX/\B?[1Q\SRP/8.K!@L/VH^ZV+N<-/2X.KR/->T]
MOX#=-:VK && +< /:/@_G(;R__:#RV)H8Q<+#S6V#('AUOO^UBO97FRYXV;_
MZR@M62KW=ZT'Q0HL83;H4H8.C5%+@FRFI0MW:;7B=,U9N6 DJGD7<"5>VX:H
MBK5!=4(HH"'M1_KWD"T55C(1 VS]:@(/&@-V(U=YQBA^<=ANRY1-S4(YS7 N
M@98_8,)+\B.SVDW5X]ISXTWQ7WP]ZT.^J4)DU#FY:S)H3?!F!/6S")44D8]/
MU<5RZ>,?[/@LQ2]I3UHUC)58/6C5O)?YL=EKM3]:4X"=30UDI.B"A6!L(SQ0
M060VW/T?TMN<K9->1WL.-4:5<UJ%0X[L6L\?O(SI?XY.8^W]=>69Q0U29I,[
M)I,)[VCA1(4^"FY2S758TF_ R84(U]<TC@U+D:-QQ[Q\_7O%R4DOLN*9&Z[:
M(HBJ^.$<F")>NP!ZLC%!-E>:%[0KR:].&MFP9^]T[5E^7+1F\HWW3K1\&W.;
M QQY9>$*2/N+/9Q5F@9\P6SSL-M)\<GHP27/FP^_Q,I4XVL?1(.Z%)/=W(]"
M3#=:I&"WQ\ER1,:Q)BG_0W\>'.U(CRN-Z?/F\6I6R4<"$4=13*^_/1+73:+N
M;;V[.D#T)8"AC8?AD]739'Z3M1F6SSEVDS5>23/FQ.085S_WJY$_&8;5*Z5G
MV(U6Y,]+4ZQ;B)+RR#QXN>Z81<+ 2U\$BTB86EB^_1&KD;BU^1JS563PL=K2
M^]9NU[@40Q0RIH-F=ANH^]Z\,?/96&>&6OK%&%^9OFKGI\_BI8-29-4,?Y91
M &R_TD(AP:B7,>SV1@KJD0=^CMJ32OQ=<'>A[!\;1S.OC0Q'5+@D^2S,BH8X
MU?B'?MZHK<R0OX=JEYCVM<!2=>WC2G:_3-%$W3KD+"B1<$'8F/6N&C'X)+_>
MENA[[Y[ LS*TTZUYDXX,F4E $['?I.<,'6<_6S;Z@0=&=[:W/2^)#:=H+#9
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MMDHX4<0 W8J 9U]HX1_ [JUD34N@6C:;/G[WY/AO,&+%\326^D\!4=,D&"]
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MF$=('ESD:5/'IM1N.YX[(1RU3 08,95?2+<.\BC_X82VLJLMI[];'#GK"3^
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M WJU,@<GLHQ)FPY670$UZ'N')*]<;A? !RNV#R@76H'>_(>XXRY_+(0)FG^
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M]DUXG6<?3+:(Z7,N/CRNYUQA6 EL:Q,0M;)XSW(KA4JB/T@'+17!:=/;P'K
MPS<5HH/5?W5BBHBZ]U2^<[KK MC;Z?"Y#'IY](UU79=YFT^$1&.;C:"&ZT(D
M_N9EFH>F]RL;UP6&!E92U7JNQQ<&%][N+:$,^&S+'.N\])5%U =(6IM,B,6]
MN>0)CP>'JEISO/YVGG&(X'%-Z?]Y;O4RWW:>XEG@^.,&B5D4Z,AY:E,G1I67
M'FW#/+^X,K]LX\[Z-_KC WP)XW'\NF/'(S(R:9\=O@TOVJ"8H@MEHNC9^@;1
MB?8S)F\CI7"  (QA8WPA>/:\5WM()K! P4+@26._\ZY-LW5.&;33!J]U TA2
M?8=]$F ZL?8\N,M\>P4&[V30C72(9)5-S?_HF/94,)O,IZ/@Z#ONS\N)7W56
MZZA,X+1=C&.&2IWJJT2!P_,ZSEVK>Q6/%ZAI;IEX;5<T7[6J,JNE9<_,)F+!
MBN@T]TG7"5"  F..6SW#(Z%;+R9E0F!G9-\P=+3VYN$]ZDC:\G\=B&[O6A3_
MJ:#0P/_VT7@>)-B#"0O]_ R9!![)_;R">/]C0+0F$B;U;YQ25=[I5:>#6O1F
M7Q<Y54&M)+GT\J\/[$?DOM6,J*9J\T+I[QN_!(R=B25G1'[)7$/\B?9#,;B]
MWE>F/4XLVC>W=\_(["@;=?.&IND.\:;>#7.T96I_$%BT**.[6>!!U,07H&VX
MD.J!-5!GK)YM<V<PUY<MZH[';V]I_W36(9-)&1RM>!(T%T&D)\C.2OQ><I/O
M/%)'FQMG\'5,EN%0\S> EF(4K'%'OB_(J;HCT+'JD^G62EN:3GAQ",<Z=0.%
M92:$G9AL'5EB)]3:+,=<,CS6-M;VK+XN^3]^F3X*W9[M".6_(L61_T<VW#XV
MS&%B4(OUG1@,:I/VS86 GFS=U[8+U>9K?*1HI[VQY_M\[T]B=?\3__464(<X
MX.9_J-J5W0! >_S^[:PW -<,^E61^Q9^+^LPFQCO,0!DUWPE,]X/2&NCGW.D
M''J%##">\G!:XZIT\I F<V3PTI"WZ%\5^8K3B?8/9]C_Y##5TJD'D>30MG!T
M-_NJDDM'46?V_^M&(H65^B!QS4^D[E-CZ\@ZJON=R%%K[8HQ?\3/LDP1XJ)$
M**07G AW>Q(FA&.MPS:0+>WRL.*[1M]G.VUUUWK6@[<^ RVHOR _OCW3V'1H
MG>JII>9=HC:!Q.!#GJ%P:@6@#=*:O <& GT2DL7L!C]/@._AS\,"%X7&98+?
MMJK?OA8@-@ULV,2$6/'$.A1".4\7KT.!KU!I@;_UP X/P:T/HD,*H5(9:C,?
M-@SFA_^QD'P*W,I8'2J&&?LJ%NL\FVYLNC32V>KV!8YL#GRF>5&Q*?JLJ5YI
M.V4L3YW0._.3"*'O$[L!D.X1NAG EGLR@3Q\;O(,J^'I71*+,XSG.ZZ92M_+
M@F$[?6.LZ&]_YQ(EV5ZW3/K%N>3O'/WU([P!QP<HS.\\=R:CHV07+FK("Q&^
MX%@C&O3P<'7 $;C>2[T?EZ\6)]U'N (#WH_)LB(R("*ZX7Z73KK&[P:XYU#$
M]-[LS+X;0$RW(.Y[_%'M+S/Y8(M$FCV3!F@5<]&[=%\TX\KXBR.!9*3O2WJ^
M&13H27#/*@-N)RGDW;I8J%COJA#L4Y9$=Y-+^R?CZ+)6X)?+:-/+=>1=ET4#
M_I86@R7-'N4=M.FEAJ?=I'SK9#C\57JMT!92Z"DUWZ=U\\8\P_C;19]>96%D
M='BQ:PL[_U.<QH91$\.Q$*+.KS&!7GP\KW'SM%"^_@LH>%7,2$!:ZK]VV^\9
M#G.WD.C-Y,-S/!/DXRKMC]\'*L"+ACNN<YS6,/#Z >A*V^I%H+$2PE)Q848B
MU>&USZ@FP_)F1,3?-*G%FHVE578NX[RB&"RU6)<1-77F5)VD$Z!49B70CK%)
MXSRNAT]A*N7Q#2".MQ6!3J8D0MYV3\*ID'I5%OU>L^_?SYJ ;E^@"^2T_/A<
M$^KI]NXV-7"H)IS=HR"(X\DS-W)N '<&.XQ+-KKL\5+U^3> /F6DNLLJ8QFL
MY2*0B6J!(TR/)C'WH<#6K8IT@B8QMC)$<BJ,VVK_FC%1XT>MOU@PK:$'\F)I
MH" @S5*/2B'"4V61@R.G0B !\!MX UB<Z_E+^SV:R[J-\_:GK@KJ_HO0\J)[
MTZ^L'$B'%7)"ZL:2Y5=(UB/>?K"B2%1W"X_MIL67$-7.3/,/^A/L#8O=%D/[
M9T:RV()NFV[>[S9L6\<]RG5T&;[4N9"&5F#?UQ4"L=.X*UAT\D=/I+PW:T&E
M@<^86'6<)W,H$HH6L:\HIY"PS/R_55OR\9QL\BXJ/IOH)@>AF"[5J? L^>G_
MI?5J!S\V=OKLD,:A6>2:!_3AD"4R@/*F4>X?B:'8)UP&Q/12MS"VKS,M5?X6
MH<"7LS:&NFG2I;43\!;),@2@4_,8\I^OV6+#X4*=3=A8MSSN2>&$WQH3-'OO
MI,P1A6J'FV7KSF=)2IJ;E=HWPL99G@JK4 B>V3#> .SOSI6G25'51V[ U-_\
ML/LZPX= N+Y=71I-[U$%,=5K-C7I^E2XT2A*]TL_T0\'T<=,O&Q%+)87E>ZG
MR=U:T^V>.!% =3"[#+M*($L$J^<%1"K(?#\]; J;"[\CT!8U#\T(;!#ZY'8[
ME_/)+P0EOWU3;+R=%-<#*M%O#.2'#MFG74""*=X8T6!!3'R-^_-1RA_XE(91
MIY+8W,<V9_W:_OC'/I,NY\P'VT)37@Y(3AJ]Q(;-1W4N)-N%SM*^NEOS7#:8
M[M)\&62B.#>K_%;&TEG%, Q_GJZK9HR.>'%,.IO"JV$3-JM.4\>RA9@3GI7@
M:TFX/OVC.W4L)7$(_JDNF,FDG=3HDAYS/X*"[]T!_:+OQJ>*VI%R"V@UAR1_
ME_[C+86INHYEI5%7%Q&!\QO QV.T[7JN2024EZ!%C,1!>E95<<FQDG[T3*;0
MI9>?%G>,ICT%6T+5UDM*1P5,2\\<^FI-MM^DR!Z8R(7/H_JMN8A"6-Y;\R#S
MEW-L:D)-,[60!QEO>5TB[2A&^QQK8X<%18^YD[._\&PJ'JGC,$MOVIH+^JD\
MOUJ-V E=S@90V4H*6$T^EQRUO[5.<T2?#5\W6&3KL6'TSY&0U4-V?=HQ; U>
MD=OG!/=GNTO?1P]Y3A;' ]9S?:/H'HU!(<DW ,>3>] )>1@OL/N'*GWY_M_<
MJ;7],)X9>9%-9$LJNPRP])'"MK$XM=)_+MSV'6L?>9L1<:K"6!25.P\_8I)'
MBGI!#^P6R!;W&_;"[5X)(VL"=3PK]5M'#D=JD7426&$$E;S48KI-U!+6N<IE
MO4X43/$MZ&.KXM0*-+ZPO8TQHK\X\3 IBP]7)S*TJ3H'=+JP"GG4.7D$&6^H
M%$*>W.6Q=T4T/_]W(/? 21//)CB^>F_59*Q\(\-;>]>%88R@,2-8^-9/-1XU
MT3G_S3HHQ-0U*6T!+++'7>^P7#U:*E._$2.<;GK]Z"I;389XE"7_G6'W;\T0
MEE+^38!B')Q]'0&'I?;7F@<]DS@M>R4('M51?_@3$,06&>YQ0DDLT&-VSPZK
M*]E/WY_CM(KY3)<5Z"^/CX];8>6S&@4L[\HX#-)':8>&?[-AD).*#^.U<D'_
MB3G^/A8<R*J;SV&;1;? GZ%(DCJ->Q>A'DG>;?&!\!P_FXFU4KNF:E$9] /;
M&*.:H<BGE7N^*YHA^R]4EI[S4+QT$3DE'Y\$;'='$%EPXYL;R=%2=1#PH01<
M FB88]2IKWQZ>JPN\_*6.:B=1\\R^G8!)=70_&-!THG=X@2R_Z]O$%CPL4<0
MW-KF^VA\^BLB"C=4)W\ EGK)FN;:]*P)R"0F.Q2W=F5K[_ME,,4!X)U."&79
MVR+^S?*'@"BKK.2F3/2?3'1Q3A9).C9,60](X3HQ8#S71D-TR%M"<?_O.LFE
MUR#;BSYMT\_#GM_&%1V4CJRT%)0FV6>59@SOVKW3!O!$O*GYGI-4OOPN4VN^
M?Z&+_F;A_P%02P,$%     @ QH&H6M*^R<OA_@  M"P* !4   !L<W1A+3(P
M,C4P,S,Q7VQA8BYX;6S4O6ESXSBR*/K]_ J\/A'O=D<8TUS !7W/.3=<6Y^Z
MK[:H<L_<B8X;"JPV9V3)0U+N\OSZ!Y"41&T4 (&T)V*FRY9)Y )E(C.1RW_\
MK^_W<_ HRJI8+O[SA_!/P0] +-B2%XO;__SAMYMW,/_A?_W7O_W;?_P_$/Z?
M5U\_@#=+MKH7BQJ\+@6I!0=_%/4=J.\$^,NR_'OQ2,"7.:GELKR'\+^:UUXO
M'Y[*XO:N!E$0)>O'UG\M?PDY3[((84ACD4$4IQ(2SA", R9E+!E!F%S=_A+F
MF$N:IC 1,H!(D@#F,<,PRE,B4$!"$@?-HO-B\?=?]'\HJ010Y"VJYM?__.&N
MKA]^^?GG/_[XXT_?:3G_T[*\_3D*@OCG]=,_=(]_/WC^C[AY.L08_]S\=?-H
M51Q[4"T;_OQ_/G[XQN[$/8'%HJK)@FD 5?%+U7SX8<E(W7#]+%[@Y!/Z-[A^
M#.J/8!C!./S3]XK_\%__!D#+CG(Y%U^%!/K?W[Z^/PD2_ZR?^'DA;O7>?A%E
ML>3?:E+6'P@5<X5]LUK]]"#^\X>JN'^8B_5G=Z60QY>=E^7.JAI+K+$,4XWE
MOY\"]O,%Z'O"MS[$U0-R#;F??.$XQ--/WM"]41I"C(]P#\S%*+=?J+<+/M5W
M=P/J8M3'Q]C7UV)9D_D$7XLMF![*<_W!!_53!T8O-*!,&SB=ZNZA*K[78L%%
MJRUWE@8%_\\?U$^S505O"7F8O2;S0IULBX*\*Y4VORLJ<4.^OUJ2DG\4]U24
MLT1F><8S 0,9"XBB,(!41@0*AB*6JP,NR+)9O?F2S\0"_O9MC4\#U!+B#Q:T
MUR=DN!35<E6R]O136.B3OT7LO[;P_^/G+8X^.#6?GOZY(^E@ QLHX*"!#GYO
MX?_?DWQ9LAU(<WW:+\M]6I?,GM:M.%6*V(9022K:4-LMIJB.T,]B7E?K3Z#^
MI)$I<W@_'VST=;FFBI3L#,^[)WYF2V7X/-1PA_VR7-X[DE\O';\C[48HM'X
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MPCD/:N13O]\75@.U[!)OP*IA>?3+ #O!M*?=6!C-R1HZU-0JO0--_;:530,
MDPBI.:%K:;5XP_Y(:$XI7=;97918%%L>>77LV$TSB;9?%MR!/MNZQ8CN\P?A
MA21;6K/.U%H=@0,T.1V Q]:;[/@;(*9_^ T]YN9LKYW\KJ5C@GF62RIAA(2
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M&3R+4!;':1Q#FA)E#<620B(R F/&HP#G"96$V4R5&8!EI5CMY\KLYL?K8@-
MZKHLZ*IM#U0O];QQ4A-P<R=*\B#4EK"FNPW[DZY7N%=BW"3XZJ(2I=<MNT4.
M\-A,-7KBG)V>,RPJN +7>ZS\0OQ.LC&@WE?[Q@%(TS9G/$_R0>M%@U<<&BO>
M"':W6,Z7MT\W)5E44I37MZ5H(IZ&KKSI,N-]D[? P1HZV("WCFX8L\6B?Z!G
M]KAU$!QDDZ?^@1:$#G80-%EGNAZ"%E3M=!&T><_M?/\+T3<4=>?;2TJQ"'$
MPUP@B CEZD1GB?HUIY$,)8^(54NLG=5'=HXZ6)9G[R[]*0XR*D@ TRS!$$6!
MA#D-&.0R9CGA(L](.'L4)5V.SH$^E$EY8&9Q.--EIYD[,"/$=XX2X,E,V%U[
M4L/@*%G[IL#QA^P4"!?%;.W<*H_D3E]S?B+W8B91++(PHY#&$5<RQ#'$6#D)
M<8)0GJ6$)+G1.,Y3 ,:.L70@P1HFT$#-!.HD3X9ER@>E=F)E2:2Q<)VC9*!L
M1KW:BI;Z82M1)Q><1*C.D;.6J[//N8PHT^E7=%D2[?SWT@B^ZNM_G:S_F<Z+
MV\: JSZ2[\7]ZGXS^OUC,1?*'5V(=>^#+Z+LTOQG*<*IB*($QEFJQ!,'$:0Y
MXLII3T.*HUP*:=[F?"0D1Q;Q+\M:P2O('-RO<=BT7+$9UC72#AEX2R^ [[:Q
M@A["NV4#+<Y-L4\/ZRO0X0TVB(,-YNND-/64#F1WV+^ K;.9R/;\6^@XN^TY
MM])RV-NX/!X>"S<2[ D'R(W+O=U1<R/#<G..>UVL7\])516R$/S5T^OEHG&]
M5V3^D=3-J:\S\)IP^XWX7K]2+/S[#"G'.<=9!K79JR?913#/XA#2A*5)E,<H
MS#(;7_H29":\E^RA";9XZJSB'J9@C6J3_VOGK5ZT*6;.[52LMCM#'3C;W2T"
MC1UHT//H0?O@DB>'^R)4)O7/?3!MWYWWLJ9CPUB=P7RCWFT:$4N6)7$4"Y@$
M"5)Z+TCU1#\!242XQ$%,,.=6?6'[JX^LPQI80 .S:LM\G!%F:L:9/#N]84Z9
M?4O68Q3XZKRZL_:T#5:/D7701_7H0ZZW[.6#-G[$;HW>.N&0!U$J @QS)'7.
M4Z0D*I1Z/%F<9RS#24JL+(E!:".+V08VX+J"U'7NSC##S,3/&QML7>$U!_9J
M:$<(<AN1Z.UN? C6Q+?C!F0?WH^;O.3J2.CK]AOR_;^;ENU/;=H;B:(H)!S!
M*,UTI)R%$,=Y")$4+" RRZG =A["$2@CRW.7]J&[-'50W3(*CW/(U%R_D&Y;
M.WQ-\I4QS0[&]0!-WJSF8S F-H<'R#RT<X<>'JEDO3I5M]=5Y[W]+DI65*(Z
M4:"W_ON7LF"Z+CVD/.!,S]_3;2U1HHYR@2#-8Q3E&<EI8-4N8UKT1]8EF^KA
M-=")"M'];K&9SGJY&V=YDVA04EZ=J2D_V/=JL'!\_11H2)NP8GR4+9FJ+-PO
M\B^K]GN4C;$N\!X'BY?6B64S#NRK4LOOEJ5^:1:G:9;DB,* I@PBD2CG-, 9
MC$(:90$-$296=>+3HC]18MK9SL<O82<]G5[/MC_^3R\_#5$V=*D?5]JCU'<E
M[?<!_*YI!1VQ/NN GF677GR?DZ/(OZP#;92-F:YCR2 6C@.ERJ6R_^NG+TI^
MZ^M%@T,S4OV3J&<RXR@.4@2Q) 0BF>60H"" 41R1+$HB%@16]PY#P,;.3>I
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M\9Q'_VX?AWO[C_KI^H^25]?\;^\6UA7H)UX?^]O?YC8U:2+J4.!_6W73@J[
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MZ<M[H$'/E]6J%*#!H$U:[]_9*F16%HF!0RP95I\>N6&G*6T8X;6!C@&U3JF
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M/$H22 CBB&=AGL9VH\T\(3:R9NVCV2M1 6M$VWF9/52UV;%&5C>X:!OY7.
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MS$ P(]&7SS\,;%H/WXCP W_>["T_$<->H& S CG*&**40$ZC&*(@X1 3*6!
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M"4=AQF-15"GA407Q'4V(>K8T-0LPI]$(*C,?TC4 ,#VEJ0<=>=UY<9^!H./
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M3EE&TP()P8@:1Z&&("<YBDE4Q")5XVI XRA&*7HVL Y[48%'$X\!9J8TG,(
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M":BS\SA)W_&(KI-CL!3!8/S-43S2U)_R Y#3>*3N6^EG3(6YU+ZCDA/[8G
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M\8C23R6,IDAE3.6"E-+4-,K/AA#UO.>V7%P%CWT^=(4I[3@!^'2F4!JXL1X
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M=D#!XN[EX6']?K52%\K7CVOC:Y:]MWS?J#P\K'268"!)2OVW?&H.,CH>U4!
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M\"KV#+_[]ZWG'K*X*&%,EZJ3.0[CYU,.D.E=R=A"OJ]+MO0#R< OS[_VG"#
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M9 QQ440(5U0UI,$Y2D52B2(66)2@(-,Y0IZW\(:L<OY;>\8Z2>PL5&;[V04
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MG!AN<(Q*,Q5LN ND<MO"WS$8=!QN%'\32!Z[)-./KP8]X+IQXD]@=_,XR:>
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M.LPN=*6N:3H/5J4&; &M2&^VL3-! ;9/&Q2N=_=U_NWI]E2#$NSME(:?-K%
M33I%\:@R+:Y)6;YFS16]ZA<A?Q)_*_.5>+?\HYAG- L](3C*0AHB3*1%2M(@
M15D61%'JQQ[F6AVB861'ME!U#M*&%T<EB#FLR\W,>2[S9:E6\3\42PZ7/$&T
M6!M>'5LV!FA V[;%2O'@7.]CU;#AU'PX[\9""F+_QD#,T!Y:0@YH(Z$ ]-M,
M[=$FM*%0"?=M*OAMPQY1Y2,I\O^IOS)[78KE%O=.?FLV7Z?/V?N\( 7+R6);
MQ7M7"9YY<BN:)@QQ5=<34^RBA 0<$2^)LC".XM@';46M<#6V#]GA<>;L-]-N
MFBCN^%3II%M.G1VKQ@G\=J9-;U<[^60 +?]$\P#O$V03-UMM@:SP-&T7()LP
M'C7]L3HXO!?O0\FORG*73G?U^%CGVET]K72[[_8,,?:Y\/8VWC8_4+^?;I_D
M_7;)HM P2[/IE=NI3C+KY,LZ)_"P5E=>4VBC_KA]XT[6$5=#N&X/7)W'X>IX
M\\_5Z]4?TLFZXK]ONJEKJN&)5T=6O_:>7!WYJSI=[S1/_L_).ZQ\%XH*4[JS
M4EIL6#L@E)%2G1IO,F7J$::K1'V/&6XGMML6=61^4'E)%6E1UO"+-)%W0DZW
M:FD7IM@E&4-AQ@C"0<00R3!'$7%I& 4TR3)0420H R/KZ%'-7=ZRX)1JG9 [
MN6Z41[%<.3\]-ZR=3VZV [VF]S\BH,8A'L7*B<)Y&W8<Q<_,:3FRZ-$;8F'+
M>8>2G]9/-P3GR"4W'<>&Q=HD[[S.W5#X 28><DD:(YQZ J4A4Q?G?!R3E&*F
MSKGT>VV>H0.R/Z9=-P\T!YXE. 16EF$OBSE#49)BE8F$48*9BUB6NDG *251
M".PF?3E<1OU=VDW?KAAZ;93A*:U#B)D87R,4+K2Q6YIC6=$CH48QECLJ;V@3
MCT3M-WW'CYM9N$]BI;HMWI7+EYP+_LOKKY7@MT4;T"@>K]@J?VF2>-.(>'&4
M8>1BDB"<^!%*/>67B<CC+. NY3'$Z.F3'MD.JN,TIKJ KE7)WKQPL@T+#MGR
M --L *QZRCX.6##]5SC5W5(W7*AJQS_]VH#VL[/EQ;D:1@UL&.  6+(5 ,*3
MF@\X((<6Q6 $>-2DWIO_6O!R\?K8B<CHAS#/#C#R[DR2%))FG0D";.;6+_=P
M#,6*R##=KDDZ)V6V&J8<%,THGG)^U,FB*H."=6,KPP\;),7\C91U0XN#7='-
M=[D5RBMQ5^9LK[Q_2H7K>QBC-)6+.DYX@BCU4B1(%!%!0^FRZZ?& (F/'5EI
MN3D1!MAPY-0L 5(]H/#VJ_G8H,&T?\/($%S.5\6.T_*C>2QMA!X@769$%,V2
M9FRC"4N>,82C-X4&.N9TB32&TNZETYB.<6E,Z3!YYT->B-N5>*KF- EC$;$
M,4X"A%GH(QIQC+PP2T-7FNJ(P%)FAFF.G1#3DTCF?%5<.#4;T%07#3"AT10K
M$!E'5@S1N2#0,BBO]:#+>8IO%( 9A.!\,&;X59B9X"*?7\DUAZMUY_V"/,X3
ME[+(#4+$4Q5L#L(4)0GF"!,>)"$)0H]I&8.CD<?. -G0<A0Q/;T^EKY?>R^2
M";A#TA-'6Q'/LMZS Y+O-)HF?]@IV/%(DZC160$VRG+^ ;A*-*41OXC'^E9E
ML?I$GL0\2S.2L( A'JH[SCB0>QDW92AB=1L.QCRN59G_'(&Q<S1JDLZ.IJ.(
MZBO*24R&]>5226%J Q02I#Y]DAAIT<D!)U.F/G&Z.M7[G$&$CO]>%R*]$\M/
M8JDZ;;TO=FV7=*-T?8.,O=!L\W[:(KSH[N:S\TG^M]>F[_URN2J6*T :8C\R
M&G$\6Z  5RH8'I;[5&D+;A;IZQUYNFB?CH![$3^M%PP[R];-$IZ?2\'R>FJ_
MJ'UL=7_UY5X_35%[L)&5N;EUV67 :3AP?I(\5,"\IV%H]':'5E&!:?,0(!93
M'<'2VNK%.4AOVNZ8NN(?]:O4?M'P'.U$CWO(*=IES>@-E+G3H994*F%FU[T6
M>))V0G*-]?=RH8$K;WV*=K)%K\7C,U#S>LW#L[=J*:\AU-'!V8_3FKWM)OM;
MW4KVJJC+?;&5JK2A?M6Y^KZ]_7%;K,J\J'+6?(=9D,0I]ET4"^(A[(4Q2C+B
MHD@(C$E ,/?]29JP7RK)Z.'CMOU&PV!]=T^T+"HG5S7S[78 VS(W:1_VB[\.
MFL[(GV&2@4[.Y;W53WU%;CI?D=_JKTA'2)/ORW1-U&W-U5NW2[]8CC]'8W1;
MTV6M!;HUALR6U.W2?%L\2UH?5)5FO]UR$<_G?BH2%/$@0#A(&*(N\9''O83Q
M* Y= >HSTT-KY&6I)N7XL.6E#QJ]!<"2P# 3W>WMTM"=.:W\(VQ!-42T9-GZ
M*$UJ>S1$/K0..J]<J+\?!5&=T^M;E=M?_F<N2E5__?7=\HGDQ9R'U \(H<CS
M:(:PFP2(B)BAV$LS-Q,^(1S470%$?;(][,SILM/M=N1L67*^-DP!\QA@< .M
MA&T03>U&!R7EG'VZ^FT8+7/# 9':MBG1HOTVQ@4"RUES QH$'NOZ(MCR192O
MG[.;LE1^C[K9MU@JDA\TTWITAQGO>[^AKL)>DOZR$,MUM7C=EEC=V^;L.+.<
M[@/%P2B"I$5@LG 21-QN; GTGMFJ^LNZDB-55:=IR=R+>9RQ.$ "JZ2>% <H
M33R!?$Y)3$7DIP&!K)TG:(R\0FXH.GQ'$K;\G<)%;Y&[4%J82F\%?:<A*'CE
MZA'%TOITBL*DJU"/B(=K3=^C%QR3WE;56O!W:]5._DZ4^9+7:]<G\4?]237'
M;NQB0BF*O-!#."12'7WL(S\+ QIE44:##'R>.D1U9 55%_?J3F&"5TUSXUR2
M)7+*ZD,9MGQZ4K74%:<&QZN#D *.6&T"97+,VM!W&@:<AH/9QON77#0/6+S6
M")+:YG'K(,WICUQU83AY[*K]LIGQN%XNY#^734.'3OBM;?NBB#9=\:(HI5Y*
M$Q1% 4.8IARE41J@@"0BB3,AW!#4=T67\,@FY&.^$-) %*KS[Y?E*UG [T1K
M0ZAG+\8 !F8R]CC8+_RV8V*2YH)0+"P9$FVRD]H2*!B'Y@3\OL%=S;8]5'V2
M_7Y=Q^'GC&#I[?O*:&2)JJK@HI0'!$FK02.Y0<%AJ-\\X02!L;,P=U_Y?R5/
MSW]U5N2[="V*:KUH"E@9=9\[!52_?; A/LP.;/J\-7D?+;D+903<?[Q05K,[
MCC"983<8>P3JO:5XZKWI;B+V<+UWV[#O.=-[$5><R[FJ[I:2P.+_Y<_72R[F
M01A)DQ*E*!:QD/8DIM(3"03R*.&4QQ'&>L=L_61&MBKM]8&6LFK5JV@[DKBC
MJ$,O2YP$JM^>V!,?9E5,)3>X0=$GV 7W*$X.._%MBC[1CN]4]#YMMG%XD*]]
MSKINQ/>\FF/"<1"1"(51["/L4HJ(B%2)M#CC'G,Y][1J+_12&5DUS[J_37O"
MSK^;5F*K;Z1P]E_ZJM@$'I6=!E1OSW Q3)8V"-80 N\4>A&PM"TX36/2/4"O
MF(<.?__#AL%&]DWP]4*.>_/TO%B^"G$ORI><B3,)/8MZZNIB\NH<XK'(_T?P
M)HYQ+:U1M;MV)**,>DQ5G$QCCC 3!%$1,M5NW$NB, QX!#(=HW$ZLOG9\-WF
M!-+CW,&AEJ@33YQF&/1'F Y@Z/144F8W&M).1).3>4V><[FZ*C:W;2>_/M3U
M\$>)C8P.J*VH[&A\3AO)'1ONH^COZ 1-(\:=CB%-Q&AG"\)4I"3C#,5Q["&<
M13%*L2N02X- !!X)6 ;*^^\C-K(=OBOS@N7/B^8L:8\1:'RX!S#=F+ =&*!N
M7H?J;** [["@UH*\/:0F#NP."WT<S-5XQR1#J=IT^E$7D>HMB.9-O!.OCJRA
M'8K..R$'>,J+-NU(_OK?]&_BG9*Z7S$M" S3Q7Y9K6VG!N0RS*(Z'F_"I*FS
MPNSG2)U_S&R9[#B*U57!/RT+LOO-@_RI4C68I1:W&?(L]CT>)RG*8C=$6(A4
MKIP\1HQ$<1"&;D(IAZR<0/I_@IB*40(R=!KTUN,1P9T^$F,]5=D0'4OK.I3Z
MI$N](32'J[_I,/!SF+:*[ZOGTX=\M1!S'D6^Y_,(\5"=YB;"1=2-&/)9Z'MN
M)#C#6F&:4X./;(1J&LJ9]_R?Z,^;2M#GFSP,@S%\PG*)B#!3 )4.=)YR3@RC
M4Y2CP28[.SDG1O?$Y.PSIMMEE818IW(U=Z$Q3W$2AG*-EPL^PI$($8E\C-R,
MB#CQ6,B%!]LB[Q,8?27?)57.G/_C_L5U/>>9E$WSF)E#UJMORU+%'IS0=6=N
M\Y]3J:!%]=<Z05-^E,PBWYVE\@.U3B4S[*:S,/';QQRR<CZJ*Q=.X,T<=2!>
M/_9.L-J<;7Z+9XY\6%W_E.O8XO6O]4/+[D7HAHP7^5LRR2S!^"(RT,W_P?3K
M;OC-)Q7J0=3S>=_,Y^8>9#U+-K?UI\6QMI4_&'[B[?MIX8ZW[&>>,S,LNUL<
MG[-N(/"+6,@=3!/SJT.%M'.%>M<&FP:>%R8!0325Q@>K&\LD%@DB/.1IQ"*Y
MSH/,T&7LC'VFTCE*.1')-^Y(?N$<Z-F"Z9"U>CPR2GMQ.UA8,CL7,C.ID;(#
MW*%)LS2JF0&\+=CR23R0[U>-R[%Z505#VZO$"2,N#G&&2((]=9K,$/4H1ESP
M*(EC]2>HTGP?L9&-5T/:D;2=+?%976W6,";2"YR>3;(%!\SB7(($V-3HB&C)
MD/22FM1,Z A]: 2TWC$,HFY:RK]?EO=D(78]A=X)NOI(5NV_OBP7<I3'OPM2
M/ORQ?/A6+M>/W]ZK-/>G9;E2FQ%EBN12E5=S08,L]2(789)&TC+X/B*^&R'7
MC9.49*IR609KVSD"EQ =,FKY^1^ED!:Z#0@N"^&\2JZ H=41)D<S_/JV@,.,
MEF*ITW5LYFRY1]FR1(K_F=/R+*U9>X[?)I7<2_878OMQ?=BC+BK5<CDD4U/X
M6<Y>*YNCA'.4O%6=@]((Z2@I+89WQT/?5@AX! ZG#1./!_%1*'E$4H81,U)]
MNRJX^NOFG^O\13*EG,95W8Y$LM#$47POB2FF,1(13]3^E:/$(Q@EG(:Q%V<T
M22@HC*9#=>S8FFI"JM2^[MHJ=FP 8TY: &H&HFS# HQ.;1"I?^AP,%/!NPT3
MMHL;@H2V%</2HCEM8 L"PU&T"_3RI<G(MX6JE%KO+NN4RWGB^6$0X! 1AF/I
MZ@F"$L$Y<EE >>!C(0$QRR8^)#5VZ&J3#KS,G [I-K44N//K 4S/'-B! 1AG
M,D3@@HS:<\)93XD](O1&.:WG!#Z?E'KV#7C2V?6WXO&V>*^J;7W.5 5/7CQ*
MT_%K\5*M^,T_5Z]7?Y2\^H^R6/';XJXL_UY6^OT?+B(PLFXK9PJIVDQ(_>1<
M?U.Q4]6HO5-;3E79DO9SU1;8JIJ;J4T_][LR7Y:-NR]W ')!)*7H5@*N5\Y?
MZXGJ.<VQ.!_]1F2RJ8#9ETEGP6))42MP&F7TF5.=+._O8F"ZV8&7#V;2]KJG
M:^NFL^NUJG6T$'P>N-*YP4F"@BB0[@ZE&%%/3IOT@-R,A"P-8JWJ3F#*(UO(
M7<-KN3W-1*XTZ">I<UREL$E]>Q9E<YBOV3\'CFR_21L5+Y@9&VC*/'.V[9LW
MO(P%&:3']4C0&3:XM@<AL+>U 0S]C:TA T[8U=I SOV6UB8#_%#-4UJ6E<M\
MKEN&E[E)DGD",1ZZ"+,H0#05 G$6A#BC(B!,J_WGFTLR\N)PT!GC1^^3HC'S
MFIOP/\-\ O?X4_5)Z0CY9^Z3HC]7/W:?% TY_C?T2=&?KHGZI  8&FGKTFZ@
MYWX2)Q$GL>JNX"/L9QY*@R!$49QB&M(THGYL=>?2$IYLX[*)%$RR;=F@:FG7
M8H#56)N6EI61\+*\93' ;>P=RQ!^]C<L!R!<O%_9C/=C;5<.I 3O5@[?-S"W
M]Z3(Y,._K,OB&WFZ*P5]W01DX\!+0BJW$G',I'6M#\A90E' XLC+ I[Z6+_V
MYGDZ8Y^!-82=EK+3D :8@AZ$-"RE';F!#O%)D8>CQR#9 5;/#@9F1@XX_3!+
M-BQ8K^'J>7TZ.S4LPYY9TGA\XI!)<[9R6U2KLOY^5/5MY8=OI&C=V#;ZNY;?
MD@.C>J*!LDB#*$L%1<*-,X0)C1%19_^<"$)$R ,<1[ ,SQ]#L-&30NW$V'\L
MT,:.J;S9#$\>8&D/0#NB=HL*;,,O'7FE^WGHGX[40_S'G,:WCKW8%>K/$8@9
M92*M167&X>[R$,T7H6YKY,7C];*H[V:MR>)!E$_M+J63S3#/$I%D6>JCF+D>
MPD&6H31.(A0D&>>,AJ[K"M. C3X;DX5O]AIK'YFS+<-.AV-'L6P>J #,!3S,
M,P["%P9]SJ.XB5]TIV$29,T#0N,@;"D\9 GIBX)%<( @H2/ Z&\62((CT!=6
M,AC-;'OW2:Q4.O==N7S)N>"_O/XJ5[?;XGU>D(*ICNNJ0D9]661[PST0KOJ_
MAU(W#1&F*@T[2.0_L4<S'Q/Y&:@)))R%D1>*^EY"MEC^T3:@RS:<.&3+BF8E
MP@M@UMOCC L>; U0K?MJ[#;<J,W'3XHA)R]^=K8\.3NF1BDH8(Z))>?>@(%)
M'7%S@ Z=Y@M&@N>4_[V\*7B;L7F8H7G]4O*_EX=YG+"4<M/QI\@H%P77S5V^
M5GG/\L<Z\WEE+X7<&/Y^2S85\C!;-B[HEC/&+X7/*&'<F.AD^>*7PM)-%[]X
M+#/W[/.S4"4]B\</@DB[T;:E>[U>EZ7<.-QOZMM^SEJ+2Q9WRRI7^XF;[RM1
M5#E=R+<JZ;1%*BF#9R@)(]7$)R8H]82'!/,R'+@AP3XH_] 68Z.G$[9L.@O%
M9[>QW\QA#;,SAY*%RB]UJF]"NC +U=,^E_S#7#QK4Z7G^+W%!,!,Z [[FL69
MLV5RYEQOH-\RJJSKEE5GPZOS=<>M<U/([7)9[Y8M>HNV@;3D0UIC:U+/TC:8
MA_ZF]?'-S++T=R4CJ]<[^85?J40\Z1;4;=^E^YNM%Q_R3,R9JSJP"Q>%6/5)
M#0A#-$T#Q),PH21(TX2#VF9HT!S9F#:$I'W,@,G7.G#I63W+(, ,VH;XS*G)
M-]G(&P9F3@O/ASYXP-8)(+ EPZ-#<5*; H#@T%Q 7GV;&R6='8*JQO)^6:H/
MY[X7I%& (R1X'*IT!X;2.! HS2+YE\AP)+3N_HW+YM@I8JJLZNX0NF806#9E
MI.D9.?_ &NB3YQ-L)ZN[\_VJN'=:]FW6=A@5W[<^Z.]G\L]Q<*\%M.WK$0/4
M#"LSB^=22'^R9J7@;8&LYB0Q"S%UL1^B6)EHS&F$$B_S$&>$>9Z7)H&(0&67
MS],:V>)V*=?N#>G0!I91[@%,SWQ:@@%F [M$9X[\UT)LP>AR,',^+8OG<LG7
MK!<;>#7D8:EME3KNH31M'>-AD8^*%&N\8I!!<RT_R!E9R"&_O&L+'G_8A8SF
MQ*<99=27SI@Z^G0]@JB71"ARPRCP/2]TA58%8AUB8Q]RMM3K;_:7?R5/SW]]
MYY0-%]TP&2 S8PB]?K6WC0E,[T_"T3+@?!@%#D ZBD58S)).+H8'EEVB*6]O
M#LG0&--EBFA*LY</HON.F3=S0TJ57%+=B7+C2N5L[KHN";@;HBA2]=4SPA!)
M:88(]:. 9B*E:0#Q8TY2&=FL?<BENTB<AV^B),]BO<J9W(S<%NPO#NLTN?FV
M7$BP*N10Q5*=&;^NN'%6_&DX];R<BT&"V;D-.4?2:S9R,Z<F:<^#Z97(DN]R
MFL:D7DNOF(?^2O_#QD%H)@2OWDO65',?=815MVS8=*29,R]R>>!QE&0T4?TG
M,Y0HQX4(''J,9UX8::7U:E,<6;E5@M%SRT.3FI6W7*C3HZZ"@^/3 TAJ1Z?M
MX0..37=@N>W TFT&934NK2>JO:CT +VI8])ZXI^(2&N^>&$#E?^L.TF_?L@+
M<;L23]4\Y9$(<9JA. @]%5)VI3'@3)H%YA,_2?T$FW5/.:0TLA'H- QI*3M?
M%6VG)F[:-N4(+CV-MP("3---Y3=OEG).-MN=4H[HO$V;E'/BGNV1<O8%>(KC
M%?_]87DGEBKR^;[8=G_7S6 \\_K(&BFIKINRP<[#TKF[^;QW>J!N#RY7Q7*E
M>6C<!T._4EI" *:.NL([7Q4S3LV-I;2_ 5F-LOK.C3E9TMZ 4-V<O*%'#=1/
MG10\/#U^+)YSU0<-KH#G!AA;!15=YR%_4N=M'S_=W3J[-FX M3LKOH;BV9 <
MJ'H]0H^A;D,2FBG<V5&G4[DAP?:4;O!A [5[?%S=%54A%;JZ?V'7U0J6N'_N
M_;&5;EMJ\$ZEEJF#\NUB4#GWHGS)Y1:LMU&3/A0:&F@!!: ":@-@.>%]2%0S
M33PWZ'2*."#6GAX./6LYL_%..KGL=;<B>#2D<N?H(A($J;HR+A"E;H!B+%(_
M8I2XL%Y-NH1'UND-&_O)?9;2'0\QU(XJ64<&'%SJ2WQL^'"^MG];77A-01@[
M&?*0[(^1$7D&#.VTR'/O&_1_D3[Y57UM>?%Z1W+^6U,5XZ,@RCL#^]6:PXU]
M9KZ7%->RXRA^G)?J+VWEG)8G0&L63:B&/8 14((9"@A (WCH0/G-^J1HTIBN
M*PI,Z+T>*,!7+^WH5@>X?WF]7I"J[5 6T=B/O( AEG@)PHG(4,H]AK(8AT%$
MDE!XGEE+MR-:(]N&;D>S)G&9OCHU]4O;NAVCIN<W6,("9@%J4K-6\"T4([9U
M.RN;];YNQY3>J+';69'/=W8[_XJ93G=24=J[5W.2)"%3+2V"E!&$,Y\CFN($
ML2!Q&2$Q=N-POEJNR$)/E8])@#1X2TC[J_N@7ME<"H6GP/5 HZ>OEPD,4],/
MW7NP+35[VGE>$DM*>8+ I+IX7L!#%>QY$NY4_U:MBL=WJY/7T*4;+S_>WD:'
M!=#  X^\F*IV!BJH>U!3\GP%!K4C;7N$'!1CT/?#X>@.>^2C @M3>8N86H[F
M&8-DY,##J4WFRAL#T77JS0<Q<P4.*I=]6JLQI<=1W];KW,79%K9*?$&#P%>E
MPZBK(H<NHAR[R(M]/XXYR[@/2C.%,C"R[=K6YR-M?;Y-7EK-C[.$%CTTQEG/
MZQ@3/9B!.BILV/!2[R(:[/;J=K[+%^NZE,X(%<1,0;'DWH#)3^K\F()SZ!H9
MCV-FIZZJ2JRJ.7%#W^-RFQ)[A"-,XA@EC$3(BU@0Q4GBQLR%;%.:82?9FI":
M%,QJM%+KV0*X+,#SPGX!P&JZSZ\EY6L'G52E]@4Y5)2#3\V^_M>*$U5+5,5F
MO^35/ZZE-Y>OU$_S@!&1T21#7IHPN747*4H]ZB.:>1&/L\#G$:C:0 ^MT2/T
M'<IJY5 T@2K3AY2>'EF2'QI[[XJN:,F=?4VW_<<4QW0:DEM2TSY*D^JNALB'
M"JWSBIF6O\^+?"4^Y"^J"J=</Q]5P:/&?G3OR*K&@44E/LFOP,,?8O$B/BZ+
MU;=J[OMNX*4L04)@(0U!)E#*B8]<005+I"T@.($8@LO8&=E6;!N)DKU[W:]J
M@[LL@"6.+@1>SZY,!R?,]#1\H9HQ9\>94[,VVW5LW;] 7T<2/O< #;8^=O"Q
M9* N9&92&V8'N$,S9VG4'ZUO51T?JVZ+.U'F2SXG/'93N:5 J:]J C#"4)KX
M*7(#P=,D3%V::C4[G9KQD:UKMT5J$_KX85I-'4R@YFGJ#S@MP*/9R=I%-1*I
MJ'$CTP]0\LEP%MZZ"!24[3]'62C#R9BN8],9^H8^^::W4[/TM=DU_'/Q1:C#
MYKQX5+?!JUVBER !#8.((B[21*XHKHL2Q@CR(QY@GPG/#T&50Z$,3)@ITW"T
M20F3KOAJ[VA*[F,W+-95"H [>3#RFF[XB'@"'>\M5K,C*(_!:]-PQMGYFX)B
MR]N&DI_6OS8$Y\BC-AW'\#) 8S.KA^45DR:S%&<3A^=!E,34HRGR A$@')$,
MI<2+4>8Q&B<9CS )YT5]680_ &X%:'.@I61IHV1'?&@KW)W\_3=52%[:KN?N
M50%A>%5 'V$]VV09,+/K BT/SFKIM%PX!U<(9IKW*^#W!,#RV[HIH$]XVKL"
M8$".;@O 1S"L7;&MAU&G*\J1-RT;WR_+]C99];F\7I#\J9I3$;LD36+$XD@@
MG'"LT@A"E/ HCL(TS6@"BE6"J(_M(M5;,%IOP5C'MP46MP#AJ6=?1D,)9F*Z
M!6Z:%&-E3S:L.-FRW%P_K.17T&G8L5@:PP0%6^4R0+2G+:%A LM160VC00S;
MZZA]7R=%\Y.4L\W9]3*6I!Z.I$/C2X<&XP E6!"41IR%E$1NFL(:YIPE-;(M
M:0(TBV7QB%:J)ZAQ8G,/6'JVPPX$,$/12+^7[KPC:[&)S*!HMMK"G"<T;:.7
M08&/6K<,OP'/B)8FX7%9"+G]4>FIK^_6XF'Y6[Y<U*OEY^P_ET_B>KDN5N7K
M!_+'U=-*-R$:.N[(.MRRXVSX<?A:*.]ZRY):!Q533LN5(]F:J?.VM>Z.Q C-
M?KT?&TA@K&04#$&)SJ9@&.4Y@XE-EN9L"D,WR]EX#-/LJ:>GO*EK(1T2U90Y
M+QY%P50=Y\3G@L><(IZF+L($IR@A 4,>IZ'GAQ%S4U#Y_QY:HV=/;2G7_O0>
M;>>G3ZJ,E8>!YWA]T.GY#98 @9F+7BQL)DP-RF8M8>H\I8D3I@9%/DZ8&G[%
M9II <PPD2=W6B5KYBU"QCJK)G)MC#S,:!S$*4DSDUH FB,98H## J1NK7IH)
M:&M@P,,D\8?CHV(;)_C]V%YR&&\-,?-S]>UY>>=(?=2$RPN0&/5LNY^#'^"8
M6@LBO1-GO:'@FYN'DLOOT8/<M.=%34A=W=/=P9Q\>62ST:%67S/4WWF<%G5X
M>W&QE#!5?RA)W=&LJ][:0H.V"KV"&>T'3H\XF=/?*U#7L^]_T*"ISP?Q2!;_
M(0I1UNTTKK@<.*_J[.L7T28?S@7W2)KP ,6>+]=T=8A)F!^AE+EQXOJI[S.F
MW=E'A^+(JEBS &A6HP52OSZ.(CI,/VOJ,Z>E[URIIEU['#@M"[:1 ?3RL8V0
M64.?RY&"=?2!2-W;UD=KH.EZ^T#DVFOP WK12N*9I-()OY[('9$/?%H6Y5XJ
MR8=M07R/>[[ 68J$*[BTD'+#0TCD(IY@+PJ3Q/<HJ'^ 5>[&CK\>YUFIF$"'
MX3-Y5^JI+M>;1*P/I@T+[,ZIWF[KS68*&.!]BTFZ-$_.#ICC)-%=R-M;9MC9
M@74@_<X2$<.&M-M2YW7[F.UFM.T5IXHN5T?9SYU4UXQ&H8A"C!+,!,(,$T2)
M("A@@1<EKHLC NH-=2$_?XJ UJ68ZYG;"9&T'.@:)<)E"0Y;37,OY&;:QKIV
MH#MJOFMI6)CAXR*?WQ2K?/5ZQ;G\EE;7\L?/Y</RCV+.:1+A4)4=#-T,X4AM
MW%TO1EX<AISZ?N(2K3MX/31&-E -5:<E.W,4896YIDCK&:D^?/H-CR6I8<;$
M2&!MXZ$A4D\03;[=V +YP\X$](TYB5IK"+5159U'#2M_RL&$^""='5$=UK,7
MF9NYA @DH@0C["<>(@RG*,4AQH$7DB#@$)^BA];HX3-%$UCXLP<9O97?DKS0
MF)DB.G,:LN.>5FD(:*M": ^E:4N%#HM\5#-4XY6+2W&?/,FJ,V[;.Y!7;)6_
M2*M1WQG;?9,3DH28<(R"6*HWCCV&5.5?E/E1E 9NXJ4A[/#[8I;&WCH<%?9N
MN-G/.-^P9ESDVW0^]"S+M"A;W5;,6KQG6XQ'O<=H#RG[!<A-&7JK.N47 MA3
MSOS2D0U+""[J[X_@I^EO#H-(YF$6>A'*2.0CC&.*J(\Y$M1E$7,9$P)T?UN/
M[-AG^W4)PNK,Q21'0,[5@'CJF3C[*%DV8]8.U,PDME4>48_HM.4304 <E5>$
MO6UF.KZ(%U&LA6K[?;U<R$^6S4E?YQMR\YTMUBJ]9._9HJY]^K=\]>UZ7:V6
M3Z*<LS!R<8(%XLP+$0YHW83-1ZX;$>PF@D=^.G\1)5WJ6AB+W$$4K,NCMIZU
M])M&]ZS+K4-V[,(,D<W9$8P2N==EB$?2\..$)XB&/D-1%% 1ILQ-7-"]U#>:
M&X,EXF!F&OIO-Q%ZR\8;P0M;6_:0W6/S<(EI.74.WFB8=?Z0W#H;=NTM1"-@
M:&FULLG9I$O:") >KGMCD#!;'#^)U6TAW4GQ85E5\\ 5429HC$(W]>3RYJ<H
M"7V,N,_C@/D,L\2#5.C>&QUD N&%NB4M9R').&2U*G.Z7M4;U=72^9!+;X(X
M#]]$29[%>I6S:N9(MOZR;0^@-B_?E@N)&C#NN(^>4 Y XJ4H(!A+]$B,$I'Z
MJK1SZ!*<)(R ^K*:HP=?0!1Z#3'G)T7N9^?J ,8[TGMO5P,?O57!6&J87;]8
M8+"I/BF8)6.[/_:DYO*D6(<&[_1#)GGY=1:XM)-7W_-*/R&_^];8N_7C1/5_
M@V3C[PG8KS*7R0;3EU/Y]U\524N=B$[+89ANOS?4A'GVIT383[ _^<1(97:K
M<T483Y9:/.@)<O-=E"ROQ%V9,S&/6>1Y0O459$0@+#(?I9G< ?N8A'[@1B+@
MKM5*N_9X'UG=]RNOME5WN7+JRLIY%F43M[-=@-?BU&J>8OR8$V8>)SQ7AK<:
MJ,-[MM+NS#GJHK01RZGEFK 4K_W)F*H:KT7.?X";CJ-.";@F[P@LP#VXNY?G
M@V-432?NZ,61#;L$R'FIE')GR_*IKGBVR[Z;.34O^G[=L=C#KMU%$L,LXPEA
MQSCI[97*R-<['FTR=^^L(%V/[_Q#ACE@<O^T5X2A;>8>$XIC2E'D<A])IRQ"
M:9!1E$1NFG$_"0.,0>E?)\F,G?FEHC?[A4^,^K>?P4C/T;E<<ICF&0@-S_WJ
ME<E6VM=I(M-F?/4*>I3LU?_TC];\Y/VRS$2^4AU=-OU/ AH(XJ8H]E2V _4$
M(F'JHTC=)/'42241!I6?)Q1!2Z\N+AV])?LCMD0YGE9+.[*)9^D';XRR^P[\
MJ7JCG)V+'[X]RC'G/]:&S/Z43-<DY3P+\ W9MDWY%?^]4J>.C[^1Q9?G4O4J
MOU\_/96OBOMJ53S01=.U7'?'!A]Y9 >S-14UQI4CN5I7366S[O%]T__DBWA>
MEJVUV#-,P'V? ;K#&\-Q@859<$-,Y1?Z!*[.UX9=2UM-<YR,]J(&Y";;K)I#
MT=W-7C *W#"]>^&\^EQ*VU?>E,5C=<<_%UL&/JW4[_^HOF0+IJ@_K!:*M#2,
MUR\E_WL)LU062(ULNM[E+SD7!:]KZC?^S0TI"ZE<E72(\KJLPKXJ%LM5\^ ?
M*@+]162+IA.H5+XFH7A/_539_FM5SU4^H;J#ZELX&],T;/(FGB&8#9QZ<BR;
M28O8&ME-&_0G,Z06P>I:5IO#&I8L6I8B?RS:TLVM8M* "U<PBH(P3!%V(X:(
M[V(4ADR$Q(TXXZ .JZ>(C&PY6Y+2P?CN7*U7WY8E^*[826CT=NF7"@PS1%U9
M_VM=YA7/66U![!D,'<%LU<0Y16+:TC8]0AY5J.E[UK3>POM\(3ZMZ^];0BA)
M21*C)* 1PE$0H20+7>1Y$>'<Y2$)M<HDGAI\['U74W! T7,:@M"Z"AT<^O7N
M4NF FQ]]P0SJ)QQ+<$'AA,Y@$U=,.!;CN%3"B6<,5[&\4*>7]0WN3H6H3264
M=VMQ1:LZB7J>1I$(_"1"/*'JKF :(IH*B@A/,DHCX0FNI5!PTJ.G) F53B[W
MW2:U%  (:BZ!H^ "7!@;'AI 9MO"=*\SE>A+1>VESZ0>5TSZWK6+_9&LUF5]
MXWG#G<W%$PR)K255G_"T"RT8D*/E%SZ"04'CNW+)A."5NHUQ3]1]Z$^?/]S/
M:4(Q#E*!.,8)PDGB(THH11[WB< \RX*0:)<P/DUC[&R7EFAS:ZDB3=$%25C3
M>O2ATV\F+,D,LP=;<15!YWXG[OWEX@(*$E\NMED)8@/Q836'^P7KK3)\YM7I
MZ@KW\[Y727C@40,#\T54<O5AWZX*_DZ\B,6R[NXJ]W/;!@>[#+*4I#CPW$!N
MR3/IP&1<;LXI84BD/)#F2'HWF5;W(RCAD4W1U5K9Z45.G U/=;V7#E?U_G;+
M%T!C(>AJ6*V1,(.9,CV0]"I$7H88P/"-A)R9-;SP:P:SC :2]YI+R'C3V5 #
M*?<,J\G[\!C+N_;KTOC]RNU_+W]3S2,<NDFH BQ41 B[28:H%Q!$2,P\SV=A
MXFEE4_;0&/NXJ*6ZMZ6I">M'7LZA,QR L2 S\  &+BXH'C,@D%%8YMR8DT5G
M!H3J!FF&'C6\>RYY5#?:EPOYT.-M(;_GHEJUX74A8H$3EB$_\@C"1&ZN*/6P
M:O=&:$K3E(2@2DY]Q$961DD:-84@&N+.AKHZ[KM?TRKG.2F!9Q*]X.D%9FQ!
M M/5?:H[+.P?4>C(9^O^=1^I::]C:PA]=#M;YQTS'6]N?=]+CZS.>-N&#I/(
M)7Z:,>2GB2N7V"!$B9\)%+%8^+%+"(Y +4W.T!E9L]L" ENR.L%"$$QZBFQ!
M>)@.F\@-5M\!J2QI[CDJDRKM@*B'^CKT^(75W=N_/N2%\.2G-.")3Q%)1-V=
M+4*$QBX2(1%92K$;8BU%[:4RS?GCMN!Y^X.C:#N?"\T(0C].PUZQ%>EA>FHL
MN'FU]U."75[O?6_4MZGX?DJPLS7?3SYLMH+>9)E@J\_9S7?V326.?Y%:_[FX
M)M4W]9]**WLA"W7$(??,JS)7:63J [ESWO]%Y\DY)WZ09BY&F(L4X3 1*/$R
MBCPB_!1+30\34#F'$7@<VR34'*NHMVAY=DK)M-/\7*F,/289@JWB8TR5G@?P
MQA, M$I;[#?L.HI?A;GB85;_Z718F3D[+MM'5*CNX)?[;S07^]9JB]&>AR\+
MB\WC1P3<DF,S!H>3.D4C0GSH4(U)RLSJU\G!5XR5:]'M=':]+E51LGD4>2G!
ML8\RIMI]T"Q$:>3%B*4D<R,_))$/*C773V[L?!5%'&9I!^#1,YKVA(;9OR9#
MO"7<;9(HK59#VYZ=TI/1DLD9(#:I]= 3_- 0:+YE6,.^;EVX[62XJR8R=]TL
MR%+/1;&7"833.$.I("F*W8AZG%+JNQ&D[N992B!-AM?@;.C.G$SU WVI+WWQ
M+6U@@?JS8.DIMQ4(8'J]D7[7#;53,<9B[?DAR6R5FS]+9]H*\T/B'A65'WP!
M?A?MO>1^68@O@JEK.*^W!?]$GK2:=)Y_>^Q3!TE"_Q;7&0'[=<V.;# E:^DY
M&X*JE"]7]Z_69.'TR@RZ$]4OEM$UIS-#3G9SJ5^D[F6D@2<OZ5ZWS4W>2]1\
MW:1I?A%/)"_DH)^SW5GCW O<#(<L07$6$(0QBQ#)_!#%V!4N$8S0 )2I;<[*
MR#JKTCM,.M\9H:JWCDZ#%<P&;/KF'22ZG\WKWK*G8@Z=% ';W?4N0<EJ\STC
M1MZ@-]\E@)UNW7?1B(9;]3V2!V43&X*;#Q]$^>3- QX30:,$I226WKZ$#U$2
M2NL6^''H$9]'(:A8&Y2!D8W8M@PJ:<N@EAL6G(7BP9%C/M5WFI=;_5TT'3!5
M>:97.2/0ZDS@*= ,$(P(+#!D<&CICFK-;MEIGG 40Q;#"(9(V HL0,E/&VHP
M!.<H^& ZCGGF8U,]Z*;@[\A*S,.$NK[OQR@.?1=A)@1*8TS5 5&2>:E+,?6@
M>8][%$:V/-LTP(:H<Z/R>259>,[C/B[#9[L72PLS!V!!C;(=3PIS4:[C_HB3
M9SJ>%.A4GN/I!PT+0FX3_)H;(G6KS+JY@\=8P%V2(1[&*H@?I2B)I%O TP1[
MKOQ?1D#;FK.41E:[S?VAID7O0%,(($9Z"[45R6$J"!(:7E!P2"!;Y?_.TIFV
M6-^0N$>E]09?@,?XZM(\#T^/'XOG_+JH>,G?+\BC;HSO]-LC:UY-U'G(GY3?
M]_'3W:TZ]I; J$I!^K&_,X(/Q_XNEQD88.\1U_FJ:%NJB-0OF%'T[\R0DT7_
M^D7J1O\&GAPQ^O=N+>:9ZP6"1QY*O$ANCFD@4,)"#T4B87X8>9R[+N0H3)?P
MR"=C356O9O_[W%(=(=*G$+08UP/B,F84;^)874?R*2-SBNR/%X?K@&$4=>N^
M_Z-55?^T+%Y$)??9;7FA-/7D3I<3Q&GBRSVPK^[^"1>Y-"%AE@4N2=C\N=X?
MW*](N=)TS:?B'Z*NAU)H:^XOXC$OZE@3)8NZKLH/6%?]<&(QEQLLEPN417&(
M<$15<VA5LH.D8>KCD+DB:"=6;OS^]-.ZD4%[4N4+?[(9U=P;_HAS!-QK3E8E
M?RO2S%H]LS>;AQ^^0OXAW_]+ZN.?F8[IJN.?8V!BUZ/EYN;[<]ZFGV\[?*1A
MD,91D**(\@SAS \0\=P49=P5F9\)U4!ZRL8MYUG5,FH7-VC9VI^:@S?IT](S
M6R.O,Q>"_U8KROZ<-8S_4+U5AG%]ZQ6BA\,_QUHP#+$UJZ]!"A[RO6VBA[NV
MS!_R0MRNQ)-.Y^WS+X^GMRU-YT0W[LKYJAAP:@XLQ4&'132*A?8,.UD\=%BT
M;DQ4XVG#&BCBC_]2Z^6KZB%0R:_UY^R!?*^_X&TM#\Z2+(P\*G>K,44X2#@B
M:AO+DY D@HI(4%@AE"&*(Y]92/I.PP"PX,D@4GKKM%7Y8=J[$]W9$%='B!OR
M8Y1 T1765AV407K3%D/1%?^H(HKVB_!%Y_-Z5:U('6VY>GQ<W92E6@JOGE:Z
M1XUG!QA9<SMT'4FXK-U]1Y)?%F*YK@X<R2=5"%__$/(\*L,KL15 8*IL$PO0
MDCPHJ]&*?'[4R1;D0<&ZZ_'PPP:=R<7RBJW69+%X50=.0*4\_?;(&GEW\]G9
M4&TZ#5VD@V<0&%; RX6':=]E<L/:E?>*9M:S_/20TS4N[Q5IKWMY_Y.&UV!?
M2+Y0W?[>+TN5O7,OF*JTGXOJG:"KMNZ^_)><Q7*5_X_:*5:[BE@D#J/,3RCB
M@9<@S+P(J?NQR!-I% 2>)\)4J]2Z%6[&3N_9T'044>#]V8M0UG.E)\,.9AT4
M<6?'R\S9\HFR98D4IS-G']L)>S]8 <W6%=^+>)GV&K -V(ZN"EL9U,P,?B3E
M/\1*$=]1W=72CB(:$#_U4.S7:0AIAI(T<%$8>V$FQV-N""KPT4MM9#-VS[X)
MOF[297=\=#049MGZ@=.S7-;@@%FFD]([7YO>MSH%VL'61DM02]:DG]:DUD)+
M[$-KH/>206(Q__UA6?M.*J-=-Y^X^]+8?L:V:[-*N.NZTO\&R"+>DW)XSV L
M($SESLMF+6G_K#1FB<)[(TV7'WQ*@+VTX),/F*U]=Z5XEON)F^]J,L15P9NZ
M.W7ACDT-)^G0TS16!<!YH"ZCA12EC*0H$SQRN9O$;@IJ/:I!<^S=>L-!7;MN
M62??L(:N0VHN8,N@#H9ZBZ%E9(!;^1:4EGH-3EL@JRVG8[TF%D!>2RNC#L5)
MUT< !(>K).15\XNI#R4IJER9Z2_B63K?<^X'J;0$#(5>G"(<I](<8-='U(T9
M=DG@XTBK'D\?D9'U?WMK<T?7:0C#+Z@>X=.OZK:D!F[$X0(;750])]%%=U6/
M!IW\NNHYL4[=6#W[K&'26[ME^YS=U&6-_Y9S\46\B&(M?GG]2'Y?EM?2JUH^
M227XY;6AF!>/]^*QSD2H]S-S$F(>9)&'(NK)!9QS@I+8CU"6)7(A3SP>>P'H
M>NOE/$VXT6TY4TE4-6_.EKF9^MV6/V?#8+L-A-Z<M3!1>E["Q/##+,VXR,-S
MUNQA92M'S0)'T^:DV8/P* ?-XM#F'LY_KTDI;<RBI3 7:>@R%J7(<SV!L/"I
MNOA($0LHHZ%/6$+ 3<<.:$SEWVS)&KLWA^#H>S<7B&SHW&A+:^3;G)'G(M?F
M<,S)/9LS0IUR;,X]:AAX:&\D/BROV#_7>2GJS<MM?5^@_F">14GJ90E&?AJ%
M" ?J)C*G"<*>B-(H"EC(M)JJ:E,<.^C0TE?1+])PX-P^/>>+I7-_]?X&&',8
MA$\SXF 3%&"\H8-'2[R--W3(6XPUZ$IJ*](P2&_:.(.N^$=1!NT788:@DHO)
M![E/>JQ#P->JE)8<X-U2%=>:AVF0,%6!.TXQ1YBF,4J(&R*>D #'F'K4U>IU
MU$=D9'7?D54],83SM:&JN:OH1:=?M6W)#--FL+C:"JPC3Y_.RO<[^BK_M=/5
MWJ$G44\=X38:J?6L8280DVO\>J$NC=7JK4X72O%-%%7^(IHF9Q^65?5)K.KT
MVWF4$<]CG"/74RYR%E&4)B1%+(E<GB0NCWU8[@^,_MBG<#MN-L<#77Z<A60%
MF ,$Q%=O\1X1->#17@>P9@G?8\5INQ3^I+CY>>9(AMIL>XO)/&98V$K? 5*?
M-F''#)JC%!W#84Q[(+9'&+MM_XJLUM4\33F)B5 -2IF/<!RGB+H^1S&+B._C
M%)-(*Q]GB-#(-J8AO3E2Z\;":NK01HAGP!K>K=N" &8P3*4WZ(;8+]H%#1'/
M##QQ3\1^\8[;(@X\;^8^?!$KZ8,(?D-*58RF:J^!!3P-J/(-0AZICJ4T1#0-
M"5)-=%+">88S4%G-TV0F= ;>B2QG.3#_]PPX>DO\Y2+#%'-#S]D0'.$J7+],
MEE;D,T0F77C[!3U<7P>>AFGFHEJ1^7_GBW7[;<L2[B<>PX@1G"'LI02EF4<0
MBS(6Q[X;4E<KA^=@W)%U3Q'24[9#>?NUZP(I8.JD: QK4*\DO V_UIN^,23:
M(V!G:K1-PAFV&QN@/E2*';I!X-7*??CX)-I\AL>-^I[[V.#:6U$55_SWZOZ%
M75>K=OIU+[V=>'?L>+;R_-4=KVU>9^7<B_(E9P)P2^:LX/T:;$-F8+AZ0%R+
M"^60<&9WW4X-.-U-MQYQ]NZY]3UGYIPV6U.Y([U:K[XMU6TBU4.KSHT.$HR]
MD'O(#;&0JV(L5T4N_YFQ1- @"#+F@3);SY,:61?; (ND[&Q)S^HF;$95X'L@
MTW-;[0 !4U!S#, >[+!XEKS8'D*3>K+# A]ZLQIOF*GS03>6IK+<YZRN551U
M;J/_0JJ<S6D4Q*'\ Z4T9G(+FKHH89F+(A)A/\6I2 0H]0U$?62EKVFTQ=G,
MZ[3!\-13_]%0@EF$H]9,#2-ULX@&M0XO,Z?FQIZ1, +!DMV T9[4E!C!<FA=
MS :!N^3WJW_<E>QS^5"5-]4J?VKKSDB+QG<7'35==)VQ1K8838N4NU+YK,O2
M>;C_XNQ8<1I>]-UV+7"&W7C;N,!LA XDSE>K-T*A0ANY^UH$)G/_(>)VMP.@
M]PPB9*>*YO_2U-V^_R;$ZDY^<S:AD3K==/?%=AD/$IJE*$Q5I_@DBE$BO0GD
MTCCP@YC*WVH=@5_(Q]@6HY/.?= >8ML=0MV<5I?%OBB;C)89^E5^V%Q#<J0.
MM7(XM2" &-@%<Z,1_9L&<9@M.MN'8P]"I\L:Y,JZ58@!8<EIH#8+8XX,.2P0
M>CE0O8'3"X:?+M!Z.09[@5D+PQG>VU)^Q;?E0KY1;>JDL\5:.:5WZN1U65RM
M5F5.UW69@X?E)XG-LEA)G.2@C[>%M-6B6LUYD/EN(#>L.&$!PMSWY?[5PRA,
MPBQ@?L ]P2!-F.RP!5IT3%LTB9H]X"4L.ZC'OD]C-_.0YZ4<8=>CB 1QAF),
ML\@+O"B@F4'KF<FQM]=7YDVF(0PCSL*((>Z%JCTW]U#J!PRE<>:F7DJ"(/;
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MZ4G$Y01=<C*;"-8C[7BN.(A&%N!&:;3D2YM@CT+#[3?NA0+=+PJ.DF 7VO^
MGZ=5"//U[^$$)ZA95)PX%SP@*!5I@T./D)T(SJ240E0-$'#SK7NAP/2.@B,D
MV042WE HOR03MA'\1Y(_OEB<SM?+LQ>+C!.M# 7>S($SY.^HD -Y/BE!R122
M)R\+EM  & \2L1=.;.\X:2?G+F#S*7Q_DTE\TS+=GE&<6\+,,7*=%>2BB!&=
M.?BB%5B7A* ],A=Y7.CQX.OW@HKK'2HM9-L%2)[E3"I8G?_S=CI'/DED'R7F
M#,AY/:1S'"BFIJV2$V\&LS&A- #(/:_>"QR^=W <*].>@/&"/GVW_+3X<SY)
M"E&9Y"%H2T*1EJ)KS\D*:E%,*CPQ?EQ$LN/%^QU=L9\$%0<*M"=,;+;&=\OW
MR\6WZ3SAQ"=IK*']4/A"X780$3R+F<0DR->25C+78D.Y_^W[H:/CD\UFHNT)
M(N\7JW68_3_3KQO7*<=L+0\&O!$)5.0%@M$<DC4JR90,<=<.(#?>O1\\.C[P
M;"36D<%1K=ZS)88-W<0O6F8\.!\(U#X5B,E:*)S))&*0J,U1<+C^MOT T/$1
MY\&B&UGE]69T]O[+8GYQ I-CL89V-<@Z2Z"-+U+<'<@%DJP8JZ+.A1^E]MMO
MW$_U'1]E'B7"D=7_$=/IDJ#+1?PT7<]P(CF+.ED-')D"Q2+9K8@9G%*8'3K)
M#3M*_;??N)_Z.S[#/$J$(ZO_TS+4[)./9R=Q,9O(R(76W('6&PF(>C%G)<CB
MC0TY9ZZ/.[Z^\;K]%-_QL>7APNMDT;_ZGKZ$^6?<G+<R(;7S$B'$&OJ2=P*.
M9?K2B&AR20;%<=[??6_=#P,='TD>+<HNPH$7I\LJKNT-7(4TZ>!T-?'1H)(,
MP1<TH+)"B*ZD*I3LO Y%Y!81X_UOWP\:W1]!-A!M%Q!Y,Z>GD3BFW_!E6(=S
MMB8RQ*!T8D1]HKU.V0S1J  L">%XB([Y%J=-][]]/XAT?Q#90+1=0*1>XRY?
MA#5^7BS/)HDG=)F<8"XSI[!7*/ J"PC!:VLE8Z[)A=>-E^Z7-M7]&>3A@NP"
M!Q]/PFSV_'0UG>-J-5'.V^ *!YXT!4,\2MH,DP.2@DA))6V4:("#&R_=#P?=
MGS8>+L@N</#J!)>?:<O[ZW+QY_K+B\7)US _FVC'4PA%@;$ZDEG+!&=K!%#
M))/,!HLZ+L!\X.7[X:+[8\;C!=L%/CY^P=GL@GJ!I92:&6JCJV<FQ4!,V@*W
M 446/$O1(G'F^COW0T/'9XY'BK$+$!#A)S6-8Y'^_O$+R6WU[G1=ZS=J9#TI
M*5E5G -F@@854@#O@B5<Y\2-Y[S8XXZ@?TS#?B#I^'2RL9C[  U);AEF;^89
MO__?>#:)P=#^QSE8G8@!3 (H\D9 5I/%DG,B'5>C<>]K]X-&QR>7QPMS[/NJ
M;:CT>KI*8?:?&)87J>5)BF2)6DBY\F"2 6<"B:7H')1+P:8C[ZYVO'D_3'1\
MJ-E$I)UDZU\Q\9J^LYIP8U0NS$*)V5$DA0%<\0Y,5#P5K62Q_BA4['CQ?J#H
M^)2SA4"[PL2V$&7+A)!!(A<%@LN,@$W[H.>J0/$FH^6!?*:6J+CVZOUPT?$1
M9QNACHR,9\1!WG Q"Y\GP>G@I*_YP]Q2%"5I][/"@A;)2RF\<>RX..3&Z_9#
M0,<GF(<+KYG6_^77.\)[2]\XO"#[W>\?W[U]\_+9IU<OGS][^^SW%Z\^_ONK
M5Y\^WJ1\SR+MG0]K5+B]'[%'%G.?KN!S"%\GF[RWJNUWY?5T'N9I2JM^L2W?
MNH02*<HA3QZ0H "*H0"?BX0DHR[HF77:/;""2EC%C<;/7[I=1CA;KRZ^<[6>
M'D/7H2;BXAW/5BM<KRZYU%$B&IXA8%:@4J1P";6B$,JF5%APA3U4S7X(ES<I
M&*=4?# D7!B5!N(><3^YH/Y%6'UY-L_UGU?_=3K]%F8DJM6S]8NP7)Y1R/T?
M879*+C4W)6(5"%%/[E,HV[@[I"*#0R-5?*B8^! ,[478N- Z1O.+H=70 ;9^
M"\N_XSK$&9XG'TQQ-=$J!*UIPU:2&U \:W"N:! B162898@/9>T= J7[Z!BG
M;\$ R#E:R!T Y5E*M3!N]0$3$O:)E]]Q/?&88XXB@Q6^EC-(14Z>8)!<3%)&
M9XIJ;73N)62<G@8#0.5X,7> E?=+_!JF^=7WKSA?(=G,=^LO%!YLI'29D%"*
M-K(DR"X)4-8@>!8R&(6B:$T11-:-D;,'6>,T0A@ 1ZU5T &J;A+/.0:/UH&T
M@O;97,@=E%D \U&H((+2S=V=QR.E^7']$!;G8+$>CHG%.LP:69K%5URNS][/
MPGQ-**^.V=<:252K6:+7CFD!UO $2@@-WCH)+K*:0IU5D0]=Y!QF8G;3,TYC
MA4%L2R.A=V!4*-Z<KO'M]!OF-Z2-^><I;;E;66VX<<9GH1FP; J0721&L+8X
MM%'$1#\*XJ$D]D,@]#!%XW1=& !$#07? 8RN[:Z_+^;IW)B63(0;7T FFT$I
MPR$(4S-I<LW+M4*7A[+@#T'/O82,TW]A - <+^8.L+*E?Z)LI,"/W*VHC"5#
MN<G-#0)D<5&AB<)CZR![^^9Q&BX,YKD\2I =N"QOIR%.9YLS -H[-TDT7Q8S
M$OJJ[J/KLTO1V*25J]G:D:O- 0$#SZW<G"295*P6MC5 ]J5MW).9P8^+!U%1
M!Y;G.E^7+ 0L*9._%JPG%D2(Y*I9!CH'*S E7]A#R2W'HJR+^X=A]/T J X1
M?@?XN3B<>A_.ZLG41<P8ZWDWZ@"&R :*$ U)Q1EBRO#@@Y+>M#[*N9^2?E!T
MD()W' 4>(>T^,+,\I;=>">?RJ*$84SBW8"33YUM_\!F8CC%8QTIZL.74@;"Y
MGYAQ-[0!D-- YAV YQX.2JDGWT*#]('D4F*A?9UQ2)DI<A8C*VY K^@Q<!GL
MNJ$U7(Z4<@<^]28NO,;&M>"0(L$2"H$=E>*@G"KU($$"LB1029(.:[TY[:9F
MW.N%UKAI)/6^[ R1;GE(&0&-K1$I1_!:)Y#9F^B\SLRWSL6Y]OIQKQ4&M"R/
MDFL')J76N$S7)YL4CWE^L9C7>GND6)-8R9Z%Z&MJ<F$)5. :O(^"OI04'$@7
MS(.M# Y*M=E-3C^^RV"Q4RME=&!J'I!0X2[R+"TX6^<I):]HS5GR[+5W*4<T
MZ%J'XD<>\3R)BS,8JAJIH@-072O(VV:A12VY]H5#YH;V7VL=<2)I__5)\B(P
M!M\\&? 6#6.GE+;1[3V&Z&!!=P"49SEOCDG#['V8YC?S%^'KE';,2<I%:&G)
M2_,J@\KH*2[4&HSG0@GO66J>C;.#E+&/E@>!30NQ=X">3TL,J]/EV49*VZ6P
M705*R*"S3!!<';.25808@P*ADLR%!6\?'&1T"'QVT3+NOC40?IH(_O$ \EL
MS?%S'1CYJ1F./N Z3.>87X7EG!RYU;.43D].9_4E+[%,TY3V=>^\R(%!-(;5
MIOH"8B@2<L;D+'&F3.LH[,=4C1N^#X2MQLKHP$Q=XV!S1%';62SQ"\Y7TV]8
M!WZ<X-O%JJ:9O"N?PO>:!VF4KX/C;*((0B&G""+76V2OI$C&:#7 _<5C2!SW
M5&"H37% -76 PKM2FP0G-*L#J)P6FH*5$,%C2&"%K9%+*(H]U,6L38 W;AKB
M0%@Z4M@=G#?]-ITOEA?]^W"UGG!A,!A'H:RN'?NLH<B"DY>8O.8B2L9Y\YK
MVS2,FVPX$%2.$G27=H5LY>RT]MYY7[N"DG+6Z^4TGFX*CCXMZJG\8KXF*NB)
MGR^Y1I&5C-I#<4Z \LQ#U%: R5+R&'62I;7+WH;R<9,9G\Q^#:[4#FS>CT[Y
M)EX;RTL]SE-(CB?6T?$8#5C'F5$F1O]@CY4A4N#ZN<)[DDREH]72#&9/UIGA
M_4837W ]I;]:W>3CR#X-MQX]<->&AQAYTAX.,289@@<L=?BF+@B1H0+.E>3)
M)R-]ZU7\%#T<KIT%DZ3?+3?OS)MSF?>XW#3&FW!GA7=658,<:R>44$OL+&19
MN#9"!"%:L[X'66,?S3?&S .']$T4TX'3=Z?CXK/3]1=R8_\;\T0[HT5A"G36
MF5@QO!I]37$QYF1*BB&T#A0>(&?L\_NGP]91BN@14V]6J]/*AE1UQ)RL X<H
M'A)>@*]]G')V5A876&1#9#?<0\K89_E/C:4#%- CCJYW@^44=F!P!;R.Y"H*
MZ6@YY.J6:F$*#QQ5ZP+*HQOP#GB"_]2(.E05!\/J&R[C8KCKQBU7)".FHJ4]
M6UA6;]UYA)B0;"[%)3(48H2U1M5.8L8^FQ\84FV4\%/TY_OXB3[^]NKW3Q_?
MO7[W_M6'9Y_>T$^/#0!W/+5][+</^8W"ONWMS"7V+H&F4"41@@*?J@>49 *G
MZ<N@G6,B9_0/3@4^9%WN(.7HC/*ON PUR_"\@\I5/FSF-O@8,_#B$BA/L/=&
M,K#<*:U]#,*VOL392<RX@5P+%-S)*6\B]PZ\H@^D"R*@=HQ[B=]PMMATR#CG
MZM7W\\/=9^F_3J?+V@+A_7*1ZJCPQ6H]T<H*RU. VC..['72X)5)(+T(R;(<
M-6\-L2/('1>$C0!S)RGB:;37 5 _XN8.X:\X)T'.B.%G^60ZGU8AUB%BYSQ/
M5"Q21 I%$@FU^A!Z6Q$D+2,.N;+JP4D[!QWB[479N <.P\!O )UT@+0[LII(
M38LED$]JM2^@HI<0:@X;)J:EJ/T?5&M_X0X1XQXR#(.?XR3=P<W@)0-7>4 3
MKZ7,U:VPN"E\-@6"+XI\BUB$,$H+WSKHNX>,<<W-H"[7@;+N "Z_+^:+FUQ<
M-#Z\$) 0-<J-&KB(#I2* IQA!2)*EGUQ,KK6Q>8_)&I<RS,$E-KJH8,MZ\W\
M&ZXVA6=;=FIK,K11%BY((C&1*?5&0"A!@DDA).:E*<W+M.XA8URON[&B%VVE
MW@%P-AFM.Z4T*=E8[Z,$6XJHA1^98@1::8R"!$_Q00FV^5[V($7C;FO#PJFA
M+CI UFY&<E(:+6W5R5A-/EX=F.(4HYT[6IZ52"ZT!M5Q>!IL;QL63VTTT(';
M=.7PO281;LNJ3XFI<X]P,5\]Q[)8GB?C?PK?<?7J.\F/U#>=A^79&W(=5CM2
M$;EB5LB405A.JRIH!5'Z #P+[80248C6YP4#LC/NO>$0KEHONN]F&1"+Y\OX
M.<ZQ3&NS)*5SY %\#;[)1!3P2#&S)?&BT@$?'AA[.(3OD#+N'>-P\#M.YAUL
MQN^7"Z)Z$S([M!7T%J1TMC:<1-ATP&&YA.(U#G#W=?7V<8MZA@#(@9+MQIP\
M9%D?RN5_M1FC.^$I84A100[);D?H.<\MF5 3Z^#MF%WK*Z 6=(];,33./ME8
MFQU8-8JWKYT%9I22%IH!X6I'?XLDN.P\V.Q0,Q,U\ZW+8V\0,&[!SR#'9 ?+
M=T3S5K-<)J_>?[R:\NF\E\9;L+S05AURJ"W"/&B5(H]HA"JWAIO>392Y_=!Q
M>Y.WU/51XNK !ERT [C(F'\>5M,T8>2=94U.&6.&/'MI+;AL*7;64F'BT7EL
M[>3<2\@XIY_'Z7316L =HN3E=':ZQCSAFDL3K 2E:GD%>?1DTX@AS[D-D3MN
M1.O0:0<IXQQL#HJ40X3< 5;^AM//7XCN9]_(<_J,OY^>1%R^*W<2E2]E)KUC
MK#:A92(1?TC\^>(4:&]L+$%12-#Z//.Q-.YGA]C/L&$]B9I^(AAN[3&RE)FU
M")R8 65J]U.L)UO2">>#D+:Y\_LH L>]!AP6*P<"\_&*ZQ>5YZ;^;C%'TM(D
M6R3HH@(),M?2;I= 6.=I1Y$ZH'@:7.XB<=P;Q1Z0V41Y/UWEQ(MWO[W_\.K?
M7_W^\<U_O'K[[F/3 HJ[#Q^VCN('S+2OHM_NZ)LFQW>Z85UB-?#$18X.=*S7
MC"4A.!D+!.EDB5:@P_:]6QY%8LMS]>BSB8;5?$4'R@4-$56!DB5/V?#DFD^7
M>>2Y^E-4RC?'Q4/G[8^0> =;YS[-XRATFBXR?;]6L^%+W/Y[*;B$RJ:<$R2N
MR2#71 "7M(9<O(S)V*RQ=0G]\51W4VD_.#:?6,,=8_J/.;$UJ]T&_GTQJ[[$
M7\-T7L7P;OX1T^ERV[1G.5W1CU[2E_//6[E<-E&,@LLH3"'&:Q$P=[79&7VP
M3JOBK8E2M-XZAN)EY+JC)\;DGDOB20'2\4+97-@MEN28S[<SC=+9IV68KTCN
M%2#SO/EJMH5+_G]/M^FFEU(0D1G.+%FK+&@+M+ELNGC4,>C*)REL:#[A8QA.
M1JZ.ZG.1/"$X.E\BESRI$%@VQ$Y@G(/REKP_0SRY[$4VGF?WI(!_%'R'*\[J
M%[X'*:Z#Y)A[V+G:>FJ'I,@422A)4%H[B$5YR,RF**.U.0S0+&T7.=TT'QK<
MO6ZEDY^BU>/UTYU7_^N/-Y_^L^7YU/D3ASV4NH_L]B=1#S47]6BRKK.U<\U8
M"=J"CTR#D286G[(SLGT?\ST(.[ZU\OE+/M5<KHG/B*9D"2GK"$HH,K*\(" Q
MS&NAM6@^U>0F!=V</C7"PMVNQP?+NP._ZI+ZK42J%5W,L8ZH^SY=3:QVW"3#
MP9A(S%B2"\51FCZ8P(-.3#:?4_L@09U@Z0!-[P+-T6+O $.W>'BY.*%P?2(+
MIA19!HRU.*F4 CX1$U*'Z%/"*'+KVIE[">D$,\<K^G9"S=%2[P ZV^[.OV&]
M:YR$$#(Y:AD\>@M*,0'1A )H(U?<N&2;YUM=?_^X0&F@SMN7(8?*M@-<7.L!
M><Y \4$%7R0%AHF!DKR68Y4$WMJ(S$0F\X##('M R.'ZW-U@\P#A=M%5<\<L
MPG-VD FNE"M@T9E:P1K!F4SLH.;!!J>\;IU7\B!!XYY?-L--.Z%W8&'V&-QU
MP5CR)6EAP3CO:C5?!B<D(S^OYB<B9AE:=UW9F[AQSW?:(6L0972 LMMS"<^Y
M4)7F5+/Y."N@F$$(4I' =) I))E4\[KR^RD9MR2\&7X:B+D#L-S3I?B<D41H
MST*&FA4OZZP:"R0I!<X&[W4BTZM;Q^$[B1FWC+L99-H(NP/4W-^^X)P73WNQ
M0J/ 2E4K-GBID[U)8-XZE)'B"=D:. _1,ZXCU#[$:B;[#G!T>5+QEBSIIC'&
MA 46;9(*N&:;.^( T7(')CMKC,J,N^;M4N]0T4F&6,,SO\,$W %$;E\0OYG?
M/5/_0&OA]6+Y9UCF299.$!<2<BRUYX&L[+D G.5B4 8F]0"=U!]#8B>'@P<B
MXFZ5_V#JZ0!]#\X%R9XSJ9*"9#*Y>J(>7I"AA9R2$3EP:5-W(UJ&[&D_'! >
M,ZWE,5HY&&%?-\DKM):6ZT8;89LQIDI9FU(!DQ@)E9P \-J00VF]9$IJ'E7K
M0Z@GG$T[9'/@)\/N")KN!N772B6\C3%':P!3=6J\+36,8H N&R^*3!Q;'W ]
MLCAER/[!3X:V R7>P<Z[D<EVKMOU=.NMO;_H^X";U"Z<KS;*FP0FHLY10MP,
MZJKMSV)*9/JQ>)4<"0Q;;\@'D#EZ2\2GM74#ZK #F%YE.:\^+79<5FPXC;<Y
M_8 DZ]5TC1]Q^6V:<"N;#Y@6G^>;IVSFKDX*49U"C?X,"45)=."2YY"]KLG4
M,GCE&F-Z:)Y&;\KX9 N@*W1TL%H>- B_XY^;'ZTF.6D;2U%@>/3U%"N#EXKV
M*Y93*8PS'MJG2>Y#V>C=(OLPW8=IJHM+_!U\;5;3%5M"6Z.0F'%*:5!&,'#>
MN#H U,BL-&L_?'4OPD;O$CDV_H[04^_F;_/#=U\WG3%??<=EFJ[J2..47>)%
M0TJ,%EAAQ"LK!HI(AEFK@M?XI"[M?52.WFAR;%BVTF"_&-TLO/L9Y-PG1&:!
MV^Q :6_!U=(^HXOWT0HC[2"'3H\A<O3VF&,CM)'^.@#H0\5]S[Z%Z:R>FY$D
M/X897JO<OEN-&J2P-B&%EJ+V%F8YDN_B,TD 2_81+3>Y,6Y;T3Y^][PGP_,H
MZNX<YD>48#MMZS05!M+5EO B($2MR6$7/#D>5/)>/2'H!Z[/Y_\0UUT=0*&+
MV.W!:S],M(L)C&"-4"1@8L0'%!!+9M'F0)O<@+GZ!U[&_D/<:#53RY'W5*_F
MN:>[6"D8+W6D%6TUQ#GZ"#%$#[J8Q!@:GECKUEA/>!?+_R&NQT90=5.0/UEK
MRF<?__WUVW=_:]N2\O*A [>BO)_X]H7_+\+JR^O9XL^K4=1%>$9^)8(KBM"A
M"!C!: $L.,T#X22GUBT8'Z*GP7B3^LSWR\6W*4GN^=D?%#^^F5_.07Y&CL>W
MK?]]V5";E@5ZFR%G7M.EK828G0'R/3QCR6%JGB/U>"H[R<@[%D'W3$L94ET=
M!$G7TAM,]-J(6,L)9015D#Z3VF^NPS#I7((=>8K8<#.%!];S[IR2QPB] [C<
MN(ZM=ZGS-)WAC:%"GQ:/%:5U@BEC6.W[)TB4,D$@IQ:28+XH)YP:]H*^$1\C
MSS%^6@B/#H0.%D,](P[SA.=-:I[-\]_"<AE()/4T;9MUL'JW?#$+TY/5)&L,
M.G()II!OK804X%FNM4^Z>'JX<;GUN=&C"!S7 H^/I]MI^8,IMP/DOD1Z<YJ&
M\U.N9R<U5/OO;?H89BN,IGV(&4_^DJN;D? .6&WK%Z(VS+1V QX@9URCVATJ
M6RFN PS>G&ZY/3OX#==?:D?+;W@N]8G)+%@E Z M""I@G9,>$;@NDKB21;/6
MM_=[$39N G1WN&ROS,<CU&\1.L?/M2/!IY8])Y:XT>RUU59'K*S2XK3VA)KG
M]TL\F9Z>K*XSFRT/TL90ZU)I2Y"R@,LL@_3%,AZMC+)U7Z3#*!TWF[H[*#^!
MNOO!]MVCXDNQGB?77LK4F:"ULAI02@X*T8)W(0)+BC.K>3&J=5GQ_M2-FQ#=
M'88'4FL?7L,MSFB];M8ER1VGWS;UWIHYQ7.==*US'5&IR!-2@I%SKK,H&0M7
M S@-/Z2KM_+2-ICX(?2.5%#/QI(V@J]AFE^>D_7J>ZT^J/VR-PD'SU8KI)W!
M%A%C5@C&H@=E=(: 7$%0TCL;)%H]O.'<A]+>2DB?")_-E=@S8C<\76T[6^8D
MX\H:IL#[1)%C9@E<Y ZLT:((%GU^BJW]'LIZ*S-](D0>K:3Q$;B90KU[+W@?
MSNI&4'WMT\LEM[I8<V^G(4YG&W=H$K4*K-#"X]+4F-%Y6GC1@O+"$=F,<7'K
M<N#N_7DK8GJK.VT*QU$TUH%'N?_%R:0HG4VB)8A)TB; 603GR(MA/$EI O<L
MMLZ0VY^Z<6WE$U\_#:2T#J;4[.!L>]1POR #6F^"V(S@<21(9ZMOPD%+EK,*
M01O6NMCS\51VTA#LB3)$6JFK _M(AO^B_#K]U^ETB;^%Y=]QD\YW52TPL:BE
MC,& Y9DX8\1>"*C!:A^4E]QIT[IEX5Z$=9E7T@P==WK'MU;5^([DM9R9A)@W
M]PNU4H4\C]_"NO)T]J[<RZ?SV@J?+: ))$F?'$3T#,@M9)@*U]D/T"#G<41V
MF3,R&#P'56&/II(X)H]D??9^%N9K8K=>C'VMOS)QFF'V+D*1KE[6<HKF,AIR
M39@6QA@;FQ\*[4]=EZ[DDQG--DKKR'+>9O -*7/^>5JCN?/#+6-4"37_4)4Z
M>)>V!9>C@"AS8,:GZ(<'XVVBQHVUQ\;@42KJ!WK[BW$BK(O(:6U)G0)Q&0($
M;P-8)E*0S!4I6]<2[T_=N->+3PS&@936;VS]>CH/\W2_(.L(TRAJH@JK254E
M9%IRAC[88%.15L78O!7[HZGL9E[LD\36K=35@\-XW2.^M[6$T\I863PHR6@U
M.]H!8A8()1<;5$F.@KDA@YB#6X$\=4S=#!4/!2U'JZ@'S)W[&A]P,[GGT^)3
M^/ZWZ?I++>(D\=7LYOO[2D8K5&T! 4'7:G=+ G0\!T"FBDQ"<QE;E^(=2FN7
M8?5@"'T*A?;C4UY?D%=)^M=*Z"=,6R-19C"Y#KZO%_9.I@C99BR.R<!*ZVN:
M'Q+594C]%#;S>!5U8#/WE]]$EBRU+@5R\(IV \,@""= &!\(-MD&USKW;'_J
MN@RJAT+A0$KK((YY50HF<K=??4]?POPS?B +^VY>F:W_K^=5W\)LNR60'*>)
M[&_]P;-YOOF-:[\YT2)K(0LYZJ$V=^(B071! /JLG5=1!-_Z$G$ -L8%^&"1
MT-@*[\ $'\7LMH/?W>26\TXEU\6Z%?7$T?[$+0O C8B@3$CUE#<"]V2-BG'6
MYM;.[M-R..Z1UF KI6.8=+!Q'&<QE!'>^<A!.%X/HC/MPTXYD!AE=$(S+EJ[
M-L-O!H/U&N\3XH]28C=C;XYC.?G$!0N:=KK:WTJZNM-)7EMN:$8NI33-X\'A
M<3M8C_).<?L8)7;=(>PEKM)RNCE$7)3GIZOI'%>KFY3OUQ7L_@>UZ02V!Y&-
MNG^]6WX.\_,JRQ>+^6HQF^:+\O;WUQAX5\X#MS"[1.BU^RX7#?<^@<IATYK6
M0TPJ@[0^:AU5YJSU#783PH_N<7L,$;6D=;98G2[Q$RGS^:P>S)AZ-^@U0LS*
M@Q)&UJI##Y[+%+-30O#6W1]:\S#N]<33X_E.L]LQ,=$L4FQM=C^>GIR$Y=FB
M?)Q^GD_+--7DGFUMPZ97Y6R:Z@'9 79XSR>W,<R'L-'(4M]]S56M,G-9!L/!
M**=!!5_K.:V"H*5#6Y(VS0LC=E-S=/?:AR1[M2J\%5K$7*"6$8"*M8>;#[(N
MUGHXB5+;U@DK^U$V<B.G-BBYTV>VO5*Z-5673?G+[:;\AYBG!Y[6QB3M2VXK
M,[1[9,$%T'(P 84L4.O0*M <!&$*!2V(.19,.;5>FC^F:H 8>)- ?3=M^MK.
M;:/E'@M()C*HI!EX4P+87)B6Q3BG6Z? 'T#FR :K+9[VB'J;JJU;*W:11AVN
M)Y8?8+_N?4X;R_5C$AO9K)TIY9<0\[PPPY@#CK72(2H%;KN%!6M*5(5QWWBE
M_I"H!ID:][_@OB"C7L#Z*.M< T_.0=027*!PPRON>"9@2]>Z7=9CZ!O71K7%
MSSWI&L/HJ5O;=-67Z3UNLZ,.L4SW/*6-7?H1>8VLTJNPG),7??F2JU/>;+TK
MNH"RL7X@;]T'90A;.6B4V0AL'<[MHN7H5(E;S[T>*FB)BC,0F0E06JIZJ!TA
M,JF%RD7XP9GLQ+HTP<&=E(4F@N_6@KP.T^5F(N!O&*J!W'92/,"(W/^@-G9D
M#R(;F9++-UUM&=?B?DX>LDJDYE3C?NT,;1[<@+/&)Z2M*K#6N10/T7.L2;GO
MV5?H3BIE;S(QBY:#$I[7'E$%A#=:.I<5:U[']"!!XYJ69KBX;5[:*:%;$W/>
M:N=Z_Z%#CG_N/J71L<\/R&MWZGSK-=M)?=51K<.DSK^XP%02:%@6!71!"M4S
M^:C!N012%2.MYE[XYD<_CZ*P03?B&_V8YOGN^^_SV[4Q7A<NZCU2+=5S$9S1
M'#+GZ&*F;;YY@XX#21W]_'HHO-W3:7AP579KW2Y;-;VM.78'F;;;CVACUQXD
MK)%1VS[Z$D0B\9S0.'".TW:E0RW$<0R"KETN1,PQM3[\N4G!L4;I+:Y6B+<D
M=P78J(-,K""P5(O7DTS@8Z ]N? HA;1"^-9)!0]3-*Z).4+[MTU(0\%W:RGN
MCI@\Z);^[E,:W<C_@+Q6AS6;1U\USPO%*@J403-E:=^I4X<9TY"44]EJI;UK
M/3/K)@7M9\3^OECC?=N=B]+&RBJW%@G$0=0>^PB%$7Y%4H69UI4I>Q,W\L'-
MX9CX\1S7%NKHUZ;<7S9\B%UYH #Y>-NR!YF-[,N5JC>5FI<O.Z\J?K%8K5<;
M<F(EYZ+F^,H/9LA#C!J8S094D!DB-[3=F"R"8"[;YL/#CZ/XZ!%:^[[]^?6W
M7UM&P646)*M[,:LM\ MX5S(P9;@+@K,\GL#N)WE<6_>$^+PS=.L)5=VMQ=S>
M27T*WP^+U:[_><M+LGL(:F00+Y]_I?Y+-"%#Z9CV$+++U65'BL"#!8ZB.)E"
M%$,TS-]%3IM);#<>?07>H(45/$G(5M;<%TP08[T-<B@9=TY:UCIV>XB>T6>H
M-,'$_>/3&FB@6_/Q$3]7J_AF7A;+D\.=K;M/:>1H_8"\5J/NMZ_Y@%_K:+'Y
MYZNK$#0"BV+@O27->B7 *:/!^,*-$E%*TSJ<VT7+T8'=K>?>!VD;;3)<<8B&
MXA.5:,%X1GNCUJ:V:Z>80K0V*GN0-?(0^Q;8N!/6-59&M_;EV6F5UFP:/M #
MB;XO89Y?XC><+3:93&1:R<;2)]-O!Z7Z/.;QC:[7#F7H"=P?EWT2TAA %VI7
MEBC 6^\!46J=0_2)M4XK'L#]V0P\N9#NLYW2O5HH:+E*]#\PNHXST:*63CM)
MGQ7!8_WI[13%':-H'O'2?OV=QX#@QHR9H43>K6UZL=A4J^#\T JSFP]H8U\>
M(*J1!:G]OJ;;J9BDZAOONP=.VDOA/,L@I!"@1/ UY[U."$1M$Z]:;QU2/8K
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MQ].<T48?!?/D$]$NJ3BYXHZ+ $YB8AYY';#<VB@-/AW\8_J"^72&[\KN=WW
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MX&WKG.:'Z#FZ7\+%L[?Y)^<2SN_F'^HZ6=(RV/0_NEH"7G.AI2GD ;C-L,X
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M\(9664+%0K*1^=CZ.O8@0D<NK>L FDU4V,^,VUTGD=;ZR"3%=UQZ5U,N)(3
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M)0 OX8(6LL6ILIY$$A .W(+.GRPR220D>#2&*@(&^=GOY1E=/Y<0TF_B.E:
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MC^OS*$*TX?W4QF.<(D5,8)=M*I^SCQ7"GD0:G/>&E#837HKW,] 8320!!>5
MR0+C$SGCLE2Q2B;K2=+%<_;^]'X>B-G3>3\/87\+6L>3MH=@B'*P.S&BWL#F
M"6;(84>0(2%8G)2)HG1ZR8OL;WH0"';V-SV$(PW Z7C"[>@LARDH7R(YE$B>
MCJ<)V,2Y-%-@Q2V3CJAX]M+#"^]O>A"LSM'?]! >-X#SMZ"M=C]C7+0K7"9
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MHHXYJI@WH1=N^GRMD?9_Y5!3G,0-O&MWR92/E,*KQ&((S F4!\#D681@2 O
MOJ6:):6P8J&T@;AA&XVT\ROZ8@VE=FTA\^4;$.\7.XL!WMY,EP4_5B3:=S.T
M$$%X(!R\NA1QK17<C-R5D+/$F"14].PW,V07C33R*R>4SL:2!H35(K"Y[TS.
M"HTQZ'?2 Q&YHQ&97. BI%768&QQ^6;</?;52(^_HN*L.#]:P-@=I1Y*/Z]<
MC,'&@!$\WW!-O-1 'AR1#E:K7/,)C_NI/*8/VVBDM5]9! VD]O& Z>9V7$XH
M?>@FW=.CW,&?1D(I%Q1A+52.9D5XV:5%0;ID+.&$\])AG]T[:J677WE)5(8)
M1T/J1YRZ[L2MV2+)PS:!*)A8$*8T6&19S@"4AG@,KW@TI271H-9L%^8E+T'V
M!MZP3],.=KT0IEXF*9A-P-< YBC-A5'8&B25L,)%ISDM;<L]?+V5]GU%,7(D
M<6N;;J_M[%O^?^YA\<..%X63D["<E+&L@?.WT]%\%&=7E'@"L/9(1RU0[I."
MG#4$1<>P)Y1$WK/7;/]OMM+=KYQ==B)Z-]ON[]5MIMAX9.\BC?9)I!%D*@A7
M^,FP]G]'?*5,RY"AQRO4+>3^@7HSFOEQ-[N=QGNH<B8BQ5HCJK,)G[L>V>A,
M%DX^)6HT=Z6;Y^W83C$-Z+\6J6<_EXD^$0P D:)!)KF$>*0JE^5&E +5Q@B0
MQL5+X#=NI&Z*0"D4;%5_CJ9YY93?SW9RO2S39%)%1DQ R7$"F]8>69(P4DH3
MABU5\.D".;[W'VP$$,<SKAM*Q198O\H@-2Y:+&"S3B_F?5F!3/"YRDX9Q9-0
MTO1JD-:'^;63<X]DUCJ[CZ!<98;_-IJ,;FYO5AOWH*<%3!V2)#$$YCQ!FDN-
M9&[B )JY4+K7I.,]+'_RT<I,/X9E70GZU6:\_?W1QH7'2GHM$5$V3^U6(;?)
MCD@Q*AW(.4%IKVRN?8Q__-%Z]<E%&'\T_1IP;:R_=._ODW2IE"*FI)$A*E=5
M*PM6%,Y>9$R-B9R(XB.=MFZF;D)?.6V@+-4;@,_FH8V?H^\F?C1>]I"]GU<U
MN[/UKJ*,<-ND0O"4*L1-Q*!44X]88-((GE3 O5Z70VHWCMII6VKHD3#I-6BS
M*,]J.^?N3W;O1(#CQ=&/Q<4-,A$JHD=1,9#S(2ID*',@J[$D40HA9+_6"KN^
MTI;$&@:<LB1MUN.V'#5['>$6Q-D G]K&=<IXS?9OL9!?+*<"CY;=F%=M,QX^
M^]Q'DKP*-FB%DF6Y[PX/R"E+$:7$!>93,ND46=J]-SCTE5O,J'G\B:4&8$B2
M'B=0]7!N4XU#1%K*A*PQ4O+@X>B]&L,=<.S-.ZG[2IT.*^LO5P$^5+:UWH_F
MH^L%9U[;V=+-0$RRQ'F)9,SYBI2 V8'S7.$@.0O&<1U+>-:>?[DN:DKPLBM&
MV*9@\17^Q:HB7#L&!]<4Z23@874BMQN1^9<I1&JXX+9$[\EMWZ_GD1G*SZW0
M.)*XM35:4!2N;^"3>11Y#'>^AL@,#3A')&@$96[Q,RE0T$)IJH+CEO729#>M
MW@KOCV585Y)Z#9C:SP3F@U+OL4XN3YL2-/?0-)0BQQ5!1CCIJ/<A1G=J1:01
M7TW!9Z4PX5N T/W%^A+G\_&B^_=R</BK/'HQAJ_=(O'ODYW.?UY1#"9]L@X)
ML3#E<A,(FSBB@C)!E&9\O;'<<%0=LL'&])<C4;$.MI.QJ/X+]OQDG^S/1;9'
MG-Y<*0]WE%*-F!>YYXADR+K@$186I#3&DE'=\S';^:'&Y-,PV!2G;(LH>7<[
M!PORM]$XSN;=)*Z.-OL4I]D3=:65BX8XGKU-'F2[!JU .(9 1_ V:2R=Q$<#
M9_>WZU:!GPM+!>G?(KS6#W;%/6:.YO"?%@&!5HE1-CU0'E7 6*0AN;U.P-Y?
MJUL+?BX(#:)QLQ[CAZ8(7Z=V,H.=O;J>QL6!!_B/>ZQ:QIM\Z/8'^I87X-CQ
MS8<<8:UCI$PA&@%^G":#K+0!"8*M]B089?K=OQX?*S>*[=$ PZ7-082B.EJ*
MI,G9[)$(Y*B3<(N"=)K:X(M;9=MW4T=9/@G+MP]0&\2"RB[ 1VW[-D[%?/Z[
M,7ZP-_=#-&BP@:*@<T<IK".RB240KD$IKSA6NH0/><@>6YFB-@PC706&50;F
MMG/<]=K6E%N%);)V,;^%663 )$7$I1"59_#.EQAGLWL7]7R5YT-!=Q*6U%;(
M?[WY/AIW=QEX42E#/,N-D\&28(KF_D .$>(86!F$Z-3/G_UXU7K8*,FFK@3-
M&G!!/A*_ORZFBX<?N7/4[&OW*J5%]M%C&T0GGIQ,#EF"19ZK*N%N) FFI;-1
M*$NU*AUA/VB#K<QG*_*HG9Y%3>'OX[\G,?P"5A&<;='T979%\Q0AYQ.2RH4\
M^5+E4TE$3=1.2.M2*CUY=M=^:B<?G@P&6P$WD"?5'[.G!WF=CS&.8742Q65*
M.2M."6805]8C$-$&.:^YB))%$/X]\PYW?*9VXN&I05.8T V(I$]WW_TR[_P_
MEV?X=3:[C>%*ZD M<PF!-D#@)$ ED_MM8NXT28QRR4KGX&_?35UG]_G$42%^
MM("LE:<>:+1L1+T('3ZB)$A7PZ*38(&P -+5*X>T<!QI&QGUW'NF;6F [=M4
M78_X&7%6E#L-P&VS!9PE]'3V;?1]%2^RU_'*N&!X, 2!*JIR:25&\)S#&\_
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M\P04$DPCG10')=8[;[2TI,BLVMX;JCF%="C/NU,SH+H!8?, I/#+[73RS=[
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MEGJ4DK2(&Y"E5@F-M%,63D)-,J(7QQ_6K//>G(GC1Y*N\LNQRD?X./T2IS]
MX5I(0:Z,8W!^Y A?U(!I9*W@B#)/A(U8<].K0GK/(['IVR^NYNE8E60P8]H
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M0W;Q@II<G!RA@[E8&ZX/?IHO<3X?+VCY[G9^.]W8>R:?^RH82IQ/+@=T<K!
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M]#N]1%_]0?[!V5G\?_ZO_Q]02P,$%     @ QH&H6B(,"53\!@   R4  !<
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MG. 6I0$INF^#NU!?S^J._UQ5+Q<<_=IH((Z+JZGS>/JP\[01^TLW8D<&-1M
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MX<X&LK2OVT" H!)4%C9_WQU>#[(!L)0_)6I.!-/>Y#IC"QC&QE)L #0M1[Z
M]T)>H:70%"8EJ%ZG^P2<[G.#8T/!<(>M()1B->1E+#&]: ^1K NJ7G%A%[CG
MA=WBRQ<4FTT0^K4>7W_V_HJEPL#O6#-@*-?!GI091GZ,SIW9B+N)0L4^E%PQ
M6SEJZXBW;KU-=@!C.^QLTYT;Y[V-V9MX77IP>!"U71CD;@= MSWHVWC[7[M$
MZU&Z!!>X:>?$K3-F"D.0D^);M\2UOQ!N4T6!6Z=UC:8EDRP#9$,P)$/'T07Z
M"E(L5\(%$;%]CP(I=Z)7-U3K&\LW=C_7M6B<V>[*E2_J,JO<4!:8A*P4?5],
MG6]P )?TCAC_^]TDOS;.(]N(NL13(:ZN;\BBNNDN$_K3[9H,F6>L'C"7BC+E
M(=R,%)KUZIL^Y;K(R*+'A9O4,?5SHBZP&YY+8V3>LYWPI2T48I(M)W'S5>1E
MDWS0]3M1U_;)!C<V0^N)ERVT[UKH74/7:9VVWXW:#Y(#/WR0]D]BL8<_V-O[
M)+&[#G(%&PVC,09?-*+&O=VXURJN(5S=B^VV<]\VE5F^OE<'&_QDJ?F35JJ"
M1EDLJ]VR5V+.4W:45;>]W]?NNJDL!OM;,<:/I7[<2FU8Q!_K]X24NFU#GVU%
MW?Z#C>CVJ>)82Q583*T1=]97?-?EI2>4A;]M;6,+8*PAV86TQ^Q5DX\>XBI6
MKF'.[.ND5(+K%&M3+3-FZ^#/;>IA6Y=S77%HL#V5K7:WYSNKS98]0QBEI+ G
M*'N1I<WL*3Z$6&N="VZKY*EQ9?-(4E8)0;1"FAJQ.US!&KL@RM2P[ASO*->;
M@69(M\<I6-O$F=2EPMOEEX/OJH!>.2G<W%%^2K=Y[Z-'(;7K;7J*9<3&Y=IG
MD-NBTM6'P2T+F:,OE6:=Y5^^G"ROU7><7??]Z&]02P,$%     @ QH&H6@!L
M>Z=5!0  DQH  !<   !L<W1A+65X,S(R7S(P,C4P,S,Q+FAT;>U9;6_;-A#^
MOE]Q<[$V 2Q'\EODEP;P' ?+T,9I[*S;IX&6J(BK1*HDE<3[]3N25F+'Z59T
M:Y-T#0)#TO&.SQV/]T(.4YUG!\.4DOC@N^'WG@>'(BISRC5$DA)-8R@5XQ?P
M-J;J'7C>:M18%$O)+E(-3;_9@;="OF.7Q-$UTQD]J.0,]]S[<,].,ER(>'DP
MC-DEL/AEC864A/O1?KS?ZOKM*%ST A(NPEZ<1%&[E73([T$-67&XXU%ZF=&7
MM9QQ+Z5F_GZ[V=CO%'IPQ6*=]@/?_Z%FAQX,$\$USB>1WSTZ,5O"-+W6'LG8
M!>];E6J.M2)'(A.R_\RW?P-#\1*2LVS9?S%G.55P0J_@3.2$OZ@KPI6GJ&2)
M&ZC8GQ0Q(3S[>N4@[Z.<C'%:J1 T#>C)=<H63$.KV6AN(K[1YO-!:M\+Z?FS
MH.L/ML#<8[@(5YK*![+<>'(V/SXZ'H_FQ],3.#T_FYV/3N8PGSYZY$$(YXU9
M8]R V61LT0>MCE]_]+A',Q@=3D_GD\,G9>[*R#V_"],CF/\T@=GH[,?1R63F
M37]]-?D-1N.YH31]?WL//IPV_W9W_E$JS9+E ^$\YA )SFFDF>!PQ70*.J7P
MIB02C9<MX8P60FI XI&0.02^]P9$ J^8(IK /*62%+34+%)U..91 W8,__-G
M8;/I#\8B+PA?VK=@L N)D%;\>R<>*(\QB;TF,DJ=P5I!W26MA&5(N<$SHU$I
MF6:H..$Q3*ZCE/ +BJDNSYE2!CO^FY$QYD5 5!1!KD-Q>E1($&L=?B;6D$Q%
MHHXS<(;H?F$1A5-)%8O1?>IPQ#CA^,G,.L>DJTJYM"_CE-$$1E$D2JY-$IXF
M"?)*8QPS[4KU.N WL[YU*$JI2H)+K 6LQ9:5Z6UL 8+ZQ:(PJ7U]>#7([(V5
M_!F1"\*I\J;7&5TB$&TH9F_4#4>^A'=<7*$1T4HZ):AY)WP"_OBI^^:>6F*-
MK2!QC&OD9331_587D6P+<I\8-^O>]X*P^/RUQOTF"!J5'E]^]L&&I0*_T3%F
MP%U>Q8&DS# H1.C<F=F,-QM4TO<ED]04E<HXXJU;[Y!=P(T5=';BW1OGO=W.
M-UMYY<%!K]6VVR"WP0'=MC<P&^Y_[1+-1^D2C&,\SXE=9TPBFB!GC%_M$E?^
M0IC)(@5&5.,:=4,F60;(AF!(AHZC"O05I!BNQ(9;\QT%QLR*W@RHQC=67TRH
M5Y5HG-F$9>>+JLR<&XH"\Y.1HNZ*J5(1#F B7A/3^'J#Y)?&>6AZ5)MX'&+W
M^YHLW4.XRO5/MZ'29)'1:L!"R)A*#^%FI%"T7ST,8J:*C"S[C-M)+=,@)_("
M&^6%T%KD?=,D7YI"(2+9:A([GR.O^N=>V.BT0M-":PQL.JXF7G77#=M=[^EX
MF]9I-\)6^X-DOQ%\D/9W8K&][W6['R5VST)VL-$P"O?@RUJK=B<:]YO%-02;
ML=B$G;NV<6;Y\E[MW^,G*\V?M%(.6DPCX:)EO\2<)\THHVY[?Z#L[WK%#.9O
MPPC?EOAQ*[6V>-_6[0DI]9]UICNGDF%Q56!U=7139U5$PWE+W^;>W?:9/9O)
MGE#>?MAJR)3,6'72"V',ZHX%T,=LC<L4+*CYG)22,Y5B-:M$1DWE_*G' +"C
MRH5R' I,%V:6>&>QN]F>F5.'<4H*<QS3;1G:W%P)0(#5V3EGIJZ>:5MHCT5,
MG1!$RX6N$-N3&JS*"R)U!6OMK$C:;@X41;HYF\%J*,H$>BL^KJXAOJJ2>^/8
M\?X>]&/ZTSLW*(50MAOJ2YJARUS2K3N5VS+45I3^+0M9H"^5>IOE'ZYA5K_N
M4FC/7D;]!5!+ 0(4 Q0    ( ,:!J%J->77N:P@! *@F#0 1
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M+3(P,C4P,S,Q7W!R92YX;6Q02P$"% ,4    " #&@:A:(@P)5/P&   #)0
M%P              @ '(0P4 ;'-T82UE>#,Q,5\R,#(U,#,S,2YH=&U02P$"
M% ,4    " #&@:A:'@J9U@P'   M)0  %P              @ 'Y2@4 ;'-T
M82UE>#,Q,E\R,#(U,#,S,2YH=&U02P$"% ,4    " #&@:A:#4[5>D(%  !&
M&@  %P              @ $Z4@4 ;'-T82UE>#,R,5\R,#(U,#,S,2YH=&U0
M2P$"% ,4    " #&@:A: &Q[IU4%  "3&@  %P              @ &Q5P4
M;'-T82UE>#,R,E\R,#(U,#,S,2YH=&U02P4&      L "P#@ @  .UT%

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>lsta-20250331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lsta="http://www.caladrius.com/20250331"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lsta-20250331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2025-05-08</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-04</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-21</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2024-08-21</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lsta:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-04</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2024-03-21</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lsta:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lsta:BolsterTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lsta:BolsterTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lsta:AscendTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lsta:AscendTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lsta:ChemistryManufacturingAndControlsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lsta:ChemistryManufacturingAndControlsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lsta:ClinicalDepartmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lsta:ClinicalDepartmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lsta:ResearchAndDevelopmentOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lsta:ResearchAndDevelopmentOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lsta:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lsta:LingmedLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-25</startDate>
            <endDate>2024-03-25</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lsta:LingmedLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-15</startDate>
            <endDate>2024-03-15</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-12</startDate>
            <endDate>2024-07-12</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lsta:ImpiloMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-14</startDate>
            <endDate>2022-09-14</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:KuvaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:KuvaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:KuvaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lsta:KuvaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lsta:ExclusiveLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>lsta:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0000320017</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-416">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-417">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-422">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-423">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-86" id="f-502">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <lsta:SaleOfStockAvailableForSalePercentage contextRef="c-94" decimals="2" id="f-532" unitRef="number">0.33</lsta:SaleOfStockAvailableForSalePercentage>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-33650</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">LISATA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">22-2343568</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">110 Allen Road, 2nd Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Basking Ridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">07920</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">842-0100</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">LSTA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">8598204</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-30" unitRef="usd">20217000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">16209000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">5616000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">15036000</us-gaap:MarketableSecurities>
    <us-gaap:AccountsReceivableNet contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">750000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">900000</us-gaap:AccountsReceivableNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">2034000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">2433000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">28617000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">34578000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">74000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">72000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">174000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">192000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">116000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">160000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">28981000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">35002000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">602000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">1284000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">3205000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">4329000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">3807000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">5613000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">72000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">72000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">3879000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">5685000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-58" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-59" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-60"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-61"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-62" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-63" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-64" unitRef="shares">8620900</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-65" unitRef="shares">8409582</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-66" unitRef="shares">8620162</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-67" unitRef="shares">8408844</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-68" unitRef="usd">9000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">8000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-70" unitRef="usd">578923000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">578418000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockCommonShares contextRef="c-4" decimals="INF" id="f-72" unitRef="shares">738</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-3" decimals="INF" id="f-73" unitRef="shares">738</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-3" decimals="-3" id="f-74" unitRef="usd">708000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">708000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-76" unitRef="usd">-552790000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">-548066000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-78" unitRef="usd">-78000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">-81000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-80" unitRef="usd">25356000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">29571000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-3" decimals="-3" id="f-82" unitRef="usd">-254000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-4" decimals="-3" id="f-83" unitRef="usd">-254000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-3" decimals="-3" id="f-84" unitRef="usd">25102000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-85" unitRef="usd">29317000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-86" unitRef="usd">28981000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-87" unitRef="usd">35002000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-3" id="f-88" unitRef="usd">2602000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-5" decimals="-3" id="f-89" unitRef="usd">3241000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-90" unitRef="usd">3245000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-91" unitRef="usd">3360000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-92" unitRef="usd">5847000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-93" unitRef="usd">6601000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-94" unitRef="usd">-5847000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-95" unitRef="usd">-6601000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet contextRef="c-1" decimals="-3" id="f-96" unitRef="usd">266000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-5" decimals="-3" id="f-97" unitRef="usd">589000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-98" unitRef="usd">-105000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-99" unitRef="usd">-187000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-100" unitRef="usd">161000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-101" unitRef="usd">402000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-102" unitRef="usd">-5686000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-103" unitRef="usd">-6199000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-104" unitRef="usd">-962000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-105" unitRef="usd">-798000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-106" unitRef="usd">-4724000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-107" unitRef="usd">-5401000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity contextRef="c-1" decimals="-3" id="f-108" unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity contextRef="c-5" decimals="-3" id="f-109" unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-110" unitRef="usd">-4724000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-111" unitRef="usd">-5401000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-112"
      unitRef="usdPerShare">-0.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-113"
      unitRef="usdPerShare">-0.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-114"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-115"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-116" unitRef="shares">8602000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-117" unitRef="shares">8602000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-118" unitRef="shares">8294000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-119" unitRef="shares">8294000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">-4724000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-121" unitRef="usd">-5401000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-122" unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-5" decimals="-3" id="f-123" unitRef="usd">-13000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-125" unitRef="usd">-49000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-127" unitRef="usd">-62000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">-4721000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-129" unitRef="usd">-5463000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="-3" id="f-130" unitRef="shares">8151000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-131" unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-132" unitRef="usd">576971000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-8" decimals="-3" id="f-133" unitRef="usd">-42000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-9" decimals="-3" id="f-134" unitRef="usd">-528081000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-10" decimals="-3" id="f-135" unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-136" unitRef="usd">48148000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-137" unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-138" unitRef="usd">47894000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-14" decimals="-3" id="f-139" unitRef="usd">-5401000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-3" id="f-140" unitRef="usd">-5401000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-141" unitRef="usd">-5401000</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-16" decimals="-3" id="f-142" unitRef="shares">157000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-17" decimals="-3" id="f-143" unitRef="usd">312000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-15" decimals="-3" id="f-144" unitRef="usd">312000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-145" unitRef="usd">312000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-18" decimals="-3" id="f-146" unitRef="usd">-13000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-15" decimals="-3" id="f-147" unitRef="usd">-13000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-148" unitRef="usd">-13000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-18" decimals="-3" id="f-149" unitRef="usd">-49000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-15" decimals="-3" id="f-150" unitRef="usd">-49000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-151" unitRef="usd">-49000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-19" decimals="-3" id="f-152" unitRef="shares">8308000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-19" decimals="-3" id="f-153" unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-20" decimals="-3" id="f-154" unitRef="usd">577283000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-21" decimals="-3" id="f-155" unitRef="usd">-104000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-3" id="f-156" unitRef="usd">-533482000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-23" decimals="-3" id="f-157" unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-24" decimals="-3" id="f-158" unitRef="usd">42997000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="-3" id="f-159" unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="-3" id="f-160" unitRef="usd">42743000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-27" decimals="-3" id="f-161" unitRef="shares">8410000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-3" id="f-162" unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-3" id="f-163" unitRef="usd">578418000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-164" unitRef="usd">-81000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-3" id="f-165" unitRef="usd">-548066000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-166" unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-167" unitRef="usd">29571000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-3" id="f-168" unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-169" unitRef="usd">29317000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-34" decimals="-3" id="f-170" unitRef="usd">-4724000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-35" decimals="-3" id="f-171" unitRef="usd">-4724000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-172" unitRef="usd">-4724000</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-36" decimals="-3" id="f-173" unitRef="shares">151000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-37" decimals="-3" id="f-174" unitRef="usd">286000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-35" decimals="-3" id="f-175" unitRef="usd">286000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-176" unitRef="usd">286000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-36" decimals="-3" id="f-177" unitRef="shares">56000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-36" decimals="-3" id="f-178" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-37" decimals="-3" id="f-179" unitRef="usd">211000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-35" decimals="-3" id="f-180" unitRef="usd">212000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-181" unitRef="usd">212000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-36" decimals="-3" id="f-182" unitRef="shares">4000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-37" decimals="-3" id="f-183" unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-35" decimals="-3" id="f-184" unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-38" decimals="-3" id="f-186" unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-35" decimals="-3" id="f-187" unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-38" decimals="-3" id="f-189" unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-35" decimals="-3" id="f-190" unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-39" decimals="-3" id="f-192" unitRef="shares">8621000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-39" decimals="-3" id="f-193" unitRef="usd">9000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-40" decimals="-3" id="f-194" unitRef="usd">578923000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-41" decimals="-3" id="f-195" unitRef="usd">-78000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-3" id="f-196" unitRef="usd">-552790000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-3" id="f-197" unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-3" id="f-198" unitRef="usd">25356000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-199" unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-3" decimals="-3" id="f-200" unitRef="usd">25102000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">-4724000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-202" unitRef="usd">-5401000</us-gaap:ProfitLoss>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">530000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c-5" decimals="-3" id="f-204" unitRef="usd">454000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">43000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-206" unitRef="usd">46000</us-gaap:DepreciationAndAmortization>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-5" decimals="-3" id="f-208" unitRef="usd">-100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">41000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-5" decimals="-3" id="f-210" unitRef="usd">152000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">-150000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-5" decimals="-3" id="f-212" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">-405000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-5" decimals="-3" id="f-214" unitRef="usd">872000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">-44000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-5" decimals="-3" id="f-216" unitRef="usd">-41000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <lsta:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">-1809000</lsta:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities>
    <lsta:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities contextRef="c-5" decimals="-3" id="f-218" unitRef="usd">-1243000</lsta:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">-5402000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="-3" id="f-220" unitRef="usd">-7027000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">5055000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-5" decimals="-3" id="f-222" unitRef="usd">18824000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">14514000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-5" decimals="-3" id="f-224" unitRef="usd">25360000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">28000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-226" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-5" decimals="-3" id="f-228" unitRef="usd">100000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-229" unitRef="usd">9431000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-5" decimals="-3" id="f-230" unitRef="usd">6436000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">8000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-5" decimals="-3" id="f-232" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">243000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-5" decimals="-3" id="f-234" unitRef="usd">142000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-235" unitRef="usd">212000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-5" decimals="-3" id="f-236" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-237" unitRef="usd">-23000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="-3" id="f-238" unitRef="usd">-142000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-239" unitRef="usd">2000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-240" unitRef="usd">-55000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-241" unitRef="usd">4008000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="-3" id="f-242" unitRef="usd">-788000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-243" unitRef="usd">16209000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-13" decimals="-3" id="f-244" unitRef="usd">22593000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-245" unitRef="usd">20217000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-26" decimals="-3" id="f-246" unitRef="usd">21805000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-247">Description of Business&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lisata Therapeutics, Inc. (together with its subsidiaries, the &#x201c;Company&#x201d;) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. The Company's investigational product, certepetide (formerly known as LSTA1 or CEND-1), is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. Certepetide has also been shown to modify the tumor microenvironment (&#x201c;TME&#x201d;) by reducing T-regulatory cells and augmenting cytotoxic T cells, thereby making tumors more susceptible to immunotherapies while also inhibiting the metastatic cascade (i.e., the spread of cancer to other parts of the body). The Company, its collaborators and other researchers have amassed and continue to amass significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies, and RNA-based therapeutics. To date, certepetide has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. The Company is exploring certepetide as a means to enable a variety of therapeutic modalities to treat a range of solid tumors more effectively. Currently, certepetide is the subject of several Phase 2 clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), cholangiocarcinoma, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. The Company's goal is to develop and commercialize products that address important unmet medical needs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a history of net operating losses and negative cash flows from operating activities, and has cash, cash equivalents and marketable securities of approximately $25.8&#160;million as of March&#160;31, 2025. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenues from its products currently in development. To manage capital for operating needs in the short-term, initiation of the FORTIFIDE study remains on hold as the Company is investigating a potentially faster and more cost-effective approach to achieving the study objective. The Company has similarly decided to delay commencement of certain phase 3 readiness activities for chemistry, manufacturing and controls (&#x201c;CMC&#x201d;). The Company believes that, as a result, it currently has sufficient cash to meet its funding requirements over the next year. To meet our long-term liquidity needs, the Company expects that it will need additional financing, which could result in additional potential issuances of debt or equity securities in public or private financings, partnerships and/or collaborations and/or sale of assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of March&#160;31, 2025, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2024 and 2023 included in our 2024 Form 10-K. Operating results for the three months ended March&#160;31, 2025 are not necessarily indicative of the results that may be expected for the year ending December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as one operating segment, the research and development of its investigational drug product. The Company's Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is its Chief Executive Officer, who manages the business on a consolidated basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Remeasurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <lsta:CashAndCashEquivalentsAndMarketableSecurities contextRef="c-3" decimals="-5" id="f-248" unitRef="usd">25800000</lsta:CashAndCashEquivalentsAndMarketableSecurities>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-249">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of March&#160;31, 2025, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2024 and 2023 included in our 2024 Form 10-K. Operating results for the three months ended March&#160;31, 2025 are not necessarily indicative of the results that may be expected for the year ending December 31, 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-250">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-251">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as one operating segment, the research and development of its investigational drug product. The Company's Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is its Chief Executive Officer, who manages the business on a consolidated basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-252"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-253">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;The Consolidated Financial Statements include the accounts of Lisata Therapeutics, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-254">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Remeasurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is the U.S. Dollar. The functional currency of Lisata Therapeutics Australia Pty Ltd., which is a foreign subsidiary of the Company, is the Australian Dollar. The assets and liabilities of Lisata Therapeutics Australia Pty Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-255">Summary of Significant Accounting Policies&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its portfolio of cash, cash equivalents, accounts receivable and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government, thereby reducing credit risk exposure. Cash is held at major banks in the United States and may exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return. The Company&#x2019;s accounts receivable balance as of March&#160;31, 2025 and December&#160;31, 2024 is derived from its license agreement dated November 30, 2024, more fully described in Note 17. The Company has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Accounts receivable is stated at historical cost, less allowance for credit losses. The Company records an expense based on a forward-looking current expected credit loss model to maintain its allowance for credit losses, which replaced the&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;allowance for doubtful accounts. When determining its allowance for trade accounts receivable, the Company considers the probability of recoverability of accounts receivable based on experience, taking into account current collection trends and general economic factors, including bankruptcy rates. The Company also considers future economic trends to estimate expected&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;credit losses over the lifetime of the asset. Credit risks are assessed based on historical write-offs, net of recoveries, as well as an analysis of the aged accounts receivable balances with allowances generally increasing as the receivable ages. Accounts receivable may be fully reserved for when specific collection issues are known to exist, such as pending bankruptcies. Account balances are written off against the allowance when it is determined that the receivable will not be recovered. As of March 31, 2025 and December 31, 2024, there was no allowance for credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities, that are not the result of credit losses, are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and credit losses recognized through an allowance for credit losses, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.334%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment. The assets are amortized on a straight-line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Share-based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#x2019;s restricted stock and restricted stock units is based on the closing market price of the Company&#x2019;s common stock on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share is based on the weighted effect of all shares of common stock issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock used in the basic loss per share calculation plus the number of shares of common stock that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To further drive the Company&#x2019;s initiatives, the Company will continue targeting key governmental agencies and not-for-profit organizations to contribute funds for the Company&#x2019;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-process Research and Development Expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#x201c;business&#x201d; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible asset consists of a single asset, a license agreement with Qilu Pharmaceutical, Co., Ltd. (&#x201c;Qilu&#x201d;) acquired in the Company's acquisition of Cend Therapeutics, Inc (the &#x201c;Cend Merger&#x201d;), with a value of $0.4&#160;million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5.00 years. Amortization expense was $17&#160;thousand for the three months ended March&#160;31, 2025, and $17&#160;thousand for the three months ended March&#160;31, 2024, respectively. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.  The projected amortization expense is $71&#160;thousand per year for the next 2.50 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company recognized no revenue for the three months ended March&#160;31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#x2019;s collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#x2019;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three months ended March&#160;31, 2025 and March&#160;31, 2024, the Company has not recognized revenue related to milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-256">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-257">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its portfolio of cash, cash equivalents, accounts receivable and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government, thereby reducing credit risk exposure. Cash is held at major banks in the United States and may exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return. The Company&#x2019;s accounts receivable balance as of March&#160;31, 2025 and December&#160;31, 2024 is derived from its license agreement dated November 30, 2024, more fully described in Note 17. The Company has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-258">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Accounts receivable is stated at historical cost, less allowance for credit losses. The Company records an expense based on a forward-looking current expected credit loss model to maintain its allowance for credit losses, which replaced the&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;allowance for doubtful accounts. When determining its allowance for trade accounts receivable, the Company considers the probability of recoverability of accounts receivable based on experience, taking into account current collection trends and general economic factors, including bankruptcy rates. The Company also considers future economic trends to estimate expected&lt;/span&gt;&lt;/div&gt;credit losses over the lifetime of the asset. Credit risks are assessed based on historical write-offs, net of recoveries, as well as an analysis of the aged accounts receivable balances with allowances generally increasing as the receivable ages. Accounts receivable may be fully reserved for when specific collection issues are known to exist, such as pending bankruptcies. Account balances are written off against the allowance when it is determined that the receivable will not be recovered.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-3" decimals="INF" id="f-259" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-4" decimals="INF" id="f-260" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-261">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities, that are not the result of credit losses, are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and credit losses recognized through an allowance for credit losses, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-262">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-263">The estimated useful lives of property and equipment are as follows:&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.334%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:358.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(589)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-46" id="f-264">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-47" id="f-265">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-48" id="f-266">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentImpairment contextRef="c-1" id="f-267">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment. The assets are amortized on a straight-line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-268">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Share-based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#x2019;s restricted stock and restricted stock units is based on the closing market price of the Company&#x2019;s common stock on the date of grant.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-269">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss Per Share&lt;/span&gt;&lt;/div&gt;Basic loss per share is based on the weighted effect of all shares of common stock issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock used in the basic loss per share calculation plus the number of shares of common stock that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c-1" id="f-270">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock contextRef="c-1" id="f-271">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To further drive the Company&#x2019;s initiatives, the Company will continue targeting key governmental agencies and not-for-profit organizations to contribute funds for the Company&#x2019;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="c-1" id="f-272">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-process Research and Development Expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#x201c;business&#x201d; as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.&lt;/span&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-3" decimals="-5" id="f-273" unitRef="usd">400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-3" id="f-274">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-275" unitRef="usd">17000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-5" decimals="-3" id="f-276" unitRef="usd">17000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c-1" id="f-277">The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-3" decimals="-3" id="f-278" unitRef="usd">71000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-279" unitRef="usd">71000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-3" decimals="-3" id="f-280" unitRef="usd">71000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-281">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.&lt;/span&gt;&lt;/div&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="INF" id="f-282" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="INF" id="f-283" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c-1" id="f-284">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#x2019;s collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#x2019;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance. For the three months ended March&#160;31, 2025 and March&#160;31, 2024, the Company has not recognized revenue related to milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-1" decimals="INF" id="f-285" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-5" decimals="INF" id="f-286" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-49" decimals="INF" id="f-287" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c-1" id="f-288">Available-for-Sale Securities&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in the Company's Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:94.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in the Company's Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:360.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's portfolio of available-for-sale securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:361.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="c-1" id="f-289">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in the Company's Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:94.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:46.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-50" decimals="-3" id="f-290" unitRef="usd">10301000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-50" decimals="-3" id="f-291" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-50" decimals="-3" id="f-292" unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-50" decimals="-3" id="f-293" unitRef="usd">10295000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-51" decimals="-3" id="f-294" unitRef="usd">16025000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-51" decimals="-3" id="f-295" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-51" decimals="-3" id="f-296" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-51" decimals="-3" id="f-297" unitRef="usd">16021000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-52" decimals="-3" id="f-298" unitRef="usd">12129000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-52" decimals="-3" id="f-299" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-52" decimals="-3" id="f-300" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-52" decimals="-3" id="f-301" unitRef="usd">12129000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-53" decimals="-3" id="f-302" unitRef="usd">6614000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-53" decimals="-3" id="f-303" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-53" decimals="-3" id="f-304" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-53" decimals="-3" id="f-305" unitRef="usd">6614000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-54" decimals="-3" id="f-306" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-54" decimals="-3" id="f-307" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-54" decimals="-3" id="f-308" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-54" decimals="-3" id="f-309" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-55" decimals="-3" id="f-310" unitRef="usd">613000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-55" decimals="-3" id="f-311" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-55" decimals="-3" id="f-312" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-55" decimals="-3" id="f-313" unitRef="usd">613000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-56" decimals="-3" id="f-314" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-56" decimals="-3" id="f-315" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-56" decimals="-3" id="f-316" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-56" decimals="-3" id="f-317" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-57" decimals="-3" id="f-318" unitRef="usd">1496000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-57" decimals="-3" id="f-319" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-57" decimals="-3" id="f-320" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-57" decimals="-3" id="f-321" unitRef="usd">1496000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-58" decimals="-3" id="f-322" unitRef="usd">560000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-58" decimals="-3" id="f-323" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-58" decimals="-3" id="f-324" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-58" decimals="-3" id="f-325" unitRef="usd">560000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-59" decimals="-3" id="f-326" unitRef="usd">905000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-59" decimals="-3" id="f-327" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-59" decimals="-3" id="f-328" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-59" decimals="-3" id="f-329" unitRef="usd">905000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-3" decimals="-3" id="f-330" unitRef="usd">22990000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="-3" id="f-331" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-3" id="f-332" unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="-3" id="f-333" unitRef="usd">22984000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="-3" id="f-334" unitRef="usd">25653000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-335" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-336" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="-3" id="f-337" unitRef="usd">25649000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="c-1" id="f-338">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in the Company's Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:360.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-339" unitRef="usd">17368000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-340" unitRef="usd">10613000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities contextRef="c-3" decimals="-3" id="f-341" unitRef="usd">5616000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities contextRef="c-4" decimals="-3" id="f-342" unitRef="usd">15036000</us-gaap:MarketableSecurities>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-3" decimals="-3" id="f-343" unitRef="usd">22984000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-4" decimals="-3" id="f-344" unitRef="usd">25649000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c-1" id="f-345">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's portfolio of available-for-sale securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:361.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis contextRef="c-3" decimals="-3" id="f-346" unitRef="usd">22990000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue contextRef="c-3" decimals="-3" id="f-347" unitRef="usd">22984000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis contextRef="c-3" decimals="-3" id="f-348" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue contextRef="c-3" decimals="-3" id="f-349" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-3" decimals="-3" id="f-350" unitRef="usd">22990000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="-3" id="f-351" unitRef="usd">22984000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-352">Property and Equipment&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:509.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:358.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:70.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(589)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s results included depreciation expense of approximately $26&#160;thousand and $29&#160;thousand for the three months ended March&#160;31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-47" decimals="-3" id="f-353" unitRef="usd">617000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-60" decimals="-3" id="f-354" unitRef="usd">589000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-61" decimals="-3" id="f-355" unitRef="usd">72000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-62" decimals="-3" id="f-356" unitRef="usd">72000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-3" id="f-357" unitRef="usd">689000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-358" unitRef="usd">661000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-359" unitRef="usd">615000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-360" unitRef="usd">589000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-361" unitRef="usd">74000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-362" unitRef="usd">72000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-363" unitRef="usd">26000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-5" decimals="-3" id="f-364" unitRef="usd">29000</us-gaap:Depreciation>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-365">Income (Loss) Per Share&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2025 and 2024, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive in the periods presented. At March&#160;31, 2025 and 2024, the Company excluded the following potentially dilutive securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-366">At March&#160;31, 2025 and 2024, the Company excluded the following potentially dilutive securities (in thousands):&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-63" decimals="-3" id="f-367" unitRef="shares">1529000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-64" decimals="-3" id="f-368" unitRef="shares">1454000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-65" decimals="-3" id="f-369" unitRef="shares">1497000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-66" decimals="-3" id="f-370" unitRef="shares">1422000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-67" decimals="-3" id="f-371" unitRef="shares">325000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-68" decimals="-3" id="f-372" unitRef="shares">354000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-373">Fair Value Measurements&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 inputs are defined as unobservable inputs for the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March&#160;31, 2025 and December&#160;31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:116.50pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:12.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities - available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash, cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value as of March&#160;31, 2025 and December&#160;31, 2024, due to the short maturity nature of these items.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-374">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of March&#160;31, 2025 and December&#160;31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:116.50pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:12.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:42.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities - available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-69" decimals="-3" id="f-375" unitRef="usd">17368000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-70" decimals="-3" id="f-376" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-71" decimals="-3" id="f-377" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-72" decimals="-3" id="f-378" unitRef="usd">17368000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-73" decimals="-3" id="f-379" unitRef="usd">10613000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-74" decimals="-3" id="f-380" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-75" decimals="-3" id="f-381" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-76" decimals="-3" id="f-382" unitRef="usd">10613000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-69" decimals="-3" id="f-383" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-70" decimals="-3" id="f-384" unitRef="usd">5616000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-71" decimals="-3" id="f-385" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-72" decimals="-3" id="f-386" unitRef="usd">5616000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-73" decimals="-3" id="f-387" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-74" decimals="-3" id="f-388" unitRef="usd">15036000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-75" decimals="-3" id="f-389" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-76" decimals="-3" id="f-390" unitRef="usd">15036000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-69" decimals="-3" id="f-391" unitRef="usd">17368000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-70" decimals="-3" id="f-392" unitRef="usd">5616000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-71" decimals="-3" id="f-393" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-72" decimals="-3" id="f-394" unitRef="usd">22984000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-73" decimals="-3" id="f-395" unitRef="usd">10613000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-74" decimals="-3" id="f-396" unitRef="usd">15036000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-75" decimals="-3" id="f-397" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-76" decimals="-3" id="f-398" unitRef="usd">25649000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-399">Accrued Liabilities&lt;div style="margin-bottom:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities as of March&#160;31, 2025 and December&#160;31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:313.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:97.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:88.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries, employee benefits and related taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical and R&amp;amp;D related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounting &amp;amp; tax consulting liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &#x2014; current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-400">&lt;div style="margin-bottom:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities as of March&#160;31, 2025 and December&#160;31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:313.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:97.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:88.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries, employee benefits and related taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical and R&amp;amp;D related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounting &amp;amp; tax consulting liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &#x2014; current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-401" unitRef="usd">1532000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-402" unitRef="usd">2640000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <lsta:ClinicalAndRDRelatedLiabilities contextRef="c-3" decimals="-3" id="f-403" unitRef="usd">1166000</lsta:ClinicalAndRDRelatedLiabilities>
    <lsta:ClinicalAndRDRelatedLiabilities contextRef="c-4" decimals="-3" id="f-404" unitRef="usd">1333000</lsta:ClinicalAndRDRelatedLiabilities>
    <lsta:AccruedGrantFunding contextRef="c-3" decimals="-3" id="f-405" unitRef="usd">133000</lsta:AccruedGrantFunding>
    <lsta:AccruedGrantFunding contextRef="c-4" decimals="-3" id="f-406" unitRef="usd">55000</lsta:AccruedGrantFunding>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-407" unitRef="usd">92000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-408" unitRef="usd">137000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-409" unitRef="usd">282000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-410" unitRef="usd">164000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-411" unitRef="usd">3205000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-412" unitRef="usd">4329000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-413">Operating Leases&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an operating lease for one office which expires on September 30, 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as the Company's lease does not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of ASU No. 2016-02, Leases (Topic 842), the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and right-of-use assets were recorded in the following captions of the Company's balance sheet as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:325.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:88.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:88.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-Use Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-416"&gt;&lt;span style="-sec-ix-hidden:f-417"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Right-of-Use Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating Lease Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-422"&gt;&lt;span style="-sec-ix-hidden:f-423"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Operating Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, the weighted average remaining lease term for the Company's operating lease was 0.50 years, and the weighted average discount rate for the Company's operating lease was 9.625%. As of December&#160;31, 2024, the weighted average remaining lease term for the Company's operating lease was 0.75 years, and the weighted average discount rate for the Company's operating lease was 9.625%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under the lease agreement as of March&#160;31, 2025 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:448.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:60.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-414">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an operating lease for one office which expires on September 30, 2025. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as the Company's lease does not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of ASU No. 2016-02, Leases (Topic 842), the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. The Company's lease includes an option for the Company to extend the lease term and/or sub-lease space in whole or in part.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock contextRef="c-1" id="f-415">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and right-of-use assets were recorded in the following captions of the Company's balance sheet as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:325.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:88.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:88.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-Use Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-416"&gt;&lt;span style="-sec-ix-hidden:f-417"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Right-of-Use Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating Lease Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-422"&gt;&lt;span style="-sec-ix-hidden:f-423"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Operating Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lsta:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-418" unitRef="usd">93000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-419" unitRef="usd">138000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-420" unitRef="usd">93000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-421" unitRef="usd">138000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-424" unitRef="usd">92000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-425" unitRef="usd">137000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-426" unitRef="usd">92000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-427" unitRef="usd">137000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-428">P0Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-3" decimals="5" id="f-429" unitRef="number">0.09625</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-430">P0Y9M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="5" id="f-431" unitRef="number">0.09625</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-432">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under the lease agreement as of March&#160;31, 2025 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:448.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:60.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-433" unitRef="usd">95000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-434" unitRef="usd">95000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-435" unitRef="usd">3000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-436" unitRef="usd">92000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-437">Stockholders' Equity&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Issuances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;At The Market Offering Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;ATM Agreement&#x201d;) with H.C. Wainwright &amp;amp; Co., LLC, as sales agent, in connection with an &#x201c;at the market offering&#x201d; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0&#160;million. As of the date of this filing and so long as the Company&#x2019;s public float remains below $75.0 million, the Company is subject to limitations pursuant to General Instruction I.B.6 of Form S-3 (the &#x201c;Baby Shelf Limitation&#x201d;), which limits the amount the Company can offer to up to one-third of its public float during any trailing 12-month period. Subsequent to the filing of a prospectus supplement to the Company's Registration Statement on Form S-3 (File No. 333-279034) relating to the at the market offering on August 21, 2024, the aggregate market value of its outstanding common stock held by non-affiliates was approximately $29.6&#160;million. Pursuant to the Baby Shelf Limitation, since the aggregate market value of the Company's outstanding common stock held by non-affiliates was below $75.0&#160;million at the time of such prospectus supplement filing, the aggregate amount of securities that the Company is permitted to offer and sell is now $9,855,890, which is equal to one-third of the aggregate market value of our common stock held by non-affiliates as of August 20, 2024. If the Company&#x2019;s public float exceeds $75.0&#160;million on a future measurement date, it will no longer be subject to the Baby Shelf Limitation. During the three months ended March&#160;31, 2025, the Company issued 55,578 shares of common stock under the ATM Agreement for net proceeds of $211,369. Since inception, the Company has issued 123,751 shares of common stock under the ATM Agreement for net proceeds of $492,216.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options and Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The following table summarizes the activity for stock options and warrants for the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.127%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,440,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,496,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,529,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,496,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at March 31, 2025&lt;br/&gt;or expected to vest in the future&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,517,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,496,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,344,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,496,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2025 and 2024, the Company issued restricted stock for services as follows (in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:322.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:72.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:4.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:73.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;203,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average estimated fair value of restricted stock issued for services in the three months ended March&#160;31, 2025 and 2024 was $3.80 and $3.08 per share, respectively. The fair value of the restricted stock was determined using the Company&#x2019;s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally between &lt;span style="-sec-ix-hidden:f-502"&gt;one&lt;/span&gt; and four years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the changes in non-vested restricted stock for the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.020%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted Stock Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Grant-Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the Year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(149,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;294,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2025 and 2024, the Company issued restricted stock units for services as follows (in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:343.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:72.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:73.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock units issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock units issued &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average estimated fair value of restricted stock units issued for services in the three months ended March&#160;31, 2025 and 2024 was $3.80 and $3.08 per share, respectively. The fair value of the restricted stock units was determined using the Company&#x2019;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the changes in non-vested restricted stock units for the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.020%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Grant-Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the Year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(97,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <lsta:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement contextRef="c-77" decimals="-5" id="f-438" unitRef="usd">50000000</lsta:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement>
    <us-gaap:CommonStockValueOutstanding contextRef="c-78" decimals="-5" id="f-439" unitRef="usd">29600000</us-gaap:CommonStockValueOutstanding>
    <lsta:OutstandingStockThreshold contextRef="c-79" decimals="-5" id="f-440" unitRef="usd">75000000</lsta:OutstandingStockThreshold>
    <lsta:SaleOfStockAvailableForSale contextRef="c-80" decimals="0" id="f-441" unitRef="usd">9855890</lsta:SaleOfStockAvailableForSale>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-81"
      decimals="INF"
      id="f-442"
      unitRef="shares">55578</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-81" decimals="0" id="f-443" unitRef="usd">211369</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-82"
      decimals="INF"
      id="f-444"
      unitRef="shares">123751</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-82" decimals="0" id="f-445" unitRef="usd">492216</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-446">The following table summarizes the activity for stock options and warrants for the three months ended March&#160;31, 2025:&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.127%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,440,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,496,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,529,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,496,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at March 31, 2025&lt;br/&gt;or expected to vest in the future&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,517,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,496,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,344,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,496,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-447" unitRef="shares">1440535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-448"
      unitRef="usdPerShare">8.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-83" id="f-449">P5Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-2" id="f-450" unitRef="usd">157000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <lsta:CommonStockWarrantsShares contextRef="c-4" decimals="INF" id="f-451" unitRef="shares">1496744</lsta:CommonStockWarrantsShares>
    <lsta:WeightedAverageExercisePriceWarrantsOutstanding
      contextRef="c-4"
      decimals="2"
      id="f-452"
      unitRef="usdPerShare">40.52</lsta:WeightedAverageExercisePriceWarrantsOutstanding>
    <lsta:WeightedAverageRemainingContractualTermWarrantOutstanding contextRef="c-83" id="f-453">P1Y3M14D</lsta:WeightedAverageRemainingContractualTermWarrantOutstanding>
    <lsta:AggregateIntrinsicValueWarrantsOutstanding contextRef="c-4" decimals="-2" id="f-454" unitRef="usd">7500</lsta:AggregateIntrinsicValueWarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c-1" decimals="INF" id="f-455" unitRef="shares">111400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-456"
      unitRef="usdPerShare">3.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <lsta:WarrantsGranted contextRef="c-1" decimals="INF" id="f-457" unitRef="shares">0</lsta:WarrantsGranted>
    <lsta:WeightedAverageExercisePriceWarrantsGranted
      contextRef="c-1"
      decimals="2"
      id="f-458"
      unitRef="usdPerShare">0</lsta:WeightedAverageExercisePriceWarrantsGranted>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-459" unitRef="shares">4329</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-460"
      unitRef="usdPerShare">1.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <lsta:WarrantsExercised contextRef="c-1" decimals="INF" id="f-461" unitRef="shares">0</lsta:WarrantsExercised>
    <lsta:WeightedAverageExercisePriceWarrantsExercised
      contextRef="c-1"
      decimals="2"
      id="f-462"
      unitRef="usdPerShare">0</lsta:WeightedAverageExercisePriceWarrantsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-463" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-464"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <lsta:WarrantsCanceled contextRef="c-1" decimals="INF" id="f-465" unitRef="shares">0</lsta:WarrantsCanceled>
    <lsta:WeightedAverageExercisePriceWarrantsCanceled
      contextRef="c-1"
      decimals="2"
      id="f-466"
      unitRef="usdPerShare">0</lsta:WeightedAverageExercisePriceWarrantsCanceled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-467" unitRef="shares">18215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-468"
      unitRef="usdPerShare">198.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <lsta:WarrantsExpired contextRef="c-1" decimals="INF" id="f-469" unitRef="shares">0</lsta:WarrantsExpired>
    <lsta:WeightedAverageExercisePriceWarrantsExpired
      contextRef="c-1"
      decimals="2"
      id="f-470"
      unitRef="usdPerShare">0</lsta:WeightedAverageExercisePriceWarrantsExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-471" unitRef="shares">1529391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-472"
      unitRef="usdPerShare">6.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-473">P5Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-3" decimals="-2" id="f-474" unitRef="usd">79000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <lsta:CommonStockWarrantsShares contextRef="c-3" decimals="INF" id="f-475" unitRef="shares">1496744</lsta:CommonStockWarrantsShares>
    <lsta:WeightedAverageExercisePriceWarrantsOutstanding
      contextRef="c-3"
      decimals="2"
      id="f-476"
      unitRef="usdPerShare">40.52</lsta:WeightedAverageExercisePriceWarrantsOutstanding>
    <lsta:WeightedAverageRemainingContractualTermWarrantOutstanding contextRef="c-1" id="f-477">P1Y18D</lsta:WeightedAverageRemainingContractualTermWarrantOutstanding>
    <lsta:AggregateIntrinsicValueWarrantsOutstanding contextRef="c-3" decimals="-3" id="f-478" unitRef="usd">0</lsta:AggregateIntrinsicValueWarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-3" decimals="INF" id="f-479" unitRef="shares">1517488</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-480"
      unitRef="usdPerShare">6.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-481">P5Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-3" decimals="-2" id="f-482" unitRef="usd">79000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <lsta:Sharesvestedandexpectedtovest contextRef="c-3" decimals="INF" id="f-483" unitRef="shares">1496744</lsta:Sharesvestedandexpectedtovest>
    <lsta:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest
      contextRef="c-3"
      decimals="2"
      id="f-484"
      unitRef="usdPerShare">40.52</lsta:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest>
    <lsta:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest contextRef="c-1" id="f-485">P1Y18D</lsta:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest>
    <lsta:AggregateIntrinsicValueWarrantsVestedAndExpectedToVest contextRef="c-3" decimals="-3" id="f-486" unitRef="usd">0</lsta:AggregateIntrinsicValueWarrantsVestedAndExpectedToVest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="c-3" decimals="INF" id="f-487" unitRef="shares">1344298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-488"
      unitRef="usdPerShare">6.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <lsta:OptionsVestedWeightedAverageRemainingContractualTerm contextRef="c-1" id="f-489">P5Y1M20D</lsta:OptionsVestedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c-3" decimals="-2" id="f-490" unitRef="usd">78000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <lsta:WarrantsVested contextRef="c-3" decimals="INF" id="f-491" unitRef="shares">1496744</lsta:WarrantsVested>
    <lsta:WeightedAverageExercisePriceWarrantsExercisable
      contextRef="c-3"
      decimals="2"
      id="f-492"
      unitRef="usdPerShare">40.52</lsta:WeightedAverageExercisePriceWarrantsExercisable>
    <lsta:WeightedAverageRemainingContractualTermWarrantsVested contextRef="c-1" id="f-493">P1Y18D</lsta:WeightedAverageRemainingContractualTermWarrantsVested>
    <lsta:AggregateIntrinsicValueWarrantsVested contextRef="c-3" decimals="-3" id="f-494" unitRef="usd">0</lsta:AggregateIntrinsicValueWarrantsVested>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="c-1" id="f-495">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2025 and 2024, the Company issued restricted stock for services as follows (in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:322.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:72.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:4.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:73.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;203,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the changes in non-vested restricted stock for the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.020%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted Stock Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Grant-Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the Year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(149,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;294,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-84"
      decimals="INF"
      id="f-496"
      unitRef="shares">215550</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-85"
      decimals="INF"
      id="f-497"
      unitRef="shares">203800</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-84" decimals="-3" id="f-498" unitRef="usd">819000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-85" decimals="-3" id="f-499" unitRef="usd">628000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-84"
      decimals="2"
      id="f-500"
      unitRef="usdPerShare">3.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-85"
      decimals="2"
      id="f-501"
      unitRef="usdPerShare">3.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-87" id="f-503">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-88"
      decimals="INF"
      id="f-504"
      unitRef="shares">228428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-88"
      decimals="2"
      id="f-505"
      unitRef="usdPerShare">3.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-84"
      decimals="INF"
      id="f-506"
      unitRef="shares">215550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-84"
      decimals="2"
      id="f-507"
      unitRef="usdPerShare">3.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-84"
      decimals="INF"
      id="f-508"
      unitRef="shares">149367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-84"
      decimals="2"
      id="f-509"
      unitRef="usdPerShare">4.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-84"
      decimals="INF"
      id="f-510"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-84"
      decimals="2"
      id="f-511"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-89"
      decimals="INF"
      id="f-512"
      unitRef="shares">294611</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-89"
      decimals="2"
      id="f-513"
      unitRef="usdPerShare">3.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-514">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2025 and 2024, the Company issued restricted stock units for services as follows (in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:343.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:72.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:73.00pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock units issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock units issued &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the changes in non-vested restricted stock units for the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.020%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.305%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Grant-Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the Year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(97,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-90"
      decimals="INF"
      id="f-515"
      unitRef="shares">78945</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-91"
      decimals="INF"
      id="f-516"
      unitRef="shares">205300</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-90" decimals="-3" id="f-517" unitRef="usd">300000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-91" decimals="-3" id="f-518" unitRef="usd">632000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-84"
      decimals="2"
      id="f-519"
      unitRef="usdPerShare">3.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-85"
      decimals="2"
      id="f-520"
      unitRef="usdPerShare">3.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-90" id="f-521">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-92"
      decimals="INF"
      id="f-522"
      unitRef="shares">103800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-92"
      decimals="2"
      id="f-523"
      unitRef="usdPerShare">3.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-90"
      decimals="INF"
      id="f-524"
      unitRef="shares">78945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-90"
      decimals="2"
      id="f-525"
      unitRef="usdPerShare">3.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-90"
      decimals="INF"
      id="f-526"
      unitRef="shares">97400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-90"
      decimals="2"
      id="f-527"
      unitRef="usdPerShare">3.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-90"
      decimals="INF"
      id="f-528"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-90"
      decimals="2"
      id="f-529"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-93"
      decimals="INF"
      id="f-530"
      unitRef="shares">85345</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-93"
      decimals="2"
      id="f-531"
      unitRef="usdPerShare">3.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-533">Share-Based Compensation&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes share-based compensation in the form of stock options, restricted stock, restricted stock units and warrants.&#160;The following table summarizes the components of share-based compensation expense for the three months ended March&#160;31, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.282%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.617%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.282%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March&#160;31, 2025 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.271%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.755%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.587%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized compensation cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected weighted-average period in years of compensation cost to be recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.32&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March&#160;31, 2025 and 2024 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:530.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:257.50pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:61.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:3.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:61.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:3.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:61.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:3.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:61.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average estimated fair value of shares granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#x2019;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-534">The following table summarizes the components of share-based compensation expense for the three months ended March&#160;31, 2025 and 2024 (in thousands):&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.282%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.617%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.282%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-95" decimals="-3" id="f-535" unitRef="usd">126000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-96" decimals="-3" id="f-536" unitRef="usd">86000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-97" decimals="-3" id="f-537" unitRef="usd">404000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-98" decimals="-3" id="f-538" unitRef="usd">368000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-539" unitRef="usd">530000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-540" unitRef="usd">454000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c-1" id="f-541">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at March&#160;31, 2025 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.271%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.755%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.587%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized compensation cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected weighted-average period in years of compensation cost to be recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.32&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-99" decimals="-3" id="f-542" unitRef="usd">393000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-93" decimals="-3" id="f-543" unitRef="usd">251000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-89" decimals="-3" id="f-544" unitRef="usd">925000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-100" id="f-545">P2Y2M15D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-90" id="f-546">P0Y9M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-84" id="f-547">P2Y3M25D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-548">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March&#160;31, 2025 and 2024 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:530.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:257.50pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:61.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:3.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:61.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:3.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:61.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:3.25pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;td style="width:61.75pt"&gt;&lt;/td&gt;&lt;td style="width:1.0pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average estimated fair value of shares granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-100" decimals="-3" id="f-549" unitRef="usd">263000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-101" decimals="-3" id="f-550" unitRef="usd">199000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-102" decimals="-3" id="f-551" unitRef="usd">150000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-103" decimals="-3" id="f-552" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-100"
      decimals="2"
      id="f-553"
      unitRef="usdPerShare">2.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-101"
      decimals="2"
      id="f-554"
      unitRef="usdPerShare">2.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-102"
      decimals="2"
      id="f-555"
      unitRef="usdPerShare">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-103"
      decimals="2"
      id="f-556"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-557">Income Taxes&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, the Company had approximately $57.9&#160;million and $43.7&#160;million, respectively, of Federal NOLs available to offset future taxable income expiring from 2030 through 2036.  The Company performed an analysis and determined that they had an ownership change of greater than 50% on September 15, 2022. As a result of the ownership change, $88.2&#160;million of Federal NOLs will expire unutilized. The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $34.0&#160;million of remaining Federal NOLs as of December 31, 2022. The write-off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the consolidated balance sheet or income statement. Losses incurred before the ownership change on September 15, 2022 will be subject to an annual limitation of zero while losses incurred after September 15, 2022 will not be subject to limitations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, Cend Therapeutics, Inc. (&#x201c;Cend&#x201d;) had approximately $3.6&#160;million of Federal NOLs available to offset future taxable income. The Company performed an analysis and determined that there was an ownership change of greater than 50% on September 15, 2022. As of September 15, 2022 Cend has approximately $3.1&#160;million of Federal and $4.3&#160;million of state NOLs. The state NOLs will expire from the 2036 through 2042 tax years.  Using a fair market value of $36.1&#160;million and applying an applicable federal rate of 2.54% Cend will have an annual limitation of approximately $917&#160;thousand each year. The Federal NOL of $459&#160;thousand incurred in the post-acquisition period September 15, 2022 to December 31, 2022 is not subject to limitation, and does not expire. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, the Company's wholly owned Australian subsidiary had approximately $2.3&#160;million and $2.4&#160;million, respectively, of NOLs which will be carried forward and do not expire. There is a full valuation allowance against the NOLs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company had federal research and development credit carryforwards of $0.5&#160;million expiring from 2027 through 2034 if unutilized, and state research and development credit carryforwards of $0.1&#160;million, which carryforward indefinitely.  Utilization of these credits may be subject to an annual limitation based on changes in ownership.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, the Company had State NOLs available in New Jersey of $24.6&#160;million and $19.4&#160;million, respectively, California of $9.2&#160;million and $9.2&#160;million, respectively, and New York City of $1.9&#160;million and $1.9&#160;million, respectively, to offset future taxable income expiring from 2032 through 2044. The usage of the Company&#x2019;s NOLs is limited given the change in ownership.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the Financial Accounting Standards Board provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, the Company&#x2019;s uncertain tax positions were $344&#160;thousand and $344&#160;thousand, respectively. The uncertain tax positions are due to the acquisition of Cend related to Federal and state credits and certain state NOLs. The Company will continue to evaluate its uncertain tax positions in future periods. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For years prior to 2021, the federal statute of limitations is closed for assessing tax. The Company&#x2019;s state tax returns remain open to examination for a period of three to four years from the date of the tax return filing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2025, the Company sold a portion of their unused New Jersey net operating losses through the State of New Jersey Economic Development Authority's (&#x201c;NJEDA&#x201d;) Technology Business Tax Certificate Transfer Program (&#x201c;Program&#x201d;). Under the Program, the Company sold $10.7&#160;million of its New Jersey net operating losses (&#x201c;NJ NOLs&#x201d;) for net proceeds of $871&#160;thousand. The sale of NJ NOLs resulted in a $962&#160;thousand deferred income tax benefit and a loss on sale of $91&#160;thousand recorded in other income (expense) in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <lsta:OperatingLossCarryforwardsBeforeWriteDown contextRef="c-104" decimals="-5" id="f-558" unitRef="usd">57900000</lsta:OperatingLossCarryforwardsBeforeWriteDown>
    <lsta:OperatingLossCarryforwardsBeforeWriteDown contextRef="c-105" decimals="-5" id="f-559" unitRef="usd">43700000</lsta:OperatingLossCarryforwardsBeforeWriteDown>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-4" decimals="-5" id="f-560" unitRef="usd">88200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards contextRef="c-105" decimals="-5" id="f-561" unitRef="usd">34000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-106" decimals="-5" id="f-562" unitRef="usd">3600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-107" decimals="-5" id="f-563" unitRef="usd">3100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-108" decimals="-5" id="f-564" unitRef="usd">4300000</us-gaap:OperatingLossCarryforwards>
    <lsta:FairValueMarketOfTaxNOLs contextRef="c-109" decimals="-5" id="f-565" unitRef="usd">36100000</lsta:FairValueMarketOfTaxNOLs>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-109" decimals="4" id="f-566" unitRef="number">0.0254</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <lsta:NetCarryforwardOperatingLossCarryforwardAnnualLimitation contextRef="c-110" decimals="-3" id="f-567" unitRef="usd">917000</lsta:NetCarryforwardOperatingLossCarryforwardAnnualLimitation>
    <lsta:OperatingLossCarryforwardsPostAcquisition contextRef="c-106" decimals="-3" id="f-568" unitRef="usd">459000</lsta:OperatingLossCarryforwardsPostAcquisition>
    <us-gaap:OperatingLossCarryforwards contextRef="c-111" decimals="-5" id="f-569" unitRef="usd">2300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-112" decimals="-5" id="f-570" unitRef="usd">2400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-113" decimals="-5" id="f-571" unitRef="usd">500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-114" decimals="-5" id="f-572" unitRef="usd">100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-115" decimals="-5" id="f-573" unitRef="usd">24600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-116" decimals="-5" id="f-574" unitRef="usd">19400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-117" decimals="-5" id="f-575" unitRef="usd">9200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-118" decimals="-5" id="f-576" unitRef="usd">9200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-119" decimals="-5" id="f-577" unitRef="usd">1900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-120" decimals="-5" id="f-578" unitRef="usd">1900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-3" id="f-579" unitRef="usd">344000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-13" decimals="-3" id="f-580" unitRef="usd">344000</us-gaap:UnrecognizedTaxBenefits>
    <lsta:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross contextRef="c-121" decimals="-5" id="f-581" unitRef="usd">10700000</lsta:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross>
    <lsta:ProceedsFromSaleOfNOLS contextRef="c-121" decimals="-3" id="f-582" unitRef="usd">871000</lsta:ProceedsFromSaleOfNOLS>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-121" decimals="-3" id="f-583" unitRef="usd">962000</us-gaap:IncomeTaxExpenseBenefit>
    <lsta:LossOnSaleOfNOL contextRef="c-121" decimals="-3" id="f-584" unitRef="usd">91000</lsta:LossOnSaleOfNOL>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-585">Segment Information&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as one operating segment, the research and development of its investigational drug product. The Company used the management approach to determine its reportable operating segment. The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer, who reviews financial information presented on a consolidated basis. The Company is a clinical-stage pharmaceutical company and has limited revenue associated with a license and collaboration agreement. The CODM uses net loss as a measure of profit and loss, and assesses Company performance through the achievement of its clinical development goals. The CODM is regularly provided with budgeted and forecasted expense information which is used to determine the Company&#x2019;s liquidity needs and cash allocation to its development programs. The CODM uses cash and marketable securities as a measure of segment assets in managing the enterprise.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no revenue during the three months ended March&#160;31, 2025 and 2024. Depreciation and amortization expense was $43 thousand and $46 thousand for the three months ended March&#160;31, 2025 and 2024, respectively. Equity method investment expense was $0 and $100 thousand for the three months ended March&#160;31, 2025 and 2024, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates our segment information for significant operating expenses and includes a reconciliation to net loss for the three months ended March&#160;31, 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.018%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.405%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development by significant expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;BOLSTER trial&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;ASCEND trial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Chemistry, manufacturing and controls&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Clinical department&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative by significant expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Investor relations/public relations/communications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Legal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Business development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Share based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,601)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(4,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(5,401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;25,833&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43,349&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Included in Other are the GBM study, FORTIFIDE study and research &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;oncology expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Included in Other are facilities expense, human resource &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;and information technology expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-586"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="INF" id="f-587" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="INF" id="f-588" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-589" unitRef="usd">43000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-590" unitRef="usd">46000</us-gaap:DepreciationAndAmortization>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-591" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-5" decimals="-3" id="f-592" unitRef="usd">-100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-593">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.018%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.405%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development by significant expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;BOLSTER trial&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;ASCEND trial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Chemistry, manufacturing and controls&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Clinical department&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative by significant expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Investor relations/public relations/communications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Legal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Business development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Share based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,601)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(4,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(5,401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;25,833&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;43,349&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Included in Other are the GBM study, FORTIFIDE study and research &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;oncology expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Included in Other are facilities expense, human resource &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;and information technology expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-122" decimals="-3" id="f-594" unitRef="usd">788000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-123" decimals="-3" id="f-595" unitRef="usd">1270000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-124" decimals="-3" id="f-596" unitRef="usd">21000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-125" decimals="-3" id="f-597" unitRef="usd">44000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-126" decimals="-3" id="f-598" unitRef="usd">220000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-127" decimals="-3" id="f-599" unitRef="usd">655000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-128" decimals="-3" id="f-600" unitRef="usd">1156000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-129" decimals="-3" id="f-601" unitRef="usd">1133000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-130" decimals="-3" id="f-602" unitRef="usd">417000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-131" decimals="-3" id="f-603" unitRef="usd">139000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-132" decimals="-3" id="f-604" unitRef="usd">2602000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-133" decimals="-3" id="f-605" unitRef="usd">3241000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-134" decimals="-3" id="f-606" unitRef="usd">1144000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-135" decimals="-3" id="f-607" unitRef="usd">1132000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CommunicationsAndInformationTechnology contextRef="c-132" decimals="-3" id="f-608" unitRef="usd">331000</us-gaap:CommunicationsAndInformationTechnology>
    <us-gaap:CommunicationsAndInformationTechnology contextRef="c-133" decimals="-3" id="f-609" unitRef="usd">285000</us-gaap:CommunicationsAndInformationTechnology>
    <lsta:FinanceGeneralAndAdministrativeExpense contextRef="c-132" decimals="-3" id="f-610" unitRef="usd">629000</lsta:FinanceGeneralAndAdministrativeExpense>
    <lsta:FinanceGeneralAndAdministrativeExpense contextRef="c-133" decimals="-3" id="f-611" unitRef="usd">580000</lsta:FinanceGeneralAndAdministrativeExpense>
    <lsta:LegalGeneralAndAdministrativeExpense contextRef="c-132" decimals="-3" id="f-612" unitRef="usd">224000</lsta:LegalGeneralAndAdministrativeExpense>
    <lsta:LegalGeneralAndAdministrativeExpense contextRef="c-133" decimals="-3" id="f-613" unitRef="usd">671000</lsta:LegalGeneralAndAdministrativeExpense>
    <us-gaap:BusinessDevelopment contextRef="c-132" decimals="-3" id="f-614" unitRef="usd">127000</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment contextRef="c-133" decimals="-3" id="f-615" unitRef="usd">172000</us-gaap:BusinessDevelopment>
    <lsta:ShareBasedCompensationExpenseGeneralAndAdministrativeExpense contextRef="c-132" decimals="-3" id="f-616" unitRef="usd">404000</lsta:ShareBasedCompensationExpenseGeneralAndAdministrativeExpense>
    <lsta:ShareBasedCompensationExpenseGeneralAndAdministrativeExpense contextRef="c-133" decimals="-3" id="f-617" unitRef="usd">368000</lsta:ShareBasedCompensationExpenseGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c-132" decimals="-3" id="f-618" unitRef="usd">386000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c-133" decimals="-3" id="f-619" unitRef="usd">152000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-132" decimals="-3" id="f-620" unitRef="usd">3245000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-133" decimals="-3" id="f-621" unitRef="usd">3360000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss contextRef="c-132" decimals="-3" id="f-622" unitRef="usd">-5847000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-133" decimals="-3" id="f-623" unitRef="usd">-6601000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-132" decimals="-3" id="f-624" unitRef="usd">161000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-133" decimals="-3" id="f-625" unitRef="usd">402000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-132" decimals="-3" id="f-626" unitRef="usd">-962000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-133" decimals="-3" id="f-627" unitRef="usd">-798000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-132" decimals="-3" id="f-628" unitRef="usd">-4724000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-133" decimals="-3" id="f-629" unitRef="usd">-5401000</us-gaap:ProfitLoss>
    <lsta:CashCashEquivalentsAndMarketableSecurities contextRef="c-136" decimals="-3" id="f-630" unitRef="usd">25833000</lsta:CashCashEquivalentsAndMarketableSecurities>
    <lsta:CashCashEquivalentsAndMarketableSecurities contextRef="c-137" decimals="-3" id="f-631" unitRef="usd">43349000</lsta:CashCashEquivalentsAndMarketableSecurities>
    <lsta:ResearchAndDevelopmentTaxIncentiveTextBlock contextRef="c-1" id="f-632">Australia Research and Development Tax IncentiveThe Company&#x2019;s Australian subsidiary, which conducts core research and development activities, is eligible to receive a refundable tax incentive between 43.5% to 48.5% (depending upon the income tax rate) for qualified research and development activities. As of March&#160;31, 2025 and December&#160;31, 2024, the Company had $0.6&#160;million and $0.6&#160;million, respectively, recorded as an income tax incentive receivable in prepaid and other current assets in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed.</lsta:ResearchAndDevelopmentTaxIncentiveTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-138" decimals="3" id="f-633" unitRef="number">0.435</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-139" decimals="3" id="f-634" unitRef="number">0.485</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <lsta:IncomeTaxIncentiveReceivable contextRef="c-3" decimals="-5" id="f-635" unitRef="usd">600000</lsta:IncomeTaxIncentiveReceivable>
    <lsta:IncomeTaxIncentiveReceivable contextRef="c-4" decimals="-5" id="f-636" unitRef="usd">600000</lsta:IncomeTaxIncentiveReceivable>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-637">Contingencies&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results. The Company has elected to recognize expense for legal fees as incurred when the legal services are provided.&lt;/span&gt;&lt;/div&gt;In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (&#x201c;Lingmed&#x201d;) claiming Lingmed was entitled to a success fee based on Cend&#x2019;s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend&#x2019;s response to the complaint was filed on June 6, 2022 and denied all of Lingmed&#x2019;s material allegations. Lingmed filed an answer to Cend&#x2019;s response on July 11, 2022, denying all of the Company&#x2019;s material allegations. On March 25, 2024 the Company entered into a settlement agreement whereby the Company was required to pay Lingmed $0.5&#160;million within 30 days of the effective date and the Company effected payment on April 4, 2024. Lingmed is also entitled to 5.0% of any future milestone payments received by the Company under the license agreement with Qilu in addition to a sum of $250 thousand with respect to the first future milestone received by the Company. On April 9, 2024, pursuant to the parties&#x2019; joint request, the Court entered a dismissal with prejudice of the entire action as to all parties and all claims and the matter was settled.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-140" decimals="-5" id="f-638" unitRef="usd">500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <lsta:LitigationSettlementPaymentTerm contextRef="c-140" id="f-639">P30D</lsta:LitigationSettlementPaymentTerm>
    <lsta:LitigationSettlementFutureMilestonePaymentsPercent
      contextRef="c-141"
      decimals="INF"
      id="f-640"
      unitRef="number">0.050</lsta:LitigationSettlementFutureMilestonePaymentsPercent>
    <lsta:LitigationSettlementMilestonePayment contextRef="c-141" decimals="-3" id="f-641" unitRef="usd">250000</lsta:LitigationSettlementMilestonePayment>
    <lsta:TechnologyTransferAgreementTextBlock contextRef="c-1" id="f-642">Technology Transfer Agreement&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Impilo Therapeutics &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023, the Company entered into a technology transfer agreement with Impilo Therapeutics (&#x201c;Impilo&#x201d;) under which the Company transferred its rights to its tumor penetrating nanocomplex (TPN) platform to Impilo. As consideration for the technology transfer, Impilo issued a total of 766,000 shares of its pre-seed preferred stock to the Company. On October 3, 2023, in connection with the Sanford Burnham Prebys license agreement (see Note 16 - License Agreements) Impilo cancelled the original stock certificate for 766,000 shares and reissued 574,500 shares of its pre-seed preferred stock to the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 15, 2024, the Company purchased a Simple Agreement for Future Equity ("SAFE") from Impilo for $100&#160;thousand. On July 12, 2024, the Company purchased an additional SAFE from Impilo for $30&#160;thousand. As of March&#160;31, 2025 and December&#160;31, 2024, the Company owned 38.6% of Impilo. These investments were expensed under the equity method of accounting in the prior year in other expense, net in the accompanying statement of operations. The SAFE has a valuation cap of $30.0&#160;million and an 80% discount rate.&lt;/span&gt;&lt;/div&gt;</lsta:TechnologyTransferAgreementTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-142"
      decimals="INF"
      id="f-643"
      unitRef="shares">766000</us-gaap:InvestmentOwnedBalanceShares>
    <lsta:InvestmentOwnedCanceledShares
      contextRef="c-143"
      decimals="INF"
      id="f-644"
      unitRef="shares">766000</lsta:InvestmentOwnedCanceledShares>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-143"
      decimals="INF"
      id="f-645"
      unitRef="shares">574500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PaymentsToAcquireOtherInvestments contextRef="c-144" decimals="-3" id="f-646" unitRef="usd">100000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments contextRef="c-145" decimals="-3" id="f-647" unitRef="usd">30000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-146" decimals="3" id="f-648" unitRef="number">0.386</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-147" decimals="3" id="f-649" unitRef="number">0.386</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <lsta:SAFEValuationCap contextRef="c-146" decimals="-5" id="f-650" unitRef="usd">30000000</lsta:SAFEValuationCap>
    <lsta:SAFEDiscountRate contextRef="c-146" decimals="2" id="f-651" unitRef="number">0.80</lsta:SAFEDiscountRate>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-652">License Agreements&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sanford Burnham Prebys&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (&#x201c;SBP&#x201d;) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of certepetide. At the time the license agreement was entered into, Cend&#x2019;s founding shareholder was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10&#160;thousand increasing to $20&#160;thousand on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6&#160;million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income received, which, pursuant to the technology transfer agreement with Impilo, resulted in SBP receiving 191,500 shares of the Company&#x2019;s pre-seed preferred stock in Impilo on October 3, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreement may be terminated in its entirety by the Company at any time by giving SBP sixty days&#x2019; prior written notice. The agreement may be terminated in its entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreement may be terminated in its entirety by either SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreement for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SBP did not own shares of the Company&#x2019;s common stock as of March&#160;31, 2025. &lt;/span&gt;&lt;/div&gt;Research Collaboration and License Agreements&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exclusive License and Collaboration Agreement - Qilu Pharmaceuticals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the &#x201c;Qilu Agreement&#x201d;) in which Cend granted an exclusive license to Qilu for the development and commercialization of certepetide in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of certepetide in its Territory. In consideration for the license, Qilu made an upfront payment of $10.0&#160;million to Cend, which was recognized as revenue by Cend prior to the Company's acquisition of Cend on September 15, 2022 (the &#x201c;Cend Merger&#x201d;). In addition, Cend received and recognized as revenue a $5.0&#160;million development milestone prior to the Cend Merger. The Company is eligible to receive additional development and commercial milestone payments up to $96.0&#160;million and $125.0&#160;million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 25, 2024, the Company entered into a settlement agreement with Lingmed whereby Lingmed is entitled to 5.0% of any future milestone payments received by the Company under the Qilu Agreement, in addition, Lingmed is also entitled to a sum of $250 thousand with respect to the first future milestone received by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All rights and obligations of Qilu with respect to such licensed patents and patent applications would terminate simultaneously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exclusive License and Collaboration Agreement - Kuva Labs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the Company entered into an Exclusive License and Collaboration Agreement in which the Company granted an exclusive license to Kuva Labs, Inc. (Kuva) to explore the synergistic potential of the Company's certepetide as a targeting and delivery agent for Kuva&#x2019;s NanoMark&#x2122; imaging technology in solid tumors. Under the Agreement, Kuva will assume full responsibility for research, development, and commercialization costs, while the Company will be responsible for supplying certepetide for additional consideration pursuant to a Clinical Supply Agreement. In consideration for the license, the Company recognized $1.0&#160;million as revenue upon delivery of the license in November 2024. The Company is eligible to receive additional development and commercial milestone payments up to $1.5&#160;million and $17.5&#160;million, respectively, a 5.0% percent royalty on net sales, and sublicensing revenues of 50%.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <lsta:SharesIssuedUnderLicenseAgreement
      contextRef="c-148"
      decimals="INF"
      id="f-653"
      unitRef="shares">382030</lsta:SharesIssuedUnderLicenseAgreement>
    <lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee contextRef="c-148" decimals="-3" id="f-654" unitRef="usd">10000</lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee>
    <lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven contextRef="c-148" decimals="-3" id="f-655" unitRef="usd">20000</lsta:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven>
    <lsta:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct contextRef="c-148" decimals="-5" id="f-656" unitRef="usd">10600000</lsta:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <lsta:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales
      contextRef="c-148"
      decimals="INF"
      id="f-657"
      unitRef="number">0.04</lsta:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales>
    <lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="c-148"
      decimals="INF"
      id="f-658"
      unitRef="number">0.25</lsta:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-149"
      decimals="INF"
      id="f-659"
      unitRef="shares">191500</us-gaap:InvestmentOwnedBalanceShares>
    <lsta:SharesHeldByThirdParty
      contextRef="c-150"
      decimals="INF"
      id="f-660"
      unitRef="shares">0</lsta:SharesHeldByThirdParty>
    <us-gaap:ContractWithCustomerLiability contextRef="c-151" decimals="-5" id="f-661" unitRef="usd">10000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-152" decimals="-5" id="f-662" unitRef="usd">5000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-153" decimals="-5" id="f-663" unitRef="usd">96000000</lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-154" decimals="-5" id="f-664" unitRef="usd">125000000</lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <lsta:RevenuePerformanceObligationPercentageOfNetSale
      contextRef="c-153"
      decimals="INF"
      id="f-665"
      unitRef="number">0.10</lsta:RevenuePerformanceObligationPercentageOfNetSale>
    <lsta:RevenuePerformanceObligationPercentageOfNetSale
      contextRef="c-154"
      decimals="INF"
      id="f-666"
      unitRef="number">0.15</lsta:RevenuePerformanceObligationPercentageOfNetSale>
    <lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues
      contextRef="c-153"
      decimals="INF"
      id="f-667"
      unitRef="number">0.12</lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues>
    <lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues
      contextRef="c-154"
      decimals="INF"
      id="f-668"
      unitRef="number">0.35</lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues>
    <lsta:LitigationSettlementFutureMilestonePaymentsPercent
      contextRef="c-141"
      decimals="INF"
      id="f-669"
      unitRef="number">0.050</lsta:LitigationSettlementFutureMilestonePaymentsPercent>
    <lsta:LitigationSettlementMilestonePayment contextRef="c-141" decimals="-3" id="f-670" unitRef="usd">250000</lsta:LitigationSettlementMilestonePayment>
    <lsta:ResearchCollaborationAndLicenseAgreementOptionToTerminate contextRef="c-155" id="f-671">P60D</lsta:ResearchCollaborationAndLicenseAgreementOptionToTerminate>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-156" decimals="-5" id="f-672" unitRef="usd">1000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-157" decimals="-5" id="f-673" unitRef="usd">1500000</lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-158" decimals="-5" id="f-674" unitRef="usd">17500000</lsta:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <lsta:RevenuePerformanceObligationPercentageOfNetSale
      contextRef="c-159"
      decimals="INF"
      id="f-675"
      unitRef="number">0.050</lsta:RevenuePerformanceObligationPercentageOfNetSale>
    <lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues
      contextRef="c-159"
      decimals="INF"
      id="f-676"
      unitRef="number">0.50</lsta:RevenuePerformanceObligationPercentageOfSublicensingRevenues>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-677">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-678">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-679">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-680">false</ecd:Rule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
